"university","title","number","patent","link","description","LLM Summary","LLM Teaser"
"University of Pennsylvania","Intuitive, easily operated bubble user interface for augmented reality","","","https://upenn.technologypublisher.com/technology/42216","An augmented reality user interface that displays information as a series of nested bubbles in 3D virtual space.Problem:Augmented reality (AR) is the process of superimposing graphics/sounds to what a person sees, typically by adding modifications to what is seen through a tablet or phone camera (e.g. social media filters, Pok√©mon GO). With widespread application from games to apps to enhanced museum experiences, it represents a rapidly growing field with a market size of 18 bn USD worldwide.As its popularity increases, so does the need for more sophisticated ways of presenting information in AR. However, designing an effective AR user interface necessitates the unique challenge of translating traditional 2D methods of organizing information into 3D.Solution:The inventors tackled the problem by taking inspiration from the directory tree organization of desktop files and folders. Rather than attempt to create an entirely new way of organizing information as others have done, they instead took advantage of a data structure with which many are already intimately familiar, resulting in a creative, user-friendly solution especially well-suited for AR.Technology Overview:The inventors designed a user interface in which information is visualized as nested bubbles superimposed on what is seen on a virtual screen. For example, when a user views his/her surroundings through a smartphone camera, an app utilizing the interface would display bubbles on screen as part of the environment. The bubbles are organized into a hierarchal structure (called the ‚Äúfoam‚Äù) similar to folders in a typical file system. Users can navigate the foam by interacting with their screen and/or moving in real space. The information associated with each bubble is displayed on screen in response to the user‚Äôs actions.Advantages:Unlike other AR interfaces, takes advantage of an intuitive structure already familiar to most usersDesigned to have widespread application in education, commerce, and beyond, instead of being limited to one AR application as other user interfaces are (e.g. an app)Offers additional features to enhance user engagement, including shadows for realism, popups, sound effects, and cues for the user to look aroundBubble User Interface. An example of how a nested hierarchy of information nodes may be organized abstractly as bubbles (drawn as circles) is depicted in (a). Note the hierarchy need not be as regular as pictured; bubbles can have different numbers of sub-bubbles. An example of how the interface may appear to users is shown in (b).Stage of Development:ConceptProof of ConceptBench PrototypeIntellectual Property:US PatentPendingResearch MaterialsReference Media:Lane, SH et al,SIGGRAPH ‚Äô20: ACM SIGGRAPH Appy Hour, 2020Desired Partnerships:LicenseCo-developmentCase ID:21-9466-tpNCSWeb Published:11/2/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42216","**Summary:** An augmented reality user interface presents information through a series of nested bubbles displayed in 3D virtual space. This design borrows from the familiar directory tree organization found in desktop environments to create a user-friendly system that effectively translates information from 2D to 3D. Users can interact with this interface while viewing their real-world surroundings through a smartphone camera, allowing for an integrated experience where digital information seamlessly overlays their environment.

**Applications:** The technology is applicable in various fields such as gaming, educational apps, social media enhancements, museum exhibits, and anywhere augmented reality can enrich user interaction with real-world settings.

**Problem Solved:** The interface addresses the challenge of organizing information in augmented reality, making it easier for users to access and comprehend complex data presented in a 3D format, thus enhancing the overall user experience in a rapidly growing market.","An augmented reality user interface presents information in a series of nested bubbles within a 3D virtual space. The AR market is rapidly growing, with a worldwide size of 18 billion USD, and is utilized across various applications, including games, apps, and museum enhancements."
"University of Pennsylvania","Improving Diagnosis and Treatment of Sarcoidosis","23-10329","","https://upenn.technologypublisher.com/technology/55694","Using a blood or tissue biomarker to improve diagnosis and identification of a new targeted treatment.Problem:Sarcoidosis is an inflammatory disease that can affect any organ, predominantly the lung, skin, and the lymphatic system. Symptoms include difficulty breathing, extreme fatigue, skin inflammation, and joint pain. Sarcoidosis compromises patients‚Äô quality of life and increases patient mortality. Even though the disease was identified in the late 1800s, confirmatory diagnostic tests and targeted treatments are still lacking.Solution:Identified novel biomarkers and targets for sarcoidosis via single-cell RNA sequencing and flow cytometry.Technology:Using single-cell RNA sequencing of affected and unaffected patient skin, the inventors identified that type 1 innate lymphoid cells (ILCs) were enriched in sarcoid skin. The affected skin also showed a significant increase in CXCR4 and CXCL12, which are a potent chemokine receptor and ligand, respectively, that function as homing agents for immune cells. Inhibition of CXCR4 with the FDA-approved CXCR4 inhibitor, Plerixafor, reduced granuloma formation in a mouse model of sarcoidosis.Advantages:Novel method to diagnose and to monitor sarcoidosis disease activity in blood or affected tissue.Targeted therapy of sarcoidosis with reduced side effects.Figure 1. Flow cytometry analysis of control (Ctrl) and sarcoid (Sar) blood for different ILC populations (NK cells not shown). *p<0.05. Figure 2. CXCR4 inhibitor (plerixafor) reduces lung granuloma formation (symptom of sarcoidosis) in relevant mouse model (n=3). *p<0.05.Stage of Development:Proof of concept in human skin biopsy and mouse modelIntellectual Property:Provisional FiledReference Media:Sati, S et al.;J Clin Invest, 2024 Sep 3; 134(17): e178711.Desired Partnerships:LicenseCo-developmentCase ID:23-10329-TpNCSWeb Published:11/27/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55694","**Summary:** The technology employs blood or tissue biomarkers to enhance the diagnosis and treatment of sarcoidosis, an inflammatory disease primarily affecting the lungs, skin, and lymphatic system. Through single-cell RNA sequencing and flow cytometry, researchers have identified that type 1 innate lymphoid cells are enriched in sarcoid-affected skin. This analysis revealed elevated levels of the chemokine receptor CXCR4 and its ligand CXCL12 in affected tissues, which play crucial roles in immune cell targeting. The use of Plerixafor, an FDA-approved inhibitor of CXCR4, demonstrated a reduction in granuloma formation in a mouse model, highlighting a new avenue for both diagnosis and therapy.

**Applications:** This technology can be applied in clinical settings to diagnose sarcoidosis more accurately using blood or tissue samples. It also enables the development of a targeted therapy that specifically inhibits CXCR4, potentially offering a new treatment option with fewer side effects for patients suffering from this disease.

**Problem Solved:** The technology addresses the long-standing challenge of diagnosing and treating sarcoidosis, which has insufficient confirmatory tests and targeted treatment options despite being recognized since the 1800s. By identifying specific biomarkers and a potential therapeutic target, the approach aims to improve patient outcomes and quality of life while reducing mortality associated with the disease.","Sarcoidosis is an inflammatory disease primarily affecting the lungs, skin, and lymphatic system, with symptoms such as difficulty breathing, extreme fatigue, skin inflammation, and joint pain. The condition impacts patients‚Äô quality of life and increases mortality, yet confirmatory diagnostic tests and targeted treatments are lacking."
"University of Pennsylvania","Eco-Friendly, Low-Maintenance Living Brick System for Sustainable Architecture","","","https://upenn.technologypublisher.com/technology/55695","A portable pot-like brick cassette encasing mycorrhizal fungi and alfalfa to promote plant growth and carbon sequestration.Problem:The building sector contributes approximately 40% of global carbon emissions related to energy use. Green walls have gained popularity as a carbon offsetting strategy due to their ability to sequester carbon from the atmosphere via plant photosynthesis. However, existing green building envelope methods often involve resource-intensive construction, relying on unsustainable materials, high energy expenditure, and costly maintenance.Solution:SimbioBrick is a versatile living system that harnesses plant-fungi symbiosis to support bio-receptive architecture or create outdoor flooring that paves walkways while offsetting building carbon emissions. It features a biologically driven modular design, produces indoor and outdoor oxygen, continuously sequesters carbon, retains water for self-irrigation, and aids in soil bioremediation. This scalable solution offers enormous potential for sustainable environmental remediation.Technology:SimbioBrick is a portable, multifunctional system that supports nutrient cycling by Arbuscular Mycorrhizal Fungi (AMF) while preserving its symbiotic relationship with alfalfa, the host plant. It contains fungal spores, seeds, water, and nutrient-storing hydrogels emulating wet soils.Constructed from 3D-printed clay bricks, the outer structure provides support and exposure to sunlight for photosynthesis, while the inner structure offers depth for fungal colonization, porosity, and sufficient drainage. The porous brick design enhances water retention and facilitates the expansion of AMF networks. The biologically driven geometry creates a habitable space for plant-fungi symbiosis while controlling moisture and sunlight exposure. The growing medium includes mycorrhizal inoculant and a nutrient solution-hydrated super absorbent polymer, enhanced with perlite for improved air permeability and root rot prevention.Advantages:The system requires minimal maintenance, including self-irrigation, and avoids the use of non-recyclable materialsThe system captures greater amounts of carbon through accelerated plant photosynthesis when deployed in urban settingsThe brick‚Äôs interlocking geometry enables self-support without additional materialsBiological behavior-driven SimbioBrick living brick system that captures carbon by enhancing plant-fungi symbiotic association. A 3D-printed clay cassette includes a sufficient watering system and porous surfaces for drainage and ventilation, allowing plant roots and mycorrhizal fungi to expand throughout the structure. This figure was obtained from Figure 3 in the paper titled ‚ÄúSimbioBrick: Carbon Sequestering Living Bricks by Fungi-Plant Symbiosis‚Äù in the Reference Media link below.Stage of Development:ConceptProof of ConceptBench PrototypeIntellectual Property:In PreparationReference Media:Bae, J.Y. et al.,Scalable Disruptors, 2024 Aug 30; DMS 2024, Springer: 372UPenn Environmental Innovations Initiative,2024 Apr 30,""Fungi on the Front Lines Against Environmental Injustice""Desired Partnerships:LicenseCo-developmentCase ID:24-10853-TpNCSWeb Published:11/27/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55695","**Summary:** The technology features a modular brick system that integrates mycorrhizal fungi and alfalfa to promote plant growth and carbon capture, addressing the high carbon emissions of the building sector. This system is designed to be low-maintenance and eco-friendly, using 3D-printed clay bricks that facilitate photosynthesis and enable nutrient cycling through plant-fungi symbiosis. It provides benefits such as continuous carbon sequestration, oxygen production, self-irrigation through water retention, and contributes to soil bioremediation, presenting strong potential for sustainable architecture and landscaping.

**Applications:** The system can be used in bio-receptive architecture, outdoor flooring for walkways, and urban greening projects. It is suitable for both residential and commercial buildings that aim to offset their carbon footprints and enhance environmental sustainability.

**Problem Solved:** The technology addresses the environmental impact of the building sector, which accounts for about 40% of global carbon emissions due to energy use. It mitigates the issues associated with conventional green building practices that often rely on unsustainable materials and high energy consumption, providing a more efficient and sustainable alternative.","A portable brick cassette containing mycorrhizal fungi and alfalfa is designed to enhance plant growth and carbon sequestration. This system addresses the building sector's substantial carbon emissions by utilizing green walls for carbon offsetting while reducing the resource intensity of traditional construction methods."
"University of Pennsylvania","Bilayer Solid-State Nanopores for the Tracking, Filtering and Guiding of DNA","","","https://upenn.technologypublisher.com/technology/55678","A bilayered solid-state nanopore material that senses and guides DNA and other biomolecules into homogeneous configurations.Problem:Current methods of DNA sensing and sequencing typically involve short read lengths, chemical labeling, labor-intensive sample preparation, and lack of portability. To minimize these issues during DNA sequencing, protein-based nanopores have been developed and commercialized for DNA sensing. However, these protein-based nanopores are not stable in the long term, and sequence collection cannot occur at high bandwidths. Additionally, the mechanism of DNA guidance, which varies depending on the protein identity and nanopore construction, limits DNA throughput.Solution:A solid-state bilayered nanoporous material allows for controlled configuration and sensing of DNA and other biomolecules. This approach does not require DNA labeling or pretreatment with enzymes, reducing sample preparation. This material is reusable, portable, stable for longer periods of time, and throughput speed can be modulated by varying the electrical potential applied to the system.Technology:A nanoporous material consisting of MoS2 and SiN guiding reusable (GURU) bilayers. As DNA passes through pores, the electrical field applied to the bilayer geometry helps pre-sort and detect DNA via electrical signals. The electric fields in the layered geometry have varying degrees of coupling, depending on the separation of the given bilayers. Electrical coupling influences the electrical conductance measured along with the number of nanopores, layer sizes, and the charges present on the given biomolecules and the material. This customizability provides electromechanical control over DNA, enabled by increased nanofabrication precision and the ability to obtain microsecond resolution detection of the biomolecules.Advantages:DNA is tracked across a 20-nanometer distance with approximately one microsecond time resolution, representing at least one order of magnitude improvement compared to tracking markers recently shown for labeled DNA, allowing for extremely high-resolution DNA detectionCustomizability of the material and geometry allows for variable electrical coupling, so DNA can be guided into a variety of shapes depending on the desired configuration using this technology, rather than the single configurational outcome typical of other nanoporous protein-based materialsUnlike other nanoporous or traditional DNA sensing and sorting platforms, this technology is portable, stable long-term, and reusable after acid washing(A) Transmission electron microscope (TEM) images of SiN trenches with varying numbers of pores. (B) Aberration-corrected scanning electron microscope (AC-STEM) images of a two-dimensional MoS2 nanopore. (C) Coupled electric field profiles with bilayer distance L = 20 nm.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:U.S. Utility Patent Application FiledReference Media:Chou, Y.-C. et al.,Nat Nanotechnology, 2024 Aug 14; Vol.19(11): 1686Niedzwiecki, D.J. et al.,ACS Sensors, 2021 Jul 23; Vol 6(7): 2534Chou, Y.-C. et al.,J Chem Physics, 2021 Mar 14; Vol 154(10): 105102Puster, M. et al.,Nano Micro Small, 2015 Dec 16; Vol 11(47): 6309Venta, K. et al.,ACS Nano, 2013 April 26; Vol 7(5): 4629Desired Partnerships:LicenseCo-developmentCase ID:22-10138-TpNCSWeb Published:11/25/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55678","**Summary:** A bilayered solid-state nanopore material has been developed to sense and guide DNA and other biomolecules into homogeneous configurations. This material addresses significant issues associated with current methods of DNA sensing and sequencing, which often rely on short read lengths and require extensive sample preparation and chemical labeling. The solid-state structure provides advantages in stability and portability while allowing for the modulation of throughput speed through varying electrical potentials.

**Applications:** The technology can be applied in DNA sequencing and sensing by facilitating the accurate tracking and filtering of DNA and other biomolecules without the need for chemical labeling or extensive pretreatment. Its reusable and stable properties make it suitable for use in research laboratories and potentially in portable diagnostic devices.

**Problem Solved:** Traditional DNA sensing methods encounter challenges such as low throughput, instability of protein-based nanopores, and labor-intensive sample preparations. The bilayered solid-state nanopore technology improves DNA guidance and detection by providing a stable, high-throughput solution that minimizes the need for sample preparation and enhances the overall efficiency of DNA sequencing processes.","A bilayered solid-state nanopore material has been developed to sense and guide DNA and other biomolecules into homogeneous configurations. This approach aims to address limitations of current DNA sensing and sequencing methods, such as short read lengths and labor-intensive sample preparation."
"University of Pennsylvania","Origami-Inspired And Remotely Adjustable Pediatric Heart Implant","","","https://upenn.technologypublisher.com/technology/55635","Pediatric pulmonary artery band (PAB) using origami-inspired fabrication that is remotely adjustable after implantation.Problem:Congenital heart defects affect 1% of births in the United States and can lead to irregular blood flow through the main pulmonary artery (MPA). A pulmonary artery band (PAB) is an implant that can be placed on the MPA to restrict blood flow. However, most PAB implants fail to accommodate growth in pediatric patients, which results in frequent reoperation and financial burden. Although remotely controlled PABs have been developed, they are mechanically complex, expensive, and prone to failure.Solution:Origami structures were incorporated into the PAB design for easy fabrication, rapid assembly, and multi-state stability. This PAB is minimally invasive and can be periodically adjusted using external magnetic fields to tune blood flow through the MPA.Technology:The geometric parameters of a square origami pattern were optimized to enable the origami-inspired PAB (OPAB) device to reconfigure to multiple states. A prototype was laser cut from a sheet of polyethylene terephthalate (PET), manually folded, and assembled using tape. Panels attached to the fold panels enable the OPAB to expand or collapse using external magnetic fields. Mechanical testing indicated that the device‚Äôs stability and shape can be predicted when adjusting the device to accommodate for patient growth. During simulated in- vivo testing, the OPAB prototype successfully restricted flow rates in a mock MPA tube.Advantages:Minimally invasive, biocompatible, and compatible with current treatmentsScalable design and easily fabricated with few constituent partsExternally adjustable using magnetic control, reducing the need for surgical reoperations(A) Illustration of the origami-inspired PAB (OPAB; in gray) constricting blood flow through the main pulmonary artery (MPA; in blue) using magnetic panels. (B) The OPAB prototype with tubing represents the MPA. (C) In a clinical setting, a surgeon would 1) place the OPAB around the patient‚Äôs MPA, 2) fully compress the OPAB to ensure range of motion, then 3) tune the inner diameter using magnetic fields until blood flow is restricted.Stage of Development:Bench PrototypeIntellectual Property:US Provisional Patent Application FiledReference Media:Unger, G. and Sung, C.,""Re-programmable Matter by Folding: Magnetically Controlled Origami that Self-Folds, Self-Unfolds, and Self-Reconfigures On-Demand.""8th International Meeting on Origami in Science, Mathematics, and Education; 2024 Jul 24U.S. National Science Foundation,""Folding the Future: The rise of origami-inspired robots""; 2024 Oct 10Penn Engineering: Medium,""Penn Engineering‚Äôs Cynthia Sung is developing ‚ÄòInteractive Robogami‚Äô; 2017 Sep 06Desired Partnerships:LicenseCo-developmentCase ID:23-10185-01-TpNCSWeb Published:11/18/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55635","**Summary:** The described technology is a pediatric pulmonary artery band (PAB) designed using origami-inspired fabrication techniques, allowing it to be remotely adjustable after implantation. It addresses the challenge of congenital heart defects in children, which can cause irregular blood flow through the main pulmonary artery. Traditional PABs often do not account for growth in pediatric patients, requiring frequent surgeries and leading to significant financial burdens. The new design includes origami structures that facilitate easy fabrication, rapid assembly, and stability in multiple configurations. The device can be adjusted minimally invasively using external magnetic fields, ensuring it can accommodate the growing needs of pediatric patients. 

**Applications:** This technology can be applied in pediatric cardiology, specifically for the treatment of congenital heart defects requiring pulmonary artery banding. It may also have broader implications for other medical devices needing adjustable configurations post-implantation.

**Problem Solved:** The innovation addresses the limitations of traditional PABs that do not adjust for patient growth, thus reducing the need for repeated surgeries and associated healthcare costs. By allowing for remote adjustments, it improves patient outcomes and overall efficiency in managing congenital heart defects in children.","A pediatric pulmonary artery band (PAB) designed with origami-inspired fabrication is remotely adjustable after implantation to accommodate growth in children with congenital heart defects. This innovative approach addresses the limitations of traditional PAB implants that often require frequent reoperations due to patients' growth."
"University of Pennsylvania","NetSpec: An Automatic And Fast Network Specification Synthesis Toolkit","","","https://upenn.technologypublisher.com/technology/55613","A specification-by-example toolkit that generates formal network specifications using only input-output examples.Problem:Many modern computer systems run on networks like cloud clusters or distributed systems. However, the network protocols that support the operation and security of these systems are notoriously difficult to debug. Formal network specifications provide a solution to a wide variety of network related tasks such as verification, analysis, and debugging. However, very few network engineers possess expertise in both network operation and writing formal specifications, creating a significant barrier to the adaptation of said specifications.Solution:NetSpec is a toolkit that synthesizes highly expressive formal network specifications using input-output example pairs. It is best-first search algorithm is scalable to large networks and can automatically query the user for additional input-output examples in the case of ambiguous specifications. This implementation makes synthesis of formal specifications available to users without prior expertise.Technology:NetSpec generates formal network specifications such as declarative logic programs that can be verified with tools like Vericon and Flowlog. It has been tested on a set of twenty-three different network protocol types and synthesizes solutions at similar or better performance levels as existing solutions while also requiring fewer computer resources. The algorithm optimizes a score based on the fraction and number of tuples in the synthesized network. In each round of optimization, NetSpec either introduces new rules, introduces new literals to existing rules, or aggregates operators. The search algorithm continues until no new programs provide an improvement over the current solution.Advantages:Capable of synthesizing specifications for twenty-three benchmarks while existing solutions only work on less than halfRuns faster or at similar speed for individual benchmarks on a single thread while existing solutions are multi-threadedOnly requires input-output examples and no network specification expertise from the userQueries the user for additional inputs in the case of ambiguous specificationsArchitecture of NetSpec. Input-output examples are provided from the user or a legacy application. NetSpec then generates candidate specifications. If the specifications are ambiguous, it will prompt the user for additional examples before finalizing the specification.Stage of Development:Bench PrototypeIntellectual Property:US Utility Patent Application FiledReference Media:Chen, H. et al.,IEEE/ACM Transactions on Networking, 2023 June; Vol 31(3): 994Desired Partnerships:LicenseCase ID:23-10297-TpNCSWeb Published:11/14/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55613","**Summary:** NetSpec is a specification-by-example toolkit designed to automatically generate formal network specifications using only input-output examples. It addresses the difficulty of debugging network protocols in modern computer systems, where few engineers possess the necessary expertise to write formal specifications. The toolkit employs a best-first search algorithm that is scalable and can query users for additional examples when faced with ambiguity. It generates highly expressive formal specifications, including declarative logic programs that can be verified with established tools.

**Applications:** The generated formal network specifications can be utilized for verification, analysis, and debugging of network protocols, benefiting cloud clusters and distributed systems.

**Problem Solved:** NetSpec effectively lowers the barrier for network engineers to adopt formal specifications by enabling them to create these specifications without prior expertise, thereby improving the reliability and security of network protocols while simplifying the debugging process.","The toolkit generates formal network specifications based solely on input-output examples, addressing the difficulty of debugging network protocols in modern computer systems. It provides solutions for verification, analysis, and debugging of network-related tasks."
"University of Pennsylvania","Adhesive Microparticle Formulation For Localized And Sustained Drug Delivery","","","https://upenn.technologypublisher.com/technology/55609","A hairy, water-in-oil-in-water microemulsion for prolonged delivery of one or more active ingredients while adhering to target tissues.Problem:Microparticles are promising drug delivery platforms due to their biocompatibility and stability. However, existing particle-based drug delivery systems are unable to fulfill the needs for prolonged delivery of drugs to a given area, as they will circulate freely in the body instead of residing in their desired locations for a certain amount of time.Solution:The inventors have developed a water-in-oil-in-water microcapsule with sticky or hairy projections that lend strong adhesive properties and can be loaded with drugs. These microcapsules can remain in their desired location even under frequent clearing and achieve prolonged drug release.Technology:Adhesive microparticles are produced through evaporation-induced self-assembly of amphiphilic copolymers. Drugs are loaded in advance of a dual-emulsion-based process, whereby microfluidic systems are used to combine aqueous and oil phases at the appropriate ratios. Finally, emulsions are processed further to produce the adhesive and hairy dendritic projections of the microcapsules.Advantages:Unique hairy structure endows the dendritic particles with stronger adhesion properties compared to traditional spherical particlesSustained drug release up to 20 hoursEncapsulate both water-soluble and -insoluble agentsBiocompatibleMultiple schemes for microparticle formulationSuccessful adhesion in wet tissue environments(A) Extracted natural teeth are used for proof of concept. (B) Adhesion properties of microparticles are structure-dependent. Compared to spherical particles (upper right), hairy particles show strong adhesion on teeth after three washes (bottom right).Stage of Development:ConceptProof of ConceptIntellectual Property:PCT Patent Application FiledWO2023235794A2Reference Media:Oh, M.J. et al.,Journ of Materials Chem B, 2024 May 22; 12(20): 4935Desired Partnerships:LicenseCo-developmentCase ID:22-10092-TpNCSWeb Published:11/13/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55609","**Summary:** A novel formulation has been developed that utilizes a water-in-oil-in-water microemulsion to create adhesive microparticles designed for the localized and sustained delivery of drugs. These microparticles feature hairy projections that enhance their adhesive capabilities, allowing them to remain at the target site instead of circulating freely in the body. They are produced through a dual-emulsion process using microfluidic systems and the evaporation-induced self-assembly of amphiphilic copolymers, enabling the encapsulation of both water-soluble and insoluble drugs.

**Applications:** This technology is applicable in various fields of medicine where localized and sustained drug delivery is crucial, such as in cancer therapy, pain management, and chronic disease treatment. The ability to adhere to target tissues can improve therapeutic outcomes and reduce systemic side effects.

**Problem Solved:** Traditional particle-based drug delivery systems face challenges in maintaining prolonged contact at targeted locations, often leading to the rapid clearance of the drug from the desired area. The adhesive microparticle formulation overcomes this issue by ensuring that drugs can be delivered effectively and sustained within a localized area for an extended period, addressing the need for improved delivery methods in various therapeutic applications.","A hairy, water-in-oil-in-water microemulsion has been developed to facilitate prolonged delivery of active ingredients while adhering to target tissues. Current microparticle systems struggle with maintaining localized drug delivery, as they tend to circulate freely in the body instead of remaining in specific areas for extended periods."
"University of Pennsylvania","Active Nematic Colloids For Microrobotics And Materials Assembly","","","https://upenn.technologypublisher.com/technology/55597","A material mixture (active colloids immersed in nematic liquid crystals) that act as microrobots for directed assembly and micromanipulation of passive colloidal particles.Problem:Colloids interact with areas of distortion, such as with walls or with defects in the environment such as sharp edges and can become trapped along disclination lines in passive systems. These strong interactions mean that once colloids are assembled, they can only be dis-assembled by going into the isotropic state to eliminate the elastic interactions, and thus cannot be deliberately positioned at a particular location in the domain. Thus, it is difficult for passive colloidal particles to undergo directed assembly or micromanipulation.Solution:Development of active colloids as microrobots for dynamic manipulation of passive colloids. The microrobots: (I) Can have shapes designed to promote lock and key interactions. (II) Can also have anchoring conditions designed to form disclination lines attached to the active colloid.Technology:For lock and key microrobotics, the authors designed a multi-armed magnetic microrobot with companion defect to manipulate passive nematic colloid. This microrobot has a companion dipolar defect on one of its arms aligned with the far-field director field and can interact with passive colloids in nematic liquid crystals. The authors deliberately use disclination lines as a tool for robotic assembly and motion and attach them to mobile colloids in nematic liquid crystals. When the colloids move under an external field, the disclinations elongate with complex dynamics, thus driving motion in active colloids and subsequent interactions with passive colloids.Advantages:Multi-armed microrobot can micromanipulate passive colloidsMicrorobot can interact with colloids in Saturn ring or dipolar defect configurationCan assemble in multiple configurations (i.e. passive colloids with dipolar defects assemble in 3 different configurations)Microscopic images of multi‚Äêarmed microrobot. Bright field (left) and cross polarizing (right). Scale bar is 20ùúáùëö.Stage of Development:ConceptProof of ConceptIntellectual Property:Utility Patent FiledUS20220389316A1Reference Media:Yao, T. et al.,Advanced Functional Materials, 2022 August 10; Vol. 32(44): 2205546Luo, Y. et al.,Nat Commun., 2018 Sep 21; 9(1): 3841Pappas, Melissa,Penn Engineering Today; 2022 November 15 SEAS Blog:""Tiny Swimming Robots.....""Desired Partnerships:LicenseCo-developmentCase ID:21-9742-TpNCSWeb Published:11/12/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55597","**Summary:** A material mixture comprising active colloids immersed in nematic liquid crystals has been developed to function as microrobots, enabling directed assembly and micromanipulation of passive colloidal particles. These active colloids can be designed with specific shapes that facilitate lock and key interactions and can create anchoring conditions to generate disclination lines, enhancing their ability to manipulate passive colloids. A multi-armed magnetic microrobot, equipped with a dipolar defect, allows for controlled interaction with passive colloids within the liquid crystal environment, utilizing disclination lines for assembly and movement.

**Applications:** The technology can be employed in microrobotics for applications such as targeted assembly of materials at the microscale, dynamic manipulation of colloidal systems, and potentially in fields like drug delivery, electronics assembly, or soft robotics where precise control over small particles is required.

**Problem Solved:** The technology addresses the challenge of passive colloids becoming trapped in regions of distortion, such as walls or environmental defects, which complicates their directed assembly and micromanipulation. By utilizing active colloids as microrobots, the solution allows for the targeted positioning and reconfiguration of passive colloidal particles in a controlled manner, overcoming limitations posed by elastic interactions in previously assembled systems.","A mixture of active colloids in nematic liquid crystals serves as microrobots for the directed assembly and micromanipulation of passive colloidal particles. Colloids interact strongly with distortions such as walls or defects, resulting in potential entrapment along disclination lines, which complicates their disassembly."
"University of Pennsylvania","High-Speed Computational Architecture For Reduced Latency In Big Data Processing","","","https://upenn.technologypublisher.com/technology/54113","Novel computational architecture designs to reduce the latency time to process large volumes of data utilizing the reconfiguration of memory and storage; streamlining read/write functions to include computational logic within the register file; and programmable schedule and memory utilization within a configurable load/store unit.Problem:The execution of big data applications used by search engines, natural language processing or classification algorithms is energy intensive and requires high throughput sorting and processing of data. Part of the inefficiency arises from:fixed data access processing between the local storage and memory and cloud storage.a conventional register file retrieves (‚Äúreads‚Äù) data for a processing operation by another component, then stores (‚Äúwrites‚Äù) the processed data back into the register file.current load/store units allow no control over or optimized organization of scheduling or which memory registers are utilized or not utilized. Memory organization can become a limitation when processing large volumes of data.Solution:Reconfigurable architecture of memory and storage in a computer to offload functions away from the central and intelligence processing units. This allows direct access to both local and remote memory, with high bandwidth and low latency.A computational register file that reduces the latency time by combining the ‚Äúwrite‚Äù and operation steps described above. Therefore, the computational register file can operate on the content during read/write, instead of performing them separately.A configurable load-store unit to reduce latency of data access by applying different scheduling and utilization policies for different load/store instructions. The programmer has direct control over the memory scheduling and utilization.Technology:To reconfigure memory and storage, logically disaggregated interconnections (Peripheral Component Interconnect Express (PCIe) switches) allow the field-programmable gate array to access both local and remote memory. The memory network serves local and remote requests using a point-to-point connection instead of the switch-based network to reduce latency.To perform operations within a computational register file, the operand name is expanded from RX to RX.Y, where X is the name of the register and Y is the port ID of the register. The name of register X selects which register in the register file to be used and port ID Y selects which computational logic to be used. Using this architecture, an operation only requires one load instruction to be performed.Each new load/store unit has its ID and respective attributes stored in a configuration table. The programmer uses the table to improve the scheduling and utilization to define the size of a single memory request, the coalescing threshold, the coalescing window, and its scheduling priority.Advantages:Reconfiguration of Memory and Storage:Fifteen microsecond latency for data access, one hundred times lower than CPU-based systems160 GB/s bandwidth, eight times higher than conventional CPU serversEnables adaptation to accommodate different index algorithm schemes and different index sizesComputational Register File:Given a photo document dataset, processes indexes with four times fewer nodes at sixty-eight times lower latency compared to CPU only; andHandles multiple types of data, including text, images, and videos.Reconfigurable and Programmable Load/Store Unit:Improved latency of big data applications by four timesBetter tradeoff between memory access latency and bandwidth by allowing control of memory schedulingFig. 1: The system architecture connects the Intelligence Processing Unit (IPU) to a storage and memory pool through a set of interconnections. Fig. 2: Comparison of the function of a conventional register file (RF) write process and the computational register file (CRF) in situ logic operation. In this example, a new data element arrives (‚Äú3‚Äù), is written into the computational register file, is compared to each other element, and then written to the vector. Fig. 3: The load/store unit includes an operand indicating the ID of attributes for the load/store request. The programmer sends a request to the load/store unit along with this attribute ID. The unit looks up the corresponding attribute stores in a configuration table according to the ID.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:US Patent Application FiledUS 2023/0116967 A1Reference Media:N/ADesired Partnerships:LicenseCo-developmentCase ID:21-9739-tpNCSWeb Published:5/3/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54113","**Summary:** Novel computational architecture designs focus on enhancing the efficiency of big data processing by reconfiguring memory and storage systems. This approach streamlines read/write functions by incorporating computational logic directly within the register file and enabling programmable scheduling and memory utilization through a configurable load/store unit. By allowing direct access to both local and remote memory with high bandwidth and low latency, the architecture aims to reduce the energy intensity and improve throughput for big data applications.

**Applications:** This technology is applicable in various fields that rely on big data processing, including search engines, natural language processing, and classification algorithms. It serves to optimize the performance and efficiency of systems handling large volumes of data.

**Problem Solved:** The technology addresses inefficiencies in big data applications that arise from fixed data access processing between local and cloud storage, as well as the limitations of conventional register files and load/store units. By reconfiguring memory architecture and integrating computational capabilities, it reduces latency and enhances the overall data processing speed, thus improving performance in energy-intensive operations.","The proposed computational architecture aims to reduce latency in processing large volumes of data by reconfiguring memory and storage, integrating computational logic within the register file, and optimizing memory utilization in a configurable load/store unit. This approach addresses the energy-intensive nature of big data applications, such as those used in search engines and natural language processing."
"University of Pennsylvania","New Paradigm of Using Hypoxia-Promoting Therapeutics for Enhancing Bone Fracture Repair","","","https://upenn.technologypublisher.com/technology/55495","Modulate oxygen-releasing erythroid progenitor cells (EPCs) to promote low oxygen conditions (hypoxia) and enhance bone fracture repair.Problem:Bone fracture repair (or healing) is a complex regenerative process aimed at restoring damaged bone to its pre-injury state. About 5% to 10% of all fractures experience delayed or failed healing during this process. Previous studies have suggested that the initial phase of the repair process is characterized by a pronounced oxygen insufficiency (low oxygen condition, or hypoxia), attributed to the disruption of blood vessels. However, due to methodological limitations, the oxygenation activities in the fracture gap remain poorly understood.Solution:The inventors employed different methods to study tissue oxygenation in the fracture gap. They observed high oxygen concentrations that may impede repair in the local area days after the fracture. To address this, the inventors showed that targeting erythroid progenitor cells (EPCs) and local hemoglobin concentrations promotes hypoxic conditions, thereby enhancing fracture repair.Technology:The inventors designed a novel device to guide the recruitment, enrichment, and differentiation of EPCs, with the additional capability of modulating the function of these cells to influence the oxygen environment in the surrounding tissue. The device consists of a scaffold that incorporates or is coated with two bioactive compositions, providing a versatile platform for potential therapeutic applications in the field of regenerative medicine.Advantages:Modulation of EPCs significantly reduced tissue oxygen, promoted hypoxia, and enhanced fracture repair in the fracture gap (demonstrated by significantly increased osteoprogenitor activation, angiogenesis, and bone formation).A potential avenue for exploring new therapeutic approaches for fracture healing.Elucidated a previously understudied phenomenon of oxygen levels underlying fracture healing.Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Lang, A et al.Nat Comm Biol, 2024 Mar 13; 7(1): 315.Lang, A et al.Bone 2022 Jan; 154: 116247.Lang, A et al.Acta Biomater 2019 Mar 1; 86: 171.McDermottAM et al.Sci Transl Med, 2019 Jun 5; 11(495): eaav7756.Herberg, S et al.Sci Adv 2019 Aug 28; 5(8): eaax2476.Desired Partnerships:LicenseCo-developmentCase ID:24-10587-TpNCSWeb Published:11/4/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55495","**Summary:** The technology involves the modulation of oxygen-releasing erythroid progenitor cells (EPCs) to create hypoxic conditions that enhance the repair of bone fractures. The initial phase of fracture healing is marked by oxygen insufficiency due to disrupted blood vessels, yet high oxygen concentrations can impede repair days after the injury. By targeting EPCs and local hemoglobin levels, the technology aims to promote a hypoxic environment conducive to fracture healing. Inventors have developed a novel device designed to recruit, enrich, and differentiate EPCs while also modulating their function to affect the surrounding tissue's oxygen environment.

**Applications:** This approach can be applied in clinical settings for improving bone fracture repair, particularly for cases where healing is delayed or has failed. The technology holds potential for use in various orthopedic procedures as well as in treating a broader range of injuries related to bone integrity.

**Problem Solved:** The technology addresses the issue of delayed or failed healing in bone fractures, which affects 5% to 10% of all fractures. By improving the understanding and manipulation of the oxygen environment at the fracture site, it seeks to enhance the regenerative processes necessary for effective bone repair.","Hypoxia-promoting therapeutics aim to modulate oxygen-releasing erythroid progenitor cells (EPCs) to create low oxygen conditions that enhance bone fracture repair. Approximately 5% to 10% of all fractures experience delayed or failed healing, often linked to initial oxygen insufficiency during the repair process."
"University of Pennsylvania","The First Curative Treatment of Phenylketonuria Using Genetic Engineering Approaches","","","https://upenn.technologypublisher.com/technology/55469","The base editing of phenylalanine hydroxylase enzyme in the liver to restore phenylalanine metabolism and prevent neurotoxic effects.Problem:Phenylketonuria (PKU) is a severe disorder affecting approximately 1 in 10,000 U.S. newborns. PKU is marked by a genetic mutation in the phenylalanine hydroxylase enzyme (PAH), resulting in phenylalanine (Phe) buildup. Early detection and management through strict dietary Phe restriction can prevent severe intellectual disability. Additional treatments include large neutral amino acids and glycomacropeptide supplementation, though with limited success. Finally, there are the FDA-approved adjuvant treatment for PKU, sapropterin dihydrochloride, and the enzyme substitution therapy pegvaliase, which also have limited efficacy. Owing to the restricted therapeutic modalities for PKU, novel approaches are required to fill this unmet need.Solution:This invention offers a genetic engineering approach to restore PAH function through the base editing of mutant PAH that enables sustained production of functional PAH capable of restoring Phe metabolism.Technology:This invention corrects one of the most common PAH variants in PKU (P281L) through corrective adenine base editing (ABE) of mutated PAH. Although the primary toxicity is in the brain, the PAH gene is largely expressed in the liver from hepatocytes presenting them as the primary therapeutic target. With the delivery of ABE8.8 mRNA and the P281L guide RNAs in vivo using lipid nanoparticles (LNPs) in humanized PKU mice, a complete and durable normalization of blood Phe levels occurs within 48 h of treatment, resulting from corrective PAH editing in the liver.Advantages:First-in-class curative strategy for PKU.First genetic engineering approach in PAH.LNPs can be used to deliver base editors in vivo, which naturally hone to the liver in vivo.Alternative strategies include AAV delivery.Improved on-target editing in humanized PKU mice with PAH1 hybrid guide RNAs. Blood phenylalanine levels in mice reduce over time, below the recommended threshold (<360 Œºmol/L) for PKU patients after treatment with a 2.5 mg/kg dose of LNP base editors in both the normal and optimized hybrid (hyb) guides iterations, which have higher levels of editing specificityStage of Development:Preclinical DiscoveryIntellectual Property:US Patent filedReference Media:Whittaker, M.N., et al.bioRxviv [Preprint], 2024 June 16; 2024.04.22.590531.Brooks D.L., et al.HGG Adv., 2024 Jan 11; 5(1): 100253.Brooks, D.L., et al.Nat Commun, 2023 June 10; 14(3451).Toal, MPenn Medicine News2023 Nov 2CHOPPress ReleaseDesired Partnerships:LicenseCo-developmentCase ID:22-10020-TpNCSWeb Published:10/28/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55469","**Summary:** The technology involves using base editing to correct a common genetic mutation in the phenylalanine hydroxylase enzyme, which is responsible for metabolizing phenylalanine. This approach aims to restore normal phenylalanine metabolism in the liver, targeting the primary site of the disorder's effects and preventing neurotoxic outcomes associated with phenylketonuria (PKU). The solution delivers adenine base editing (ABE) mRNA and specific guide RNAs into the liver using lipid nanoparticles, facilitating the correction of the P281L variant of the PAH gene.

**Applications:** The primary application of this technology is in treating individuals diagnosed with phenylketonuria (PKU), particularly those with the P281L mutation in the PAH gene. This genetic engineering approach could provide a curative solution for patients by allowing normal phenylalanine metabolism and mitigating potential neurological damage.

**Problem Solved:** The invention addresses the limitations of existing treatments for PKU, which include strict dietary management and pharmacological therapies that have shown limited efficacy. By restoring functional PAH activity, the technology offers a potential curative option to alleviate the severe effects of the disorder and reduce the dependency on restrictive diets.","Phenylketonuria (PKU) is a genetic disorder caused by a mutation in the phenylalanine hydroxylase enzyme, leading to the accumulation of phenylalanine. A proposed treatment involves base editing of the phenylalanine hydroxylase enzyme in the liver to restore phenylalanine metabolism and prevent its neurotoxic effects."
"University of Pennsylvania","Lipid Nanoparticles That Specifically Target The Lungs","","","https://upenn.technologypublisher.com/technology/55381","Lung-targeting lipid nanoparticles allowing organ specific mRNA delivery for gene therapy applications.Problem:Gene therapy via mRNA delivery allows the rapid generation of therapeutics and vaccines for a wide range of applications. However, mRNA is especially vulnerable to degradation in the body, necessitating packaging within lipid nanoparticles. While these lipid nanoparticles protect mRNA and facilitate delivery, to date they act in a non-specific manner, entering cells regardless of therapeutic relevance.Solution:This library of lipids allows the production of lipid nanoparticles that specifically target the lungs. This allows lung-specific targeting of mRNA gene therapy, increasing the efficiency of gene delivery and improving therapeutic efficacy. Further, these lipid nanoparticles are readily biodegradable, ensuring they can be cleared from the body after delivering their mRNA payload.Technology:To identify lipid nanoparticles that exhibit organ-specific targeting, the inventors combined lipid materials to produce a total of 180 different lipid nanoparticle formulations. Using barcoded mRNA and genetic sequencing, the inventors were able to follow these lipid nanoparticles through the body and identify what lipids resulted in increased barcode distribution into the lungs. Top performers from this screen were further validated by using the lipid nanoparticles to guide expression of a bioluminescent reporter molecule, allowing visualization of the specific targeting of the lungs and cell types of transfections in the lungs. Leads loading CRISPR-based gene editors exhibited therapeutic potential for antiangiogenic cancer therapy within a lung tumor model in female mice.Advantages:Lipid nanoparticles that specifically target lungs result in ~90% of total transfection observed in the lungsBiodegradable, dramatically enhancing safety profilePreferentially delivers mRNA to lungs at a clinically relevant dose of 0.3 mg/kgDepiction of combinatorial synthesis and screening strategy to identify lung-targeting lipid nanoparticles. Synthesized lipids were used to form lipid nanoparticles which were loaded with barcoded mRNA, allowing deep sequencing to identify which lipids preferentially transfected lungs.Stage of Development:Proof of ConceptIntellectual Property:US Provisional Patent Application FiledReference Media:Xue, L. et al.,Nature Commun., 2024 Feb 29; 15(1): 1884Desired Partnerships:LicenseCase ID:24-10568-TpNCSWeb Published:10/17/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55381","**Summary:** This technology focuses on the development of lipid nanoparticles engineered for the specific targeting of the lungs, facilitating the delivery of mRNA for gene therapy applications. The lipid nanoparticles are designed to protect mRNA from degradation and to enhance the precision of gene delivery by ensuring that the therapeutic agents are directed specifically to lung tissues. The nanoparticles are biodegradable, allowing for safe clearance from the body post-delivery.

**Applications:** The primary applications of this technology include mRNA-based gene therapy and vaccine development targeting lung diseases and conditions. This platform can be utilized to create therapeutics for a broad range of respiratory ailments, potentially improving treatment outcomes for patients with conditions such as cystic fibrosis, asthma, and other pulmonary disorders.

**Problem Solved:** The technology addresses the challenge of mRNA degradation in the body and the non-specific nature of traditional lipid nanoparticles that could lead to inefficiencies in therapeutic targeting. By creating lung-specific lipid nanoparticles, the solution enhances mRNA delivery efficiency and therapeutic efficacy while minimizing off-target effects, ultimately improving the effectiveness of gene therapy approaches in treating lung-related diseases.","Lung-targeting lipid nanoparticles enable organ-specific mRNA delivery for gene therapy, addressing the vulnerability of mRNA to degradation in the body. These nanoparticles protect mRNA and facilitate delivery, overcoming the current limitation of non-specific cellular uptake."
"University of Pennsylvania","Space Shuttle-Inspired Branched Lipid Nanoparticles As Potent mRNA Transporters","","","https://upenn.technologypublisher.com/technology/55691","Lipid nanoparticles (LNPs) with reversibly attached branched lipid tails for the delivery of mRNA for gene therapy.Problem:Delivery of mRNA to target cells enables the expression of engineered proteins but mRNA is unstable and negatively charged, necessitating a delivery vehicle to ensure its entry into cells. LNPs can ferry mRNA across the cell membrane, but their key component - lipidoid - can be difficult to synthesize, and their efficacy in delivering mRNA is variable. LNPs with degradable alkyl branched tails have been found to improve cell penetration, but these lipids are difficult to synthesize due to a lack of commercially available branched building blocks.Solution:A combinatorial method for one-pot, high-throughput, and cost-effective production of a wide variety of lipidoids with variable headgroups, body tails, and branch tails. Using this method, they create a lipidoid with ‚Äúspace-shuttle resembling‚Äù branched alkyl tails with degradable linkers. These tails dramatically improve mRNA delivery by enhancing endosomal escape, increasing the mRNA delivered to the cell's translation machinery. The addition of these tails to inefficacious lipidoids can increase mRNA delivery by up to three orders of magnitude. This greatly improves therapeutic protein expression. Nanoparticles created with these lipidoids would, therefore, improve outcomes for several gene therapy applications, including vaccines and cancer therapeutics.Technology:This method can be used to rapidly synthesize branched lipidoids for the construction of LNPs. LNPs sequester negatively charged mRNA and facilitate entry into the cell via their neutral charge and hydrophobic alkyl tails. The escape of the LNPs from the cell to deliver mRNA to translation machinery is facilitated by branched tails that can then detach to promote mRNA delivery, like booster rockets detaching from a space shuttle. Using a one-pot, two-step, three-component reaction, the inventors synthesized a library of lipidoids with branched tails connected via a degradable linker. This synthetic strategy is highly efficient, producing over 80% yield, with easily removable dichloromethane or triethylamine solvents, and with byproducts easily quenched with ethanol.Advantages:Degradable linkers connecting branched alkyl tails enhances endosomal escape to improve transfection efficiencyFive-fold greater therapeutic protein expression of FGF-21 compared to industry standardRapid, cost-efficient, and high-throughput synthesis schemeRuleset for structural criteria governing lipidoid potency(A) Depiction of space shuttle-inspired strategy to enhance lipid nanoparticle mRNA delivery via the addition of branched tails with degradable linkers. Degradation of these linkers and detachment of the branched tails facilitates mRNA delivery, increasing translation efficiency and therapeutic protein expression.Stage of Development:Preclinical DiscoveryIntellectual Property:PCT Patent Application FiledReference Media:Han, X. et al.,Nature Commun., 2024 Feb 26; 15(1): 1762Han, X. et al.,Nature Nanotechnology, 2023 Sep; 18(9): 1105Desired Partnerships:LicenseCo-developmentCase ID:23-10491-TpNCSWeb Published:11/26/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55691","**Summary:** The technology focuses on lipid nanoparticles (LNPs) designed with reversibly attached branched lipid tails for effectively delivering mRNA in gene therapy applications. It addresses the inherent instability and negative charge of mRNA, which requires a suitable delivery system to facilitate cellular entry. The developed method allows for the efficient synthesis of a diverse range of lipidoids that enhance the mRNA delivery process. These lipidoids feature ""space-shuttle resembling"" branched alkyl tails with degradable linkers, significantly improving the performance of LNPs by promoting endosomal escape and thus increasing the mRNA accessibility to the cell's translation machinery.

**Applications:** This technology has potential applications in various fields of gene therapy, specifically in enhancing mRNA delivery for vaccines and cancer therapeutics, leading to improved therapeutic protein expression and potentially better clinical outcomes.

**Problem Solved:** The technology solves the problem of inefficient mRNA delivery by creating a more effective lipid nanoparticle platform, mitigating issues associated with the synthesis of lipidoids and enhancing cellular uptake and expression of therapeutic proteins.","Lipid nanoparticles (LNPs) designed with reversibly attached branched lipid tails facilitate the delivery of mRNA, addressing its instability and negative charge. While LNPs can transport mRNA into cells, challenges remain in synthesizing their key component, lipidoid, and achieving consistent delivery efficacy."
"University of Pennsylvania","An Improved and Targeted Approach to Genetic Screening for Primary Open-Angle Glaucoma in African Ancestry Population","22-10097","","https://upenn.technologypublisher.com/technology/55357","A method for more targeted pre-screening for Primary Open-Angle Glaucoma (POAG) in individuals of African ancestry.Problem:POAG, the leading cause of irreversible blindness worldwide, currently affects 44 million individuals globally and is expected to impact 80 million people by the year 2040. Of particular concern is its disproportionate burden on individuals of African ancestry, who experience a fivefold higher prevalence than European Americans and are up to 15 times more likely to suffer from vision loss due to this condition. Despite its considerable impact, the genetic basis of POAG in African ancestry populations remains largely understudied.POAG is often called the ‚Äúsilent thief of sight‚Äù because it is asymptomatic in early stages. It is estimated that approximately 50% of individuals with POAG are unaware that they have the disease. Early detection and intervention are essential because vision loss from POAG is irreversible. Treatments for POAG, though imperfect, can help to slow or halt disease progression in many patients.There is an urgent need for improved diagnostic methods for identifying subjects of African ancestry at risk for this blinding disease. Because POAG is familial with a strong genetic component, screening by genetic testing is a viable option. Recent studies suggest that polygenic risk scores (PRS) may have clinical utility in POAG prediction and classification, but almost all PRS have been generated from variants identified in populations of European or Asian ancestry, with diminishing predictive value in African ancestry individuals.Solution:A genome-wide association study (GWAS) conducted by the inventors unveiled novel genetic risk factors associated with POAG, in addition to confirming known risk factors. These findings open new avenues for understanding the genetic complexities of POAG among African ancestry populations and offer potential targets for future diagnostic and therapeutic interventions. The inventors also developed a polygenic risk score for POAG in African ancestry individuals that can identify the patients at highest risk for the disease.Technology:The inventors conducted a GWAS where they utilized advanced genotyping and sequencing technologies to comprehensively analyze the genomes of 11,275 individuals of African ancestry. They detected 46 risk loci associated with POAG at genome-wide significance. Further functional and in silico analysis were conducted to validate the findings, identifying three likely causal variants for POAG. For individuals of African ancestry, a PRS for POAG (African ancestry individuals) outperformed a PRS from summary statistics of a much larger GWAS derived from European ancestry individuals.Advantages:A total of 46 risk loci found in significant association with POAG in individuals of African ancestry.The large sample size allowed maximal statistical power for improved risk loci identification in African ancestry individuals.A significant addition to the previous POAG GWAS that predominantly contained European or Asian ancestry individuals.Improves targeted screening and therapeutic intervention for POAG in African ancestry individuals.Quantification of the genetic architecture similarities and differences between African and non-African populations for this blinding disease.PRS derived from our African ancestry population outperformed much larger PRS from European ancestry population when tested in African datasets, showing its clinical utility to this ancestry group.Performance of PRS generated from summary statistics from GBMI (European individuals) and the discovery mega-analysis (African individuals) in independent datasets of African ancestry individuals. Summary statistics from GBMI (European individuals) and discovery mega-analysis (African individuals) were each used to create a PRS. Each PRS was measured in three independent datasets of African ancestry individuals (eMERGE, GGLAD-2, PMBB). Fig. 6A: The Nagelkerke R2 is shown on the x-axis and the test datasets are shown on the y-axis, with the P-value corresponding to the Nagelkerke p-value. Fig. 6B: The odds ratio (x-axis) was calculated by comparing individuals in top 20% PRS with rest of the test datasets (y-axis). The P-value corresponds to regression p-value.Stage of Development:Preclinical discoveryIntellectual Property:Provisional Patent FiledReference Media:Salowe, R & O'Brien, J Research Feature 2022 Jan 17 :https://researchfeatures.com/primary-open-angle-african-american-glaucoma-genetics-study/Desired Partnerships:LicenseCo-developmentCase ID:22-10097-TpNCSWeb Published:10/16/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55357","**Summary:** A method has been developed for targeted pre-screening of Primary Open-Angle Glaucoma (POAG) specifically in individuals of African ancestry. This condition is a leading cause of irreversible blindness, with a significantly higher prevalence in this demographic compared to European Americans. As many as 50% of those affected may remain unaware of their condition due to the asymptomatic nature of early-stage POAG. The genetic basis of POAG among individuals of African ancestry is under-researched, despite its familial nature and strong genetic components. The new approach correlates with the increasing utilization of polygenic risk scores (PRS) which may assist in identifying individuals at risk for this disease.

**Applications:** This targeted genetic screening method is applicable for early detection and risk assessment of Primary Open-Angle Glaucoma in individuals of African ancestry, potentially guiding more effective interventions and management strategies for those identified as at risk.

**Problem Solved:** The technology addresses the urgent need for improved diagnostic methods tailored for individuals of African ancestry at risk for POAG, aiming to enhance early detection and reduce the incidence of irreversible vision loss associated with this condition.","A targeted pre-screening method for Primary Open-Angle Glaucoma (POAG) aims to address the disease's disproportionate impact on individuals of African ancestry, who have a prevalence five times higher than that of European Americans. POAG currently affects 44 million people worldwide and is projected to reach 80 million by 2040."
"University of Pennsylvania","Contactless, Reversible Material Deposition From Liquid Droplets To Solid Surfaces","","","https://upenn.technologypublisher.com/technology/55282","A microfluidic device allowing spatiotemporal manipulation of droplets that can be applied to high-resolution analytical techniques.Problem:Electrowetting methods such as electrowetting-on-dielectric (EWOD) have been developed to support high-resolution analytical techniques such as mass spectrometry and atomic force microscopy. EWOD allows processing of liquid droplets on solid surfaces or within a thin space. However, the applicability of EWOD is limited by the contact between the droplet and the electrode, which limits droplet size. While other contactless wetting technologies have been developed, they perform poorly in modifying contact angle of the droplet. In addition, microfluidic devices that allow recovery of deposited materials from solid surfaces can benefit subsequent analysis or tagging of individual droplets.Solution:The inventors developed a contactless method to induce reversible droplet wetting and dewetting on chemically inert substrates, employing the technology of discharge-based dielectric charge injection (DCI). This method allows larger droplet size without sacrificing the ability to modify contact angle of the droplet.Technology:DCI uses a sharp conductive probe placed above the droplet that induces dielectric breakdown of the surrounding dielectric medium (e.g., air or oil), leading to corona discharge, a phenomenon where the dielectric ionizes and injects charges onto the substrate surface. The substrate surface in DCI shares a similar design to that of EWOD, where a thin dielectric film is deposited above an electrode. The system demonstrates voltage-dependent contact angle saturation, with a prototype reaching the lowest contact angle of about 20¬∞. As a reversible system, complete dewetting is achieved by turning off the power source, which leads to charge dissipation.Advantages:Simple designContactless, allowing flexibility in droplet sizeReversible, allowing material deposition and recoverySmall contact angle that is competitive with traditional EWODSpatiotemporally controlledFluorescent images of the four corners of the droplet wetting area on the substrate surface after droplet removal and drying, demonstrating successful deposition of material by dielectric charge injection (DCI)-facilitated electrowetting. The droplet contains 0.1 mg/ml of bovine serum albumin (BSA) conjugated with the fluorophore Alexa Fluor 488. Bright spots in the images indicate deposition of the fluorescent BSA onto the underlying surface.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:PCT Patent FiledWO 2022/266625 A1Reference Media:Rummaneethorn, P. and Lee, D.,J Colloid Interface Sci., 2023 Jun; 639: 241Desired Partnerships:LicenseCo-developmentCase ID:21-9747_TpNCSWeb Published:10/4/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55282","**Summary:** The described technology features a microfluidic device that enables the manipulation of liquid droplets on solid surfaces while maintaining high resolution for analytical techniques. Utilizing discharge-based dielectric charge injection, it provides a contactless approach to induce reversible wetting and dewetting of droplets on chemically inert substrates. This innovation allows for larger droplet sizes and effective contact angle modification without the limitations posed by traditional electrowetting methods.

**Applications:** The technology can be applied in high-resolution analytical techniques such as mass spectrometry and atomic force microscopy, enhancing the capability for droplet manipulation and material deposition in various scientific and industrial processes.

**Problem Solved:** The development addresses the limitations of existing electrowetting techniques by eliminating the restrictions imposed by droplet-electrode contact, thus allowing for the use of larger droplets while still being able to modify their contact properties. Additionally, it facilitates the recovery of deposited materials from solid surfaces, which is beneficial for further analysis or tagging of individual droplets.","A microfluidic device enables the spatiotemporal manipulation of droplets, enhancing high-resolution analytical techniques. Electrowetting methods, like electrowetting-on-dielectric (EWOD), facilitate the processing of liquid droplets on solid surfaces but are limited by droplet contact issues."
"University of Pennsylvania","A Difluoromethylene Linchpin/Synthon For Creating With High Diasteroselectivity","","","https://upenn.technologypublisher.com/technology/55258","Diverse difluoromethylene scaffolds via novel, organodifluorine synthons.Problem:Organofluorine compounds are used in numerous applications across society, including in refrigerants, pharmaceutical ingredients, and agrochemicals. Most current methods to incorporate fluorine atoms into organic compounds use monovalent synthons, which only permit linear syntheses that do not provide a point of diversification.Solution:The technology is an ambiphilic organodifluoromethylene synthon that can be used in a one-pot three-component reaction to create a variety of adducts with high diasteroselectivity.Technology:This technology is a one-pot three-component union with Anion Relay Chemistry (ARC) by using an ambiphilic linchpin in which the anionic carbon is stabilized by geminal fluorine substituents. Œ±, Œ≤- unsaturated aldehyde electrophiles and enantioenriched sulfonyl imine electrophiles are amenable to the reaction. Alkyl, vinyl, alkynyl, aryl, and dithianyllithium reagents are viable nucleophiles in the reaction as well.Advantages:One-pot synthesisDivergent strategyThree-component adduct‚Äîa variety of nucleophiles, linchpins, and electrophiles can be employedFunctional group tolerance(a) Fluorination synthons; (b) Prior coupling tactic employing a dianion synthon; (c) fluoroorganic synthon and three-component coupling tactic via Type II Anion Relay Chemistry (ARC).Stage of Development:Bench PrototypeIntellectual Property:US Patent Application FiledUS 2023/0135826 A1Reference Media:O'Brien, K. T. et al.,Org Lett., 2021 Mar 5; 23(5): 1521Desired Partnerships:LicenseCo-developmentCase ID:21-9554-TpNCSWeb Published:10/3/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55258","**Summary:** This technology involves the development of a novel ambiphilic organodifluoromethylene synthon that allows for the formation of diverse difluoromethylene scaffolds through a one-pot three-component reaction. The method employs Anion Relay Chemistry (ARC), utilizing a linchpin structure where an anionic carbon is stabilized by geminal fluorine substituents. This process is compatible with a range of electrophiles, including Œ±, Œ≤-unsaturated aldehydes and enantioenriched sulfonyl imines, as well as various nucleophiles such as alkyl, vinyl, alkynyl, aryl, and dithianyllithium reagents. It aims to enhance the diasteroselectivity of adduct formation in comparison to existing methods.

**Applications:** The technology has potential applications in fields where organofluorine compounds are significant, including the production of pharmaceutical ingredients, agrochemicals, and fluorinated materials, as well as in the development of new reagents and catalysts.

**Problem Solved:** Current methods for incorporating fluorine into organic compounds are limited to linear syntheses that lack points of diversification. This technology addresses this issue by allowing for a more versatile and efficient synthesis of organofluorine compounds, enabling the production of diverse scaffolds with high diasteroselectivity in a single reaction step.","The technology introduces an ambiphilic organodifluoromethylene synthon that enables the creation of diverse difluoromethylene scaffolds with high diastereoselectivity. This approach addresses the limitations of existing monovalent synthons by allowing for more versatile synthetic pathways in organofluorine compound development."
"University of Pennsylvania","Ionizable Lipid Nanoparticles with Low Immunogenicity Which Enable Repeated Administrations of mRNAs Encoding Gene Editors, Tumor Neoantigens, and Vaccine Payloads.","","","https://upenn.technologypublisher.com/technology/55248","Using Mannich reaction-based combinatorial libraries to identify ionizable lipids for low-immunogenic and high-efficiency mRNA delivery.Problem:Lipid nanoparticle (LNP)-based delivery systems for mRNA-based therapeutics have recently demonstrated their clinical success in applications such as ONPATTRO¬Æ and the Pfizer/BioNTech and Moderna COVID-19 vaccines. However, existing LNP-based delivery systems have intrinsic high immunogenicity, restricting the mRNA therapeutics' protein expression levels, durability, and broader applications (e.g., redosing).Solution:The inventors constructed a series of Mannich reaction-based combinatorial libraries and used high throughput in vitro and in vivo screenings to identify the top-performing ionizable lipid, C-a16. This antioxidant lipid effectively reduces cellular inflammatory responses, extends intracellular protein expression duration, and mitigates intracellular reactive oxygen species (ROS), a pro-inflammatory signal induced by LNP-mRNA treatment.Technology:The inventors designed six combinatorial libraries utilizing Mannich reactions between (1) amines, (2) formaldehyde, and (3) various compounds such as phenols, thiols, dialkyl ketones, pyrroles, and benzophenones. This approach established a comprehensive screen comprising structurally diverse ionizable lipids (310 in vitro and 11 in vivo). They identified the strongest candidate, C-a16 lipid, and compared its expression level, half-life, and immunogenicity with different commercially available ionizable lipids (e.g., MC-3 and SM-102). Then, the team performed further proof-of-concept studies to demonstrate the superiority of the C-a16 LNP in delivering mRNA therapeutics encoding gene editor, tumor neoantigen, and SARS-CoV-2 spike protein.Advantages:Use Mannich reactions to establish combinatorial ionizable lipid libraries with higher structure diversity and physicochemical properties.A newly identified ionizable lipid, C-a16, shows improved mRNA delivery and lower immunogenicity than commercially available lipids, such as MC-3, SM-102, and ALC-0315.~5-fold higher luminescence expression intensity compared to MC-3 LNP.~30% increase in the half-life of luciferase in C-a16 LNP-treated mice (53 hours) compared to MC-3 LNP-treated mice (40 hours).C-a16 LNPs contain phenolic tails, which display significantly greater transfection efficiency than other lipids with similar carbon numbers on the tails.Significantly lower expression of oxidative stress-, cell death-, innate immune activation-, RNA- and protein-degradation genes in C-a16 LNP-treated cells.Significantly Lower reactive oxygen species (ROS) in C-a16 LNP-treated Mice than in the MC-3 LNP-treated group.C-a16 LNPs can effectively traffic to the lymph nodes after intramuscular injection.C-a16 LNPs co-delivering Cas9 mRNA and a guide RNA for transthyretin (TTR) genome editing achieved 5-fold higher TTR gene editing than MC-3 LNP.C-a16 LNPs delivering fibroblast growth factor 21 (FGF21) mRNA led to a 3-fold increase in FGF21 expression in vivo compared to MC-3 LNP.C-a16 LNPs encapsulating tumor neoantigen or SARS-CoV-2 spike protein mRNA induced superior antigen-specific immune responses compared to SM102 LNP.Construction of Mannich reaction-based combinatorial libraries for in vitro and in vivo screening of ionizable lipids. a. Schematic representations of Mannich reactions involving phenol, thiol, dialkyl ketones, pyrroles, and benzophenones for synthesizing structurally diverse ionizable lipids. For different Mannich reactions, the team mixed different derivatives (phenol, thiol, dialkyl ketones, pyrroles, and benzophenones) with formaldehyde and amines at particular molar ratios in ethanol and/or water. b-g. Heat maps illustrating the luminescence levels of MC38 cells (a mouse melanoma cell line) following treatment with various lipid nanoparticles (LNPs). Notably, lipids synthesized using the phenol Mannich reaction (Fig. b) exhibited higher luminescence levels than lipids derived from other Mannich reactions. h-i. Intravenously inject the seven top-performing LNPs (B-a11, B-a16, C-a9, C-a10, C-a11, C-a12, C-a15, C-a16, D-a9, D-a11, and D-a16) in mice and examine the biodistribution of LNPs (Fig. h) and the expression of luciferase in vivo (Fig. i). The results showed that most luciferase signals localize in the liver for all LNPs, with C-a16 LNP displaying the highest expression level. j. Intravenously administered eleven top-performing LNPs in mice and quantified the overall luminescence levels. Mice receiving C-a16 LNPs have approximately five times greater luminescence levels than those with MC-3 LNPs (n=3). k-l. In vivo luminescence signal visualization in mice and organs through IVIS images after intramuscular injection of C-a16 LNPs. m. Quantifying the luminescence levels in mice following intramuscular injection of the eleven top-performing LNPs (n=3). C-a16 LNPs induced the highest luciferase expression at the injection site (Fig. m) and in the lymph nodes (results not shown).Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Mitchell, M et al.Nat Nanotechnol 2023 Sept; 18(9): 1105Hamilton, AG et al.PLoS Biol 2023 Apr 24; 21(4): e3002105.Palanki, R et al.ACS Nano 2023 July 25; 17(14): 13594Xue, L et al.Nat Rev Mater 2023 Dec; 9: 100Desired Partnerships:LicenseCo-developmentCase ID:24-10624-TpNCSWeb Published:10/1/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55248","**Summary:** This technology focuses on the development of low-immunogenic ionizable lipid nanoparticles (LNPs) specifically designed for the efficient delivery of mRNA therapeutics. Using Mannich reaction-based combinatorial libraries, the inventors identified a top-performing ionizable lipid, C-a16, which minimizes cellular inflammatory responses, enhances the duration of intracellular protein expression, and decreases the levels of reactive oxygen species. This advancement enables more durable protein expression and supports repeated administrations of mRNA therapies, overcoming limitations faced by existing LNP systems.

**Applications:** The technology is applicable in various fields, including gene editing, the presentation of tumor neoantigens, and vaccine development. Its ability to facilitate repeated dosing positions it as a valuable tool for long-term therapies requiring ongoing mRNA delivery.

**Problem Solved:** The technology addresses the high immunogenicity associated with traditional LNP-based delivery systems for mRNA therapeutics, which often limits protein expression levels and the frequency of administration. By reducing immunogenicity and enhancing therapeutic efficacy, it enables more effective use of mRNA in therapeutic applications.","Recent advancements in lipid nanoparticle (LNP) delivery systems for mRNA therapeutics have highlighted the need for formulations with low immunogenicity to enhance protein expression levels. The study utilizes Mannich reaction-based combinatorial libraries to identify ionizable lipids that enable efficient mRNA delivery while minimizing immune responses."
"University of Pennsylvania","Safe and Potent mRNA Lipid Nanoparticles (LNPs) for Ex-Vivo Engineering of Immunosuppressive T cells in Autoimmunity Therapies.","","","https://upenn.technologypublisher.com/technology/55247","Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties.Problem:Autoimmune disorders (e.g., type 1 diabetes, multiple sclerosis, and myasthenia gravis) are mediated by self-reactive lymphocyte (B or T cells) expansion. Available suppressive medications like steroids, require frequent dosing and are non-specific, resulting in systemic immunosuppression and increased susceptibility to infections. Adoptive cell therapy is a safer and targeted alternative as it utilizes patient-derived cells to achieve immunosuppression and limits extreme side effects such as cytokine release syndrome. Specifically, regulatory T cells (Tregs) have gained attention due to their critical role in immunosuppressive modulation. However, harvesting, purifying, and growing Tregs to therapeutically relevant numbers is challenging.Solution:The inventors identified a proprietary ionizable lipid (C14-A1) and subsequent lipid nanoparticle formulation and encapsulated Foxp3 mRNA in the LNP to target and convert primary human CD4+ T cells into Foxp3-positive T (FP3T) cells that function like immunosuppressive Tregs ex-vivo. The FP3T cells have a cytokine profile and suppressive functionality like endogenous Tregs.Technology:From a library of ionizable lipids (an essential component of LNP) including both polyamine cores containing ether linkers (E1-E3) and their analogous structures containing alkyl linkers (A1-A3), the inventors identified C14-A1 as the top-performing lipid with high transfection efficiency and low toxicity. Using microfluidic mixing to formulate LNPs that encapsulate mRNA encoding Foxp3 (a master transcription factor that causes T cells to suppress unwanted effector CD4+/CD8+ cell proliferation by upregulating suppressive cytokine (IL-10 and TGF-Œ≤1) secretion), the team delivered the Foxp3 mRNA-LNP formulation to primary human CD4+ T cells to induce Treg-like cells.Advantages:Newly identified ionizable lipid, C14-A1, shows improved mRNA delivery to T cells compared to industry standards, like C12-200.Safe and potent ex-vivo engineering of primary human T cells as immunotherapies for autoimmune disorders (e.g., type 1 diabetes, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis).Facilitated greater intracellular mRNA expression, indicated by significant (p< 0.01) 2-3 fold increase in median fluorescence intensity (MFI).Potential application in graft-versus-host disease prevention after organ transplantation surgeries.Potential application in hypersensitivity during allergic reactions.Potential non-viral and in-vivo gene (mRNA) delivery to T cells.Figure 1: Graphical Abstract: Development of a mRNA lipid nanoparticle (mRNA-LNP) platform for immunosuppressive Foxp3-T (FP3T) cell engineering. (A) Schematic of Foxp3 mRNA-LNPs delivered to CD4+ T cells to generate Foxp3-T (FP3T) cells that can suppress effector T cell proliferation. (B) Chemical structures of six polyamine cores with either alkyl (A1‚ÄìA3) or ether (E1‚ÄìE3) spacers. (B) Chemical structures of epoxide tails with three varying carbon chain lengths‚îÄC12, C14, or C16. (C) Scheme of the SN2 reaction chemistry used to synthesize each unique ionizable lipid.Stage of Development:Proof of ConceptIntellectual Property:PCT FiledReference Media:Mitchell, M et al.PLoS Biol 2023 April 24; 21(4): e3002105.Prazeres, PH et al.Int J Nanomedicine. 2023 Oct 18; 18: 5891.Hamilton, AG et al.Adv. Healthc Mater. 2023 Dec; 12(30): e2301515.Gong, N et al.Nat. Mater. 2023 Dec; 22(12): 1571.Thatte, AS et. al.Nano Lett 2023 Nov 22; 23(22): 10179Desired Partnerships:LicenseCo-developmentCase ID:23-10394-TpNCSWeb Published:10/1/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55247","**Summary:** The technology utilizes mRNA lipid nanoparticles (LNPs) to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells, effectively engineering Foxp3-positive T (FP3T) cells that exhibit immunosuppressive properties akin to regulatory T cells (Tregs). The approach leverages a proprietary ionizable lipid, C14-A1, to encapsulate Foxp3 mRNA, enabling the targeted conversion of primary human CD4+ T cells into FP3T cells ex-vivo. These engineered cells display a cytokine profile and suppressive functionality similar to endogenous Tregs, aiming to address challenges in the cultivation of Tregs for therapeutic purposes.

**Applications:** The primary application of this technology lies in the treatment of autoimmune disorders such as type 1 diabetes, multiple sclerosis, and myasthenia gravis. By providing an alternative to existing immunosuppressive medications, which can lead to systemic side effects and increased infection risk, this method aims to offer a more targeted and safer approach to immunotherapy through adoptive cell therapy utilizing patient-derived cells.

**Problem Solved:** Autoimmune disorders are characterized by the expansion of self-reactive lymphocytes and can be inadequately managed with current suppressive medications like steroids, which often result in systemic immunosuppression and heightened infection susceptibility. The technology addresses the difficulties in harvesting, purifying, and expanding Tregs to therapeutic levels by providing a method to generate FP3T cells from a patient's own CD4+ T cells, thereby minimizing extreme side effects and improving treatment specificity.","The study utilizes mRNA lipid nanoparticles to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells, engineering Foxp3-positive T (FP3T) cells with immunosuppressive properties. This approach aims to address autoimmune disorders like type 1 diabetes and multiple sclerosis by providing a targeted alternative to non-specific suppressive medications."
"University of Pennsylvania","Adjuvanted Lipid Nanoparticles (LNPs) Enhance Protective Immunity Imparted by SARS-CoV-2 mRNA Vaccine","23-10147","","https://upenn.technologypublisher.com/technology/55245","A lipid nanoparticle formulation that elicits a strong innate immune response for improved vaccine protectionProblem:Lipid nanoparticle (LNP)-formulated mRNA vaccines have revolutionized modern vaccinology through their ability to deliver mRNA vaccines with remarkable manufacturing flexibility. However, the modified (pseudouridylated) mRNA used in this platform is optimized for protein production and, consequently, the mRNA itself does not activate innate immune sensors strongly. This diminishes the protective immunity imparted by the vaccine.Solution:LNPs are modular in that lipids may be functionalized to impart different capabilities upon them. Here, the inventors enhance the immunogenicity of the COVID19 LNP-mRNA vaccine by incorporating adjuvant-derived lipidoid into the encapsulating LNP. Delivery of immunostimulatory molecules at the site of antigen production causes a strong innate immune response and greater protective immunity compared to the conventional COVID19 LNP-mRNA vaccine.Technology:The pseudouridylation of mRNA vaccines allows for optimized antigen production, but a muted innate immune response. However, a robust innate immune response is critical to generate protective immunity. Here, the functionalization of LNPs with adjuvant-derived lipidoid stimulates the innate immune response at the site of antigen production. This is accomplished via the ring opening reaction between amine-containing TLR7/8 agonist 1 and C12 epoxide. Adjuvanted LNPs display greater mRNA delivery efficiency compared to conventional LNPs and result in greater protective immunity in a pre-clinical mouse model via several correlates of immunity including dendritic cell activation, T cell responses, and humoral responses.Advantages:Enhanced mRNA delivery and innate immunogenicityAdjuvant-derived lipidoid delivered precisely at the site of antigen productionEasily implemented into the current manufacturing pipelineImproved protective immunity without alteration to the antigen (here, the Spike protein)Figure 1. (A) Chemical reaction of the ring opening reaction between amine-containing TLR7/8 agonist 1 and C12 epoxide to synthesize the adjuvanted lipidoids. (B) Schematic demonstrating the functional affect of the adjuvanted lipidoid, where TLR7 and TLR8 are activated upon transfection. (C) Downstream humoral responses of adjuvanted LNPs compared to unmodified LNPs demonstrate the enhanced protective immunity imparted by adjuvanted LNPs.Stage of Development:Proof of ConceptIntellectual Property:PCT FiledReference Media:Han, X et al.Nat Nanotechnol., 2023 Sept, 18(9): 1105Shepherd, SJ et al.Proc Natl Acad Sci USA, 2023 Aug 15, 120(33): e2303567120Hamilton, AG et al.Adv Healthc Mater., 2023 Dec, 12(30): e2301515Desired Partnerships:LicenseCo-developmentCase ID:23-10147-TpNCSWeb Published:10/1/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55245","**Summary:** A new lipid nanoparticle formulation has been developed that enhances the immune response elicited by SARS-CoV-2 mRNA vaccines. Standard LNP-formulated mRNA vaccines have shown significant flexibility in manufacturing but exhibit a weaker innate immune response due to the optimization of mRNA for protein production. The inventors address this issue by incorporating adjuvant-derived lipidoid into the LNP, which stimulates a strong innate immune response at the antigen production site. This modification leads to improved protective immunity compared to conventional LNP-mRNA vaccines.

**Applications:** This technology can be applied to the development of more effective COVID-19 vaccines, potentially increasing their efficacy by providing enhanced protection against the virus. It may also be applicable to other mRNA vaccines in need of improved immune stimulation for various infectious diseases.

**Problem Solved:** The technology addresses the limitation of traditional LNP-mRNA vaccines, which have a strongly optimized mRNA for protein production but fail to activate innate immune sensors effectively. By enhancing innate immune activation, this innovation seeks to improve the overall protective immunity provided by these vaccines.","Lipid nanoparticle-formulated mRNA vaccines improve vaccine protection by eliciting a strong innate immune response. However, the modified mRNA used in these formulations is optimized for protein production and does not significantly activate innate immune sensors."
"University of Pennsylvania","PanoRadar: A High Resolution, Radio Frequency-Based 3D Imaging System","","","https://upenn.technologypublisher.com/technology/54976","A radio frequency-based 3D imaging system that can generate LiDAR-comparable images with reduced power and processing needs.Problem:With the emergence of robotic and autonomous systems in areas such as transportation, search and rescue, construction, healthcare assistance, and warehouse management, radio frequency (RF) signal-based sensing and imaging is a promising approach generate accurate and robust visualization and object detection of surroundings. RF systems offer distinct advantages over traditional optical sensors as they are resilient against environmental challenges such as dust, fog, and adverse lighting conditions. However, the fundamental limitation of RF sensors lies in their poor resolution. Unlike cameras, RF sensors typically consist of significantly fewer antennas, resulting in limited angular resolution, and smeary or indistinct appearance of objects.Solution:PanoRadar - an RF imaging system capable of LiDAR (Light Detection and Ranging) quality imaging.Technology:PanoRadar utilizes a motor-operated, rotating, single-chip millimeter wave (mmWave) radar signal generator coupled with a synthetic array of antennas in a unique cylindrical configuration to generate and capture high resolution images. The dense array and compact wave generation design, coupled with image processing allows for a significantly increased resolution of images.Advantages:Allows for LiDAR quality imaging with RF price points.Capable of predicting the surface orientation of objects inside a scene (surface normal estimation).Capable of categorizing each pixel in an image into a class or object (semantic segmentation).Enables object detection and human recognition.(1) PanoRadar design. Left: The system rotates a single-chip mmWaveradar using a motor. Right: this rotation emulates a dense cylindrical array of antennas. (2) RF imaging and visual recognition with PanoRadar. This figure illustrates the capabilities of the system, showing (a) the 3D panoramic LiDAR range image as a reference, and (b) the RF-based prediction generated by the system. The LiDAR-comparable results enable a variety of visual recognition tasks, including (c) surface normal estimation, (d) semantic segmentation, and (e) object detection and human localization.Stage of Development:PrototypeIntellectual Property:U.S. Provisional Patent Application FiledReference Media:Lai, H. et al.,ACM MobiCom '24, 2024 May: 388Moraschi, A. Penn Engineering CIS blog:In the Spotlight 2023 FebDesired Partnerships:LicenseCo-developmentCase ID:24-10645-TpNCSWeb Published:8/23/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54976","**Summary:** The technology is a radio frequency-based 3D imaging system designed to produce high-resolution images comparable to LiDAR while utilizing reduced power and processing resources. It employs a rotating, motor-operated single-chip millimeter wave radar in conjunction with a synthetic array of antennas arranged in a cylindrical configuration, effectively enhancing image quality and resolution. This innovation addresses the limitations of traditional RF sensors, which typically suffer from low resolution due to fewer antennas and resultant angular constraints.

**Applications:** The technology is applicable in various domains, including transportation, search and rescue, construction, healthcare assistance, and warehouse management. Its resilience to adverse environmental conditions allows it to function effectively in areas where traditional optical sensors may fail.

**Problem Solved:** PanoRadar addresses the challenges faced by existing radio frequency sensors that provide poor resolution and image quality. By enhancing the imaging capabilities of RF systems, it offers a reliable solution for accurate visualization and object detection in environments where visibility is compromised by factors such as dust, fog, and poor lighting.","This system utilizes radio frequency-based technology to produce high-resolution 3D images comparable to LiDAR while requiring less power and processing. It aims to enhance visualization and object detection for robotic and autonomous applications across various industries."
"University of Pennsylvania","SNMF ‚Äì An On-the-Fly, Multi-Filament Single-Nozzle for 3D Printing","","","https://upenn.technologypublisher.com/technology/54974","A printing system with a single nozzle/printhead that can dispense multiple materials in a controlled manner.Problem:Multi-material additive manufacturing transcends the limitations of traditional manufacturing processes by allowing the fabrication of complex, functionally graded components with tailored material properties. However, limitations remain in its adoption and scalability. Many existing 3D printers have multiple nozzles that require the swapping in and out of filament material during material processing. The trending slicing software lacks the ability to incorporate differentiated material information and merge it into machine instruction programs, and the material transition process critical for producing high quality prints has received little investigation. These limitations result in downtime and inconsistent material parameters.Solution:An integrated single-nozzle multi-filament (SNMF) system with hardware, software and firmware design eliminates the need for material swap-out during printing and allows for controlled gradient compositions and transitions.Technology:The SNMF printing system, rooted in the fused deposition modeling (FDM) technique, consists of three primary components: a single 4-in-1-out (four input chambers that merge at the center and subsequently connect to one output chamber) nozzle for depositing material, an auger embedded in the nozzle for extruding and blending materials, and a set of stepper motors for feeding different materials. In addition to hardware that is compatible with multiple thermoplastic filaments, the slicing software embeds differentiated material information, and the firmware enables material composition control with intricate motor regulation.Advantages:Permits a seamless transition between materials without the need for material swap out during production, allowing for printing without stoppingCan extrude and blend multiple filaments with precise control, enabling higher material continuity, graded material transitions and programmable compositionsCan create complex 2D patterns and 3D structuresMay be used for macro-scale productionsDepiction of the single-nozzle multi-filament (SNMF) printing system. a) The proposed SNMF printer with a nozzle for depositing material, a blending auger embedded in the nozzle, and a set of stepper motors for feeding varied materials. b) The 4-in-1-out printhead prototype.Stage of Development:Bench PrototypeIntellectual Property:U.S. Provisional Patent Application FiledReference Media:Teng, T. et al.,IASS 2023, Proceedings of the IASS Annual Symposium ; 2023 Oct: 1Lab webpage:Polyhedral Structures LaboratoryDesired Partnerships:LicenseCo-developmentCase ID:24-10644-TpNCSWeb Published:8/23/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54974","**Summary:** The technology features a printing system equipped with a single nozzle capable of dispensing multiple materials in a controlled manner. It is based on the fused deposition modeling (FDM) technique and consists of a unique nozzle design that merges inputs from four different chambers into one output. This system incorporates an auger for extrusion and blending of the materials, along with stepper motors that facilitate the feeding of these various materials. 

**Applications:** The SNMF system is designed for multi-material additive manufacturing, enabling the creation of complex, functionally graded components tailored to specific requirements. It is particularly useful in industries that demand advanced material properties and customization, such as aerospace, automotive, healthcare, and consumer products.

**Problem Solved:** The technology addresses the issues associated with traditional multi-material 3D printing, including the downtime and inconsistency that result from material swap-out and the limitations of existing slicing software in handling differentiated material information. The integrated approach of the SNMF system enhances the efficiency and quality of prints by allowing seamless transitions between materials and optimized material properties throughout the printing process.","The system features a single nozzle/printhead capable of dispensing multiple materials in a controlled manner, addressing the limitations of traditional manufacturing through multi-material additive manufacturing. This approach enables the creation of complex components with customized material properties, overcoming challenges associated with existing 3D printers that require multiple nozzles and filament swapping."
"University of Pennsylvania","3D Printable, Lightweight, High-Strength Concrete for Carbon Capture and Storage","24-10625","","https://upenn.technologypublisher.com/technology/54973","The formulation replaces up to 50 weight percent of ordinary Portland cement (OPC) with the highly porous, biomineral, diatomaceous earth.Problem:Concrete is the world‚Äôs second-most-used material, and its production process is carbon-intensive, contributing significantly to greenhouse gas emissions. One promising solution is carbon capture and storage within the concrete, with extensive research on mixing processes, carbonation curing of cast concrete, and recycling waste aggregates. However, some challenges remain unaddressed, including relatively slow carbonation kinetics and difficulties ensuring uniform carbonation in large or thick concrete structures. To achieve net-zero carbon emission goal, simply by absorbing CO2 in concrete is not enough.Solution:This invention is a 3D-printable concrete formulation derived from naturally abundant materials. It incorporates hierarchical porous biominerals, which significantly reduce mineral waste, carbon footprint, and enhance the concrete's carbon absorption and storage capacity.Technology:Supplementary cementing materials (SCMs) can reduce the use of cement while providing carbon capture and storage capabilities. The inventors replace up to 50 wt.% of ordinary Portland cement (OPC) with a natural SCM, diatomaceous earth (DE), which improves the material‚Äôs printability and the structural integrity of the prints. The pores of DE store water, which mitigate drying-induced shrinkage and thus fractures in the printed layers. The negative charge of DE can bind calcium ions and form calcium carbonate, further strengthening the concrete and enabling continuous carbon capture and storage.Advantages:Reducing greenhouse gas emissionsThe porosity of diatomaceous earth offers the concrete formulation with buildability, 3D printability, and strength mandated for conventional concreteThe concrete formulation replaces up to 50 wt.% of ordinary Portland cement with DE, contributing to reduced material waste and improved sustainabilityStable stacking of up to 111 print layers (200 mm) compared to the version without DE (51 layers, 98.6 mm)The concrete efficiently absorbs 145% more CO2 than concrete without DELeft: Concrete mixture from diatomaceous earth (DE)/Cement = 0.3 weight ratio extruded through 2 mm nozzle. Right: Scanning electron microscopy (SEM) images of the pores in the structure of DE at different magnification.Stage of Development:ConceptProof of ConceptIntellectual Property:U.S. Provisional Patent Application FiledReference Media:Teng, T. et al.;IASS 2023, Melbourne Symposium, 2023 Oct; Additive Manufact. 3D Printing: 1Desired Partnerships:LicenseCase ID:24-10625-TpNCSWeb Published:8/23/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54973","**Summary:** The technology describes a concrete formulation that utilizes diatomaceous earth to replace up to 50 weight percent of ordinary Portland cement, resulting in a material that is lightweight, strong, and highly printable in three dimensions. This formulation also incorporates hierarchical porous biominerals, aiming to reduce mineral waste and the overall carbon footprint while enhancing the concrete's capacity for carbon absorption and storage.

**Applications:** This innovative concrete can be utilized in various construction projects, particularly those requiring sustainable building materials. Its 3D-printable nature allows for efficient manufacturing processes and the potential to create complex structures. Additionally, it has applications in carbon capture and storage technologies, contributing to efforts to mitigate climate change effects.

**Problem Solved:** The technology addresses the significant greenhouse gas emissions associated with conventional concrete production, which is carbon-intensive and heavily reliant on ordinary Portland cement. By enhancing the carbonation process and storage capabilities while minimizing waste and emissions, this solution contributes toward achieving net-zero carbon emission goals in the construction industry. It also tackles challenges related to slow carbonation kinetics and uniformity in large or thick concrete structures, which have been barriers to effective carbon capture.","The formulation incorporates up to 50 weight percent of diatomaceous earth to replace ordinary Portland cement, resulting in a lightweight and high-strength concrete. This approach addresses the carbon-intensive nature of concrete production and supports carbon capture and storage efforts."
"University of Pennsylvania","A Fully Automated, Origami-Inspired Approach for Manufacturing Self-Assembling, Self-Reconfiguring, and Reprogrammable Structures.","","","https://upenn.technologypublisher.com/technology/54897","An origami-based approach to generate complex shapes by folding magnetically programmed sheets.Problem:Shape-changing materials are desirable in applications such as soft robotics, implantable and wearable devices, minimally invasive medicine, and micromachines. Common control signals used for self-folding, such as temperature, diffusion, and capillary forces, often require long wait times for the signal to dissipate, making repeated folding and unfolding challenging. Faster methods using chemical, electrochemical, or light signals are difficult to reprogram into different structures. Systems using active computation and directed actuation for folding control can generate different shapes over multiple folding steps, enabling the formation of different 3D shapes from the same material. However, these systems are not scalable.Solution:Magnetic actuation offers a simple option for fast, reprogrammable shape change simply by applying an external magnetic field to a precisely-oriented magnetized sample.Technology:The Sung Lab developed a fully automated approach for manufacturing self-assembling, self-reconfiguring, and reprogrammable structures. Like the magnetic writing commonly used in hard disk drive perpendicular recording, this approach uses a magnetic write head that programs a thin magnetic sheet with North or South signals at the pixel level. Previous magnetic folding systems (for example, direct ink, lithography-based, bottom-up assembly-based) relied on fabricating the fold pattern directly into the sheet, making the reconfiguration difficult without human input. However, the system presented here is fully automated after inserting the programmable sheet.Advantages:The system provides distinct advantages compared to existing magnetic folding approaches in its ability to accommodate any flat-foldable pattern.The system enables simultaneous programming and mass production of custom-folded structures.The obtained structures are recyclable and reprogrammable.Adding different components (such as electronics for control, sensing, or feedback) to the programmable sheets is possible.Foldable electronic display. (A) The unfolded display has LEDs on each face. (B) To fold into a ‚ÄúP,‚Äù the first step is to fold the bottom left corner. (C) The second step is to fold the left side. (D) When the display is on, the LEDs light up into a red and blue pattern. (E) Magnetic program used to generate the required folding sequence. (F) Magnetic image of the program on the fabricated sheet. (G) Reference Penn logo used for the display.Stage of Development:Bench PrototypeIntellectual Property:Provisional Patent Application FiledReference Media:Liu, A. et al.,J Mechanisms Robotics, 2022 Dec; 14(6): 060904Yang, Z. et al.,IEEE Robotics and Automation Letters, 2021 Oct; 6(4): 7145Desired Partnerships:LicenseCo-developmentCase ID:23-10185-TpNCSWeb Published:8/14/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54897","**Summary:** The technology utilizes an origami-inspired method to create complex shapes through the folding of magnetically programmed sheets. It addresses the challenge of slow signal dissipation associated with common self-folding control mechanisms, which hampers the ability to quickly repeat folding and unfolding processes. By employing magnetic actuation, the approach enables rapid, reprogrammable shape changes through the application of an external magnetic field to a specifically oriented magnetized substrate. The Sung Lab's automated manufacturing system for these self-assembling and reconfigurable structures employs a magnetic write head to program thin magnetic sheets at a pixel level.

**Applications:** This technology can be applied in various fields, including soft robotics, implantable and wearable devices, minimally invasive medical procedures, and micromachines, where the ability to change shapes quickly and efficiently is essential.

**Problem Solved:** The approach effectively addresses the limitations of existing shape-changing materials that often require prolonged wait times to activate control signals, enabling faster and more versatile reconfiguration of structures. By overcoming scalability issues associated with previous methods, it offers a practical solution for creating adaptable and multifunctional materials.","The described approach utilizes magnetically programmed sheets to create complex shapes through an origami-based folding method. This technique aims to address the limitations of common control signals, enabling faster self-folding and unfolding for applications in soft robotics, medical devices, and micromachines."
"University of Pennsylvania","An Adaptive, Language-Agnostic, and Generalizable Method to Determine the Hearing Level and Speech Perception Abilities of a Patient","23-10476","","https://upenn.technologypublisher.com/technology/54884","This hearing test is tuned to a patient‚Äôs hearing level and changes based on performance to accurately diagnose hearing abilityProblem:Currently, no single hearing evaluation can determine multiple facets of an individual‚Äôs hearing ability. For example, some tests may determine hearing awareness at specific frequencies, but gather no data regarding speech understanding. Others may test understanding, but are limited to specific languages and, thus, are not generalizable. Furthermore, previous attempts to assess linguistic understanding at various levels of background noise levels suffer from the inability to compare different tests and different levels making changes after intervention difficult to track.Solution:This hearing test involves testing the components of speech and language at different levels of loudness and background noise. Furthermore, this test is language agnostic and, therefore, can be administered to a broad patient population. The testing is performed in an adaptive manner so that a wide range of abilities can be incorporated into a single testing paradigm.Technology:A method whereby the hearing level and speech perception abilities of a patient is determined. Test stimuli are provided to the patient and the patient is presented with three stimuli, from which they must identify one stimulus that is different from the other two. The patient must choose between the three (forced choice, in an ‚Äúodd one out‚Äù paradigm) in order for the test to progress. Whether the patient makes the correct choice determines the course of the test via an adaptive algorithm that tailors subsequent stimuli to target the patient‚Äôs hearing ability. The test stimuli will be comprised of the sounds that make up portions of words and form the building blocks of language.Advantages:The test is presented at a loudness determined to be adequate for that person‚Äôs hearing level, without background noise, and to either (or both) ears.The ability is scored on multiple domains based on a validated set of scores from people of all hearing abilities.This test is language-agnostic and, therefore, can be applied broadly to diverse patient populations.Stage of Development:Proof of ConceptDesired Partnerships:LicenseCo-developmentCase ID:23-10476-TpNCSWeb Published:8/12/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54884","**Summary:** This hearing test adapts to a patient's hearing level and adjusts based on their performance, allowing for an accurate diagnosis of hearing ability across various dimensions. It evaluates not only hearing awareness at specific frequencies but also speech understanding, which has traditionally been constrained by language limitations. The method includes testing speech components at varying loudness and background noise levels, thus enabling a comprehensive assessment that is language agnostic and suitable for a diverse patient population. The test employs a forced-choice format, where patients identify an outlier stimulus among three options to facilitate an adaptive assessment process.

**Applications:** The technology can be utilized in clinical settings for diagnosing hearing loss and speech perception abilities in patients from different linguistic backgrounds. It offers a versatile tool for audiologists and hearing specialists to evaluate the comprehensive hearing capabilities of individuals, potentially improving personalized treatment plans and interventions.

**Problem Solved:** The method addresses the limitations of current hearing evaluations that often focus on singular aspects of hearing ability, such as frequency detection or speech understanding in specific languages. It overcomes the challenges of testing under various background noise conditions and provides a standardized approach that allows for comparability across different tests and the ability to track changes post-intervention.","The proposed hearing test is adaptable to a patient's individual hearing level and adjusts based on performance to provide a comprehensive diagnosis of hearing ability. It aims to address the limitations of existing tests, which often evaluate either hearing awareness or speech understanding but lack generalizability across different languages."
"University of Pennsylvania","SCALPEL or Secure Compartments Automatically Learned and Protected by Execution Using Lightweight Metadata","Docket # 21-9625","","https://upenn.technologypublisher.com/technology/54813","SCALPEL is a lightweight optimization tool for automatically compartmentalizing policies for hardware-accelerated enforcement in a tagged architecture. The tool also creates a layer or protection (or hardening) by learning and allowing certain privileges based on learned expectations.Problem:The languages of operating systems, device drivers and embedded applications are large and unwieldy at times ‚Äì resulting in unsafe and exploitable systems. Privilege separation separates a system into components, each limited to the privileges it requires to operate. Privilege separation relies on coarse-grained, process-level separation, where the virtual memory system provides isolation. Although isolating vulnerability in one component from other system components makes the system more robust to attackers, this approach often negatively affects system performance.Solution:Research from Andre DeHon‚Äôs lab at the University of Pennsylvania have developed a flexible, tag-based hardware security monitor that provides an opportunity to enforce fine-grained, hardware-accelerated privilege separation which can optimize system performance while decreasing opportunities for system exploitation.Technology:SCALPEL enables rapid self-learning of low-level privileges and the automatic creation and implementation of compartmentalization security policies for a tagged architecture. Researchers from the DeHon Lab used this tool for a hardware-accelerated security monitoring design called the PIPE (Processor Interlocks for Policy Enforcement) architecture. On the back-end,SCALPEL is a tool that automatically lowers compartmentalization policies to the PIPE for hardware-accelerated enforcement. On the front end, SCALPEL provides an optimization opportunity through a set of compartment generation algorithms to help security engineers explore the privilege-performance tradeoff space that a runtime environment can achieve.SCALPEL enables fine-grained privilege separation with hundreds of compartments to achieve a low over-privilege ratio with low overheads.Advantages:SCALPEL created policies can reduce over-privilege by orders of magnitude with hundreds of logical compartments while imposing low overheads (<5%).In cases where human expertise is available for additional fine-tuning, SCALPEL easily integrates human-supplied knowledge in its policy exploration.SCALPEL automatically implements compartmentalization strategies across the privilege-performance tradeoff space, all without manual tagging or code restructuring.Stage of Development:Proof of ConceptIntellectual Property:US PatentPendingReference Media:Roessler, N. and Dehon, A;ACM J Emerg Technol Comput Syst, 2021 Sept; 18(1): 1.Desired Partnerships:LicenseCo-developmentCase ID:21-9625-TpNCSWeb Published:8/2/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54813","**Summary:** SCALPEL is an optimization tool designed to enhance hardware-accelerated enforcement of security policies within a tagged architecture. It employs a self-learning mechanism to automatically generate and enforce compartmentalization policies, effectively managing privileges based on expected behaviors. The tool aims to improve system safety and performance by enabling fine-grained privilege separation, thereby reducing the surface area for potential exploitation.

**Applications:** SCALPEL can be utilized in operating systems, device drivers, and embedded applications where security and performance are critical. It is particularly valuable in environments that require robust protection against vulnerabilities by separating components based on their operational needs, thereby mitigating risks associated with unauthorized access.

**Problem Solved:** The technology addresses the challenges posed by the complexity and unwieldy nature of conventional software languages, which can lead to exploitability in systems. By introducing fine-grained privilege separation and minimizing performance impacts associated with coarse-grained isolation methods, SCALPEL enhances the robustness of systems and creates a safer computing environment.","SCALPEL is a lightweight optimization tool designed to automatically compartmentalize policies for hardware-accelerated enforcement in tagged architectures while providing a layer of protection by learning and managing specific privileges. It addresses issues of complexity in operating systems, device drivers, and embedded applications, which can lead to unsafe and exploitable systems."
"University of Pennsylvania","Dye-Loaded Micelles for Direct Visualization of Colorectal Cancer","","","https://upenn.technologypublisher.com/technology/54810","A tissue-selective, biocompatible contrast agent enables the visual identification of tumors and tumor margins during proceduresProblem:Dye-based chromoendoscopy (DBC) helps endoscopists visualize colorectal mucosa and identify inflammatory polyps that could progress toward colorectal cancer in patients with inflammatory bowel disease (IBD). However, current dyes often present similar uptake in tumors as normal tissue and do not improve recognition of tumor margins.Solution:Biocompatible and biodegradable micelles loaded with the visually detectable Zinc Phthalocyanine (ZnPC) dye are generated to enable selective delivery into tumors with minimal uptake in normal tissue. Upon injection, the ZnPC-loaded micelles clearly demarcate tumor margins in the colon and small intestine tissues.Technology:The inventors use micelles composed of diblock copolymer poly(ethylene glycol)-co-poly(caprolactone) (PEG-PCL) to effectively encapsulate various hydrophobic derivatives of the blue dye, ZnPC. The formed nanoparticles selectively deliver ZnPC into tumors either via the enhanced permeability and retention (EPR) effect or through modulation of the micelle surface with tissues targeting ligands. Both methods enhance contrast by limiting dye uptake by normal tissues. Upon accumulation in polyps, the blue color coming from ZnPC can be directly observed by the naked eye.Advantages:Biodegradable and biocompatible copolymerDirect visualization of tumors and tumor marginsSelective uptake by tumor tissueA fast and high-contrast methodAlternative imaging methods such as photoacoustic imaging, fluorescence, and absorbance can also be applied(Left) Schematic illustration of IV injected ZnPC-encapsulated micelles accumulating in colon tumors with blue color. (Right) With micelles injected, inflammatory polyps in colons and small intestines are stained in blue 24 hours post-injection.Stage of Technology:ConceptProof of ConceptIntellectual Property:US Patent FiledReference Media:Luo, L et al.ACS Appl Bio Mater, 2020 Apr 20, 3(4): 2344.Desired Partnerships:LicenseCo-developmentCase ID:21-9752-TpNCSWeb Published:8/2/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54810","**Summary:** Biocompatible and biodegradable micelles loaded with Zinc Phthalocyanine (ZnPC) dye are developed as a contrast agent to improve the visualization of colorectal tumors and their margins during medical procedures. These micelles, made from diblock copolymers, facilitate selective delivery of the dye to tumors while minimizing uptake in normal tissue, allowing for clear demarcation of tumor boundaries by the naked eye.

**Applications:** The technology enhances chromoendoscopy procedures, enabling endoscopists to better visualize colorectal mucosa and identify inflammatory polyps that may lead to colorectal cancer, particularly in patients with inflammatory bowel disease (IBD).

**Problem Solved:** Current dye-based chromoendoscopy methods fail to effectively distinguish between tumor and normal tissue due to similar dye uptake. This innovation resolves the issue by providing a contrast agent that selectively targets tumors, thereby improving the recognition of tumor margins and enabling more accurate diagnoses during endoscopic procedures.","A tissue-selective, biocompatible contrast agent enhances the visual identification of tumors and their margins during procedures. Current dye-based chromoendoscopy methods fall short as existing dyes do not distinguish between tumors and normal tissues effectively."
"University of Pennsylvania","Photoactivated Selective Release (PHASR) of Droplets from Microwell Arrays","","","https://upenn.technologypublisher.com/technology/54809","A photoresponsive polymer layer that can be integrated into microfluidic devices for selective release of unique dropletsProblem:Droplet microfluidics are used for single molecule detection and analysis, such as isolation of protein biomarkers for monitoring of disease progression. Current techniques for recovering unique molecules or cells from droplet microfluidic device studies are complex and cumbersome, not allowing for monitoring or diagnosis of multiple conditions. Manipulation of individual droplets is extremely important as it enables multiplexed high dimensional phenotyping of the targets, going beyond surface phenotyping.Solution:This technology is an optically transparent, photoresponsive polymer layer within existing droplet microfluidic devices allows for monitoring of real time events and recovery of unique analytes or cells for further analysis.Technology:A static microdoplet array that utilizes U-shaped traps to arbitrarily capture flowing droplets while the exhaust channels ensure single droplet capture and retention and serve as release channels for recovery of the captured droplets. This is a simple, yet highly effective droplet capture system that is capable of capturing and releasing hundreds of droplets. The microarray can be functionalized by the inclusion of hydrogel that are photoresponsive which will allow capture and release of target microdroplets.Advantages:Unique ability to manage on an individual basis a microdroplet for management and analysis from a larger system. Currently, the team can manipulate on an individual basis 1 of 40,000 droplets.Stage of Development:Bench PrototypeIntellectual Property:US PatentPendingReference Media:Han, S et al.;ACS Appl Mater Interfaces2020 Jan 22; 12(3): 3936.Desired Partnerships:LicenseCo-developmentCase ID:19-9056-TpNCSWeb Published:8/2/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54809","**Summary:** A photoresponsive polymer layer can be integrated into microfluidic devices, allowing for the selective release of unique droplets. This technology features a static microdroplet array that employs U-shaped traps to capture flowing droplets while utilizing exhaust channels for single droplet capture and release. The inclusion of photoresponsive hydrogels enables the functionalization of the microarray, facilitating the management and analysis of individual microdroplets.

**Applications:** The technology can be used for single molecule detection and analysis, such as the isolation of protein biomarkers for monitoring disease progression. It enables multiplexed high-dimensional phenotyping, which allows for comprehensive analysis across multiple conditions.

**Problem Solved:** The technology addresses the complexity and cumbersome nature of current techniques for recovering unique molecules or cells from droplet microfluidic studies. By allowing real-time monitoring and the simple recovery of unique analytes or cells, it enhances the efficiency of diagnosis and research in various medical and biological contexts.","A photoresponsive polymer layer enables the selective release of unique droplets from microwell arrays, enhancing droplet microfluidics for single molecule detection and analysis. This technology simplifies the recovery of specific molecules or cells, improving the ability to monitor and diagnose multiple conditions."
"University of Pennsylvania","Scalable, Low Voltage Device For Liquid Crystal-Based Technologies","","","https://upenn.technologypublisher.com/technology/54792","A multi-stable liquid crystal (LC) device based on saddle-spray director variation that enables fast optoelectronic switching and has low power requirements.Problem:LC devices are crucial for a number of modern technologies including monitors, electronic switches, and storage devices. These devices rely on an optoelectrical process by which applied current induces changes in the intrinsic molecular orientation of an LC. However, currently available devices are limited by complex fabrication processes, high threshold voltage requirements and slow switching speeds.Solution:The current invention addresses this problem by providing a fast, multi-stable LC device with low threshold voltage requirements, showing a threshold switching electric field of 0.5V/mm. The device consists of annular ring-based arrays plated on copper electrodes which are easily manipulated by applying current across the device. Unique to this invention is the utilization of saddle-splay effects, which are routinely suppressed in other LC systems. Therefore, generic, achiral liquid crystals exhibit spontaneously broken surface symmetries, leading to emergence of chiral and polar arrangements that can couple to directional DC fields and be extended across the domains. Thus, this technology opens new avenues for the development of more advanced, higher efficiency LC based technologies.Technology:The technology takes advantage of ‚Äúsaddle-splay‚Äù elasticity in LCs. Using combinations of lithographic patterning and selective surface functionalization, surface patterns are created with spatially defined geometry and precisely controlled surface chemistry. Broken symmetry regimes are defined, and the desired patterning geometry results in a multi-state stable LC display device that can be switched at an extremely low voltage density.Advantages:The threshold switching electric field of 0.5V/mm demonstrates the low switching fieldHas a low threshold voltage resulting in low power requirementsThe fabrication process is simple and easily scalable, and compatible with the conventional photolithography processSaddle-splay technology enables switching between eight states compared to just four with traditional LC systemsDemonstration of a multistable LC switching device from a patterned square array of annuli. a) Schematic of the device setup with top and bottom copper electrodes patterned on glass slides. b‚Äîe) A set of stable, cardinal states that can be switched upon the application of a small (0.5 V/Œºm) transverse, directional electric field as indicated by the yellow arrow. Each of these states remains stable upon removal of the field and any starting state can be used as a precursor to any chosen new state. f) By careful tuning of the applied field, the system can also access the four ordinal states, in which the defects reside along system diagonals (total of eight states vs. four from the conventional LC devices). All scale bars are 20 Œºm. Insets show the simulation configuration, with the distorted regions highlighted.Stage of Development:Prototype multi-stable device capable of octo-state switchingIntellectual Property:US Patent No.US12038667B2Reference Media:Xia, Yu et al.,Nature Communications, 2019 Nov 8; 10(1): 5104Desired Partnerships:LicenseCo-developmentCase ID:19-8917-tpNCSWeb Published:7/30/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54792","**Summary:** This technology introduces a multi-stable liquid crystal device that utilizes saddle-splay director variation to achieve fast optoelectronic switching while operating at low voltage requirements. It features a threshold switching electric field of just 0.5V/mm, and is constructed with annular ring-based arrays on copper electrodes, making it easily manipulable through applied current. The device leverages saddle-splay effects that are typically suppressed in other liquid crystal systems, allowing for the emergence of unique chiral and polar arrangements in achiral liquid crystals.

**Applications:** The device has potential applications in various liquid crystal-based technologies such as displays, electronic switches, and data storage systems, where fast switching times and low power requirements are essential for performance and energy efficiency.

**Problem Solved:** This invention addresses the limitations of existing liquid crystal devices, which suffer from complex fabrication processes, high voltage thresholds, and slow switching speeds, thus enabling advancements in liquid crystal technology that can lead to more efficient and simpler devices.","A multi-stable liquid crystal device utilizing saddle-spray director variation allows for rapid optoelectronic switching while maintaining low power consumption. Current liquid crystal technologies face limitations due to complicated fabrication processes, affecting their application in monitors, electronic switches, and storage devices."
"University of Pennsylvania","Biocompatible, Reversible, and Strong Multilayered Tape for Advanced Wound Care","24-10524","","https://upenn.technologypublisher.com/technology/54703","A hydrogel-based adhesive with a hydrophobic backing layer protects it from exposure to water and offers painless removal and easy repositioning.Problem:Reversible adhesives have gained popularity in industries with a growing emphasis on reducing waste and improving sustainability. Previously, the inventors have developed a strong and reversible adhesive film from poly (vinyl alcohol) (PVA) and boric acid (BA) for wound care. However, when water in the adhesive completely evaporates, the film becomes dry and stiff, resulting in a skin-stretching sensation. Additionally, continuous exposure to water could degrade the performance and ultimately dissolve the adhesive.Solution:To overcome this limitation, a biocompatible waterproof backing is added to protect the PVA/BA adhesive layer and wound site from continuous exposure to water, thus preventing the film from being dissolved. Moreover, the backing layer could provide a strong contract force that closes wounds while keeping moisture around the skin from evaporating. The film remains soft and flexible, improving patient comfort and healing. Additional water absorbing sealant and water proofing materials could be added at the edge of the adhesive to further improve the sealing.Technology:The tape comprises two layers. The adhesive layer has three components: instant adhesives consisting of water absorbing elastic hydrogel together with a water-activated instant sealant layer (PVA/BA), and a waterproof layer. Upon activation by water or moisture, this layer forms an immediate bond with the substrate. The hydrophobic backing layer contains silicone, an air-permeable and thermal-insulating material that protects adhesive layers from external moisture and other environmental factors. It imparts additional mechanical support to the adhesive, ensuring the tape remains adhered to the skin or the wound site during extended use. Combining both layers offers a higher adhesion strength than the current topical wound dressing products while offering additional protection to the wound dressing and wound site.Advantages:Biocompatible and ReversibleInstant adhesion to a wide range of substrates, including plastics, fabrics, glass, metals, ceramics, and skinAesthetically versatile (transparent or colored), allowing for customization and personalized usageProvides additional applications such as drug delivery, monitoring, and simulationAllows for industrial-scale productionSchematic illustrations of PVA/BA adhesives. (A and B) Instant softening of the top near-surface region upon water activation (A), allowing for fast adhesion to the wound site through dynamic covalent bonds (B).Stage of Development:ConceptProof of ConceptBench PrototypeIntellectual Property:Provisional FiledReference Media:Chen, M et al.Proc Natl Acad Sci U S A. 2022 Jul 19; 119(29): e2203074119Desired Partnerships:LicenseCase ID:24-10524-TpNCSWeb Published:7/22/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54703","**Summary:** This technology involves a hydrogel-based adhesive layered with a hydrophobic backing to provide enhanced protection against water exposure. The adhesive layer is designed to be reversible and strong, composed of a water-activated instant sealant and a water-absorbing elastic hydrogel, which maintains flexibility and comfort for patients. The additional waterproof backing layer serves to prevent degradation of the adhesive by continuous water exposure while ensuring moisture retention around the wound to promote better healing.

**Applications:** The multilayered tape can be applied in advanced wound care, particularly for patients requiring sustained hydration and protection of wounds in wet environments. It is also suitable for applications in industries focused on reversible adhesives with an emphasis on sustainability and waste reduction.

**Problem Solved:** The innovation addresses the issues of conventional reversible adhesives that become dry and stiff after water evaporation, leading to discomfort. It also mitigates the problem of adhesive dissolution upon prolonged water exposure, ultimately enhancing the durability and effectiveness of wound care solutions while improving patient comfort during the healing process.","The hydrogel-based adhesive features a hydrophobic backing layer that provides water protection and enables painless removal and easy repositioning. Previous developments included a strong and reversible adhesive film composed of poly (vinyl alcohol) and boric acid for wound care, though the adhesive's performance is affected by the evaporation of water."
"University of Pennsylvania","Targeted Organ or Multiple Organ Delivery of mRNA with Ionizable Amphiphilic Janus Dendrimers","","","https://upenn.technologypublisher.com/technology/54702","A library of easily synthesized ionizable amphiphilic Janus dendrimer (IAJD) compounds that deliver mRNA either to targeted organs or multiple organs, depending on the IAJD design.Problem:Four-component lipid nanoparticles (LNPs) are the benchmark synthetic vector for the delivery of mRNA. Despite their high biosafety, low toxicity, and immunogenicity, their drawbacks involve the need for microfluidic or T-tube technology for assembly and low temperature for long-term storage (‚àí70 ¬∞C). Additionally, four component LNPs have shown a low transfection efficiency (1-2%).Solution:To eliminate the weaknesses of LNPs, the inventors developed a library of one-component compounds designed with precise placement of the IAJD‚Äôs functional groups. The mRNA encapsulation step is fast and simple, allowing rapid screening of the properties of each new IAJD and uncovering molecular design principles for targeted delivery.Technology:The one-component IAJDs in this library can be synthesized in just three steps. Each is made using symmetrically trialkylated pentaerythritol (PE) in the hydrophobic domain and four different piperazine-based ionizable amines in the hydrophilic part. These IAJDs coalesce with mRNA to form vesicles of predictable sizes, namely dendrimersome nanoparticles (DNPs). This process is achieved through a straightforward injection into an acetate buffer. After conducting in vivo screening, highly effective IAJDs were identified, specifically targeting the spleen, liver, and lymph nodes. One primarily targets the spleen and liver, while six exhibit equal distribution to the spleen, liver, lung, and lymph nodes.Advantages:The first system to demonstrate delivery of mRNA to multiple organs (lung, liver, spleen, and lymph nodes).One-component IAJDs can be fabricated in as few as three steps.Design changes in the IAJD, such as a decrease in alkyl length, have been shown to increase mRNA transfection.IAJDs exhibit higher stability than 4-component LNPs due to symmetric achiral architecture.Concepts of four-component LNPs (a), one-component IAJD-based DNPs (b), three-step synthesis of PE-based IAJDs (c), and the mechanism of cell transfection of DNPs encapsulating Luc-mRNA (d). This is figure 1 from their recent publication in JACS.Stage of Development:ConceptProof of ConceptIntellectual Property:Provisional Patent FiledReference Media:Lu, J et al.;J Am Chem Soc, 2023 Aug; 145(34): 18760.Desired Partnerships:LicenseCo-developmentCase ID:23-10453-TpNCSWeb Published:7/22/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54702","**Summary:** A library of ionizable amphiphilic Janus dendrimer (IAJD) compounds has been developed for the delivery of mRNA to targeted organs or multiple organs. These one-component compounds can be synthesized through a simple three-step process involving symmetrically trialkylated pentaerythritol and piperazine-based ionizable amines. The resultant dendrimersome nanoparticles (DNPs) form through a straightforward injection into an acetate buffer, facilitating rapid encapsulation of mRNA and enabling efficient screening of properties for targeted delivery.

**Applications:** The IAJD compounds can be utilized for targeted mRNA delivery to various organs, particularly in therapeutic contexts where precise delivery is crucial. Potential applications may include gene therapy, vaccine development, and treatment of organ-specific diseases.

**Problem Solved:** This technology addresses several limitations of traditional four-component lipid nanoparticles (LNPs), including the complexity of assembly, stringent storage requirements, and low transfection efficiency. By introducing a library of simpler, one-component IAJDs that allow for rapid encapsulation and efficient targeting, the inventors have overcome these shortcomings, enhancing the viability and effectiveness of mRNA delivery systems.","A library of ionizable amphiphilic Janus dendrimer (IAJD) compounds has been developed for the targeted delivery of mRNA to specific or multiple organs, depending on their design. Traditional four-component lipid nanoparticles (LNPs), while safe and low in toxicity, require complex assembly methods and low-temperature storage, highlighting the potential advantages of IAJD compounds."
"University of Pennsylvania","Single-Step Wettability Patterning for Microfluidic Generation of Emulsions","22-10109","","https://upenn.technologypublisher.com/technology/54701","Method to transfer wettability properties of a mold to microfluidic devices, defining hydrophobic/hydrophilic regions through variable perfluoropolyether concentration.Problem:Current wettability patterning methods involve sequentially flowing chemicals into channels, blocking areas where treatment is not desired. These multi-step methods are labor intensive and have limited spatial resolution. Additionally, the scalability of these processes is not feasible, as each device must be patterned individually. These processes are additive and generate surfaces that are not flat, limiting the available topographies of these microfluidic devices.Solution:A technique that patterns a mold, which then transfers its wettability properties to the microfluidic device, allowing for single-step generation of hydrophobic/hydrophilic regions. The mold is reusable, allowing for mass-production of microfluidic channels. This process is less time-consuming and labor-intensive compared to traditional wettability patterning, and is not additive, so smooth surfaces can be generated.Technology:This method allows selective hydrophobic perfluoropolyether (PFPE) enrichment in regions, rather than uniform distribution, by patterning a silica mold substrate with hydrophobic silane-treated regions. The wettability of the mold is then transferred to the network surface as areas adjacent to the silane-treated regions become PFPE-enriched and thus hydrophobic, while the unenriched regions remain relatively hydrophilic. The polymer network is then cured with UV light, peeled off the mold, and dried to form the channel.Advantages:Single-step definition of hydrophobic/hydrophilic regions allows for faster fabrication of microfluidic devices compared to multi-step treatment with individual hydrophobic/hydrophilic components.The method is compatible with traditional soft lithography techniques.The use of a reusable mold that transfers wettability allows for faster fabrication and more facile scalability, as each device does not need to be individually patterned.The resulting microfluidic devices are solvent resistant.The process is non-additive, allowing for generation of smooth surfaces, which is not possible for traditional wettability patterning.Micrometer-level spatial resolution compares favorably to the resolution afforded by multi-step techniques.(A) Scheme for generating and curing hydrophilic/hydrophobic networks with silanized patterning used to dictate wettability. (B) Chemical structures of hydrophobic PFPE and hydrophilic PEGDA polymers.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:PCTFiledReference Media:Wu, J et al.;ACS Appl. Mater. Interfaces, 2023, 15(7): 10212.Wu, J et al.;Appl. Phys. Rev., 2021 Sept, 8(3): 31304.Desired Partnerships:LicenseCo-developmentCase ID:22-10109-TpNCSWeb Published:7/22/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54701","**Summary:** This method enables the transfer of wettability characteristics from a patterned mold to microfluidic devices by defining hydrophobic and hydrophilic regions through varying concentrations of perfluoropolyether (PFPE). It utilizes a reusable mold patterned with hydrophobic silane-treated areas, facilitating the selective enrichment of PFPE in desired regions, while adjacent areas remain hydrophilic. This process allows for the creation of smooth surfaces, improving the quality of the microfluidic devices.

**Applications:** The technology can be utilized in various fields requiring microfluidics, such as biomedical diagnostics, chemical analysis, and the generation of emulsions in pharmaceutical and food industries. It may also be applicable in creating microfluidic devices for research purposes in material science and biology.

**Problem Solved:** The method addresses the limitations of traditional wettability patterning techniques that involve labor-intensive, multi-step processes with low spatial resolution and scalability issues. By offering a single-step approach and reusability of molds, it simplifies the production of microfluidic devices and maintains surface flatness, thus enhancing their performance and manufacturability.","A method has been developed to transfer wettability properties from a mold to microfluidic devices by defining hydrophobic and hydrophilic regions through varying perfluoropolyether concentration. This approach addresses the limitations of current multi-step wettability patterning methods, which are labor-intensive and lack scalability and spatial resolution."
"University of Pennsylvania","Effective Anti-Fouling Surface Coating of Microfluidic Mixing Devices for Robust mRNA Lipid Nanoparticles (LNP) Manufacturing","","","https://upenn.technologypublisher.com/technology/54648","Employment of omniphobic, thin-layer perfluorocarbon (TLP) coating to prevent fouling and clogging in microfluidic mixing devices during mRNA LNP formulations.Problem:Lipid nanoparticle (LNP)-based delivery systems for mRNA and other therapeutics recently gained popularity because of their application in the Pfizer/BioNTech and Moderna COVID-19 vaccines. Compared to traditional bulk mixing and batch process approaches, microfluidic technology for mRNA-LNP manufacturing enables precision synthesis via rapid mixing and fluid flow control. However, fouling and clogging in microfluidic channels pose significant problems for LNP formulation as numerous existing hydrophilic/hydrophobic coatings only inhibit biomolecule adsorption and fouling in aqueous solutions, while the condition for LNP formation is a mixture of hydrophilic aqueous and amphiphilic ethanol (EtOH) solvents.Solution:Coating a silicon (Si)/glass-based microfluidic mixing device with omniphobic, thin-layer perfluorocarbon (TLP) improves chemical resistance, suppresses non-specific biomolecule adsorption, and prevents nanoparticle aggregation.Technology:The TLP layer consists of an immobilized tethered perfluorocarbon (TP) overlaid by a thin liquid perfluorocarbon (LP) layer, which is an FDA-approved material. Application of TLP coating to a Si/glass microfluidic mixing device repels water, EtOH, and water/EtOH mixture while suppressing non-specific adsorption of biomolecules such as BSA, glycine, and mRNA-LNP constituents. This prevents fouling of mRNA and LNP constituents.Advantages:An antifouling resistant GMP compatible manufacturing platform using FDA-approved material.High-precision mRNA-LNP production (size < 100 nm, encapsulation efficiency > 90%).Robust mRNA-LNP production (operation t > 50 min without clogging).Prevents aggregation of nanoparticles, which expands its application to other nanomaterials and devices lined by anti-adsorption and antifouling surfaces.Schematic for robust mRNA-LNP formulation using fouling-resistant microfluidic mixing device. Compared to (a) the conventional bulk formulation method and (b) bare microfluidic mixing device that produce large and more heterogeneous LNPs with variable RNA delivery, (c) the fouling-resistant microfluidic device produces smaller, more homogeneous LNPs with potent in-vivo RNA delivery and activity. It also extends the operation to over 50 minutes without clogging. (d-h) Cryo-EM images of LNPs produced with bulk formulation, bare device, and fouling-resistant device, respectively.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:PCT Patent Application Filed PCT/US2024/029998Reference Media:Kim, B. Q. et al.,Nano Small, 2023 Sept 27; Vol.19(39): e2302676Shepherd, S. J. et al.,Proc Natl Acad Sci USA, 2023 Aug 15; 120(33): e2303567120Tran, H.-H. et al.,Rep. Prog. Phys., 2023 May 22; Vol. 86(6): 066601Rose, K.A. et al.,Soft Matter, 2022 Dec 7; Vol. 18(47): 9045Wu, J. et al.,Applied Phys. Reviews, 2021 July 19; Vol. 8(3): 031304Shepherd, S. J. et al.,Science Direct, Biomaterials, 2021 Apr. 26; Vol. 274: 120826Desired Partnerships:LicenseCo-developmentCase ID:23-10440-tpNCSWeb Published:7/15/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54648","**Summary:** The technology involves the use of an omniphobic, thin-layer perfluorocarbon (TLP) coating on microfluidic mixing devices to enhance the manufacturing process of mRNA lipid nanoparticles (LNPs). This coating addresses issues of fouling and clogging that arise during the formulation of LNPs, which require a mixture of hydrophilic aqueous and amphiphilic ethanol solvents. The TLP coating improves the chemical resistance of the silicon/glass-based devices and effectively suppresses non-specific biomolecule adsorption, thereby preventing nanoparticle aggregation during the mRNA delivery system fabrication.

**Applications:** The primary application of this technology is in the manufacturing of mRNA lipid nanoparticles, particularly relevant for the production of therapeutics similar to those used in the Pfizer/BioNTech and Moderna COVID-19 vaccines. It is suitable for microfluidic systems that facilitate precision synthesis through rapid mixing and controlled fluid flow.

**Problem Solved:** The technology effectively addresses the significant challenges of fouling and clogging in microfluidic channels during LNP formulations by employing a coating that is capable of repelling both water and ethanol-based solvents, while also preventing non-specific adsorption of biomolecules that can interfere with the manufacturing process.","The study details the use of an omniphobic, thin-layer perfluorocarbon coating to prevent fouling and clogging in microfluidic mixing devices used for formulating mRNA lipid nanoparticles (LNPs). This advancement addresses challenges faced in LNP-based delivery systems, particularly in the context of their application in COVID-19 vaccines."
"University of Pennsylvania","LNP Delivery of Gene-Editing Machinery to Cure Hereditary Tyrosinemia Type 1g","","","https://upenn.technologypublisher.com/technology/54597","Problem:Hereditary tyrosinemia type 1 (HT1) is a genetic metabolic disease caused by the inability to break down tyrosine, an amino acid present in many meats, dairy products, fruits, and nuts. This disease can be fatal within the first few months of life and increases the risk of liver cancer. The current treatment involves a strict drug regimen and dietary restrictions. Many people are unable to maintain this regimen and require a liver transplant. Therefore, patients need a lasting cure for HT1.Solution:Inventors developed a gene-editing method to restore tyrosine processing and cure HT1. The cure can be administered to patients with HT1 or to a fetus before birth. This method targets a non-mutated gene, making it universal for all patients regardless of their specific causal mutation. Additionally, the gene-editing method is highly specific to the target gene and the liver, minimizing off-target effects.Technology:The inventors developed a gene-editing strategy to inhibit the function of 4-Hydroxyphenylpyruvate dioxygenase (HPD) that acts upstream of the HT1-mutated enzyme (FAH). This loss of HPD function shunts the tyrosine byproducts to an alternative pathway. Specifically, the inventors used an adenine-base editor and guide RNA that targets a splice site in HPD. They packaged the editor and guide RNA in lipid nanoparticles to enhance delivery to the liver. These lipid nanoparticles can be injected by a one-time IV infusion.Advantages:One-time durable cure eliminates the need for lifelong drug treatment and dietary restrictions.Lipid-nanoparticle delivery increases on-target delivery to the liver (60-70% of alleles edited) rather than off-target organs (0-1.5% edited).Adenine base editing of a splice site has high on-target efficiency and low off-target editing: 60-70% of target alleles were edited, while none of the top 100 predicted off-target sites were edited.Stage of Development:Target IdentifiedPreclinical DiscoveryIND Enabling StudiesIntellectual Property:PCT filedDesired Partnerships:LicenseCo-developmentCase ID:23-10295-TpNCSWeb Published:7/10/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54597","**Summary:** The technology offers a gene-editing solution for hereditary tyrosinemia type 1 (HT1), a severe genetic metabolic disorder characterized by an inability to process tyrosine. The method targets the enzyme 4-Hydroxyphenylpyruvate dioxygenase (HPD) to redirect tyrosine byproducts through an alternative pathway, effectively restoring normal tyrosine processing. The treatment is designed for specific targeting in the liver and can potentially be administered to both existing patients and fetuses, allowing for a universal application across different mutations of the disease. The gene-editing components are encapsulated in lipid nanoparticles, facilitating a one-time intravenous infusion.

**Applications:** This gene-editing technique can be applied to individuals diagnosed with hereditary tyrosinemia type 1, as well as to unborn fetuses at risk of inheriting the disease. It aims to provide a long-lasting cure by correcting the metabolic pathway involved in tyrosine breakdown.

**Problem Solved:** The technology addresses the critical need for a durable cure for hereditary tyrosinemia type 1, which currently relies on difficult-to-maintain drug regimens and dietary restrictions, with many patients ultimately requiring liver transplants. This innovation offers hope for a permanent solution that mitigates the health risks of the disease, including its potential fatality and the increased risk of liver cancer.","Hereditary tyrosinemia type 1 (HT1) is a genetic metabolic disorder that results from the inability to metabolize tyrosine, leading to severe health risks, including potential fatality in early life and increased liver cancer risk. Current treatment options involve a strict drug regimen and dietary restrictions, with many patients ultimately requiring a liver transplant."
"University of Pennsylvania","Fluorescent Probes for the Selective Detection of Alzheimer's and Parkinson's Diseases","23-10337","","https://upenn.technologypublisher.com/technology/54519","Bimane-based fluorescent probes with turn-on fluorescence in the presence of Œ±-synuclein, a known hallmark of Altzeimer‚Äôs and Parkinson‚Äôs diseases.Problem:Small fluorogenic probes with high sensitivity and selectivity are powerful tools for studying the accumulation of amyloid fibrils in cells or tissue samples from patients with Alzheimer's disease (AD), Parkinson's disease (PD), and many neurodegenerative disorders. Thioflavin-T (ThT) is a widely used dye for staining amyloid fibrils because its binding to amyloid fibrils increases its fluorescence intensity. However, ThT has a relatively small Stokes shift (50 nm), which is problematic when combined with other spectrally similar molecules. It also has poor selectivity for fibrils over other aggregates, and poor cellular uptake.Solution:Bimane-based fluorescent probes that exhibit turn-on fluorescence in the presence of AD/PD biomarkers with good cellular uptake and without binding to other fibrils, allowing for early, facile, rapid detection of AD/PD and other neurodegenerative diseases.Technology:A synthetic route that enables rapid access to fluorescent probes from bimane chromophores, which show good fluorescent turn-on and selectivity among fibril types. The current probes can detect amplified fibrils (AFs) from patient tissues, while the previous method, ThT, cannot detect them effectively. In addition, the probes have large Stokes shifts in the presence of pre-formed fibrils (PFFs) and low background fluorescence in cell lysate, making them a potential PD/AD biomarker.Advantages:Simple synthetic route allows for easy and potentially scalable synthesisLarge stokes shifts (approx. 200 nm) compare favorably to current dyes used in this approach (approx. 50 nm), giving better signal to noise signalsThe selectivity of these probes is favorable compared to other typical probes, which suffer from lack of selectivity in fibril identity as well as poor cellular uptakeSynthesis of bimane fluorescent probes with tunable emission for the detection of Œ±-synuclein, a known hallmark of Altzeimer‚Äôs and Parkinson‚Äôs diseases.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:US Patent FiledReference Media:Venkatesh, Y et al.;Chem Sci 2024 Mar 26; (16): 6053.Desired Partnerships:LicenseCo-developmentCase ID:23-10337-TpNCSWeb Published:6/27/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54519","**Summary:** This technology utilizes bimane-based fluorescent probes that demonstrate a significant increase in fluorescence intensity when in the presence of Œ±-synuclein, a protein associated with both Alzheimer's and Parkinson's diseases. These probes are designed for high sensitivity and selectivity to detect amyloid fibrils, surpassing the limitations of the conventional dye Thioflavin-T, which suffers from a small Stokes shift, low selectivity, and inadequate cellular uptake. The synthetic method developed allows for the rapid production of these probes, which are capable of identifying amplified fibrils in patient samples effectively.

**Applications:** The fluorescent probes can be applied in research and clinical settings for the early diagnosis of Alzheimer's and Parkinson's diseases, as well as in the study of other neurodegenerative disorders that involve the accumulation of amyloid fibrils.

**Problem Solved:** The technology addresses the challenges associated with existing fluorescent probes like Thioflavin-T by offering a more effective solution for the selective detection of amyloid fibrils, facilitating better diagnostic capabilities and research on neurodegenerative diseases.","Bimane-based fluorescent probes exhibit turn-on fluorescence in the presence of Œ±-synuclein, which is associated with Alzheimer‚Äôs and Parkinson‚Äôs diseases. These small, highly sensitive, and selective fluorogenic probes are effective tools for studying the accumulation of amyloid fibrils in samples from patients with these neurodegenerative disorders."
"University of Pennsylvania","Deep Learning Model Discovers Antibiotic Drugs in Extinct Organisms Effective Against Drug-Resistant Superbugs","24-10510","","https://upenn.technologypublisher.com/technology/54518","Antibiotic Peptide de-extinction (APEX) is a deep-learning AI solution that can unearth ancient antibiotics to effectively combat superbugs and tackle antibiotic resistance on a global scale.Problem:Escalating antibiotic resistance around the globe has emerged as one of the pressing problems of our time, with antibiotic-resistant infections causing approximately 1.27 million deaths annually worldwide. Without effective new drugs, this number could surge to 10 million fatalities by 2050. Traditional drug discovery approaches have been unable to keep pace with the evolution of antibiotic-resistant bacterial strains, resulting in a critical shortage of novel antibiotics to combat these resistant pathogens. These developments can seriously jeopardize public health in the future.Solution:Researchers have developed a deep learning AI technology that analyzes a protein database of long-extinct organisms to rediscover lost, never-before-used antibiotic compounds, which display considerable efficacy against pathogens resistant to more traditional antibiotics.Technology:In their experimentation, the researchers employed the Antibiotic Peptide de-extinction (APEX) approach, which relies on deep learning techniques. APEX systematically scanned proteomes of extinct organisms, encompassing various species across different time periods. A multitask deep learning model, trained on both public and in-house peptide sequences from natural and synthetic sources. The peptide sequences generated by APEX range from 8 to 50 residues in length, and predicted antibiotic activity against the most relevant pathogenic strains. Based on predicted antibiotic properties, the highest-ranking peptides underwent extensive in vitro characterization, including assessing antibiotic activity, mechanism of action, secondary structure, synergy, and cytotoxicity. Testing the selected peptides using in vivo mouse models validated and showcased the peptides‚Äô potential antibacterial effectiveness.Advantages:Automates the process of finding new antibiotic peptides essential to counter antibiotic-resistant pathogens.The deep learning approach allows large databases of ancient proteomes to be mined for relevant molecules.Encrypted peptides discovered reduce bacterial load in a mouse model by 2-3 orders of magnitude.The encrypted peptides operate via new pathways that circumvent the drug resistance of superbugs.Discovered peptides can be used as general antibiotics in non-specialised applications.APEX mines available proteomes of extinct organisms. A multitask deep learning model trained on public and in-house peptide data evaluates amino acid sequences for potential antibiotic activity. The highest-ranked peptides were thoroughly characterized against clinically relevant pathogens in vitro and animal models and the resulting proteins were experimentally validated in mouse models.Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Wan, F et al.Nat Biomed Eng 2024 June 11Knapton, S.The Telegraph 2024 June 15; 13h30 BSTDesired Partnerships:LicenseCase ID:24-10510-TpNCSWeb Published:6/26/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54518","**Summary:** A deep-learning AI technology called Antibiotic Peptide de-extinction (APEX) has been developed to identify ancient antibiotics from the proteins of long-extinct organisms. This innovation aims to address the significant global challenge of antibiotic resistance, which currently leads to approximately 1.27 million deaths each year and is projected to reach 10 million fatalities annually by 2050 without new drug interventions. Traditional methods for drug discovery have fallen short in keeping up with the rapid evolution of antibiotic-resistant bacteria, resulting in a critical lack of new antibiotics.

**Applications:** The APEX technology has the potential to rediscover lost or previously unused antibiotic compounds that are effective against drug-resistant superbugs. These compounds could play a crucial role in the development of new treatments for infections resistant to conventional antibiotics, thus enhancing public health interventions and potentially saving millions of lives.

**Problem Solved:** The technology addresses the urgent need for new antibiotics in the face of rising antibiotic resistance, which poses a significant threat to global health. By unlocking the potential of ancient compounds, APEX offers a novel approach to combat previously untreatable infections, which is vital for preventing the escalating death toll associated with antibiotic-resistant pathogens.","Antibiotic Peptide de-extinction (APEX) is a deep-learning AI solution designed to discover ancient antibiotics that can combat drug-resistant superbugs. Antibiotic resistance is a significant global issue, resulting in approximately 1.27 million deaths annually, with projections of up to 10 million fatalities by 2050 without new effective drugs."
"University of Pennsylvania","Antimicrobial Peptides (AMPs) Mined from Human Gut Metagenome Are Effective Against Antibiotic Resistant Pathogens","","","https://upenn.technologypublisher.com/technology/54517","The collective genomes of the human gut microbiome, known as the metagenome, encode peptides that are effective against antibiotic-resistant bacteria.Problem:Antimicrobial resistance poses a major threat to public health. The development of drug-resistance outpaces traditional drug discovery approaches. As a result, the supply of drugs available to treat multi-drug resistant microbes, a leading cause of nosocomial infections, is shrinking. There is a need for new antimicrobial drugs and new methods of their discovery for more rapid drug development. Thus far, no significant technological advance has capitalized on this market, which is set to grow at a compound annual growth rate (CAGR) of 5.27% through 2030.Solution:The human gut is lined with a diverse population of microbes competing for limited resources. Thus, these microbes have evolved strategies to survive including antimicrobial peptides (AMPs), which can be leveraged to treat infections in humans. These peptides kill pathogens by puncturing their outer membrane and, importantly, this mechanism of action is less likely to cause antimicrobial resistance.Technology:The inventors mined the human gut metagenome by analyzing publicly available metatranscriptomic data for small open reading frames (smORFs). Candidate AMPs were synthesized and analyzed for membrane permeabilization and depolarization, propensity toward alpha helix formation, and functional antimicrobial activity. The inventors used two separate mouse models of infection to test their candidate AMPs. In the deep thigh infection model, mice were pre-treated with immunosuppressant drugs (cyclophosphamide) immediately preceding infection to simulate nosocomial infection of a deep tissue. The authors identified five lead peptides, of which one has antimicrobial activity comparable to that of polymyxin B (an approved antibiotic).Advantages:Development of resistance toward AMPs, which have non-specific mechanisms of action, is rare.Five lead compounds showed antimicrobial activity that reduced infection by as many as four orders of magnitude, which is comparable to the approved antimicrobial drug polymyxin B.Many of the discovered peptides have antimicrobial activity and synergize with each other.These AMPs modulate commensal bacteria, which may be useful to engineer the gut microbiome.Figure 1. Schematic of the workflow employed to generate lead AMPs and the subsequent screening conducted to confirm their functional efficacy. From bottom left, publicly available metatranscriptomic data was annotated with MetaProdigal to identify smORFs, which were clustered with CD-Hit into 444,054 families. These families were then analyzed further by SmORFinder to generate 4,539 High Confidence Families likely to code for peptides and compared against peptides with purported antimicrobial activity generated by AmPEP to produce 323 high confidence families with predicted antimicrobial activity. 79 were synthesized and screened for bacterial growth inhibition of pathogenic and commensal bacteria and the top candidates subjected to functional membrane permeabilization assays, circular dichroism and structure prediction, and in vivo activity.Stage of Development:Preclinical DiscoveryIntellectual Property:Provisional FiledReference Media:Torres, MDT et al.bioRxiv, 2023 Aug 31 : 555711 (preprint)de la Fuente labX:@delafuenteupennDesired Partnerships:LicenseCo-developmentCase ID:23-10451-TpNCSWeb Published:6/26/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54517","**Summary:** Antimicrobial peptides (AMPs) derived from the human gut metagenome have been identified as effective agents against antibiotic-resistant bacteria. Such peptides are a natural part of the microbial ecosystem in the gut, which has evolved them to survive in a competitive environment. The research involved analyzing publicly available metatranscriptomic data to identify small open reading frames (smORFs) that may encode AMPs. Synthesized peptides were tested for their ability to permeabilize membranes, form alpha helices, and exhibit antimicrobial activity, showing promise in combating infection.

**Applications:** The AMPs can be developed into new antimicrobial drugs to address infections caused by multi-drug resistant pathogens, potentially used in both clinical settings and hospital environments where such resistant strains are common. The peptides may also contribute to the broader field of antimicrobials by providing a novel approach for rapid drug development.

**Problem Solved:** This technology addresses the critical issue of antimicrobial resistance, which currently poses a substantial risk to public health due to the limited effectiveness of existing antibiotics against resistant pathogens. By focusing on naturally occurring AMPs from the human gut microbiome, the research presents a fresh avenue for discovering new treatments that are less likely to contribute to resistance compared to traditional antibiotics.","The human gut metagenome encodes antimicrobial peptides that are effective against antibiotic-resistant bacteria. This is crucial as antimicrobial resistance poses a significant public health threat and the supply of effective drugs for treating multi-drug resistant microbes is declining."
"University of Pennsylvania","Low-Cost, Point-of-Care Test for Rapid Visual Diagnosis of COVID-19","21-9678","","https://upenn.technologypublisher.com/technology/54515","A rapid, low-cost, portable swab-based SARS-CoV-2 biosensor whose test result can be detected with naked eyeProblem:COVID-19 has killed over 2.84 million people worldwide and has disproportionately affected people in lower-income and resource-limited geographies. High-frequency testing can prevent rapid virus spread and reduce COVID-19-related hospitalizations and deaths, but this can only be realized with accessible, low-cost, and rapid testing. The most widely used tests today (i.e., RT-PCR) are slow, expensive, and require highly skilled workers and designated lab space to collect and interpret the results.Solution:This SARS-CoV-2 biosensor is fabricated on cotton swabs and can be manufactured at low cost. This technology is extremely portable without the need of any heavy equipment for SARS-CoV-2 detection, enabling use at the point-of-care and at home. It also allows SARS-CoV-2 detection within 5 minutes in two simple steps, and the test result can be assessed with naked eye while quantitative results can also be generated using a smartphone camera and a free app.Technology:The COvid-19 Low Cost Optodiagnostic for Rapid Testing (COLOR) consists of a cotton swab whose surface is modified with angiotensin converting enzyme 2 (ACE2), the binding receptor for the spike proteins on SARS-CoV-2. To perform the test, the cotton swabs are immersed into nasopharyngeal or oropharyngeal samples for one minute, then are soaked in a wine-colored AuNP-cys-ACE2 solution for three minutes. If the sample contains SARS-CoV-2, the interactions between the spike proteins, ACE2 on the cotton swabs, and the gold nanoparticles (AuNP) induce aggregation of AuNP, which subsequently cause the color shift from wine to purple. Detection can occur qualitatively with naked eye or quantitatively through a smartphone camera and a free app.Advantages:Can be manufactured for $0.15 with readily available materialsAllows detection of SARS-CoV-2 within 5 minutes and without any lab equipmentCan be used at home to detect SARS-CoV-2Displayed 90% accuracy, 96% sensitivity, and 84% selectivity in a clinical sample studySchematic of COLOR technology in SARS-CoV-2 diagnosis: 1) ACE2 immobilization on the surface of cotton swab, 2) sample collection, 3) attachment of SARS-CoV-2 to the swab, 4) incubation in AuNP-cys-ACE2 solution, and 5) color changes of both the swab and the AuNP-containing solution due to AuNP aggregation in the presence of SARS-CoV-2 (bottom) or no color change without the presence of SARS-CoV-2 (top).Stage of Development:Minimum Viable ProductIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:21-9678-TpNCSWeb Published:6/26/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54515","**Summary:** A rapid, low-cost, and portable biosensor for detecting SARS-CoV-2 has been developed, utilizing cotton swabs that can yield test results visible to the naked eye. This technology enables COVID-19 testing within 5 minutes and is designed to be easily used at the point-of-care and at home, eliminating the need for expensive laboratory equipment or highly skilled personnel.

**Applications:** The biosensor can be utilized in various settings including at-home testing, clinics, and remote or resource-limited areas where traditional testing methods may be inaccessible or infeasible. It is suitable for high-frequency testing scenarios to help manage and control the spread of COVID-19.

**Problem Solved:** This technology addresses the critical need for accessible, rapid, and low-cost testing solutions for COVID-19, particularly in lower-income and resource-limited regions that have been severely impacted by the pandemic. By providing results quickly and easily, it aims to facilitate more frequent testing, thereby reducing virus transmission and associated hospitalizations and deaths.","A portable, low-cost, swab-based biosensor allows for rapid visual diagnosis of SARS-CoV-2, with results detectable by the naked eye. This testing solution aims to increase accessibility and frequency of testing, particularly in lower-income and resource-limited regions affected by COVID-19."
"University of Pennsylvania","Strategies for Mitigating Acute Side Effects of Lung-Targeted Nanocarriers","23-10449","","https://upenn.technologypublisher.com/technology/54463","Approaches and Design Techniques to Alleviate Coagulation-Related Acute Side Effects of Lung-Targeted NanocarriersProblem:Lipid nanoparticles (LNPs) play a crucial role in drug delivery, enabling targeted drug administration to specific tissues. LNPs tailored for lung-specific delivery often incorporate cationic (positively charged) lipids. Unfortunately, this inclusion has resulted in adverse effects, including inflammation, lethargy, and internal lung tissue damage. These unresolved side effects currently render such lung-targeted LNPs unsuitable for human therapeutic use.Solution:Extensive mouse model testing inDr. Brenner'slab has identified excessive coagulation occurs as a result of cationic LNP delivery and is the primary cause of these downstream acute side effects. Addressing this issue could involve several strategies: pre-treatment of patients with direct thrombin inhibitors such as Bivalirudin, limiting nanocarrier size to less than 100nm, and attaching anticoagulants such as PPACK to the LNP's surface. These measures effectively mitigate coagulation while preserving the lung-targeting capabilities of LNPs in mouse models.Advantages:Pretreatment with Bivalirudin (an anticoagulant agent) prevents coagulation while sustaining the lung-targeting capacity of nanocarriers.Nanocarrier surface attachment of anticoagulant agents eliminates the need for a separate anticoagulant administration.Altering nanocarrier size to less than 100 nm reduces fibrinogen uptake in the lung, preventing coagulation and preserving lung-targeting specificityStage of Development:In vivo proof of conceptIntellectual Property:Patent pendingReference Media:Omo-Lamai, S et al.;Adv Mater 2024 Feb 23 : e2312026.Desired Partnerships:LicenseCo-developmentCase ID:23-10449-TpNCSWeb Published:6/21/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54463","**Summary:** The technology focuses on addressing the acute side effects associated with lung-targeted lipid nanoparticles (LNPs), particularly those caused by cationic lipids, which have been linked to inflammation, lethargy, and damage to internal lung tissues. Research conducted in mouse models has identified excessive coagulation as a primary cause of these adverse effects. Various strategies have been proposed to mitigate coagulation, including the pre-treatment of patients with direct thrombin inhibitors like Bivalirudin, reducing the size of the nanocarriers to less than 100 nm, and attaching anticoagulant agents such as PPACK to the nanocarrier surface. These strategies are designed to maintain the targeting ability of LNPs while preventing coagulation-related side effects.

**Applications:** The technology has applications in the development of safer and more effective lung-targeted drug delivery systems using lipid nanoparticles, potentially improving the therapeutic options for respiratory diseases or conditions requiring targeted treatment in the lungs.

**Problem Solved:** It addresses the issue of acute side effects caused by the use of cationic lipid nanoparticles in lung therapies, specifically by alleviating coagulation-related issues that currently hinder the clinical applicability of these drug delivery systems.","Lipid nanoparticles (LNPs) designed for lung-specific delivery often contain cationic lipids, which can lead to adverse effects such as inflammation, lethargy, and damage to internal lung tissues. Strategies are needed to mitigate these coagulation-related acute side effects associated with LNPs."
"University of Pennsylvania","Predicting Post-Surgical Cardiovascular Events via Extracellular Vesicle Analysis","18-8716","","https://upenn.technologypublisher.com/technology/54435","Flow cytometry-based method for predicting post-surgical cardiovascular events.Problem:Cardiovascular events that occur after non-cardiac vascular surgery are significantly associated with post-surgical mortality. In fact, the mortality rate of patients who experience heart attacks following non-cardiac vascular surgery is 65%. Additionally, one in five patients suffer a cardiovascular event within one year of surgery. Stratification of patient population by risk factors is crucial to inform management of pre-, peri-, and post-surgical care for better outcome. Various intervention clinical trials aimed at improving surgical outcomes have produced conflicting results. A more precise and systematic approach is necessary.Solution:The inventors developed a flow cytometry-based method of analyzing extracellular vesicles (EVs) in patient samples collected prior to surgery to predict post-surgical cardiovascular event risk.Technology:The inventors demonstrated that surface markers on EVs collected prior to surgery (including CD31, CD105, and CD64) may predict risk of cardiovascular events following a non-cardiac surgical procedure (full panel includes: CD47, CD3, CD31, CD105, CD64, CD41a, and CD144). Analysis of EVs was done by 1) collecting pre-surgical patient blood samples, 2) isolating EVs, 3) labeling EV isolate, and 4) analyzing via high-sensitivity flow cytometry. The presence of EVs expressing CD31+, CD105+, and CD64+ was significantly correlated with cardiovascular events.Advantages:Cost effectiveRapid analysisCan achieve higher sensitivity and specificity in predicting cardiovascular events than any existing methodology.Graph comparing the discovered EV phenotype in the two groups of patients. Heavy line corresponds to the median value within groups. Box boundaries are the 1st and 3rd quantiles. Each dot corresponds to an individual patient. The y-axis has units of ‚ÄúEVs per ul Plasma‚Äù.Stage of Development:Proof of concept demonstrated with patient samples in a prospective multi-site clinical trial (N=212).Intellectual Property:US national phasefiledEPO national phasefiledReference Media:Mizus, M. et al.Arterioscler Thromb Vasc Biol. 2016 Sep;36: A355Kumar, M. et al.J Extracell Vesicles, 2020, Vol.9(S1): 1784511Kurtzman, N. et al.Cytometry B Clin Cytom 2013 Jul-Aug; 84(4): 255Rogers, W. et al Cytometry BClin Cytom 2017 Jul; 92(4): 258Desired Partnerships:LicenseCo-developmentCase ID:18-8716-TpNCSWeb Published:6/17/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54435","**Summary:** This technology utilizes a flow cytometry-based method to analyze extracellular vesicles (EVs) in blood samples from patients prior to non-cardiac vascular surgeries to predict the risk of post-surgical cardiovascular events. The analysis focuses on specific surface markers on EVs, such as CD31, CD105, and CD64, which have been shown to correlate significantly with the likelihood of cardiovascular events following surgery. 

**Applications:** The method can be applied in clinical settings to stratify patients based on their risk for cardiovascular events, allowing for improved management during pre-operative, peri-operative, and post-operative care. This approach could help inform decisions related to patient monitoring and interventions, possibly leading to enhanced surgical outcomes.

**Problem Solved:** The technology addresses the high rates of cardiovascular events and associated mortality following non-cardiac vascular surgery, which significantly impact patient outcomes. By implementing a more precise and systematic risk prediction approach using EV analysis, it aims to better inform healthcare professionals on patient management strategies to reduce the incidence of these events.","Cardiovascular events following non-cardiac vascular surgery have a high mortality rate, with 65% of patients experiencing heart attacks dying post-surgery. Furthermore, one in five patients suffers a cardiovascular event within one year of the procedure, highlighting the need for effective risk stratification."
"University of Pennsylvania","3D Printed Heterogeneous Density Modulators for Enhanced Precision in Radiation Therapy","23-10370","","https://upenn.technologypublisher.com/technology/54395","Range modulators with variable density enhancing precision to control dosage and spatial distribution of radiation.Problem:Particle radiation therapy, increasingly standard for eligible patients, requires precise energy selection to effectively target tumors. Conventional range modulators, primarily varying in thickness, lack the precision needed, especially for irregular tumor shapes with varying dose requirements across regions.Technology:Using the PixelPrint method developed at Penn, inventors have created a process and system for manufacturing 3D-printed modulators with heterogeneous densities, which enable control over spatial dose distribution in radiation therapy. This approach facilitates the design of personalized range modulators tailored to the specific tumors of individual patients. Beyond custom-made modulators for each patient, the technology also supports the use of modular units with varied densities. These pre-made components can be assembled into a modulator customized for each patient, streamlining the process while maintaining personalized care.Advantages:Enhanced precision through density and thickness variations for optimal energy selectionTailored designs to accommodate diverse patient needsPotential use of modular units for adaptable usage by medical practitioners in ultra-fast radiation deliveryFig.1 (a) 3D printed heterogeneous density range modulating devices. (b) Axial view of CT scan and (c) saggital view of CT scan. (d) Density profiles across the device.Stage of Development:Proof of ConceptBench PrototypeMinimum Viable ProductIntellectual Property:Provisional FiledDesired Partnerships:LicenseCo-developmentCase ID:23-10370-TpNCSWeb Published:6/11/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54395","**Summary:** The technology involves the development of 3D-printed range modulators that utilize heterogeneous densities to enhance the precision of radiation therapy, effectively controlling the dosage and spatial distribution of radiation for tumor targeting. It leverages the PixelPrint method from Penn to create customizable modulators that can be tailored to the unique characteristics of individual tumors rather than relying on conventional thickness-varied modulators that may lack the necessary precision for irregular tumor shapes.

**Applications:** This technology is primarily applicable in particle radiation therapy, where it can be used to create personalized range modulators for cancer patients. Additionally, it supports the assembly of modular units with varied densities for adaptability in treatment plans, particularly in ultra-fast radiation delivery settings.

**Problem Solved:** The technology addresses the challenge of accurately selecting energy levels in radiation therapy, which is critical for effectively targeting tumors with varying dose requirements across different regions. It overcomes the limitations of traditional range modulators by providing enhanced precision through the ability to customize density and thickness for targeted treatment.","Researchers have developed 3D printed range modulators with variable density to enhance the precision of radiation therapy by better controlling dosage and spatial distribution. The new technology addresses the limitations of conventional modulators, which primarily vary in thickness and lack the necessary precision for irregular tumor shapes."
"University of Pennsylvania","Physical Neural Network for Fast, Scalable, and Power-Efficient Machine Learning Computation","","","https://upenn.technologypublisher.com/technology/55457","A physical embodiment of a locally-learning neural network, which learns faster than current CPU-based nets.Problem:Machine learning is a ubiquitous tool that has found uses in engineering, science, and medicine. Neural networks are some of the most powerful machine learning algorithms, but they train very slowly when they become large. This hampers software pipelines involving data collection, machine learning, and analysis in real-time computing applications. In addition, current CPU and GPU-based neural networks consume vast amounts of electrical power.Solution:Designing a physical (circuit-based) neural network that learns using only local information at each node offers fast, scalable, and power-efficient performance. This product leverages the optimization built into the laws of physics to train the neural network on known data. The design is computationally efficient and scalable down to low-power microelectronic applications.Technology:Electrical current follows the most efficient path through a circuit. This built-in optimization inspired the authors to design a locally-learning network of individual circuits. Cycling through ‚Äúfree states‚Äù ‚Äì letting the current follow the easiest path ‚Äì and ‚Äúclamped states‚Äù ‚Äì forcing the network to output the correct voltage ‚Äì settles the network via gradient descent. This finds the optimal network state for a given machine learning application.Advantages:Computes faster than current O(n2) CPU-based methods.May physically scale down to microelectronic (10-6m) scale.Current design contains only 15 elements per circuit, and 16 circuits total.Low-power, cost-efficient, and robust against damage.Free (left) and clamped (right) states of the network. The free state sets the voltage at the red nodes and allows the blue node to achieve its natural steady-state voltage. The clamped mode sets all three colored nodes to have specific voltages. Adjusting the resistance of each edge in proportion to its relative power loss trains the network to naturally produce the desired output voltage at the blue node.Stage of Development:Proof of ConceptIntellectual Property:US PatentUS 2022/0383205 A1FiledReference Media:Stern et al.Phys. Rev. X, 2021 May, 11 (2): 021045Desired Partnerships:LicenseCo-developmentCase ID:21-9647-tpNCSWeb Published:10/24/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/55457","**Summary:** A locally-learning neural network in physical form learns faster than traditional CPU-based networks by utilizing a circuit-based design. This approach allows the network to process information efficiently using local data, leading to fast training and performance improvements. By taking advantage of the inherent optimization properties of electrical current flow, the network can settle into an optimal state for specific machine learning tasks through a process of cycling between free and clamped states. 

**Applications:** This technology can be applied in various fields such as engineering, science, and medicine, particularly in real-time computing applications where rapid data analysis, machine learning, and decision-making are required. 

**Problem Solved:** The technology addresses the slow training speed of large neural networks when implemented on traditional CPU and GPU platforms, which hinders their application in real-time scenarios. Additionally, it reduces the significant electrical power consumption associated with these conventional methods, making machine learning more efficient and scalable down to low-power microelectronic applications.","A locally-learning neural network has been developed that learns faster than traditional CPU-based neural networks, addressing the slow training speeds of large neural networks. This advancement aims to enhance real-time computing applications in various fields such as engineering, science, and medicine."
"University of Pennsylvania","A Stable Post-Pyloric Retention Gastrojejunal (GJ) Feeding Tube That Minimizes Dislodgement","","","https://upenn.technologypublisher.com/technology/54320","The proposed invention is a gastric-jejunal (GJ) feeding tube that includes a retention device to maintain its position once placed in a patient.Problem:Enteral feeding devices, e.g., gastric (G) or gastrojejunal (GJ) feeding tubes, offer a safe and efficient means of delivering essential nutrition directly into the gastrointestinal tract. In particular, GJ tubes deliver directly to the jejunum (middle part of the small intestine) and are desirable long-term solutions. Existing GJ tubes incorporate retention modifications (e.g., balloons and discs) to keep the tube from falling out. However, these designs do not address a common problem - the migration of the jejunal component backward into the stomach, a medical emergency requiring urgent intervention to position the tube back into the jejunum.Solution:The inventor proposed a new GJ tube design with a post-pyloric retention device to help maintain its positioning in the small intestine once placed. The post-pyloric retention device leverages the natural anatomy (e.g., strong muscle and narrow lumen) of the junction between the stomach and small intestine to improve stability and prevent the GJ tube from moving backward.Technology:The present invention is a GJ tube containing a post-pyloric retention device immediately distal to the pylorus. The pylorus is a naturally narrow channel that prevents the retention device from dislodging and migrating back into the stomach. The retention component may be an inflatable balloon or other deployable retention device, which secures the entirety of the tube once inflated. This design effectively improves the stability of the GJ tube and avoids dislodgement by leveraging the natural anatomy of the junction between the stomach and small intestine.Advantages:Improve GJ tube retention and address the migration and dislodgement issues by adding a post-pyloric retention device.Improve gastrojejunal (GJ) retention: Keep the jejunal component of the tube from migrating back into the stomach.Less gastric outlet obstruction: Avoid possible gastric outlet obstruction by placing the retention device distal to the gastric outlet.Allow for shorter duodenal/jejunal portion of GJ tube: Increase the potential absorptive area of the gut and provide more physiologic delivery of nutrition into the duodenum rather than the jejunum.Prevent migration events that may result in unnecessary hospitalization, emergency room visits, and procedures, as well as significant dissatisfaction among patients and caregivers due to disruptions in routines, concerns about receiving adequate nutrition and/or hydration, etc.Potentially provide a safe and long-term feeding solution for patients who are immobile or immobilized.Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Kuo, YC et al.J Vasc Interv Radiol 2008 Apr (19)4: 557.Trerotola, SO et al.J Vasc Interv Radiol 2003 Nov (14)11: 1387.Trerotola, SO et al.J Vasc Interv Radiol 2005 Dec (16)12: 1613.Trerotola, SO and Pyeritz, RE.J Vasc Interv Radiol 2009 June (20)6: 824.Trerotola, SO et al.J Vasc Interv Radiol 2010 Feb (21)2: 203.Desired Partnerships:LicenseCo-developmentCase ID:23-10338-TpNCSWeb Published:5/31/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54320","**Summary:** The proposed invention is a gastrojejunal (GJ) feeding tube featuring a retention device designed to secure its position in a patient after placement. This GJ tube aims to enhance the stability and prevent backward migration into the stomach, addressing a common issue with existing devices.

**Applications:** The GJ tube is intended for enteral feeding, particularly suitable for patients requiring long-term nutrition delivered directly to the jejunum of the small intestine, thereby enhancing patient care in clinical settings.

**Problem Solved:** The innovation resolves the issue of jejunal component migration into the stomach, a medical emergency that necessitates urgent repositioning. By utilizing a post-pyloric retention device that capitalizes on the natural anatomy of the pyloric junction, the new design improves the overall safety and effectiveness of GJ feeding tubes.","The invention is a gastric-jejunal feeding tube designed with a retention device to securely maintain its position in patients. This addresses the challenge of dislodgement often associated with existing enteral feeding devices."
"University of Pennsylvania","Biodegradable Batteries Operational In The Air, Environment, And Soil","","","https://upenn.technologypublisher.com/technology/54227","A method to fabricate batteries from biodegradable materials that can operate in the environment, such as on or under soil, and are scalable in size.Problem:Recently there have been significant developments in biodegradable sensors, which can perform environmental measurements (e.g., on or below the surface of soil) for a specific time and then degrade harmlessly into the environment. Such sensors often require power sources for standalone implementation. These power sources may be used to drive electronic components, take electrochemical measurements, and enable wireless communication with other external devices. To fully realize fully biodegradable sensor systems for these applications, their power sources must also be biodegradable.Solution:Researchers at the University of Pennsylvania developed a method to fabricate metal-air batteries from biodegradable materials that operate in air or on/under soil. The battery can be scaled down to the approximate size of a corn-kernel for potential deployment with planters. The use of biodegradable materials allows for terrestrial implementation with lower sustainability risks compared to commercial batteries. A power source can be more stable on the surface and below it if it is enclosed in wax, which shields it from the surrounding conditions.The disclosure demonstrated the fabrication of zinc-air batteries constructed from thin-film-based anodes, catalyst-containing cathodes, a biodegradable gel electrolyte, and a wax-based enclosure. Material selection is leveraged to allow for the preferential permeation of oxygen relative to the passage of water or carbon dioxide to power the battery. The technology can deliver a consistent output voltage of up to 1.2 volts for months in the air and underground, thanks to accurate power cell design. Current work involves further optimization to transition the batteries into integrated sensor platforms for wireless applications.Advantages:A fabrication route to construct metal-air electrochemical cells (e.g., Zn-air) from biodegradable materials with selective passage of relevant chemical species for operation (water, oxygen, carbon dioxide).Provides a route to assemble the metal-air electrochemical cell with a biodegradable enclosure (e.g., wax) for ambient protection, allowing for stability in subsurface environments (e.g., soil) as well as air environments.Displays battery performance in surface and sub-surface environments such as soil over months-long periods with output voltages up to 1.2 volts, highlighting potential for usage in wireless sensors.Cross-sectional view of the fabrication process for Zinc-air batteries composed of biodegradable materials and sealed in a wax-based enclosure. With careful sealing, the batteries can operate in both air and soil environments.Stage of Development:Bench PrototypeIntellectual Property:PCT Patent Application In PreparationReference Media:Venkatesh, V. et al.,J. Micromech. Microeng., 2023 March 13; Vol. 33(05): 5001Zhang, J. et al.,ACS Appl Mater Interfaces., 2023 Feb 8; 15(5): 6807Venkatesh, V. et al.,IEEE Xplore; 2021 Aug. 6, 21st Int'l Conference on Solid-State Sensors, Actuators & Microsystems, June 2021: 1134Desired Partnerships:LicenseCo-developmentCase ID:23-10421-tpNCSWeb Published:5/20/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54227","**Summary:** Researchers at the University of Pennsylvania have developed a method to create metal-air batteries from biodegradable materials that can function in air, on, or beneath the soil. These batteries are scalable, being able to be manufactured to the size of a corn kernel, making them suitable for deployment with agricultural planters. The design utilizes biodegradable components such as thin-film anodes, catalyst-containing cathodes, and a gel electrolyte, all encased in a protective wax enclosure to enhance stability in diverse environmental conditions. 

**Applications:** The biodegradable batteries can be used to power standalone sensors for environmental monitoring, allowing for electrochemical measurements and wireless communication. They are particularly applicable in agricultural settings where soil or environmental health assessments are needed without leaving harmful waste.

**Problem Solved:** The technology addresses the need for sustainable power sources for biodegradable sensors that can operate in soil or air without contributing to environmental waste. Traditional battery technologies pose sustainability risks, and this innovation provides a solution that is not only effective but also environmentally friendly, allowing sensors to degrade harmlessly after use.","A method has been developed to fabricate scalable, biodegradable batteries that can operate in various environmental conditions, including on or under soil. These batteries are designed to power biodegradable sensors that perform environmental measurements and degrade harmlessly after use."
"University of Pennsylvania","Scalable and Eco-Friendly Manufacturing of Tunable Heterogeneous Nanoparticle Films","","","https://upenn.technologypublisher.com/technology/54207","A scalable heterogeneous nanoparticle film with controllable manufacturing methods with tunable properties that could be useful for a variety of applications.Problem:Current techniques for manufacturing polymer-infiltrated nanoparticle films (PINFs) include immersion in polymer melts, capillary rise infiltration, and solvent-driven infiltration. These methods only produce homogenous PINFs that have a uniform composition and structure throughout the thickness. Heterostructured PINFs with varying structures would be useful for certain applications including drug delivery, membrane separation, and photonics, but there is a lack of scalable and controllable methods to produce such PINFs.Solution:The inventors developed a scalable and controllable method to produce tunable heterostructued PINFs with a high-volume fraction of nanoparticles. The thickness and porosity of these PINFs can be modulated, creating films with varying physical and optical properties that can be customized for different applications. Additionally, the method does not use organic solvents, making it eco-friendly.Technology:A layer of silicon dioxide (SiO2) nanoparticles is spin-coated onto a layer of larger polystyrene nanoparticles. These dispersions may also be mixed and blade-coated in one step for better manufacture scaling. The bilayer is heated above polystyrene‚Äôs glass temperature (100‚Å∞C), and the polystyrene particles melt and wick into the SiO2 layer. The space occupied by the polystyrene nanoparticles is left void of SiO2 nanoparticles. The film‚Äôs refractive index can be tuned by changing the relative volume of inorganic nanoparticles, and therefore the relative pore size. Films of alternating refractive indices can be stacked to form a Bragg reflector.Advantages:Greater than 60% volume fraction of nanoparticlesAllows for production of nanoparticle films specific to different applicationsEco-friendly option that eliminates need for organic solventsThe figure shows SEM images before and after nanocomposite annealing. SiO2 nanoparticles are layered on polystyrene particles, which melt and form a matrix upon solvent-driven annealing. This leaves the space previously occupied by SiO2 unoccupied. The films can be produced by using either a blade or a spinner to coat the substrate.Stage of Development:Bench PrototypeIntellectual Property:Utility Patent Application FiledUS 2023/0244006 A1Reference Media:Kim, B. Q., et al.,Adv. Mater. Interfaces; 2021 Feb 5, Vol 8(3): 2001421Desired Partnerships:LicenseCo-developmentCase ID:20-9443-tpNCSWeb Published:5/16/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54207","**Summary:** A new method has been developed for the scalable manufacturing of heterogeneous nanoparticle films, allowing for tunable properties and customizable structures. This approach enables the creation of polymer-infiltrated nanoparticle films (PINFs) with varying thickness and porosity, providing control over their physical and optical characteristics. The technique avoids the use of organic solvents, contributing to its eco-friendly profile.

**Applications:** The tunable heterogeneous nanoparticle films are applicable in various fields, including drug delivery systems, membrane separation technologies, and photonics, adapting to the specific requirements of these areas through their customizable properties.

**Problem Solved:** Traditional manufacturing methods for PINFs typically yield only homogenous films, restricting their utility in applications requiring varied structures. The new method provides a solution by enabling the production of heterostructured PINFs with diverse compositions and properties that can be adjusted according to specific application needs, enhancing the versatility and effectiveness of nanoparticle films.","The research outlines a scalable method for creating heterogeneous nanoparticle films (PINFs) with tunable properties suitable for various applications. Current manufacturing techniques yield only homogeneous PINFs, which lack the desired structural variation throughout their thickness."
"University of Pennsylvania","Immune Modulator Encoded Lipid Nanoparticle Formulation Improves T Cell Response to Vaccines","22-10096","","https://upenn.technologypublisher.com/technology/54201","Researchers developed an LNP-mRNA-based vaccine that encodes different cytokine mRNAs, as a method to enhance CD8+ T cell responses and memory formation.Problem:Lipid nanoparticles (LNPs) are an emerging technique to deliver mRNA in vivo more efficiently. While recent progress in mRNA technology has allowed the rapid development of SARS-COV2 vaccines, these protective responses often require high doses and boosting to generate long lived protective T cell responses.Solution:Dr. Hunter and his team have developed a method to promote T-cell immune responses to vaccines, by delivering mRNA that encodes cytokine (IL-12 or IL-27) concurrently with the antigen encoding mRNA. With this approach, they enable the future development of new vaccines by ‚Äúmixing and matching‚Äù target antigens with different cytokines to enhance the memory T cell pool.Technology:The inventors previously discovered the importance of IL-27 in eliciting immune responses of CD8+ T cells post-mRNA LNP immunization. To validate this vaccine approach, the inventors first test IL-27 overexpression in vivo with a low dose of the antigen encoding mRNA. They then test the effects of the cytokine/antigen combination vaccine for restoring T cell expansion in IL-27 knock-out mice demonstrating the ability to produce functional cytokine in vivo. In wildtype mice administration of the cytokine/antigen combination vaccine improves the size of the CD8+ T cell memory pool, which is essential for long-term protection. Further, inclusion of cytokine mRNA improved the therapeutic efficacy of an anti-tumor antigen vaccine. Similar studies utilizing IL-12 mRNA showed that IL-12 could also be leveraged to improve memory CD8+ T cell formation and therapeutic efficacy of mRNA-LNPs to malignancy.Advantages:All the components of the LNP-mRNA vaccine can be modified, including the components that make up the LNPs and cytokine sequenceA small single dosage of the vaccine can induce a 10-fold increase in IL-12 or IL-27 expression in vivoCytokine mRNA (IL-12 or IL-27) improves the induction of antigen-specific CD8+ T cell responses to the vaccineCytokine mRNA (IL-12 or IL-27) augments memory CD8+ T cell poolCytokine mRNA (IL-12 or IL-27) enhances the efficacy of a therapeutic vaccine against murine melanomaStage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:PCTFiledReference Media:Park, J et al.Infect Immun, 2019 Dec, 87(12): ‚Äì e00455-19.Desired Partnerships:LicenseCo-developmentCase ID:22-10096-TpNCSWeb Published:5/15/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54201","**Summary:** Researchers have developed an LNP-mRNA-based vaccine that encodes various cytokines, specifically IL-12 and IL-27, to enhance CD8+ T cell responses and memory formation. Previous advancements in mRNA technology have facilitated the rapid development of vaccines, such as those for SARS-CoV-2, but often require high doses and additional boosting to achieve durable T cell responses. The new approach promotes T-cell immune responses by delivering cytokine-encoding mRNA alongside antigen-encoding mRNA. Initial validations included testing IL-27 overexpression in vivo with a reduced dose of antigen-encoding mRNA. The results showed that combining the cytokine with antigen vaccines could restore T cell expansion in IL-27 knock-out mice and improve the CD8+ T cell memory pool in wildtype mice, suggesting enhanced long-term protective effects.

**Applications:** This technology has the potential to improve vaccine formulations by allowing for the customization of cytokines and antigens, thereby enhancing the efficacy of vaccines against various infectious diseases and potentially other conditions requiring strong T cell-mediated immunity.

**Problem Solved:** The approach addresses the challenge of generating long-lasting protective T cell responses typically required in vaccination strategies, especially those using mRNA technology, by utilizing lipid nanoparticles to effectively deliver cytokine mRNAs that enhance T cell proliferation and memory formation.","Researchers developed a lipid nanoparticle-mRNA vaccine that encodes various cytokine mRNAs to enhance CD8+ T cell responses and memory formation. This approach aims to improve the effectiveness and longevity of protective T cell responses generated by current mRNA vaccines."
"University of Pennsylvania","An Electrophoresis Microfluidic System for Measuring Size, Shape, Charge, and Deformability of Single Particles","","","https://upenn.technologypublisher.com/technology/54148","A microfluidic system that uses transverse alternating-current (AC) electrophoresis for multi-parameter analysis of single biological particles including mammalian or bacterial cells.Problem:With broad distributions of bacterial species in the human gut microbiome, there is a growing need for characterization methods capable of obtaining the signatures of complex bacterial communities. Currently, there are insufficient methods available to characterize bacteria from other samples, especially those that are capable of bacterial sorting. While modern methods such as metagenomics or metatranscriptomics can detect range and diversity of bacteria in the microbiome, the methods are limited by their ability to measure shifts in composition to functional changes. Thus, there is a need for a tool capable of not only obtaining bacterial signatures, but also of tracking changes in composition for longitudinal studies. Finding such methods will allow for better characterization of human gut microbiomes and have great implications for host health.Solution:This disclosure presents a microfluidic system using electrophoresis for multi-parameter analysis such as charge, shape, size, and deformability for single bacterial cells. This methodology provides advanced physical analysis while being compatible with current microfluidic sorting technology used in research. The technology has potential to also bridge classical physical characterization with current molecular analyses such as single-cell genomics. When coupled to downstream sorting, the physical characterization of the technology can be utilized to bypass repetitive isolation of biological species higher in abundance.Technology:The inventors leverage transverse AC electrophoresis in a microfluidic system for physical characterization, a novel process combining particle tracking velocimetry and AC electrophoresis. By applying electric waves transversely to bulk flow, particles oscillate allowing for characterization of size and charge through particle oscillation. By modulating the parameters of the electric field and timing of application, hydrodynamic shape and deformabilities can be further collected. Large dimensions in the microchannel of the microfluidic device allow for facile characterization without clogging of the device and averaging multiple wave cycles allows for increased precision in characterization.Advantages:Characterizes a single bacteria‚Äôs charge, size, shape, and deformability in a single analysisAvoids water hydrolysis and bubble production for facile characterization with short inter-electrode distancesCan acquire fecal microbiome signatures rapidly (in minutes to seconds) and inexpensively (uses commercial materials)Has potential to be extended for use in other biological particles such as mammalian cells and virionOverview of the transverse AC electrophoresis microfluidic system: (Left) schematic of the microchannel used in the device; and, (Right) the integration of on-line labeling.Stage of Development:Bench PrototypeIntellectual Property:Utility Patent Application 18/587,324 FiledReference Media:Choi, M. H. et al.,Lab Chip, 2023 Dec 20; 24(1): 20Desired Partnerships:LicenseCo-DevelopmentCase ID:22-10005-tpNCSWeb Published:5/8/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54148","**Summary:** This technology involves a microfluidic system utilizing transverse alternating-current (AC) electrophoresis for the detailed analysis of single biological particles, specifically focusing on mammalian or bacterial cells. It aims to characterize bacterial populations in the gut microbiome, addressing the limitations of existing methodologies that struggle with tracking functional changes over time. The system measures key parameters such as size, shape, charge, and deformability, thereby providing a comprehensive characterization tool that works in conjunction with contemporary microfluidic sorting technology.

**Applications:** The microfluidic system can be applied in microbiome research to identify and characterize bacterial species and communities, which is critical for understanding their role in human health. Additionally, it could be utilized in longitudinal studies to monitor changes in bacterial composition and functionality, with implications for various fields including clinical diagnostics and personalized medicine.

**Problem Solved:** The technology addresses the inadequacy of current methods in characterizing complex bacterial communities within the human gut microbiome. It overcomes the limitations of metagenomics and metatranscriptomics by providing a means to track not only the diversity but also the functional changes of bacterial populations over time, enhancing the understanding of host-microbiome interactions and potential health outcomes.","A microfluidic system utilizes transverse alternating-current (AC) electrophoresis for multi-parameter analysis of single biological particles, including mammalian and bacterial cells. This method addresses the need for effective characterization techniques for complex bacterial communities in the human gut microbiome."
"University of Pennsylvania","Augmented Reality Interface for Radiation-Free Screw Insertion during Intramedullary Nail Insertion for Long Bone Fractures","22-9939","","https://upenn.technologypublisher.com/technology/53942","The NailedIt Augmented Reality (AR) Surgical Navigation System, comprised of a Windows-based desktop application, augmented reality headsets (HMDs) worn by surgeons, handheld mobile devices supporting remote viewing and surgical site annotation, and spatially tracked medical devices and instruments, assists and guides surgeons while they perform orthopedic surgical tasks using an immersive augmented reality user interface.Problem:Long-bone fracture surgery involves placement of intramedullary nails requiring radiation-based intraoperative fluoroscopy, which creates safety issues along with challenges in implant positioning.Solution:The inventors have created an augmented reality system designed to assist surgeons with precisely placing screws during intramedullary nail insertion for long-bone fractures. This innovative method projects accurate insertion points for screws directly onto the surgical field and interactively guides the surgeon to drill corresponding screw holes with the correct orientation and depth. This approach circumvents the need for fluoroscopy by employing an augmented reality interface tailored to the individual's anatomy, thereby enhancing procedural accuracy and reducing recovery times.Technology:The NailedIt software application enables display of comprehensive pre-operative surgical details on both the desktop display and in the head-mounted display (HMD) worn by the surgeon. This includes the current surgical plan and precise instructions. The system also is compatible with a variety of HMD and mobile augmented reality (AR) devices. Beyond text-based instructions, surgeons can see markups of the physical surgical site superimposed over their normal field of view as well view interactive 3D graphical anotations that guide the surgeon through each step of the procedure. Critical information displayed in real-time includes the location of distal nail holes, current position and orientation of drill guides and other tracked instruments, desired drill axis postion and orientation and depth of the currently drilled hole. Furthermore, the guidance provided by this innovative augmented reality system can be shared among a team of surgeons, enhancing collaboration and precision. This platform technology allows for expansion into other orthopaedic care spaces where navigation can be beneficial such as minimally invasive plate osteosynthesis, spine, hip or pelvis.Advantages:Decreased radiation exposureDecreased operative timeIncreased accuracy using patient-specific anatomySurgeons can collaborate in the AR space during procedureCan work with different AR devicesDevice company agnostic (can be used with any IM Nail system)NailedIt Application comprising the desktop/server software, the HMD AR interface, and use of the smart insertion handle with accompanying surgical guide during a demoed procedure.Stage of Development:Bench Prototype (minimally viable product)Intellectual Property:Provisional FiledReference Media:NailedIt ProjectDesired Partnerships:LicenseCo-developmentCase ID:22-9939-TpNCSWeb Published:4/10/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53942","**Summary:** The NailedIt Augmented Reality Surgical Navigation System is an innovative AR-based technology designed to assist surgeons in orthopedic procedures, specifically for the insertion of intramedullary nails during long-bone fracture surgeries. Utilizing a combination of a Windows-based desktop application, augmented reality headsets, handheld mobile devices, and spatially tracked medical instruments, this system provides an immersive user interface that enhances surgical precision and facilitates accurate screw placement without the use of radiation-based fluoroscopy. 

**Applications:** This technology is primarily applicable in orthopedic surgeries, particularly for the treatment of long-bone fractures requiring intramedullary nailing. It enhances surgical navigation and enables the precise placement of screws during procedures, ultimately improving patient outcomes and efficiency in surgical practices.

**Problem Solved:** The system addresses the challenges associated with traditional long-bone fracture surgeries, which rely on radiation-based intraoperative fluoroscopy for the placement of intramedullary nails. By providing a radiation-free alternative that projects accurate insertion points directly onto the surgical field, the NailedIt system improves implant positioning, enhances procedural accuracy, reduces the risks related to radiation exposure, and potentially shortens patient recovery times.","The NailedIt Augmented Reality Surgical Navigation System aids surgeons in orthopedic procedures by utilizing a combination of a desktop application, augmented reality headsets, mobile devices for remote viewing, and spatially tracked instruments. It is designed to assist with the insertion of intramedullary nails during long-bone fracture surgeries while ensuring a radiation-free environment."
"University of Pennsylvania","A Stretch-Activated Adhesive Microcapsule For The Controlled Release of Drugs In Wound-Healing Dressings","","","https://upenn.technologypublisher.com/technology/53913","An adhesive drug-loaded microcapsule which releases therapeutic cargo upon mechanical stretching.Problem:Medicated dressings can improve healing of open wounds and improve pain management in patients. However, drug-coated bandages lack stimuli-response release mechanisms, so therapeutics are not released in a controlled and sustained manner. Poor control of cargo release in current wound-healing membranes generates large fluctuations in dosing, whereas controlled release mechanisms create relatively constant drug concentrations at the wound site. Stable drug-release maintains therapeutic dose over the entire duration of wound-healing and promotes better antimicrobial and pain-killing effects.Solution:The technology is mechanically-activated microcapsules (MAMCs) which can be loaded with therapeutic cargo. The MAMCs are coated in an adhesive polymer so they can be bonded to fabrics, membranes, or bandages. Once MAMC-coated dressings are applied to a wound, stretching of the material due to bodily movement induces tensile strain which releases drug from capsules at the wound site. The mechano-responsive microcapsules can be loaded with any combination of antibiotics, anti-inflammatory medication and painkillers depending on the medical need.Technology:Uniform drug-loaded poly(lactic-co-glycolide) acid microcapsules are made using a capillary microfluidic device. Strain-responsive polymeric capsules are coated with poly-dopamine which serves as an adhesive for coating MAMCs onto wound-healing fabrics and membranes. When mechanical strain is applied to MAMC-coated materials, therapeutic molecules are released form microcapsules due to Poisson-ratio squeezing, controlling the release of drugs.Advantages:Adhesive coating prevents detachment of drug-loaded microcapsules from wound dressingsSignificant drug release from adhesive microcapsules at 50% stretch strain(a) Microscopy images of gauze embedded with MAMCs. The red circles indicate microcapsules. (b) Photographs of the MAMC-embedded gauze membrane before and after stretching using a custom micromechanical device. (c) Confocal images of the MAMCs containing bovine serum albumin (green) with labeled microcapsules (red). (d) Microscopy images of the adhesive MAMCs in the gauze before and after stretching.Stage of Development:Bench PrototypeIntellectual Property:European PatentPendingUS PatentPendingReference Media:Mohanraj, B et al.Adv Funct Mater, 2019 Apr 11, 29(15): 1807909Desired Partnerships:LicenseCo-developmentCase ID:20-9300-tpNCSWeb Published:4/8/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53913","**Summary:** The described technology involves an adhesive microcapsule that releases drugs upon mechanical stretching. These microcapsules, which can contain various therapeutic agents such as antibiotics, anti-inflammatory medications, and painkillers, are designed to enhance wound healing and improve pain management. The microcapsules are coated with an adhesive polymer, allowing them to bond effectively to dressings and fabrics. When the dressing undergoes stretching as a result of bodily movement, the tensile strain activates the microcapsules, triggering the controlled release of the therapeutic cargo at the wound site.

**Applications:** This technology is primarily applicable in the field of wound care, particularly in medicated dressings that require controlled and sustained release of drugs. It can be used in various medical settings where effective healing of open wounds and pain management are crucial, such as in post-surgical care, burn treatment, and chronic wound management.

**Problem Solved:** Traditional medicated dressings often lack effective mechanisms for controlled drug release, resulting in inconsistent dosing and poor therapeutic outcomes. This technology addresses the issue by providing a stable and continuous release of medication, ensuring that therapeutic doses are maintained over the duration of wound healing. This mechanism enhances the antimicrobial properties and pain-relieving effects of the dressing, leading to improved patient outcomes.","An adhesive drug-loaded microcapsule releases therapeutic cargo in response to mechanical stretching, addressing the lack of controlled release mechanisms in medicated dressings. This innovation aims to improve the healing of open wounds and pain management by providing a sustained and regulated release of therapeutics."
"University of Pennsylvania","Modified Antimicrobial Peptides For Enhanced Antibiotic Properties","","","https://upenn.technologypublisher.com/technology/53600","Modified antimicrobial peptides with protein sequences for augmenting antimicrobial and antibiofilm properties.Problem:Antibiotic resistant bacteria are becoming more prevalent, while antibiotic innovation has slowed. Novel antimicrobial agents are needed to treat the 35,000 annual deaths from antibiotic resistant infections. While antimicrobial peptides (AMPs) have antibiotic potential, they lack potency to fight infections. The ability to modify AMPs and improve their antibiotic properties would result in a new generation of antimicrobial agents.Solution:The modified AMPs have robust antibiotic properties against lethal, drug resistant bacteria. The AMPs also disrupt biofilm formation when combined with low doses of common antibiotics.Technology:The inventors used computational modeling to determine the ideal pairing of AMP and activating protein sequence. The sequence is added to the AMP to improve its enzymatic activity. The modified AMPs have increased effectiveness against antibiotic resistant bacteria. The AMPs permeabilize bacterial membranes with reduced red blood cell toxicity. When combined with conventional antibiotics at low doses, the AMPs disrupted biofilm formation.Advantages:8-fold higher potency towards antibiotic resistant bacteria than original AMPEffectively permeabilizes bacterial membranesReduced red blood cell toxicityDecreases antibiotic concentration required to disrupt biofilm by 32-foldAntimicrobial peptides (AMPs, light blue helix) are appended with activating protein sequences (ATCUN motifs, yellow, blue, and red). The modified AMPs have enhanced antimicrobial properties. When combined with common antibiotics, the AMPs also disrupt biofilms.Stage of Development:Preclinical DiscoveryIntellectual Property:Utility Patent Application FiledUS20220064219A1Reference Media:Agbale, C. M., et al.,Biochemistry., 2019 Sep 10; 58(36): 3802Torres, M. D. T., et al.,J Mol Biol., 2019 Aug 23; 431(18): 3547Desired Partnerships:LicenseCo-developmentCase ID:20-9127-tpNCSWeb Published:3/13/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53600","**Summary:** Modified antimicrobial peptides have been developed to enhance antimicrobial and antibiofilm properties, offering a potential solution to the growing issue of antibiotic-resistant bacteria. These peptides have shown robust effectiveness against lethal, drug-resistant strains due to their modified protein sequences, which improve their enzymatic activity and overall potency. By disrupting bacterial membranes while minimizing toxicity to red blood cells, the modified peptides can better target infections without compromising patient safety. 

**Applications:** This technology can be applied in clinical settings for treating infections caused by antibiotic-resistant bacteria and may also be useful in developing new formulations of antimicrobial agents that could be used alongside traditional antibiotics to combat biofilm-related complications.

**Problem Solved:** The technology addresses the pressing problem of increasing antibiotic resistance, which leads to approximately 35,000 annual deaths from related infections, by providing an innovative approach to enhance the efficacy of antimicrobial agents.","Modified antimicrobial peptides are being developed to enhance their antimicrobial and antibiofilm properties in response to the rising prevalence of antibiotic-resistant bacteria. This innovation aims to address the significant issue of approximately 35,000 annual deaths resulting from infections that are resistant to current antibiotics."
"University of Pennsylvania","An Effective Method to Evaluate the Risk of Heart Failure with Preserved Ejection Fraction (HFpEF) Using Endotrophin (ProC6) Biomarkers.","","","https://upenn.technologypublisher.com/technology/53596","Measuring endotrophin (ProC6) in plasma predicts the risk of death, heart failure admission, and composite cardiovascular events in HFpEF patients.Problem:HFpEF, which accounts for over half of heart failure (HF) cases, is a condition in which the heart cannot supply enough oxygen and nutrients to the body despite normal ejection fraction levels. Widely used biomarkers, such as MAGGIC risk score and NT-proBNP, failed to predict the risk of the disease. Despite the availability of treatments and disease management approaches (e.g., blood pressure management and lifestyle modification), the 5-year mortality remains high at approximately 76% due to unpredicted cardiovascular events. Thus, there is a need for biomarkers that can effectively predict HFpEF.Solution:The inventor identified a blood biomarker, endortrophin (i.e., collagen ProC6 neoepitope or ProC6), which strongly predicts the risk of (1) Death, (2) heart failure admission, and (3) other cardiovascular events (e.g., resuscitated cardiac arrest) in HFpEF patients and greatly outperforms other biomarkers (e.g., MAGGIC risk score and NT-proBNP).Endotrophin (ProC6) is a collagen type VI‚Äìderived peptide that has not been studied in human heart failure (HF). To examine the association between circulating endotrophin and outcomes in HFpEF patients, the inventors measured the endotrophin level in plasma samples of 205 patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Then, the inventors conducted a participant-level meta-analysis (n=810) comprising six independent studies to further validate the findings. They discovered that high plasma concentrations of endotrophin were strongly associated with death, heart failure admission, and other primary endpoints of the trial (e.g., cardiovascular death or resuscitated cardiac arrest).Advantages:A newly identified prognostic biomarker that can predict and stratify the risk of (1) Death, (2) heart failure admission, and (3) other cardiovascular events (e.g., resuscitated cardiac arrest) in HFpEF patients.Superior predictive power of death or HF admission compared with MAGGIC risk score alone or combined with NT-proBNP.Provide prognostic information that is largely independent of MAGGIC risk score and NT-proBNP.Adding endotrophin to existing models (e.g., MAGGIC risk score and NTproBNP) significantly improved their Harrel‚Äôs C index and reclassification.Potential application in predicting the risk of HF with reduced ejection fraction (HFrEF).Multivariable Cox proportional-hazards models that include endotrophin (ProC6), NT-proBNP (N-terminal pro B-type Natriuretic Peptide), and MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) risk score as predictors of: (A) the primary endpoint (including cardiovascular mortality, aborted cardiac arrest, or hospitalization for the management of HF), (B) all-cause death, and (C) death or heart failure‚Äìrelated hospital admission (DHFA) in TOPCAT trials (n=205). The endotrophin levels in plasma were associated with the TOPCAT primary endpoint (standardized hazard ratio [HR]=2.10; 95% CI=1.62‚Äì2.71; P<0.001), all-cause death (standardized HR=1.74; 95% CI=1.36‚Äì2.24; P<0.001), and DHFA (standardized HR=2.11; 95% CI=1.67‚Äì2.67; P<0.001). In all three cases, endotrophin (ProC6) shows stronger associations than NT-proBNP or MAGGIC risk score.Stage of Development:Proof of ConceptIntellectual Property:US Patent -PendingJapanese Patent -PendingKorean Patent -PendingEuropean Patent -PendingChinese Patent -PendingReference Media:Chirinos, JA et al.NEJM Evid 2022 Oct;1(10): 10.Desired Partnerships:LicenseCo-developmentCase ID:19-8834-TpNCSWeb Published:3/12/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53596","**Summary:** Measuring endotrophin (ProC6) in plasma has been shown to predict the risk of mortality, heart failure admissions, and other cardiovascular events in patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is a prevalent form of heart failure characterized by an inability to provide sufficient oxygen and nutrients to the body despite a normal ejection fraction. Current biomarkers, including the MAGGIC risk score and NT-proBNP, do not accurately predict the risk in these patients, contributing to a high five-year mortality rate of approximately 76%. The identification of endotrophin as a significant biomarker offers a promising advancement in risk assessment for patients with HFpEF.

**Applications:** The application of endotrophin (ProC6) can be utilized in clinical settings to enhance risk stratification for HFpEF patients, potentially guiding treatment strategies and improving patient outcomes. Its incorporation into diagnostic protocols may aid healthcare professionals in early identification of patients at higher risk for adverse cardiovascular events, thereby allowing for more targeted interventions.

**Problem Solved:** The technology addresses the challenge of inadequate risk prediction for patients with HFpEF, a condition with high mortality and morbidity. By providing a reliable biomarker that outperforms existing tools, it resolves the gap in effective monitoring and management of HFpEF, ultimately aiming to reduce mortality and enhance patient care.","Measuring endotrophin (ProC6) in plasma is an effective predictor of death, heart failure admission, and composite cardiovascular events in patients with heart failure with preserved ejection fraction (HFpEF). Current widely used biomarkers, such as the MAGGIC risk score and NT-proBNP, are insufficient for accurately assessing the risk of this condition."
"University of Pennsylvania","A Precise, Analytical Model to Measure Visual Function and Monitor Retinal Disease","23-10412","","https://upenn.technologypublisher.com/technology/53546","A model to estimate the change in photoreceptor outer segment length that occurs upon light stimulation ‚Äì a biomarker of cone function in the retina.Problem:Vision relies on the isomerization of photopigments within photoreceptors (cones and rods) by light. Traditionally, researchers and clinicians have relied on functional assessments of photoreceptor function such as electroretinography (ERG) to diagnose and treat retinal disease. While these techniques are sensitive to photoreceptor loss, their resolution is insufficient to discern functional changes in individual photoreceptors. Retinal imaging with adaptive optics (AO)-enhanced ophthalmoscopes is noninvasive and has the resolution necessary to observe human photoreceptors at a cellular scale and detect structural abnormalities; however, there is a need for methods that analyze this imaging data as a noninvasive alternative to quantifying visual function.Solution:A model-based analytical tool for AO data that estimates the change in photoreceptor outer segment length upon light stimulation rather than standardizing reflectance to a pre-stimulation interval. The photoreceptor change in length is associated with cellular function, so this estimation provides a non-invasive biomarker of cone function with increased precision, signal to noise ratio, customizability, and high spatial resolution.A method for extracting the functional responses of single cone photoreceptors to light stimulation from AO imaging data. Previous methods estimate single cone responses by quantifying variability in the amount of light reflected at each time point. The method described here provides a model-based approach of analyzing the same measurements to describe the effect of a change in cone optical path length (OPL) on the reflected light, accounting for the heterogeneity of the response across acquisitions. By fitting the model to the data from multiple acquisitions for each cone, that change in cone OPL over time is estimated directly.Advantages:This method demonstrates an improved signal-to-noise ratio compared to the existing variability-based method.Functional results obtained via this model may be compared against and/or calibrated with measurements of the same phenomena using other measurement modalities.The physically-based analysis approach may be more readily associated with the underlying biophysical mechanisms that mediate cone functionSingle-cone AO optoretinography is noninvasive and offers the possibility of functional measurements in the areas of the human retina with the highest cone density and smallest cone size.This model can be customized by changing key parameters, optimizing the basic formulation to different conditions, generalizing across various metrics, or varying the data fitting procedure, among others.Stage of Development:Proof of ConceptBench PrototypeReference Media:Warner, RL et al.Biomed Opt Express 2022 Dec 1; 13(12): 6561.Lassoued, A et al.Proc Natl Acad Sci USA, 2021 Nov 18, 118(47): e2107444118.Cooper et al.Opt Express 2020 Dec 21; 28(26): 39326.Pandiyan, VP et al.Sci. Adv. 2020 Sept 9, 6(37): eabc1124.Zhang, F et al.Proc Natl Acad Sci USA 2019 Apr 16; 116(16): 7951.Desired Partnerships:LicenseCo-developmentCase ID:23-10412-TpNCSWeb Published:3/6/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53546","**Summary:** The technology presents a model that estimates the change in photoreceptor outer segment length in response to light stimulation, serving as a biomarker for cone function in the retina. This approach addresses the limitations of traditional functional assessments like electroretinography (ERG), which, while useful for detecting photoreceptor loss, lack the resolution to discern functional changes at the individual photoreceptor level. The model uses adaptive optics (AO)-enhanced imaging, which is a noninvasive technique capable of observing photoreceptors at a cellular scale and identifying structural abnormalities. 

**Applications:** This technology can be applied in both clinical and research settings to monitor and assess retinal diseases, providing insights into cone function and facilitating the evaluation of treatment efficacy. It may be particularly useful for guiding therapeutic interventions and in the development of targeted therapies for retinal diseases.

**Problem Solved:** The technology overcomes the challenges posed by the insufficient resolution of existing methods to evaluate individual photoreceptor function and the need for more precise noninvasive biomarkers of visual function. By providing a detailed, quantifiable assessment of changes in outer segment length upon light stimulation, it enhances the understanding of retinal health and disease progression at a cellular level.","A model has been developed to estimate changes in photoreceptor outer segment length, which serves as a biomarker for cone function in the retina following light stimulation. This approach aims to enhance the understanding and monitoring of retinal disease, moving beyond traditional assessments like electroretinography."
"University of Pennsylvania","Ultrasensitive, High-Throughput, Single-Scale Detection of Extracellular Vesicles","","","https://upenn.technologypublisher.com/technology/53424","An optofluidic platform to detect extracellular vesicles (EVs) at the single-particle level by parallelizing droplet generation and analysis of EVs.Problem:Extracellular vesicles (EVs) are lipid bound nanomaterials carrying various molecular cargo that can be representative of their cells of origin. EVs play a critical role in intercellular communication and have enormous potential as biomarkers for a wide range of biomedical applications. Because EVs are heterogenous, there has been an effort to measure EVs at the single particle resolution. However, current assays for EV detection do not have the sensitivity to detect individual nanoscale EVs, lack the specificity to distinguish EV subpopulations, and have insufficient throughput to probe rare EV subpopulations.Solution:The Droplet-based Extracellular Vesicle Analysis (DEVA) platform is a high-throughput, ultrasensitive digital assay that can quantify rare EV subpopulations at the single particle resolution by capitalizing on the parallelization of droplet generation, processing, and analysis of EVs.Technology:The DEVA assay uses fluorescent paramagnetic microbeads conjugated to a capture antibody that binds to the surface protein of EV subpopulations from samples. Captured EVs are further processed by ELISA (enzyme-linked immunosorbent assay), where they are labeled with a biotinylated antibody and streptavidin-horseradish peroxidase (HRP) enzyme to form enzyme-linked immunocomplexes. The EV-bead immunocomplexes are mixed with a fluorescence enzyme substrate, loaded into aqueous droplets using parallelized droplet generators, and flowed through a detector with 90 parallelized microfluidic channels where a machine vision camera records the encoded fluorescent signal (from enzyme-substrate reaction) and transfers the data to cloud computation for analysis.Advantages:Achieves 100-fold improvement in throughput (~20 million drops/min) compared to standard single EV characterization methodsCan be multiplexed to analyze >100 EV subpopulations simultaneouslyCapable of quantifying rare EV subpopulations from complex samples with high backgroundReduces the limit of detection (LOD) to 9EVs/uL, which represents a 100-fold improvement in LOD compared to the gold standard assay for EV detectionUses accessible and affordable optics (<$1,000) and fabrication methods(A) Target EVs can be captured from complex samples such as plasma using DEVA. (B) Schematic of bead-based digital enzyme-linked immunosorbent assay (ELISA) for single EV detection. Fluorescent microbeads (green) conjugated with capture antibodies are used to target EV surface proteins. Targeted EVs are subsequently labeled with biotinylated antibody and streptavidin-HRP enzyme to enable fluorescence detection (red). (C) (I) Miniaturized microfluidic platform for DEVA that integrates droplet generation, incubation, and detection. (II) All droplets flow through a delay line chamber for incubation to enable fluorescent signal generation before flowing through a detection section consisting of 90 parallelized microfluidic channels. (III) A parallelized flow focusing droplet generator that encapsulates the beads into droplets. (IV) The EV-bead immunocomplex turns the droplet fluorescent during the incubation in the delay line. (V) A machine vision camera records the fluorescent signals from the immunocomplexes that flow through the 90 parallelized microfluidic channels in the DEVA‚Äôs detection segment. S: substrate, B: beads. S+ B+ is a droplet with a signal originating from both substrate and bead. S- B+ represents a droplet containing a bead without detection signal. S- B- refers to a blank droplet. Parallelization of droplet generation, incubation, and detection enables a throughput of~20million droplets/minute.Stage of Development:Proof of ConceptIntellectual Property:PCT Application WO 2023/215820Reference Media:Yang, Z. et al.,Nano Lett., 2022 Jun 8; 22(11): 4315Dr. David Issadore Webpage:Issadore LabDr. David Issadore Twitter:@DavidIssadoreDesired Partnerships:LicenseCo-developmentCase ID:22-10061_tpNCSWeb Published:2/26/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53424","**Summary:** The technology utilizes an optofluidic platform for the detection of extracellular vesicles (EVs) at the single-particle level through the parallel generation and analysis of droplets. This method addresses the challenges posed by the heterogeneity of EVs, which are important for intercellular communication and serve as potential biomarkers for various biomedical applications. Current detection assays often lack the necessary sensitivity, specificity, and throughput to analyze rare EV subpopulations individually. The Droplet-based Extracellular Vesicle Analysis (DEVA) platform offers a high-throughput and ultrasensitive digital assay capable of quantifying these rare subpopulations with high accuracy. The system employs fluorescent paramagnetic microbeads conjugated to antibodies that specifically bind EV surface proteins, followed by an ELISA processing step to form enzyme-linked immunocomplexes that facilitate detailed analysis.

**Applications:** The technology can be applied in various biomedical fields, including diagnostics for early disease detection, monitoring of disease progression, and evaluation of therapeutic responses. Given its precise measurement capabilities, it can also be beneficial in research studying intercellular communication and the role of EVs in different physiological and pathological contexts.

**Problem Solved:** This technology addresses the limitations of current EV detection methods that fail to provide the sensitivity necessary for single-molecule detection, the specificity to differentiate between EV subpopulations, and the throughput to analyze rare EVs effectively. By enabling the single-scale detection of EVs, it allows for more accurate assessments of their roles and contributions in biological processes.","An optofluidic platform has been developed to detect extracellular vesicles (EVs) at the single-particle level by parallelizing the generation and analysis of droplets containing EVs. This approach addresses the challenge of EV heterogeneity and aims to advance their potential as biomarkers for various biomedical applications."
"University of Pennsylvania","A Flexible, Scalable, Low-Cost Integrated Photonics Processor With On-Chip Training","","","https://upenn.technologypublisher.com/technology/53222","A flexible photonics processor enabling on-chip optimization of light-speed information processing without requiring complex fabrication.Problem:Integrated photonics processors allow for high-speed transmission of large-bandwidth data with unlimited parallelism. However, these integrated photonics processors require intricate construction, necessitating costly and sensitive lithography. Further, these devices require exponentially complex architectures as they are scaled up for modern, large dataset technologies. In addition, existing platforms are static and require error-prone lithographic manufacturing, limiting yield. To meet the information processing requirements necessary to advance large scale technologies like artificial intelligence, improved computing power by eliminating the information transfer and manufacturing constraints of traditional processors is required.Solution:A lithography-free method to generate an integrated photonics processor that allows for reconfigurable control of an imaginary index on a semiconductor platform. This allows light-speed information transfer without the energy loss or heat generation of electrical processors. Using spatially distributed optical gain and loss, the device mimics complex lithographic pathways, creating flexible optical ‚Äúcircuits‚Äù without the need for expensive and highly precise manufacturing. Because of this flexibility, these pathways can be optimized via on-chip training to shape the processor to the specific application. This reconfigurable integrated photonic processor outperforms current methods by providing the potential to process large, non-local datasets with the throughput necessary for modern artificial intelligence applications.Technology:Dynamically altering spatial patterning of optical gain across a central unpatterned slab of III-V semiconductor provides the basis for circuit construction. Optical coding of patterned light delivered by a spatial light modulator (SLM) defines the gain and loss distribution across the semiconductor wafer, spatially modulating an imaginary index that takes the place of a real index constructed by lithography. This approach allows for optical coding and real-time feedback, enabling on-chip training and flexible configuration by algorithmic optimization of matrix elements.Advantages:No requirement of highly precise lithography for constructionFlexible information processing architectureCompact, 21x smaller footprint than conventional platforms14 THz bandwidthLossless transmission of optical signalDepiction of the lithography-free photonics processor. (a) An imaginary index created via a pattern generated by a spatial light modulator (SLM) onto a wafer of unpatterned indium gallium arsenide phosphide (InGaAsP). (b) This allows the processing scheme to be reconfigurable without the need for complex lithographic manufacturing.Stage of Development:Bench PrototypeIntellectual Property:Provisional Application FiledReference Media:Wu, T. et al.,Nature Photonics, 2023 April 27; Vol. 17: 710Zhang, Z. et al.,Nature, 2022 Dec 08; 612(7939): 246Ji, Z. et al.,Science, 2020 May 15; 368(6492): 763Desired Partnerships:LicenseCase ID:23-10393-tpNCSWeb Published:2/5/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53222","**Summary:** A newly developed photonics processor enables high-speed, on-chip optimization of data processing without the need for intricate fabrication methods. This processor utilizes a lithography-free approach to create reconfigurable optical circuits on a semiconductor platform, facilitating efficient light-speed information transfer while avoiding the drawbacks of electrical processors, such as energy loss and heat generation. 

**Applications:** This technology is particularly applicable in advanced computing fields, such as artificial intelligence, where the need for improved computing power and efficient processing of large datasets is critical. 

**Problem Solved:** The technology addresses the challenges posed by existing integrated photonics processors, which often involve complex and costly constructions, making them unsuitable for rapid scaling needed for modern demands in information processing. Additionally, it overcomes the limitations of traditional processors, such as manufacturing constraints and the inefficiencies associated with electric data transfer.","A novel photonics processor enables on-chip optimization for high-speed information processing without the need for complex fabrication techniques. It addresses the limitations of traditional integrated photonics processors, which require intricate construction and costly lithography for scaling."
"University of Pennsylvania","Efficient Data Processing: TeShu Unleashes Speed, Adaptability, And Simplified Optimization","","","https://upenn.technologypublisher.com/technology/53206","A versatile system that optimizes and adapts data shuffling in distributed systems, simplifying complex operations and enhancing overall performance.Problem:Large-scale data analytics in modern data centers involve three main steps: workers process data independently (compute), preliminary results can be locally processed (combine), and data is reshaped for the next stage (shuffle). Poor planning in the shuffle phase can significantly impede system throughput and latency. This phase poses a primary bottleneck in data analytics on emerging cloud platforms, and optimizing it is challenging due to workload dependencies and evolving data center architectures, compounded by the growing complexity of big data systems using disaggregated storage and intricate network interactions.Solution:The inventors have proposed a templated shuffle (TeShu) layer that can adapt to application data and data center infrastructure, enabling it to serve as an extensible unified service layer common to all data analytics, on top of which existing and future systems can be built.Technology:TeShu is a technology that optimizes data shuffling in distributed systems for improved performance and adaptability. It offers customizable shuffle templates, simplifying adaptation across various upper-layer applications. TeShu's adaptive capabilities consider workload, combiner logic, shuffle patterns, and network topology, enhancing shuffle efficiency. It instantiates execution plans at runtime, directing the shuffle data for higher layers, and can be used as a service by various big data platforms. Moreover, its sampling-based approach dynamically adjusts to query workloads and network conditions, achieving accuracy with minimal data sampling.Advantages:Reduces communication overhead by 66.8% to 89.8%, leading to more efficient utilization of network resourcesSimplifies the customization of shuffling processes, saving development time and effortAchieves high accuracy (above 90%) with minimal overhead, allowing for effective optimization without significant data samplingTeShu's adaptive features ensure that data shuffling adjusts to workload changes and network conditions, ensuring consistent performanceLeads to a substantial increase in data processing speed, with execution time speedups ranging from 3.9x to 14.7x, depending on network conditionsThe architecture of TeShu. When shuffle is invoked, a shuffle manager ships shuffle templates to the application.Stage of Development:ConceptProof of ConceptIntellectual Property:Provisional Application FiledReference Media:Zhang, Q. et al.,arXiv:2207.10746v3: 1Desired Partnerships:LicenseCase ID:23-10483-tpNCSWeb Published:2/1/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53206","**Summary:** TeShu is a versatile system designed to optimize data shuffling in distributed environments, enhancing performance and adaptability. It provides customizable templates for shuffling, allowing easy integration across different applications in data analytics. By adapting to specific workloads and infrastructure, TeShu improves the efficiency of the shuffle process, which is crucial for maximizing throughput and minimizing latency in large-scale data analytics.

**Applications:** TeShu can be applied in various data analytics platforms within modern data centers, supporting both existing systems and future developments. Its extensible service layer allows for seamless integration with diverse upper-layer applications that rely on effective data processing.

**Problem Solved:** TeShu addresses the bottleneck caused by inefficient data shuffling in the analytics workflow, particularly during the shuffle phase, which can hinder system performance due to the complexities of workload dependencies and evolving data architectures. By providing an adaptable layer for data shuffling, it seeks to improve overall system throughput and reduce latency in cloud-based analytics.","TeShu is a versatile system designed to optimize and adapt data shuffling in distributed systems, simplifying complex operations and enhancing performance. It addresses issues in large-scale data analytics by improving the shuffle phase, which is crucial for increasing system throughput and reducing latency."
"University of Pennsylvania","Base Metal Catalysts For Cyclic Conjugated Polymer Formation","","","https://upenn.technologypublisher.com/technology/53173","A class of base metal catalysts (as opposed to expensive platinum and heavier group metals) with facile preparation methods for cyclic conjugated polymer synthesis.Problem:There is a demand for facile synthesis and purification of cyclic conjugated polymers due to their applications as lubricants, conductors, or materials with high refractive indices. Current methods for cyclic polymerization make use of catalysts with lengthy synthetic techniques and costly purification requirements. Additionally, the metals used in these catalysts, such as Rhodium (Rh), Molybdenum (Mo), and Tungsten (W), are expensive, limiting their commercial potential and rely on imports from countries around the globe (China (top producer), Vietnam, Russia, Bolivia and Rwanda), which puts a large demand on a volatile supply chain.Solution:A class of catalysts that can be synthesized in two steps using base metals, rather than expensive platinum group and heavier metals. This type of catalyst is less expensive and easier to make compared to current technologies, and can be made in gram-quantities, allowing for facile scale-up.Technology:A catalyst consisting of an allene dianion ligand, [Me3SiCCCSiMe3]2-and a base metal, such as Ti (Titanium), V (Vanadium), or Fe (Iron). Once synthesized, the catalysts perform polymerization catalysis on alkyne substrates, which form rings with no beginning or ending functional groups unlike linear polymers. By addressing the need for synthetic routes capable of large-batch production of catalysts, the catalyst addresses a longstanding need for the development of industrial cyclic conjugated polymer materials. Furthermore, these cyclic conjugated polymers can be further functionalized with existing technologies to make bottlebrush polymers, conductive polymers, and unsaturated polymers that resemble commercial polymers.Advantages:Use of base metals Ti, V, and Fe are less expensive than the traditional metals used for cyclic polymerization catalysts such as Rh, Mo, and W.Two-step ligand synthesis followed by single-step metalation provides an easy, inexpensive synthetic route for a cyclic polymerization catalyst compared to traditional catalysts.Gram-scale production of the catalyst indicates that scale-up for industrial use is feasible.Metal identity is shown to be variable, allowing for flexibility in synthetic route and scale-up compared to traditional cyclic polymerization catalysts.Previous technology to access cyclic conjugated polymers (top). Our recent technology into cyclic conjugated polymers (bottom). Cost analysis approximated based on cost of chemicals from our strategic suppliers at the University of Pennsylvania in January of 2024.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:Provisional Patent ApplicationReference Media:Russell, J.B. et al.,Angew Chem Int Ed Engl., 2023 Dec 18: e202318956Jafari, M. G. et al.,J Am Chem Soc., 2024 Jan 25; jacs.3c08149: SI1Other references and related media are available upon requestDesired Partnerships:LicenseCo-developmentCase ID:23-10298-tpNCSWeb Published:1/29/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53173","**Summary:** A new class of base metal catalysts has been developed for the synthesis of cyclic conjugated polymers, presenting an alternative to the more expensive platinum and heavier group metal catalysts. These catalysts can be produced through a straightforward two-step preparation process and utilize base metals like titanium, vanadium, and iron, making them more economical and scalable. The synthesis of these catalysts allows for the polymerization of alkyne substrates to create cyclic polymers without terminal functional groups, addressing the increasing demand for efficient and cost-effective polymerization methods.

**Applications:** Cyclic conjugated polymers produced using these base metal catalysts have potential applications as lubricants, conductive materials, and substances with high refractive indices. These polymers can be utilized in various industries where advanced material properties are required.

**Problem Solved:** The technology addresses the challenges of current cyclic polymerization methods, which often rely on costly and complex catalysts that necessitate extensive purification processes. By utilizing base metals and simplifying the catalyst synthesis, the technology reduces costs and dependency on volatile supply chains associated with precious metals.","A class of base metal catalysts enables easier preparation methods for synthesizing cyclic conjugated polymers, which are sought after for their applications as lubricants, conductors, and materials with high refractive indices. Current cyclic polymerization methods using costly platinum and heavier group metals require lengthy synthesis and purification processes."
"University of Pennsylvania","Hidden Antibiotics In The Human Proteome For The Treatment Of Antibiotic-Resistant Infections","","","https://upenn.technologypublisher.com/technology/53018","Antimicrobial peptides computationally mined from the human proteome.Problem:Novel antibiotics are needed to counter the emergence of drug-resistant bacteria as traditional discovery approaches have not yielded new classes of antimicrobials for decades. Antimicrobial resistance (AMR) is a growing public health concern and, thus far, no significant technological advance has capitalized on this market.Solution:The inventors developed an algorithm to mine the human proteome for the first time as a source of antibiotics. The human proteome contains a plethora of peptides that conduct countless functions. Here, the inventors discovered that many of these peptides have antimicrobial activity outside of their primary function in the cell, and these newly discovered antimicrobial peptides (AMPs) do not readily select for bacterial resistance and display potent anti-infective activity in preclinical mouse models.Technology:The inventors used a computational approach to mine the human proteome for peptides with specific physicochemical properties. They intentionally screened peptides that do not resemble previously described AMPs and screened fifty-six of the discovered 2,603 candidate AMPsin vitro. Importantly, these AMPs kill bacteria by targeting the membrane and do not readily select for bacterial resistance. Most of the peptides mined displayedin vitroantimicrobial activity against eight clinically relevant pathogens ranked on the World Health Organization (WHO)‚Äôs watchlist. Of clinical importance, two candidate peptides, SCUB1-SKE25 and SCUB3-MLP2225, and a combination treatment of the two, reduced bacterial burden in anin vivoskin scarification mouse model of infection.Advantages:Of 2,603 peptides mined, fifty-five were synthesized and evaluated, the majority (63.6%) of which displayed antimicrobial activity against eight clinically relevant pathogens ranked on the WHO‚Äôs watchlistAMPs have antimicrobial activityin vitroand in twoin vivomouse models of infectionNo significant changes in weight were observed, a proxy for toxicityTreatment with SCUB1-SKE25 and SCUB3-MLP2225 significantly decreased bacterial counts ofP. aeruginosaandA. baumanniiby three orders of magnitude respectively and combination treatment reduced bacterial counts of each pathogen by 7 and 5 orders of magnitude respectively in a mouse model of infectionAMPs affect commensal bacteria, which can be exploited for microbiome engineering applications(A) Day two and (B) day threein vivoskin scarification data of AMP activity of SCUB1-SKE25 and SCUB3-MLP22 and combination treatment againstP. aeruginosaPAO1 (left) andA. baumanniiATCC 19606 (right) show that these AMPs reduce bacterial burden by three orders of magnitude alone against each pathogen at days two and three and six; and, five orders of magnitude reduction on day two and seven; and, five orders of magnitude on day three respectively with combination treatment.Stage of Development:Target IdentifiedPre-clinical DiscoveryIntellectual Property:PCT Patent Application FiledWO2022/217285 A1Reference Media:Torres, M.D.T. et al.,Nat Biomed Eng., 2022 Jan; 6(1): 67Torres, M.D.T. & de la Fuente-Nunez, C.,Chem Commun (Camb)., 2019 Dec 28; 55(100): 15020Torres, M.D.T. et al.,Commun Biol., 2018 Dec 7: 1(221); 1University of Pennsylvania,de la Fuente LabDesired Partnerships:LicenseCo-developmentCase ID:21-9655-tpNCSWeb Published:1/4/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53018","**Summary:** Antimicrobial peptides have been computationally identified from the human proteome to create novel antibiotics. This approach addresses the urgent need for new antimicrobial agents due to the growing issue of antibiotic-resistant bacteria and the stagnation in traditional antibiotic discovery. The inventors utilized an algorithm to identify a variety of peptides that possess inherent antimicrobial properties while largely avoiding the development of bacterial resistance, demonstrating potent anti-infective activity in preclinical models.

**Applications:** This technology has the potential to be developed into new classes of antimicrobial treatments for infections caused by drug-resistant bacteria. By targeting specific pathogens identified on the WHO‚Äôs watchlist, these peptides could play a significant role in public health initiatives aimed at combating antimicrobial resistance.

**Problem Solved:** The technology aims to tackle the critical shortage of novel antibiotics resulting from the emergence of antimicrobial resistance, which presents a significant threat to global health. It provides a fresh approach by mining human-derived compounds, offering a potential solution to the ineffectiveness of traditional antibiotic discovery methods.","Novel antibiotics are urgently needed to combat drug-resistant bacteria, as traditional discovery methods have failed to produce new antimicrobial classes for decades. Researchers have developed an algorithm that mines the human proteome for antimicrobial peptides to address this issue."
"University of Pennsylvania","Human-AI Hybrid Intelligence Model to Accurately Recognize and Segment Organs on Medical Scans 70% Faster Than Physicians","","","https://upenn.technologypublisher.com/technology/52982","AAR-DL (Automatic Anatomy Recognition ‚Äì Deep Learning) is a hybrid intelligence recognition and delineation segmentation model that outputs automatically delineated organs in medical images by combining natural intelligence‚Äôs (i.e., human knowledge‚Äôs) and artificial intelligence's strengths to map organs and their boundaries in the given images.Problem:Doctors often require organs and anatomical regions of interest to be highlighted in contrast to the background within images from a medical scan. This process is usually done manually by doctors, for whom recognizing the region of interest (ROI) is trivial, but highlighting the accurate boundaries of the part can be very labor-intensive. In contrast, AI models struggle with recognizing the location of an ROI in the image but can quickly delineate the organ of interest from the rest of the image once the ROI is identified. Users are often forced to choose between the opposing approaches without finding a comfortable middle ground.Solution:Researchers have now developed a method to combine the ability of humans to recognize the ROI and the accurate delineation abilities of AI to create an automated hybrid intelligence organ recognition and delineation model, mitigating both methods' weaknesses. This process has four steps. First, a computer trims the picture from the medical scan. Then, the computer makes a rough guess about the important part within the picture based on what a knowledgeable human would guess. After that, the computer draws boxes around that area. Finally, the computer makes the selected part look neat and tidy.Technology:The model encompasses four distinct phases in image analysis. Initially, the computer system conducts image cropping, denoted as BRR (Body Region Recognition) during the first phase. In the subsequent stage, the system employs a fuzzy recognition approach, named AAR-R (Automatic Anatomy Recognition - Object Recognition), which incorporates human knowledge, to annotate the area of interest. Following this, the system applies a convolutional deep learning network to establish 2D bounding boxes around the identified region, referred to as DL-R (Deep Learning-Based Object Recognition). Lastly, the fuzzy region generated by the preceding phase is precisely delineated with smooth boundaries by an AI system, referred to as DL-D (Deep Learning-Based Object Delineation). When tested on thoracic and head and neck medical images, this approach achieved accuracy at least as good as manual methods for organ segmentation and was more than 70% faster.Advantages:Scores with at least as good accuracy as of clinical manual delineation methods, which represent the reference standard70% faster when compared to the reference standardCompatible with large data set analysis in which analysis is time-sensitiveAvoids the need for AI models to be trained on high-level anatomic dataHigh adaptability allows it to find potential utility in all manner of imaging data, including CT, MRI, and PET scansA schematic representation of the different stages (modules) in the proposed hybrid intelligence (HI) system. BRR, body region recognition; AAR‚ÄêR, automatic anatomy recognition object recognition; DL‚ÄêR, deep‚Äêlearning‚Äêbased object recognition; MM, model morphing; DL‚ÄêD, deep‚Äêlearning‚Äêbased object delineation.Stage of Development:Minimum Viable ProductIntellectual Property:Provisional FiledReference Media:Udupa, J et al.Med Phys. 2022 Nov; 49(11): 7118Desired PartnershipsLicenseCase ID:21-9511-TpNCSWeb Published:12/21/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52982","**Summary:** AAR-DL is a hybrid intelligence model that integrates human expertise with artificial intelligence to enhance the recognition and segmentation of organs in medical scans. This innovative approach leverages the strengths of human knowledge in identifying regions of interest and the capabilities of AI in accurately delineating these areas, resulting in a process that is 70% faster than the traditional methods employed by physicians. The model operates through a four-step process: initial trimming of the medical scan, a rough estimation of the important area based on human input, and further refinement using AI techniques.

**Applications:** The model can be utilized in various medical imaging contexts, enhancing the efficiency and accuracy of organ recognition and segmentation. It is particularly beneficial for radiologists and medical professionals who need to highlight specific organs or anatomical regions in scans for diagnostic or treatment planning purposes.

**Problem Solved:** The technology addresses the challenges faced by physicians in manually identifying and delineating organs from medical images, a process that is labor-intensive and time-consuming. It also overcomes the limitations of existing AI models that struggle with recognizing regions of interest but can quickly segment once they are identified. By combining human and AI strengths, the model provides a more efficient and effective way to obtain precise anatomical delineations.","AAR-DL is a hybrid intelligence model that combines human knowledge and artificial intelligence to automatically recognize and segment organs in medical images. It significantly enhances the speed of this task, achieving results 70% faster than physicians."
"University of Pennsylvania","High-Throughput and Independent Temperature Regulation In Biological Samples","","","https://upenn.technologypublisher.com/technology/54359","A device that provides independent thermal regulation for biological samples in a 96-well microwell plate.Problem:Thermal control of cellular processes allows for remote control through tissue or opaque media, allowing for precise targeting of therapies in the body as well as broad control of metabolic processes in bioreactors. However, current research tools for modulating the temperature of biological samples are slow, expensive, and often limited to small numbers of concurrent samples. There exists a need for a high-throughput method to modulate the temperature of biological samples.Solution:The inventors developed a device capable of housing a 96-well microwell plate and independently adjusting the temperature of the sample in each well. Furthermore, the device is compatible with most assays designed for 96-well plates in addition to traditional cell culture incubators. The inventors have successfully used the device to regulate temperature in mammalian cell cultures.Technology:The device consists of an Arduino microprocessor paired with a custom printed circuit board. The circuit board allocates a pair of waterproofed thermistors to each well of the 96-well plate. One thermistor provides heating to the sample while the other measures the current temperature. A proportional‚Äìintegral‚Äìderivative (PID) control algorithm adjusts the duty ratio of each heating thermistor to maintain the user-defined temperature.Advantages:Independent temperature for individual samples in 96-well platesSupports dynamic temperature regulation profilesCompatible with existing research tools designed for 96-well platesDesign and use of the ThermoPlate for simultaneous, independent temperature control of multiple wells in a 96 well plate. Image of a fully assembled ThermoPlate device for regulating temperature in individual wells of a 96 well plate.Stage of Development:Bench PrototypeIntellectual Property:U.S. Non-Provisional Patent ApplicationReference Media:Benman, W. et al.,Nat Chem Biol. 2022 Feb; 18(2): 152Desired Partnerships:LicenseCo-developmentCase ID:22-9804-tpNCSWeb Published:6/6/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54359","**Summary:** A device has been developed that allows for independent thermal regulation of biological samples in a 96-well microwell plate. This technology addresses the limitations of existing temperature modulation tools, which tend to be slow, costly, and restricted to fewer samples. By employing a controllable system, the device enables precise thermal adjustments for each sample individually, enhancing the research capabilities in both cellular processes and metabolic control in bioreactors.

**Applications:** The device is compatible with most assays designed for 96-well plates and can be integrated with traditional cell culture incubators. It has been successfully utilized to regulate temperature in mammalian cell cultures, suggesting its potential for broader applications in various biological research fields.

**Problem Solved:** The need for a high-throughput method to modulate temperatures of biological samples is addressed by this device, which allows for remote and precise targeting of therapies and control over metabolic processes in a variety of research and clinical settings.","A device has been developed that independently regulates temperature for biological samples in a 96-well microwell plate, enabling precise thermal control. Current thermal modulation tools are slow, costly, and typically limit concurrent sample processing."
"University of Pennsylvania","Nuclear Speckles Predict Patient Outcome and Therapy Response in Cancer","","","https://upenn.technologypublisher.com/technology/52839","Nuclear speckles marker predicts cancer patients survival as well as response to therapy, particularly HIF2Œ± inhibitors.Technology:Nuclear speckles are membrane-less bodies within the cell nucleus enriched in RNA biogenesis, processing, and export factors. Inventors at the University of Pennsylvania School of Medicine demonstrated that RNA-based speckle signature is evident in 24 different cancer types and can be used as a predictor of cancer patient survival in 6 cancer types. Clear cell renal cell carcinoma (ccRCC) showed the particularly prominent correlation and is known to be associated with hyperactivation of HIF-2a in nearly all clinical cases. In ccRCC, inventors find differential drug sensitivities to drugs such as PD1 and HIF-2Œ± inhibitors.Further, using immunofluorescent imaging of nuclear speckle protein, SON, inventors demonstrated that SON distribution in the nucleus strongly correlated with ccRCC patient survival. Hence, RNA or imaging methods may be used interchangeably for nuclear speckle assessment.Advantages:Selection marker for ccRCC patients for treatment with HIF2Œ± inhibitorsDetermination of drug sensitivity of ccRCC patientsCancer patient outcomes predictions 6 cancer types, particularly in ccRCCA: ccRCC patient overall survival in response to nivolumab (PD1 inhibitor) or everolimus (mTOR inhibitor) in patients with different RNA-based speckle signatures.B: Kaplan Meier plot of ccRCC split by SON immunofluorescence pattern in the nucleusC: Kaplan Meier plot of Grade 1 and 2 ccRCC split by SON immunofluorescence pattern in the nucleus.Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Alexander, KA et al.Mol Cell, 2021 Apr 15, 81(8): 1666Alexander, KA et al.bioRxiv, 2023 Sept 16: preprintDesired Partnerships:LicenseCo-developmentCase ID:22-9922-TpNCSWeb Published:11/28/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52839","**Summary:** Nuclear speckles, which are membrane-less structures within the cell nucleus that play a role in RNA biogenesis, processing, and export, have been identified as predictive markers for cancer patient outcomes. Research conducted by inventors at the University of Pennsylvania School of Medicine indicates that an RNA-based speckle signature is present in 24 different cancer types and serves as a predictor of survival in 6 of these types, with a significant association found in clear cell renal cell carcinoma (ccRCC). In ccRCC, which often features hyperactivation of HIF-2Œ±, differences in drug sensitivities to inhibitors like PD1 and HIF-2Œ± have been observed. The distribution of the nuclear speckle protein SON has a strong correlation with patient survival outcomes in ccRCC, allowing for the use of both RNA analysis and imaging methods for assessment.

**Applications:** The technology can be applied for selecting ccRCC patients for treatment with HIF-2Œ± inhibitors, determining the drug sensitivity of ccRCC patients, and predicting cancer patient outcomes across multiple cancer types, particularly in ccRCC where it can inform treatment choices involving nivolumab or everolimus based on their RNA-based speckle signatures.

**Problem Solved:** The technology addresses the challenge of predicting cancer patient survival and therapeutic response by providing a reliable marker that indicates which patients are likely to benefit from specific treatments, aiding in more personalized and effective cancer therapies.","Nuclear speckles are membrane-less structures in the cell nucleus that are enriched in RNA processing factors and can predict survival and therapy response in cancer patients, particularly with HIF2Œ± inhibitors. Research from the University of Pennsylvania School of Medicine revealed that an RNA-based speckle signature is present in 24 cancer types and serves as a survival predictor in 6 of these types."
"University of Pennsylvania","Pyrazole Derivatives for the Treatment of Lung Cancer Tumors","23-10336","","https://upenn.technologypublisher.com/technology/52809","A class of pyrazole derivatives that inhibit palmitoyl-transferases, resulting in increasing cancer cell responsiveness to epidermal growth factor receptor inhibitor and KRas mutant lung cancer growth inhibition as a single agent.Problem:Pancreatic and lung cancers are largely driven by either Epidermal growth factor receptor (EGFR) mutation KRAS mutations. However current therapies targeting either of these mutated proteins are either unavailable (KRas G12S/D/V/R) or rapidly develop resistance mutations (EGFR, KRas G12C). No targeted therapeutic options exist for mutant KRAS G12S/D/V/R tumors, making treatment of these cancers difficult and dependent on conventional chemotherapy and radiation.Solution:Pyrazole derivatives that increase sensitivity to EGFR inhibitors by creating a dependency on EGFR signaling for cancer cell survival, increasing responsiveness to EGFR inhibitor therapy. Additionally, the increase in EGFR signaling induces synthetic lethality in KRAS-mutation-bearing tumors. This treatment circumvents acquired resistance to EGFR inhibitors and offers a therapeutic strategy for mutant KRAS tumors.Technology:The pyrazole derivatives target an EGFR palmitoylation enzyme, DHHC20, which modulates EGFR signaling. When DHHC20 is inhibited, EGFR signaling becomes crucial for cancer cell survival. Inhibiting DHHC20 also causes synthetic lethality in mutant KRAS tumors because oncogenic mutations in KRAS and EGFR are mutually exclusive, and the co-occurrence of these mutations is deleterious to the cancer cell.Advantages:A first-in-class drug that increases the response to current EGFR inhibitor drugs, increasing efficacy for these treatments in lung cancer patients.Offers a therapy independent of the type of KRAS mutation on the tumor, allowing for reliable treatment of these types of tumors via a single agent.Target pyrazole derivatives have been shown to inhibit KRAS mutant lung tumor growth in xenografts, significantly increasing overall survival with no impact on animal weight following oral dosing, demonstrating therapeutic potential.(A) Imaging of xenograft tumors grown from A549 (Kras G12S) human lung cancer cells stably transduced with inducible control shRNA or DHHC20 shRNA. shDHHC20. (B) Quantification of tumors on day 8 after shRNA induction with tamoxifen. (B) Silencing DHHC20 expression by shRNA increases sensitivity to 5 ŒºM gefitinib (EGFR inhibitor) induced cell death in KRAS mutant breast (MDA-MB-231) and lung (SW1573) cancer cells.Stage of Development:Target IdentifiedPreclinical DiscoveryPreclinical in vivo Proof of Concept with oral dosingIntellectual Property:Patent pendingReference Media:Kadry, YA et al.Open Biol 2021 Oct, 11(10): 210033.Nelson, JC et al.Curr Biol 2020 July, 30(14): 2729.Kharbanda, A et al.Sci. Signal., 2020 March 3, 13(621): eaax2364.Kharbanda, A et al.Biochem Biophys Res Commun 2017 Nov 4, 493(1): 213.Runkle,KB et al.Mol Cell 2016 May 5, 62(3): 385.Desired Partnerships:LicenseCo-developmentCase ID:23-10336-TpNCSWeb Published:11/20/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52809","**Summary:** A class of pyrazole derivatives has been developed that targets palmitoyl-transferases, enhancing the sensitivity of lung cancer cells to epidermal growth factor receptor (EGFR) inhibitors and inhibiting the growth of KRas mutant lung cancers. These derivatives create a dependency on EGFR signaling, making cancer cells more responsive to EGFR inhibitors while inducing synthetic lethality in tumors with KRAS mutations. The technology addresses a significant gap in treatment options for pancreatic and lung cancers driven by EGFR and KRAS mutations, particularly for KRas mutations that do not currently have targeted therapies available.

**Applications:** The pyrazole derivatives can be utilized in the treatment of lung cancers, specifically those characterized by mutations in KRAS and deficiencies in current therapies targeting these mutations. They may also be applied in combination with EGFR inhibitors to improve treatment outcomes for patients with mutant KRAS tumors.

**Problem Solved:** The technology provides a novel therapeutic strategy to overcome the limitations of existing treatments for pancreatic and lung cancers driven by mutations in EGFR and KRAS. It aims to address the lack of effective targeted options for challenging KRAS variants, particularly KRas G12S/D/V/R, and mitigate the problem of rapid resistance development associated with current EGFR-targeted therapies.","A class of pyrazole derivatives inhibits palmitoyl-transferases, enhancing cancer cell responsiveness to epidermal growth factor receptor inhibitors and exerting growth inhibition on KRas mutant lung cancer as a standalone treatment. Current therapies targeting mutated proteins in pancreatic and lung cancers are either unavailable for certain KRas mutations or quickly develop resistance."
"University of Pennsylvania","Bio-Absorbable Envelope For Improved Breast Reconstruction Outcomes In Cancer Patients","","","https://upenn.technologypublisher.com/technology/53888","Bio-absorbable mesh envelope for use in breast reconstruction to enhance long-term cosmetic outcomes and minimize operative time and cost.Problem:In the United States, about 1 in 8 women will develop invasive breast cancer over their lifetime and this number is rising due to improved detection by screening and patient education. Numerous women elect to have some form of breast reconstruction after treatment or preventative mastectomy. However, it is currently very labor-intensive to achieve an aesthetically pleasing result. Plastic surgeons spend extensive intra-operative time to properly shape autologous tissue transfers into the complex shape of the human breast. Additionally, sutures often do not hold the tissue‚Äôs shape for extended periods, leading to revision operations.Solution:To overcome these issues, inventors including engineers, scientists and surgeons at the University of Pennsylvania have developed a bio-absorbable, mesh-based breast reconstruction envelope. The novel design provides increased tissue support and the ability to achieve the desired complex shape.Technology:The innovative design envelope contains a number of discontinuous cuts that form an elastic network that shapes and provides mechanical support to the implant, thereby mimicking the complex breast geometry that will facilitate tissue regeneration properly. The envelope enables surgeons to use only a single ADM sheet to hold the implant in place. The kirigami ADM sheet can generate a natural teardrop breast contour, even when inserting round-shaped implants ranging from 400 to 620 cc in volume. The size of the mesh envelope can also be customized to each patient by using a template with re-sizing guidelines.Advantages:Improved support of transplanted tissues or implantEnhanced cosmetic outcomesShortened intra-operative times and reduced costPotential for patient-specific designsDemonstration of the Keller Funnel insertion of the round-shaped silicone gel implants of different volumes into the same optimized kirigami ADM sheet. The width and height of the kirigami ADM sheet are 10 cm √ó 12 cm. Figures (A) and (B) are removed from the figure. (C) Snapshots of the experimental demonstration of the Keller Funnel insertion process. (D) Photo of the upright shape of the wrapped implant after suturing the edges of the ADM sheet on an artificial chest (left) with the FEA model (denoted as blue lines) overlaid on top (right). (E) Comparison of breast reconstruction shapes varying with the volume of implants (400, 500, 620 cc) that are wrapped with the same kirigami ADM sheet.Stage of Development:Developed in a laboratory environmentEvaluated in select clinical casesIntellectual Property:US Patent11,642,215Reference Media:Lee, Y.-J. et al.,Adv Mater. 2023 Feb; 35(6): e2208088Desired Partnerships:LicenseCo-developmentCase ID:18-8567-tpNCSWeb Published:4/4/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/53888","**Summary:** The technology is a bio-absorbable mesh envelope designed to improve breast reconstruction outcomes for cancer patients. It addresses the challenges faced by surgeons in achieving aesthetically pleasing results during breast reconstruction, which often requires extensive operative time and labor. The envelope's innovative design offers increased tissue support and maintains the desired complex shapes through an elastic network, ultimately enhancing cosmetic outcomes while minimizing the need for sutures and revisions.

**Applications:** This technology is applicable in the field of plastic and reconstructive surgery, particularly for patients undergoing breast reconstruction after mastectomy due to breast cancer.

**Problem Solved:** The development of this bio-absorbable envelope solves the problem of the labor-intensive process of shaping autologous tissue transfers in breast reconstruction, as well as the limitations of traditional sutures that fail to maintain tissue shape over time, thereby reducing overall operative time and costs while improving long-term cosmetic results.","A bio-absorbable mesh envelope is designed for breast reconstruction to improve long-term cosmetic outcomes and reduce operative time and costs. The rising incidence of invasive breast cancer in the U.S. has led many women to opt for breast reconstruction following treatment or preventative mastectomy, which is currently a labor-intensive process."
"University of Pennsylvania","Suture Device for Rotator Cuff Surgery in Patients with Osteoporosis","","","https://upenn.technologypublisher.com/technology/52768","An integrated device for anchor replacement and biologic cement injection during rotator cuff repair.The rotator cuff is a group of muscles and tendons that surround the shoulder joint (humerus). When rotator cuffs tear due to injury, suture anchors are typically employed to reattach the torn rotator cuff tissue back on to the humerus. However, for patients with bone abnormalities‚Äînamely, osteoporosis‚Äî current devices often lack fixation strength, ultimately causing postoperative loosening out of the suture anchor. Moreover, the use of biologic cement to augment anchor strength is uncommon due to difficulties associated with current suture anchor designs and the risk of releasing excess bone cement, which can lead to inflammation.Solution:To improve the weak attachment of suture anchors in osteoporotic bones, the inventor designed a novel integrated device that implants an anchor and injects bone cement (calcium phosphate) during rotator cuff repair. Design of suture anchor and efficient injection of bone cement at same time improved the pull-out strength significantly relative to the existing anchors in saw bone model system.Advantages:Addresses the issue of anchor pullout and looseningImproves safety and reliability of calcium phosphate injection for rotator cuff repairUses a single device that integrates anchor driving and bone cement injectionStage of Development:ConceptIntellectual Property:US Patent Application in ProcessReference Media:Jia, L et al.UPOJ, 2021 June, 31: 182.(pdf)Desired Partnerships:LicenseCo-developmentCase ID:22-10127-TpNCSWeb Published:11/10/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52768","**Summary:** An integrated device has been developed for anchor replacement and biologic cement injection during rotator cuff repair, particularly addressing the needs of patients with osteoporosis. The device combines the implantation of a suture anchor with the simultaneous injection of calcium phosphate bone cement, which enhances the fixation strength of the anchor in bones affected by osteoporosis. This innovation significantly improves the pull-out strength compared to existing suture anchors utilized in medical procedures. 

**Applications:** The device is intended for use in surgical procedures that repair rotator cuff injuries, especially in patients exhibiting osteoporotic bone conditions where traditional repair methods are less effective. 

**Problem Solved:** The technology addresses the challenge of insufficient fixation strength of suture anchors in osteoporotic bones, which can lead to postoperative loosening. By integrating anchor placement with biologic cement injection, the device enhances the overall reliability and effectiveness of rotator cuff repairs in this vulnerable patient population.","An integrated device designed for anchor replacement and biologic cement injection is used during rotator cuff repair. It addresses the issue of inadequate fixation strength in patients with osteoporosis, which can lead to postoperative loosening of traditional devices."
"University of Pennsylvania","Topical LSD1 Inhibition for Treating Skin Diseases","24-10603","","https://upenn.technologypublisher.com/technology/52767","Topical LSD1 inhibition can treat skin diseases that include cutaneous squamous cell carcinoma (cSCC), actinic keratoses, and viral warts.Problem:Current treatment options (i.e. cryotherapy, laser therapy, surgery, chemotherapy) for skin diseases such as cSCC, actinic keratoses, and viral warts are often non-targeted and destructive, and can cause toxicity and damage to local tissue. In addition, treatment of larger and deeper lesions is associated with permanent scarring or disfigurement.Solution:The inventors developed a topical targeted LSD1 inhibitor that effectively treats skin lesions without harming local tissue.Technology:LSD1 is a histone demethylase that regulates a wide range of physiological processes including stem cell maintenance and differentiation. Dysregulation of LSD1 can be oncogenic and is overexpressed in a variety of cancers. The inventors demonstrated that topical LSD1 inhibition suppressed cSCC in mice. Additionally, LSD1 inhibition activated retinoid signaling. As tretinoin (activator of retinoid signaling) is used for multiple skin conditions such as acne, psoriasis, actinic keratosis, and viral warts, topical LSD1 inhibition may be useful for skin diseases other than cancer.Advantages:Limited toxicity due to local application.Non-invasive treatment of various skin diseases.Figure 1. (A) Representative images of cSCC mouse model treated with either control or topical LSD1 inhibitor. (B) Tumor growth graph of cSCC mouse model treated with either control or topical LSD1 inhibitor.Figure 2. Immunofluorescence staining of mouse epidermis treated with either DMSO or topical LSD1 inhibitor. Rbp2 stains for retinoic acid signaling target and keratin 14 (K14) stains for basal skin keratinocytes of the epidermis.Stage of Development:Proof of concept in relevant cSCC mouse modelIntellectual Property:Provisional filed.Reference Media:Egolf, S et al.;Cell Rep 2019 Aug 20; 28(8): 1981.Desired Partnerships:LicenseCo-developmentCase ID:24-10603-TpNCSWeb Published:11/8/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52767","**Summary:** Topical LSD1 inhibition has been identified as a potential treatment for various skin diseases, including cutaneous squamous cell carcinoma, actinic keratoses, and viral warts. Conventional treatment methods tend to be destructive and can lead to toxicity and damage to surrounding tissue, with larger lesions often resulting in permanent scarring or disfigurement. The developed topical LSD1 inhibitor offers a targeted approach that effectively manages skin lesions without harming adjacent tissue. LSD1, a histone demethylase, is involved in regulating numerous physiological processes and is overexpressed in many cancers. Research indicates that topical LSD1 inhibition can suppress cSCC in animal models and enhance retinoid signaling, suggesting potential applications for other skin conditions.

**Applications:** The topical LSD1 inhibitor may be used to treat cutaneous squamous cell carcinoma, actinic keratoses, viral warts, and possibly other skin diseases that are responsive to retinoid signaling such as acne and psoriasis.

**Problem Solved:** The technology addresses the limitations and drawbacks of current treatment options for skin diseases, which are often non-targeted, invasive, and can cause significant local tissue damage, toxicity, and cosmetic concerns like scarring or disfigurement.","Topical LSD1 inhibition offers a targeted treatment option for skin diseases, including cutaneous squamous cell carcinoma, actinic keratoses, and viral warts. This approach addresses limitations of current treatment methods, which often lead to toxicity, tissue damage, and potential disfigurement."
"University of Pennsylvania","Revolutionizing CT Imaging: Gold Nanoparticles with Biodegradable Polymer Encapsulation","Z6642","","https://upenn.technologypublisher.com/technology/52750","Innovative CT contrast agent using biodegradable polymer-encapsulated gold nanoparticles for enhanced imaging and safe excretion.Problem:Gold particles emerged as promising contrasting agents due to their high X-ray attenuation, but their size-dependent behavior posed a challenge. Particles larger than 5nm raised toxicity concerns due to potential accumulation in the body, whereas particles smaller than 5nm were excreted too quickly to be useful.Solution:The inventors introduce a novel CT contrast agent, utilizing biodegradable polymer encapsulated gold nanoparticles and optimizing particle size for superior imaging quality while ensuring safe and complete excretion post-imaging.Technology:Leveraging the biocompatibility and degradation properties of polymers such as polyphosphazene, the inventors encapsulated gold particles, creating a stable and effective contrast agent. The encapsulation ensures that smaller gold particles remain in the bloodstream long enough for imaging, then degrades to release the particles for safe excretion.Advantages:Gold nanoparticles provide superior contrast in CT images compared to iodinated agents, facilitating better diagnostics and patient care.Can be given to patients for whom iodinated agents are contraindicated (i.e. patients with type 2 diabetes).A) Attenuation of gold nanoparticles (Gold-NP) compared to iodine (Iodine-CA). B) Spectral CT image of gold nanoparticles accumulated in the aorta of an atherosclerotic mouse.Stage of Development:Proof of concept in vivo mouse modelIntellectual Property:US10,940,217Reference Media:Dong, YC et al.Sci Rep 2019 Oct 17; 9(1): 14912.Higbee-Dempsey, EM et al.J Am Chem Soc. 2020 Apr 29; 142(17): 7783.Desired Partnerships:LicenseCo-developmentCase ID:z6642-TpNCSWeb Published:11/7/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52750","**Summary:** Innovative CT contrast agents are being developed using biodegradable polymer-encapsulated gold nanoparticles. These agents enhance imaging quality through optimal particle size while addressing safety concerns related to toxicity and excretion. 

**Applications:** This technology can be employed in CT imaging, particularly for patients who have contraindications to traditional iodinated contrast agents, such as those with type 2 diabetes. 

**Problem Solved:** The technology effectively resolves the challenge of utilizing gold nanoparticles, which have high X-ray attenuation but pose risks of toxicity when larger than 5nm or are ineffective when smaller than 5nm due to rapid excretion. The biodegradable polymer encapsulation allows for prolonged circulation in the bloodstream and safe excretion post-imaging.","This study presents a new CT contrast agent comprised of biodegradable polymer-encapsulated gold nanoparticles, addressing the size-dependent toxicity and excretion challenges of gold particles. The innovative formulation enhances imaging quality while ensuring safe excretion from the body."
"University of Pennsylvania","Direct and Effective Method To Reverse The Effects of Fragile X Syndrome","","","https://upenn.technologypublisher.com/technology/52729","A method of treating Fragile X syndrome by correcting the abnormal DNA clusters causing the characteristic symptoms.Problem:Fragile X syndrome (FXS) affects approximately 1 in 4,000 males and 1 in 8,000 females and is characterized by symptoms such as:Inherited Intellectual DisabilityAnxietyAttention Deficit Disorder (ADD)Skin, Ovaries and Testes AbnormalitiesFXS is caused by an excess number of regulatory CGG trinucleotides found in the Fragile X Mental Retardation 1 (FMR1) gene, termed short tandem repeats (STRs).Compared to individuals with a normal number of STRs (30 to 40), those with over 200 STRs develop symptoms. The only current option for patients is symptom management with existing medications.Solution:Rather than addressing each symptom separately, this new method targets the root cause of FXS-associated symptoms by deleting the excess STRs, thus preventing abnormal DNA structures.Technology:The inventors linked the pathology of FXS to the formation of abnormal DNA clustering between excess STRs in the FMR1 gene and in genes of neighboring chromosomes, blocking their normal expression.The type of DNA abnormalities and FXS symptom severity depend on STR length, with more severe disease observed in patients with over 450 repeats. Excision of the excess STRs down to 190 repeats reverses this abnormal DNA clustering and restores expression in affected genes (see Figure 1).Shortening the STRs could be achieved using pharmacological or genetic-based methods.Advantages:Reduces the number of medications FXS patients must takeMore effective than treating symptomsMore specific than any option on the market currentlyCould be adapted to other diseases caused by STR abnormalities, such as Huntington‚Äôs disease, amyotrophic lateral sclerosis, and Friedreich‚Äôs ataxiaSchematic model of abnormal DNA organization among short tandem repeats (STRs) in Fragile X Syndrome. When STRs (symbolized by CGG trinucleotides, red lines in the figure) are of normal length (30-40, first box, top row), the FMR1 gene (black arrow) does not cluster with distal genes on neighboring chromosomes (gray arrows). When STRs reach 55 to 190 repeats (premutation length, second box, top row), FMR1 expression increases and forms inclusion bodies in the nucleus (blue circle) but does not interact with distal genes. When the STRs reach 200 repeats (short mutation-length, third box, top row), FMR1 expression drastically decreases, DNA instability occurs and distal genes cluster together through interactions between H3K9me3 domains (pink shading), altering their expression. When STRs reach 450 repeats (long mutation-length, fourth box, top row), the FMR1 gene forms an RNA-DNA hybrid structure (green and blue lines) which silences distal genes. Cutting the STRs from 450 to 190 repeats (first box, bottom row) reverses the abnormal interactions between FMR1 and distal genes. By contrast, cutting FMR1 STRs from 450 repeats to normal-length 30-40 repeats (second box, bottom row) does not reverse the abnormal DNA clustering.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:US Utility Application US 2022-0323553 A1 FiledReference Media:Malachowski, T., et al.,Cell 186 2023 Dec. 21: Vol.186, Issue 26; 5840Desired Partnerships:LicenseCo-developmentCase ID:20-9433-tpNCSWeb Published:11/6/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52729","**Summary:** A method has been developed to treat Fragile X syndrome by correcting abnormal DNA clusters that contribute to the condition's symptoms. Fragile X syndrome, affecting approximately 1 in 4,000 males and 1 in 8,000 females, is characterized by inherited intellectual disability, anxiety, attention deficit disorder, and physical abnormalities. The underlying cause is an excess number of CGG trinucleotide repeats in the FMR1 gene, with those having over 200 repeats experiencing symptoms. Current treatments focus on symptom management, but this method instead targets the root cause by excising the excess repeats, thereby preventing the formation of abnormal DNA structures. The approach is based on the link between FXS pathology and the clustering of excess STRs, which hinders normal gene expression. Reducing the STRs to 190 is proposed to reverse abnormal clustering and restore normal gene function.

**Applications:** This technology could serve as a groundbreaking treatment for individuals with Fragile X syndrome by directly targeting the genetic cause rather than managing symptoms. It may lead to improved cognitive and physical outcomes for affected individuals.

**Problem Solved:** The method addresses the underlying genetic abnormality responsible for Fragile X syndrome, offering a solution to correct the excessive STRs in the FMR1 gene, which are linked to the condition's symptoms, thereby potentially reversing the effects of the syndrome.","Fragile X syndrome (FXS) affects approximately 1 in 4,000 males and 1 in 8,000 females, leading to symptoms such as intellectual disability, anxiety, attention deficit disorder, and various physical abnormalities. The condition is caused by an excess number of CGG trinucleotide repeats in the FMR1 gene."
"University of Pennsylvania","Low Toxicity Antimicrobial Peptides To Overcome Antibiotic Resistance","","","https://upenn.technologypublisher.com/technology/52723","Combining naturally occurring peptides by hybridizing them with known active peptides to synthesize effective antimicrobial peptides with minimal cytotoxicity.Problem:Antibiotic resistance is a significant concern that poses a potential risk of increased harm from future infectious diseases. Consequently, antimicrobial peptides (AMPs) are regarded as an alternative to antibiotics as they are less prone to bacterial resistance. However, AMPs often exhibit toxicity, instability, and substantial costs. Therefore, careful design choices will have to be considered to address these challenges. One major hurdle that still needs to be surmounted is AMPs potential toxicity to human cells.Solution:To mitigate toxicity, a method has been developed that involves hybridization of peptides. This technique combines different segments of natural peptides to create hybridized AMPs (hAMPs). By leveraging the hybridization process, the antimicrobial properties of hAMPs are optimized while minimizing cytotoxicity.Technology:The design of hAMPs utilizes VmCT1, an AMP derived from scorpion venom, as well as other established amphiphilic AMP templates. Hybridized amphiphilic molecules are synthesized for therapeutic screening through a combination of hydrophobic and hydrophilic moieties. Extensive testing evaluates these newly formed peptides' antimicrobial, antiplasmodial, and cytotoxic properties, enabling the identification of clinically relevant hAMPs.Advantages:hAMPs derivatives exhibit lower toxicity than the parent peptideshAMPs show strong resistance to proteolytic degradationTwo of the hAMPs showed stronger anti-infective properties in a mouse model than parent peptidesFlowchart showing the method of design for the hAMPs. Components from the scorpion venom (VMCT1) along with AMPs from frog and wasp venom are used as templates for creating combinations of functional groups in hAMPs. These hAMPs can then be evaluated for antimicrobial, antiplasmodial, and cytotoxic activity.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:U.S. Provisional Application 63/493,521 FiledReference Media:Pedron, C. N. et. al.,Commun Biol. 2023 Oct 19; 6(1): 1067Desired Partnerships:LicenseCo-developmentCase ID:23-10378-tpNCSWeb Published:11/3/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52723","**Summary:** This technology focuses on creating hybrid antimicrobial peptides (hAMPs) by combining naturally occurring peptides with known active peptides to optimize antimicrobial efficacy while reducing cytotoxicity. Recognizing the significant risk posed by antibiotic resistance, the approach capitalizes on the properties of antimicrobial peptides, which generally have a lower tendency for bacterial resistance compared to traditional antibiotics. However, traditional AMPs often suffer from issues of toxicity, instability, and high costs, necessitating careful design to mitigate these concerns. 

**Applications:** The hybridized peptides developed through this technology can be applied in therapeutic settings to combat a range of infectious diseases, potentially serving as alternatives to conventional antibiotics. They are specifically tested for antimicrobial and antiplasmodial properties, paving the way for new treatments in managing infections resistant to standard antibiotic therapies.

**Problem Solved:** This approach addresses the critical issue of antibiotic resistance, which poses a significant threat to public health. By enhancing the effectiveness and safety of antimicrobial compounds through hybridization, the technology aims to reduce the potential toxicity of AMPs to human cells while maintaining their therapeutic efficacy against resistant pathogens.","The text discusses the synthesis of effective antimicrobial peptides (AMPs) by hybridizing naturally occurring peptides with known active peptides to minimize cytotoxicity. It highlights antibiotic resistance as a major concern, noting that AMPs are considered a viable alternative because they are less likely to induce bacterial resistance."
"University of Pennsylvania","Treating Prostate Cancer with Novel Sugar-Antigen-Targeting CAR-T Cells","21-9684","","https://upenn.technologypublisher.com/technology/52653","Problem:While the 5-year relative survival rate for patients with local or regional prostate cancer is nearly 100%, the 5-year relative survival rate drops to 32% for patients with metastatic or advanced disease. These patients may initially respond to available therapies, but most patients will develop therapy resistance and succumb to disease.Solution:A CAR construct that targets specific sugar-bearing prostate cancer cells and a subset of breast cancer cells.Technology:The inventors designed a CAR construct that targets metastatic prostate cancer, based on the first structurally defined F77 sugar antigen. About 85% of metastatic prostate cancer cells express this unique antigen. This novel CAR construct exhibited exquisite specificity and efficacy in highly relevant human prostate cancer cell lines, RWPE1 and RWPE2. F77 CAR-T cells effectively killed prostate cancer cells both in vitro and in vivo models.Advantages:F77 CAR-T kills androgen-independent prostate cancer cells (these may include androgen negative cancer and hormone therapy resistant cancer)F77 expression is restricted to prostate cancer and a small subset of breast cancer‚Äì limiting off-target effectsFigure 1. % Cytolysis determined through xCELLigence impedance measurement at 5:1 E:T ratio of CAR T cells and cancer cells. % Cytolysis for cancer cells was calculated after 24 h of cancer cell addition (A) PC3, (B) RWPE-1, (C) RWPE-2, and every 5 h after effector cells addition. Impedance monitoring was validated using T cells without any CAR (NTD), F77 CAR1, F77 CAR2 and control CAR effector (cells over GFP labeled target cells at E:T ratios of 5:1. Normalized Cell Index (NCI) was used to calculate % Cytolysis and plotted ¬± SEM. Significance of difference in activity of each CAR compared to NTD was determined using One-way ANOVA followed by Dunnett's correction for multiple comparisons. Asterisks indicate significance (** p<0.0001 and ns refers to p‚â•0.05).Figure 2. Treatment of mice bearing PC3 subcutaneous tumors with F77 effector cells leads to tumor regression (n=5).Stage of Development:Proof of concept in vitro and in vivo human prostate cancer xenograft modeIntellectual Property:US Patent FiledReference Media:Zhang, G et al.;Proc Natl Acad Sci USA 2010 Jan 12, 107(2): 732.Grover, P et al.;Biochem Biophys Res Commun 2023 Nov 5, 680: 51.Desired Partnerships:LicenseCo-developmentCase ID:21-9684-TpNCSWeb Published:10/25/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52653","**Summary:** This technology offers a promising therapeutic approach for metastatic prostate cancer by employing a CAR construct that targets the F77 sugar antigen, which is expressed by approximately 85% of these cancer cells. The CAR-T cells designed for this purpose demonstrated strong specificity and effectiveness in both in vitro studies and in vivo models, successfully killing prostate cancer cells. Additionally, the technology shows potential in addressing androgen-independent prostate cancer, including cases that are resistant to hormone therapy.

**Applications:** The CAR construct can be utilized in treating advanced metastatic prostate cancer, particularly those cases that have developed resistance to standard therapies. It may also have applications in targeting a small subset of breast cancer cells that express the F77 antigen.

**Problem Solved:** The technology addresses the significant drop in survival rates for patients with metastatic prostate cancer, who currently face limited treatment options and a high likelihood of developing resistance to available therapies, ultimately improving therapeutic outcomes for this patient population.","The 5-year relative survival rate for metastatic or advanced prostate cancer drops to 32% due to therapy resistance. Researchers have developed a CAR construct that targets specific sugar-bearing prostate cancer cells and a subset of breast cancer cells."
"University of Pennsylvania","Stable Biological Membrane Mimetic For Enhanced Protein Recruitment","","","https://upenn.technologypublisher.com/technology/52594","Synthetic biological alternative to natural lipids for conjugation with nitrilotriacetic acid (NTA) for enhanced His-tagged protein interaction and long-term stability.Problem:Biomimetic lipid vesicles, such as liposomes, have multiple biotechnology and drug delivery applications as their lipid bilayer innately interacts with natural cell membranes. To enhance cellular interactions, the surfaces of liposomes are arrayed with proteins using nitrilotriacetic acid (NTA)-conjugated lipids. However, limited commercially available NTA-conjugated lipids exist. Further, the activity and stability of NTA-conjugated lipids decreases rapidly following exposure to air and within weeks to months following storage at -20¬∞C.Solution:Janus dendrimers (JDs) are synthetic alternatives to natural lipids that effectively self-assemble, encapsulate high concentrations of organic compounds, and exhibit ideal mechanical properties allowing interactions with natural lipid bilayers. NTA-conjugated JDs exhibit increased stability and protein affinity when compared to NTA-conjugated lipids.Technology:Qi Xiao and the Percec group have developed JDs conjugated to both monovalent NTA and TrisNTA as biological membrane mimetics. Although TrisNTA provides greater protein affinity than monovalent NTA, TrisNTA is complex and expensive to synthesize. A modular, synthetic approach allowed for the development of a library of both JD-NTA and JD-TrisNTA compounds. Both types of compounds do not decompose when exposed to air, remain highly stable at room temperature, and provide higher affinities to His-tagged proteins when compared to NTA-conjugated lipid-based approaches.Advantages:Provides infinitely higher stability at room temperature, which is key for conjugation conditions and long-term storageDisplays ~30-fold enhanced protein affinity with JD-NTA compared to lipid-NTA, which is key for maximizing protein interactions in biological approachesProvides ~1000-fold enhanced protein affinity with TrisNTA compared to monovalent NTA, which is key for conserving expensive reagents without compromising sensitivity(A) Janus dendrimer conjugated to a nitrilotriacetic acid (NTA) ligand (RH-NTA) with scheme of RH-NTA binding to histidine (His) residues from proteins. Figure from Torre, P. et. al.,Proc. Natl. Acad. Sci. USA, 2019 Jul 30; 116 (31): 15378Stage of Development:ConceptProof of ConceptBench PrototypeIntellectual Property:In PreparationReference Media:Torre, P. et. al.,Proc. Natl. Acad. Sci. USA, 2019 Jul 30; 116 (31): 15378Desired Partnerships:LicenseCo-DevelopmentCase ID:20-9282-tpNCSWeb Published:10/16/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52594","**Summary:** The technology involves the development of synthetic biological alternatives to natural lipids, specifically Janus dendrimers (JDs) that are conjugated with nitrilotriacetic acid (NTA). These JDs enhance the recruitment of His-tagged proteins and demonstrate long-term stability, outperforming traditional NTA-conjugated lipids that degrade quickly when exposed to air and during storage. The JDs can self-assemble, encapsulate a high concentration of organic compounds, and maintain ideal mechanical properties for interaction with natural lipid bilayers.

**Applications:** The synthetic JDs have potential applications in biotechnology and drug delivery due to their enhanced protein interaction capabilities and stability compared to conventional liposomes.

**Problem Solved:** The technology addresses the limited availability and rapid degradation of NTA-conjugated lipids used in biomimetic lipid vesicles for protein recruitment and delivery, improving both the stability and affinity of these biomimetic systems.","Synthetic biological alternatives to natural lipids are developed for conjugation with nitrilotriacetic acid (NTA) to improve interactions with His-tagged proteins and enhance long-term stability. Biomimetic lipid vesicles, like liposomes, can benefit from this approach in various biotechnology and drug delivery applications."
"University of Pennsylvania","Double Digital Assay for Isolation and Analysis of Single Extracellular Vesicles for Early Detection of Disease Biomarkers Including Cancer","","","https://upenn.technologypublisher.com/technology/52562","An ultrasensitive diagnostic tool that isolates single extracellular vesicles (EVs) and measures their contents to single molecule resolution.Problem:EVs contain biomolecules that can identify a variety of disease states and, thus, have emerged as a promising source for diagnostics. Within the EV diagnostic field, there are two major challenges: (1) the isolation and compartmentalization of single EVs to resolve their heterogeneity and (2) the precise measurement of the proteins contained within them, which tend to be of very low abundance. Previous attempts to isolate and analyze the contents of single EVs rely on bulk analysis of their molecular cargo and include techniques like modified flow cytometry and fluorescence imaging. However, these technologies have limitations of the inability to accurately quantify EV molecular cargo with ultra-high resolution.Solution:Here, a double digital assay overcomes the challenges of isolating and compartmentalizing single EVs as well as detecting their low-abundance proteinaceous contents. This technology flows a sample containing EVs over a microwell array and relies on the Poisson distribution to load single EVs into a single microwell. Then, an ultrasensitive digital enzyme-linked immunosorbent assay (dELISA) detects target proteins to single molecule resolution.Technology:This technology comprises two layers: a flow cell (top layer) and a honeycomb-inspired microwell array (bottom layer). Antibody-conjugated beads and spacer beads coat the bottom of the microwells. Sample containing EVs is flowed over the microwells, loading single EVs into single microwells. This technique relies on the Poisson distribution (l=0.1) to isolate single EVs whereby the statistical likelihood of two EVs being deposited into one well is very low. The EVs are then lysed, and their proteinaceous contents detected by dELISA, using tyramide signal amplification (TSA), which can detect analytes to single molecule resolution.Advantages:Does not require expensive equipment nor technically challenging methods of separationAllows for the detection of rare biomarkers that may be missed with bulk analysis techniquesAllows for detection of low abundance biomarkers that may be important for early detection of cancer and other diseasesSamples may be taken from patients‚Äô blood, which is convenient and non-invasive compared to procedures such as tissue biopsySignificant (100-fold) improvement in the limit of detection over conventional ELISAFigure 1. (A) Schematic depicting the experimental overview of the double digital EV assay. Microwells are coated with antibody-conjugated beads separated by spacer beads. Sample containing EVs is flowed over the microwells whereby single EVs are deposited into single wells. Lysis buffer is then flowed into the wells to release the contents of the EVs into the microwells followed immediately by oil to prevent cross-contamination. The contents of EVs are then captured by digital ELISA enhanced by TSA, which produces the fluorescent signal used to detect single protein molecules. (B) Honeycomb-inspired microwells demonstrating raw signal output of the digital ELISA enhanced by TSA from single EV samples.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:US Provisional Application FiledReference Media:Reynolds, D. E. et. al.,Methods Mol Biol., 2023; 2689: 211Morales, R.-T. T., & Ko, J. et al.,ACS Nano., 2022 Aug 23; 16(8): 11619Dr. Jina Ko, Schmidt Science Fellows, inSPIREd; 2019 July 26,Can a fusion of disciplines help us to fight rare diseases?Desired Partnerships:LicenseCo-DevelopmentCase ID:23-10430-tpNCSWeb Published:10/9/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52562","**Summary:** This technology offers an ultrasensitive method for isolating single extracellular vesicles (EVs) and analyzing their molecular contents with high resolution. It addresses critical challenges in the EV diagnostic field, including the heterogeneity of EVs and the detection of low-abundance proteins. By utilizing a double digital assay that incorporates a microwell array, the technology allows for the loading of a single EV into each well through a Poisson distribution method, followed by the application of a digital enzyme-linked immunosorbent assay (dELISA) for precise protein detection.

**Applications:** The primary applications of this technology include the early detection of disease biomarkers, particularly in the context of cancer diagnostics. It may also be valuable for broader medical diagnostics where EVs play a role in identifying various disease states through their molecular content.

**Problem Solved:** The technology resolves the significant challenges of effectively isolating individual EVs to study their heterogeneity and accurately measuring the often low-abundance proteins they contain. Traditional methodologies have struggled with these aspects, leading to inadequate quantification of EV molecular cargo, which this new approach effectively addresses.","An ultrasensitive diagnostic tool isolates single extracellular vesicles (EVs) and measures their contents at single molecule resolution, addressing challenges in resolving EV heterogeneity and accurately measuring protein content. This method aims to facilitate the early detection of various disease biomarkers, including those for cancer."
"University of Pennsylvania","Versatile Algorithm For Safe And Accurate Deep Learning","","","https://upenn.technologypublisher.com/technology/52529","Model-based robust deep learning algorithms allow for more accurate and robust predictions in varying environmental conditions.Problem:In applications that rely on safe and reliable predictions such as autonomous vehicles, medical imaging, and robotics, it is essential that the prediction systems be made robust against nuisance variability such as changes in lighting or weather conditions. It is well known that various deep learning algorithms are fragile to seemingly innocuous changes to the environment such as background, lighting, blurring, or contrast. Currently there are no general-purpose algorithms that provide robustness against these variations in data.Solution:The novel model-based training paradigm comprises three training algorithms which provide robustness against many different forms of nuisance-based variation. The three training algorithms, which are broadly applicable to deep learning, produce training data that leads to more reliable predictive systems.Technology:A model of natural variation‚Äîa function which captures the variation in data‚Äîis first obtained either by learning the variation directly from data or by exploiting the physical laws governing the problem. Depending on the setting, such models can capture nuisances in the data such as lighting, background color, haze, snow, or contrast. Once a model has been obtained, it is used in conjunction with a robust optimization problem to train deep neural networks which are robust to the source of variation captured by the model. The main insight is that the optimization problem seeks worst-case nuisances captured by the model, and then trains the neural networks to classify correctly on these worst-case data points. In this work, three algorithmic variants are proposed which collectively facilitate a trade-off between robustness and efficiency. This pipeline is, in principle, more flexible than standard classification, as it can integrate human priors regarding relevant nuisances by selecting or composing models of natural variation.Advantages:Provides safety to systems that rely on accurate prediction such as autonomous vehiclesReusable in any number of different machine-learning systems, allowing for a wide range of applications30 percentage point improvement over state-of-the-art image classifiers when tested on subsets of ImageNet-cCan be used in non-computer vision applications, providing more versatility than current image classifiersA gallery of learned models of natural variation. For a range of datasets, we show images generated by passing data through leaned models of natural variation. The generated images mimic image changes due to naturally occurring environmental conditions and can be used in training data. The right side of the table shows examples of these generated images based on the type of natural variation (brightness, contrast, hue, etc.). The three images in the brightness section, for example, show a range of generated images when the brightness parameter is tweaked. Figure fromRobey, A. et. al., arXiv 2005.10247v2; 2020 Nov. 2: 1, Page 20, Table 1.Stage of Development:Minimum Viable ProductIntellectual Property:US Patent Application FiledReference Media:Robey, A. et. al., arXiv2005.10247v2; 2020 Nov. 2: 1Desired Partnerships:LicenseCo-developmentCase ID:20-9404-tpNCSWeb Published:10/4/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52529","**Summary:** Model-based robust deep learning algorithms enhance accuracy and robustness in predictions under varying environmental conditions. These algorithms address the fragility of existing deep learning models to nuisance variability, such as changes in lighting, background, and other environmental factors. A new training paradigm comprises three training algorithms that generate robust training data, leading to more reliable predictive systems.

**Applications:** The technology is applicable in fields that require safe and reliable predictions, including autonomous vehicles, medical imaging, and robotics.

**Problem Solved:** The solution addresses the lack of general-purpose algorithms that can effectively manage variations in data caused by nuisance factors, ensuring that prediction systems remain robust and accurate in dynamically changing environments.","Model-based robust deep learning algorithms enhance prediction accuracy and reliability under varying environmental conditions. Ensuring robustness against nuisance variability is crucial for applications like autonomous vehicles, medical imaging, and robotics, as typical deep learning models can be sensitive to minor changes in environmental factors."
"University of Pennsylvania","Easily Fabricated Polymer Brushes For pH-Mediated Nanoparticle (NP) Control","","","https://upenn.technologypublisher.com/technology/52527","A polymer brush coating on a substrate made through block copolymer coating and exfoliation for pH-mediated nanoparticle sorting, transport, and diffusion.Problem:NP-based technologies in fields such as biotherapeutics, separation, and purification require precise control of nanoparticle transport, absorption, and diffusion. Polymer brushes exhibit an effective stimuli-response surface for controlling the interaction with nanoparticles, with potential stimuli including the solution pH or external electric field. Existing methods of polymer brush preparation methods make use of complex chemical synthesis for brush fabrication. These techniques covalently bond polymer brushes using ‚Äúgrafting-from‚Äù or ‚Äúgrafting-to‚Äù methods on the substrate. These methods can be time consuming (e.g., growing a polymer brush from the surface), narrowly applicable, energy intensive, and expensive.Solution:A fabrication method that uses selective exfoliation of a block copolymer coating to expose brush material, avoiding work-intensive chemical grafting approaches. The brush swells and stretches in response to pH stimulus, allowing for selective adsorption of nanoparticles.Technology:A grafted polystyrene (gPS) layer is fabricated on an oxide substrate (e.g., SiO2) using an œâ-hydroxy-terminated polystyrene (PS), resulting in a smooth, hydrophobic surface. Over this ‚Äúprimer‚Äù layer, a block copolymer coating, containing PS-block-poly (2-vinyl pyridine) (P2VP) layers, is thermally annealed on the gPS, forming a parallel lamellar bilayer with PS domains on top due to the high surface energy of P2VP. To invert the structure and obtain an outer P2VP domain, methanol is used in conjunction with sonication to selectively penetrate and dissolve the P2VP domain, removing the outermost PS-block-P2VP coating and exposing the P2VP outer domain. The P2VP domain, anchored to the gPS via the glassy PS domain, can stretch and swell in response to pH, allowing pH-mediated gold nanoparticle adsorption by controlling the permeability depending on the size of the nanoparticles.Advantages:Simple, robust exfoliation fabrication method that avoids the complex chemical grafting processes used for traditional polymer brushesTunable adsorption of nanoparticles with pH-dependent size selectivity, allowing for nanoparticle sorting, rather than just transport and diffusion applicationsBrushes can release nanoparticles back into solution, allowing for reusability(a) Schematic illustration of P2VP brush on a Si wafer (blue is PS and green is P2VP). (b) AFM height image (512-by-512 pixels). (c) Height profiles collected from every pixel row (total 512 rows) shown in light blue. A representative height profile shown in blue. (d) Photo of a water droplet on the P2VP brush. (e) A schematic of the side view of the BCP monolayer. (f) X-ray reflectivity profiles and (g) the electron density profile along the z-axis of a neat BCP monolayer and after incorporation of AuCl4- ions in the protonated P2VP brush. A dashed line indicates the position of the junction between the PS and P2VP blocks.Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:Provisional Application FiledReference Media:Kim, Y. C. et. al., ACS Nano., 2023 May 23; 17(10): 9224Desired Partnerships:LicenseCo-developmentCase ID:23-10260-tpNCSWeb Published:10/3/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52527","**Summary:** The technology involves the creation of a polymer brush coating on a substrate through a block copolymer coating and exfoliation technique that enables pH-mediated control of nanoparticle (NP) sorting, transport, and diffusion. Traditional methods of polymer brush preparation often rely on complex and time-consuming chemical synthesis techniques, such as ""grafting-from"" or ""grafting-to"" methods, which can be expensive and energy-intensive. In contrast, this innovative approach simplifies the fabrication process by utilizing selective exfoliation to reveal the brush material, which can respond to pH changes by swelling and stretching, thereby facilitating selective nanoparticle adsorption.

**Applications:** This technology has potential applications in various fields where control over the behavior of nanoparticles is crucial, including biotherapeutics, separation processes, and purification techniques. The ability to mediate nanoparticle interaction based on pH could enhance the efficacy and efficiency of drug delivery systems, bioseparation technologies, and other nanoparticle-based applications.

**Problem Solved:** The technology addresses the need for precise control of nanoparticle transport, absorption, and diffusion in NP-based technologies. By offering a more efficient and cost-effective method of polymer brush fabrication, it overcomes the limitations associated with existing complex chemical methods, thereby enhancing the performance and versatility of nanoparticle applications in various industries.","A polymer brush coating on a substrate is created using block copolymer coating and exfoliation to facilitate pH-mediated sorting, transport, and diffusion of nanoparticles. This approach addresses the need for precise control over nanoparticle transport, absorption, and diffusion in various NP-based technologies."
"University of Pennsylvania","VASH1 Depletion for Heart Failure Therapy","","","https://upenn.technologypublisher.com/technology/52510","Non-replicating viral delivery of shVASH1 to treat heart failure.Problem:Heart failure (HF) is condition in which the heart cannot pump enough blood throughout the body to meet its need. Approximately 6 million American adults live with the condition, and close to 400,000 people die from it annually. Mainstay treatment for HF are lifestyle changes and medications that include ACE inhibitors, beta blockers, diuretics, and sodium-glucose cotransporter-2 inhibitors. Despite several treatment options, the 5-year mortality rate remains high at approximately 75%.Solution:One hallmark of HF is increased stiffness of cardiomyocytes (CM), which is due to the detyrosination of cardiac microtubules. Vasohibin-1 (VASH1) is an enzyme that detyrosinates cardiac microtubules. The inventors discovered that VASH1 depletion was sufficient to reduce microtubule detyrosination and restore CM function.Technology:The inventors demonstrated that VASH1 protein could be depleted using short-hair RNA molecules in human CMs. Moreover, they showed that depletion of VASH1 resulted in significant reduction in detyrosinated tubulin expression. VASH1 knockdown was associated with increased contraction speed and relaxation in CMs isolated from patients with failing hearts. Finally, the inventors demonstrated that VASH1 knockdown reduced CM stiffness.Advantages:VASH1 depletion has minor effects on non-failing CMs.Potential for lower off-target effects (compared to the detyrosinating enzyme inhibitor parthenolide).Graphical representation of the relationship between microtubule detyrosination and cardiomyocyte function (TTL: Tubulin Tyrosine Ligase ‚Äì enzyme that tyrosinates microtubules)Stage of Development:In vitro proof of concept in CMs isolated from patients with HFIntellectual Property:USPendingReference Media:Chen, CY et al.;Circ Res 2020 July 3; 127(2): e14Desired Partnerships:Co-developmentCase ID:20-9311-TpNCSWeb Published:10/2/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52510","**Summary:** Non-replicating viral delivery of short-hairpin RNA targeting VASH1 has been developed as a therapy for heart failure, a condition that affects approximately 6 million American adults and leads to nearly 400,000 deaths annually. Current treatments, including lifestyle changes and medication, have not sufficiently reduced the five-year mortality rate, which remains around 75%. The technology addresses the hallmark feature of heart failure: the increased stiffness of cardiomyocytes caused by detyrosination of cardiac microtubules, mediated by the enzyme VASH1. By depleting VASH1, the inventors have shown a significant reduction in microtubule detyrosination, leading to improved contraction and relaxation in cardiomyocytes from patients with heart failure, alongside decreased stiffness.

**Applications:** This technology has the potential to be used specifically in heart failure therapy by restoring normal cardiac function through targeted intervention in cardiomyocytes.

**Problem Solved:** The approach effectively targets the underlying issue of cardiomyocyte stiffness in heart failure, aiming to enhance heart function and reduce mortality associated with this condition.","Heart failure affects approximately 6 million American adults and leads to nearly 400,000 deaths annually. Current treatments focus on lifestyle changes and medications such as ACE inhibitors, beta blockers, diuretics, and sodium-glucose cotransporter-2 inhibitors, but there remains a need for innovative therapies."
"University of Pennsylvania","High Density Multidimensional Microlaser Array For High-Power, Narrow-Divergence Applications","","","https://upenn.technologypublisher.com/technology/52479","A high-power laser array based on quantum physical properties for 3D sensing and displays and Light Detection and Ranging (LIDARs).Problem:There is a widespread need for high power, narrow divergence, and high coherence lasers. Accomplishing this requires phase locking, a challenging method combining multiple laser outputs. Previous approaches to address this issue can be applied only to a one-dimensional laser array or involve complicated designs, making it challenging to package densely or downsize. However, the development of scalable, single-mode high-powered lasers is crucial for developing light detection and ranging (LiDAR) applications used in technologies such as self-driving cars.Solution:The inventors take advantage of the physical concept of supersymmetry (SUSY), a theory derived from quantum mechanics. While the physical nature of other non-SUSY systems results in multiple competing laser modes (making single-mode laser arrays challenging), applying supersymmetry to laser arrays overcomes this limitation and allows the lasers' power to focus into a single mode, high-powered system.Technology:A SUSY-inspired microlaser array amplifies a single laser mode, providing a coherent high-powered signal. The design is scalable to any number of dimensions. It also does not require optical mode leakage communication between optical elements ‚Äì a considerable simplification to existing single-mode technologies. This technology applies supersymmetry partners to a microlaser array. It has been experimentally demonstrated as a two-dimensional array and it can theoretically be applied to three-dimensional arrays as well.Advantages:First instance of supersymmetry (SUSY) techniques for 2D laser arrays (all previous arrays were limited to 1D)Twenty-five times (25x) increase in power output compared to single laser>100x power density compared to that of a single-mode laser arrayScalable design down to the order of micronsA multidimensional SUSY microlaser array, comprising a 5x5 main array with two SUSY partners and three auxiliary partner rings. This design eliminates high-order transverse supermodes to facilitate high-radiance single-mode laser action.Stage of Development:ConceptProof of ConceptIntellectual Property:PCT/US2022/071817 Application FiledReference Media:Qiao, X. et al.,Science, 2021 Apr 23; 372(6540): 403Desired Partnerships:LicenseCo-developmentCase ID:21-9680-tpNCSWeb Published:9/26/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52479","**Summary:** A novel laser array technology utilizing the principles of supersymmetry from quantum mechanics enables a high-power, coherent output while overcoming the challenges posed by multiple competing modes in conventional laser systems. This scalable microlaser array is designed to amplify a single laser mode, delivering a focused high-powered signal without the need for optical mode leakage communication, simplifying the design compared to existing single-mode technologies.

**Applications:** The technology is primarily intended for high-power, narrow divergence applications, including 3D sensing, displays, and Light Detection and Ranging (LIDAR) systems, which are essential for advanced technologies such as self-driving cars.

**Problem Solved:** This invention addresses the widespread demand for high power, narrow divergence, and high coherence lasers by providing a manageable solution to phase locking across multidimensional laser arrays, which has been a significant challenge in the development of scalable laser systems.","A high-power laser array utilizing quantum properties is designed for applications in 3D sensing, displays, and LIDARs, addressing the need for high power, narrow divergence, and high coherence. Current methods for phase locking are limited to one-dimensional arrays or complex designs, complicating dense packaging."
"University of Pennsylvania","Cellulose Nanofiber-Based Substrates For Fabricating High-Fidelity And Biodegradable, Printed Electronics","","","https://upenn.technologypublisher.com/technology/52458","A method for manufacturing biodegradable nano-cellulose infiltrated paper (NCIP) substrates with low surface smoothness and low porosity for printed electronics and packaging applications.Problem:Electronics and sensors today are typically fabricated on non-biodegradable substrates, which means they are poorly suited for a range of important uses including agricultural monitoring and integration with packaging. Currently, printed electronics manufactured on polymer substrates or paper with polymer coatings such as polyimide, are non-biodegradable.Solution:The inventors have developed biodegradable NCIP substrates with exceptional properties, including a smooth and non-porous surface. Both the substrate and the fabrication process are ideal for use in the large-scale manufacturing of printed electronics and sensors with high uniformity. The combination of nanocellulose with a conventional paper substrate.Technology:Printed electronics are a class of low-cost device made by printing conductors and dielectrics on substrates. The inventors have developed a multi-step process of coating and drying aqueous CNF solution onto paper substrates. The controlled process allows for the fabrication of large area NCIP substrate with minimal distortions. The substrates can be engineered to be moisture responsive, allowing them to be used as a transducer material for humidity and soil moisture sensors. Biodegradable sensors have a wide array of applications in medicine, agricultural monitoring, and packaging.Advantages:NCIP substrates are biodegradable and sustainable, unlike other substrates currently in use.The fabrication method for NCIP substrates is low-cost and scalable for large areas and high-volume manufacturing.NCIP substrates have high smoothness, translating to less variability in printed feature thickness and in-plane dimensions.An example of a moisture-responsive screen-printed capacitor on an NCIP substrate.Stage of Development:Bench PrototypeIntellectual Property:Provisional FiledReference Media:Zaccarin, A.M. et al.,IEEE Sensors Journal, 2023 Aug 15: p. 1; doi: 10.1109/JSEN.2023.3299430Iyer, G. M. et al.,2022 IEEE Sensors, 2022 Dec 08: p. 1UPenn 2023-2024 Y-Prize Competition Finalist,Cellulose-Based Materials for Biodegradable Soil Moisture SensorsDesired Partnerships:LicenseCo-DevelopmentCase ID:23-10395-tpNCSWeb Published:9/20/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52458","**Summary:** The technology involves manufacturing biodegradable nano-cellulose infiltrated paper (NCIP) substrates specifically designed for printed electronics and packaging applications. These substrates possess low surface smoothness and low porosity, addressing the shortcomings of traditional non-biodegradable materials used in electronic fabrication.

**Applications:** The biodegradable NCIP substrates are suitable for printed electronics, sensors, and smart packaging. They can be particularly useful in agricultural monitoring and medical applications, where biodegradability and moisture responsiveness are beneficial.

**Problem Solved:** The technology addresses the environmental concerns associated with non-biodegradable substrates used in electronics and sensors, making it possible to manufacture components that are more compatible with eco-friendly practices, especially in fields such as agriculture and healthcare. The invention provides a solution for creating high-fidelity, biodegradable electronic devices that can decompose without leaving harmful residues.","A method has been developed to create biodegradable nano-cellulose infiltrated paper (NCIP) substrates that feature low surface smoothness and low porosity, specifically for printed electronics and packaging applications. This approach addresses the issue of non-biodegradable substrates currently used in electronics and sensors, enhancing their suitability for agricultural monitoring and packaging integration."
"University of Pennsylvania","Coherent Generation Of High-Dimensional Structured Light Using A Hyperdimensional Spin-Orbit Microlaser","","","https://upenn.technologypublisher.com/technology/52439","The current invention describes next-generation high-capacity noise-resilient communication and computing technology. The invention describes a method to coherently generate high-dimensional structured light, including spin-orbit states, in an integrated and scalable way.Problem:On-chip information technologies are mostly limited to two-level systems due to the lack of sufficient reconfigurability to satisfy the stringent requirement for degrees of freedom, i.e., for a system with more than two energy levels, a very large number of independent parameters or degrees of freedom must be precisely controlled to generate the desired high-dimensional structured light. Generally, the expansion of dimensionalities relies on the complicated interferometric setup, which is cumbersome, requires manual tuning, and is not scalable. Recent developed vector lasers and microcavities could increase the dimensionality in a more compact way. However, it still remains a challenge to actively tune the diversified, high-dimensional superposition states of light on demand. Thus coherent generation of high-dimensional structured light, including spin-orbit states, does not seem to be practical for large-scale production.Solution:The current invention demonstrates a semiconductor micro laser exploiting spin-orbit coupling of light, wherein the polarization of the light becomes dependent on the on-chip direction of propagation, increasing the number of degrees of freedom by generating structured light states with unique polarization and phase properties. Two microcavities, coupled through a non-Hermitian synthetic gauge field, are designed to emit structured light states with six degrees of freedom using the spin-orbit coupling of light, allowing for a much larger amount of information to be encoded and processed.Technology:A hyperdimensional, spin-orbit microlaser for chip-scale flexible generation and manipulation of arbitrary four-level states, which uses integrated photonic circuits on the III/V semiconductor platform to emit spin-orbit states and uses an external laser to control the on-chip coupling, thereby coherently generating all the spin-orbit superposition states in the 4-dimensional Hilbert space. Tunable asymmetric couplings enabled by a synthetic imaginary gauge field provide flexible control of up to six degrees of freedom (DOFs), thus enabling the full coverage of a 4D Hilbert space. The vectorial state of the emitted laser beam in free space is mapped on a Bloch hypersphere defining an SU(4) symmetry, which demonstrates the dynamical generation and reconfiguration of high-dimensional superposition states with high fidelity.Advantages:Potential to further promote the precision limit in metrology, imaging, and information science.The carefully selected four spin-orbit-coupled states possess the same propagation properties and completely overlap in both space and time, thereby maintaining long-distance coherence, which is ideal for free-space quantum communication, including satellite-to-earth communication, tower to tower communication, and intracity communication.Space-division multiplexing can be used to transmit information with the use of the spin-orbit microlaser, increasing the channel capacity and the security of the communication channel.(a) The hyperdimensional microlaser, emitting in a 4D Hilbert space, consists of two same-sized microrings fabricated on a III-V semiconductor platform with 200 nm thick InGaAsP multiple quantum wells. The micro rings are coupled through an imaginary gauge formed by four control waveguides, which are themselves connected using two 3-dB directional couplers. (b) Scanning Electron Microscope (SEM) image of the 3 dB directional coupler. (c) Scanning Electron Microscope (SEM) image of the right microring laser with the angular grating inscribed on the inner side wall.Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Zhang, Z. et al.,Nature, 2022 Dec; 612 (7939): 246Desired Partnerships:LicenseCo-developmentCase ID:23-10269-tpNCSWeb Published:9/18/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52439","**Summary:** The current invention introduces a method for coherently generating high-dimensional structured light, including spin-orbit states, using an integrated and scalable semiconductor microlaser. This technology addresses the limitations of on-chip information systems, which are predominantly restricted to two-level configurations due to the challenges in reconfigurability and control of numerous independent parameters necessary for producing high-dimensional light.

**Applications:** This technology can be applied to next-generation communication systems and computing platforms, particularly those that require high-capacity, noise-resilient performance through advanced light manipulation and control, enhancing data transmission rates and computational efficiency.

**Problem Solved:** The invention overcomes the limitations of traditional interferometric setups, which are complex and non-scalable. By utilizing spin-orbit coupling and integrating it into a semiconductor microlaser, it enables the active tuning and generation of diversified, high-dimensional light states on demand, thereby facilitating practical applications for large-scale production in information technologies.","The invention presents a method for coherently generating high-dimensional structured light, including spin-orbit states, in a scalable manner to enhance communication and computing technologies. It addresses the limitations of current on-chip information systems, which primarily rely on two-level systems and lack the necessary reconfigurability."
"University of Pennsylvania","Small Molecule Activators of Valosin-Containing Protein (VCP) as Therapeutics for Neurodegenerative Diseases with Ubiquitinated Protein Aggregates","","","https://upenn.technologypublisher.com/technology/52431","Small molecule therapeutics that aid in clearing abnormal protein deposits observed in neurodegenerative diseases.Problem:Dementia, characterized by the impairment of at least two brain functions, such as memory loss and judgment, currently has no cure. Two common neurodegenerative diseases that cause dementia are Frontotemporal Dementia (FTD) and Alzheimer‚Äôs Disease (AD). In the United States, FTD affects an estimated 50,000 to 60,000 people, and AD, more than 6 million people. These diseases are characterized by the abnormal accumulation of protein aggregates, specifically tau and TDP-43 aggregates. Tau and TDP-43 proteins undergo abnormal folding and clump together into aggregates, which disrupt normal cellular function. Valosin-containing protein (VCP) is responsible for solubilizing and breaking down the tau and TDP-43 aggregates, preventing their accumulation, but pathogenic variants of VCP impair the breakdown of protein aggregates. Notably, other neurodegenerative diseases, such as Paget‚Äôs disease of bone, Parkinson‚Äôs Disease, and amyotrophic lateral sclerosis, are also associated with pathogenic variants of VCP.Solution:The inventors identified four small molecules that allow pathogenic VCP to effectively unfold and degrade the insoluble aggregated forms of tau and TDP-43.Technology:VCP plays a role in protein quality control, and many ubiquitinated proteins (proteins tagged by ubiquitin for degradation) require pre-processing by VCP to be degraded by the proteasome. From a panel of approximately one hundred structurally distinct small molecules, the inventors discovered four compounds that increase VCP‚Äôs ATPase activity, allowing VCP to remove protein aggregates more efficiently.Advantages:VCP activity decreased tau filament aggregation by 30.1%.Small molecules increased VCP ATPase activity by more than 2 standard deviations from the mean and showed better clearing of protein aggregates.A schematic highlighting mechanisms that lead to neurodegeneration in Alzheimer‚Äôs Disease and Frontotemporal Lobar Degeneration. Soluble tau proteins aggregate to form fibrillar structures leading to disease. At the top right, wild-type VCP solubilizes and breaks down the problematic fibrillar tau. Mutant (pathogenic) VCP, on the other hand, impedes this process (lower right). The four discovered VCP compounds overcome the effects of pathogenic VCP and increase the efficiency of wild-type VCP for clearing protein aggregates.Stage of Development:Target IdentifiedIntellectual Property:Provisional FiledReference Media:Darwich et al,Science. 2020 Nov 20; 370(6519): eaay8826.Penn Medicine News,Penn Medicine Researchers Discover A Rare Genetic Form of DementiaDesired PartnershipsLicenseCo-developmentCase ID:22-9828-TpNCSWeb Published:9/15/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52431","**Summary:** Small molecule therapeutics have been developed to facilitate the clearance of abnormal protein deposits associated with neurodegenerative diseases, specifically targeting tau and TDP-43 aggregates. These protein aggregates, which result from abnormal folding of tau and TDP-43, disrupt normal cellular function and are implicated in conditions such as Frontotemporal Dementia and Alzheimer‚Äôs Disease. The technology focuses on enhancing the activity of valosin-containing protein (VCP), which is crucial for breaking down these aggregates, especially when pathogenic variants of VCP are present that hinder this process.

**Applications:** The small molecule activators are intended to treat neurodegenerative diseases characterized by the accumulation of ubiquitinated protein aggregates, including Frontotemporal Dementia, Alzheimer‚Äôs Disease, Paget‚Äôs disease of bone, Parkinson‚Äôs Disease, and amyotrophic lateral sclerosis. By restoring the functionality of VCP, these therapeutics may improve cellular health and potentially slow disease progression.

**Problem Solved:** The technology addresses the lack of effective treatment options for neurodegenerative diseases marked by protein aggregation, particularly the challenges posed by pathogenic variants of VCP that impair the degradation of dysfunctional protein aggregates. Through activating VCP, the small molecules may enhance the cellular clearance of toxic aggregates and mitigate the associated cognitive decline seen in diseases like dementia.","Small molecule therapeutics are being explored to clear abnormal protein deposits associated with neurodegenerative diseases like Frontotemporal Dementia and Alzheimer‚Äôs Disease, which currently have no cure. In the United States, an estimated 50,000 to 60,000 people are affected by FTD, while more than 6 million people are affected by AD."
"University of Pennsylvania","Targeted modulation of noncoding BMPR2 sequences increases protein expression for treatment of pulmonary arterial hypertension","","","https://upenn.technologypublisher.com/technology/52322","Problem:Pulmonary arterial hypertension (PAH) is a severe lung disease characterized by elevated pulmonary arterial pressure that is estimated to affect 5,000-15,000 people in the US. Without proper treatment, the elevated pressure leads to heart failure and eventually death‚Äîmedian survival without treatment is around 2-3 years. Management and treatment of PAH may help slow down disease progression, but the mortality rate in patients with intermediate- to high-risk (approximately 88% of patient population) remains high.Solution:Molecular profiling and clinical studies have identified the loss of bone morphogenetic protein receptor type II (BMPR2) as a major contributor to PAH pathogenesis and progression. Increasing BMPR2 protein has been shown to effectively treat PAH in mouse models.Technology:Upstream open reading frames (uORFs) are open reading frames found in the 5‚Äô untranslated region of an mRNA, and they can control protein expression by modulating the rate of translation. Targeting certain regions of uORFs using antisense oligonucleotides (ASOs) has been shown to increase protein expression. The inventors identified uORF sequences of BMPR2 that could be targeted by ASOs to increase BMPR2 protein expression both in vitro and in vivo.Advantages:Potential for stopping disease progression.(A) Targeting uORF 6, but not uORF 9, increases endogenous BMPR2 protein expression. Western blot for BMPR2 protein expression 24 hours post-transfection with 100nM ASOs in HeLa cells. (B) WT C57BL/6J mice were injected with ASO at 10mg/kg of bodyweight via tail vein injection. 48hrs later, mice were euthanized, and postmortem tissues were collected. Tissue lysates were assayed for murine BMPR2 protein by ELISA. n=8 controls, n=4 uORF-ASO, *p=0.0162 unpaired, two-tailed t-test.Stage of development:Proof of concept in WT mice.Intellectual Property:US PatentPendingReference Media:Lee, DSM. et al.Nat Commun 2021 March; 12: 1515Desired Partnership:LicensingCo-developmentCase ID:21-9470-TpNCSWeb Published:8/22/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52322","**Summary:** Targeted modulation of upstream open reading frames (uORFs) in the noncoding regions of the BMPR2 gene can lead to increased protein expression of BMPR2. This approach utilizes antisense oligonucleotides (ASOs) to enhance the expression of BMPR2, which is critical given that its loss is a key factor in the progression of pulmonary arterial hypertension (PAH). The technology has shown effectiveness in both in vitro and in vivo settings, specifically demonstrating that targeting uORF 6 results in a significant increase in BMPR2 protein levels.

**Applications:** This technology may be applied in the treatment of pulmonary arterial hypertension, particularly for patients who exhibit a loss of BMPR2 function. By boosting BMPR2 protein levels, the intervention aims to mitigate the severe consequences of PAH and potentially improve patient outcomes.

**Problem Solved:** The technology addresses the high mortality rates associated with pulmonary arterial hypertension by targeting the underlying pathophysiology linked to the loss of BMPR2 protein. By increasing levels of this protein, the approach aims to slow disease progression and improve survival rates in affected individuals.","Pulmonary arterial hypertension (PAH) is a severe lung disease affecting an estimated 5,000-15,000 people in the US, characterized by elevated pulmonary arterial pressure that can lead to heart failure and has a median survival of 2-3 years without treatment. Management strategies aim to slow disease progression, yet the mortality rate remains high among intermediate- to high-risk patients, impacting approximately 88% of this population."
"University of Pennsylvania","Transplantation of defined gut microbial consortia in the treatment of urease associated diseases","","","https://upenn.technologypublisher.com/technology/52310","Problem:Urease is an enzyme found in human gut bacteria that hydrolyzes urea into ammonia. High levels of bacterial urease are associated with inflammatory bowel disease (IBD). Moreover, the increased ammonia resulting from urease activity can worsen symptoms for patients dealing with hyperammonemia ‚Äì a condition associated with severe consequences such as brain edema, neurological impairment, liver dysfunction, and even death. Despite available treatments, managing IBD and hyperammonemia remains challenging as many patients develop treatment resistance.Solution:Bacterial urease levels found in the gut microbiota can be altered by engineering the gut microbiome. Here, the inventors identified a microbial consortium that has minimal urease activity.Technology :An altered Schaedler flora (ASF) with low urease activity was transplanted into conventional mice pretreated with antibiotics resulting in decreased urease activity and ammonia levels. Reduction of urease activity and ammonia was associated with reduced mortality and cognitive impairment in mice. While this technology was initially used to demonstrate efficacy in hyperammonemia, it shows promise for potential applications in the treatment of other urease-associated diseases such as IBD.Advantages:Potential for better disease control and reduction of disease associated complications.As microbial consortia stably colonize, has potential for longer term remission.(A) Diagram of the experimental method.Stage of Development:Functional data in murine in vivo modelsAssociations in human subjectsIntellectual Property:US10,842,832US10,058,576EPO3052111Australia2014331610Canada2,926,466South Africa201602948BReference Media:Ni, J et al.Sci Transl Med, 2017 Nov 15, 9(416): eaah6888.Hecht, A et al.bioRxiv 2023 Jun 11 11;2023.05.25.542283Tanes, C et al.Cell Host Microbe 2021 March 10; 29(3): 394Shen, TC et al.J Clin Invest, 2015 Jul 1, 125(7): 2841.Desired Partnerships:LicenseCo-developmentCase ID:14-6818-tpNCSWeb Published:8/18/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/52310","**Summary:** Bacterial urease, an enzyme produced by gut bacteria, is linked to inflammatory bowel disease (IBD) and hyperammonemia, leading to severe health issues like neurological impairment and liver dysfunction. The technology involves engineering the gut microbiome by transplanting a microbial consortium with low urease activity into antibiotic-pretreated mice, which resulted in decreased urease and ammonia levels. This intervention led to reduced mortality and cognitive impairment in the mice, indicating its potential efficacy for treating hyperammonemia and other urease-associated conditions.

**Applications:** The technology can be applied in the treatment of urease-associated diseases, particularly inflammatory bowel disease (IBD) and hyperammonemia, with additional potential uses in other related conditions that involve high levels of bacterial urease activity.

**Problem Solved:** This approach addresses the challenges of managing IBD and hyperammonemia, including treatment resistance encountered with existing therapies, by effectively reducing urease activity and ammonia levels, thereby improving patient outcomes and quality of life.","Urease, an enzyme produced by gut bacteria, hydrolyzes urea into ammonia, with elevated levels linked to inflammatory bowel disease (IBD) and worsening symptoms in patients with hyperammonemia. This condition can lead to severe complications, including brain edema, neurological impairment, liver dysfunction, and death, posing challenges in management despite available treatments."
"University of Pennsylvania","mRNA Therapeutics for Corneal Endothelium Regeneration","","","https://upenn.technologypublisher.com/technology/51782","A novel mRNA-based therapy that induces corneal endothelium regeneration to restore vision lossProblem:Corneal endothelial cells are critical for maintaining a clear cornea, mainly by pumping fluid out of the tissue. Decrease in number of these cells results in the clouding of the cornea that leads to vision loss. The standard of care for Fuchs Endothelial Corneal Dystrophy (FECD) is corneal transplantation. However, in addition to the procedure being invasive and costly, there is an immense shortage of cornea donors (approximately 1 cornea available for 70 needed).Solution:Induce proliferation of corneal endothelial cells to reverse loss of cells using mRNA therapeutics delivered directly into the eye.Technology:Cells of the corneal endothelium do not proliferate to replenish their number, which causes a decline in cell density with age. Confounding genetic factors or injury lead to further decline that results in the clouding of the cornea and loss of vision. The inventor created a combination of mRNA therapeutics that include Cdk4, Ccnd1, Myc, Sox2, and Yap. When these mRNAs were delivered directly into the eyes of aged mice, they effectively led to corneal endothelium regeneration by inducing a transient wave of cell proliferation.Advantages:No major surgery required ‚Äì less complications.No cornea donor required.Cost and safety profile of mRNA therapeutics.Easy to modulate mRNA dosage.A) Experimental design for induced proliferation of corneal endothelial cells in vivo, via direct eye injection of mRNAs therapeutics. Cells that incorporate the mRNAs are traced by real-time live imaging to analyze efficacy. B) Quantification of change in the number of labeled cells that receive the mRNA therapeutics (CCMSY) versus Control. [N = 7 corneas, P < 0.0001; two-way ANOVA]. C) Graph showing the change in cell density in the corneal endothelium after injection with the mRNA therapeutics. The standard curve represents the normal decline in endothelial cell density with age. Note that the mRNA therapeutics reverse the effective age phenotype of one-year-old mouse to that of a three-month-old.Stage of Development:Proof of concept in mouse model.Intellectual Property:PCTfiled.Reference Media:Marshall, M et al.;bioRxiv 2022 Dec 15: 520611Desired Partnership:Licensing ‚Äì sponsored researchCase ID:23-10232-TpNCSWeb Published:7/27/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51782","**Summary:** A novel mRNA-based therapy has been developed to regenerate corneal endothelial cells, which are essential for maintaining a clear cornea and preventing vision loss. The therapy targets the problem of decreased cell density in the corneal endothelium, leading to corneal clouding and vision impairment. By delivering a combination of specific mRNA sequences directly into the eye, the therapy induces a temporary increase in cell proliferation, thus aiding in the regeneration of the corneal endothelium.

**Applications:** This therapy can potentially be used as a treatment for Fuchs Endothelial Corneal Dystrophy (FECD) and other conditions associated with corneal endothelial cell loss, providing a non-invasive alternative to corneal transplantation.

**Problem Solved:** The approach addresses the significant issue of corneal endothelial cell depletion, which leads to vision loss, and overcomes limitations associated with corneal transplantation, such as its invasiveness, high cost, and donor scarcity.","A novel mRNA-based therapy has been developed to induce regeneration of corneal endothelial cells, which are essential for maintaining a clear cornea. The therapy aims to address vision loss caused by a decrease in these cells, particularly in conditions like Fuchs Endothelial Corneal Dystrophy (FECD), which traditionally requires invasive and costly corneal transplantation."
"University of Pennsylvania","Shape Memory Polymer-Based Adhesive Gripper With High Conformability and High Load Capacity","","","https://upenn.technologypublisher.com/technology/51725","Dry adhesion-based shape memory polymer (SMP) gripper with high-load capacity and a high adhesion switching ratio.Problem:Robotic arms that aim to grip and manipulate objects require grippers that can conform to flat and 3D objects while sustaining large loads. Friction-based robotic grippers can pick up 3D objects but merely flat objects and small objects. Furthermore, other adhesion-based grippers can only pick flat objects but not 3D objects. Even though there exist additional adhesion gripper designs that can grip 3D objects, their load capacity and/or adhesion switchability are not high enough.Solution:A dry adhesion-based gripper with a high adhesive load capacity that exploits an unstructured shape memory polymer (SMP) membrane with tunable stiffness, enabling rapid gripping and releasing of 3D objects. SMPs are known to be polymeric smart materials that have the ability to return from a deformed state to their original shape when triggered by an external stimulus. The stiffness of the shape memory polymer is managed by temperature control, wherein heating enables it to conform to an object‚Äôs shape while cooling stiffens the material and enables high load capacity.Technology:The inventors demonstrate a shape memory polymer (SMP)-based adhesive gripper with variable stiffness to pick and place 3D objects. Shape memory polymers (SMPs) are materials that can remember their original shape, stay in temporarily deformed shapes, and return to the original shape by an external stimulus, which makes them particularly useful in applications where flexibility and adaptability are important. The gripper is fabricated with an unstructured flat thermally responsive SMP membrane composed of two-part epoxy (EPON826 resin and Jeffamine D230 (poly (propylene glycol) bis (2-aminopropyl) ether curing agent. The SMP is connected to a flexible heater and a thermocouple attached to a heater used for measurement and control of the temperature.When the SMP is in a soft state, it is flexible and can conform to the shape of the object being picked up. This allows the gripper to make good contact with the object, which is important for achieving a strong adhesive bond. The soft state of the SMP also allows the gripper to conform to objects with irregular shapes or surfaces that might be difficult to pick up with a rigid gripper. Due to the variable stiffness of SMPs, once the SMP-based adhesive gripper has contacted the object, it can switch to a stiff state, which increases the adhesive load capacity of the gripper. This allows the gripper to hold the object securely, even if it is of a high load or has an irregular shape.Advantages:The SMP membrane is comprised of a material with low modulus in the soft state, as well as a membrane geometry with low axial and negligible bending stiffness, which makes it highly effective at adapting and conforming to nonplanar and deformable objectsUnstructured flat variable stiffness SMP membrane requires no microfabrication and can be manufactured via a simple casting processUnstructured flat variable stiffness SMP membrane enables the gripper to achieve a high load capacity and a high adhesion switching ratio, in comparison to gripper based on elastomer membranesSMP membrane exhibits no adhesion at rest, which prevents any unintended adhesionOnce the SMP membrane encounters an object and stiffens, it can passively maintain a high adhesion state without requiring continuous actuation. Soft robotic gripper offers better conformability and reduces the risk of object damage.Adhesion-based grippers can provide gripping forces that act both tangential and normal to a surfaceThe figure depicts the principle of operation of the SMP adhesive gripper. When not heated, the SMP membrane is stiff and cannot easily make conformal contact with other surfaces. During use, the SMP membrane is heated to 70oC to soften the SMP, then the membrane is contacted with the object. The contact forms by displacing the chamber supporting the SMP membrane to bring the membrane in contact with the object. While maintaining contact, the SMP membrane is cooled to 30oC. On cooling and stiffening, higher load capacity is achieved, allowing the gripping of various objects and shapes. Objects are released through the heating and softening of the SMP membrane.Stage of Development:Proof of ConceptIntellectual Property:WO PCT Provisional Application FiledReference Media:Luo, A. et al.,Soft Robot. 2022 Dec; 9(6): 1177Desired Partnerships:LicenseCo-developmentCase ID:22-9909-tpNCSWeb Published:7/19/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51725","**Summary:** The technology involves a dry adhesion-based gripper made from shape memory polymers (SMPs) that offers a high load capacity and an efficient adhesion switching mechanism. This gripper can adapt its stiffness through temperature control, allowing it to conform to various shapes of objects, particularly 3D ones, while maintaining grip strength. The unique properties of SMPs enable the gripper to quickly transition between states, providing effective manipulation of both flat and irregularly shaped objects.

**Applications:** This adhesive gripper can be applied in robotic arms used in industries such as manufacturing, logistics, and packaging, where there is a need for versatile gripping mechanisms capable of handling diverse object shapes and sizes without compromising load capacity.

**Problem Solved:** The technology addresses the limitations of existing robotic grippers that struggle with conformability and load capacity when handling both flat and three-dimensional objects. It overcomes the challenges faced by friction-based and other adhesion-based grippers, which are either limited to small or flat objects or incapable of efficiently gripping 3D items with sufficient load support.","The dry adhesion-based shape memory polymer (SMP) gripper features a high load capacity and a significant adhesion switching ratio, enabling it to conform to both flat and 3D objects. This advancement addresses the limitations of current robotic grippers that struggle with handling various object shapes while sustaining large loads."
"University of Pennsylvania","Xenon Biosensors Improve Early Breast Cancer Detection","","","https://upenn.technologypublisher.com/technology/51718","A nuclear magnetic resonance (NMR) based enzyme-detection system comprising xenon (129Xe) biosensors complexed with an enzyme-specific peptide substrate.Problem:In 2023, about 298,000 American women will be diagnosed with breast cancer, with an estimated 43,700 deaths. Early cancer detection in the localized stage increases the five-year relative survival rate by up to 99%. Despite this, conventional methods are not highly effective in detecting cancer cells at an exceedingly early stage.Solution:129Xe biosensors offer an attractive alternative to conventional MRI methods due to their higher sensitivity and improved magnetic signal. Conjugating with respective substrates129Xe MRI contrast reagents allow more accurate detection of the activity of different enzymes in biological samples, including and not limited to early biomarkers of breast cancers such as matrix metalloproteinases (MMPs). Early detection is among the most promising approaches to reducing the growing cancer burden.Technology:The biosensor utilizes a hyperpolarized element129Xe, in complex with a cryptophane-A coupled peptide. The peptide is a substrate-specific to the target enzyme. As the enzyme interacts with the biosensor, it cleaves its substrate, causing electrostatic environment changes in the element.129Xe NMR spectroscopy can distinguish between the intact and cleaved biosensors with high sensitivity, enabling analysis of the chemical shift to indicate the activity of enzymes, including metalloproteinases for early breast cancer diagnosis.Advantages:Enables high-resolution, high-sensitivity detection of different early biomarkers of breast cancerWide chemical-shift window (> 200 ppm in water)Large signal (10-70% alignment of Xe nuclear spins compared to thermal polarization of 0.00027% at 37C and 3T)Simultaneous detection of different MMPs can help distinguish cancer cells from healthy cells more accuratelyAllows multiplexing using different cryptophanes to help identify aggressive tumor phenotypesStructure of an MMP-7- responsive129Xe biosensor. Underlined in blue is the preferred peptide substrate of MMP-7, and the star indicates the enzyme cleavage site.Stage of Development:Preclinical DiscoveryIntellectual Property:Issued U.S. PatentUS8470587B2Reference Media:Wei, Q. et al.,J Am Chem Soc. 2006 Oct 11; 128(40): 13274Desired Partnerships:LicenseCo-DevelopmentCase ID:R3978-tpNCS-02Web Published:7/18/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51718","**Summary:** The technology involves a nuclear magnetic resonance (NMR) based enzyme-detection system that employs xenon (129Xe) biosensors complexed with enzyme-specific peptide substrates. The biosensor utilizes hyperpolarized 129Xe in conjunction with a cryptophane-A coupled peptide to detect enzyme activity. Changes in the electrostatic environment occur when the enzyme interacts with the biosensor and cleaves the substrate, allowing for high sensitivity detection of the resulting chemical shifts. 

**Applications:** The primary application of this technology is in the early detection of breast cancer by identifying specific enzyme activities associated with the disease, such as matrix metalloproteinases (MMPs), which are known early biomarkers. 

**Problem Solved:** The technology addresses the challenge of detecting breast cancer cells at an exceedingly early stage, where conventional methods may not be effective. By providing higher sensitivity and improved magnetic signals, the 129Xe biosensors enhance the potential for early detection, which is critical for significantly improving survival rates among patients.","A nuclear magnetic resonance (NMR) enzyme-detection system utilizing xenon (129Xe) biosensors and an enzyme-specific peptide substrate offers a new approach to early breast cancer detection. With an estimated 298,000 American women diagnosed and 43,700 deaths due to breast cancer in 2023, the need for more effective early detection methods is critical, as localized cancer detection dramatically increases the five-year relative survival rate."
"University of Pennsylvania","Non-Toxic, Potent Antimicrobial Peptides Derived From Wasp Venom For Use Against Antimicrobial Resistant (AMR) Pathogens","","","https://upenn.technologypublisher.com/technology/51678","Synthetic antimicrobial peptides derived from wasp venom to treat antibiotic-resistant infections.Problem:Antibiotics have transformed modern medicine as they are just one of the most effective drugs in history. However, the rise of antimicrobial resistance (AMR) currently threatens to undermine these achievements, posing a major threat to public health. Millions of patients worldwide, including tens of thousands in the US, die each year from untreatable infections due to the emergence and spread of antibiotic resistance while the arsenal of effective drugs shrinks. As a result, the market for these drugs is set to grow 3-7% until 2030. Venoms represent an underexplored potential source of new antibiotics; however, they are limited by their toxicity.Solution:Here, rationally designed, synthetic variants of two natural or wild-type (WT) antimicrobial peptides (AMPs) found inEumenes micadowasp venom are non-toxic against human cell lines, active in anin vivomouse model, have enhanced antimicrobial activity against Gram-negative bacteria, and a reduced propensity toward antibiotic resistance.Technology:Naturally occurring peptides found inEumenes micadowasp venom have antimicrobial properties. Through structure-function-guided design including alanine and lysine screening, the inventors developed synthetic variants of two WT AMPs from theEumenes micadowasp venom. Synthetic peptides with improved physicochemical properties such as net charge, helicity and amphiphilicity, were then subjected toin vitrotoxicity and antibiotic efficacy and resistance studies compared to the WT peptides and conventional antibiotics, such as ciprofloxacin and polymyxin B. Those synthetic peptides that were not selected for antibacterial resistance and had improved antimicrobial activity were also non-toxic and had potent bactericidal activity in a preclinical mouse model, which confirm their improved performancein vivo.Advantages:Reducedin vitroaggregation and increased amphiphilicity compared to the WT peptides, both of which are beneficial for manufacturing purposesNo development of antibiotic resistance inEscherichia coliover the course of a 20-day treatment compared to ciprofloxacin, whose minimal inhibitory concentration (MIC) increased 1,000-fold over the same time courseNon-toxic at concentrations 4- to 8-fold above their therapeutic dose in primary human keratinocytes and no side effects or toxicityin vivo(indicated by no momentous change in the body weight of the treated mice compared to untreated mice)A 38- to 4,600-fold reduction inPseudomonas aeruginosaATCC strain PAO1 bacterial titer in mouse model of infection(A) A schematic describing the structure-function study design leading to second generation, synthetic peptides. (B) Antibiotic resistance studies of two lead synthetic peptides, K13-2, and K12-1, compared to one WT peptide and a conventional fluoroquinolone antibiotic, ciprofloxacin, utilizing the bacteriumE. coliJW2703 DmutS::kan hypermutant strain from the Keio collection, and measured by minimum inhibitory concentration (MIC) over a 20-day time course. AMPs did not produce AMR whereas ciprofloxacin produced AMR after four days. (C) Results of anin vivomouse model of infection whereby mice infected via an incision in the back withP. aeruginosaATCC strain PA01, treated second-generation peptides, K12-1, K13-1, or K13-2, versus a WT control 1h post-infection. Quantification of bacterial load (by colony forming unit (CFU) per milliliter (mL)) from skin tissue samples collected 5 days post-infection showed that synthetic AMPs have improved antimicrobial activity compared to WT.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:U.S. Provisional Application No. 63/497,795 FiledReference Media:Boaro, A. et al.,Sci Direct. Volume 4, Issue 7; 19 July 2023: 101459Desired Partnerships:LicenseCo-developmentCase ID:23-10379-tpNCSWeb Published:7/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51678","**Summary:** Synthetic antimicrobial peptides have been developed from the venom of the Eumenes micado wasp. These peptides demonstrate non-toxic effects on human cell lines while exhibiting significant antimicrobial activity, particularly against Gram-negative bacteria. The innovative design process involved structure-function-guided optimization, resulting in peptides with enhanced properties that minimize the risk of developing antibiotic resistance. 

**Applications:** These peptides can be employed in the development of new treatments for infections caused by antimicrobial-resistant pathogens, addressing a critical need in modern medicine.

**Problem Solved:** The technology addresses the growing concern of antimicrobial resistance, which is jeopardizing the effectiveness of existing antibiotics and contributing to millions of untreatable infections and deaths globally. By utilizing non-toxic antimicrobial peptides derived from wasp venom, this approach holds promise for overcoming the limitations of conventional antibiotics and improving health outcomes.","Synthetic antimicrobial peptides derived from wasp venom offer a potential treatment for infections caused by antimicrobial-resistant pathogens. The rise of antimicrobial resistance poses a significant threat to public health, resulting in millions of deaths annually from untreatable infections."
"University of Pennsylvania","Synthetic Antibiotic Derived From Plasma Protein Human Apolipoprotein B Targets Key Pathogens in Hospital-Acquired Infections","","","https://upenn.technologypublisher.com/technology/51363","Peptides derived from the human apolipoprotein B that are antimicrobial, anti-inÔ¨Çammatory, highly cytotoxic, and do not select for bacterial resistance.Problem:In 2019, more than 2.8 million people in the U.S. suÔ¨Äered from antibiotic-resistant infections, leading to over 35,000 deaths. Such infections are of great concern, especially for ESKAPE pathogens, which have growing resistance to commonly used antibiotics. It has been estimated that 10 million people would die each year from these untreatable diseases by the year 2050 at the present rate. Therefore, there is an urgent need to develop alternatives to conventional antibiotics to treat drug-resistant infections.Solution:Four encrypted peptides that have been derived from human apolipoprotein B exhibit antimicrobial, anti-inÔ¨Çammatory, and highly cytotoxic properties. When combined, the peptides potentiated the activity of conventional antibiotics against bacteria and do not select for bacterial resistance. In addition, a retro-inverso variant of the lead encrypted peptide that is protease-resistant was produced and showed anti-infective efficacy in a mouse model.Technology:The inventors identified a class of encrypted peptides derived from the plasma protein human apolipoprotein B by using an algorithm developed by their group. Three ApoB-derived peptides were demonstrated to exhibit potent antimicrobial activity against drug-resistantKlebsiella pneumoniae,Acinetobacter baumannii,andStaphylococcibothin vitroand in an animal model. In addition, a protease-resistant variant was synthesized by reversing its peptide sequence, to avoid proteolytic degradation and ensure efficacy against common hospital-acquired infections.Advantages:The peptides were found to exert signiÔ¨Åcant antibacterial eÔ¨Äects (minimal inhibitory concentration ranging from 2.5‚àí20 ¬µmol L-1) against 5 key pathogenic genera implicated in hospital-acquired infections including Staphylococcus, Acinetobacter, Klebsiella, Enterococcus, and Pseudomonas.(ri)-r(P)ApoBsProhas increased peptide stability as its antimicrobial activity remained constant after 16 h of preincubation in serum, while its parent peptide r(P)ApoBsProcompletely lost its activity upon incubation.(ri)-r(P)ApoBsProincreases the translational potential of its parent peptide without altering its antimicrobial and cytotoxic activities.The strategy of synthesizing a retro-inverso variant makes the molecules more suitable for future preclinical and clinical studies.When combining ApoB-derived encrypted peptides with conventional antibiotics, synergistic eÔ¨Äects were detected and the peptides potentiated the activity of conventional antibiotics against bacteria and do not select for bacterial resistance.Figure caption: (A) Antimicrobial activity of (ri)-r(P)ApoBsPro(¬µmol L-1) against seven bacterial strains. (B) Cytotoxic effects of increasing concentrations of retro-inverso ApoB ((ri)-r(P)ApoBsPro) on HDF (human dermal fibroblasts) cells. (C) Resistance to degradation of (ri)-r(P)ApoBsProexposed to fetal bovine serum (FBS) proteases for 4 h.Stage of Development:Proof of ConceptIntellectual Property:US Utility Patent Application FiledReference Media:Cesaro, A. et al.,ACS Nano., 2022 Feb 22; 16(2): 1880Desired Partnerships:LicenseCo-DevelopmentCase ID:22-9974-tpNCSWeb Published:6/15/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51363","**Summary:** Four encrypted peptides derived from human apolipoprotein B demonstrate antimicrobial, anti-inflammatory, and highly cytotoxic properties without promoting bacterial resistance. These peptides were identified through a specialized algorithm and have shown effective activity against key drug-resistant pathogens such as Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus in both in vitro and animal models. Additionally, a protease-resistant retro-inverso variant of a lead peptide has exhibited anti-infective efficacy in animal testing.

**Applications:** The peptides could serve as alternative treatments for hospital-acquired infections, particularly those caused by ESKAPE pathogens, aiding in the management of antibiotic-resistant infections in clinical settings. Their ability to potentiate conventional antibiotics suggests potential use in combination therapies.

**Problem Solved:** The technology addresses the pressing public health crisis posed by antibiotic-resistant infections, which affected over 2.8 million people in the U.S. in 2019 alone. With projections indicating a potential rise to 10 million annual deaths from untreatable diseases by 2050, these peptides offer a promising solution to combat drug-resistant pathogens and reduce mortality associated with such infections.","Peptides derived from human apolipoprotein B exhibit antimicrobial and anti-inflammatory properties, are highly cytotoxic, and do not promote bacterial resistance. In 2019, over 2.8 million people in the U.S. experienced antibiotic-resistant infections, resulting in more than 35,000 deaths, highlighting the critical challenge posed by ESKAPE pathogens."
"University of Pennsylvania","Non-Invasive Early-Pregnancy Diagnostic for Miscarriage and Ectopic Pregnancy","","","https://upenn.technologypublisher.com/technology/51309","A diagnostic test to determine both the viability and location of an early pregnancy through a panel of biomarkers.Problem:25% of clinically recognized pregnancies result in miscarriage and 1-2% result in an ectopic pregnancy (EP). The diagnosis can be devastating, and EP can be life-threatening. Up to 33% of pregnant women present with vague abdominal pain or bleeding symptoms in the first trimester and require a pelvic exam, blood tests, and ultrasounds to determine pregnancy status. Even after undergoing such tests, clinicians are unable to determine the status of early pregnancy for up to 40% of women. Therefore, we need an improved method for detecting miscarriage and EP that is non-invasive and conclusive.Solution:The inventors developed a non-invasive diagnostic test to determine an early pregnancy's viability and location. The test uses a panel of biomarkers to detect early pregnancy viability, location, or both. Biomarkers have cutoff thresholds to minimize false positives and false negatives. A multi-tiered algorithm maximizes sensitivity and specificity for each metric (viability and location). The results are combined to give a final pregnancy diagnosis.Advantages:Less invasive than the combination of pelvic exams, blood tests, and ultrasounds.Less time-consuming for healthcare professionals and patients.Assesses both miscarriage and ectopic pregnancy in one test.Maximizes accuracy, specificity and sensitivity for each condition.Stage of Development:Proof of ConceptIntellectual Property:PCT PendingReference Media:Bollig et al.J Assist Reprod Genet, 2023 Apr; 40(4): 837.Desired PartnershipsLicenseCo-developmentCase ID:19-8863-tpNCSWeb Published:6/7/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51309","**Summary:** The diagnostic test leverages a panel of biomarkers to non-invasively assess both the viability and location of an early pregnancy, addressing a significant gap in current medical practice where traditional methods may not conclusively determine pregnancy status. It aims to provide an efficient solution for the estimated 25% of pregnancies that result in miscarriage and the 1-2% that are ectopic, especially in the context of early pregnancy complications that lead to premature assessments.

**Applications:** This technology can be utilized in clinical settings to quickly and accurately diagnose early pregnancy outcomes, enabling healthcare providers to deliver timely care and counseling to patients presenting with symptoms like vague abdominal pain or bleeding.

**Problem Solved:** The test addresses the limitations of existing diagnostic methods that often require invasive procedures and are sometimes inconclusive, resulting in a significant number of women facing uncertainty regarding their pregnancy status. By providing a non-invasive option that combines the assessment of both miscarriage and ectopic pregnancy in one test, it significantly enhances the diagnostic capabilities for early pregnancy complications.","A diagnostic test using a panel of biomarkers aims to determine both the viability and location of early pregnancies. This addresses the challenges faced by 25% of clinically recognized pregnancies that result in miscarriage and 1-2% that result in ectopic pregnancies, particularly for women presenting with vague abdominal pain or bleeding in the first trimester."
"University of Pennsylvania","Design Of Artificial Proteins As Ultrafast, Genetically Encoded Electrophysiological Reporters","","","https://upenn.technologypublisher.com/technology/51306","Problem:Recording neuronal activityin vivousing optical methods can help to distinguish between normal and diseased brains. An ideal electrophysiological sensor would have a customizable structure and mechanism, providing excellent spatial contrast while minimizing background noise. However, current genetically encoded protein-based voltage indicators (GEVIs) face two significant limitations. The first is slow temporal resolution due to structural reorganization during voltage sensing. The second is engineering constraints imposed on natural proteins, as protein engineering can lead to dramatic changes that compromise proper folding and the function of protein machines.Solution:To overcome the limitations of current GEVIs, researchers have proposed a new approach for creating next-generation sensors through rational design using non-biologically derived proteins from first principles. This approach is not limited by the constraints of modifying natural proteins, enabling the optimization of molecular content and biophysical mechanisms to achieve outstanding temporal resolution, sensitivity, and adaptability.Technology:The inventors used maquette technology to design GEVIs. Maquettes are rigid 4-helix bundle proteins that act as custom scaffolds for biological co-factors like fluorophores or redox sensors. During voltage sensing, the fluorophore within maquette GEVIs provides an ultrafast fluorescence signal change independent of structural reorientation. The physical-chemical properties of GEVIs can be easily tuned by re-engineering the maquette without the risk of protein unfolding, as the starting maquette is stable and robust. Furthermore, this technology can be applied to other physiological reporters by changing the combination of cofactors anchored to the maquette.Advantages:High tolerance to sequence modification, redesign, and tuning of maquette functional propertiesA biosensing platform for different electrophysiological signalsUltrafast response with outstanding temporal resolution and sensitivityExpressable in mammalian cells(A) Transmembrane 4-helix bundle maquette with polar (cyan) and nonpolar regions (gray) using cysteine (yellow) to anchor a field-sensing biliverdin fluorophore (red). (B) Sequences are based on heptad repeats that place polar groups on one face of the helix and nonpolar groups in membrane-spanning regions.Stage of Development:ConceptProof of ConceptIntellectual Property:Issued Patent(s):US11084848B2,WO2017079656A2US Application:US20210340183A1Reference Media:Mancini, J. et al.,J R Soc Interface. 2018 Apr; 15(141): 20180021Desired Partnerships:LicenseCo-developmentCase ID:15-7570-tpNCSWeb Published:6/7/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51306","**Summary:** Researchers have developed a novel method for creating genetically encoded electrophysiological sensors that aims to enhance the recording of neuronal activity by addressing the limitations of current genetically encoded protein-based voltage indicators (GEVIs). By utilizing non-biologically derived proteins through rational design, this approach circumvents the challenges associated with modifying natural proteins, thus allowing for better optimization of the sensors' molecular content and biophysical mechanisms. This results in improved temporal resolution, sensitivity, and adaptability of the electrophysiological reporters.

**Applications:** The technology can be applied in the study of neuronal activity in vivo, offering potential insights into the differences between normal and diseased brain states. It can be especially valuable in neurobiological research, the development of new therapeutic strategies for neurological disorders, and advancements in the field of neurotechnology, where precise voltage measurement is critical.

**Problem Solved:** The innovation addresses the slow temporal resolution and structural reorganization issues faced by current GEVIs, which can hinder accurate recordings of neuronal activity. By utilizing a design that relies on rigid 4-helix bundle proteins, the technology mitigates the negative impacts of structural changes during voltage sensing, ultimately leading to enhanced performance of electrophysiological sensors.","Current genetically encoded protein-based voltage indicators (GEVIs) are limited by slow temporal resolution caused by structural changes during voltage sensing and inadequate spatial contrast, which affects their effectiveness in recording neuronal activity in vivo. An ideal electrophysiological sensor would feature a customizable structure and mechanism to improve these performance aspects."
"University of Pennsylvania","RGD Peptide-Based Lipids For Targeted mRNA Delivery and Gene Editing Applications","","","https://upenn.technologypublisher.com/technology/51219","A combinatorial library of RGD peptide (arginine-glycine-aspartic acid)-based lipids designed to formulate lipid nanoparticles for targeted mRNA delivery to the liver and the spleen.Problem:Lipid Nanoparticles (LNPs) are becoming an established choice of vehicle to deliver mRNA-based therapeutics, including vaccines, protein replacement therapies, and gene editing therapies. An outstanding challenge remains to deliver the LNP and its mRNA cargo in a site-specific manner. Non-targeted delivery can compromise transfection and genome editing efficiency and result in off-target toxicity.Solution:Mitchell et al., developed a library of RGD-based LNPs whereby the RGD motif serves as a targeting ligand to direct the LNP to cells with cell-surface integrins, opening the potential for cancer cell targeting. The inventors have identified a lead candidate that demonstrates an improved safety profile and transfection efficiency compared to a non-targeted LNP.Technology:The technology comprises a library of novel RGD-based lipids and a method of synthesizing RGD-based LNPs. The assembly process involves addition of the RGD lipid to the conventional four lipid components and subsequent microfluidic mixing with the mRNA cargo.In vitroevaluation of a lead 1A RGD LNP showed significantly improved cell viability, mRNA delivery, and gene editing efficiency compared to a non-targeted LNP. The lead RGD LNP also resulted in greater whole-body expressionin vivoin mice, with selectivity toward the liver and the spleen.Advantages:Efficient mRNA encapsulation (close to 90%)Improved transfection and gene editing efficiencies compared to a non-targeted LNPUp to 90% gene editing efficiency demonstrated in vitroTargeted delivery to the liver and the spleenImproved cell viabilityPotential application in cancer cell targeting(A) Schematic of the assembly process for generating RGD-based LNPs loaded with an mRNA cargo. (B) RGD-based LNPs target cells with cell-surface integrin, allowing for potential tumor targeting. (C-D) The lead 1A RGD LNP demonstrates: (C) Improved transfection efficiencyin vitro; and, (D) Increased whole body expression in micein vivocompared to a non-targeted LNP control. (E) Delivery of 1A RGD LNP predominates in the mouse liver and spleen. (F) Toward gene editing applications, the RGD LNP shows effective co-delivery of Cas9 mRNA and single guide RNA, achieving up to 90% knockout efficiencyin vitroand outperforming a non-targeted LNP control.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:US Provisional Application FiledReference Media:Qin, J. et al.,RSC Adv. 2022 Sep 7; 12(39): 25397Desired Partnerships:LicenseCo-DevelopmentCase ID:22-10072-tpNCSWeb Published:6/1/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51219","**Summary:** A library of RGD peptide-based lipids has been developed to formulate lipid nanoparticles for targeted mRNA delivery, particularly to the liver and spleen. This approach aims to enhance the safety and effectiveness of mRNA therapeutics by ensuring site-specific delivery, which is essential for successful transfection and gene editing.

**Applications:** The technology can be utilized in various applications, including mRNA vaccines, protein replacement therapies, and gene editing therapies. The targeted delivery mechanism may also have potential in cancer therapeutics by directing the lipid nanoparticles specifically to cancer cells expressing cell-surface integrins.

**Problem Solved:** The technology addresses the challenge of non-targeted delivery of lipid nanoparticles, which can lead to reduced transfection efficiency, ineffective gene editing, and increased off-target toxicity. By employing RGD peptides as targeting ligands, the solution enhances the specificity of mRNA delivery, leading to improved therapeutic outcomes.","A combinatorial library of RGD peptide-based lipids has been developed to formulate lipid nanoparticles aimed at targeted mRNA delivery to the liver and spleen. This approach addresses the challenge of non-targeted delivery in mRNA-based therapeutics, including vaccines and gene editing therapies."
"University of Pennsylvania","Methods for Cryopreservation of Cells for Improved Commercial Manufacture of NK Cell Therapies","","","https://upenn.technologypublisher.com/technology/51303","A method that maintains the viability and function of NK cells following cryopreservation, enabling the production, storage, and transportation of therapeutic doses of NK cells to treatment centers.Problem:There is a growing interest in using NK cells as immunotherapies for diseases such as cancer. Making commercially viable NK cell therapies requires large-scale production of NK cells which need to be cryopreserved for storage and transportation to the clinic. However, NK cells do not cryopreserve well; there is a significant loss of cells after cryopreservation, and those that survive are less functional. Poor recovery of NK cells after cryopreservation is a significant barrier to successful commercial development of NK cell therapies.Solution:Pre-treatment of NK cells with the cytokines, interleukin (IL)-15 & 18, under the correct conditions before cryopreservation enables a cryopreserved product of equipotency post thaw without recovery/restimulation in cytokine media.Technology:As cytokines play an essential role in the activation, development, and maturation of NK cells, it was hypothesized that pre-treating NK cells with different cytokines before cryopreservation might help improve NK cell recovery and function. The inventors discovered that NK cells with the pre-treatment of recombinant IL-15 & IL-18 prior to cryopreservation reduced autolysis of the NK cells and pre-treated NK cells maintained their cytotoxicity function post-thaw. In addition to patent rights covering methods of cytokine pre-treatment of NK cells prior to cryopreservation, the technology includes know-how related to cytokine suppliers, concentrations, order of addition and duration of pretreatment.Advantages:‚Ä¢ Enables an equipotent cryopreserved NK product.‚Ä¢ Enables the production, storage, and transportation of therapeutic doses of NK cells to the bedside.‚Ä¢ Leverages commercially-available sources of GMP-grade IL-15 & IL-18.B.Figure caption: (A) A bar graph showing NK cell loss after 24 hours thawing Cryopreserved NK cells. Adding IL-15+IL18 before cryopreservation significantly improved recovery. (B) A bar graph comparing the cytotoxic function of different interleukin-treated NK cells before and after cryopreservation. Cryopreserved NK cells pre-treated with IL-18 maintained their cytotoxicity (at a level comparable to fresh cells). NK cells not treated with cytokines or treated with IL-15 or IL-12 before cryopreservation had decreased cytotoxicity (compared to fresh NK cells).Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Lab webpage -Sheppard LabDesired Partnerships:‚Ä¢ License‚Ä¢ Co-developmentCase ID:22-10107-tpNCSWeb Published:6/7/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51303","**Summary:** A method has been developed that enhances the viability and function of NK cells after cryopreservation, facilitating the efficient production, storage, and transportation of NK cell therapies for clinical use. The method addresses the significant losses and decreased functionality typically associated with cryopreserved NK cells, which have hindered commercial viability.

**Applications:** This technology is applicable in the field of immunotherapy, particularly for the treatment of diseases such as cancer where NK cell therapies are being considered. It allows for large-scale production and effective delivery of therapeutic doses of NK cells to treatment centers.

**Problem Solved:** The method effectively addresses the challenge of poor recovery of NK cells after cryopreservation, which has been a major obstacle in the commercial development of NK cell therapies. By pre-treating NK cells with specific cytokines before cryopreservation, the solution decreases cell loss and preserves the cytotoxic functionality of the cells post-thaw, thus improving prospects for successful clinical applications.","A method has been developed to maintain the viability and function of NK cells after cryopreservation, facilitating their production, storage, and transportation as therapeutic doses. This advancement addresses the challenge of scaling up NK cell immunotherapies for clinical use."
"University of Pennsylvania","Tunable, Caged Molecules For In Vivo and In Situ Transcriptomic Analyses","","","https://upenn.technologypublisher.com/technology/51113","Compounds are designed to detect and characterize specific RNAs in a cell or sub-cellular compartment using light activation.Problem:Cellular RNAs provide critical information on gene expression and regulation. A variety of methods have been developed to isolate mRNA from target cells to understand gene function; however, these methods lack the ability to effectively detect and compare nucleic acid molecules longitudinally, or among different cells or subcellular compartments. Further, the ability to effectively capture all RNA, not just the mRNA transcripts responsible for protein translation, remains elusive. There is a need for tunable compounds that can be multiplexed to detect the nucleic acid fingerprint of single cells in live and fixed tissue samples in diverse biological contexts.Solution:A ‚Äúcaged‚Äù molecule that is activated with near-UV or visible light with single-cell and high spatiotemporal resolution ‚Äì ‚Äúcaged‚Äù molecules are those whose function is blocked until activated by specific stimuli, allowing for tunable activation. The molecule can capture and label RNA of interest in live and fixed tissue for longitudinal transcriptomic detection over time.Technology:Light is often employed as an external stimulus to control biological processes. ‚ÄúCaged‚Äù biomolecules that are blocked until activated by specific stimuli are useful for this application. These molecules activate with near-UV or visible light, which introduce few side reactions and allow for convenient modulation with high spatiotemporal resolution. The ‚Äúcaged‚Äù molecules described here, transcriptomein vivoanalysis (TIVA) and transcriptomein situanalysis (TISA)-tags, penetrate cells to isolate and label select RNAs through antisense oligonucleotide and ruthenium-based photolinker domains in a targeted manner.Advantages:‚ÄúCaged‚Äù tags that can be activated with near-UV or visible light, introducing few aberrant reactions, and allowing for high-resolution modulation.Stimuli applied and removed noninvasively and directed at a precise time to a specific location with variable intensity, offering fine-tuning.The light stimulus does not interfere with most natural biological processes.The tags can be designed for multiplexed detection of various RNAs of interest or longitudinal detection of RNAs over time.The molecular tags offer single-cell resolution and can be used in fixed or live tissue, broadening their use and application.The molecular tags can capture and label microRNAs, lincRNAs, intron-containing RNAs, hnRNAS, in addition to poly-A+ mRNA and polyA-mRNA.Schematic of the TIVA tag ‚Äì a multifunctional, caged RNA-capture molecule. The TIVA tag is composed of several functional groups that facilitate cell entry, photoactivation, annealing to target mRNA and transcriptomic analysis. Figure located in Lovatt et al.,Nat. Methods, 2014, 11 ‚Äì 190Figure 1, page 190.Stage of TechnologyProof of ConceptBench PrototypeIntellectual Property:Issued Patent(s):11,021,502 B2Reference Media:Yang et al.,ChemPhotoChem. 2021 Oct; 5(10): 940Yeldell et al.,ACS Chem Biol. 2020 Oct 16; 15(10): 2714Yeldell et al.,Org Biomol Chem. 2017 Dec 6; 15(47): 10001Griepenburg et al.,Chem Sci. 2015 Apr 1; 6(4): 2342Lovatt et al.,Nat Methods. 2014 Feb; 11(2): 190Desired Partnerships:LicenseCo-developmentCase ID:15-7214-tpNCS-02Web Published:5/18/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51113","**Summary:** This technology involves the design of compounds that utilize light activation to detect and characterize specific RNAs within cells or sub-cellular compartments. The compounds are referred to as ""caged"" molecules, which remain inactive until they are triggered by near-UV or visible light, offering the advantage of tunable activation. This approach allows for the direct capture and labeling of RNA in both live and fixed tissue samples, enabling longitudinal transcriptomic analyses.

**Applications:** The technology can be used to examine cellular RNAs in various biological contexts, including live and fixed tissue samples. It is suited for multiplexed detection of RNA, allowing researchers to analyze the nucleic acid profiles of single cells over time and across different conditions.

**Problem Solved:** The technology addresses the challenge of effectively detecting and comparing RNA molecules longitudinally across different cells or subcellular compartments. Traditional methods have been limited primarily to isolating mRNA transcripts, which do not fully capture the complex RNA landscape necessary for understanding gene function and regulation. By providing a method to capture all RNA types through light-mediated activation, this innovation enhances the ability to analyze gene expression in greater detail.","Compounds are engineered to identify and analyze specific RNAs in cells or sub-cellular compartments through light activation. Current methods for isolating mRNA do not adequately allow for longitudinal detection or comparison of nucleic acids across different cells or compartments."
"University of Pennsylvania","Cholesterol Analogues Incorporated Into LNPs For Enhanced mRNA Delivery","","","https://upenn.technologypublisher.com/technology/51080","Hydroxycholesterols are used to formulate lipid nanoparticles (LNPs) for enhanced mRNA delivery into T cells.Problem:In recent times, the delivery of mRNA has become a major focus for therapeutics. Intracellular delivery is the major challenge. Intracellular delivery requires ionizable lipids for mRNA delivery. In addition to this, these constituents of LNPs can affect the potency of the treatment.Solution:This invention demonstrates that cholesterol analogues such as Hydroxycholesterol incorporated into LNPs enhance mRNA delivery into T cells. In addition, an example of incorporating dexamethasone into the LNP formulation is shown to reduce inflammatory responses.Technology:Cholesterol analogues such as Hydroxycholesterol and Dexamethasone which has a structure similar to cholesterol, when incorporated into LNPs enhance the mRNA delivery into cells. The addition of hydroxyl groups to the cholesterol molecule can alter the cholesterol recycling mechanism exhibited by the endosome; and Dexamethasone having anti-inflammatory properties, reduces inflammation in cells which leads to higher expression of the payload mRNA, leading to greater potency of the treatment. A library of 24 LNPs was formulated using 6 X-hydroxycholesterol modifications (7ùõº, 7ùõΩ, 19, 20, 24, 25). Each of the 6 hydroxycholesterols were substituted in various ratios relative to unmodified cholesterol (12.5%, 25%, 50%, and 100% substitutions).Advantages:Hydroxycholesterol substitutions, particularly in the 7ùõº position, at substitution ratios of 25% and 50%, demonstrate a statistically significant increase in delivery of mRNA to T cellsThe incorporation of hydroxycholesterols has an impact on the shape of LNPs when observed with TEM, suggesting that morphological changes may contribute to improved mRNA deliverySize, PDI, zeta potential, and encapsulation efficiency did not differ significantly between the particle formulations and S2, indicating that the incorporation of hydroxycholesterols allowed for LNP formationReduced inflammation and potentially fewer side effects with Dexamethasone than conventional LNPs1.5X expression of payload mRNA with Dexamethasone than conventional LNPsEngineering lipid nanoparticles (LNP) with hydroxycholesterol substitution: motivation, design, and synthesis. (A) Schematic of LNP components, formulation, and expected structure. An ethanol phase containing lipid-anchored PEG (polyethylene glycol), cholesterol, X-hydroxycholesterol, DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine), and C14‚Äì4 ionizable lipid and an aqueous phase containing mRNA are mixed in a microfluidic device to produce LNPs. (B) Diagram of LNP delivery into a T cell and the endosomal trafficking mechanisms involving the Rab family of proteins. Rab5, Rab7, and Rab11 associate with the early, late, and recycling endosomes, respectively. (C) Design of an LNP library incorporating the substitution of various hydroxycholesterols for unmodified cholesterol.Stage of Development:Preclinical DiscoveryIntellectual Property:PCT Application FiledReference Media:Patel et. al.,J. Control Release 2022 Jul; 347: 521Zhang et. al.,J. Biomed Mater Res A. 2022 May; 110(5): 1101Desired Partnerships:LicenseCo-developmentCase ID:22-9845-tpNCSWeb Published:5/16/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51080","**Summary:** Hydroxycholesterols are utilized to create lipid nanoparticles (LNPs) that significantly improve the delivery of mRNA into T cells. The challenge in mRNA therapeutics lies in intracellular delivery, which necessitates the use of ionizable lipids that can influence treatment efficacy. This invention reveals that the incorporation of cholesterol analogues like Hydroxycholesterol into LNPs enhances their ability to deliver mRNA efficiently into cells. Additionally, the inclusion of dexamethasone in the formulation decreases inflammatory responses, thereby promoting higher expression levels of the mRNA payload, which contributes to the overall effectiveness of the treatment.

**Applications:** This technology can be applied in developing mRNA-based therapeutics for various diseases, particularly those requiring targeted delivery into T cells, such as cancer immunotherapies and vaccines.

**Problem Solved:** The technology addresses the significant challenge of intracellular delivery of mRNA therapeutics by utilizing modified cholesterol analogues to enhance the effectiveness of lipid nanoparticles, thereby improving therapeutic potency and reducing inflammatory responses.","Hydroxycholesterols are used to formulate lipid nanoparticles (LNPs) to improve mRNA delivery into T cells by addressing the challenges of intracellular delivery. The incorporation of cholesterol analogues enhances the efficacy of mRNA therapeutics."
"University of Pennsylvania","Quick, Reversible, Moisture-Activated Adhesive","","","https://upenn.technologypublisher.com/technology/51015","Activated by water quickly, dry hydrogel film adhesive produces a strong and reversible adhesion.Problem:Adhesives are used in numerous applications in our daily lives. In general, adhesives are either strong but irreversible or weak but reversible. There is a need for stronger and reversible adhesives. One potential solution is a formulation of poly (vinyl alcohol) (PVA) and boric acid (BA), which is capable of high strength and reversible, but so far is limited by long drying time and susceptibility to water solvation.Solution:The current invention is a PVA/BA adhesive formulation that can quickly bond to surfaces with water after it has been prepared dry. This formulation is water-resistant at low volumes, and this resistance can be improved further by the addition of phenylboronic acid (PBA). Adhesion is reversed by rehydration without the addition of PBA.Technology:The present technology is a hydrogel formulation with dynamic covalent bonds using poly (vinyl alcohol) and boric acid. Both components are commercially available. The hydrogel is dried before use and activated with water. Hydration results in a softened surface that makes close contact with the surface. At body temperature, the water quickly evaporates resulting in a strong adhesion to the surface.Advantages:A few seconds to a few minutes to apply or remove, makes this much faster than current technologiesStrong adhesion comparable to current technologiesReversible by waterAdding phenylboronic acid increases water resistance to up to 7 days underwater or in the human bodyPartially hydrated PVA/BA film for instantaneous adhesion. Figure (a) Chemical structures and bond of partially hydrated film; Figure (b) Bonding process between adhesive and wound tissues.Stage of Development:Proof of ConceptIntellectual Property:PCT Patent Application FiledReference Media:Chen, M.et al.,Proc Natl Acad Sci USA 2022 Jul 19; 119(29): e2203074119Desired Partnerships:LicenseCo-development (this replaces collaboration or sponsored research)Case ID:22-9848-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51015","**Summary:** The technology involves a moisture-activated adhesive formulated from poly (vinyl alcohol) (PVA) and boric acid (BA), which allows for quick bonding to surfaces by absorbing water. The adhesive forms a dry hydrogel film that bonds strongly and reversibly, and its resistance to water can be further enhanced by incorporating phenylboronic acid (PBA). The adhesion can be reversed through rehydration, making it versatile for various applications.

**Applications:** This adhesive can be utilized in a range of settings where temporary and strong bonds are necessary, including medical applications, packaging, and construction materials, where rapid adhesion and removal are advantageous.

**Problem Solved:** The technology addresses the limitations of existing adhesives, which are often either strong but irreversible or weak but reversible. By providing a strong, moisture-activated adhesive that can reverse its adhesion upon rehydration, it meets the need for an efficient, adaptive adhesive solution.","A water-activated hydrogel film adhesive provides strong and reversible adhesion, addressing the need for adhesives that combine strength and reversibility. A formulation of poly (vinyl alcohol) and boric acid shows promise but has limitations due to long drying times and susceptibility issues."
"University of Pennsylvania","Engineered Wasp Venom for Safe and Effective Antibiotics","","","https://upenn.technologypublisher.com/technology/51018","A method for manipulating wasp venom peptide to maintain antimicrobial properties while reducing human toxicity.Problem:Almost 20% of global deaths (~11 million) are from sepsis, often caused by bacterial infections. 35,000 of these deaths are due to drug-resistant bacteria, which are becoming more prevalent. Drug-resistant bacteria are also dangerous in secondary infections. These drug-resistant infections pose a large threat during global pandemics such as the current COVID-19 pandemic. Therefore, there is a need for new and effective antibiotics. Toxins contained in venom have antibiotic potential, however these venoms are inherently toxic to humans.Solution:Modified wasp venom peptide has potent antibacterial activity while avoiding the toxicity of normal wasp venom. The modified peptide also reduces inflammation while activating an effective immune response to bacterial infection.Technology:The inventors searched a database of antimicrobial peptides to find common peptide sequences for activating the immune system. The peptide sequence attaches to wasp venom peptide. This peptide damages the outer membrane of bacteria, recruits immune cells that fight bacterial infections, and reduces inflammation. Since this peptide is still toxic to certain human cell types, the inventors further refined the added peptide sequence by swapping amino acids. The final modified peptide maintains the antibacterial properties of the initial peptide while eradicating its toxicity.Advantages:Permeabilizes outer membrane of bacteriaIncreases leukocyte recruitment to bacterial infectionDecreases inflammatory markers in response to bacterial infectionTreatment of mouse bacterial infections comparable to current standard-of-care antibiotics5-fold reduction in human cell toxicity with final refined peptideThe wasp venom protein, mast-L (green), modified with the addition of an engineered protein sequence (red), resulting in the mast-MO antibiotic protein. Mast-MO plays dual purposes in fighting bacterial infections. The protein modulates the immune system through neutrophil/leukocyte recruitment and inflammatory marker suppression. Mast-MO also functions as an antimicrobial agent by damaging the outer membrane of bacteria. Figure taken from Figure 5A of Silva ON et al.,Proc Natl Acad Sci USA 2020 Oct 27; 117(43): 26936.Stage of Development:Preclinical DiscoveryIntellectual Property:U.S. Utility Patent FiledReference Media:Torres & de la Fuente,Chem Commun (Camb), 2019, 55(100):15020-15032Torres et al.,J Mol Biol, 2019, 431(18):3547-3567Desired Partnerships:LicenseCo-developmentCase ID:20-9434-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51018","**Summary:** A method has been developed to manipulate wasp venom peptides to enhance their antimicrobial properties while significantly minimizing their toxicity to humans. This innovation aims to address the pressing issue of bacterial infections, particularly drug-resistant strains that contribute to a substantial number of global deaths from sepsis. The modified wasp venom peptide exhibits strong antibacterial activity, activates the immune response against infections, and helps reduce inflammation.

**Applications:** The engineered wasp venom peptide has potential applications in developing new antibiotics to combat drug-resistant bacterial infections, as well as enhancing treatments for secondary infections that may arise during global health crises, such as pandemics.

**Problem Solved:** The technology addresses the urgent need for effective antibiotics in the face of rising drug resistance, which poses a significant health threat globally, contributing to millions of deaths annually, particularly during periods when immune systems may be compromised by other illnesses.","A method has been developed to modify wasp venom peptides to retain their antimicrobial properties while minimizing their toxicity to humans. This innovation aims to address the global challenge of sepsis and drug-resistant bacterial infections, which contribute to approximately 11 million deaths each year."
"University of Pennsylvania","A Method to Design 2D Composite Sheets That Transform to 3D Curved Surfaces Having Optimal Mechanical Properties","","","https://upenn.technologypublisher.com/technology/51020","A method for fabricating stronger 3D curved surfaces by stacking multiple layers of 2D sheets, each having a specified cutting pattern, into one composite materialProblem:Morphing flat sheets into three-dimensional (3D) curved surfaces has recently attracted significant attention in diverse applications such as soft robotics, architectural structures, and biomedical devices. Current approaches to create structures with desired curved surface often relies on soft and stretchable materials or by introduced cuts, which weaken the mechanical properties. More specifically, the ability to achieve high mechanical strength and 3D curvatures has not yet been demonstrated.Solution:This method uses an optimized cutting approach to transform multiple two-dimensional (2D) composite plies into a 3D curved stacked surface. This surface is able to conform to complex shapes of arbitrary curvatures while maintaining lightweight and high mechanical strength.Technology:In traditional approaches, multiple cuts are necessary in order to transform a 2D sheet into a curved surface. However, each cut weakens the overall strength of the structure. This approach calculates pathways to cut and unfold a 3D curved surface from multiple 2D sheets while avoiding overlapping cuts on adjacent layers. This results in a strong, lightweight optimized structure with no self-overlapping.Advantages:Multi-layered structure designed with this approach withstood 40% larger load forces when compared to a randomized cutting schemeCan be used to conform to complicated surfaces without any folds or wrinklesAll existing algorithms on unfolding polyhedral mesh can be easily integrated into this approachThe figure shows various approaches to conforming 2D sheets towards 3D curved surfaces. A) Wrapping a flat sheet results in wrinkles. B) Kirigami patterns can prevent wrinkles but small hinges and uncovered regions limit the strength. C) Computational wrapping algorithm provides full coverage but overlapping cuts weaken the strength of the structure. D) This new approach which avoids cuts overlapping at the same position upon stacking, thus increasing strength. Figure obtained from the paper ‚ÄúMorphing flat sheets to 3D curved surfaces with optimized mechanical performance.‚ÄùStage of Development:Bench PrototypeMinimum Viable ProductIntellectual Property:U.S. Utility Application FiledReference Media:Jin, L, et al;Sci Adv 2022 Oct 14; 8(41): eabq3248Desired Partnerships:LicenseCo-developmentCase ID:22-9934-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51020","**Summary:** A method has been developed to fabricate stronger 3D curved surfaces using an optimized cutting technique that transforms multiple layers of 2D composite sheets into a composite material. This innovative approach allows for the creation of surfaces that can conform to complex shapes of arbitrary curvatures while ensuring high mechanical strength and a lightweight design. The method effectively determines cutting pathways that avoid overlapping cuts in adjacent layers, thereby enhancing the structural integrity of the produced 3D shapes.

**Applications:** This technology can be applied in diverse fields such as soft robotics, architectural structures, and biomedical devices, where the need for flexible yet strong components with complex geometries is crucial.

**Problem Solved:** The method addresses the challenge of morphing flat sheets into 3D shapes without compromising mechanical strength, a common issue with traditional techniques that often require multiple cuts that weaken the material. By using a strategic cutting approach, this solution achieves both high strength and the desired 3D curvature.","A method has been developed for fabricating stronger 3D curved surfaces by stacking layers of 2D sheets with specific cutting patterns. This approach addresses the challenge of transforming flat sheets into 3D curved surfaces, which is important for applications in soft robotics, architectural structures, and biomedical devices."
"University of Pennsylvania","Ultra-Fast Soft Robots That Grasp Objects in 3.75 ms Upon Contact","","","https://upenn.technologypublisher.com/technology/51019","A class of metacaps with rich nonlinear mechanical behaviors, which addresses the challenges of limited and often slow actuation speeds, complex control systems, and the absence of sensing capabilities associated with soft robots.Problem:Soft Robots have undergone considerable development over the past decades due to their intrinsically compliant body, which enables safe interaction with humans and adaptability to unpredictable environments. Spherical caps have been widely used in the design of rapidly responsive soft robots, but the performance of the robots is restricted by the intrinsic properties of the caps, such as limited and often slow actuation speeds, requirement of complex control systems, and absence of sensing capabilities.Solution:A class of metacaps with rich nonlinear mechanical behaviors, which enable a variety of soft robotic systems with unprecedented functionalities, including a passive gripper with sensing capabilities that enable grasping of objects in 3.75 ms upon contact, a pneumatic actuated gripper with tunable actuation speeds to grasp objects of different mass and rigidity or softness (e.g. a strawberry vs. a plastic sphere), a swimming robot with amplified swimming speeds, and an untethered, electronics free-swimming robot with tunable actuation speeds.Technology:The inventors designed a metacap consisting of an array of ribs on a simple cap such that the bending stiffness of the cap can be fine-tuned locally. The finite element analyses revealed that metacaps showed a more pronounced snap-through behavior, i.e. the ability to turn inside-out due to a pneumatic, hydraulic, electric or magnetic trigger, as compared to other caps, and could achieve another equilibrium state after the occurrence of a snap, so called bistability, in contrast to simple spherical caps.Advantages:Greater energy storage and release than other caps as a result of the snap-through behaviorBistability: Metacap has two stable positions- undeformed and evertedMetacap enabled grippers are capable of grasping objects both passively and rapidly, and gently manipulating soft and delicate objects vs. rigid and strong onesMetacaps can be used to amplify the mechanical responses of other actuators for applications that require a high transient output power(A) Simple spherical caps with uniform thickness and clamped borders are typically monostable and are extremely sensitive to imperfections when the thickness to radius ratio is small, leading to limited energy release upon snapping. (B) Even though increasing the thickness to radius ratio can make the caps more robust, the large thickness would compromise snapping behavior. (C) The inventors designed a metacap by introducing an array of ribs to a simple cap aligned in the circumferential and radial directions, which gives rise to rich nonlinear mechanical properties and enables a variety of soft robotic systems with unprecedented functionalities.Stage of Development:Proof of ConceptIntellectual Property:U.S. Provisional Application FiledReference Media:Yang et. al, 2022, Ultra-fast, programmable, and electronics-free soft robots enabled by snapping metacaps,arXivDesired Partnerships:LicenseCo-developmentCase ID:23-10190-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51019","**Summary:** A novel class of metacaps has been developed, featuring rich nonlinear mechanical behaviors that enhance the performance of soft robots. This technology addresses prevalent challenges in soft robotics, such as slow actuation speeds, complex control requirements, and lack of sensing capabilities. With this advancement, soft robots can now grasp objects in just 3.75 milliseconds upon contact and utilize various functionalities tailored to distinct tasks.

**Applications:** The technology enables a multitude of applications, including passive grippers with sensing capabilities for quick object grasping, pneumatic actuated grippers that adapt their speeds to accommodate objects of varying mass and rigidity, and enhanced swimming robots designed for improved speed and maneuverability. Additionally, it permits the creation of untethered, electronics-free swimming robots that can also modulate their actuation speed.

**Problem Solved:** The technology effectively overcomes the limitations of traditional soft robots, which have been hindered by slow actuation, complex control systems, and inadequate sensing. By introducing metacaps that allow for rapid and adaptable interactions with objects, this advancement enhances the responsiveness and versatility of soft robotic systems.","Researchers have developed a class of metacaps with advanced nonlinear mechanical behaviors that enhance soft robots‚Äô actuation speeds and control systems. This innovation improves their ability to grasp objects rapidly and addresses existing limitations in sensing capabilities."
"University of Pennsylvania","Superstrong and Reversible Hydrogel Adhesives","","","https://upenn.technologypublisher.com/technology/51024","Ultrastrong hydrogel adhesives that can carry greater than 50kgs of weight and yet can be rendered reversible.Problem:The current limit for the strength of reversible and reworkdable dry adhesives is in the range of 10-100 N/m2. This range is not enough to carry large weights greater than 50kgs.Solution:The current invention reports ultrastrong hydrogel patches made from poly(hydroxyethylmethacrylate) (PHEMA) that exhibit one order of magnitude higher adhesive strength of up to 892 N/m2in the dry state and yet can be rendered reversible by moisturizing the patch with water to release it effortlessly. The hydrogel system can change its elastic modulus from 200kPa (in the wet state) to a few GPa (in the dry state), which helps in ‚Äúlocking‚Äù the patch to the target.Technology:This invention was inspired by the epiphragm of snails, that is by the drying of the mucus that helps lock shells to targets. This PHEMA hydrogel system can change its elastic modulus from 200kPa (in the wet state) to GPa (in the dry state). When the wet gel patch is loaded onto the target, the softened gel conforms to the target and make a good contact. Upon drying, its modulus increases significantly while remaining to be conformally contacted with the target such that it gets ‚Äúlocked‚Äù to the rough surface, leading to a high pull-off strength of 223N and 1058N with 0.25 cm2and 2 cm2, respectively. When rewet, the patch is softened again, the adhesion stress is released and the patch is peeled off easily.Advantages:The hydrogel system can change its elastic modulus from 200kPa (in the wet state) to a few GPa (in the dry state), which helps in ‚Äúlocking‚Äù the patch to the target conformallyProduces a high pull-off strength of 223N and 1058N with patch area of 0.25 cm2and 2 cm2, respectivelyWhen rewet, the patch is softened, the adhesion stress is released and the patch is peeled off easily, hence is reversibleUltrastrong patches that exhibit one order of magnitude higher adhesive strength of up to 892 N/m2, comparable or superior than that of the superglue, which is a liquid based adhesiveCan carry large weights of greater than 50kgsThe patch can be reusableA) Epiphragm of snail demonstrating interlocking with rough surfaces; B) Chemical structure of PHEMA; C) Advantages of PHEMA adhesivesStage of Development:ConceptProof of ConceptBench PrototypeIntellectual Property:U.S. Patent Application FiledReference Media:H. Cho et. al.,Proc. Nat. Acad. Sci., 2019, 116 (28), 13774Desired Partnerships:LicenseCo-developmentCase ID:18-8400-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51024","**Summary:** Ultrastrong hydrogel adhesives made from poly(hydroxyethylmethacrylate) (PHEMA) can support over 50 kilograms of weight while remaining reversible. These adhesives achieve an adhesive strength of up to 892 N/m¬≤ in a dry state, significantly surpassing the current limit for similar adhesives. The material's elastic modulus varies from 200 kPa when wet to several GPa when dry, effectively allowing the adhesive to lock onto surfaces. The technology draws inspiration from the epiphragm of snails, where drying mucus aids in surface adhesion.

**Applications:** The hydrogels can be utilized in various fields requiring robust yet reversible adhesive solutions. Potential applications include medical devices, construction, and consumer products where strong yet removable bonding is necessary.

**Problem Solved:** The invention addresses the limitations of existing reversible adhesives, which typically offer lower strength, making them inadequate for carrying heavy loads. By significantly enhancing adhesive strength and maintaining reversibility through moisture application, this technology meets the need for high-performance adhesive solutions.","Ultrastrong hydrogel adhesives can support weights exceeding 50 kg, exhibiting adhesive strengths of up to 892 N/m¬≤, significantly surpassing the current limit of 10-100 N/m¬≤ for reversible dry adhesives. These adhesives are made from poly(hydroxyethylmethacrylate) (PHEMA) and are designed to be both strong and reversible."
"University of Pennsylvania","Naturally Flexible, Adhesive, and Conductive Hydrogel Electrodes for Medical Sensing","","","https://upenn.technologypublisher.com/technology/51021","A hydrogel that combines conductive additives with the strength of dynamic bonds to create a naturally flexible and adhesive electrode.Problem:Biocompatible sensors offer immense opportunities in neurological and cardiac testing, health and fitness tracking, medical robotics, and prosthetics. Unfortunately, modern sensors use hard materials like silicon and metal which break after strains of just 3% and require adhesives for medical applications. These materials also require electrolytic gels to reduce impedance, leading to long-term breakdown and skin irritation. In addition, hard materials are difficult to miniaturize for next-generation implantable technologies, such as deep brain stimulators, which can treat neurological disorders like Parkinson‚Äôs Disease.Solution:The research team combined the biocompatibility and flexibility of hydrogels with the high conductivity found in two-dimensional MXenes and other conductors to create a naturally flexible and adhesive electrode. This device easily contours and adheres to the human form while maintaining high conductivity and low impedance.Technology:First, a base hydrogel comprising polyvinyl alcohol, boronic acid and chitosan is created. It is then mixed in a conductive filler made of carbon nanotubes, reduced graphene oxide, PEDOT:PSS, or two-dimensional MXenes with up to 5 wt%. The conductive hydrogel mix can achieve DC conductivities ranging over three orders of magnitude depending simply on the loading percentage and conductive filler type. Preliminary tests on skin also show lower impedance than commercial 3M 2360 adhesive electrodes.Advantages:DC conductivity up to 500 mS/cm at 5 wt% MXene loading, more than two orders of magnitude larger than the conductivity of water.Fine-tunable conductivity between 10 and 1000 mS/cm achievable with varying composition of reduced graphene oxide, PEDOT:PSS, MXene, carbon nanotube, salts, and antioxidants.Stage of Development:Proof of ConceptIntellectual Property:US PatentPendingReference Media:Driscoll et al.Curr Opin Biotechnol, 2021 Dec, 72 : 76Driscoll et al.Sci. Transl. Med., 2021 Sept 22, 13 (612): eabf8629Odorczyk,Penn Today, 2021 Sept 3Desired Partnerships:LicenseCo-developmentCase ID:22-10026-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51021","**Summary:** The described technology features a hydrogel that integrates conductive additives with dynamic bonds to produce electrodes that are naturally flexible and adhesive. This innovation blends the advantages of biocompatibility and flexibility found in hydrogels with the high electrical conductivity of two-dimensional MXenes and other conductive materials. 

**Applications:** The electrodes are particularly beneficial for use in biocompatible sensors aimed at neurological and cardiac testing, health and fitness monitoring, medical robotics, and prosthetics. They are also suitable for next-generation implantable technologies, such as deep brain stimulators designed to treat neurological disorders like Parkinson‚Äôs Disease.

**Problem Solved:** The technology addresses several challenges associated with traditional sensors, which utilize hard materials like silicon and metal that have low strain tolerance and can lead to breakage. These traditional materials require adhesives for medical applications, which can cause skin irritation and breakdown over time. Additionally, the innovation resolves issues related to the miniaturization of devices necessary for advanced implantable technologies.","A hydrogel has been developed that incorporates conductive additives and dynamic bonds, resulting in a flexible and adhesive electrode suitable for medical applications. Current sensors made from hard materials such as silicon and metal are limited by their low strain tolerance and need for adhesives."
"University of Pennsylvania","Cloud-Based Machine Learning Platform for Real-Time Clinical Image Analysis","","","https://upenn.technologypublisher.com/technology/51023","A cloud-based machine learning platform accessible by clinicians for real-time image analysis supporting multiple machine learning algorithms.Problem:Recent developments in deep-learning algorithms have led to a rapid rise in the use of machine learning for diagnostic image analysis. This application of machine learning and artificial intelligence has the potential to save radiologists time, reduce costs, and improve diagnostic accuracy. Ideally, the AI solution should be available on a picture archiving and communication system (PACS) before a radiologist reads the study, to mitigate potential report addendums. However, most PACS systems cannot execute computationally-intensive AI algorithms and specialized hardware for on-site image processing can be cost-prohibitive.Solution:The inventors developed a medical image processing pipeline for real-time clinical use. Because the pipeline hosts machine learning algorithms on a cloud server, clinical PACS systems can access these algorithms for real-time image processing of newly-acquired patient data. This tool improves diagnostic accuracy and saves radiologists‚Äô time without needing to alter existing workflows. Furthermore, the platform flexibly supports multiple machine learning algorithms, giving additional diagnostic options for clinicians.Technology:The invention has two primary components. The first component is a medical image analysis platform hosted on a cloud-based server that scrapes medical text and protected health information (PHI) from uploaded images. The platform stores PHI on a PHI-compliant server and sends the de-identified images to a separate cloud server to test different machine learning algorithms and generate clinical predictions. The invention's second component is custom software that smoothly integrates the machine learning predictions with relevant data fields in the radiologist‚Äôs patient report. This smooth integration provides the clinician directly with additional diagnostic information.Advantages:Platform can run in parallel with current radiology workflows without any changes to existing PACS systemsClinicians receive near real-time predictions of diagnostic images which are integrated into patient reportsPlatform supports multiple machine learning algorithms and tools for image analysisNo need for cost-prohibitive specialized machine learning hardwareSchematic of the cloud-based medical image analysis platform.Stage of Development:Minimum Viable ProductPilot Project UnderwayIntellectual Property:Provisional Patent FiledReference Media:Radiology Business Journal‚Äôs 3rdAnnual Innovation AwardDesired Partnerships:LicenseCase ID:22-9780-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51023","**Summary:** The technology is a cloud-based machine learning platform designed for real-time analysis of clinical images, enabling clinicians to utilize advanced machine learning algorithms. It addresses the challenge of limited computational capabilities in traditional picture archiving and communication systems (PACS), which often cannot support the intensive processing required for AI applications.

**Applications:** This platform can be used in various healthcare settings to analyze medical images, thereby assisting radiologists in diagnosing conditions more accurately and efficiently. Its ability to integrate with existing PACS systems makes it a practical solution for enhancing diagnostic workflows.

**Problem Solved:** The technology tackles the limitations of current PACS systems that are unable to process complex AI algorithms due to hardware constraints. It aims to save time for radiologists, reduce costs associated with diagnostic imaging, and improve overall diagnostic accuracy by providing real-time analysis of images prior to a radiologist's evaluation.","A cloud-based machine learning platform enables clinicians to perform real-time image analysis using various machine learning algorithms. This technology aims to enhance diagnostic efficiency, decrease costs, and improve the accuracy of image interpretations."
"University of Pennsylvania","Model Zoo: Machine Learning Model for Cases with Limited Data Sets or That Would Benefit from a Reduced and Selected Training Dataset","","","https://upenn.technologypublisher.com/technology/51022","A machine learning classification algorithm that incorporates several smaller algorithms trained on specific tasks and selectively focuses on synergistic tasks to reduce data requirements while increasing accuracy.Problem:There is a need in the field of machine learning to reduce the amount of data required to train models for diverse tasks. For example, image processing algorithms are important for self-driving cars, which need to be trained on many different types of images. In addition, in certain models some tasks conflict with one another resulting in less accuracy due to the competition among the dissonant tasks.Solution:Model Zoo is a boosting-based algorithm built on many smaller algorithms. As a result of this method, higher accuracy is obtained as compared to the accuracy obtained when multiple data sets are fitted to one algorithm. Furthermore, this method requires less data for training and allows for training on tasks whose accuracy may compete with other tasks, without compromising accuracy.Technology:The inventors utilize multiple models together in a way that increases the power of the whole system without compromising the accuracy of each independent model. The resulting algorithm combines many small models trained on specific tasks. It selectively uses relevant tasks while filtering out tasks where there is a negative or no statistical benefit to their inclusion.Advantages:Thoroughly tested on image classification benchmarksImproved accuracy over state of the art algorithmsOutperforms five tested algorithmsDecreased training cost for large datasetsFigure shows the training of similar tasks together, for example, training Model 1 for P1 using learning from P2, P5, and P6. Ultimately, all models that were trained on a particular task would be used to make predictions. For example, in the case of P5, Models 1, 2, and 3 would be used. (P refers to a task.) Figure taken from background information ‚Äú22-9818_2021_08_18_DISCL.pdf‚Äù included with Disclosure 22-9818, page 5.Stage of Development:Proof of ConceptIntellectual Property:U.S. Utility Patent FiledReference Media:Rahul Ramesh and Pratik Chaudhari. ‚ÄúModel Zoo: A growing Brain That Learns Continually.‚Äù International Conference on Learning Representations, 2022. Access link:arXiv, 2021Desired PartnershipsLicenseCo-developmentCase ID:22-9818-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51022","**Summary:** The technology is a machine learning classification algorithm that integrates multiple smaller algorithms trained on specific tasks to reduce data requirements while enhancing accuracy. By focusing on synergistic tasks and filtering out conflicting ones, the algorithm aims to address the challenge of training complex models with limited datasets. 

**Applications:** The model is particularly relevant in fields such as image processing for self-driving cars, where diverse and high-volume data is crucial for training but may be limited or conflicting across various tasks.

**Problem Solved:** The technology addresses the need for reduced data requirements in machine learning, specifically in scenarios where tasks may compete against each other, leading to decreased accuracy in traditional models. By adopting a boosting-based approach, it ensures higher accuracy and efficiency in training, ultimately mitigating the issues associated with limited datasets.","The described machine learning classification algorithm utilizes multiple smaller algorithms that are trained on specific tasks, aiming to decrease data requirements while enhancing accuracy. This approach addresses the challenge of training models effectively in scenarios with limited data, such as image processing for self-driving cars."
"University of Pennsylvania","High-Resolution and Energy-Efficient Voltage-Tunable Device for Holographic and Reflective Displays","","","https://upenn.technologypublisher.com/technology/51026","An array of individually addressable microscale optical resonators that offer higher resolution, lower power consumption, extremely rich color tones, and a unique manufacturing path.Problem:Current display devices, with either active or reflective displays, are limited by high power consumption, inadequate resolution, and limited viewing angles. Moreover, these technologies allow control over the amplitude or phase of light, but not both.Solution:The current invention offers a reflective display that reduces power consumption and increases resolution while making the device easier to operate outdoors. Since each optical resonator is individually addressable, both phase and amplitude can be controlled.Technology:The invention consists of a series of optical cavities, each with a bottom layer of silicon mirror and a top film of Platinum (Pt) that is partially reflective. The two layers are separated by a thin gap typically filled with water. The top layer can be tuned using a voltage that causes the layer to expand and subsequently alter its spectral reflectance. Incident light is reflected by the bottom mirror and partially by the top layer, which is further split by the bottom mirror, forming an optical resonator. The thickness of the top layer, as controlled by the voltage, determines the wavelength of light reflected by the optical resonator.Advantages:The device requires a power source of less than 1V (estimated 0.2V), so it would use less power and extend battery life over current display technologiesIncreased resolution with pixel size 1-10 microns, well below the resolution limit of human vision, compared to 10-100 microns pixel size of current display technologyEach pixel can operate within voltage range (~1V) and switch at speed upwards of 100msecThe device is manufactured using atomic layer deposition, which decreases the size of each pixel. Nearly 10,000 pixels fit within the smallest space resolvable to the naked eye, almost 10-fold smaller than current technologies.A schematic cross-section of the device. The device consists of a bottom layer that is a mirror and a top Pt layer that is semi-reflective. Incident light is reflected by the bottom and top layers, forming an optical resonator. The user can tune the voltage in the resonator to modulate the color of light reflected.Stage of Development:ConceptProof of ConceptIntellectual Property:Provisional Patent Application FiledDesired Partnerships:LicenseCo-development: with cell phone manufactures or specialized optics manufacturers (Thorlabs, Edmund, Nikon, etc.)Case ID:22-10112-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51026","**Summary:** The technology features an array of microscale optical resonators that are individually addressable, significantly enhancing display resolution, reducing power consumption, and delivering rich color tones. Each optical resonator comprises a silicon mirror base and a partially reflective platinum film separated by a thin gap typically filled with water. By applying a voltage, the platinum layer can be expanded, allowing for tuning of the device's spectral reflectance. This enables control over both the amplitude and phase of light, addressing the limitations of existing display technologies.

**Applications:** Potential applications include holographic displays and reflective displays suited for outdoor use, where higher efficiency and resolution are essential.

**Problem Solved:** The invention addresses the challenges of current display technologies, which suffer from high power consumption, low resolution, and limited viewing angles. By offering a method to control both amplitude and phase of light while significantly reducing power usage, the device facilitates enhanced display performance.","The invention features an array of individually addressable microscale optical resonators that achieve higher resolution, lower power consumption, and a broader range of color tones. This technology addresses limitations of current display devices by enabling control over both amplitude and phase of light, improving performance in reflective displays."
"University of Pennsylvania","A Modular Strategy for Distributed, Embodied Control of Electronics-Free Soft Robots","","","https://upenn.technologypublisher.com/technology/51027","A kirigami-inspired robot made without hard electronic controls, with soft modular sensors for navigating diverse environments.Problem:Soft robots are promising new machines that can adapt and operate in diverse confined and dynamic environments. Such machines are promising for industrial manufacturing, exploratory, and medical applications. For instance, engineers have created soft robotic gloves that assist the human grip, octopus-shaped swimmers that navigate tight spaces underwater, and even tiny crawling robots that can deliver drugs inside the human body. Current designs for soft robots incorporate sensors and actuators made from hard electronic materials, limiting their flexibility and possibilities for miniaturization.Solution:This technology is a soft robot designed with zero hard electronics-based actuators or sensors. The robot is outfitted with multiple soft modular control units that enable decision-making in diverse environments. This enables superior flexibility and potential for miniaturization, as no traditional electronics are needed.Technology:Soft robots unlock their full potential when their components are as flexible as possible. Guided by this principle, the authors developed a clever soft robot design incorporating kirigami ‚Äì the traditional Japanese art of folding and cutting paper ‚Äì to control the robot‚Äôs moving direction. Their design uses an inflatable silicone actuator to drive kirigami expansion, which powers locomotion through angled feet. Materials responsive to heat, light, or chemicals like liquid crystal elastomers or hydrogels activate control modules within the kirigami to sense and pilot the robot, all with zero electronics.Advantages:Zero hard electronic materialsSensitive to heat, light, or chemical changesBending angle up to 30 degreesOperates at temperatures up to 150¬∞CDecision-making capabilities by constructing logic gates using sensing modulesDesign of the electronics-free soft autonomous robot. The soft robot comprises a kirigami-inspired body, a pneumatic actuator (mechanical valve is optional), multiple types of control modules (with responsive materials), and feet (to enable locomotion).Stage of Development:ConceptProof of ConceptIntellectual Property:US Provisional Application FiledDesired Partnerships:LicenseCo-developmentCase ID:22-10001-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51027","**Summary:** This technology describes a soft robot designed without any hard electronic actuators or sensors, utilizing modular soft components to facilitate navigation in diverse environments. The robot's design is guided by performance principles that emphasize flexibility, relying on kirigami-inspired structures to control movement through the expansion of inflatable silicone actuators. This innovative approach enhances the robot's adaptability and potential for miniaturization, as it avoids traditional electronic components.

**Applications:** The soft robot is expected to find applications across various fields such as industrial manufacturing, medical assistance, drug delivery, and underwater exploration due to its ability to operate in confined and dynamic environments. Its design allows it to assist in tasks that require adaptability, like soft robotic gloves for enhancing grip and navigating through tight spaces.

**Problem Solved:** This technology addresses the limitations of current soft robotics, which often rely on rigid electronic components that restrict flexibility and miniaturization. By eliminating hard electronics and employing fully soft modular control units, the robot can better adapt to diverse environments, unlocking new potentials for soft robotic applications.","The development features a kirigami-inspired robot designed without traditional electronic controls, utilizing soft modular sensors for navigation in various environments. This approach enhances the adaptability of soft robots for applications in industrial manufacturing, exploration, and medicine."
"University of Pennsylvania","Ionizable Lipid Nanoparticles For In Vivo mRNA Delivery To The Placenta During Pregnancy","","","https://upenn.technologypublisher.com/technology/51146","Lipid nanoparticles for selective mRNA delivery to the placenta to treat pre-eclampsia, FGR, and other pregnancy-related disorders.Problem:3-8% of pregnant women experience pre-eclampsia, or insufficient blood flow to the placenta. In severe cases, this can cause fetal growth restriction (FGR), in which the developing fetus cannot receive adequate blood flow. The only curative option for pre-eclampsia and FGR is to deliver the fetus regardless of gestational age. Because of this, pre-eclampsia and FGR are the leading causes of premature and stillbirths.Several groups have developed gene therapies to try to address pre-eclampsia and FGR. However, these viral-based approaches have the potential for permanent off-target effects in other organs and must be delivered directly into the placenta via an invasive uterine injection.Solution:The inventors identified a lipid nanoparticle composition to deliver mRNA-based therapeutics to the placenta effectively. mRNA-based therapies are safer than viral alternatives as they last for a shorter time inside the body. The mRNA lipid nanoparticles can be loaded with mRNAs to treat pre-eclampsia, FGR, or other pregnancy-related disorders. They can be delivered through a regular IV without requiring invasive actions.Technology:The inventors designed and screened a library of 15 lipid nanoparticle compositions for their ability to deliver mRNA to placental cells. They then tested the lead compositions for their ability to target the uterus and placenta in mice. The lead LNP (A4) showed enhanced delivery to the placenta compared to an industry-standard LNP. Importantly, the LNPs delivered mRNA to the placenta, but not the fetuses, suggesting this therapy is safe for placental targeting.The inventors then delivered VEGF mRNA, a vascular growth factor known to stimulate blood flow, via LNPs. The A4 LNP increased fetal blood vessel dilation, indicating on-target VEGF delivery.Advantages:LNPs are delivered by IV, which is less invasive than the intrauterine injections used to deliver viral therapiesmRNA-based therapies have fewer long-term risks than viral-based therapiesThe A4 LNP delivers more mRNA (62%) to the placenta than the industry standard LNP (34%)The A4 LNP delivers mRNA to the placenta but not the fetuses, suggesting fetal safetyThe A4 LNP delivers mRNA to more of the relevant cells (3.1%) than the industry standard LNP (1.7%)The A4 LNP shows a lower potential for liver toxicity than the industry standard LNP. (The industry standard shows 8.7-fold higher expression of a marker of liver toxicity than A4)LNP delivery shows no signs of causing placental inflammationThe A4 LNP specifically increases fetal blood vessel dilation, while the industry standard LNP increases maternal blood vessel dilation. Fetal blood vessel dilation indicates increased on-target local delivery by A4, and maternal blood vessel dilation indicates broader systemic delivery by the industry standardEngineered ionizable LNPs for mRNA delivery to the placenta with applications in mediating placental vasodilation.Stage of Development:Proof of ConceptIntellectual Property:US Provisional FiledReference Media:Swingle, et al,J. Am. Chem. Soc.2023 March 1; 145(8): 4691Desired PartnershipsLicenseCo-developmentCase ID:22-10089-tpNCSWeb Published:5/22/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51146","**Summary:** Lipid nanoparticles have been developed for the selective delivery of mRNA to the placenta, aimed at treating conditions such as pre-eclampsia and fetal growth restriction (FGR). These conditions affect 3-8% of pregnant women, resulting from inadequate blood flow to the placenta, which can lead to severe complications including premature and stillbirths. Current gene therapies often rely on viral vectors, which pose risks of off-target effects and require invasive delivery methods, such as uterine injections. The proposed technology utilizes a safer mRNA-based approach that allows for non-invasive intravenous delivery of treatments.

**Applications:** This technology can be applied to treat pre-eclampsia and FGR, as well as potentially other pregnancy-related disorders. By delivering mRNA-based therapeutics directly to the placenta, it offers a novel method for addressing significant maternal and fetal health challenges during pregnancy.

**Problem Solved:** The technology addresses the critical health issues of pre-eclampsia and fetal growth restriction, conditions that currently have limited treatment options and often necessitate early delivery of the fetus, posing risks to both mother and child. By providing a non-invasive, safer alternative to existing gene therapies, it reduces the likelihood of complications associated with viral vectors and invasive procedures.","Lipid nanoparticles are being developed for targeted mRNA delivery to the placenta to address conditions such as pre-eclampsia and fetal growth restriction (FGR), which affect 3-8% of pregnant women. Pre-eclampsia can lead to insufficient blood flow to the placenta, making delivery of the fetus the only curative option in severe cases."
"University of Pennsylvania","Method for Creating Super Resolution Medical Images","#22-9999","","https://upenn.technologypublisher.com/technology/51028","The deep learning algorithm retrospectively improves the resolution of routine medical images (e.g., CT, MRI, etc.) without the need for increased radiation or scan time.Technology:Clinical medical images often have low resolution due to radiation-dose or scan-time restrictions. Inventors developed a probabilistic deep learning model to improve resolution of routinely acquired medical images. The method is particularly suited for situations where high resolution imaging using MRI, CT, or PET is not clinically feasible. This method produces significantly better performance in terms of superior image quality, greater quantitative-measurement accuracy, and low bias compared to other methods using convolutional neural networks and generative adversarial networks (GAN). For example, this method allows the measurement of microstructural trabecular bone thickness, separation, number, and strength which can assist in evaluating bone health without the need for a bone biopsy.Advantages:Improved resolution of routine low resolution clinical imagesSaving MR scan timeReducing radiation dose for CT scanningProviding information on bone health at a low radiation doseOpportunistic scanning for osteoporosis using low dose CT scansImproved performance compared to other super-resolution methodsStage of Development:Validated using 60,000 CT images from cadaveric human bone for CT and hundreds of MRI images from human subjects for MRI.Intellectual Property:PCTFiledReference Media:Chan, TJ & Rajapakse, CS;Radiol Artif Intell 2023 Sept 20: e220251Yee, KM.2023 Sept 21 Clinical News - CT AuntMinnie.comDesired Partnerships:LicenseCo-developmentCase ID:22-9999-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51028","**Summary:** A probabilistic deep learning algorithm has been developed to enhance the resolution of routine medical images like CT and MRI scans without necessitating additional radiation exposure or increased scan times. This technology overcomes the limitations of low-resolution clinical images, particularly in scenarios where high-resolution imaging is not viable. It significantly surpasses other available methods, including convolutional neural networks and generative adversarial networks, in terms of image quality, quantitative measurement accuracy, and bias reduction.

**Applications:** The method can be utilized to assess bone health by measuring microstructural features such as trabecular bone thickness, separation, number, and strength, all without the need for invasive procedures like bone biopsies. Furthermore, it allows for opportunistic scanning for osteoporosis using low-dose CT scans and enhances MRI protocols by saving scan time.

**Problem Solved:** The approach effectively addresses the challenge of low resolution in clinical imaging due to restrictions on radiation doses and scan times, thus enabling better diagnostic capabilities and patient safety.","A deep learning algorithm enhances the resolution of routine medical images, such as CT and MRI, without increasing radiation exposure or scan duration. This probabilistic model is specifically designed to improve the quality of images obtained under typical clinical conditions."
"University of Pennsylvania","Ligand-Tethered Lipid Nanoparticles for Targeted RNA Delivery to Treat Liver Fibrosis","22-9782","","https://upenn.technologypublisher.com/technology/51029","A new class of anisimide-functionalized lipids that enables targeted delivery of lipid nanoparticles (LNPs) to activated fibroblasts in the liver.Problem:Lipid nanoparticles (LNPs) have been successfully used in FDA-approved therapies to deliver messenger RNA (mRNA) and small interfering RNA (siRNA) . One of the biggest challenge in developing a successful RNA therapies is its targeted delivery. Typically, LNPs require targeting ligands to be coated onto their surface to enable targeted delivery after the lipid is made. This added step often complicates the fabrication process.Solution:Rather than functionalizing LNPs with targeting ligands post-fabrication, this technology incorporates targeting capabilities directly into the lipid component to create ligand-thethered LNPs. This creates an affinity to the notoriously hard-to-target activated fibroblasts in the liver responsible for the buildup of collagen.Technology:The method incorporates small targeting moieties into the ionizable lipid which enable the generation of ligand-tethered LNPs. The lead AA-lipidoid AA-T3A-C12 mediates greater RNA delivery and transfection of activated fibroblasts than its analog without anisamide and the FDA-approved MC3 ionizable lipid. In a preclinical model of liver fibrosis, AA-T3A-C12 enables ~65% silencing of heat shock protein 47, a therapeutic target primarily expressed by activated fibroblasts, which is 2-fold more potent than MC3, leading to significantly reduced collagen deposition and liver fibrosis.Advantages:Enables targeted LNP creation without the need for post-fabrication processesCan be used to deliver genetic medicines such as mRNA and siRNA therapiesIncreased selectivity and ability to target liver fibroblasts(a) Formulation of AA-T3A-C12/siHSP47 LNP via microfluidic mixing. (b) Scheme of targeted AA-T3A-C12/siHSP47 LNP delivery to activated HSCs to knockdown HSP47 and treat liver fibrosis. HSCs are located in the space of Disse, an area between LSECs and hepatocytes. After rapidly shedding PEG in circulation, the LNP exposes multivalent anisamide ligands on its surface that can strongly bind with sigma receptors overexpressed on activated HSCs to mediate cellular uptake. b was created with BioRender.com. Figure obtained from the inventor's Nature Communications publication.Stage of Development:Proof of ConceptIntellectual Property:PCT Application FiledReference Media:Pappas, M., 2023 Jan. 17;Penn Engineering TodayHan, X., et al.,Nat Commun. 2023 Jan 17; 14(1): 75Desired Partnerships:LicenseCo-developmentCase ID:22-9782-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51029","**Summary:** This technology introduces a novel class of anisimide-functionalized lipids that facilitates the targeted delivery of lipid nanoparticles (LNPs) specifically to activated fibroblasts in the liver. By integrating targeting capabilities directly into the lipid components, the method eliminates the need for post-fabrication coating with targeting ligands, thereby simplifying the manufacturing process. The lead compound, AA-T3A-C12, demonstrates superior RNA delivery and transfection efficiency in activated fibroblasts compared to both a non-anisamide analog and the FDA-approved MC3 ionizable lipid.

**Applications:** This technology is applicable in developing RNA-based therapies for diseases involving liver fibrosis, particularly by targeting activated fibroblasts that contribute to collagen accumulation and fibrosis progression. It may also have potential in other therapeutic areas where targeting specific cell types is critical.

**Problem Solved:** The technology addresses the challenge of targeted delivery in RNA therapies, which typically require additional steps to attach targeting ligands to lipid nanoparticles. By incorporating targeting moieties directly into the lipid component, it enhances the effectiveness of LNPs in delivering RNA treatments, particularly in targeting difficult-to-reach activated fibroblasts in liver fibrosis while streamlining the fabrication process.","A new class of anisimide-functionalized lipids allows for targeted delivery of lipid nanoparticles (LNPs) specifically to activated fibroblasts in the liver. This advancement addresses a significant challenge in RNA therapy development, which is the need for effective targeting ligands on LNP surfaces."
"University of Pennsylvania","Modified Lipid Nanoparticle Formulations with Improved Therapeutic Delivery to the Bone Microenvironment In-vivo","","","https://upenn.technologypublisher.com/technology/51030","A library of bi-phosphonate ionizable lipids and LNP formulations to facilitate mRNA delivery to the bone microenvironment.Problem:The increasing prevalence of skeletal diseases such as osteoporosis, osteoarthritis and bone cancer have motivated efforts to target the bone microenvironment therapeutically. However, therapeutic agents must overcome multiple challenges in order to reach the key compartments of bone including reduced blood flow compared to highly vascularized tissue, poor penetration of the blood-bone marrow barrier, insufficient perfusion of bone, and low chemical affinity for bone mineral.Solution:Biphoshphonate (BP) lipid-like materials improve the ability of LNPs to deliver encapsulated mRNAs to the bone microenviroment. Enhanced protein expression is observed in leg bone after in-vivo injection, and within cells of both the myeloid and lymphoid lineages arising from the bone marrow compartment.Technology:BP lipid-like materials incorporated into lipid nanoparticle (LNP) formulations interact strongly with hydroxyapatite, a key inorganic component of bone. Using a single biphosphonate compound as a core scaffold, the inventors derive 21 unique compounds and test their ability to facilitate mRNA and protein expression in-vitro and in-vivo compared to LNPs with no biphosphonates in their formulation.Advantages:21 BP-lipid like LNP variations with a lead formulation identifiedIncreases mRNA delivery in bone and in the bone marrow cells including T cells, B cells and monocytesEnhanced mRNA encoded protein production on bone surface and in bone marrowBP lipid-like containing LNPs can encapsulate diverse therapeutic approaches enhancing or silencing protein expressionFigure caption: a) LNPs fluorescently labeled with near infrared dye (DiR) track mRNA delivery to bone. b-d) Elevated fluorescence within left and right mouse leg bone is detectable after injection of biphosphonate lipid-like formulations (490BP-C14) compared to standard LNPs (490-C14).Stage of Development:TherapeuticsTarget IdentifiedPreclinical DiscoveryIntellectual Property:PCT In PreparationReference Media:Xue, L. et al.,J. Am. Chem. Soc. 2022 June 8, 144(22): 9926Desired Partnerships:LicenseCo-developmentCase ID:22-9991-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51030","**Summary:** A collection of biphosphonate ionizable lipids and lipid nanoparticle (LNP) formulations has been developed to enhance the delivery of mRNA to the bone microenvironment. The presence of biphosphonate lipid-like materials strengthens the interaction with hydroxyapatite, enabling better cellular uptake and expression of proteins following in-vivo administration. This technology has shown increased mRNA delivery efficiency to the bone and specifically to cells originating from the bone marrow, including T and B lymphocytes.

**Applications:** The technology is applicable in treating skeletal diseases such as osteoporosis, osteoarthritis, and bone cancer by facilitating targeted delivery of therapeutic mRNA to the bone microenvironment, potentially improving therapeutic outcomes.

**Problem Solved:** The advancements address the challenges associated with delivering therapeutic agents to the bone, including low blood flow, poor penetration of the blood-bone marrow barrier, insufficient perfusion, and inadequate chemical affinity for bone mineral, ultimately enabling more effective treatment options for skeletal diseases.","A library of bi-phosphonate ionizable lipids and lipid nanoparticle (LNP) formulations has been developed to enhance mRNA delivery specifically to the bone microenvironment. This approach addresses the therapeutic delivery challenges posed by skeletal diseases, including osteoporosis and bone cancer, due to factors like reduced blood flow and poor penetration in bone tissue."
"University of Pennsylvania","Library of Novel Anesthetic (Propofol) Antagonists","","","https://upenn.technologypublisher.com/technology/51031","A library of chemical compounds that reverse the anesthetic effects of propofol.Problem:Propofol is one of the most commonly used anesthetics in medical care. It is used to induce and maintain sedation in surgeries, ICU care, emergency care, and other procedures. However, there currently is no pharmacological method for reversing propofol-induced sedation, meaning that doctors must wait for patients' bodies to wake from sedation naturally. This can be problematic when patients stop breathing or are slow to wake from sedation.Solution:The inventors developed a library of compounds that antagonize the effects of propofol. In animal models these compounds produce increased arousal and reversal of propofol-induced sedation. Furthermore, these compounds are effective at dosages of a non-lethal level to the animal.Advantages:Drug compounds antagonize propofol across a wide range of propofol dosagesEffective at a dosage less than an order of magnitude lower than LD50Many more variations of this compound can be synthesized and testedStage of Development:Proof of ConceptReference Media:Woll, KA et al.ACS Chem Neurosci., 2015 June 17, 6(6): 927White, ER et al.ACS Chem Neurosci., 2021 Jan 6, 12(1): 176Desired Partnerships:LicenseCase ID:22-10000-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51031","**Summary:** A library of chemical compounds has been developed to reverse the anesthetic effects of propofol, which is extensively used for sedation in various medical settings. Currently, there is no pharmacological solution for reversing propofol-induced sedation, requiring patients to naturally awaken, which can lead to complications such as respiratory issues or delayed recovery. The invented compounds effectively antagonize propofol, inducing increased arousal and reversing sedation in animal models at non-lethal dosages.

**Applications:** These compounds can be used in surgical, ICU, and emergency settings to facilitate the faster recovery of patients after the use of propofol, thus enhancing patient safety and efficiency in medical procedures.

**Problem Solved:** The technology addresses the significant limitation regarding the lack of an antidote for propofol, allowing for rapid recovery from sedation, which is crucial in situations where immediate responsiveness is necessary, such as patients who stop breathing or are slow to wake.","A collection of chemical compounds has been developed to reverse the anesthetic effects of propofol, which is widely used for sedation in various medical settings. The absence of a pharmacological reversal method for propofol-induced sedation poses challenges, particularly in critical situations where patients may stop breathing."
"University of Pennsylvania","Accurate Blood Biomarkers for Early Diagnosis of Synovial Joint Disease in the Mucopolysaccharidoses","","","https://upenn.technologypublisher.com/technology/51033","Ten candidate serum and synovial protein levels provide early indication of joint impairment in lysosomal storage disorders.Problem:The Mucopolysaccharidoses (MPS) group of lysosomal storage diseases occur once in every 25,000 births, all MPS subtypes share deficits in enzymatic degradation. Children with MPS suffer from a suite of variable and severe symptoms including respiratory/cardiac deficits, and commonly synovial joint skeletal abnormalities. There are no known specific biomarkers used to track MPS patients at risk for joint complications and with the potential to be responsive to earlier intervention.Solution:The inventors used a canine model of MPS I, and obtained serum and synovial fluid samples to identify 10 significant and highly predictive biomarkers.Technology:To identify candidate proteins that are altered early in MPS I, the inventors took joint fluid and blood from canines aged 1 years old. Hundreds of proteins were assayed simultaneously using tandem liquid chromatography-mass spectrometry. Ultimately out of 812 total identified proteins, 151 are differentially abundant in the synovial fluid of MPS groups and 154 are different in serum of diseased canines. These MPS affected proteins are filtered further to identify 32 candidates that correlate and share MPS-dependent directionality in both joint fluid and serum. Finally using spearman rank correlation, the inventors produce a shortlist of ten useful markers, that are validated across joint fluid and blood, and can be assayed to significantly predict synovial joint disease.Advantages:Multiple viable biomarkersAll biomarkers are correlated to and validated by elevated serum samples9 out of 10 biomarkers demonstrate one-hundred percent predictive ROC valuesBiomarkers serve as targetable therapeuticsStage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:US Application in ProcessReference Media:Smith, LJ et al.JOR Spine, 2020, 3(4), e1134.Desired Partnerships:LicenseCo-developmentCase ID:22-9830-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51033","**Summary:** Ten candidate serum and synovial protein levels have been identified as early indicators of joint impairment in lysosomal storage disorders, specifically targeting the Mucopolysaccharidoses (MPS). The study was conducted using a canine model of MPS I, revealing that out of 812 identified proteins, a significant number were differentially abundant in the synovial fluid and serum of affected canines. Ultimately, a shortlist of ten validated biomarkers was produced, which may help track MPS patients at risk for joint complications.

**Applications:** This technology can be used to monitor MPS patients for early signs of joint disease, enabling clinicians to implement earlier interventions and manage symptoms more effectively. Additionally, it may have implications for research into other lysosomal storage diseases and joint impairment conditions.

**Problem Solved:** The technology addresses the absence of specific biomarkers for tracking joint complications in MPS patients, which is crucial for timely intervention and improved patient outcomes. By identifying predictive biomarkers, this approach offers a method to recognize early joint impairment, potentially reducing the severity of associated symptoms in affected children.","Ten candidate serum and synovial protein levels have been identified as early indicators of joint impairment in Mucopolysaccharidoses, a group of lysosomal storage disorders occurring in about 1 in 25,000 births. These disorders are characterized by deficits in enzymatic degradation, leading to severe symptoms, including synovial joint skeletal abnormalities."
"University of Pennsylvania","Machine learning device for quickly identifying tissue malignancy during live surgery","","","https://upenn.technologypublisher.com/technology/48541","Machine learning device for quickly identifying tissue malignancy during live surgery.Problem:When a patient presents with potentially malignant pulmonary tissue via pre-operative imaging, surgery and early removal of the cancerous tissue is their best avenue for treatment. However, when proceeding with the operation, the surgeon must remove a diagnostic resection of the lesion and wait for the pathology department to confirm the presence of cancer, a process that adds up to 35 minutes to the procedure. Recent developments in endomicroscopy provide cellular resolution imaging that allows for the classification of tissues without the need for lengthy diagnostic tests, but the interpretation of such visual data requires extensive training for operators.Solution:The inventors developed a machine learning methos that assesses the potential malignancy of tumor cells in real-time in the operating room. The device only takes a few seconds to perform classification and evaluates the 3D structure of the tumor. Furthermore, it also indicates any potential sampling errors to further lower the risk of user error.Technology:Near-infrared needle-based confocal laser endomicroscopy (NIR-nCLE) is an imaging method providing cellular level resolution of potential tumors. The inventors used NIR-nCLE combined with an NIR contrast imaging agent to build a high-fidelity training set with over 1500 videos and trained a convolutional neural network to identify malignant tissues.Advantages:Predicts malignancy of tissue with >93.5% accuracyPerforms prediction on single-cell nCLE imaging in real timeInforms operator if tissue sampling is adequateDevice can be tailored for cloud-based remote lesion assessmentStage of Development:Bench PrototypeIntellectual Property:Provisional FiledReference Media:Newton et al.;J Thorac Dis., 2016, 8:S697-S704.Desired Partnerships:LicenseCo-developmentCase ID:22-10041-tpNCSWeb Published:10/3/2022Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/48541","**Summary:** The technology utilizes a machine learning device that rapidly identifies tissue malignancy during live surgery. When a patient presents with potentially malignant pulmonary tissue, the traditional surgical approach requires a diagnostic resection and a waiting period for pathology confirmation, delaying crucial treatment. This device leverages near-infrared needle-based confocal laser endomicroscopy (NIR-nCLE) alongside a high-fidelity training set of over 1500 videos to classify tissue in real-time, eliminating the need for extended diagnostic waiting periods and providing immediate feedback regarding sampling errors.

**Applications:** This device can be applied in surgical settings, particularly for procedures involving potentially malignant tissues, such as pulmonary surgery. It allows surgeons to make immediate decisions about tumor excision without delay, improving patient outcomes.

**Problem Solved:** The technology addresses the lengthy wait time required for pathology confirmation during surgeries, thereby streamlining the surgical process and reducing the risk of diagnostic errors, ultimately expediting the treatment of cancerous tissues.","A machine learning device has been developed to quickly identify malignancy in pulmonary tissue during live surgery, addressing the time-consuming process of waiting for pathology confirmation. This technology aims to reduce the typical 35-minute delay associated with diagnosing cancerous tissue after a surgical resection."
"University of Pennsylvania","Manipulation of the microenvironment to increase the number of functional cells in kidney organoids","","","https://upenn.technologypublisher.com/technology/48091","Problem:Kidney organoids are masses of kidney cells grown in a lab for medical and research purposes to mimic kidney functions. With further development, doctors could use kidney organoids and engineered tissues in transplant settings to replace the need for human donors. A major roadblock in this technology is achieving enough differentiated nephrons (functional cells) to allow the organoid to act as a functioning kidney. Normally in kidney development, multiple rounds of nephron differentiation result in hundreds of nephrons. However, organoids currently undergo only one round of differentiation, limiting their current usefulness for research and medicine.Solution:The inventors noted that, in normal kidney development, the growth and branching of the developing ureter tubes apply pressure to the organ's cells in cyclic rounds, and this pressure is required to differentiate them into nephrons. Therefore, the inventors developed a method to mimic these rounds of cellular tension to increase the number of differentiated nephrons in the organoid.Technology:The inventors identified the crucial role of cellular tension in nephron development in vivo. By adding inhibitors that block the cell's ability to sense tension, the inventors mimic these cyclical tension changes to generate kidney organoids with increased numbers of differentiating nephrons. Using these inhibitors, the inventors see a 2-10 times increase in differentiating nephron cells in kidney organoids.Advantages:ROCK inhibition yields kidney organoids that have 2-10 times higher levels of LHX1 (a nephron marker) and two times higher levels of Six2 (a marker of cells transitioning into nephrons) than organoids grown without manipulation of cellular tension.Non-muscle myosin inhibition yields kidney organoids with two times higher levels of LHX1 than organoids grown without manipulation of cellular tension.Both ROCK and non-muscle myosin inhibitors are commonly used and accessible reagents allowing easy adoption into culturing protocols.(Images of kidney organoids grown in various conditions. Cyan indicates LHX1, a marker of early-stage nephrons, and magenta indicates SIX2, a marker of cells transitioning into nephrons. Levels of LHX1 and SIX2 are quantified in the plots to the right. Combinatorial treatment of organoid growth factor (CHIR) and ROCK inhibition (Y-27632) yields 2-10 fold higher LHX1 and two-fold higher SIX2, suggesting increased nephron yield. Similarly, non-muscle myosin inhibition (bleb.) yields two-fold higher LHX1.Stage of Development:ConceptProof of ConceptBench ProtoypeIntellectual Property:Provisional FiledReference Media:Viola et al.bioRxiv, 2022Desired Partnerships:LicenseCo-developmentCase ID:22-10094-tpNCSWeb Published:8/17/2022Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/48091","**Summary:** The development of kidney organoids for medical and research purposes faces a significant challenge in producing sufficient functional nephrons. These organoids typically undergo only one round of differentiation, limiting their effectiveness. The inventors recognized that normal kidney development involves multiple rounds of nephron differentiation stimulated by cellular tension caused by the developing ureter tubes. They devised a method to imitate these cyclic pressure changes, resulting in increased nephron differentiation within the organoids. By utilizing specific inhibitors to block tension sensing in cells, a notable increase in the number of differentiating nephron cells‚Äîranging from 2 to 10 times‚Äîwas achieved in kidney organoids.

**Applications:** This technology has potential applications in the field of regenerative medicine, particularly in transplant settings where engineered kidney tissues could serve as substitutes for human donor organs. It may also be beneficial in drug testing and disease modeling by providing a more functional in vitro model of the kidney.

**Problem Solved:** The primary problem addressed by this technology is the insufficient differentiation of nephrons in kidney organoids, which limits their utility in research and potential clinical applications. By enhancing the number of functional nephron cells, the technology improves the viability and functionality of kidney organoids, facilitating their use in various medical applications.","Kidney organoids are lab-grown masses of kidney cells that mimic kidney functions for medical and research purposes, with potential use in transplant settings to reduce reliance on human donors. A significant challenge in this field is producing a sufficient number of differentiated nephrons to enable the organoid to function effectively as a kidney."
"University of Pennsylvania","Superlattices of Atomically Thin Materials with Strong Light Absorption for Next-Generation Optical Devices","","","https://upenn.technologypublisher.com/technology/51034","A design and method to create superlattices, alternating stacks of two-dimensional materials and semiconductors to obtain strong light absorption.Problem:Next-generation optical technologies like light detection and ranging (LiDAR) and on-chip optical modulators have wide-ranging applications in autonomous vehicles, device communication, and computing. Unfortunately, existing technologies are hampered by their sensitivity, often requiring specific substrates and operating environments. Two-dimensional materials like transition metal dichalcogenides (TMDs) have highly desirable optical and electronic properties for such applications, but offer uneven sample thickness, small lateral dimensions, and weak light absorption.Solution:The researchers developed a method to create semiconductor-TMD superlattices. These superlattices offer controllable thickness, device-scale lateral size, and strong light absorption. In addition, they maintain the quantum effects found in TMD monolayers such as exciton-polariton splitting. This introduces exciting avenues for optical device engineering.Technology:TMDs offer an excellent platform for optical devices due to their direct bandgap, strong quantum confinement, and nonradiative exciton-hole energy loss. The authors were inspired by these benefits to devise a method to harness TMDs‚Äô upsides while mitigating the downsides of sample preparation and geometry. They accomplished this by stacking TMDs and thin semiconductors together using a wet chemical transfer process. This stabilizes the TMDs and enables quantum device designs on the order of square centimeters.Advantages:Method creates samples on the order of 1 cm2 for real-world device applicationsSuperlattices exhibit over 80% light absorption at TMD excitonic frequencyPreserves quantum effects of the monolayer TMDs, including exciton-polariton Rabi splitting up to 170 meVCavity mode quality factor as large as 300Operates at room temperatureStructure of a superlattice combining 2D TMD sheets with nanometer-scale semiconductor slabs. Such a superlattice offers over 80% light absorption at the TMD exciton peak and hosts interesting quantum effects like exciton-polariton splitting.Stage of Development:ConceptProof of ConceptIntellectual Property:US Provisional FiledReference Media:Pappas, M.Penn Engineering Today, 10 Dec 2021.Kumar, P et al.Nat. Nanotechnol., 2021 Dec, 17: 182.Desired Partnerships:Case ID:21-9665-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51034","**Summary:** The researchers have developed a novel design and method to create superlattices by alternating stacks of two-dimensional materials and semiconductors. This approach enables strong light absorption, while also allowing for controllable thickness and device-scale lateral size. The new structure retains the beneficial quantum effects characteristic of transition metal dichalcogenides (TMDs), such as exciton-polariton splitting, which enhances the potential for optical device applications.

**Applications:** This technology offers significant advancements for next-generation optical devices, including light detection and ranging (LiDAR) systems and on-chip optical modulators. It is particularly relevant for autonomous vehicles, device communication, and computing, where improved optical properties are essential.

**Problem Solved:** The solution addresses the limitations of existing optical technologies that often struggle with sensitivity and require specific substrates and operating conditions. By leveraging the strengths of TMDs while overcoming challenges related to sample thickness, lateral dimensions, and light absorption, this technology enhances the performance and applicability of optical devices.","The research presents a design and method for creating superlattices using alternating stacks of two-dimensional materials and semiconductors to achieve strong light absorption. This innovation aims to enhance next-generation optical technologies, such as LiDAR and on-chip optical modulators, which are crucial for applications in autonomous vehicles, device communication, and computing."
"University of Pennsylvania","Pico-Washing: High Throughput Droplet Fluid-Exchange for Microfluidic Platforms","22-9984","","https://upenn.technologypublisher.com/technology/51035","Device that simultaneously injects fluid into and removes fluid from droplets in flow.Problem:Droplet microfluidic technology is rapidly developing, unlocking newer high-throughput approaches in various fields including single-cell transcriptomics, genomics, and proteomics. One unit operation that remains underdeveloped in droplet microfluidics is the exchange of fluid through droplets in a continuous flow, high-throughput modality. Current technologies in this space include either a pico-injection, which adds a buffer to droplets that are then split into two, or the transfer of one droplet content into another. These approaches do not necessarily remove fluid from the droplets and are limited to approximately 100-fold dilutions at a throughput of 100Hz (100 droplets per second).Solution:A droplet unit operation with innovative fabrication, design, and quantification that increases throughput 10-fold to 1KHz, and simultaneously exchanges fluid from droplets in flow with high efficiency.Technology:The pico-washer's specific design geometry and operational parameters lend themselves to a stable and efficient fluid exchange. The moving droplet makes contact with a high-pressure wash and a low-pressure waste stream in the presence of an electric field, which facilitates the fluid transfer.Advantages:1KHz throughput, a 10-fold increase compared to current technologiesThe cross-flow design exchanges (as opposed to adds) material through droplets in continuous flowThe ability to scale parallelized arrays of pico-washers, each with KHz throughput, could collectively realize MHz throughputsCompatible with existing droplet microfluidic technology to efficiently achieve multi-step high-throughput droplet biological and chemical assaysSchematic of the various fluidic channels in the droplet generator and pico-washer (highlighted in red): a high-pressure (PH) wash stream, low-pressure (PL) waste stream, continuous oil (PC), and dispersed aqueous (PD) stream. The aqueous stream has a green dye to visualize and quantify washing efficiency.Stage of Development:Proof of ConceptIntellectual Property:Provisional FiledReference Media:Siedlik, MJ & Issadore, D.Microsyst Nanoeng, 2022April 29, 8:46.Desired PartnershipsCase ID:22-9984-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51035","**Summary:** The technology is a device designed for droplet microfluidics that allows for the simultaneous injection and removal of fluid from droplets flowing through a system. It addresses a significant gap in droplet microfluidics where fluid exchange in a continuous and high-throughput manner is underdeveloped. With innovative design and operational parameters, it achieves a throughput of 1KHz, which is a tenfold increase over existing methods that are limited to about 100Hz and primarily focus on adding fluids or transferring contents rather than exchanging them.

**Applications:** This technology has potential applications in high-throughput environments such as single-cell transcriptomics, genomics, and proteomics, where efficient fluid exchange is crucial for analyzing biological samples and conducting various assays.

**Problem Solved:** The device resolves the limitations of current droplet microfluidic technologies by enabling efficient fluid exchange at a significantly higher throughput, thereby enhancing the capabilities for experiments that require rapid processing of large sample volumes.","The device allows for the simultaneous injection of fluid into and removal of fluid from droplets in a continuous flow, high-throughput manner. This advancement addresses the underdeveloped operation of fluid exchange in droplet microfluidics, which is crucial for applications in single-cell transcriptomics, genomics, and proteomics."
"University of Pennsylvania","AI-Powered Optical Tool for Fluorescence-Guided Oncological Surgery","","","https://upenn.technologypublisher.com/technology/51036","Problem:When a patient is diagnosed with cancer, fluorescence-guided surgery is often their best treatment option. This highly successful procedure uses an inert near-infrared dye to discern tumors from healthy cells. However, every potential tumor must be checked by an oncologist. This step adds upwards of 30 minutes and costs thousands of dollars per potential tumor.Solution:The authors developed OptiDX, a smart camera powered by AI to evaluate tumor fluorescence in real time. This tool provides immediate and accurate tumor identification without the frozen section staining process normally required.Technology:Fluorescence-guided methods are powerful tools to identify tumors as small as 2mm in length. The diversity of shapes, sizes, and intensities among differing health populations makes direct fluorescence evaluation difficult. Thus, the authors employed deep learning and computer vision toolkits to predict cancer probability from fluorescence, demographic, and co-morbidity data.Advantages:Identifies tumors immediately, saving over 30 minutes and thousands of dollars per tumor per operation.Requires energies under 0.1 eV, significantly lower than the operating room lights.Reliable and consistent algorithm eliminates observer bias.Area under receiver-operating curve is 0.897, close to a perfect score of 1.0, indicating few false positives and false negatives.Intuitive and easy to useStage of Development:ConceptIntellectual Property:Patent Application In ProcessReference Media:Singhal, SunilJAMA Surg., 2016 Feb, 151 (2) : 184Desired Partnerships:LicenseCo-developmentCase ID:21-9623-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51036","**Summary:**  
The technology is a smart camera known as OptiDX, designed to enhance fluorescence-guided surgical procedures for cancer treatment by utilizing artificial intelligence to analyze tumor fluorescence in real time. This innovative tool eliminates the need for the traditional frozen section staining process, providing immediate and accurate identification of tumors.

**Applications:**  
OptiDX is intended for use during oncological surgeries to improve the accuracy and efficiency of tumor identification, significantly benefiting surgical teams in the operating room.

**Problem Solved:**  
The solution addresses the time-consuming and costly procedure of manually assessing potential tumors by oncologists, which can extend surgery by over 30 minutes and add significant expenses. By streamlining the identification process and mitigating observer bias, the AI-powered tool not only enhances surgical outcomes but also reduces the overall cost and duration of surgical procedures.","Fluorescence-guided surgery is an effective treatment for cancer, but requires oncologists to manually check potential tumors, resulting in significant time and cost. The authors created OptiDX, an AI-powered smart camera designed to evaluate tumor fluorescence in real time, streamlining the surgical process."
"University of Pennsylvania","Amniotic Fluid Stabilized Lipid Nanoparticles (LNPs) for In Utero Intra-Amniotic mRNA Delivery","","","https://upenn.technologypublisher.com/technology/51037","Nanoparticles for potent encapsulation and delivery of therapeutic molecules for prenatal fetal therapy in the amniotic sacProblem:Many prenatal genetic diseases suffer from ineffective postnatal treatments. For this reason, therapies that are delivered to the fetus before birth hold promise to treat diseases prior to or in the early stages of pathology and reduce disease burden, morbidity, and mortality. Viral vectors can deliver nucleic acids to the fetus for prenatal protein and enzyme replacement; however, they have limitations regarding immunogenicity, genomic integration, and repeat dosing. Non-viral nucleic acid delivery methods avoid these risks yet face challenges with rapid nucleic acid degradation and hindered transport into cells.Solution:A lipid nanoparticle nucleic acid delivery system was developed that remains stable upon delivery in utero and potently delivers nucleic acid material intracellularly, providing robust protection and delivery of cargo to fetal tissues in contact with amniotic fluid.Technology:Ionizable lipid nanoparticles are made by mixing ionizable lipid B-4, cholesterol, DOPE, and PEG2000 with an aqueous phase containing messenger RNA (mRNA). Both phases are mixed at controlled flow rates in a microfluidic device to generate the mRNA-loaded nanoparticles. The mRNA is tailored to encode for the protein/enzyme of interest required in the fetal tissue. After screening for stability and potency in amniotic fluid, selected nanoparticles are delivered in utero through controlled injection into the amniotic sac.Advantages:Prevents off-target mutations by not integrating with genomic DNAStable in amniotic fluid (from. mouse, sheep, pig, and human)Enhanced cellular uptake for potent intracellular delivery of therapeutic cargoAchieves nucleic acid delivery in fetal lungs, intestines, liver, and other tissues in direct contact with amniotic fluidOverview of LNP library design, formulation, and ex utero screening in amniotic fluids to predict intra-amniotic delivery. A library of 16 LNP formulations was generated using orthogonal design of experiments (DOE) to explore four molar ratios of each of four excipients. Next, each LNP was synthesized by combining an ethanol phase of lipid excipients ‚Äì including ionizable lipid, DOPE phospholipid, cholesterol, and lipid-PEG ‚Äì with an aqueous phase containing luciferase mRNA. The two phases were mixed at controlled flow rates in a microfluidic device to form LNPs. Then, LNPs were screened ex utero in fetal fluids to identify stable and unstable LNPs for intra-amniotic delivery.Stage of Development:Proof of ConceptIntellectual Property:PCT Application FiledReference Media:Riley et al.Sci Adv, 2021, 7(3):eaba1028.Swingle et al.Journal of Controlled Release, 2022 Jan, 341: 616.Desired Partnerships:LicenseCo-developmentCase ID:21-9713-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51037","**Summary:** The technology involves the development of lipid nanoparticles designed for the encapsulation and delivery of therapeutic nucleic acids, particularly mRNA, for prenatal treatment of genetic diseases within the amniotic sac. By utilizing ionizable lipids in conjunction with cholesterol, DOPE, and PEG2000, these nanoparticles can effectively protect and transfer nucleic acids to fetal tissues, ensuring stability and potency within the amniotic fluid environment.

**Applications:** This delivery system has potential applications in treating a range of prenatal genetic disorders by enabling timely intervention before birth. It allows for protein and enzyme replacement therapy at the fetal stage, reducing disease burden and improving the long-term health outcomes of affected pregnancies.

**Problem Solved:** The technology addresses the limitations of postnatal treatments for genetic diseases, which are often inadequate, by providing a safer, effective non-viral method for in utero therapy. This approach minimizes the risks associated with viral vectors, such as immunogenicity and genomic integration, while overcoming challenges related to rapid degradation of nucleic acids and cellular uptake.","Amniotic fluid stabilized lipid nanoparticles (LNPs) provide an innovative method for delivering therapeutic molecules to the fetus in utero, potentially addressing genetic diseases before birth. This approach aims to improve outcomes by treating conditions prior to the onset of symptoms and reducing the associated disease burden."
"University of Pennsylvania","Stretchable, Adhesive, and Self-Healing Hydrogels for Next-Generation Medical Adhesives","","","https://upenn.technologypublisher.com/technology/51047","A hydrogel that can naturally stretch and self-heal while adhering to the body, enabling new designs for medical adhesives.Problem:Hydrogels are naturally biocompatible materials which could revolutionize diverse medical technologies ranging from artificial muscles to wearable electronics. Their simple non-toxic composition along with their non-rigid structure allows the material to easily conform to the human body. Hydrogels, however, could have poor stretchability, weak adhesion (especially when wet), and limited self-healing mechanisms. This prevents their use in spaces like the cranial cavity, where electronic signals could be administered to treat seizures.Technology:First, polyvinyl alcohol is dissolved in a buffer solution. Then, boronic acid and optional chitosan is added, resulting in a thick hydrogel. Additives like dyes or conductive MXene sheets can be added for extra functionality such as increased electric conductivity. The dynamic boronic ester bonds enable bond exchanges which promote high strength and fast healing at defect sites. The bonds in chitosan allow quick adhesion in air or water alike.Advantages:Stretchable up to 310 times original length.Chitosan enables strong adhesion in air or water.Self-healing within 5 seconds.May be imbued with MXenes or carbon nanotubes to achieve conductivity around 30 ŒºS/cm.May be encapsulated with drugs or dyes.Non-toxic composition.Requires simple mixing of inexpensive ingredients, leading to low manufacturing costs.The hydrogel comprises polyvinyl alcohol dynamically crosslinked with boronic acid (left), with additional chitosan to provide extra strength and wet adhesion (right). A typical recipe has a 15:1 weight ratio of PVA to BA with around 2 wt% chitosan. This provides extreme stretchability, natural adhesion in both air and water, and nearly instant self-healing.Stage of Development:ConceptProof of ConceptIntellectual Property:In PreparationReference Media:Driscoll, N. et al.Curr Opin Biotechnol, 2021 December 72: 76.Desired Partnerships:LicenseCo-developmentCase ID:22-10027-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51047","**Summary:** A novel hydrogel has been developed that possesses the capabilities of stretchability, self-healing, and strong adhesion, facilitating innovative applications in medical adhesives. This hydrogel is made by dissolving polyvinyl alcohol in a buffer and adding boronic acid, with optional chitosan for enhanced properties. It exhibits exceptional stretchability, being able to expand up to 310 times its original length, and provides strong adhesion whether in air or underwater due to the chitosan component. The hydrogel heals quickly at damage sites, with a self-healing time of approximately 5 seconds, and can be enhanced with additional materials like MXenes for increased electrical conductivity.

**Applications:** The hydrogel is suitable for a variety of medical applications, particularly in areas requiring flexible and durable adhesives such as cranial cavity treatments, wearable electronics, and potentially in the development of artificial muscles due to its biocompatibility and conformability to the human body.

**Problem Solved:** Traditional hydrogels face challenges such as limited stretchability, weak adhesion in wet conditions, and subpar self-healing mechanisms, which restrict their effectiveness in critical medical environments. The new hydrogel addresses these issues, making it viable for use in delicate medical applications that require reliable adhesion and the ability to endure dynamic conditions.","A newly developed hydrogel is capable of stretching, self-healing, and adhering to the body, presenting innovative possibilities for medical adhesives. While hydrogels are biocompatible and can conform to the human body, they often face challenges with stretchability and adhesion strength."
"University of Pennsylvania","Simple Polymer Mesogen to Create Stable Nanoporous Crystals for Filtration, Catalysis, and Ion Transport","","","https://upenn.technologypublisher.com/technology/51038","A polymer mesogen which self-assembles into a stable cubic nanoporous liquid crystal, for use in filtration, catalysis, and ion transport.Problem:Cubic nanoporous liquid crystals (CNLCs) are ordered materials with nanoscale holes created using polymers called mesogens. CNLCs hold extraordinary promise in nanoscale filtration, with obvious applications in filtering salt or organic solvents from water. CNLCs also have catalytic applications, such as hosting Bronsted acid sites in petroleum hydrocracking. Further, CNLCs offer highly selective, temperature-independent lithium ion conductivity in liquid electrolyte batteries. Unfortunately, CNLCs require complicated mesogens and are often unstable. This severely limits their commercial and industrial applicability. Achieving robust molecular selectivity in harsh operating environments holds the key to unlocking the next generation of these wide-ranging technologies.Solution:The authors created a simple single-head/single-tail polymer mesogen that can assemble into stable CNLCs. This mesogen is easy to manufacture, cross-links itself upon UV light exposure, and creates CNLCs that are stable when exposed to heat, water, acids, and bases. This requires no co-monomers or cross-linkers, unlike prior single-head/single-tail monomer systems.Technology:Previous CNLC mesogen designs incorporated a single-head/single-tail structure which was straightforward to produce, but required complicated chemical stabilizers and crosslinkers to form a CNLC. This technology leverages a polymerizable methacrylamide group near the single ionic headgroup and a polymerizable diene group in the single hydrophobic tail. This mesogen can self-crosslink with a simple photoinitator and UV light and remains stable to elevated temperatures and submersion in water, acids, and bases for extended periods.Advantages:Mesogen assembles stable CNLC with nanoscale gaps of size 1.5 nmSimple single-head, single-tail design takes just 3 hours to crosslink ‚Äì significantly shorter than other CNLC methods which process overnightPressure-driven filtration of vitamin B12 attains 98% solute rejection, indicating strong potential in organic solvent filtrationCaptures 90% of negatively charged molecules with size 0.7 nm but 0% of negatively charged molecules with size 1.9 nm, exhibiting robust size selectivity for ion transportationStable up to temperatures of at least 210¬∞C and upon exposure to 1N NaOH or 1N HCl for 96 hoursThe mesogen designed by the authors includes a polymerizable methacrylamide group near an ionic headgroup and a polymerizable diene group in a hydrophobic tail. The structure cross-links and self-assembles into a cubic nanoporous liquid crystal (CNLC). This CNLC contains a gyroid structure with nanometer-scale gaps created by the hydrophilic and hydrophobic portions of the mesogens.Stage of Development:ConceptProof of ConceptIntellectual Property:US Patent PendingReference Media:Imran et al.,Chem Comm, 2021, 57 (83): 10931.Desired Partnerships:LicenseCo-developmentCase ID:22-9802-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51038","**Summary:** A novel polymer mesogen has been developed that self-assembles into stable cubic nanoporous liquid crystals (CNLCs). These materials exhibit ordered nanoscale holes and demonstrate robustness against harsh conditions, including heat, water, acids, and bases. The simplicity in design allows for easier manufacturing and eliminates the need for co-monomers or external cross-linkers commonly required in previous CNLC systems. 

**Applications:** The stable cubic nanoporous liquid crystals created from this polymer mesogen are intended for use in various fields, including filtration for removing salts and organic solvents from water, catalytic processes like petroleum hydrocracking, and enhancing lithium-ion conductivity in liquid electrolyte batteries.

**Problem Solved:** The technology addresses the instability and complexity of earlier cubic nanoporous liquid crystal systems, which hindered their commercial and industrial use by introducing a more straightforward and reliable polymer mesogen that self-cross-links, thereby enabling robust performance in demanding environments.","A polymer mesogen self-assembles into stable cubic nanoporous liquid crystals (CNLCs) that possess nanoscale holes. These materials have potential applications in filtration, catalysis, and ion transport."
"University of Pennsylvania","Controlled Levitation of Nanostructured Thin Films for Sun-Powered Near-Space Flight","","","https://upenn.technologypublisher.com/technology/51039","Levitation of polymer nanocomposite film upon illumination in upper atmospheric conditions.Problem:Airborne objects cannot sustain flight within the mesosphere, the upper layer of the Earth‚Äôs atmosphere. This layer, which resides 50-80km above the Earth‚Äôs surface, lacks the air density needed for airplane lift yet is too dense for satellite orbit. While unoccupied by airborne objects, the mesosphere is a critical resource for surveillance and climate research. Therefore, the ability to sustain flight in the mesosphere is needed for atmospheric data collection and airspace monitoring.Solution:The microscale disks can levitate with illumination. This levitation is sustained under mesospheric pressures and light intensities. The direction of incident light does not affect levitation, allowing for these disks‚Äô real-world applications within the Earth‚Äôs atmosphere. These disks may withstand micro-payloads such as weather sensors that collect atmospheric data.Technology:Photophoresis uses light to displace gas or liquid particles. This particle movement can result in propulsive forces that lift objects. This photophoretic lifting force is often driven by temperature gradients between the top and bottom of an object. However, this force can also originate from varied surface topologies of an object‚Äôs top and bottom surfaces. The inventors leverage this phenomenon by creating mylar disks of submicron thickness. The bottoms of these disks are coated in carbon nanotubes (CNTs). Upon illumination, these CNT networks trap air molecules, which collide with multiple surfaces before escaping with higher velocity. This difference in molecule velocity creates a lifting force that levitates the ultrathin disks.Advantages:Disk levitates under 0.5 W/cm2 incident light intensity, comparable to natural sunlightLevitation achieved under ~10 Pa pressure, comparable to mesospheric pressuresDisk levitation can be controlled and ‚Äútrapped‚Äù by casting rings of higher light intensityDisks may withstand up to 10 mg payloadOverview of disk and levitating mechanism (A) Schematic of disk surface topology and propulsive force mechanism. While air molecules have single collisions with the disk‚Äôs smooth top surface, the carbon nanotubes (CNTs) coating the bottom surface trap incoming air molecules. This leads to multiple collisions and increased escape velocity, which creates an upward lift force on the disk. (B) Macroscale photo of CNT-coated mylar disks, which are ~6mm in diameter. (C) Electron micrograph of top and bottom disk surface topology. While the top mylar surface is smooth, the CNT-coated bottom surface creates a nanofiber network that traps air molecules. (D) Video screenshots in which two disks levitate upon illumination.Stage of Development:Proof of ConceptIntellectual Property:Provisional Application FiledResearch MaterialsReference Media:Azadi, M et al.Sci Adv, 2021 Feb 12, 7(7):eabe1127.Desired Partnerships:LicenseCo-developmentCase ID:20-9390-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51039","**Summary:** The technology involves the levitation of polymer nanocomposite films when illuminated in upper atmospheric conditions, specifically designed for the mesosphere, which exists at an altitude of 50-80 km above the Earth's surface. This region lacks sufficient air density for conventional flight, presenting challenges for airborne objects. The invention utilizes microscale disks that can levitate under the conditions unique to the mesosphere, enabling the incorporation of micro-payloads such as weather sensors to facilitate atmospheric data collection and airspace monitoring. The method relies on photophoresis, where light generates propulsive forces due to temperature gradients or surface topology differences, with the specially designed mylar disks coated in carbon nanotubes to optimize performance.

**Applications:** The technology could be used for surveillance, climate research, and atmospheric data collection in the mesosphere. Its ability to maintain levitation under specific pressures and light conditions allows for the integration of sensors to monitor weather patterns and atmospheric conditions without the need for traditional aircraft.

**Problem Solved:** The technology addresses the challenge of sustaining flight in the mesosphere, a region critical for both scientific research and airspace monitoring, where traditional airborne vehicles cannot operate due to insufficient lift. By enabling levitation with minimal weight, it provides a solution for gathering necessary atmospheric data in this otherwise inaccessible layer of the atmosphere.","The study explores the levitation of polymer nanocomposite films when illuminated, addressing the challenge of maintaining flight in the mesosphere, which has insufficient air density for traditional aircraft lift. This capability could enable surveillance and climate research in this critical upper atmospheric layer, located 50-80 km above the Earth's surface."
"University of Pennsylvania","Treatment for the Prevention of Permanent Vision Loss in Glaucoma Patients","#20-9435","","https://upenn.technologypublisher.com/technology/51048","Problem:Glaucoma is the number one cause of irreversible blindness worldwide. High pressure in the eye can lead to optic nerve damage, which can progress to permanent vision loss. For this reason, reduction of intraocular pressure is the main therapeutic mechanism available. Unfortunately, glaucoma can continue to progress even in patients with normalized intraocular pressure. Therefore, there is an urgent need for the development of new therapeutic approaches with distinct mechanistic targets that prevent vision loss in glaucoma patients.Solution:Targeting glucagon-like peptide 1 receptor (GLP1-R) prevents the cellular death responsible for vision loss in glaucoma. Even in cases where intraocular pressure remains elevated, the therapeutic is able to improve the survival of cells required for vision.Technology:Pro-inflammatory astrocytes in glaucoma contributes to the death of retinal ganglion cells, which make up the optic nerve and are required for vision. Reduction of intraocular pressure does not prevent activation of these astrocytes. Investigators identified that targeting GLP1-R in a mouse model of glaucoma reduces ocular inflammation and prevents the damaging effects of these astrocytes, thereby rescuing retinal ganglion cells.Advantages:Reduces expression of pro-inflammatory factors in resident microglia and infiltrating macrophages (IL-1a, TNF-a, C1q)Improves retinal ganglion cell survival in environment of elevated intraocular pressure (~25% after 42 days in mouse model of glaucoma)Stage of Development:In vivo proof of conceptIntellectual Property:US PatentpendingReference Media:Sterling, J et al.Cell Rep, 2020 Nov 3, 33(5): 108271Sterling, J et al.Br J Ophthalmol, 2023 Feb; 107(2): 215Desired PartnershipsLicenseCo-developmentCase ID:20-9435-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51048","**Summary:** This technology addresses the prevention of permanent vision loss in glaucoma patients by targeting the glucagon-like peptide 1 receptor (GLP1-R). Glaucoma is the leading cause of irreversible blindness, primarily due to high intraocular pressure which damages the optic nerve. Furthermore, glaucoma can progress despite normalized intraocular pressure, indicating the need for alternative therapeutic strategies. The identified approach mitigates the death of retinal ganglion cells caused by pro-inflammatory astrocytes, reducing ocular inflammation and enhancing cell survival even under elevated intraocular pressure conditions.

**Applications:** The technology can be applicable in clinical settings for the treatment of glaucoma patients, particularly in those who continue to suffer vision loss despite conventional pressure-lowering therapies. It could lead to new pharmacological interventions aimed at preserving vision by targeting specific inflammatory pathways associated with glaucoma-related cellular damage.

**Problem Solved:** The technology addresses the challenge of continued vision loss in glaucoma patients, particularly when traditional treatments fail to manage intraocular pressure effectively. By focusing on the cellular mechanisms of damage caused by inflammatory responses, this approach aims to preserve retinal ganglion cells and prevent irreversible blindness.","Glaucoma is the leading cause of irreversible blindness globally, primarily due to high intraocular pressure causing optic nerve damage. While reducing intraocular pressure is the main treatment, glaucoma can still progress even when pressure is normalized, highlighting the need for new therapeutic strategies."
"University of Pennsylvania","Platform Technology for Cell Engineering and Cell Programming","","","https://upenn.technologypublisher.com/technology/51040","A platform technology utilizing synthetic organelles to modulate cell cycle, cell behavior, and stemness/differentiation status which could be used for cell engineering, cell therapy etc.TechnologyCells compartmentalize enzymes and their substrates into organelles to insulate or facilitate biochemical reactions. The ability to artificially construct organelles in cells can allow for modification of cellular behavior and to control of cellular activity.Dr. Matthew Good, PhD and his team at the Medical School of the University of Pennsylvania developed a platform approach for generation of membraneless organelles in human cells allowing them to regulate endogenous cellular activities through sequestration and insulation of native proteins. The inventors were able to efficiently control cellular behavior including proliferation, division, and cytoskeletal organization, and regulate the on-off state using light and heat. The invention allows for engineering of cells with built-in reversible switch regulating cellular behaviors. The technology can have a broad range of use from research tools for cellular studies to a synthetic controllable hub for immunotherapy and stem-cell therapy.AdvantagesReversibilityApplicationsCellular engineering and cell therapyPluripotency inductionCell differentiationCell cycle controlSchematic overview assembling synthetic organelles from disordered scaffold proteins to target clientsStage of Development:Preclinical DiscoveryIntellectual PropertyPCTPendingReference MediaGarabedian, MV et al.Nat Chem Biol 2021 Sept, 17(9): 998Desired PartnershipsLicenseCo-DevelopmentCase ID:22-9807-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51040","**Summary:** A platform technology has been developed that employs synthetic organelles to modulate the cell cycle, cell behavior, and stemness/differentiation status in human cells. This approach enables the artificial construction of membraneless organelles, which can manipulate endogenous cellular activities by sequestering and insulating native proteins. Researchers led by Dr. Matthew Good at the University of Pennsylvania have demonstrated the technology's ability to regulate cellular behavior, including proliferation, division, and cytoskeletal organization, with control achieved through light and heat. This invention introduces a reversible switch mechanism for altering cellular actions.

**Applications:** The technology has potential applications in cellular engineering, cell therapy, pluripotency induction, cell differentiation, and cell cycle control. It serves as a valuable tool for cellular studies and can function as a synthetic, controllable hub for immunotherapy and stem-cell therapy.

**Problem Solved:** The technology addresses the need for precise control over cellular behavior and the ability to engineer cells with reversible functionality, thereby facilitating improvements in therapies and research methodologies involving cell manipulation.","A platform technology employs synthetic organelles to modulate cell cycle, behavior, and differentiation status, enabling applications in cell engineering and therapy. This technology allows for the artificial construction of organelles, which can modify cellular behavior and control activity."
"University of Pennsylvania","Spine TK: Deep Learning AI Toolkit for Spine Health Assessment","","","https://upenn.technologypublisher.com/technology/51041","Fast quantification of spine fractures, curvature, vertebral deformities, vertebral texture, vertebral strength, bone density, and intervertebral disk measurements using CT, MR, DXA, PET, or X-ray images for evaluation of spine health and surgery planning.Problem:Bone mass and quality deficiencies are the leading cause of bone disease in the United States. Vertebral fractures attributed to poor bone quality (e.g., osteoporosis) are a major medical concern that may require surgical treatment and often result in physical disability. Unfortunately, use of medical imaging leads to detection of only one third of vertebral deformities/fractures as vertebral measurements are generally obtained by radiologists and orthopaedic surgeons by manual annotation of vertebrae. Patients undergoing spine surgeries or those at risk for osteoporosis could benefit from state-of-the-art spine health analysis.Technology Overview:The invention is an automated, neural network used for analysis of the vertebral bodies on spine MR, CT, PET, or X-ray imaging. This approach allows to determine vertebra-by-vertebra deformity including scoliosis and lordosis as well as to monitor changes in bone strength, density, and structures over time. It allows for simultaneous intervertebral disk measurements and can be used for the diagnosis of disk degeneration and spine fusions. The invention presents an opportunity for early diagnosis of vertebral health which would permit early interventions, could be useful for spine surgery planning, intra-operative surgical decision making, and robotic surgical guidance.Advantages:Saves time for radiologists and orthopaedic surgeonsAvoids subjectivity introduced by manual measurementsBasic overview of the method.Stage of Development:The AI model is fully trained, tested, and validated using a large number of real-world spine images of patients. Fully functional software had been developed.Intellectual Property:US PatentPendingReference Media:Suri, A et al.;Radiol Artif Intell 2023 June 21; 5(4): e220158Suri, A et al.,Bone, 2021 Aug, 149: 115972Suri, A et al.,Radiol Artif Intell, 2022 Jan 4(1):e210015Desired Partnerships:LicenseCo-developmentCase ID:21-9508-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51041","**Summary:** This technology utilizes an automated neural network for the analysis of vertebral bodies in CT, MR, PET, or X-ray imaging, enabling the quantification of spine fractures, curvature, deformities, and bone quality. It facilitates the assessment of vertebral strength and bone density, as well as intervertebral disk measurements, allowing for a comprehensive evaluation of spine health and aiding in surgery planning.

**Applications:** The toolkit can be used for the early diagnosis of vertebral health issues, monitoring of bone strength and density changes, assessment of scoliosis and lordosis, diagnosis of disk degeneration, and planning for spinal surgeries.

**Problem Solved:** The technology addresses the challenge of detecting vertebral deformities and fractures, which are often missed in manual evaluations by radiologists and orthopaedic surgeons. It aims to improve detection rates and management of conditions related to poor bone quality, such as osteoporosis, thereby potentially reducing the incidence of surgical interventions and associated physical disabilities.","The toolkit enables fast quantification of spine fractures, curvature, vertebral deformities, and other spine health metrics using various imaging modalities. It addresses bone mass and quality deficiencies, particularly vertebral fractures linked to conditions like osteoporosis, which are significant medical concerns requiring potential surgical intervention."
"University of Pennsylvania","Rapid manufacturing of soft, comfortable electrodes","","","https://upenn.technologypublisher.com/technology/54404","Rapid, low-cost, and scalable production of comfortable electrode arrays suitable for measuring biosignalsProblem:Medical electrodes convert ionic currents within the human body into electric currents used to diagnose and monitor diseases. The global medical electrode market is currently valued at over $1B and continues to grow in response to new applications for these devices. Solutions-based processing methods are limited by a lack of conductive and biocompatible inks, making it difficult to produce electrodes with the same performance quality as metallic electrodes. Current fabrication processes are time-consuming, costly, and small in size. They are also incompatible with CT and MRI imaging.Solution:MXtrodes are bioelectric interfaces with low-cost, scalable production. These large-area multichannel electrode arrays have an electrochemical performance on par with that of Pt electrodes. MXtrode geometries can be customized to different applications and patient size. They can function gel-free and are compatible with CT and MR imaging.Technology:MXtrodes are made by patterning an absorbent material with a laser cutter and infusing laser-cut segments with a conductive ink. PDMS or an alternative rubber is poured directly onto the treated cloth and allowed to penetrate fully into the pores in order to introduce strength and flexibility. Electrode openings are exposed manually using a 3mm biopsy punch. The MXtrodes were shown to have reduced impedance and higher cathodal charge storage capacity compared to standard Pt electrodes.Advantages:Compatible with many different material combinationsEasy modification of electrode array patterning due to laser manufacturingLonger battery life than Pt electrodes due to more efficient charge transferReduced manufacturing costCompatible with CT and MR imagingFigure (a) shows the process of fabricating laser-patterned planar and 3D pillar MXene electrode assays. Figures (b)-(e) show various electrode array arrangements and their intended applications, including EMG (b), ECG (c), EEG (d), and ECoG monitoring (e).Stage of Development:Wearable PrototypesIntellectual Property:Australian, Canadian, European, Japanese, Hong Kong, US PatentsPendingDesired Partnerships:LicenseCo-developmentCase ID:19-9002-TpNCSWeb Published:6/11/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54404","**Summary:** Rapid and low-cost production methods for comfortable electrode arrays have been developed, enabling scalable manufacturing of biosignal measuring devices. The MXtrodes exhibit electrochemical performance comparable to platinum electrodes and can be customized for various applications and patient sizes. They also feature gel-free functionality and compatibility with CT and MRI imaging.

**Applications:** The primary application of this technology is in the medical field, specifically for the diagnosis and monitoring of diseases through the measurement of biosignals. The customizable nature of the MXtrodes allows them to be used across different patient demographics and specific medical requirements.

**Problem Solved:** The technology addresses the limitations of current medical electrode production, which is hindered by the scarcity of conductive and biocompatible inks, high costs, lengthy fabrication processes, and size constraints. By offering a scalable solution that matches or exceeds the performance of traditional metallic electrodes, it improves the usability and effectiveness of biosignal monitoring while ensuring safety with imaging techniques.","The text discusses the development of rapid, low-cost, and scalable production methods for comfortable electrode arrays that measure biosignals, addressing a market valued at over $1 billion. It highlights the challenges in producing these electrodes due to the limited availability of conductive and biocompatible inks."
"University of Pennsylvania","Effective and pain-reducing foot device to treat pain and loss of feeling from diabetic neuropathy","","","https://upenn.technologypublisher.com/technology/43113","Implantable foot device to restore feeling and reduce pain associated with diabetic nerve complications.Problem:Sixty to seventy percent of the 400 million diabetes patients worldwide suffer from nerve complications like distal sensory polyneuropathy (DSP), which is characterized by foot pain and loss of feeling. If left unchecked DSP progresses, resulting in gait instability, falls, and can even lead to amputation. Current treatments are limited, consisting of either pain medication or biofeedback devices to alleviate sensory loss. No individual therapeutic addresses both pain and sensory issues simultaneously. To further complicate matters, all current methods suffer from lack of patient compliance (as low as 36%).Solution:In response, the inventors developed a nerve stimulation device that treats both pain and loss of feeling. In addition, as an implantable device there are no compliance issues.Technology Overview:The inventors designed a minimally invasive implantable system to activate nerves in the leg in response to pressure on of the foot. The device is composed of two implantable components: a pressure sensor implanted under the skin on the bottom of the foot, and a battery-powered base unit implanted in the thigh connected to the leg nerves. When the foot sensors detect pressure, they wirelessly transmit signals to the base unit to provide nerve stimulation as therapy.Advantages:Treats both the pain and loss of feeling associated with DPS simultaneously, unlike current treatments which target each concern separatelyImplant circumvents patient noncompliance, resulting in more comprehensive treatmentGreatly reduces the risk of diabetic foot ulcers and diabetes-associated amputationProposed device for DSP. Pressure signals from subcutaneous sensors in the numb foot wirelessly drive electrical stimulation of peripheral nerves near the knee and result in therapeutic sensory feedback.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:21-9530-tpNCSWeb Published:3/4/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/43113","**Summary:** The technology is an implantable device designed to alleviate foot pain and restore sensation in patients suffering from diabetic nerve complications, specifically distal sensory polyneuropathy (DSP). It consists of a pressure sensor implanted in the foot and a battery-powered base unit implanted in the thigh, which stimulate nerves in response to pressure detected by the foot sensor. This minimally invasive solution addresses both pain and sensory loss simultaneously and eliminates patient compliance issues commonly associated with current treatments.

**Applications:** This device can be applied to patients with diabetic neuropathy, particularly those experiencing foot pain and loss of feeling, helping to improve their quality of life and potentially reduce the risk of complications like falls and amputations.

**Problem Solved:** The technology addresses a significant gap in current diabetic neuropathy treatments by providing a dual solution for pain and sensory loss, targeting the limitations of existing therapies that typically focus on either symptom management or sensory loss without addressing both at once.","A novel implantable foot device has been developed to restore feeling and alleviate pain associated with diabetic nerve complications, particularly distal sensory polyneuropathy (DSP), which affects 60-70% of the 400 million diabetes patients globally. Current treatment options are limited to pain medication or biofeedback therapies."
"University of Pennsylvania","Tumor Suppression by Retinoic Acid Pathway Inhibition","","","https://upenn.technologypublisher.com/technology/54474","Targeting retinoic acid (RA) synthesizing enzymes or RA receptors with small molecules boosts the immune system towards a tumor rejection responseProblem:Hepatocellular carcinoma (HCC) is the most common liver cancer globally. In the US alone, 33 000 patients are diagnosed yearly, 27 000 of which will die. Once metastasized, HCC shows a grim 5-year survival rate of 2%. Though immunotherapy has shown promise against several cancer types, it has thus far shown poor efficacy against HCC. There remains an unmet clinical need for better therapies against HCC.Solution:Researchers at the Perelman School of Medicine found that the RA pathway is crucial in modulating the immune response against tumors. Dr. Haldar and his team have found that inhibiting this pathway, either alone or combined with immunotherapy, promotes a tumor-rejecting immune response.Advantages:Efficient against aggressive cancers such as HCCTargets a specific isoform (RALDH1) to minimize side-effects from broader range inhibitors (e.g. that inhibit RALDH1, 2 and 3)Synergizes with immune checkpoint blockade (ICB) therapy to reduce ICB-resistant tumor size by over 50%Overview of retinoic acid (RA) pathway in solid tumor biology and compound #86 mechanism of action. Many solid tumors produce high levels of RA that inhibit the formation of tumor-suppressive dendritic cells (DCs) through activation of the RA and retinoid X (RX) receptors. It instead promotes the differentiation of tumor-permissive macrophages, thus allowing tumor persistence and growth. When RA synthesis (by targeting RALDH1 with C-86) and/or signaling (by inhibiting RAR/RXR) is inhibited, monocytes differentiate into DCs that activate T cells, which in turn kill tumors such as hepatocellular carcinoma (HCC). Shifting the tumor microenvironment balance through inhibition of RA production is therefore desirable from a therapeutic perspective. Moreover, this approach can be combined to checkpoint inhibitors to enhance immune checkpoint blockage therapy.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:PCT FiledReference Media:Devalaraja, S. et al.;Cell 2020 Mar 19 180(6): 1098.Desired Partnerships:LicenseCo-developmentCase ID:21-9539-TpNCSWeb Published:6/21/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54474","**Summary:** Researchers have identified that targeting the retinoic acid (RA) pathway plays a critical role in enhancing the immune response against tumors, particularly hepatocellular carcinoma (HCC), a prevalent and aggressive liver cancer with a low survival rate once metastasized. By focusing on inhibiting specific enzymes responsible for RA synthesis or the RA receptors, the immune system can be potentiated to reject tumors more effectively. This approach not only facilitates a stronger immune reaction but can also be combined with existing immunotherapies to improve outcomes in patients with HCC.

**Applications:** The technology is primarily applicable in treating hepatocellular carcinoma, especially in cases resistant to traditional immunotherapy. It may also have potential applications in other solid tumors known to produce high levels of retinoic acid, where manipulation of the RA pathway could enhance immunotherapeutic efficacy.

**Problem Solved:** This approach addresses the urgent clinical need for improved therapeutic strategies against hepatocellular carcinoma, a cancer that has demonstrated poor responses to current immunotherapy options, thereby aiming to increase survival rates and offer a viable treatment alternative for affected patients.","Targeting retinoic acid synthesizing enzymes or receptors with small molecules enhances the immune system's ability to reject tumors. Hepatocellular carcinoma (HCC) is the most common liver cancer worldwide, with 33,000 diagnoses and 27,000 deaths annually in the US, and a 5-year survival rate of only 2% once metastasized."
"University of Pennsylvania","Site-blocking oligos (SBO) upregulate utrophin for treatment of Duchenne Muscular Dystrophy (DMD","","","https://upenn.technologypublisher.com/technology/51043","Synthetic oligonucleotides blocking natural degradation of utrophin to treat muscular dystrophy.Problem:Duchenne Muscular Dystrophy (DMD) is a severe form of muscular dystrophy affecting males. A genetic mutation causes decreased production of dystrophin, a critical protein connecting cells to surrounding tissue. This leads to improper muscle development and muscle loss. Patients suffer from motor and respiratory impairment, and many people afflicted with DMD do not survive beyond their 20s. One strategy to treat DMD is to increase utrophin, a protein with similar structure and function to dystrophin. However, current strategies to artificially upregulate utrophin have not progressed clinically, because they fail to prevent the natural degradation of utrophin mRNA following transcription.Solution:The solution is a set of synthetic site-blocking oligonucleotides (SBO) which inhibits natural degradation of utrophin mRNA. These SBOs block downregulation of utrophin, increasing its expression in muscle cells which alleviates DMD symptoms. The invention works by binding to a site in utrophin mRNA which is usually targeted for degradation. Utrophin-upregulating SBOs may be used in combination with other upregulation strategies to further increase cellular expression of therapeutic utrophin.To increase production of therapeutic utrophin in muscle cells, a set of five SBOs ranging from 24-29 base pairs were synthesized. All SBOs target the same utrophin mRNA 3‚Äô-UTR region. The SBOs increase utrophin expression by hybridizing to the Let-7c microRNA binding site. This prevents Let-7c microRNA from binding to utrophin mRNA and facilitating degradation through the RNA-induced silencing complex. Utrophin-upregulating SBOs are created using a nucleic acid mimic known as a phosphorodiamidate morpholino oligonucleotide (PMO) to decrease undesirable toxicity and increase tissue accumulation.Advantages:- Higher binding affinity and tissue concentration compared to other oligo alternatives- Endogenous utrophin signal increases by 1.5-fold for 48 hours in vitro- Two-fold higher utrophin protein expression in skeletal muscles in DMD mouse modelSchematic representation of the PMO-based SBO strategy to alleviate repression of utrophin gene. The left panel shows Let-7c miRNA mediated repression of utrophin in control PMO treated mice. The right panel shows PMO mediated blocking of Let-7c miRNA binding to utrophin 3‚Ä≤UTR, resulting in higher utrophin expression and improvement in dystrophic pathophysiology.Stage of Development:Preclinical DiscoveryIntellectual Property:US PatentPendingReference Media:Sengupta, K et al.Sci Rep, 2020, 10(1): 21492.Desired Partnerships:LicenseCo-developmentCase ID:21-9570-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51043","**Summary:** Synthetic oligonucleotides have been developed to inhibit the natural degradation of utrophin mRNA, aiming to increase utrophin levels in muscle cells for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is caused by a genetic mutation that reduces dystrophin production, leading to severe muscle and respiratory impairments. The oligonucleotides specifically bind to the utrophin mRNA, preventing its degradation and enhancing expression. This approach addresses previous clinical challenges in upregulating utrophin, as existing strategies failed to protect utrophin mRNA from degradation. The invention includes a set of five site-blocking oligonucleotides that target the 3‚Äô-UTR region of the utrophin mRNA to effectively increase its levels within muscle cells.

**Applications:** The site-blocking oligonucleotides can be utilized for therapeutic interventions in patients with Duchenne Muscular Dystrophy to upregulate the production of utrophin, which may alleviate muscle deterioration and associated symptoms. Furthermore, these oligonucleotides can potentially be combined with other strategies aimed at upregulating utrophin to enhance treatment efficacy.

**Problem Solved:** The technology addresses the critical issue of reduced dystrophin production in DMD patients by providing a means to increase utrophin expression in muscle cells, countering the degradation of utrophin mRNA that hinders effective treatment strategies for this severe muscular degeneration.","Synthetic oligonucleotides can effectively block the natural degradation of utrophin, a protein that may help compensate for the absence of dystrophin in patients with Duchenne Muscular Dystrophy. This approach aims to upregulate utrophin levels to address the muscle development and loss associated with the disease."
"University of Pennsylvania","Neuroprotection in TBI/Concussion via Dietary Supplement","","","https://upenn.technologypublisher.com/technology/51042","A dietary supplement that protects brain cells from the effects of TBI and concussionProblem:Traumatic brain injury (TBI) is a major cause of death and disability. Mild TBIs (such as concussion) are particularly common for athletes and warfighters and can produce disabilities without immediate brain cell death. This may be due to damage to the plasma membrane of brain cells, which is a wall of lipids and proteins that separate the inside of the cell from its surrounding environment.Solution:Dietary intake of polyunsaturated fatty acids (PUFAs), preferably in the form of a liquid ""sports drink,"" may be particularly neuroprotective because they are anti-inflammatory, support neuron health, and alter the properties of the plasma membrane.Technology Overview:The ""sports drink"" includes a PUFA, omega-6 docosapentaenoic acid (DPAn6), that has been shown to decrease lesion size in an animal model of concussion. This increase in DPAn6 allows for great plasma membrane elasticity, providing a prophylactic effect for those susceptible to brain injury such as athletes and soldiers.Advantages:Prophylaxis for common brain injuryNon-invasive method for mitigating risk of brain injuryRepresentative H&E images from anterior sections of animals fed Control (A), High Fat diets (B).Stage of Development:Preclinical testing in animal models of brain injuryIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-DevelopmentPotential start-upCase ID:21-9518-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51042","**Summary:** A dietary supplement designed to protect brain cells from traumatic brain injury (TBI) and concussion has been developed, utilizing polyunsaturated fatty acids (PUFAs) to offer neuroprotection. The supplement is ideally consumed in the form of a liquid ""sports drink"" that contains omega-6 docosapentaenoic acid (DPAn6), known for its anti-inflammatory properties and its ability to improve neuron health and plasma membrane flexibility. Preclinical testing indicates that increased DPAn6 can reduce lesion size in animal models of concussion, potentially providing protective benefits for individuals at risk of brain injuries, such as athletes and military personnel.

**Applications:** This dietary supplement has the potential for use by athletes, warfighters, and anyone at risk for mild traumatic brain injuries, offering a non-invasive method to mitigate the risks associated with concussions and other forms of TBI.

**Problem Solved:** The technology addresses the significant issue of traumatic brain injuries, particularly mild TBIs like concussions, which can lead to long-term disabilities without causing immediate brain cell death. By improving the health and resilience of brain cells through dietary supplementation, the solution aims to reduce the impact of such injuries on individuals' lives.","A dietary supplement has been developed to protect brain cells from the effects of traumatic brain injury (TBI) and concussion. This protection is crucial, as mild TBIs can lead to disabilities by damaging the plasma membrane of brain cells without causing immediate cell death."
"University of Pennsylvania","Versatile virtual reality system for functional vision evaluation","","","https://upenn.technologypublisher.com/technology/45319","Virtual reality-based system and software for quick, accurate, and reproducible evaluation of functional vision capacity following clinical treatmentProblem:In 2013, the total economic burden of eye disorders and vision loss in the United States was $139 billion with projections to increase by ~20% over the following 10 years. Developing treatments for vision disorders face the unique challenge of requiring functional testing paradigms that reflect real-world situations while accurately evaluating visual function. Physical mobility test systems currently used to evaluate visual performance involve time consuming set-up procedures, cumbersome physical objects, and subjective evaluation parameters.Solution:Virtual reality provides a platform to overcome the challenges with physical mobility tests and set ups. A virtual reality system minimizes the physical space needed to perform a mobility test while accurately reflecting real-world situations and allowing for unbiased quantification of patient performance.Technology Overview:Dr. Jean Bennett and her colleagues developed a virtual reality-based system and accompanying software of virtual mobility tests to effectively evaluate visual function. This versatile system isolates and controls multiple aspects of functional vision, allowing for an infinite number of outcomes depending on the patient‚Äôs response.Further, virtual reality mobility tests reflect daily physical challenges while eliminating the currently used subjective scoring system for patient performance. By systematically measuring multiple aspects of visual function in a diverse set of situations, this virtual reality-based system and tests provide an accurate and reproducible evaluation of visual function.Advantages:Provides rapid virtual reality mobility testing in as little as 10 minutes, which is key for efficiently evaluating vision functionEliminates physical objects, which is key for reducing set up time and removing physical collision and tripping risksProvides testing adaptability based on patient performance, which is key for evaluating visual function throughout the entire spectrum of patients with vision lossAllows for objective and quantitative measurement of multiple vision parameters, which is key for reproducibly and accurately evaluating visual functionEliminates need for recording the subject‚Äôs performance through video or other means, thereby avoiding using of personal identifiers and assuring confidentiality.Schematics of virtual reality-based representation of a mobility test for evaluation of functional vision using different luminance conditions with A) low luminance conditions, B) medium luminance conditions and C) high luminance conditions.Stage of Development:Stage of Technology (Non-therapeutics)ConceptProof of ConceptBench PrototypeMinimum Viable ProductIntellectual Property:In PreparationProvisional Filed - US 2018/62662737PIssued Patent(s):WO 2019/210087A1Reference Media:Related PCI technology available for licensing: Virtual reality for low vision patientsAleman et al, Clin Ophthalmol 2021;15:939Desired Partnerships:LicenseCo-developmentCase ID:20-9248-tpNCSWeb Published:11/9/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45319","**Summary:** A virtual reality-based system and software have been developed for the efficient evaluation of functional vision capacity following clinical treatment. This system addresses the need for accurate and reproducible testing paradigms that can simulate real-world situations while assessing visual function. It overcomes the limitations of traditional physical mobility test systems, which are often time-consuming and subjective.

**Applications:** The technology can be used in clinical settings to evaluate patients following treatment for various vision disorders, facilitating the assessment of their functional vision capabilities in a controlled yet realistic environment.

**Problem Solved:** This system addresses the economic burden of eye disorders and the challenges faced in developing effective treatments by providing a more streamlined and objective method for evaluating visual performance, which is crucial for understanding the effectiveness of treatments in a practical context.","A virtual reality-based system and software have been developed for the quick, accurate, and reproducible evaluation of functional vision capacity after clinical treatment. Eye disorders and vision loss had a total economic burden of $139 billion in the U.S. in 2013, with projections of a 20% increase in the following decade."
"University of Pennsylvania","Efficient, scalable and CMOS-compatible nonlinear photonic device based on AlScN","","","https://upenn.technologypublisher.com/technology/45161","An on-chip nonlinear optical device that uses AlScN films to undergo scalable manufacturing processesProblem:Nonlinear photonics is a growing field that uses chip-sized devices to control light signals. These devices are used in telecommunications, biosensing, and quantum computing. For known nonlinear materials, there are few options for affordable, large-scale production of nonlinear photonic devices because many are either too weak, or not compatible with CMOS processing, the primary fabrication process used in modern-day electronics. As a result, there is a need for new nonlinear materials that can be used in scalable CMOS processes.Solution:This technology uses aluminum scandium nitride (AlScN) films as a nonlinear material to make efficient CMOS-compatible photonic devices. Because most contemporary microchips are fabricated using CMOS processes, devices designed with CMOS-compatible AlScN films can be made in the same environment, lowering production costs.Technology Overview:AlScN exhibits stronger second-order optical nonlinearity than currently used materials, such as AlN. It can also be grown directly on CMOS devices due to its low sputtering temperature. The CMOS-compatibility of AlScN makes it a viable candidate to interface with silicon photonic devices as a strongly nonlinear material. In a proposed photonic device design, silicon nitride is used to define a waveguide and ring resonator structure on top of an AlScN film. When interfaced with electrical devices, the optical resonance shifts, enabling electro-optic modulation.Advantages:Highly scalable and easy to interface with silicon photonic devices due to its CMOS-compatibilityCan be used to make efficient electro-modulators as it exhibits a second-order optical nonlinearity 12 times higher than other CMOS-compatible nonlinear materials such as AlN and 2 times higher than other strongly nonlinear materials such as lithium niobate (LN)Initial design of an electro-optic modulator that uses AlScN as its nonlinear material. The ring resonator is able to take incoming light signals and change their properties such as frequency, amplitude, and wavelength. Image a) shows the optical waveguide structure made using silicon nitride on top of AlScN, b) shows the pattern of electrodes on top of the ring resonator.Stage of Development:Stage of Technology (Non-therapeutics): Proof of ConceptIntellectual Property:US Patent PendingReference Media:Yoshioka et al.APL Materials 9, 101104 (2021)Desired Partnerships:LicenseCo-developmentCase ID:21-9762-tpNCSWeb Published:10/21/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45161","**Summary:** This technology introduces an on-chip nonlinear optical device utilizing aluminum scandium nitride (AlScN) films that allow for scalable manufacturing processes. AlScN has superior second-order optical nonlinearity compared to existing materials like AlN and can be fabricated at low sputtering temperatures, making it compatible with current CMOS technology.

**Applications:** The device is applicable in various fields, including telecommunications, biosensing, and quantum computing, where the control of light signals is critical.

**Problem Solved:** The technology addresses the limitation of current nonlinear photonic materials that are either weak or incompatible with CMOS fabrication, which hinders affordable mass production of nonlinear photonic devices. By utilizing AlScN, it facilitates integration with existing silicon photonic devices while reducing manufacturing costs.","An on-chip nonlinear optical device utilizing AlScN films enables scalable manufacturing processes. This development addresses the limitations of existing nonlinear materials, which are often too weak or incompatible with CMOS processing for large-scale production."
"University of Pennsylvania","Non volatile resistance switching Si based thin film devices","","","https://upenn.technologypublisher.com/technology/39325","Technology Overview:Current non-volatile memory products, a $30B market, are dominated by flash memories. However, flash memory is facing challenges of unable to scale down for future market.Resistance-switching cell is one of the most promising contenders for replacing flash memory. The new member cell developed at Penn is a resistance-switching device using Si-based amorphous materials. The entire device is fabricated on Si substrate using standard CMOS equipment, therefore compatible with IC process. The memory cells showed very promising performance: 25ns switching time, 2~4V threshold, 100 or better on/off ratio, and long memory retention time.Intellectual Property:US9,425,393US9,905,760Reference Media:Choi, BJ et al.;Adv Mater 2011 Sept 1, 23(33): 3847Case ID:Y6149-tpNCDWeb Published:3/19/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39325","**Summary:** This technology presents a non-volatile memory device that utilizes resistance-switching principles based on silicon (Si)-based amorphous materials. Developed at Penn, the device is fabricated on a silicon substrate using standard CMOS equipment, which ensures compatibility with existing integrated circuit processes. The device exhibits rapid switching capabilities with a response time of 25 nanoseconds, a voltage threshold of 2 to 4 volts, an on/off ratio of 100 or better, and a long memory retention time. 

**Applications:** The primary application of this technology is in non-volatile memory solutions, serving as a potential replacement for traditional flash memory in consumer electronics and various computing devices. Its compatibility with current IC fabrication processes positions it well for integration into future electronic systems.

**Problem Solved:** This technology addresses the limitations of flash memory, particularly its difficulty in scaling down as required for future market demands. By providing a new type of non-volatile memory that leverages resistance-switching mechanisms, it offers an alternative solution with improved performance metrics suitable for next-generation memory applications.","Non-volatile memory products, primarily flash memories, face scalability challenges in a $30 billion market. A new resistance-switching device using Si-based amorphous materials developed at Penn is compatible with IC fabrication due to its construction on a Si substrate using standard CMOS equipment."
"University of Pennsylvania","Differentiation of induced pluripotent stem cells into retinal progenitor cells and mature, functional human retinal ganglion cells","","","https://upenn.technologypublisher.com/technology/45010","Simplified and reproducible two-step differentiation method optimized for efficient differentiation of human-induced pluripotent stem cells into retinal progenitor cells and functional retinal ganglion cellsProblem:More than three million Americans live with glaucoma ‚Äì a disease that can cause blindness resulting from optic nerve damage. In glaucoma, retinal ganglion cells (RGCs) - a type of nerve cell found in the retina that processes visual information from the eye to the brain - are killed and cannot be naturally replaced. Therefore, transplantation of RGCs into the eye to replace dead RGCs promises to rescue vision loss in glaucoma patients and patients with RGC loss due to traumatic brain injury. Human-induced pluripotent stem cells (hiPSCs) can be differentiated into functional RGCs, yet differentiation methods remain limited due to their complexity, irreproducibility, low yield, and use of genomic manipulation.Solution:A simplified, two-step human iPSC differentiation method optimized for the effective and reproducible generation of functionally mature RGCs. The methodology is highly efficient, enabling a highly scalable process for RGC generation. Moreover, it solely employs chemical agents for differentiation and avoids safety concerns involving genetic manipulation.Advantages:Use of chemically-defined medium avoids off-target risks involving genetic modificationHigh yield of RGCs (>95% of cells)Simultaneous production of retinal progenitor cells which can be used for transplantation to rescue photoreceptor lossDoes not require cell sorting for enrichment of RGC population in cultureSimplified technique in 2D monolayer avoids complexity and variability involving 3D organoid useiPSC-derived RGCs are mature and electrophysiologically functional (i.e. can generate action potentials)iPSC-derived RGCs when transplanted into mouse eyes integrate and extend axons through optic nerve headStage of Development:Proof of ConceptIntellectual Property:US PatentPendingReference Media:Chavali et al.Nat Sci Rep, 2020, 10:11828Desired Partnerships:License or collaborationCase ID:22-9778-tpNCSWeb Published:10/4/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45010","**Summary:** A simplified and reproducible two-step differentiation method has been developed to optimize the efficient conversion of human-induced pluripotent stem cells into retinal progenitor cells and functional retinal ganglion cells. This method addresses the challenges associated with traditional differentiation techniques, which are often complex and yield low numbers of viable cells. By employing only chemical agents for differentiation, the methodology minimizes safety concerns related to genetic manipulation and increases productivity.

**Applications:** This technology can be used for the transplantation of retinal ganglion cells into patients suffering from glaucoma, traumatic brain injury, and other conditions that lead to the loss of these important retinal nerve cells, ultimately aiming to restore vision.

**Problem Solved:** The method addresses the critical issue of retinal ganglion cell loss in conditions such as glaucoma, where these cells cannot regenerate naturally. By providing an efficient means to generate functional retinal ganglion cells from induced pluripotent stem cells, it offers a potential therapeutic solution to replace lost cells and mitigate vision loss.","A simplified two-step differentiation method has been developed to efficiently convert human-induced pluripotent stem cells into retinal progenitor cells and functional retinal ganglion cells. This advancement is significant for addressing conditions like glaucoma, which affects over three million Americans and involves the loss of retinal ganglion cells."
"University of Pennsylvania","Novel Nanoparticle Composition Targeting Marginated Leukocytes","","","https://upenn.technologypublisher.com/technology/51044","Problem:Acute inflammatory diseases, including sepsis, pneumonia, and acute respiratory distress syndrome (ARDS), account for over 1.5 million hospitalizations and 300,000 deaths per year in the US. These diseases all share a common cellular player known as marginated leukocytes.Marginated leukocytes are white blood cells that accumulate in the blood vessels of inflamed organs and potentiate disease progression by releasing toxins and pro-inflammatory cytokines and induce clotting and further inflammation. Accumulation of marginated leukocytes can ultimately lead to organ dysfunction.Solution:Drs. Brenner, Muzykantov and Meyerson developed a molecular label consisting of an IgG antibody bound to dibenzocyclooctyne (D20 tag). When attached to nanoparticles, the D20 tag almost exclusively localized to marginated leukocytes to alleviate disease symptoms in a small animal model of acute inflammatory injury. Using the D20 tag to target marginated leukocytes with imaging agents or drugs could better enable clinical diagnosis and treatment of acute inflammatory diseases.Advantages:Provides ~ 50% more protection against cellular leakage than non-tagged nanoparticles following inflammatory injury, which is key for alleviating acute inflammatory disease progressionProvides ~ 2x specificity to inflamed lung tissue versus heart, liver, spleen, and kidneys following inflammatory lung injury, which is key for accurately diagnosing and effectively treating acute inflammatory diseasesCompatible with liposomes for small molecule drug or imaging agent delivery and solid lipid nanoparticles for modified mRNA deliveryStage of Development:In vivo proof of conceptIntellectual Property:US PatentPendingReference Media:Myerson, JW et al:Nat Nanotechnol 2022 Jan 17(1): 86.Desired Partnerships:LicenseCo-developmentCase ID:20-9222-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51044","**Summary:** The technology addresses the issue of acute inflammatory diseases, such as sepsis and pneumonia, which are linked to the harmful actions of marginated leukocytes‚Äîwhite blood cells that gather in the inflamed organs and contribute to disease progression. Researchers have developed a molecular label composed of an IgG antibody connected to a dibenzocyclooctyne (D20 tag) that, when attached to nanoparticles, specifically targets these marginated leukocytes. This targeting mechanism enhances the effectiveness of imaging agents or drugs used in clinical settings, demonstrating improved localization to inflamed tissue in animal models.

**Applications:** The technology could be applied in clinical diagnostics and targeted treatments for acute inflammatory conditions by improving the delivery of therapeutics to inflamed tissues and potentially reducing adverse outcomes associated with these diseases.

**Problem Solved:** The approach effectively addresses the challenge of controlling the inflammatory response mediated by marginated leukocytes, thereby mitigating their harmful effects, which can lead to organ dysfunction and improve patient outcomes in acute inflammatory diseases.","Acute inflammatory diseases, such as sepsis and pneumonia, lead to over 1.5 million hospitalizations and 300,000 deaths annually in the US, with marginated leukocytes playing a critical role in disease progression. These white blood cells accumulate in inflamed organs' blood vessels, releasing toxins and pro-inflammatory cytokines that exacerbate inflammation and induce clotting."
"University of Pennsylvania","Adoptive T cell therapy for cancer using Mutant KRAS-specific T cell receptors for T cell engineering","","","https://upenn.technologypublisher.com/technology/45082","We have isolated, cloned, and characterized multiple T cell receptors (TCRs) from human donors specific for common mutations in KRAS and restricted to highly prevalent HLA types. These TCRs, protected by a Penn provisional filing, are suitable for T cell engineering for the adoptive immunotherapy of cancer patients of select HLA types and tumors expressing particular KRAS mutantions.The comprehensive bioinformatics, biochemical and immunological assessment of these TCRs is in press (Bear et al, Nature Communications).Problem:Mutations of the KRAS gene (mKRAS) serve as the driving oncogene in multiple cancers including lung cancer, colon cancer, and up to 95% of pancreatic ductal carcinoma.KRAS inhibitors have garnered FDA approval, proving the value of KRAS as a cancer target.However, there is no approach to target KRAS immunologically.Solution:We have shown that peptides derived from mKRAS are expressed on HLA molecules on the surface of tumor cells and can be recognized by cytotoxic T cells, leading to tumor death in vitro and in vivo.We have isolated mKRAS-specific TCRs and demonstrated that their engineered re-expression confers mKRAS-specific killing ability.Mutant KRAS specific T cells and TCRs do not recognize wildtype KRAS, addressing a major limitation of CART/TCR efforts for which the target is often expressed in normal tissue.Technology Overview:Using blood samples form healthy donors and cancer patients, the team has devised a platform to identify and isolate TCR sequences that bind to peptide-HLA class I complexes with high specificity and potency for mKRAS.Based on this knowledge, the team has developed a novel mKRAS cancer vaccine (currently being tested in an actively enrolling clinical trial) and has also advanced the data set needed to file an IND for mKRAS TCR-based adoptive T cell clinical trial.In addition, knowledge of these immunogenic peptide-HLA complexes has driven the development of novel laboratory tools useful for discovery and patient assessment, such as reporter cell lines and dextramers.The platform and approach is deployable for isolating TCRs specific for other mutated oncogenes, beyond KRASAdvantages:Specific to tumor-associated KRAS mutantsDoes not affect healthy cells expressing wild-type KRASApplicable for novel cancer vaccinesApplicable for novel engineered adoptive T-cell therapyStage of Development:Target Identified ‚Äì In vitro POCPreclinical Discovery ‚Äì In vivo POCIND Enabling StudiesAt INDIntellectual Property:US and foreign applications pending (link)Reference Media:New cell therapy shows potential against solid tumors with KRAS mutations(Penn Today)Nature Communications2021 Jul 16;12(1):4365. doi: 10.1038/s41467-021-24562-2Desired Partnerships:NewcoLicenseCo-developmentCase ID:19-8867-tpNCSWeb Published:10/9/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45082","**Summary:** A collection of T cell receptors (TCRs) has been isolated from human donors that specifically target common mutations in the KRAS gene and are compatible with prevalent HLA types. These TCRs have been characterized for their utility in T cell engineering aimed at adoptive immunotherapy for cancer patients with specific HLA types and tumors harboring particular KRAS mutations. The relevant research is currently in press, and the technology is protected under a provisional filing held by Penn.

**Applications:** The engineered TCRs can be applied in the treatment of various cancers driven by KRAS mutations, such as lung cancer, colon cancer, and pancreatic ductal carcinoma, facilitating targeted immunotherapy approaches for patients whose tumors express these mutations.

**Problem Solved:** KRAS mutations are prevalent oncogenic drivers in multiple cancers, yet immunological targeting of KRAS has not been achieved until now. The technology addresses this gap by demonstrating that peptides derived from mutant KRAS can be presented on HLA molecules, allowing recognition and destruction of tumor cells by specific cytotoxic T cells. The engineered TCRs provide a means to precisely target mutant KRAS without affecting the normal wildtype KRAS, mitigating the risk of targeting normal tissue.","Multiple T cell receptors specific for common mutations in KRAS have been isolated and characterized from human donors, with a focus on prevalent HLA types. These TCRs, protected by a Penn provisional filing, are suitable for T cell engineering in adoptive immunotherapy for cancer patients with select HLA types and tumors expressing specific KRAS mutations."
"University of Pennsylvania","Microfluidic device for large-scale production of lipid nanoparticles","","","https://upenn.technologypublisher.com/technology/45081","A scalable, parallelized, multi-channel microfluidic device for generating lipid nanoparticles.Problem:Lipid nanoparticles are a promising delivery technology for RNA therapeutics and vaccines. However, there is a lack of formulation strategies that can produce nanoparticles with precisely defined properties that have scalable throughputs ranging from early development to clinical translation. Prior microfluidic technologies have been used to produce lipid nanoparticles with high potency and desirable physical properties, but are limited by their ability to scale to throughputs relevant for clinical studies.Solution:A scalable, parallelized microfluidic device (PMD) that incorporates an architecture that allows for large-scale production of lipid nanoparticles and achieves >100x production rates compared to microfluidic small scale (single channel) lipid nanoparticle formulation strategies.Technology Overview:The PMD incorporates an array of 128 mixing channels for large scale production of lipid nanoparticles with a single set of inlets and outlet. The PMD is composed of polydimethylsiloxane/glass and is fabricated using double-sided imprinting. The device consists of lithographically defined filters at each inlet designed to avoid channel clogging. It includes a ladder geometry with small channels that increases fluidic resistance to ensure that each mixing channel in the array produces lipid nanoparticles with identical physical parameters.Advantages:>100x production rates compared to single microfluidic channels.Generate large scale lipid nanoparticles while maintaining physical properties and potency typical of microfluidic-formulated lipid nanoparticlesScalable throughput from drug discovery to clinical manufacturingFabrication of a scalable PDMS-based microfluidic platform for precise and large-scale RNA lipid nanoparticle (LNP) formulations. Microfluidic formulation produces smaller and more homogeneous LNPs for potent RNA delivery, while larger and more heterogeneous LNPs produced by bulk methods are more variable in terms of RNA delivery. Microfluidic formulation can be scaled up using the same design (staggered herringbone micromixers) for rapid mixing to produce comparable LNPs for RNA delivery.Stage of Development:ConceptProof of conceptIntellectual Property:PCT Application FiledPendingReference Media:Shepherd, S. et al.,Nano Lett. 2021 July 14 21(13): 5671Lerner, E.Penn Engineering Today, 30 June 2021Lerner, E.Penn Today, 6 July 2021Desired Partnerships:LicenseCo-developmentCase ID:21-9566-tpNCSWeb Published:10/9/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45081","**Summary:** A scalable and parallelized multi-channel microfluidic device has been developed for producing lipid nanoparticles, which are increasingly important in RNA therapeutics and vaccine delivery. This device addresses the challenge of generating nanoparticles with precisely defined properties while achieving the high throughput necessary for clinical applications. The design features an array of 128 mixing channels that allow for substantial increases in production rates, exceeding 100 times that of traditional small-scale microfluidic methods.

**Applications:** The technology is applicable in the formulation of lipid nanoparticles for RNA therapeutics and vaccines, supporting both preclinical studies and clinical translation efforts.

**Problem Solved:** The device resolves the limitations of existing microfluidic technologies, which struggle to achieve scalable throughputs and consistent nanoparticle properties suitable for clinical studies.","A scalable, parallelized, multi-channel microfluidic device has been developed to generate lipid nanoparticles, which are important for RNA therapeutics and vaccines. This technology addresses the need for formulation strategies that ensure precise properties and scalable throughput for clinical applications."
"University of Pennsylvania","Low-Cost, Stable, and Easy-to-Use Guide for Accurate Intraventricular Access with Minimal Footprint","","","https://upenn.technologypublisher.com/technology/54512","A single-use device which assists in stereotactic catheter placement into the cerebral ventricles and draining of cerebral spinal fluid (CSF)Problem:Hydrocephalus leads to increased intracranial pressure and an external ventricular drain (EVD) or ventricular-peritoneal shunt (VPS) is needed to drain excess CSF. However, the success of EVD/VPS requires the accurate catheter placement. Currently, freehand techniques using anatomical landmarks suffer from a variable success rate, reported as low as 39.9% and often require multiple catheter passes. Additionally, existing devices (such as the Ghajar Guide) are cumbersome, non-adjustable, require a large incision and have a tendency to allow the catheter migrate following placement.Solution:The inventors developed a stereotactic guide, Device for Intraventricular Entry (DIVE), to assist in the placement of ventricular catheters. DIVE provides an orthogonal trajectory for catheter placement while functioning as a low-profile skin retractor during an EVD or VPS procedure.Technology Overview:The device consists of a hollow conical base, with small footplates coming off each edge to secure the device underneath the skin. From the midpoint of the base, a slotted shaft creates an orthogonal trajectory in line with the burr hole. The catheter can be aligned within the shaft for an orthogonal trajectory into the lateral ventricle or with an adjusted angle if the patient anatomy is atypical (i.e. midline shift). A clip is attached to the base to hold the catheter in place following placement. Additionally, the device will be made of a single piece of plastic, which is cheap and autoclavable.Advantages:100% accurate placement in fewer passes0% clinical complication rateInexpensive and disposableAdjustable angle based on patients' scanHands-free with minimal footprintSecure and stable with Improved ergonomicsBuilt-in skin retractorStage of Development:Clinically TestedBench PrototypeMinimum Viable ProductIntellectual Property:US PatentPendingEuropean PatentPendingAustralian PatentPendingCanadian PatentPendingJapanese PatentPendingReference Media:Cleveland Clinic.External Ventricular Drain(EVD). [video]Yuen, J et al.Ann R Coll Surg Engl, 2018, 100(3): 221.Kim, D et al.Acta Neurochir (Wien), 2015, 157(4): 699.Desired Partnerships:LicenseCo-developmentCase ID:20-9261-TpNCSWeb Published:6/26/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54512","**Summary:** A single-use device has been developed to assist in the accurate placement of catheters into the cerebral ventricles for the drainage of cerebrospinal fluid (CSF). This device aims to improve the success rate of procedures such as external ventricular drainage (EVD) and ventricular-peritoneal shunt (VPS), which are necessary for managing hydrocephalus and preventing increased intracranial pressure. Traditional freehand techniques and existing guides face challenges, including variable success rates and the need for larger incisions. The device, known as the Device for Intraventricular Entry (DIVE), features a hollow conical base with footplates for secure placement and a slotted shaft that guides the catheter in an orthogonal trajectory aligned with the burr hole.

**Applications:** The device is intended for use in neurosurgical procedures requiring precise intraventricular catheter placement, particularly in cases of hydrocephalus where draining CSF is critical for patient health.

**Problem Solved:** The technology addresses the issues related to inaccurate catheter placement associated with current techniques and devices, which can result in variable success rates and complications. By providing a stable and easy-to-use guide and minimizing the footprint of the setup, the DIVE improves procedural accuracy and reduces the need for multiple catheter passes or invasiveness during surgery.","The device is a single-use tool designed to assist in the accurate stereotactic placement of catheters into the cerebral ventricles for draining cerebrospinal fluid (CSF). It addresses the challenges of hydrocephalus and increased intracranial pressure by improving the success rate of external ventricular drains (EVD) and ventricular-peritoneal shunts (VPS)."
"University of Pennsylvania","A homogenous self-heating, temperature-regulating composite material","","","https://upenn.technologypublisher.com/technology/43550","A cost-effective homogenous, composite material provides sustained heat at a desired temperature for point-of-care diagnostics and other applications.Problem:Point-of-care (POC) diagnostic tests have the potential to greatly enhance patient care and accessibility by reducing the time and equipment necessary for testing. Many current POC tests require 30-40 minutes of stable temperatures which, in turn, requires expensive and complex heating platforms that limit wide-scale use of POC tests. A reliable, safe heat-source that maintains fixed temperature would enable low cost, disposable devices for the biochemical reactions necessary for testing.Solution:The heat-source composite material developed in the Bau Laboratory can achieve a range of high temperatures required for many POC tests. These temperatures can be sustained for upwards of 40 minutes, and the POC reaction can occur within something as common as a Styrofoam cup. The material can be engineered to achieve separate temperature plateaus or to sustain a desired temperature for a specified period.Technology Overview:Commercially available exothermic materials provide portable heat sources, for example for hand warmers and meals ready-to-eat. However, these materials lack the temperature regulation needed for POC test protocols. Although phase change materials(PCM) have been usedbefore to stabilize temperatures, they were separated from the heat source, slowing ramp uptimes. The homogenous combination of exothermic material and PCM material providesrapidheating andcan be engineered to support sophisticated heating protocols for biochemical reactionssuch as those needed for two stage amplification (i.e.,16-7708).Other applications may include electricity-free, self-heating, temperature-regulating blankets, garments, packages, and shelters.Advantages:Reaches up to 65‚Å∞C in less than 3 minutes.Sustains desired temperature for upwards of 40 minutes independent of ambient conditions.Material costs less than $1 to incubate samples at the POC.Enables instrument-free molecular diagnostics (with colorimetric detection).Compatible with smartphone apps for fluorescence excitation, detection, and analysis.Top Image: Schematic ofpotential material application. POC test tube samples are supported by a holder and immersed in the composite material (bronze). The material provides heat for a colorimetric biochemical reaction that differentiates positive samples (P, +, yellow) from negative samples (N, -, red)Bottom Chart: Vial‚Äôs temperature curve and POC test reaction schematic. Upon addition of water, the composite material temperature quickly rises to an equilibrium temperature between 60-65‚Å∞C. This range of temperature is optimal for loop-mediated isothermal amplification (LAMP) reactions, a common molecular POC test method. These optimal temperatures are maintained upwards of 40 minutesindependent of ambient temperatures. An example testing setup involves a POC sample immersed in the composite material and contained within a Styrofoam cup (inset).Stage of Development:Bench PrototypeIntellectual Property:Patent PendingDesired Partnerships:Co-development or LicensingCase ID:21-9500-tpNCSWeb Published:5/7/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/43550","**Summary:** A cost-effective composite material provides a consistent heat source capable of maintaining a specific temperature for over 40 minutes, making it suitable for point-of-care diagnostics. This material overcomes the limitations of existing POC tests, which often require complex and expensive heating systems to maintain stable temperatures during biochemical reactions. The composite can be tailored to create specific temperature plateaus or sustain a desired temperature for predetermined durations. 

**Applications:** The technology can be utilized in point-of-care diagnostic tests, allowing for quick and efficient biochemical reactions in settings that require simplicity and low cost. Its engineering versatility supports a range of applications, potentially expanding its use beyond diagnostics into other fields that require regulated heating.

**Problem Solved:** The technology addresses the challenge of maintaining stable temperatures during POC diagnostics without the need for costly and intricate heating platforms, facilitating the development of affordable and disposable testing devices that enhance accessibility and patient care.","A cost-effective composite material provides sustained heat at a desired temperature for point-of-care diagnostics and other applications. It addresses the challenge of existing POC tests, which require lengthy periods of stable temperatures and often rely on expensive heating platforms."
"University of Pennsylvania","Mannan-Degrading Enzymes (MDEs) Disrupting Bacterial-Fungal Biofilms for Prevention of Dental Cavities","","","https://upenn.technologypublisher.com/technology/43348","Enzymes that degrade mannose to prevent the formation of bacterial-fungal biofilms, which cause dental cavitiesProblem:Dental cavities are among the most common oral diseases among children and adults in the United States, with treatments for this condition exceeding $81 billion annually. Dental cavities occur when the bacteria Streptococcus mutans feeds off residual sugar on teeth and produces tooth-decaying lactic acid. Additionally, S. mutans can cause even more severe tooth decay when it associates with the fungus Candida albicans. A surface-bound carbohydrate, mannose mediates synergistic growth of bacteria/fungus colonies by helping the two species bind to each other. Disruption of mannose-mediated bacterial-fungal biofilms interaction on teeth would prevent severe dental cavities caused by these two pathogenic microorganisms.Solution:The technology is mannan-degrading enzymes (MDEs) which break down mannose on Candida albicans cell walls to prevent bacterial binding. Specific degradation of mannans on fungal cell walls stops Streptococcus mutans from adhering to the fungal cells‚Äîconsequently, less co-species biofilm forms on teeth. Limiting biofilm formation decreases the exposure of teeth to microbe-generated acids and inhibits the formation of dental cavities.Technology Overview:Three mannan-degrading enzymes are used to target fungal cell walls. The enzymes: Œ±-mannosidase, Œ≤-mannosidase, or Œ≤-mannanase breakdown mannose on Candida albicans surfaces. These enzymes target beta-mannose sugars on mannan chains. Ultimately, this reduces the viscosity of biofilms and removes binding sites used by Streptococcus mutans on enamel.Advantages:15-fold decrease in S. mutans-C. albicans interaction force after 5-minute treatment2.5-fold decrease in biofilm dry weightUp to 90% biofilm removal by mild fluid shear stress after treatmentIncreases pH on mineral surfaces (less acidity) and decrease in enamel demineralizationEfficacy of MDEs against S. mutans-C. albicans biofilms. (A) the pH of biofilm supernatants, (B) dry-weight per biofilm, CFU of (C) S. mutans, and (D) C. albicans per biofilm. At optimal units, all MDEs had a significant antibiofilm effect on S. mutans-C. albicans biofilms as measured at 18, 28, and 42h. (E) Representative confocal images of untreated and MDE treated 746 biofilms at 18 h. Scale bar indicates 20 ¬µm. Statistics: *** represents p < 0.001 for unpaired t-tests against the vehicle control (n‚â•3).Stage of Development:Therapeutics: Preclinical DiscoveryIntellectual Property:US PatentPendingReference Media:Kim, HE, et al.;mBio 2021 May 18; 12(3): e00651Hwang, G et al.;PLoS Pathog., 2017 June 15; 13(6): e1006407Baillie, KU;Penn Today 2021 May 18Baillie, KU;PennToday2017 June 20Desired Partnerships:LicenseCo-developmentCase ID:21-9552-tpNCSWeb Published:4/6/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/43348","**Summary:** Mannan-degrading enzymes (MDEs) break down mannose on the cell walls of Candida albicans, preventing bacterial binding and the formation of harmful bacterial-fungal biofilms that lead to dental cavities. The disruption of the mannose-mediated interaction between Streptococcus mutans and Candida albicans reduces the co-species biofilm on teeth and minimizes the exposure to tooth-decaying acids.

**Applications:** This technology can be applied in dental care products and treatments aimed at preventing the formation of dental caries, particularly in individuals at higher risk of cavities due to the presence of both bacteria and fungi. 

**Problem Solved:** The technology addresses the issue of dental cavities, a prevalent oral disease that incurs high treatment costs due to the synergistic growth of Streptococcus mutans and Candida albicans facilitated by mannose, which contributes to severe tooth decay.","Mannan-degrading enzymes (MDEs) prevent the formation of bacterial-fungal biofilms, which contribute to dental cavities. These cavities are prevalent oral diseases caused by the bacterium Streptococcus mutans, which produces lactic acid from residual sugars, leading to tooth decay."
"University of Pennsylvania","Novel Pyrimidine Derivatives to Treat Alzheimer‚Äôs Disease","","","https://upenn.technologypublisher.com/technology/43214","Brain penetrating compounds as promising therapeutics for treatment of neurodegenerative disorders.Problem:An estimated 6.2 million Americans live with Alzheimer‚Äôs Disease (AD), and this number is projected to reach over 13 million by 2050 with societal costs expected to rise to $1.1 trillion. A key feature of AD-affected brain tissue is the presence of insoluble tangles within neurons, leading to their dysfunction and subsequent death. These tangles are comprised of tau protein, which is normally responsible for stabilizing microtubules that are critical to normal neuronal function. However, in AD and related neurodegenerative diseases tau dissociates from microtubules, which compromises microtubule function and facilitates tangle formation.Solution:Compounds that cross the blood-brain barrier and stabilize microtubules can normalize microtubule function in AD and related diseases. Such compounds from the triazolopyrimidine chemical family have been demonstrated to be effective in vitro and in mouse models of AD.Technology Overview:A prototype triazolopyrimidine has been shown to be efficacious in normalizing microtubule function, reducing neuronal cell death and attenuating tau tangle formation in a mouse model of AD. Moreover, this prototype compound was also found to reduce the generation of amyloid plaques, another hallmark pathology of AD. Numerous novel compounds from the triazolopyrimidine family bearing various carbon 6 (C6) and carbon 7 (C7) modifications have been designed, synthetized and tested in multiple cellular assays to assess microtubule stabilization. The most promising of these compounds show improved potency and pharmaceutical properties relative to the initial prototype, including excellent brain exposure, greater solubility and enhanced metabolic stability.Advantages:Novel compounds with likely IP protectionMore potent in vitro than previously identified compoundsAbility to cross the blood-brain barrierBased on refined SAR and computation modeling, numerous additional novel compounds are being synthesized with likely enhanced activityLeft panel: Appearance of normal axons within the optic nerve (ON) of control wild-type mice treated with vehicle (WT Vehicle). Middle panel: Appearance of axonal dystrophy in PS19 mice harboring tau tangles used as a model for AD. Right panel: bi-weekly injections of compound 51657 at 10 mg/kg in PS19 mice prevents axonal dystrophy. Scale bar is 2 um.Therapeutics Stage of Development:In vitro activity and in vivo efficacy with safety in AD mouse modelsPreclinical DiscoveryIntellectual Property:US PatentPendingAustralian PatentPendingCanadian PatentPendingChinese PatentPendingEuropean PatentPendingJapanese PatentPendingReference Media:Alzheimer's Disease Facts and Figures, an annual report released by the Alzheimer's AssociationZhang, B et al.;Mol Neurodegener 2018 Nov 7; 13(1): 59Desired Partnerships:LicenseCo-developmentStart-upCase ID:20-9278-tpNCSWeb Published:3/16/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/43214","**Summary:** This technology centers around the development of brain-penetrating compounds from the triazolopyrimidine chemical family that target the underlying mechanisms of Alzheimer‚Äôs Disease. These compounds have been shown to normalize microtubule function, reduce neuronal cell death, and mitigate tau tangle formation in mouse models, addressing the pathological features of the disease. Additionally, these compounds have demonstrated efficacy in decreasing the production of amyloid plaques, offering a multifaceted approach to treatment.

**Applications:** The primary application of these novel pyrimidine derivatives is in the treatment of Alzheimer‚Äôs Disease and potentially other neurodegenerative disorders where tau protein dysfunction and amyloid plaque formation play critical roles.

**Problem Solved:** The technology addresses the significant challenge posed by Alzheimer‚Äôs Disease, which affects millions of individuals and incurs substantial socio-economic costs. By stabilizing microtubules and preventing tau dissociation, these compounds could help restore neuronal function, reduce cell death, and ultimately improve outcomes for those affected by this debilitating condition.","An estimated 6.2 million Americans currently live with Alzheimer‚Äôs Disease, a figure projected to exceed 13 million by 2050, leading to expected societal costs of $1.1 trillion. A hallmark of the disease is the formation of insoluble tau protein tangles within neurons, resulting in their dysfunction and death."
"University of Pennsylvania","Durable and Targeted Nanoparticle Treatment for Osteoarthritis","","","https://upenn.technologypublisher.com/technology/43087","An osteoarthritis treatment comprised of TGFa nanoparticles that penetrate cartilage and persist in the joint.Problem:Osteoarthritis (OA), a degenerative joint disease, is the most common form of arthritis, with over 32 million adults affected in the US alone. Despite its prevalence and debilitating nature, no cure or disease-modifying treatment exists. The epidermal growth factor receptor (EGFR) signaling pathway controls many key cellular functions, and mice lacking EGFR develop OA. Transforming growth factor alpha (TGFa) stimulates the EGFR pathway and reduces OA in mice. However, its short circulation lifespan drastically reduces efficacy.Solution:An engineered nanoparticle delivery system increases penetration of TGFa into the cartilage, prolongs retention of TGFa in the knee joint, and blocks OA progression in an animal model.Technology Overview:TGFa molecules are affixed to nanoparticles by specific chemistry. To reduce surface charge and increase cartilage penetration, the resulting TGFa-nanoparticles (TGFa-NP) were further engineered with a copolymer. The resulting TGFa-NP bound specifically to bovine cartilage cells and penetrated bovine cartilage tissue in vitro. Injecting engineered TGFa-NPs into the mouse knee joint prevented cartilage degeneration and promoted cartilage integrity over the course of months in a model of injury-induced OA.Advantages:Specific binding to cartilage-producing cells via TGFa-Cartilage penetration 4.76-fold better than free TGFaJoint retention 3 times longer in OA mouse joints when compared to free TGFaReduced physiological symptoms of OA in a mouse model, whereas free TGFa provides no reliefSurgical destabilization of the medial meniscus (DMM) was used to induce OA in mice. Sham denotes mice that did not receive DMM. TGFa-NP and controls PBS, free TGFa (TGFa-DBCO), and control nanoparticles (Ctrl-NP) were injected in to the knee every 3 weeks after DMM. (A) Immunostaining of p-EGFR (brown) reveals enhanced EGFR activity in TGFa-NP treated mice 1 month after surgery. (B) Safranin O and Fast Green staining reveal cartilage (red) and non-cartilage (blue) in the knee joints of treated mice 2 and 3-months post DMM. Low: low magnification; high: high magnification. (C) OA severity at 3 months post-DMM was quantified by Mankin score. Higher scores indicate more severe OA. (D) Average uncalcified cartilage thickness (Uncal. Th) of knee joints 3 months post-DMM. Reduced thickness indicates more severe OA.Stage of Development:Preclinical DiscoveryIntellectual Property:US PatentPendingReference Media:Qin, L and Beier, F.JBMR PLUS, 2019 Feb 13, 3(2):e10177Desired Partnerships:LicenseCo-developmentCase ID:20-9332-tpNCSWeb Published:2/26/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/43087","**Summary:** This technology focuses on a treatment for osteoarthritis (OA) using transforming growth factor alpha (TGFa) nanoparticles that effectively penetrate cartilage and remain in the joint for an extended period. Osteoarthritis affects over 32 million adults in the US and currently lacks a cure or disease-modifying treatments, making the need for innovative therapies critical. The engineered nanoparticle system enhances the delivery of TGFa, which stimulates the epidermal growth factor receptor (EGFR) pathway, thereby potentially reducing OA progression. The TGFa is attached to nanoparticles through specific chemistry, allowing for superior cartilage binding and penetration compared to free TGFa.

**Applications:** The primary application of this technology is in treating osteoarthritis by delivering TGFa directly to the affected joints, potentially improving cartilage health and preventing degeneration. This treatment could be beneficial for millions of individuals suffering from OA, offering a targeted approach to manage and possibly modify the disease's progression.

**Problem Solved:** The technology addresses the need for effective treatments for osteoarthritis, a degenerative joint disease without any current disease-modifying options. By enhancing the delivery and retention of TGFa in cartilage, it aims to combat the degeneration associated with OA and improve overall joint health in affected individuals.","Osteoarthritis is a prevalent degenerative joint disease affecting over 32 million adults in the US, with no existing cure or disease-modifying treatment. A treatment using TGFa nanoparticles has been developed to penetrate cartilage and persist in the joint, targeting the epidermal growth factor receptor (EGFR) signaling pathway, which is crucial for multiple cellular functions in relation to OA."
"University of Pennsylvania","Gum-Health Promoting Smart Dental Implant System","","","https://upenn.technologypublisher.com/technology/42976","Dental implant that inhibits plaque accumulation and gingival tissue inflammation by photobiomodulation therapy delivered by embedded light-emitting diodes (LEDs) powered by electricity generated from the patient‚Äôs own oral motion.Problem:More than half of adults will lose one or more teeth in their lifetime. When a patient loses a tooth the treatment options are to either not replace it, use a denture in place of the missing tooth, or insert a dental implant. While dental implants are the most invasive, costly and time-consuming option, they tend to provide the most long-term benefit to the patient.Currently, an estimated 5 million implants are placed each year in the U.S. Dental implants look and feel like natural teeth, while also being secure, unlike dentures. However, peri-implant mucositis occurs in around 40% of implants and about 15% of all cases over ~19 years post implant placement fail. Currently, there is no effective preventive measure to reduce the incidence of peri-implant diseases.Solution:Dental implants smart enough to that auto-deliver photobiomodulation therapy (PBM) to prevent plaque build-up and gum inflammation. The PBM is delivered via LEDs integrated into the dental implant and powered by the patient‚Äôs own natural oral motion.Technology Overview:The smart dental implant utilizes piezoelectric nanoparticles embedded in the dental crown to generate electricity which powers microLEDs in the abutment to create an oral photobiomodulation system that will maintain tissue health while preventing bone loss. The electricity generated by the nanoparticles within the crown is derived from the patient‚Äôs own mouth movements such as chewing, brushing and rinsing.Advantages:Sustained inhibition of bacterial growth/adhesionMaintain homeostasis of oral microbiome due to non-microbicidal infection controlConvert oral motion into electrical energy to deliver photobiomodulation therapy to the surrounding gum tissue(A) Healthy condition maintained by proposed advanced dental implant (Smart Dental Implant System), (B) unhealthy scenario with normal implant, (C) the first-generation of Smart Dental Implant systemStage of Development:Bench PrototypeIntellectual Property:US PatentPendingEuropean PatentPendingCanandian PatentPendingJapanese PatentPendingChinese PatentPendingReference Media:Park,M et al.Adv. Healthc. Mater. 2020Aug; 9(16): e2000658.Desired Partnerships:LicenseCo-developmentCase ID:20-9166-tpNCSWeb Published:2/9/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42976","**Summary:** The dental implant system uses photobiomodulation therapy, delivered by integrated light-emitting diodes (LEDs), to inhibit plaque accumulation and gum inflammation. It operates by converting the mechanical energy from the patient's oral motions into electricity, which powers the embedded LEDs. This innovative approach aims to enhance the longevity and health of dental implants through automatic therapy.

**Applications:** The primary application is in dental care, specifically for patients receiving dental implants, to promote oral health and prevent peri-implant diseases, such as mucositis and other inflammatory conditions.

**Problem Solved:** The technology addresses the high incidence of peri-implant mucositis and the lack of effective preventive measures in dental implants. By automating therapeutic interventions, it reduces the risk of complications and supports long-term success for dental implant patients.","The dental implant incorporates photobiomodulation therapy via embedded light-emitting diodes (LEDs) to reduce plaque accumulation and gingival tissue inflammation, with power generated from the patient's oral motion. This innovation addresses the issue of tooth loss, which affects more than half of adults during their lifetime."
"University of Pennsylvania","Efficient and easy-to-use decision support tool for coronary artery disease tests","","","https://upenn.technologypublisher.com/technology/42673","Tool that evaluates the utility of various tests for coronary artery disease, saving time by allowing non-cardiologists to order an appropriate test.Problem:There are many clinical situations where a patient needs to be evaluated for coronary artery disease (emergency room, pre-transplant surgery, etc.). Non-cardiologists often lack the expertise needed to select the correct test. A cardiologist usually orders the test, but the process can be inefficient due to delays caused by waiting for the cardiologist to see the patient, schedule the test, and then to review the results when they become available.Solution:This web-based application allows non-cardiologists to decide which cardiac tests should be ordered. If the appropriate test is ordered in advance, the results can be available when the patients are first seen by the cardiologist, or in some cases, eliminate the need for the patient to be seen. This would expedite a number of workflows, such as patient disposition in the ER or listing for transplant. Improved testing may also improve the diagnosis of a patient with chest pain in an emergency room.Technology Overview:The user answers a survey of 15 clinical questions that are adapted for different clinical contexts. Each question has an ‚Äúinfo‚Äù button that provides more information. Based on the answers, utility scores are assigned to each of 10 possible tests. 10 points, color-coded green, means there are no drawbacks to using that test. 1-9 points, color-coded yellow, means that the test may be reasonable, but with concerns. 0 points, color-coded red, indicates that the test should not be used. Rationales for the assigned scores that help inform the provider‚Äôs decision are available with one click. Clicking on the test name provides information about the test. Results can be pended or saved, and can be recalled later with the patient‚Äôs MRN.Advantages:92% agreement with decisions made by attending cardiologists in a retrospective studyAllows non-cardiologists to make informed decisionsExpedites decision regarding listing for transplantImproves workflow efficiency with faster scheduling of testsThe figure shows a sample screen of the decision support tool. On the left are clinical questions that the health care provider must answer. On the right are results showing the color-coded numerical scores for each test. The rationale for a given test is shown below the test name. [Figure origin: Obtained from inventor‚Äôs PowerPoint ‚ÄúCoronary Artery Disease Decision Support Tool‚Äù (Gomberg, 2020).Stage of Development:IND received, with tests ongoing at PennIntellectual Property:CopyrightDesired Partnerships:LicenseCo-developmentCase ID:19-8986-tpNCSWeb Published:1/6/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42673","**Summary:** A web-based decision support tool evaluates the appropriateness of various tests for coronary artery disease, allowing non-cardiologists to make informed choices about which tests to order. By streamlining the testing process, the tool helps expedite patient care and reduce delays commonly associated with involving cardiologists.

**Applications:** The technology can be utilized in settings such as emergency rooms, pre-transplant evaluation, and any clinical scenario requiring assessment for coronary artery disease. It enhances the efficiency of workflows, especially in urgent care situations.

**Problem Solved:** The tool addresses the challenges faced by non-cardiologists who often lack the necessary expertise to select the correct tests for coronary artery disease. By enabling faster test selection and results availability, it mitigates delays in patient care related to waiting for cardiologist involvement.","The decision support tool evaluates the utility of various tests for coronary artery disease, enabling non-cardiologists to efficiently order appropriate tests. This addresses the challenge of delays in patient care due to the reliance on cardiologists for test selection in critical situations."
"University of Pennsylvania","High Performance CRISPR-Cas12a System for Combinatorial Genetic Manipulation","","","https://upenn.technologypublisher.com/technology/42251","CRISPR-Cas12a allowing for simultaneous editing of multiple genes in mammalian cellsProblem:CRISPR-based gene editing technique has revolutionized the field of molecular biology. While CRISPR-Cas9-based methods are effectively used for single-gene knockout, multiplex gene editing remains a major challenge. Unlike Cas9, Cas12a can be used for multigene editing from a single RNA transcript but demonstrates low gene editing efficiency in mammalian cells.Solution:Dr. Shi and his team have optimized the Cas12a gene editing system to allow for highly efficient knockout of multiple genes (up to 20) in mammalian cells. The system allows for multiple applications including (i) stratification of process of multiple gene editing for research projects, gene therapy, or cell therapy, (ii) combinatorial genetic screening in various cell types, (iii) fine-tuning expression of a gene of interest by controlling expression of multiple regulatory areas, and (iv) discovering gene interactions across diverse disease types.Advantages:Multiplex capacity ‚Äì deletion of up to 20 genes simultaneouslyHigh-throughput gene screening capabilityHigh-efficiency100bp to 1000bp deletions with 80-90% efficiencyGene expression regulation by controllingIntellectual Property:US PatentPendingReference Media:Gier, R et al;Nat Commun, 2020 Jul 13, 11(1): 3455Desired Partnerships:LicenseCo-developmentCase ID:20-9242-tpNCSWeb Published:11/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42251","**Summary:** The technology features an optimized CRISPR-Cas12a system designed for highly efficient gene editing in mammalian cells, allowing for the knockout of multiple genes simultaneously, specifically up to 20 genes from a single RNA transcript. This advancement addresses the limitations of traditional CRISPR-Cas9 methods, which are primarily effective for single-gene modifications, particularly in terms of efficiency in mammalian systems.

**Applications:** The enhanced system has several applications, including the stratification of gene editing processes for research initiatives, gene therapy, and cell therapy. It also facilitates combinatorial genetic screening across various cell types, the fine-tuning of gene expression by modulating multiple regulatory areas, and the exploration of gene interactions linked to diverse disease types.

**Problem Solved:** This technology resolves the significant challenge of multiplex gene editing, which has been a barrier in advancing CRISPR applications beyond single-gene modifications. By providing a method for efficient simultaneous editing of multiple genes, it enhances the capabilities of genetic research and therapeutic strategies.","Dr. Shi and his team have developed an optimized CRISPR-Cas12a system that enables simultaneous editing of multiple genes in mammalian cells. This advancement addresses the challenge of low gene editing efficiency associated with Cas12a in multiplex gene editing."
"University of Pennsylvania","Low-cost rapid diagnostic for COVID-19","","","https://upenn.technologypublisher.com/technology/42247","A COVID-19 diagnostic approach, utilizing a SARS-CoV-2 binding biosensor, that allows for real-time virus detection, without the need for sample processing, ultimately leading to population-level surveillance, outbreak tracking, reduced healthcare costs, improved treatment outcomes, and saved lives.Problem:SARS-CoV-2, the virus that causes COVID-19, continues to kill people at a staggering pace, threatening both public safety and the global economy. According to theWorld Health Organization, as of November 2020, there were more than 50 million reported cases of COVID-19 worldwide, resulting in over 1.2 million deaths. Due to the rapid rate of transmission and risk of secondary bacterial infections, there is an urgent need to develop approaches to quickly detect and diagnose viral infection in order to inform subsequent treatment and to enable population-level surveillance and outbreak tracing. Currently, available diagnostics are limited by their high cost of production and slow detection time, thus hindering their widespread use in the population.Solution:The de la Fuente lab has created a low-cost, pocket-sized biosensor that is capable of diagnosing COVID-19. The sensor, which costs 7¬¢ to produce, is a printed circuit-board electrode that can diagnose SARS-CoV-2 infected samples in real time. The device can be implemented on a large-scale or connected to a smartphone to enable personalized, viral detection.Technology Overview:The biosensor‚Äôs electrode is functionalized by anchoring human Angiotensin Converting Enzyme 2 (ACE2), the host target of SARS-CoV-2, to the surface. A small saliva sample (2-10 ŒºL) is transferred to the device. The selective binding between ACE2 and the spike protein of SARS-CoV-2 is measured through electrochemical impedance spectroscopy (EIS) and detected using a potentiostat. Variations in the resulting signal are used to obtain qualitative and quantitative results for the diagnosis of COVID-19. This versatile technology has the potential to be modified and applied in the diagnosis of other viral infections.The novel diagnostic device can detect the SARS-CoV-2 virus within 4 minutes, a vast improvement on the current state-of-the-art which has a detection time of 30 minutes. Ongoing studies have demonstrated its powerful diagnostic capabilities, achieving 97% accuracy (96% sensitivity, 100% specificity) in detecting SARS-CoV-2, when compared to RT-qPCR results. Additional efforts are being made to incorporate the sensor into protective face masks for continuous infection monitoring.Advantages:Sensor production cost: $0.07Detection time: 4 minutesDetection limit: 100 fg/mLMinimal sample volume (2 ¬µL) requiredSample does not require any processingInitial study results: 97.1% Accuracy, 96.2% Sensitivity, 100 % SpecificityLarge-scale, point-of-care testingDisposable/recyclable materialsFigure: (A) Functionalization of electrodes with ACE2 (B) Virus present in samples can be detected by the interaction of its spike protein with ACE2 (C) Samples are added to the surface of the electrode and impedimetric measurements determine whether the samples are infected.Stage of Development:Bench PrototypeIntellectual Property:Provisional FiledReference Media:Nemo Prize Awardedde Lima, L. et al.,Sci Direct Vol. 4, Issue 8; 16 August 2023: 101476Desired Partnerships:LicenseCo-developmentCase ID:21-9515-tpNCSWeb Published:11/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42247","**Summary:** The described diagnostic approach employs a SARS-CoV-2 binding biosensor for real-time detection of COVID-19 without the need for sample processing. This low-cost biosensor, which can be produced for just 7 cents, allows for large-scale implementation and can be connected to smartphones for personalized and efficient viral detection.

**Applications:** The technology can be used for population-level surveillance, outbreak tracking, and facilitating early diagnosis, ultimately contributing to improved healthcare outcomes and saving lives.

**Problem Solved:** The rapid transmission of SARS-CoV-2 poses significant threats to public safety and economic stability, with millions of cases and deaths recorded globally. Current high-cost and slow detection methods hinder widespread testing, whereas this innovative biosensor addresses the urgent need for quick and accessible diagnostics to aid in effective treatment and monitoring of outbreaks.","The described COVID-19 diagnostic approach employs a SARS-CoV-2 binding biosensor for real-time virus detection without sample processing. This method facilitates population-level surveillance, outbreak tracking, and has the potential to reduce healthcare costs and improve treatment outcomes."
"University of Pennsylvania","Scanner Independent Method for Medical Image Standardization","","","https://upenn.technologypublisher.com/technology/42215","A computer algorithm to standardize medical images acquired using positron emission tomography.Problem:Positron emission tomography (PET) is a commonly utilized imaging modality used for body-wide assessments of a variety of diseases, including cancer. Measurements derived from PET images are used to make diagnostic, staging, and treatment decisions for improved patient care. The standardized uptake value (SUV) is a quantitative measurement widely utilized for a semi-quantitative PET assessment in clinical practice. Patient-related factors including body weight and habitus, and technical factors including image acquisition methods and image reconstruction methods may adversely affect the accuracy of PET-derived measurements. Attempting to account for all adverse factors remains a challenge to the goal of accurate and reproducible measurements from PET images.Solution:A computer algorithm to standardize PET images and reduce errors in PET quantification. This algorithm does not use patient-related or scanner-related factors which allows it to be applied across scanners and image acquisition protocols and even for already existing data sets.Technology Overview:The standardization operation is applicable to both PET and SUV images. A calibration step is first applied to a series of training images from which key parameters characterizing a standardization mapping are determined. This operation is performed only once. Subsequently, for any given image to be standardized, a standardization transformation is applied by estimating the corresponding parametric values for the given image and utilizing the learned parametric values. PET and SUV images are standardized separately.Advantages:Post-acquisition applicationApplicable to whole-body PET imagesDecrease in variability of measurements of radiotracer uptake within and between patient scans within tissues or lesions of interestCan be incorporated into existing PET image analysis software packagesFully automatedStage of Development:ConceptProof of ConceptBench PrototypeMinimum Viable ProductIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:20-9225-tpNCSWeb Published:11/2/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42215","**Summary:** A computer algorithm has been developed to standardize medical images obtained through positron emission tomography (PET) to improve the accuracy of quantitative measurements used in clinical practice. This algorithm addresses the variability in standardized uptake values (SUV) caused by patient-related and technical factors without relying on these variables, making it versatile for various scanners and imaging protocols.

**Applications:** This technology can be utilized in clinical settings where PET imaging is employed for the assessment of diseases such as cancer, aiding in diagnostic, staging, and treatment decision-making processes. It is also applicable to existing PET datasets, enhancing the usability of previously acquired images.

**Problem Solved:** The solution addresses the challenge of achieving accurate and reproducible PET-derived measurements by mitigating the influence of disparate patient and scanner variables, thus enhancing the reliability of PET imaging in medical assessments.","A computer algorithm has been developed to standardize medical images acquired using positron emission tomography (PET), which is commonly used for diagnosing and assessing various diseases, including cancer. The standardized uptake value (SUV) is a key quantitative measurement derived from PET images for semi-quantitative assessment in clinical decision-making."
"University of Pennsylvania","Nonvolatile memory devices fabricated at a complementary metal‚Äìoxide‚Äìsemiconductor (CMOS)-compatible temperature","","","https://upenn.technologypublisher.com/technology/42214","High-performance nonvolatile memory devices integrated with ferroelectric Aluminum Scandium Nitride (AlScN) films that can be directly deposited on the silicon at low temperature (‚â§ 350 ¬∞C)Problem:Strong demand for high-density non-volatile memory (NVM) devices with low power consumption is being driven by new applications of non-von Neumann computing architectures, the Internet of Things (IoT), and artificial intelligence. Ferroelectric field effect transistor (FeFET)-based nonvolatile memories are the most compelling emerging NVM devices due to their high access speed, high endurance, and low energy consumption. However, applications of FeFETs suffer from the lack of reliable industrial-scale production of ferroelectric films and incompatibility with complementary metal‚Äìoxide‚Äìsemiconductor (CMOS) processing temperatures.Solution:The researchers developed AlScN FeFET memory devices that integrate Aluminum Scandium Nitride (AlScN) films. The integration and fabrication process can be done at a CMOS-compatible temperature (‚â§350 ¬∞C). The resulting memory devices offer high performance with a large memory window ranging from 20 to 40 V, a high on/off ratio of over 106, and a maximum on-current of 3 mA with channel dimensions W/L = 12 Œºm/3 Œºm.Technology Overview:AlScN alloys have large coercive fields and high remnant polarizations, which allows them to be scaled into thinner ferroelectric layers with smaller FeFET gate dimensions while maintaining large memory windows and large bit density. The low deposition temperature (‚â§ 350 ¬∞C) of AlScN also allows for FeFET integration directly into a CMOS. The AlScN thin films are used as ferroelectric gate dielectrics in FeFET-based memories, so that film deposition can be done at a CMOS-compatible temperature.Advantages:Deposition of AlScN films can be done at a CMOS-compatible temperature (‚â§ 350 ¬∞C)The on/off ratio of the fabricated AlScN FeFETs is ~106, 100+ times higher than currently available FeFETs.The normalized memory window over the thickness of the ferroelectric film is 40 V/100 nm, which is the highest among all the reported FeFETs at room temperature.The anticipated memory window on a 13-nm AlScN is 2X that of the HfZrO with the same thickness, which lowers the voltage required to polarize the gate dielectricsSchematic of the experimental AlScN FeFET in On- and Off-States; the blue part represents the AlScN film.Stage of Development:Bench PrototypeIntellectual Property:US PatentPendingReference Media:Liu, X et al.;Nano Lett 2021 May 12 21(9): 3753Desired Partnerships:LicenseCo-developmentCase ID:20-9330-tpNCSWeb Published:11/2/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42214","**Summary:** High-performance nonvolatile memory devices utilizing ferroelectric Aluminum Scandium Nitride (AlScN) films can be fabricated at complementary metal‚Äìoxide‚Äìsemiconductor (CMOS)-compatible temperatures of 350 ¬∞C or lower. These devices demonstrate impressive characteristics, including a memory window of 20 to 40 V, an on/off ratio exceeding 10^6, and a maximum on-current of 3 mA with specific channel dimensions. The application of AlScN alloys, which have large coercive fields and high remnant polarizations, allows for the scaling of ferroelectric layers and FeFET gate dimensions while preserving performance metrics.

**Applications:** The technology targets high-density nonvolatile memory needs arising from emerging applications in non-von Neumann computing architectures, the Internet of Things (IoT), and artificial intelligence, where low power consumption and high access speed are critical.

**Problem Solved:** The integration of AlScN FeFET memory devices addresses the growing demand for reliable, high-performance nonvolatile memory that is compatible with existing CMOS manufacturing processes, thereby enabling industrial-scale production and improving performance in modern computing applications.","High-performance nonvolatile memory devices using ferroelectric Aluminum Scandium Nitride (AlScN) films can be fabricated at temperatures not exceeding 350 ¬∞C. These devices meet the increasing demand for high-density, low-power non-volatile memory in applications like non-von Neumann computing, the Internet of Things, and artificial intelligence."
"University of Pennsylvania","Novel Inhibitors of Ferroptosis","","","https://upenn.technologypublisher.com/technology/51046","Novel derivatives of oleic acid effectively inhibiting ferroptosis that could be used for treatment of Friedreich Ataxia, neurodegenerative diseases, and neuropsychiatric diseases.Problem:Ferroptosis is a non-apoptotic form of cell death characterized by the iron-dependent accumulation of toxic lipid-reactive oxygen species. Ferroptosis has been suggested to be the main driver of neurological cell death in diseases such as Parkinson's disease, Alzheimer disease, and Huntington's disease as well as in neuropsychiatric conditions such as bipolar disorder, schizophrenia, and depression.In addition, previous studies from Dr. Wilson‚Äôs lab showed that Friedreich ataxia (FRDA), an inherited neurodegenerative disorder, may involve ferroptosis in its pathogenesis (Cotticelli et al., 2019). Thus, the development of novel ferroptosis inhibitors is currently considered a promising avenue for treatment of neurodegenerative and neuropsychiatric diseases.Solution:Based on reports that oleic acid acts as a ferroptosis inhibitor, the inventors evaluated whether it, other fatty acids, and fatty acid derivatives could rescue viability in cellular models of FRDA. Thirteen new analogs were synthesized, with a focus on improving metabolic stability and improving physico-chemical properties. Several compounds were significantly more potent than oleic acid in rescuing cell viability in cells treated with ferroptosis inducers or FRDA sensitizers. The new ferroptosis inhibitors could potentially serve as a therapeutic for treatment of FRDA, as well as other diseases with implicated ferroptosis.Protection from FAC + BSO induced toxicity in primary human FRDA fibroblasts by (R)-24 and (S)-2. (*** = p < 0.005, * = p < 0.05, by Student‚Äôs t test. CC = Carrier Control (DMSO)) (Cotticelli, M et al.ACS Chem Neurosci. 2020, 11(17):2535-2542.)Stage of Development:Preclinical Discovery in FRDA modelsIntellectual Property:US PatentPendingReference Media:Cotticelli, M. et al.;ACS Chem Neurosci. 2020 Sept 2, 11(17): 2535.Cotticelli, M. et al.;J Pharmacol Exp Ther. 2019 Apr;369(1): 47.Desired Partnerships:LicenseCo-developmentCase ID:20-9206-tpNCSWeb Published:5/12/2023Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/51046","**Summary:** The technology involves the development of novel derivatives of oleic acid that effectively inhibit ferroptosis, a form of cell death linked to the accumulation of toxic lipid-reactive oxygen species and iron dependency. These inhibitors have shown promise in cellular models for treating Friedreich ataxia, neurodegenerative diseases, and neuropsychiatric disorders. The inventors have synthesized thirteen new analogs, focusing on enhancing metabolic stability and physico-chemical properties, with several compounds demonstrating greater efficacy than oleic acid in protecting cell viability under conditions that induce ferroptosis.

**Applications:** The novel inhibitors have potential applications in the treatment of Friedreich ataxia, various neurodegenerative diseases, and neuropsychiatric conditions, including but not limited to Parkinson's disease, Alzheimer's disease, Huntington's disease, bipolar disorder, schizophrenia, and depression.

**Problem Solved:** The technology addresses the issue of ferroptosis as a primary mechanism of cell death in neurodegenerative and neuropsychiatric diseases, providing a novel therapeutic strategy aimed at reducing cell death and improving cell survival in affected individuals.","Novel derivatives of oleic acid have been identified as effective inhibitors of ferroptosis, potentially aiding in the treatment of Friedreich Ataxia, neurodegenerative diseases, and neuropsychiatric disorders. Ferroptosis is characterized by the iron-dependent accumulation of toxic lipid-reactive oxygen species and is linked to neurological cell death in conditions like Parkinson's, Alzheimer‚Äôs, and Huntington‚Äôs diseases."
"University of Pennsylvania","A reconfigurable topological photonic insulator","","","https://upenn.technologypublisher.com/technology/41106","A topological insulator that routes optical signals from one port to another in a flexible manner, making use of its entire footprint.Problem:Controlling light flow is required for photonic infrastructures used in data processing, communication, and computing. However, current photonic integrated infrastructures are limited by crosstalk and disorder-induced scattering losses. As such, these infrastructures lack flexibility and require large footprints, making large-scale integrated photonic applications impractical.Solution:A topologic insulator has been developed which allows for the control of light flow across the surface of the insulator using optical pumping of spatial light patterns.Technology Overview:A non-Hermitian control of patterned gain/loss distribution is used to actively steer topological light along any route in a photonic integrated circuit. This control is conducted by optically pumping the photonic lattice to create distributed gain and loss domains. Using the non-Hermitian manipulation redefines the topological domain wall without altering the structure.Advantages:Does not require physical manipulation of the insulatorLight flow is only restricted by the size and shape of resonator arrayCan be applied to optical switches, circulators, and wave amplifiersMinimizes unwanted feedback and lossNon-Hermitian control of light propagation in a topological microring lattice. (A). Schematic of creating the topological edge channels along the gain/loss interface in the bulk of the photonic lattice with uniform global topology. (B) The topologic edge states can be dynamically reconfigured to steer light along any boundary.Stage of Development:ConceptProof of conceptBench prototypeIntellectual Property:PCTPendingCase ID:20-9135-tpNCSWeb Published:7/22/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/41106","**Summary:** A novel topological insulator has been developed that enables flexible routing of optical signals by manipulating light flow across its surface without the need for physical alterations. Utilizing non-Hermitian control methods, the technology modifies the patterned gain and loss distribution to effectively guide topological light along desired paths within photonic integrated circuits. This approach enhances control over light propagation while minimizing scattering losses and crosstalk.

**Applications:** The technology is applicable in various photonic infrastructures, particularly in optical switches, circulators, and wave amplifiers, making it suitable for use in data processing, communication, and computing systems.

**Problem Solved:** The solution addresses the challenges of controlling light flow in current photonic integrated infrastructures, which often suffer from limited flexibility, crosstalk, and disorder-induced scattering losses that hinder large-scale applications.","A topological insulator enables flexible routing of optical signals across its entire footprint, addressing the need for improved control over light flow in photonic infrastructures. Current systems face limitations due to crosstalk and disorder-induced scattering losses, resulting in reduced flexibility and larger footprints."
"University of Pennsylvania","Efficient, ultra-thin nanofiltration membranes for water filtration","","","https://upenn.technologypublisher.com/technology/41980","The technology is a fouling resistant nanofiltration membrane that filters out harmful contaminants from water and greatly reduces levels of hardness. The membrane is highly permeable and rejects divalent salts efficiently due to its unique water-channel architecture.Problem:Nanofiltration is an important emerging technology for low-pressure, and therefore low-cost, industrial wastewater remediation. It allows for the removal of pesticide residues, harmful organic small molecules, and macromolecules. Nanofiltration is also valued for water purification and softening through the removal of divalent ions that harden water, while at the same time, retaining minerals that Reverse Osmosis (RO) would otherwise remove.However, nanofiltration is not commonly used at industrial scales due to performance compromises originating in the broad pore size distribution that is inherent to current commercial membranes. Moreover, current nanofiltration membranes are expensive and need to be replaced periodically to prevent biofouling and chlorine degradation during cleaning.Solution:Bicontinuous, single-nanometer water channel architecture enables efficient membrane filtration due to its very low internal hydraulic resistance. This membrane architecture is highly selective and permeable, and it rejects divalent ions and small molecules efficiently. The membranes are resistant to fouling and last longer in chemical cleaning agents.Technology Overview:This highly selective nanofiltration membrane is made by crosslinking a lyotropic liquid crystal based on a cationic surfactant. The quaternary ammonium in the polar head of the surfactant provides fouling resistance. Self-arrangement in columnar profiles allows single-nanometer water-bi-continuous transport. This leads to efficient nanofiltration with higher permeability and better solute selectivity.Advantages:Improved purification capability via small molecule and salt rejectionSuperior hydraulic performance over 10 Lm2h-1bar-1Fouling resistant and longer lasting membranesNanofiltration rejection efficiencies: (top) Dominant rejection of divalent ions in various salt solutions with a consistent ionic strength. PVDF supported membrane shows a higher rejection efficiency for all ions. (bottom) Plot depicts a quantitative performance evaluation of this membrane. The experiment is conducted at a constant transmembrane pressure with solutions containing NaCl (solid symbol) or MgCl2 (hallow symbol) as solutes. This membrane technology (H1) demonstrates hydraulic flux around 55 Lm-2h-1 and a rejection rate around 90%.Stage of Development:Bench PrototypeIntellectual Property:PCTPendingReference Media:Zhang, Y et al.;Science Advances 16 March 2022 8(11): eabm5899Lerner, EPenn Engineering Today 27 April 2022Pappas, MPenn Engineering Today 25 April 2022Desired Partnerships:LicenseCo-DevelopmentCase ID:20-9369-tpNCSWeb Published:9/29/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/41980","**Summary:** The technology features a fouling-resistant nanofiltration membrane designed for effective water filtration by eliminating harmful contaminants and significantly reducing water hardness. It utilizes an innovative water-channel architecture that enhances its permeability and allows for the efficient rejection of divalent salts.

**Applications:** This membrane technology is applicable in industrial wastewater remediation, contributing to the removal of pesticide residues, harmful organic molecules, and macromolecules. It also serves in water purification and softening, making it suitable for industries requiring clean water with retained beneficial minerals.

**Problem Solved:** The technology addresses the limitations of traditional nanofiltration membranes, including performance issues related to pore size distribution and high costs. It mitigates the challenges posed by biofouling and chemical degradation, enabling a more sustainable and efficient solution for low-pressure water treatment applications.","The described technology features a fouling-resistant nanofiltration membrane that effectively removes harmful contaminants and reduces water hardness. Its highly permeable design efficiently rejects divalent salts, making it suitable for low-pressure industrial wastewater remediation."
"University of Pennsylvania","Self-adhesive multi-fiber materials that bond under mechanical strain","","","https://upenn.technologypublisher.com/technology/41043","Multi-fiber materials that adapt to mechanical loading through changes in fiber network structure and inter-fiber bonding, enabling self-adhesion and increased tensile strength.Problem:Multi-fiber materials are utilized in many applications ranging from textiles to tissue engineering. While current multi-fiber materials are able to adapt their shape to the structure of interest, they have limited mechanical strength, and therefore, fail easily under strain. Furthermore, these materials have weak self-adhesive properties, preventing them from holding their shape once in place.Solution:This invention describes a new approach for designing multi-fiber materials that provides several advantages over currently available materials. Individual fibers in the materials are designed to have specific chemistries that allow new chemical bonds to form under mechanical strain. As a result, these new bonds increase the tensile strength of the material and allow it to adhere to itself.Technology Overview:In this technology, multi-fiber materials are synthesized to have at least two fiber populations with compatible chemistries, such as aldehyde and hydrazide groups (See Figure). Upon mechanical strain, the chemical groups on each fiber population will come into contact and undergo a chemical reaction to form new bonds. Even after the mechanical strain is removed, these new bonds maintain the fiber alignment and help increase tensile strength. This also provides the multi-fiber material with exceptional self-adhesive properties, allowing it to hold its shape without the need for additional glues or bonding steps.Advantages:Provides 14-fold higher adhesive strength compared to traditional multi-fiber materialsThe fiber backbone, chemical groups, and processing methods can all be fully customized for the application of interestSelf-adhesion is possible under a variety of strains including stretching, twisting, stacking and rollingThe tensile strength of the material improves under strain, and fiber alignment is maintained after the strain is removedSchematic for the self-adhesive multi-fiber materials. In this multi-fiber system, fibers are synthesized to have complementary chemistries such as aldehyde (green) and hydrazide (red) groups. (A) When these fibers experience mechanical strain (such as stretching), these groups come into contact and form new chemical bonds with each other. Even when the mechanical strain is removed, these new bonds remain in place. (B) Complex interactions and self-adhesion can also be achieved by twisting, stacking, and rolling the multi-fiber system. (Figure source:Davidson et al. Advance Materials, 2019, 32, 1905719)Stage of Development:Proof of ConceptBench PrototypeIntellectual Property:US PatentPendingReference Media:Davidson, M et al.;Adv Mater 2020 Feb 32(8): e1905719Desired Partnerships:LicenseCo-developmentCase ID:19-8967-tpNCSWeb Published:7/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/41043","**Summary:** Multi-fiber materials are engineered to adapt to mechanical loading by altering their fiber network structure and inter-fiber bonding, thus enabling self-adhesion and enhanced tensile strength. The materials consist of different fiber populations, each with specific chemistries such as aldehyde and hydrazide groups. When subjected to mechanical strain, these fibers form new chemical bonds with one another, substantially enhancing their durability and preserving their shape even after stress is removed.

**Applications:** These advanced multi-fiber materials can be utilized across a wide range of fields, including textiles, tissue engineering, and other applications where adaptable, strong, and self-adhesive materials are essential.

**Problem Solved:** The technology addresses the limitations of conventional multi-fiber materials, which often exhibit low mechanical strength and poor self-adhesive properties. By allowing the fibers to bond under strain, the new materials maintain their integrity and shape, thereby preventing failure and improving overall performance under stressful conditions.","Multi-fiber materials can adjust their structure and inter-fiber bonding in response to mechanical loading, which enhances self-adhesion and tensile strength. However, existing materials still exhibit limited mechanical strength and are prone to failure under strain."
"University of Pennsylvania","Device for MRI Scanner Intra-Bore Disinfection","","","https://upenn.technologypublisher.com/technology/45130","Magnetic field-safe device for rapid disinfection of MRI bore and other types of scanners (CT, PET, PET-MR, SPECT) that is effective against COVID19, MRSA and other pathogens.Problem:With the advent of COVID-19, renewed emphasis has been placed on disinfecting surfaces in the medical environment. Disinfecting the MRI scanner bore is of particular importance due to the substantial time the patient spends in the bore, the close contact between the patient and the bore, and continuous patient turnover. The scanner bore presents a significant challenge to disinfect due to the strong magnet field and the space constraints imposed by the bore size and geometry. Also, for maximum effectiveness at controlling pathogen spread, disinfection of the bore must occur between each patient without disrupting the MRI schedule.Current method of disinfecting the bore involves the use of harsh chemicals manually applied by the MRI technician, which is inconsistent, time-consuming, and challenging to perform between patients due to scheduling constraints and MRI technician‚Äôs patient responsibilities. Additionally, the harsh chemical residues and fumes produced by the current method can corrode sensitive electronic systems as well as affect some patients.Solution:To address the limitations of the current manual method of MRI bore disinfection, a device was developed that can rapidly and effectively disinfect this area using UV-C light.The device is specifically designed to use non-ferrous materials and shielding of the electronic components to eliminate magnetic field interference. The system produces an intensity of UV-C which disinfects the entire MRI bore within minutes, enables rapid setup and removal, eliminates the use of harsh chemicals, minimizes the MRI technician involvement, and provides the capability to rapidly and effectively disinfect the MRI bore between patients.Advantages:Magnetic field safeRapid and effective disinfectionEasy set up and operationSmall sizeLow costApplication:Disinfection of bore for MRI and other types of scanners (CT, PET, PET-MR, SPECT)Stage of Development:Built prototypeConfirmed effectivenessIntellectual Property:US PatentPendingPCTPendingDesired Partnerships:LicenseCo-developmentCase ID:20-9379-tpNCSWeb Published:10/14/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45130","**Summary:** The technology is a magnetic field-safe device designed for the rapid disinfection of MRI scanner bores and other imaging modalities, such as CT, PET, PET-MR, and SPECT. It effectively targets pathogens, including COVID-19 and MRSA, providing an essential response to the heightened need for disinfection in medical settings, especially in light of the pandemic.

**Applications:** This device is applicable in hospitals and medical imaging facilities where MRI and other diagnostic imaging services are performed, particularly in areas requiring stringent infection control measures between patient scans.

**Problem Solved:** The device addresses the challenges associated with the manual disinfection of MRI scanner bores, which is difficult due to strong magnetic fields, space constraints, and the need for efficient turnover between patients. By utilizing UV-C light for disinfection, it minimizes the reliance on harsh chemicals that can leave residues harmful to both equipment and patients, thereby streamlining the process and enhancing safety and operational efficiency.","A magnetic field-safe device is designed for rapid disinfection of MRI scanners and other imaging equipment, effectively addressing pathogens such as COVID-19 and MRSA. The importance of disinfecting the MRI scanner bore is heightened due to the close contact and significant time patients spend inside it."
"University of Pennsylvania","Targeted Drug Delivery Using Red-Blood Cells for Transport","","","https://upenn.technologypublisher.com/technology/40454","Platform technology for targeted drug delivery using red blood cells for transport.Problem:Drug delivery can often result in up to 99% of the drug being delivered to off-target organs. This can lead to side-effects and toxicities. Current methods that bind drugs to red-blood cells for transport can require modifying the structure of the red blood cell.Solution:A platform technology for targeted drug delivery to target organs while reducing off target drug effects. This platform technology can be used with a variety of small molecule drugs required for treating organ sites without modifying the structure of the red blood cell.Technology Overview:Liposomes have been engineered to display antibodies that target red-blood cells and specific organ-sites, allowing for dual targeting. The liposomes can be loaded with a variety of small molecule drugs. Binding the liposome loaded with the drug molecule to red blood cells allows for leveraging red blood cells as drug shuttles and carriers.Advantages:2x greater drug delivery to the targeted organ as compared to passive red blood cell bindingControl of nanocarrier binding to red blood cell to reduce variabilityUtilization with a broad range of nanocarriersIncreased plasma half-life of nanocarriersStage of Development:In vivo proof of conceptIntellectual Property:US PatentPendingReference Media:Ferguson, LT et al.ACS Nano 2022 March 22 16(3):4666.Desired Partnerships:LicenseCo-developmentCase ID:20-9162-tpNCSWeb Published:6/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/40454","**Summary:** This technology provides a platform for targeted drug delivery by utilizing red blood cells for transport without modifying their structure. It addresses the inefficiencies in current drug delivery systems, where a substantial percentage of drugs are delivered off-target, leading to potential side effects and toxicity. The approach involves engineering liposomes to display antibodies that attach to red blood cells and specific organ sites, facilitating dual targeting. The liposomes can carry various small molecule drugs, enhancing targeted delivery effectiveness.

**Applications:** This technology can be applied in the treatment of various diseases requiring targeted drug delivery, ensuring that therapeutic agents reach specific organ sites while minimizing systemic exposure and side effects. 

**Problem Solved:** The platform technology effectively reduces the issue of off-target drug delivery, significantly improving the precision of drug targeting to specific organs, which helps alleviate associated side effects and toxicities commonly encountered with conventional drug delivery methods.","A platform technology has been developed for targeted drug delivery using red blood cells to reduce off-target effects, which can result in significant side effects and toxicities. This approach aims to enhance delivery efficiency without the need to modify the structure of the red blood cells."
"University of Pennsylvania","Protein Drugs Encapsulated in Plant Cells as Low-Cost Prevention and Treatment of Lung Injury in COVID-19 Patients","","","https://upenn.technologypublisher.com/technology/40119","Use of functional recombinant ACE2 and Angiotensin-(1-7) proteins to improve the clinical course of patients with symptomatic COVID-19 infection.Problem:COVID-19 is associated with high rates of respiratory failure, cardiac injury and death. Patients suffering from COVID-19 generally present with reduced expression of angiotensin converting enzyme 2 (ACE2) and depletion of ACE2‚Äôs protein product, the anti-inflammatory peptide Angiotensin-(1-7). This down-regulation of ACE2 expression is induced by viral invasion of SARS-CoV-2, the virus causing COVID-19 disease. Decreased ACE2 expression has been linked to acute respiratory distress, severe lung injury, multi-organ failure and death, especially in older patients.Solution:As a potential treatment for the severe complications of COVID-19 disease, oral supplementation of ACE2 and Angiotensin-(1-7) are being tested in a clinical trial to determine whether this intervention elicits protective effects on cardiac and respiratory function in COVID-19 patents. Restoring ACE2 with this therapeutic may mitigate virus-mediated lung and cardiac injury in COVID-19 patients.Technology Overview:Dr. Daniell and colleagues have developed a platform for producing recombinant ACE2 and Angiotensin-(1-7) in lettuce plants that is shelf-stable. Preclinical studies in pulmonary hypertension animal models showed that orally delivered ACE2 made in plant cells accumulated ten times higher in the lungs than in the blood and treated pulmonary hypertension at doses without any toxic effects. This application of plant-derived ACE2 therapy to patients with COVID-19 infection is enabled, in part, by prior toxicology studies done at Stanford Research Institute funded by NIH SMARTT program. The fact that freeze-dried plant cells can be stored at ambient temperature for one year and can be taken at home by COVID-19 patients are other attractive features of this novel approach.Advantages:Low-cost delivery compared to traditional protein therapies and/or gene therapiesPotential for reducing the use of high-cost, high-demand medical supplies such as ventilatorsTreatment for lung injury caused by COVID-19 diseaseOral ACE2 and Ang(1-7) Supplementation In Symptomatic COronaVIrus Disease (The OAASIS COVID trial): Background information on application of invention to COVID-19 patients.Angiotensin Converting Enzyme 2 (ACE2) is the binding site for SARS-CoV-2 entry into the lungs.Downregulation of ACE2 by SARS-CoV-2 leads to excess Ang II (pro-inflammatory) and reduced Ang (1-7) (anti-inflammatory)Intervention: Supplement ACE2 and Ang(1-7) with an orally-delivered plant-based formulation to debulk SARS-CoV2 and restore a more favorable balance of AngII and Ang(1-7)Stage of Development:Therapeutics: Phase I/II clinical trialIntellectual Property:US10,314,893US10,806,775US11,241,487EP3,058,074CA2,957,211Reference Media:Daniell, H. et al.;Biomaterials, 2020 Mar, 233: 119750Kwon, K & Daniell, HPlant Biotechnol J, 2015 Oct, 13(8): 1017Shenoy, V. et al.;Hypertension, 2014 Dec, 64(6): 1248Shil, PK et al.;Mol Ther, 2014 Dec, 22(12): 2069Baillie, KUPenn Today 5.5.20Penn Dental Med Website. Spotlight on Penn‚Äôs Vagelos LSM Capstone Course, 2018 Apr 27Desired Partnerships:LicenseCase ID:14-6881-tpNCSWeb Published:6/2/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/40119","**Summary:** This technology focuses on using functional recombinant ACE2 and Angiotensin-(1-7) proteins produced in lettuce plants to improve outcomes for patients suffering from symptomatic COVID-19 infection. It addresses the issue of reduced ACE2 expression and depletion of Angiotensin-(1-7), which are linked to severe respiratory and cardiovascular complications in COVID-19 patients. Clinical trials are assessing the efficacy of oral supplementation of these proteins to protect lung and heart functions in individuals infected with the virus.

**Applications:** The primary application of this technology is in the treatment and prevention of acute respiratory distress and cardiac injury associated with COVID-19 disease. It may serve as a therapeutic option for patients experiencing severe complications from COVID-19, particularly in older populations who are more vulnerable to such outcomes.

**Problem Solved:** This approach aims to mitigate the severe complications of COVID-19, including respiratory failure, cardiac injury, and multi-organ failure, which are exacerbated by the down-regulation of ACE2 due to SARS-CoV-2 infection. By restoring ACE2 levels and enhancing the availability of Angiotensin-(1-7), the therapy seeks to improve clinical outcomes and reduce the mortality associated with COVID-19.","COVID-19 is linked to increased respiratory failure, cardiac injury, and mortality, often due to reduced levels of angiotensin converting enzyme 2 (ACE2) and its protective product, Angiotensin-(1-7). The study investigates the use of functional recombinant ACE2 and Angiotensin-(1-7) proteins to enhance the clinical outcomes in symptomatic COVID-19 patients."
"University of Pennsylvania","Therapeutic Antibodies Against Pathological Tau Proteins for the Treatment of Alzheimer‚Äôs Disease (AD)","","","https://upenn.technologypublisher.com/technology/39972","Two novel monoclonal antibodies were discovered that target pathological conformations of the tau protein. The antibodies were shown in vitro and in vivo to inhibit the spread of pathological tau protein aggregates, which is one of the defining characteristics of AD.Problem:More than 5 million Americans are living with Alzheimer‚Äôs disease which is the 6th leading cause of death (Alzheimer‚Äôs Association. 2020 Alzheimer‚Äôs Disease Facts and Figures. Alzheimer‚Äôs Dement 2020). Current treatments do not adequately slow the progression of the diseases. By 2022, the market for AD therapeutics is expected to reach nearly USD $9 billion, a significant percentage of which is anticipated to be novel antibodies directed against tau, and beta amyloid proteins (Potential Pipeline Disruptors, Kalorama Information, 2017).Intracellular tau protein aggregates are a pathological hallmark of AD. In the disease state, misfolded tau spreads from cell to cell thereby introducing seed aggregates in neighboring cells which perpetuate the pathology of the disease.Solution:The novel monoclonal antibodies are designed to bind to the misfolded tau released from neurons and prevent it from entering nearby cells, thus slowing down disease progression.Technology Overview:Two monoclonal antibodies were developed against the pathological form of tau. These antibodies have been fully sequenced and shown to be active in vitro, and in vivo in a murine model of Alzheimer‚Äôs disease. The antibodies were generated by immunization of mice using AD-tau paired helical filaments (PHFs).These novel conformation-selective tau antibodies selectively bind to pathological tau compared to recombinant tau monomer, block the uptake of tau fibrils into cells, and prevent the cell-to-cell transmission of tau pathology in primary neurons and in a mouse model of AD.Advantages:Selective binding to pathological tau conformersPrevention of cell-to-cell transmission of aggregated tauPotential ability to slow down Alzheimer‚Äôs disease progressionAntibody DMR7 inhibits seeded aggregation of tau protein in mouse primary neurons. Fluorescent microscopy of pathological mouse tau aggregates (green) and cell nuclei (blue) demonstrates that DMR7 inhibits human AD brain derived tau (AD-tau) seeds from recruiting endogenous mouse tau in the primary neuron assay described in Guo, J. L. et al. J. Exp. Med. (2016) 213: 2635-2654.Stage of Development:Preclinical DiscoveryIND Enabling StudiesIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:20-9306-tpNCSWeb Published:5/15/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39972","**Summary:** Two novel monoclonal antibodies have been developed that specifically target pathological conformations of tau protein associated with Alzheimer‚Äôs disease. In both in vitro and in vivo studies, these antibodies have demonstrated efficacy in inhibiting the spread of tau protein aggregates, a key feature of the disease. These antibodies are fully sequenced and have shown to be active in a murine model of Alzheimer‚Äôs.

**Applications:** The primary application of these antibodies is in the treatment of Alzheimer‚Äôs disease, particularly for slowing its progression by preventing the spread of misfolded tau proteins within the brain.

**Problem Solved:** The technology addresses the significant challenge of Alzheimer's disease, which affects over 5 million people in the U.S. and currently lacks effective treatments to slow its progression. By targeting the pathological tau aggregates that contribute to the disease, these antibodies aim to provide a new therapeutic option in a market projected to reach nearly USD $9 billion by 2022.","Two novel monoclonal antibodies targeting pathological conformations of the tau protein were discovered, demonstrating the ability to inhibit the spread of tau protein aggregates in vitro and in vivo. Alzheimer's disease affects over 5 million Americans and is the sixth leading cause of death, with current treatments being insufficient."
"University of Pennsylvania","Functional Nerve Guidance Conduit for the Rapid Treatment of Peripheral Nerve Injuries","","","https://upenn.technologypublisher.com/technology/39786","A collagen-based nerve guidance conduit containing functional Schwann cell precursor-like cells derived from stem cells for the rapid treatment of peripheral nerve injuries.Technology Overview:A peripheral nerve injury (PNI) occurs in approximately 3% of all trauma patients. While treatment options for PNIs have improved with advances in microsurgical techniques and development of nerve guidance conduits, less than 50% of PNIs show full functional recovery. The current gold standard of treatment for PNI is the use of nerve autografts, which is further limited by the availability of nerve sources, donor/recipient mismatch, and severe donor‚Äêsite morbidity associated with secondary surgical procedure.Schwann cells are peripheral nervous system glial cells that make myelin around axons. Schwann cells play a critical role in repairing damage to the peripheral nervous system related to axonal regrowth during nerve repair and regeneration.The Le group has developed a method of generating functionalized nerve guidance conduits for use in repairing PNIs. This method utilizes mesenchymal stem cells from gingiva tissue (GMSC) of a neural crest-origin and converts them into neural crest stem-like (NCSC) or Schwann cell precursor (SCP)-like cells encapsulated and cultured in 3D-collagen hydrogel.Whereas nerve guidance conduits in combination with various types of supportive cells have previously been tested for repairing PNIs, their success has varied due to a lack of uniformity in their cellular makeup and matrix embedding. GMSC-laden collagen hydrogels offer an improved approach for direct conversion of GMSCs into NCSC/SCP-like cells with the capability to trans-migrate and integrate into the aligned wall matrix of natural nerve, forming a functionalized nerve guidance conduit with unique capability for PNI regeneration and functional recovery as demonstrated in the crush-injured rat sciatic nerve model.Advantages:Fewer donor/recipient mismatch issues expectedEnhanced capability to differentiate into Schwann-like cellsShorter time interval for differentiation into Schwann-like cellsMesenchymal stem cells from gingiva are more proliferative than those from bone marrowApplications:Treatment of peripheral nerve injuriesStage of Development:Proof of concept demonstrated in ratsIntellectual Property:US PatentPendingReference Media:Zhang, Q et al.Mol Neurobiol.2018 Aug; 55(8): 6965.Mao, Q. et al.Tissue Eng Part A., 2019 Jun, 25(11-12): 887.Zhang, Q. et al.Sci Rep. 2018 Apr, 8(1): 6634.Zhang, Q. et al.Stem Cells Transl Med. 2017 Feb, 6(2): 458.Desired Partnerships:LicenseCo-developmentCase ID:19-9008-tpNCSWeb Published:5/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39786","**Summary:** A novel collagen-based nerve guidance conduit incorporates functional Schwann cell precursor-like cells derived from stem cells to accelerate the repair of peripheral nerve injuries. Currently, treatment options for peripheral nerve injuries, which affect approximately 3% of trauma patients, involve nerve autografts, but these approaches have limitations, including donor site morbidity and variable recovery rates. The advancement of the conduit aims to address these shortcomings by utilizing neural crest stem-like cells from mesenchymal stem cells, which are encapsulated in a 3D-collagen hydrogel to enhance nerve regeneration.

**Applications:** This technology could be applied in clinical settings for the treatment of peripheral nerve injuries, particularly in cases where traditional methods such as nerve autografts are less viable due to donor site availability or recovery concerns.

**Problem Solved:** The innovation offers a promising solution to the challenges currently faced in the treatment of peripheral nerve injuries, aiming to improve functional recovery rates by providing a supportive scaffold and the necessary cellular environment for effective nerve repair and regeneration.","A collagen-based nerve guidance conduit containing Schwann cell precursor-like cells derived from stem cells is designed for the rapid treatment of peripheral nerve injuries. Current treatments for peripheral nerve injuries yield less than 50% full functional recovery despite advancements in microsurgery and nerve conduits."
"University of Pennsylvania","Lipid nanoparticle-based mRNA delivery for CAR T-cell engineering","","","https://upenn.technologypublisher.com/technology/39766","A library of ionizable lipid nanoparticles (LNPs) was screened for ability to deliver mRNA to T-cells, leading to an optimized LNP formulation for delivery of mRNA to T-cells. This thereby enhances the ability to generate transient chimeric antigen receptor (CAR)-expressing T-cells for cancer immunotherapy.Problem:Chimeric antigen receptor (CAR) T-cells are T-cells that have been genetically engineered to express a synthetic T-cell receptor that gives them the ability to initiate immune responses against specific proteins.By engineering T-cells to target proteins expressed specifically by cancer cells, CAR T-cells are a highly effective cancer immunotherapy. The current manufacturing process of generating CAR T-cells utilizes viruses to permanently express the CAR on the T-cell surface. This permanent CAR expression is associated with adverse side effects such as cytokine storm and neurotoxicity long after the CAR T-cells have performed their therapeutic function.Solution:This technology overcomes the challenges associated with virally engineered CAR T-cell therapy is by utilizing LNPs to transfect T-cells with CAR-encoding mRNA. Because mRNA is translated without genomic integration, this results in transient CAR expression.Technology Overview:This technology is a novel ionizable lipid (C14-4) and a method of synthesizing (C14-4)-based LNPs. A library of novel ionizable lipids was generated and screened for their ability to transduce T-cells with mRNA when combined into LNPs. The novel ionizable lipid with the highest T-cell transfection efficiency was C14-4 and this was subsequently shown to be more effective than lipofectamine electroporation at generating CAR T-cells via delivery of CAR mRNA. CAR T-cells generated with (C14-4)-based LNPs are effective at killing cancer in vitro.Advantages:C14-4 LNP-based delivery of CAR mRNA to T-cells results in transient CAR expression, thereby decreasing the likelihood of adverse side effects caused by permeant CAR expression resulting from viral T-cell engineering.Enhanced mRNA delivery to T-cells relative to electroporation with lipofectamine.Less toxic to T-cells than electroporation with lipofectamine.(A) Schematic of the components used to generate LNPs via microfluidic mixing and the expected structure of the resulting LNPs. (B) The size (z-average) distribution of a representative sample of C14‚Äì4 LNPs, revealing a diameter of approximately 70 nm using dynamic light scattering. Error bars represent the standard deviation across three samples. (C) Schematic of CAR mRNA loaded LNPs inducing CAR expressionin T cells, resulting in tumor cell targeting and killing.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:Patents Pending in US, Australia, Canada, China, Europe, Japan, and ROKReference Media:Billingsley et al.Nano Lett. 2020 March 11 20(3): 1578Desired Partnerships:LicenseCo-developmentCase ID:20-9151-tpNCSWeb Published:5/4/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39766","**Summary:** A library of ionizable lipid nanoparticles (LNPs) was developed and screened, resulting in an optimized formulation that effectively delivers mRNA to T-cells. This approach enhances the generation of transient chimeric antigen receptor (CAR)-expressing T-cells, which are used in cancer immunotherapy. Unlike traditional methods that utilize viral vectors for permanent CAR expression, this technology leverages LNPs to deliver CAR-encoding mRNA, allowing for temporary expression of the CAR on T-cell surfaces.

**Applications:** This technology can be applied in the field of cancer immunotherapy, specifically in the engineering of CAR T-cells that target cancer cell-specific proteins. It provides a safer alternative for generating CAR T-cells, potentially reducing adverse side effects associated with permanent CAR expression.

**Problem Solved:** The technology addresses the challenges of traditional CAR T-cell therapy, which relies on viral delivery methods that can lead to long-term side effects such as cytokine storms and neurotoxicity. By using LNPs for mRNA delivery, it allows for transient CAR expression, minimizing the risks associated with permanent genetic modifications.","A library of ionizable lipid nanoparticles (LNPs) was screened to optimize the delivery of mRNA to T-cells, improving the generation of transient CAR-expressing T-cells for cancer immunotherapy. This approach enhances the ability of these engineered T-cells to initiate an immune response against cancer."
"University of Pennsylvania","Rapid Method to Design and Screen Novel Lipid Nanoparticles for mRNA Delivery In Vivo","","","https://upenn.technologypublisher.com/technology/39765","A platform technology to rapidly identify novel lipid nanoparticle (LNP) formulations to carry mRNA-based therapeutics to target organs/cells in vivo.Problem:Messenger RNA (mRNA) has emerged as a promising new class of nucleic acid therapy, with the potential to induce protein production to treat and prevent a range of diseases. While significant progress has been made in the design of in vitro-transcribed mRNA, the widespread use of mRNA as a therapeutic requires safe and effective delivery of the mRNA to tissues in vivo.Ionizable lipid nanoparticles (LNPs) are an emerging method to deliver mRNA to cells in vivo. However, targeting LNPs to deliver their mRNA cargo to a specific tissue of interest following intravenous injection has hampered their utility.Solution:This is a platform technology to screen for novel LNP formulations that optimize mRNA delivery to a desired cell type or organ in vivo.Technology Overview:The technology consists of a library of engineered LNPs that encapsulate functional, custom-designed barcoded mRNA (b-mRNA). These b-mRNA are similar in structure and function to regular mRNA and contain barcodes that enable their delivery to be quantified via deep sequencing.Using a mini-library of b-mRNA LNPs, a pool of different b-mRNA LNP formulations can be simultaneously administered intravenously into mice as a single pool. The relative delivery efficacy of different b-mRNA LNPs to any target organ can then be determined via deep sequencing to determine the relative abundance of all b-mRNA LNPs in the organ of interest.Advantages:Accelerates the in vivo screening and design of LNPs for mRNA therapeutic applications such as CRISPR-Cas9 gene editing, mRNA vaccination, and other mRNA-based regenerative medicine and protein replacement therapies.This platform can be used to identify LNP formulations that target antigen presenting cells for mRNA-based vaccine development.Novel LNPs + luciferase encoding b-mRNA are formulated via microfluidic mixing such that each novel b-mRNA is encapsulated by a novel LNP formulation. Different LNP formulations are then pooled together and administered intravenously to mice. Organs were harvested 4 h post injection, and b-mRNA delivery was quantified using both whole-organ bioluminescence imaging and deep sequencing of unique barcodes.Stage of Development:Proof of ConceptIntellectual Property:Patents Pending in US, Europe, CanadaReference Media:Guimaraes et al.,J Control Release 2019 Dec 28 316: 404Oberli et al.Nano Lett 2017 Mar 8, 17(3):1326Desired Partnerships:LicenseCo-developmentCase ID:19-9058-tpNCSWeb Published:5/4/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39765","**Summary:** This platform technology enables the rapid identification of novel lipid nanoparticle (LNP) formulations designed for effective mRNA delivery to specific organs or cells in vivo. It incorporates a library of engineered LNPs that encapsulate barcoded mRNA (b-mRNA), which allows for the quantification of mRNA delivery and ensures that the mRNA maintains its functional integrity.

**Applications:** The primary application of this technology is in the development of mRNA-based therapeutics for the treatment and prevention of various diseases. By optimizing the delivery of mRNA to targeted tissues, this technology can enhance the therapeutic efficacy of mRNA therapies in vivo.

**Problem Solved:** The technology addresses the challenge of delivering mRNA therapeutics effectively to specific tissues in vivo, which has been a significant barrier to the broader application of mRNA therapies. By improving the targeting of ionizable lipid nanoparticles, it enhances the potential of mRNA to induce protein production necessary for therapeutic action.","A platform technology has been developed to quickly identify novel lipid nanoparticle (LNP) formulations for delivering mRNA-based therapeutics to specific target organs or cells in vivo. This advancement addresses the need for safe and effective delivery methods for mRNA as a promising class of nucleic acid therapy."
"University of Pennsylvania","Treating Melanoma with CAR-T Cells","","","https://upenn.technologypublisher.com/technology/39785","This invention describes construction and initial functional testing of engineered chimeric antigen receptors transduced into human T-cells (CAR-T cells) for selective killing of melanocytes and melanoma cells.Technology Overview:Invasive melanoma is the most lethal and costly skin cancer with over 75,000 new cases and 10,000 deaths per year in the U.S with more than one life claimed every hour. Over the past few years, immunotherapies that target common genetic mutations has dramatically changed the landscape of melanoma treatment but some patients with advanced metastatic melanoma still have a significant risk of mortality. New therapeutic approaches are needed.Dr. Ridky proposes a CAR-T cell based technology to selective killing of melanocytes. These CARs do not target uveal melanocytes. Killing of melanoma cells and melanocytes, with little to no killing of human fibroblasts using these engineered CAR T-cells was shown in vitro as well as in vivo in NSG mice. But melanocytes are dispensable.Advantages:Would circumvent relapse seen with check point inhibitors and other forms of treatment for melanoma.Offers selective killing of melanoma cells and melanocytes with little toxicity on other cells types.Applications:CAR T-cell based treatment is an option to treat invasive melanoma as it causes regression of the tumor by selectively killing melanoma cells and melanocytes.Can provide an alternative treatment for patients with advanced metastatic melanoma and for patients on whom immunotherapy/check point inhibitors does not work.Stage of Development:Killing of melanoma cells and melanocytes in vitro and in in vivo in NSG mice.Intellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:17-8000-tpNCSWeb Published:5/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39785","**Summary:** This invention focuses on the construction and initial functional testing of engineered chimeric antigen receptors (CAR-T cells) designed to selectively kill melanocytes and melanoma cells. Invasive melanoma is a highly lethal skin cancer with significant annual incidence and mortality in the U.S. Despite advances in immunotherapy targeting common genetic mutations, advanced metastatic melanoma still poses a serious mortality risk, highlighting the need for new treatment options. The proposed technology demonstrated effective killing of melanoma cells and melanocytes in vitro and in vivo, with minimal effects on human fibroblasts, indicating a targeted therapeutic approach with reduced toxicity. 

**Applications:** CAR-T cell-based treatment offers a promising option for invasive melanoma by promoting tumor regression through selective targeting of melanoma cells and melanocytes. This technology could serve as an alternative treatment for patients suffering from advanced metastatic melanoma, particularly for those who have not responded adequately to existing therapies.

**Problem Solved:** This approach addresses the limitations of current melanoma treatments, such as checkpoint inhibitors, which can lead to relapses. By providing a selective killing mechanism with less toxicity to surrounding healthy cells, this technology enhances the potential for effective treatment outcomes in melanoma patients.","This invention involves the development and initial testing of engineered chimeric antigen receptors in human T-cells (CAR-T cells) aimed at selectively targeting and eliminating melanocytes and melanoma cells. Melanoma is identified as the most lethal skin cancer, with over 75,000 new cases and 10,000 deaths annually in the U.S."
"University of Pennsylvania","Novel Uses of Androgen Receptor Inhibitors in Cancer","","","https://upenn.technologypublisher.com/technology/39703","Repurposing of androgen receptors inhibitors for prostate cancer treatment to treat other cancer in males such as melanoma.Problem:For many cancer types, women have lower incidence and better outcomes than men. The role of sex steroid hormones, such as estrogen and testosterone, has been studied in reproductive organ cancers such as prostate and breast cancer, but not in other non-androgen (AR)-driven cancers. Recent studies have shown that testosterone promotes cancer cell proliferation.Solution:Inhibiting testosterone-induced tumor growth as a new therapeutic approach for non-AR-driven cancer.Technology Overview:Dr. Ridky and colleagues demonstrated that testosterone promotes cancer cell proliferation through a non-AR-dependent mechanism. Four existing FDA-approved androgen receptor inhibitors, flutamide, bicalutamide, enzalutamide, and apalutamide, are inhibiting the proliferation of different cancer cell lines, from non-reproductive non-AR expressing tissues. Hence these therapeutics may have a way broader therapeutic effect than earlier contemplated.Advantages:Enhance effectiveness of current cancer therapy treatment using already approved drugsTop Figure: Both bicalutamide (CDX) and enzalutamide (ENZ) completely block testosterone-induced proliferation of melanoma cell lines. Bottom Figure: Tumor growth in SCID male mice bearing WM46-derived subcutaneous tumors was inhibited by Apalutamide (20mg/kg/day via oral gavage).Stage of Development:In Vivo POCIntellectual Property:US11,992,478Reference Media:Aguirre-Portoles, C et al.;Cancer Res 2021 Dec 1; 81(23): 5991.Desired Partnerships:Sponsored research and licensingCase ID:20-9153-tpNCSWeb Published:4/28/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39703","**Summary:** The research focuses on repurposing existing androgen receptor inhibitors, which are currently used to treat prostate cancer, for the treatment of other cancers in males, such as melanoma. Studies indicate that testosterone can promote cancer cell proliferation even through non-androgen receptor mechanisms, providing a new avenue for therapeutic intervention.

**Applications:** The approach involves using FDA-approved androgen receptor inhibitors‚Äîflutamide, bicalutamide, enzalutamide, and apalutamide‚Äîto inhibit tumor growth in non-androgen receptor driven cancers. This strategy could enhance the effectiveness of current cancer treatments for a wider range of cancer types.

**Problem Solved:** There is a disparity in cancer incidence and outcomes between males and females, with males suffering from a higher incidence in many cancers and often poorer outcomes. By targeting testosterone's role in tumor growth, the new therapeutic approach aims to improve treatment options and outcomes for male patients with various forms of cancer beyond those typically associated with androgen receptors.","Androgen receptor inhibitors, originally used for prostate cancer treatment, are being explored for their potential in treating other male cancers, including melanoma. Research indicates that testosterone may promote cancer cell proliferation in various non-androgen-driven cancer types."
"University of Pennsylvania","Up-regulators of utrophin expression for the treatment of muscular dystrophy","","","https://upenn.technologypublisher.com/technology/39678","Small molecules targeting utrophin mRNA untranslated regions overcome post-transcriptional repressionProblem:Duchenne Muscular Dystrophy (DMD) is an X-linked neuromuscular disorder that affects approximately 1 in 3500 males worldwide. DMD is caused by mutations in the DMD gene that lead to severe reduction or loss of dystrophin protein. Without appropriate dystrophin expression, patients experience progressive muscle degeneration and weakness that leads to early death around the third decade of life. While corticosteroids can be used to slow disease progression, there is no definitive cure for DMD.Solution:In the absence of dystrophin, the autosomal homolog utrophin has been shown to partially replace dystrophin function. Utrophin is highly expressed during fetal development, but is actively down-regulated in adult muscle through numerous post-transcriptional repression mechanisms. Rather than supplement utrophin expression using gene therapy, this technology prevents repression of endogenous utrophin transcripts in adult muscle to enhance expression.Technology Overview:Scientists in the Khurana lab used high-throughput screening to identify small molecule compounds that increase utrophin expression by acting at the 5‚Äô and/or 3‚Äô untranslated regions (UTRs) of the utrophin transcript. Lead compounds were prioritized using an algorithm developed by the Inventors that incorporates specificity and dose-response characteristics. The top 5 hits from a SelleckChem Bioactive Compound library (detailed in Table 2 Loro, Emanuele et al.) are all approved by the FDA for clinical testing. In vivo validation of the top hit, trichostatin A (TSA) showed increased utrophin expression and muscle function after three months in a mouse model of DMD (see figure). A second screen comprising 96,000 small molecules revealed five additional novel compounds that may be developed as DMD therapeutics.Advantages:Eight of the top 10 SelleckChem compounds increase utrophin expression over 1.5-foldSeven of the top 10 SelleckChem hits have been used in clinical trials which provide safety and tolerability information in humansApproach enables expression of full-length protein, in contrast to gene replacement strategies that are limited by vector sizeUse of small molecules avoids potential toxic immune response against viral vectors or transgenesIn vivo preclinical validation of TSA treatment in the mdx mouse model of DMD. (A) Body weight monitored during TSA treatment. Utrophin mRNA (B) and protein (C) levels in TA muscle after TSA treatment. (D) Rotarod performance test after TSA treatment. Twitch (E) and tetanic (F) specific forces of EDL muscles after TSA treatment. (G) EDL force decrement after 5 consecutive eccentric contractions. Values are mean and standard error of the mean. *p < 0.05. Caption modified from Loro, Emanuele et al. Scientific reports. 2020.Figure origin: Figure 4 from Loro, Emanuele et al. ‚ÄúHigh-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy.‚Äù Scientific reports vol. 10,1 2132. 7 Feb. 2020.Stage of Development:Target IdentifiedPreclinical DiscoveryIntellectual Property:USPendingReference Media:Loro, E. et al;Sci Rep 2020 Feb 7; 10(1): 2132Frank, Otto;Penn Medicine News. 24 Feb. 2020Desired Partnerships:LicenseCo-developmentCase ID:20-9100-tpNCSWeb Published:4/28/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39678","**Summary:** Small molecules have been identified that target the untranslated regions of utrophin mRNA, effectively overcoming post-transcriptional repression and enhancing utrophin expression in adult muscle. This approach aims to utilize the naturally occurring utrophin protein to compensate for the loss of dystrophin in individuals with Duchenne Muscular Dystrophy (DMD), a condition characterized by severe muscle degeneration and weakness due to mutations in the DMD gene.

**Applications:** The technology may be applied as a therapeutic strategy for treating DMD by increasing the expression of utrophin, thereby potentially slowing disease progression and improving muscle function in affected patients.

**Problem Solved:** The method addresses the absence of effective dystrophin in DMD patients by leveraging utrophin, which can partially fulfill the functional role of dystrophin, without the need for invasive gene therapy techniques.","Duchenne Muscular Dystrophy (DMD) is an X-linked disorder caused by mutations in the DMD gene, resulting in reduced or absent dystrophin protein, which leads to progressive muscle degeneration. Small molecules that target utrophin mRNA untranslated regions show potential in overcoming post-transcriptional repression to increase utrophin expression as a therapeutic approach for DMD."
"University of Pennsylvania","Gene Therapy for Achromatopsia","","","https://upenn.technologypublisher.com/technology/39441","Problem:There currently is no cure for Achromatopsia which affects up to 1: 50,000 patients in the US.Solution:Dr. Jean Bennett, MD, PhD, Kirby Professor of Ophthalmology at the University of Pennsylvania‚Äôs Perelman School of Medicine, one of the first investigators to develop a gene therapy for a rare inherited form of retinal blindness has developed a novel gene therapy for Achromatopsia, an inherited retinal degeneration characterized by the loss of cone photoreceptor function resulting in partial or total absence of color vision.Dr. Bennett and her team at Penn‚Äôs Center for Advanced Retinal and Ocular Therapeutics (CAROT) have developed an adeno associated viral vector for the delivery of an optimized CNGA3 gene. Mutations in the alpha subunit of the cone photoreceptor cyclic nucleotide-gated channel (CNGA3) genes underlie ~25% of Achromatopsia cases.When delivered to the retina of the CNGA3-/- mice, these constructs have shown a dose dependent expression in the targeted cone cells with minimal adverse effects on the rod function. Similar results in humans would offer a potential cure for Achromatopsia.Stage of Development:A complete data package on the lead clinical candidate are available for reviewIntellectual Property:US11,090,392EP3,389,724AU2016370487JP7057281CN109069668RU2762747Reference Media:Achromatopsia Disease Overview(pdf)Delivery of vector in CNGA3-/-mice(pdf)Desired Partnerships:LicensingCo-DevelopmentCase ID:16-7660-tpNCSWeb Published:4/1/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39441","**Summary:** Gene therapy developed by Dr. Jean Bennett and her team at the University of Pennsylvania‚Äôs Perelman School of Medicine aims to provide a potential cure for Achromatopsia, a rare inherited retinal degeneration that leads to the loss of color vision and affects approximately 1 in 50,000 individuals in the US. This therapy utilizes an adeno-associated viral vector for the delivery of an optimized CNGA3 gene, targeting the specific mutations in the CNGA3 gene, which accounts for about 25% of Achromatopsia cases. Initial studies in CNGA3-/- mice indicate successful gene expression in cone cells with minimal adverse effects. 

**Applications:** The gene therapy primarily targets Achromatopsia, aiming to restore cone photoreceptor function and improve or restore color vision in affected patients.

**Problem Solved:** The technology addresses the lack of effective treatments or cures for Achromatopsia, a condition that significantly impairs color vision due to mutations affecting cone photoreceptors.","Achromatopsia, affecting approximately 1 in 50,000 patients in the US, currently has no cure. Dr. Jean Bennett from the University of Pennsylvania has developed a novel gene therapy targeting this inherited retinal degeneration, which leads to the loss of cone photoreceptor function."
"University of Pennsylvania","CAR T cell therapy for the treatment of ovarian cancer and other gynecologic malignancies","","","https://upenn.technologypublisher.com/technology/39143","Anti-Mullerian inhibiting substance type II receptor (MISRII) specific CAR T cell therapy for the targeted, safe treatment of ovarian cancer.Technology Overview:Ovarian cancer is the 5th leading cause of cancer-related deaths in women and is the most lethal of all gynecologic malignancies with an overall 5-year survival rate of 46%. The M√ºllerian Inhibiting Substance Type 2 Receptor (MISIIR),a member of the TGF-Œ≤ receptor family, overexpressed in the majority of ovarian tumors and other gynecologic tumors, makes it an appealing target for cell immunotherapy.Dr. Powell and colleagues have developed MISIIR-specific CAR T cells with distinct single-chain antibody variable fragments of MISIIR, coupled to CD27 and CD3z intracellular signaling domains. The select GM7-27Z CAR variant exhibits antigen-specific reactivity, cytokine secretion and tumor cell lysis in vitro against a broad range of human tumor cell lines including ovarian and endometrial cancer expressing variable levels of endogenous MISIIR. GM7-27Z does not exhibit cytotoxicity when co-cultured with a broad panel of normal primary human cells, suggesting a safe profile of targeting. Additionally, in vivo GM7 CAR T cells showed potent antitumor effect in immunocompromised mice bearing large established subcutaneous C30.MISIIR tumors, completely clearing 60% of the tumors and significantly prolonging mice survival. Overall, the GM7-27Z variant supports the potential of MISIIR as a novel target for the efficacious and safe treatment of ovarian cancer and other gynecologic malignancies using CAR T cell therapy.Advantages:Enhances capability of CAR T therapy use for the treatment of solid tumors, particularly those related to ovarian cancerImproved safety, specificity, and targeting of CAR T cells to tumor cells given very low expression levels of MISIIR in healthy tissue tissue but overexpression in gynecologic cancersApplications:CAR T therapy for the treatment of ovarian cancer and other gynecologic malignancies(A)Schematic representation of MISIIR CAR constructs based on 4 different scFv and containing CD27 and CD3z I trace lunar domains. CD19 CAR was used as a control. (B) GM7-27Z CAR shows specific activation and response in vivo.Stage of Development:In Vivo anti-tumor effect of MISIIR-CAR T cells demonstrated in several subcutaneous tumor models in miceIn vitro efficacy using patient-derived ovarian cancer cell: upregulation of T cell activation markers and cytokine secretionIntellectual Property:Provisional patent filedReference Media:Rodriguez-Garcia et. al. Molecular Biology 2020 Feb; 28(2): 548Desired Partnerships:LicenseCo-developmentCase ID:15-7298-tpNCSWeb Published:3/11/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39143","**Summary:** CAR T cell therapy targeting the M√ºllerian Inhibiting Substance Type 2 Receptor (MISIIR) presents a novel approach for treating ovarian cancer and other gynecologic malignancies. This therapy utilizes genetically modified T cells that specifically recognize and attack tumors expressing MISIIR, which is overexpressed in the majority of ovarian tumors. The GM7-27Z CAR variant has demonstrated a strong ability to induce tumor cell lysis and secrete cytokines in vitro against a diverse range of human cancer cell lines while maintaining a safe profile by sparing normal human cells from cytotoxicity. In vivo studies in immunocompromised mice have shown promising results, with a significant reduction in tumor burden and prolonged survival among treated subjects.

**Applications:** The technology is intended for the treatment of ovarian cancer and other gynecologic malignancies, particularly those characterized by the expression of MISIIR. It aims to provide a more targeted and effective immunotherapy option for patients suffering from these cancers.

**Problem Solved:** This CAR T cell therapy addresses the high mortality rate associated with ovarian cancer, which is the fifth leading cause of cancer-related deaths in women, by targeting specific receptors that are overexpressed in tumors. It offers a new therapeutic option that promises effectiveness while minimizing damage to normal tissues, thereby improving safety and outcomes for patients with these malignancies.","Ovarian cancer is the most lethal gynecologic malignancy, with a 5-year survival rate of 46%, and the M√ºllerian Inhibiting Substance Type 2 Receptor (MISIIR) is overexpressed in most ovarian tumors. Anti-Mullerian inhibiting substance type II receptor (MISRII) specific CAR T cell therapy aims to provide a targeted and safe treatment for ovarian cancer and other gynecologic malignancies."
"University of Pennsylvania","Improving Drug Delivery Using Red Blood Cell Hitchhiking","","","https://upenn.technologypublisher.com/technology/38534","Problem:A major challenge in drug delivery is ensuring that the drug reaches the target organ at a concentration sufficient to treat the disease. This is particularly problematic for acute illnesses of the vasculature, such as acute respiratory distress syndrome (ARDS), ischemic stroke, and myocardial infarction. In these diseases, patients are often too sick to tolerate off-target drug side effects, and systemically delivered drugs rarely accumulate to a significant extent in the organs affected by pathology.Solution:Drs. Jacob Brenner and Vladimir Muzykantov have developed a drug delivery system that can address these challenges. The drug delivery system, ‚ÄúRed Blood Cell (RBC)-Hitchhiking Nanoparticles‚Äù (RHNs), utilizes soft nanoparticles, such as liposomes and nanogels, loaded with drugs and the natural properties of RBCs to target the lung endothelium. The nanoparticles are adsorbed onto the surface of the RBC and delivered intravascularly. Once the nanoparticle-RBCs encounter their first capillary bed, the RBCs are physically squeezed, causing the release of the drug-loaded nanoparticles into the capillary endothelium. Since delivery is dependent on the squeezing of RBCs, the nanoparticles do not release their drug cargo until they enter the pulmonary capillaries. This approach minimizes delivery of the drug to sites other than the target organ and ensures that sufficient drug concentration reaches the target site.Advantages:Minimize off-target drug effectsMaximize delivery of drug to target organCan be delivered intravenously to target the lungs or via intra-arterial catheters to deliver to any target organ, including the brain and heartApplications:Targeted drug delivery for treatment of diseases of the capillary endothelium: ARDS, ischemic stroke, acute myocardial infarctionImage courtesy ofBrenner JS et al. Nat Commun, 9(1):2684covered byCreative Commons license.Stage Of Development:Validation studies completed in rodent and pig modelsIntellectual Property:US11,123,441Reference Media:Brenner JS et al.Nat Commun, 2018 July 11 9(1): 2684Pan DC et al.Sci Rep, 2018 Jan 25 8(1): 1615Muzykantov VR and Brenner JS.Hepatology, 2018 Nov 68(5): 1672Desired Partnerships:LicenseCo-developmentCase ID:16-7880-tpNCSWeb Published:2/13/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38534","**Summary:** This technology tackles the challenge of drug delivery to target organs, particularly in critical conditions affecting the vasculature, such as acute respiratory distress syndrome, ischemic stroke, and myocardial infarction. Traditional drug delivery methods often lead to insufficient drug accumulation at the necessary sites while causing undesirable side effects. The innovative approach of using Red Blood Cell-Hitchhiking Nanoparticles allows for drug-loaded soft nanoparticles to attach to red blood cells and be transported to the lung endothelium. Upon reaching the capillaries, the nanoparticles are released where they are needed most, minimizing off-target effects and maximizing therapeutic concentrations at the site of interest.

**Applications:** The developed drug delivery system is particularly applicable in treating acute vascular conditions like acute respiratory distress syndrome, ischemic stroke, and myocardial infarction where targeted therapy is essential to avoid side effects and improve patient outcomes.

**Problem Solved:** This technology addresses the critical issue of effective drug targeting in acute illnesses, ensuring that therapeutic agents are delivered specifically to the affected organs at sufficient concentrations, while reducing systemic off-target effects that can be detrimental to patients who are already in precarious health conditions.","A significant challenge in drug delivery is ensuring adequate drug concentration at target organs, especially for acute vascular illnesses like acute respiratory distress syndrome, ischemic stroke, and myocardial infarction. Patients with these conditions often cannot tolerate off-target side effects, and systemically delivered drugs seldom accumulate sufficiently in the affected organs."
"University of Pennsylvania","Solid-state nanopore membranes for DNA detection and sequencing","","","https://upenn.technologypublisher.com/technology/38520","A technology portfolio comprising fabrication and detection methods for improved DNA sequencing using nanoporous membranes.Problem:Biomolecule detection and sequencing lay a foundation for personalized medicine and drug discovery. DNA sequencing has emerged as a primary tool for understanding the whole genome. Such measurements can be made by passing a biomolecule through a nanopore and measuring resulting changes in ion current values. Primary barriers to efficient DNA sequencing include high signal to noise ratios allowing for discrimination between DNA bases and detection of short nucleotide sequences through nanoporous membranes.Solution:This technology portfolio allows for the detection of short DNA sequences using ultra-thin membranes with small diameter nanopores, resulting in higher ionic conductance and increased bias current. Additionally, it allows for insulated electrode gaps, resulting in improved signal to noise ratios.Technology Overview:This technology portfolio consists of fabrication methods for generating ultra-thin Silicon Nitride (SiN) membranes and ultra- low capacity, glass supported dielectric membranes for DNA sequencing. Ultra-thin SiN membranes are generated using local thinning via ion etching on a defined region onto which nanopores are generating using electron beans. Ultra-thin SiN membranes allow for the detection of short nucleic acid molecules. Glass-only supported SiN membranes reduce silicon-supported nanopore device capacitance, and are generated by selectively etching small pores in a aSi/SiN/Glass/SiN/aSi substrate.Additionally, fabrication methods for generating 1-2nm diameter nanopores in membranes and generating insulated nanoscale electrode gaps have been developed. The small nanopore diameter is comparable with the width of single stranded DNA. A silicone chip is first coated with silicon dioxide with silicon nitride subsequently deposited. The chips are then etched, and the resulting window is locally thinned and nanopores are drilled. The insulated nanoscale electrode gaps are fabricated using beam lithography to create coarse gaps. A dielectric material is then added to provide insulation to focus the current density between electrodes.Lastly, methods for generating and using graphene nanopore membranes to measure DNA translocation have been developed. The use of graphene-based nanopore devices improves the overall signal-to-noise ratio. A Chemical Vapor Deposition technique is used to fabricate a multi-layer graphene membrane. Transmission electron beam ablation lithography and UV/ozone treatments are then applied to create nanopores within the membrane.Advantages:Optimized detection of short nucleic acid molecules and single stranded DNAIncreased bias current and higher ionic conductanceFocused current density between nanoelectrodes due to electrode insulationImproved signal to noise values during DNA sequencingReduced device capacitance from other Si-supported designs from ~50pF to ~0.1 pF, the capacity for sequencing free-running DNADetails of solid-state nanopore fabrication. Stacked silicon chips covered with silicon dioxide and SiN (A). The chips are etched to create a window from which nanopores are drilled (B). The nanopore has a diameter of approximately 1.4 nm(C). The thickness of the thinned region (D), and the experimental design of SNA passing through the nanopore (E).Stage of Development:Proof of ConceptPrototype developedIntellectual Property:US10,761,043US10,876,157US9,121,823US10,017,813US10,274,478EPO2537026Reference Media:Venta K, et al.ACS Nano, 2013 May 28, 7(5): 4629Merchant CA, et al.Nano Lett, 2010 Aug 11, 10(8): 2915Desired Partnerships:LicenseCo-developmentCase ID:Z6635-tpNCSWeb Published:2/11/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38520","**Summary:** This technology portfolio comprises methods for the fabrication and detection of DNA using solid-state nanopore membranes, specifically focusing on improving DNA sequencing efficiency. It utilizes ultra-thin Silicon Nitride (SiN) membranes created through ion etching and electron beam techniques to generate nanopores. These membranes facilitate the detection of short nucleic acid sequences by enhancing ionic conductance and bias current, while also incorporating insulated electrode gaps to improve the signal-to-noise ratio.

**Applications:** The primary applications of this technology include personalized medicine and drug discovery, where efficient DNA sequencing is essential for understanding the genome and developing tailored therapeutic strategies.

**Problem Solved:** This technology addresses the challenges of high signal-to-noise ratios in DNA sequencing, which hinder the ability to accurately discriminate between DNA bases and detect short nucleotide sequences, thereby facilitating more reliable biomolecule detection and sequencing.","The technology portfolio includes fabrication and detection methods utilizing nanoporous membranes to enhance DNA sequencing. Key challenges addressed are the limitations in efficiency associated with current DNA sequencing techniques."
"University of Pennsylvania","Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells","","","https://upenn.technologypublisher.com/technology/38359","The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing mesothelin.Problem:Though engineered anti-mesothelin chimeric antigen receptor (CAR) T cells show encouraging pre-clinical results against certain cancer types, their clinical efficiency is stunted by their poor long-term persistence in infused human patients.Indeed, anti-mesothelin CARs are generally designed using mouse antibody fragments, which can trigger a detrimental immune response against the CAR T cells and destroy them (Maus et al, 2014), thus limiting their cancer destroying potential to a narrow time-frame.Solution:Instead of using a mouse antibody fragment for engineering CARs, Dr. Powell and his team have produced a fully human anti-mesothelin CAR that shows high cancer killing potential, yet very low immunogenicity.Advantages:In vivo persistence of infused CAR T cells after infusion.Low immunogenicity compared to mouse-derived antibody fragments.Not inhibited by soluble mesothelin secreted by cancer cells.Application:Therapy efficient against mesothelin-expressing tumor cells.Human ovarian tumor regression in an immunodeficient mouse model. Top panels: Mice infused with fully human anti-mesothelin (P4-28z) CAR T cells show significant regression of ovarian tumor (in color) between day 12 (day of infusion) and day 29. Bottom panels: Mice infused with negative control CD19-28z CAR T cells show ovarian tumor progression (Lanitis et al, 2012).Stage of Development:Target identifiedPreclinical discoveryIntellectual Property:US20140301993Reference Media:Lanitis et al, Mol Ther. 2012 Mar; 20(3): 633‚Äì643.Desired Partnerships:LicenseCo-developmentCase ID:Y6105-tpNCSWeb Published:1/29/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38359","**Summary:** This technology describes the development of a fully human chimeric antigen receptor (CAR) that targets mesothelin, a protein commonly overexpressed in various cancers. The CAR utilizes P4, a human antibody fragment that specifically binds to mesothelin, integrated with T cell signaling domains. Research indicates that T cells modified to express this CAR can effectively reduce tumors in mouse models of human ovarian cancer that overexpress mesothelin. The significant issue addressed is the poor long-term persistence of traditional CAR T cells due to immune responses against mouse antibody fragments, which limit their effectiveness. The fully human design of this CAR is aimed at achieving prolonged persistence and reducing immunogenicity while maintaining strong anti-tumor efficacy.

**Applications:** This technology is intended for therapeutic use against mesothelin-expressing tumor cells, particularly in the treatment of human ovarian tumors, as demonstrated by regression in immunodeficient mouse models.

**Problem Solved:** It resolves the issue of low long-term persistence and high immunogenicity associated with conventional anti-mesothelin CAR T cells due to reliance on mouse-derived antibody fragments, enabling a more sustained and effective anti-tumor response.","A fully human CAR targeting mesothelin has been developed, using the P4 antibody fragment fused to T cell signaling domains like 28z. Engineered T cells expressing this CAR demonstrated tumor shrinkage in a mouse model with human ovarian tumors overexpressing mesothelin."
"University of Pennsylvania","X-Ray Irradiation-Activated Hydrogel for Effective On-Demand Treatment of Glioblastoma and Other Tumors","","","https://upenn.technologypublisher.com/technology/37646","Primary tumor reoccurrence often occurs following surgical resection in glioblastoma multiforme patients. Current hydrogel approaches deliver therapeutics using light or pH, but these approaches are limited by the tumor microenvironment. Researchers have developed an injectable hydrogel with unique materials that can be activated by X-ray irradiation for sustained, on-demand therapeutic delivery. These hydrogels can be loaded with CT contrast agents and therapeutic drugs without affecting their functionality, morphology, or injectability.Problem:Glioblastoma multiforme (GBM) is one of the most aggressive types of brain cancers. Patients diagnosed with GBM have a median survival of 14 months and two-year survival rate of 27%. These patients undergo extensive treatment, including surgical tumor resection followed by chemotherapy infusion and radiation, yet 70% of patients experience reoccurrence of the primary tumor. Injectable hydrogel biomaterials allow for the sustained delivery of anti-cancer therapeutics within the tumor cavity. Activation of hydrogels with light or changes in pH allow for the on-demand release of therapeutics. However, these activation approaches are limited by the inability of light to penetrate deeper into tissue and unanticipated fluctuations in pH of the tumor microenvironment.Solution:Dr. Bouche and colleagues at the Perelman School of Medicine at the University of Pennsylvania have developed an injectable hydrogel that can be activated by X-ray irradiation for on-demand release of anti-cancer therapeutics. X-ray irradiation is highly focused and not limited by tissue depth. Further, patients undergoing treatment for GBM are already prescribed radiation, eliminating the need for an additional treatment for drug delivery activation. Sustained release by radiation-sensitive hydrogels with dual loaded contrast agents and anti-cancer drug therapies could enhance post-surgical resection radiation targeting and prevent primary tumor reoccurrence.Advantages:On-demand drug delivery deeper in tissue compared to current activated hydrogelsConvenient drug delivery activation method for cancer patientsTunable properties for spatiotemporal control of drug deliveryApplications:Cancer therapeuticsDrug deliveryMedical imagingTreatment of brain tumors with X-ray irradiation-activated hydrogelsStage of Development:Prototyped & tested in small animal modelPre-clinical discoveryIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:19-8911-tpNCSWeb Published:1/7/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/37646","**Summary:** Researchers have developed an injectable hydrogel that utilizes X-ray irradiation for the sustained and on-demand delivery of therapeutics in the treatment of glioblastoma multiforme and potentially other tumors. This hydrogel can be loaded with contrast agents and therapeutic drugs without compromising their performance or injectability, addressing the limitations of existing hydrogel systems that rely on light or pH changes, which are often inadequate due to tissue penetration issues or fluctuations in tumor microenvironment.

**Applications:** The primary application of this technology is in the local treatment of glioblastoma multiforme post-surgical resection, enabling sustained therapeutic delivery directly within the tumor cavity. It may also have potential applications for other tumors where targeted drug delivery is necessary.

**Problem Solved:** The technology addresses the high recurrence rate of glioblastoma multiforme after surgical resection, which currently sees 70% of patients experiencing tumor reoccurrence due to the limitations of existing drug delivery methods that cannot effectively penetrate tissues or adapt to the tumor's fluctuating microenvironment.","Researchers have developed an injectable hydrogel that can be activated by X-ray irradiation for sustained therapeutic delivery, addressing the issue of primary tumor recurrence in glioblastoma multiforme patients. This hydrogel can be loaded with CT contrast agents and therapeutic drugs while maintaining their efficacy."
"University of Pennsylvania","Motion and event detection in images using self-supervised neural networks","","","https://upenn.technologypublisher.com/technology/37324","A method to detect motion or an indication of an event from images obtained from multiple cameras using self-supervised neutral networks unlike the currently available algorithms such as optical flow.Technology Overview:This technology developed by the researchers at the University of Pennsylvania is capable of predicting events from images with potentially higher temporal resolution than the currently available methods.Conventional cameras provide images where the intensity of a pixel represents the amount of light detect by the sensor. Event-based vision is an emerging technology wherein computer algorithms process imagery obtained from a camera and provide time-stamped images where pixel intensity corresponds to dynamic changes in the images and how recent the change has been. Such images can be used as an input to a convolutional neural network to detect and predict events.Existing methods require the use training datasets to train convolutional neural networks that can subsequently predict motion. This process is computationally intense and requires the method to discard image frames for real-time applications, thereby reducing the temporal resolution of the event detection.Researchers at the University of Pennsylvania have developed an algorithm that can use a self-supervised convolutional neutral network to detect motion and predict an indication of an event from images obtained using one or multiple cameras. The method uses a multilayer convolutional neural network to detect motion and flow of the pixels at different spatial resolutions. The images obtained from multiple cameras can be used in the algorithm to more accurately associate discretized time stamps to each change, and ultimately improve the temporal resolution of event detection and prediction.Advantages:Enables use of self-supervised learning for motion detection in imagesUnsupervised learning using a self-supervised neural network requires minimal or no manual labeling of a training datasetHigh dynamic range in event-based vision enables more sensitive detection of motion and events.Applications:Navigation for self-driving automobiles and dronesEvent based camerasSelf-supervised learning to detect motion and events using event-based camerasMotion and event prediction from imagesExample of a timestamp image. Left: Grayscale image. Right: Timestamp image, where each pixel represents the timestamp of the most recent event. Brighter is more recent.Stage of Development:Proof-of-concept demonstrated in a laboratory settingIntellectual Property:US11,288,818Desired Partnerships:LicenseCo-developmentCase ID:19-8754-tpNCSWeb Published:12/6/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/37324","**Summary:** This technology leverages self-supervised neural networks to detect motion and predict events from images captured by one or multiple cameras. Developed by researchers at the University of Pennsylvania, it offers potentially higher temporal resolution compared to conventional methods like optical flow. The approach utilizes event-based vision, in which time-stamped images represent dynamic changes rather than just light intensity, allowing for enhanced input into convolutional neural networks. This novel approach reduces the need for extensive training datasets typically required for event prediction, thus streamlining the detection process.

**Applications:** The technology can be applied in various fields such as surveillance, robotics, autonomous vehicles, and any system requiring real-time motion and event detection. It is particularly useful in scenarios where high temporal resolution is essential.

**Problem Solved:** The method addresses the limitations of existing algorithms that rely on traditional image processing, which often results in reduced temporal resolution due to frame discarding. By employing a self-supervised learning approach, this technology enhances event detection capabilities while maintaining higher temporal fidelity, thus improving the performance and utility of motion detection systems.","Researchers at the University of Pennsylvania have developed a method for detecting motion or events from images captured by multiple cameras using self-supervised neural networks, offering potentially higher temporal resolution than existing algorithms like optical flow. This technology leverages the intensity of pixel representations in conventional camera images."
"University of Pennsylvania","Anti-Pulfrich monovision ophthalmic corrections that reduce depth misperception","","","https://upenn.technologypublisher.com/technology/39060","Technology Overview:Presbyopia is the age-related loss of your eyes‚Äô ability to focus on objects that are up close. A normal part of the aging process, the effects of presbyopia typically begin in humans sometime around 45 years of age.Researchers have estimated that there are close to 2 billion worldwide that have presbyopia.Monovision is a common prescription lens correction for presbyopia. With monovision, each eye is corrected to focus light from a different distance, causing one image to be blurrier than the other. The brain suppresses the blurrier image and preferentially processes the sharper one, thereby expanding the depth of field. This differential blur that occurs between the lenses results in a motion illusion that makes people misperceive the distance and directional movement of three-dimensional objects. This depth misperception has been coined as the reverse Pulfrich effect.By tinting the lens that causes the blurry image, the depth misperceptions will be eliminated. This non-invasive technique has been shown by measuring how blur differences affect neural processing times with sub-millisecond precision.Currently, the biggest challenge with monovision corrections comes from the decrease in stereovision and depth misperceptions. The ability to eliminate depth misperceptions enables a new branch of ‚Äúpremium monovision corrections‚Äù that will have a positive impact in the prescription of this type of corrections.Advantages:Eliminates depth misperceptions currently experienced by users of monovision corrected lensesApplications:Premium monovision ophthalmic correction lensesScreening device to assess the reverse Pulfrich effect caused by interocular blur differencesClassic and Reverse Pulfrich EffectsStage of Development:Corrected monovision misperceptions have been validated with 3 human observers in visual perception and visual opticsPrototype apparatus and software have been developedIntellectual Property:PCTPendingUS PatentPendingEuropean PatentPendingReference Media:Burge J, et al.:Curr Biol 2019 Aug 5, 29(15): 2586Case ID:19-8887-tpNCSWeb Published:3/4/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39060","**Summary:** This technology addresses the issues associated with presbyopia, a common age-related condition that affects the ability to focus on close objects, impacting nearly 2 billion people worldwide. Monovision is a prevalent correction method for presbyopia but can lead to depth misperception due to the different focal points for each eye, causing one image to appear blurrier. By tinting the lens that produces the blurrier image, the technology can eliminate the resulting depth misperceptions caused by the differential blur, improving visual perception. 

**Applications:** This technique can be applied to enhance monovision prescriptions for individuals suffering from presbyopia, resulting in improved stereovision and more accurate depth perception in daily activities. It is suitable for use in ophthalmic corrections and can contribute to a new category of premium monovision lenses.

**Problem Solved:** The technology resolves the problem of depth misperception that often arises from traditional monovision corrections, thus allowing individuals to experience clearer and more accurate visual perception without the drawbacks of the reverse Pulfrich effect.","Presbyopia, an age-related condition affecting the ability to focus on close objects, typically begins around age 45 and affects nearly 2 billion people globally. Monovision is a common corrective method where each eye is prescribed lenses to focus on different distances."
"University of Pennsylvania","Histone Deacetylase and DNA Methyltransferase Inhibitors for Preventative Cardiac Care and Ischemic Injury Treatment","","","https://upenn.technologypublisher.com/technology/45079","HDAC and DNMT Inhibitors such as Trichostatin A (TSA) and 5-aza-cytidine are preventative therapies and reduce myocardial infarct volume following cardiac eventsTechnology Overview:Every 40 seconds, someone in the United States has a heart attack. Although several therapeutic options for heart attack recovery exist, ischemic injuries are responsible for a significant amount of morbidity and mortality throughout the world. New therapeutics that offer significant improvements for those already exposed to, or at risk for, ischemic injury are needed.Drs. Epstein, Gruber, and Abdullah have shown several histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors, epigenetic regulators, reduce the risk of and help heal ischemic injuries in animal models. The HDAC and DNMT inhibitors, small molecules such as Trichostatin A, reverse the effects of myocardial infarction by reducing infarction volume. The use of the epigenetic regulators alone, or in combination with known ischemic injury treatments, has therapeutic potential, and offers increased therapeutic efficacy for the healing or prevention of ischemic injuries such as heart attacks.Advantages:HDAC inhibitors can be formulated into bioavailable oral agentsProven clinical efficacy for HDAC inhibitors in other human diseasesSeven candidates to advance into clinical developmentApplications:Small molecule therapeutics that prevent ischemic injury and reverse myocardial infarction effectsInhibition of HDACs promotes cell survival during hypoxia in isolated cardiac myocytes. Quantitative evaluation. *P = 0.04; **P = 0.01; 500 cells counted in 5 fields for each condition; n = 3. (FASEB J. 2008 Oct;22(10): 3549)Stage of Development:Proof of concept in vivoIntellectual Property:US8,889,742US9,393,222Reference Media:Granger, A. et al;FASEB 2008 Oct; 22(10): 3549.Desired Partnerships:LicenseCase ID:R3701-tpNCSWeb Published:10/9/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45079","**Summary:** HDAC and DNMT inhibitors such as Trichostatin A (TSA) and 5-aza-cytidine are emerging as preventative therapies that can significantly reduce myocardial infarct volume following cardiac events. Given the alarming frequency of heart attacks in the United States, these epigenetic regulators aim to improve recovery outcomes for individuals affected by ischemic injuries. Research by Drs. Epstein, Gruber, and Abdullah indicates that these small molecules can reverse the damage caused by myocardial infarction, showcasing their potential in both the prevention and treatment of ischemic injuries.

**Applications:** The technology offers small molecule therapeutics designed to prevent ischemic injury and mitigate the effects of myocardial infarction. These inhibitors can be formulated into bioavailable oral agents and have shown promise in combination with existing ischemic injury treatments, enhancing their therapeutic efficacy.

**Problem Solved:** This approach addresses the significant morbidity and mortality associated with ischemic injuries, particularly heart attacks, for which current treatment options are limited. By providing a new avenue for both prevention and recovery, these inhibitors fill a critical gap in the management of cardiac health for at-risk populations.","HDAC and DNMT inhibitors, such as Trichostatin A and 5-aza-cytidine, serve as preventative therapies and reduce myocardial infarct volume after cardiac events. Ischemic injuries contribute to considerable morbidity and mortality, highlighting the need for improved therapeutic options for heart attack recovery."
"University of Pennsylvania","Pharmaceutical therapeutic for the treatment of respiratory diseases","","","https://upenn.technologypublisher.com/technology/37163","Histone deacetylase (HDAC) inhibitors such as Trichostatin A to treat bronchoconstrictive diseases including asthma and chronic obstructive pulmonary disorder (COPD)Technology Overview:Asthma and COPD are diseases of variable airflow obstruction affecting more than 40 million Americans. Although some patients respond to conventional therapies, patients with severe disease disproportionately utilize healthcare resources. Therefore, new methods for treating asthma and COPD are needed.Histone deacetylase (HDAC) inhibitors improve pulmonary function in animal models. The HDAC inhibitors, small molecules such as Trichostatin A, reverse the effects of drug-induced broncho-constriction by acting directly on pulmonary smooth muscle cells, a novel mechanism of action. The use of HDAC inhibitors alone, or in combination with known bronchodilators or corticosteroids, has therapeutic potential and offers increased therapeutic efficacy for the treatment of chronic obstructive pulmonary disorders.Advantages:Potential combination therapyUse for HDAC inhibitors for the treatment of broncho-constrictive disordersApplications:Small molecule therapeutic that dilates bronchi to treat asthma and other lung diseasesTrichostatin A (TSA) che| HDAC InhibitorStage of Development:Proof of concept in vivoIntellectual Property:US9,827,212Reference Media:Banerjee, A. et al.;AmJ Respir Cell Mol Biol 2012 Feb; 46(2): 132.Desired Partnerships:LicenseCase ID:V4967-tpNCSWeb Published:11/14/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/37163","**Summary:** The technology involves the use of histone deacetylase (HDAC) inhibitors, specifically Trichostatin A, for the treatment of bronchoconstrictive diseases such as asthma and chronic obstructive pulmonary disorder (COPD). These conditions affect over 40 million Americans and can lead to significant healthcare resource utilization, especially among patients with severe disease who may not respond adequately to conventional therapies. HDAC inhibitors have shown promise in improving pulmonary function in animal models by reversing drug-induced broncho-constriction through a novel mechanism of action targeting pulmonary smooth muscle cells. This treatment approach may offer combined therapeutic efficacy when used alone or alongside established bronchodilators or corticosteroids.

**Applications:** The primary application of this technology is as a small molecule therapeutic aimed at dilating the bronchi to alleviate symptoms associated with asthma and other respiratory diseases, including COPD. 

**Problem Solved:** The approach addresses the need for new treatment methods for asthma and COPD, particularly for patients with severe disease who experience inadequate relief from existing therapies and tend to consume disproportionate healthcare resources.","Histone deacetylase (HDAC) inhibitors, such as Trichostatin A, are being explored for the treatment of bronchoconstrictive diseases like asthma and chronic obstructive pulmonary disorder (COPD). These diseases affect over 40 million Americans, and while some patients respond to standard therapies, those with severe cases often require additional healthcare resources."
"University of Pennsylvania","Ultrasensitive, mechanically responsive optical metasurfaces via strain amplification","","","https://upenn.technologypublisher.com/technology/39059","A general platform of microstructured elastomeric substrates that amplifies the mechano-sensitivity of flexible and stretchable devices. The microstructured elastomeric substrates are constructed as a pair of mirror-symmetric, tapered microrods with opposing tips separated by a small distance on the surface of polydimethylsiloxane (PDMS).Technology Overview:Recent advances in materials that are surface plasmon resonators and responsive to external stimuli have advanced the development of high-end optical devices, such as- active optical components;- high resolution displays; and- multiplexed holograms.‚ÄãIn particular, materials that change their properties based on how much they are stretched or compressed are effective at integrating optical and mechanical functionalities.Current state-of-the-art surface plasmon resonators are not sensitive enough to detect small mechanical deformations needed for the most common applications. This technology solves the problem by locally increasing the deformations at the resonator, which effectively makes the resonator more sensitive to small deformations.The resonator consists of a lattice of rods embedded in an elastomer positioned between the tips of two tapered rods. As the two rods are pressed together or brought apart, they deform the lattice. Since the metal components are incompressible relative to the elastomer, the elastomer experiences almost all the applied deformation, significantly increasing its strain.This amplification can be tuned to a desired value by altering the geometry of the metal-elastomer lattice. The result is a highly sensitive optical sensor or actuator that can detect or be manipulated by externally applied deformations.Advantages:10x greater stain sensitivity than other state-of-the-art stretchable surface plasmon lattice techniques.Tunable strain amplificationMaterial flexibilityApplications:Strain gaugesOptical lensesHologramsDisplaysTop Figure: A schematic of the fabrication process of the lattice using electron beam lithography (EBL) and elastomer (PDMS) casting. Middle Figure: A schematic of the plasmonic grating with alternating metal ‚Äì elastomer components. Bottom Figure: Finite element analysis modeling of the strain distribution on the metastructure on the surface of the elastomer in response to a 3% applied strain.Stage of Development:Prototypes developedStudies are ongoing to extend the proof-of-concept to wearable devices and sensorsIntellectual Property:US PatentPendingReference Media:Chen, W et al.;ACS Nano 2018 Nov 27, 12 (11): 10683Desired Partnerships:LicenseCo-developmentCase ID:19-8791-tpNCSWeb Published:3/4/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39059","**Summary:** The technology involves a general platform of microstructured elastomeric substrates designed to enhance the mechano-sensitivity of flexible and stretchable devices. These substrates are formed by mirror-symmetric, tapered microrods positioned on a surface of polydimethylsiloxane (PDMS), with the tips of the rods separated by a small distance. The recent advances in materials responsive to mechanical stimuli have facilitated the development of high-quality optical devices, such as active optical components, high-resolution displays, and multiplexed holograms. The technology effectively increases the sensitivity of surface plasmon resonators to small mechanical deformations by locally amplifying the deformations at the resonator itself.

**Applications:** The technology can be applied in the creation of sensitive optical devices that require detection of small mechanical changes, enhancing functionalities in active optical components, high-resolution displays, and multiplexed holograms. It may also find applications in advanced sensors and devices that benefit from integrated optical and mechanical capabilities.

**Problem Solved:** This technology addresses the insufficient sensitivity of current surface plasmon resonators in detecting small mechanical deformations, which are critical for various practical applications. By significantly amplifying the strain experienced by the elastomer, the resonators become more sensitive to minor changes, improving their functionality in optical applications.","A platform of microstructured elastomeric substrates enhances the mechano-sensitivity of flexible and stretchable devices by utilizing mirror-symmetric, tapered microrods separated by a small distance on polydimethylsiloxane (PDMS). This technology leverages recent advances in materials that act as surface plasmon resonators and respond to external stimuli."
"University of Pennsylvania","Self-healing cellular metals","","","https://upenn.technologypublisher.com/technology/36950","A unique structural material composed of cellular metals that can heal; a property useful for recovery of material and strength along the path(s) of stress in the structural member.Problem:There is an increasing demand for greater reliability and longevity in load-bearing structures. Often failure of these structures could endanger lives and are increasingly too costly to repair. Additionally, additive manufacturing has enabled parts with complex shapes, but repairing these parts is very difficult using conventional technologies. There has always been a need and a vision of the future which includes structures with the ability to heal. Research efforts in healing materials have been largely based on polymeric and ceramic based composites with very little discussion of metallic-based healing materials.Solution:This material is a new class of metallic structural members that:1. can be healed at room temperature in response to catastrophic failure;2. strengthen areas that experience loads near their yield to prevent future failure; or3. modulate the stiffness of structural member.These capabilities can be built into a new or currently used structural member or developed as a repair process where they member is removed, healed, and reinstalled.The healing and reinforcing properties are enabled by a cellular metal infiltrated with an electrolyte. Upon applying a voltage to the metal, additional metal is electroplated to heal or strengthen the desired area. The target area and healing capability can be controlled using a tunable insulating coating on the conductive metal. The cellular nature of the structural member is required and facilitates metal transport from other areas of the material to the area that needs reinforcement, thus, enabling a faster mass-transport process at room temperature.Technology Overview:This healing cellular metal is a new structural material that can continuously self-repair cracks and redistribute cellular materials within itself at room temperature. This material is capable of reinforcing itself through the path of stress within the member while under standard conditions.Advantages:Improved chemical and mechanical properties that respond to the way the material is usedFaster metal ion transport in electrolyteRapid healing process at room-temperatureCan be healed continuouslyAbility to target healing, reinforcement, or stiffness modulationApplications:Construction of bridges, buildings etcHigh value structural members with unique or complicated geometries (e.g. 3D printed parts)RoboticsProstheticsAutomobilesElectronicsTop Image: The inventors used cellular metal for the study. Middle Image: Nanosized metal grains deposited on cellular metal via an electrochemical process.Stage of Development:A prototype of healing cellular Ni has been developed and tested for tensile strength in labThe kinetics and mass transport governing electrodeposition for healing were simulated computationallyCharacterization of the healing efficiency and required input energy to achieve targeted healing effectiveness.Intellectual Property:PatentPendingReference Media:Hsain and Pikul;Adv. Funct. Mater. 2019, 29(43): 1905631Pikul, JH et.al.2016 IEEE 29th International Conference on Micro Electro Mechanical Systems (MEMS), 2016, pp. 451Desired Partnerships:LicenseCo-developmentCase ID:19-8784-tpNCSWeb Published:10/30/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/36950","**Summary:** A unique structural material has been developed that consists of cellular metals capable of self-healing, providing recovery of material and strength along stress paths within structural members. This material addresses the growing need for enhanced reliability and longevity in load-bearing structures, which are critical for safety and can incur high repair costs. Unlike previous research primarily focused on polymeric and ceramic healing materials, this innovative technology utilizes metallic components to achieve self-healing capabilities. The structural members can heal at room temperature after catastrophic failure, reinforce areas under load to avoid future failures, and adjust stiffness based on requirements. The process involves electroplating additional metal to specified regions when a voltage is applied, effectively allowing for repair and strengthening of the material.

**Applications:** This self-healing metallic material can be incorporated into new construction or used to repair existing load-bearing structures in various industries, including aerospace, automotive, civil engineering, and any application requiring reliable and enduring structural integrity. Its ability to heal and strengthen makes it suitable for critical infrastructure, reducing the risk of catastrophic failures and lowering maintenance costs.

**Problem Solved:** The technology addresses the challenge of maintaining and repairing load-bearing structures that are increasingly complex due to advancements in additive manufacturing. By enabling self-repair and reinforcement, it mitigates the risks associated with structural failures that can endanger lives and incur significant financial liabilities, offering a sustainable solution for future engineering demands.","A novel structural material made of cellular metals possesses self-healing capabilities, enhancing the recovery of material and strength along stress pathways. This innovation addresses the growing need for reliability and longevity in load-bearing structures, which are often expensive and risky to repair following failure."
"University of Pennsylvania","Multi-Channel Photodynamic Therapy Light Dosimetry System","","","https://upenn.technologypublisher.com/technology/36602","PDT dosimetry instrument and system capable of measuring light fluency rate, reactive oxygen species, and photosensitizer concentration simultaneously at multiple sites and allowing to adjust the PDT dose in real-time during treatment.Technology Overview:Photodynamic therapy (PDT) is a treatment modality that is often used during surgeries to eradicate remaining cancer cells. PDT utilizes a drug - photosensitizer (PS) which becomes activated when exposed to a specific wavelength of light and produces reactive oxygen species (ROS) that destroys adjacent cancer cells. PDT has been approved by FDA for treatment of several types of cancers and is being tested in a number of clinical trials for treatment of brain, skin, prostate, cervix, and peritoneal cavity malignancies.Dosing PDT is a critical aspect of the treatment - inadequate treatment dose may lead to residual cancer cells, while excessive doses may result in severe damage to the tissue leading to burns, swelling, pain, and scarring. Effective PDT dose depends on multiple factors such as local PS dose, tissue optical properties, oxygenation level, photobleaching, absorption and scattering of light, hemoglobin levels, damage to the tissue by surgery which are all dynamic. In addition, there is significant inter- and intra-patient variability in the PS pharmacokinetics, tissue optical properties, and local tissue oxygenation. Thus, there is a critical need for reliable dose metrics which would allow to deliver optimum PDT dose to treated tissues.Dr. Timothy Zhu of Penn Medicine has developed PDT device and system which measures light fluence rate, PS concentration, and tumor blood flow. This approach allows for the calculation of local ROS concentration for accurate prediction of PDT outcome and dose adjustment. The inventor demonstrated the utility of the device in clinical settings using photofrin-mediated PDT assessing ROS levels simultaneously at multiple sites in real time.Advantages:Improved PDT treatment outcome through real-time adjustment of PDT doseSimultaneous reading from multiple channels (up to 16)Entire spectrum light measurementsAssessment of local light fluency, PS concentration and created ROSApplications:Measurement and adjustment of PDT dose at up to 16 sitesStage of Development:Clinical human data on photofrin-mediated PDT in pleural cavityTissue simulating phantoms and animal dataIntellectual Property:US PatentPendingReference Media:Ong, YH et al.Phys Med Biol. 2017 Dec 29;63(1): 015031.Qiu, H et al.Photochem Photobiol. 2017 Jul;93(4): 1115.Sheng, T et al.Proc SPIE Int Soc Opt Eng. 2019 Feb;10860.Sheng, T et al.Proc SPIE Int Soc Opt Eng. 2019 Feb;10861.Ony, YH et al.Proc SPIE Int Soc Opt Eng. 2018 Feb;10476.Case ID:19-8830-tpNCSWeb Published:10/11/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/36602","**Summary:** This technology is a dosimetry system designed to enhance the efficacy of photodynamic therapy (PDT) by measuring critical parameters such as light fluency rate, reactive oxygen species (ROS), and photosensitizer concentration in real-time and across multiple treatment sites. This enables the adjustment of PDT doses during procedures, addressing the need for precise dosing to optimize treatment outcomes while minimizing potential harm to surrounding healthy tissue. 

**Applications:** The system can be utilized in surgical settings for the treatment of various cancers, including brain, skin, prostate, cervix, and peritoneal cavity malignancies, where PDT is approved or under clinical evaluation. 

**Problem Solved:** This technology addresses the challenge of accurately dosing PDT, which is crucial because improper dosing can lead to residual cancer cells if the dose is too low, or significant tissue damage if the dose is too high. The system provides reliable metrics that account for patient-specific variability and dynamic treatment factors, thereby improving treatment safety and effectiveness.","The system measures light fluency rate, reactive oxygen species, and photosensitizer concentration simultaneously at multiple sites, enabling real-time adjustments to the PDT dose during treatment. Photodynamic therapy is commonly used during surgeries to eliminate remaining cancer cells by activating a photosensitizer with specific light wavelengths."
"University of Pennsylvania","VerroTouch: Tactile augmentation for robot-assisted minimally invasive surgery","","","https://upenn.technologypublisher.com/technology/39291","Providing tactile and audio feedback during robotic surgery produces an immersive experience for surgeons that can lead to safer and more efficient procedures.Technology Overview:Robotic systems allow surgeons to carry out minimally invasive procedures using remote hand controls to guide surgical instruments. While video feeds provide visual access to the surgical site, the surgeon lacks the important tactile cues that are available during conventional surgery.The sense of touch, or haptic sensation, is invaluable in a surgeon‚Äôs interaction with tools and patient tissue. However, transferring this information to the operator of a robotic system is a challenging technical problem; thus, commercially available surgical robot controllers rarely provide any haptic feedback. In the few cases where haptic feedback does exist, the technology is generally imprecise, noisy, and slow.Existing robotic surgery systems can be made more immersive through the incorporation of VerroTouch technology. Any rigid-arm robotic system can be equipped with this technology to provide tactile and audio sensations that let the surgeon perceive the strength and type of surgical tool contact.VerroTouch provides adjustable, crisp, lag-free feedback without the need for specialized goggles or additional handles. When asked to complete a series of dry-lab tasks using a robotic surgery system outfitted with this technology, 95% of surgeons preferred the addition of vibrational feedback, saying it made them more aware of instrument contacts. Surgeons also respond positively to auditory feedback, which has the potential to enhance procedural and ambient awareness for the entire operating room staff.Overall this technology promises to accelerate surgeon learning and could lead to safer procedures for patients.Advantages:Immersive, crisp, and natural feedback that does not interfere with robot operationAudio and tactile feedback exist even when visual cues are obstructedEnhances the awareness of surgeons and increases training efficiencyApplications:Enhances procedural awareness in robot-assisted minimally invasive surgeryTraining tool for robotic surgeonsStage of Development:Bench PrototypeIntellectual Property:US9,333,039KR20127023470Reference Media:Ted Talk on the Technology of TouchBark, K. et al.;Surg Endosc, 2013 Feb, 27(12): 656Koehn & Kuchenbecker;Surg Endosc, 2015 Oct, 29(10): 2970Desired Partnerships:LicenseCase ID:W5395-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39291","**Summary:** The technology enhances robotic surgery by integrating tactile and audio feedback, creating an immersive experience for surgeons. This feedback compensates for the lack of haptic cues traditionally found in conventional surgical methods, improving the interaction between the surgeon and surgical tools. VerroTouch can be adapted for any rigid-arm robotic system, offering clear and immediate feedback without requiring specialized equipment. 

**Applications:** The technology is applicable in minimally invasive surgeries where precision and sensitivity in tool handling are critical. It can be utilized in various surgical disciplines that employ robotic assistance, allowing surgeons to perform procedures with improved accuracy and awareness of instrument interaction.

**Problem Solved:** The technology addresses the significant gap in haptic feedback present in existing robotic surgical systems, which typically provide only visual feedback. By supplying real-time tactile and auditory information, VerroTouch helps surgeons better sense tool dynamics and tissue interaction, ultimately leading to safer and more effective surgical outcomes.","Providing tactile and audio feedback during robotic surgery enhances the immersive experience for surgeons, promoting safer and more efficient procedures. Robotic systems enable minimally invasive surgeries through remote hand controls, but traditional tactile cues are absent, making haptic sensation critical for improved performance."
"University of Pennsylvania","Small Molecule Therapeutics for Hematologic Malignancies","","","https://upenn.technologypublisher.com/technology/43156","Small molecule inhibitors of a key cancer cell signaling pathway cause hematologic cancer cell death, but have low toxicity towards healthy cells.Technology Overview:Hematologic malignancies begin in blood-forming tissue, like the bone marrow or in the cells of the immune system. Non-Hodgkin lymphoma and leukemia were the 7th and 10th most diagnosed cancers in the US, respectively. New therapeutics for relapsed or refractory hematologic malignancies are needed as currently, there is no clinical standard of care for relapse of every type of hematologic malignancy.The Robertson group has developed a small molecule therapeutic for hematologic malignancies that inhibit a key cancer cell signaling pathway, causing cell death. This small molecule therapeutic has increased inhibitory action on cancer cells and decreased toxicity to healthy cells as compared to existing treatments. This results in a more specific mechanism of action that reduces the incidence of side effects such as nausea, fever, chills, and anorexia. The molecules are expected to be applicable to a broad range of hematologic malignancies.Advantages:Enhanced efficiency: 90% of cancer cells are inhibited post-treatmentDecreased toxicity to healthy cellsDecreased incidence of adverse events such as nausea, fever, chills, anorexiaApplications:Treatment of primary hematologic malignanciesTreatment of relapsed and refractory hematologic malignanciesThe small molecule inhibitors are analogs of an existing hematologic malignancy therapeutic, with improved inhibitory effects on cancer cells and reduced toxicity to healthy cells. Multiple hematopoietic malignant cell lines were untreated or treated with #14, #15, #26, #31, or #1 compound (100nM) for 72 hours. Cell viability was determined by detecting luminescence. ALL, acute lymphoblastic leukemia; BL, Burkitt‚Äôs lymphoma; DLBCL, 817 diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; AML, acute myeloid 818 leukemia; MM, multiple myeloma; LCLs, lymphoblastoid cell lines. Tumor sizes were monitored in the mice after treatment of the indicated compounds. Tumor sizes at 12-day post-treatment with different analogs are highlighted.Stage of Development:Pre-clinical mouse modelsIntellectual Property:US PatentPendingReference Media:Hwang, N. et al.;Bioorg Med Chem Lett. 2020 Dec 1;30(23):127553.Pei, Y et al.;Communications Biology 2020. May 27, 3(267):s42003.Desired Partnerships:LicenseCo-developmentCase ID:19-9029-tpNCSWeb Published:3/9/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/43156","**Summary:** Small molecule inhibitors developed target a critical signaling pathway in cancer cells, leading to their death while exhibiting minimal toxicity to healthy cells. This therapeutic approach shows significant promise for treating various hematologic malignancies, which have limited treatment options, particularly for relapsed or refractory cases. The technology demonstrates enhanced efficacy, inhibiting approximately 90% of cancer cells after treatment, and has a better side effect profile compared to standard therapies.

**Applications:** The technology is applicable in the treatment of primary hematologic malignancies as well as relapsed and refractory cases, potentially addressing an unmet need in hematologic cancer care.

**Problem Solved:** This approach addresses the need for new therapeutics in hematologic malignancies, particularly in instances where existing treatments are ineffective due to relapse or refractory conditions, while also reducing the common adverse events associated with cancer therapies.","Small molecule inhibitors targeting a key cancer cell signaling pathway induce cell death in hematologic cancers while exhibiting low toxicity to healthy cells. There is a demand for new therapeutics to address relapsed or refractory hematologic malignancies, given the prevalence of conditions like non-Hodgkin lymphoma and leukemia."
"University of Pennsylvania","Therapeutic for Type 2 Diabetes and Other Obesity-Related Metabolic Disorders","","","https://upenn.technologypublisher.com/technology/35906","Obesity is associated with buildup of fat within the cells of the liver, heart, and skeletal muscle. Intracellular fat accumulation leads to impairment in the ability of these cells to absorb glucose from the blood in response to insulin, called insulin resistance. However, the linkage between intracellular fat accumulation and insulin resistance is poorly understood. This invention has defined the upstream connection between fat accumulation in muscle cells and insulin resistance defining a new candidate target strategy for the treatment of obesity-related metabolic disorders.Technology Overview:Obesity is driving a dramatic increase in insulin resistance (type 2 diabetes), fatty liver disease, and cardiovascular disease. Obese individuals have intracellular lipid (fat) accumulation within the liver, heart, and skeletal muscle; organs which normally are responsible for absorbing glucose from the blood in response to insulin. Intracellular lipid accumulation in these tissues impairs the response to insulin, leading to insulin resistance and type 2 diabetes. The elusive connection between intracellular lipid accumulation and insulin resistance has been poorly understood, and thus, there are currently no therapeutics that target both the tissue toxicity downstream of lipid buildup and insulin resistance. This invention has identified a potential therapy.Dr. Kelly and his colleagues developed a small molecule therapeutic that inhibits intracellular lipid accumulation in the liver and skeletal muscle while also reducing insulin resistance. This effect occurs by inhibiting the transcription factor MondoA.Inhibition of MondoA has the potential reduce both the end-organ lipid toxicity and insulin resistance driven by obesity and type 2 diabetes. It could prevent intracellular lipid accumulation and enhance insulin signaling.Advantages:Treatment of obesity-related dysfunction in the absence of diet/exerciseIncreases insulin sensitivityApplications:Treatment of obesity-related metabolic disordersTreatment for insulin resistance (type 2 diabetes)Stage of Development:Preclinical discovery ‚Äì lead compoundIntellectual Property:US11,028,061DivisionalPendingReference Media:Ahn B., et al.JCI Insight. 2019 Aug 8; 4(15): e129119Ahn B., et al.J Clin Invest. 2016 Sept 1; 126(9): 3567.Desired Partnerships:LicenseCo-developmentCase ID:18-8544-tpNCSWeb Published:9/5/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/35906","**Summary:** This technology focuses on addressing the detrimental effects of obesity on metabolic health, specifically targeting the relationship between intracellular fat accumulation and insulin resistance. The researchers have identified a mechanism linking fat buildup in muscle cells to insulin resistance, which can lead to type 2 diabetes and other related disorders. A small molecule therapeutic has been developed to inhibit intracellular lipid accumulation, thereby aiming to restore the normal function of key metabolic tissues.

**Applications:** The potential applications of this therapeutic include treatment for type 2 diabetes, fatty liver disease, and cardiovascular disease, particularly in obese individuals who suffer from insulin resistance due to intracellular fat accumulation.

**Problem Solved:** The invention aims to solve the problem of insulin resistance linked to obesity by addressing the underlying issue of intracellular fat accumulation in crucial organs, which impairs glucose absorption in response to insulin. By targeting this connection, the therapy offers a novel approach to treat obesity-related metabolic disorders.","Obesity causes fat accumulation in liver, heart, and skeletal muscle cells, leading to insulin resistance, which impairs glucose absorption. The invention clarifies the connection between fat accumulation in muscle cells and insulin resistance."
"University of Pennsylvania","Stapled Peptide Therapeutic for the Treatment of Herpes Ocular Keratitis","","","https://upenn.technologypublisher.com/technology/35877","A topically administered stapled peptide prevents Herpes Simplex Virus-1 DNA replication for improved treatment of Herpes Ocular Keratitis.Technology Overview:Nearly two thirds of the world population is infected with Herpes simplex virus-1 (HSV-1). Following initial infection, recurrent activation along the ophthalmic branch of the cranial trigeminal nerve can lead to Herpes Ocular Keratitis (HK), the leading cause of corneal blindness in the US and in the world.The gold standard for treatment of HK is acyclovir (ACV), a drug that targets viral thymidine kinase (TK). While this drug remains effective against oral and genital herpes, there is an emergence of ACV-resistant HK infections caused by mutations in the HSV-1 TK gene, and a need for therapies against alternative HSV-1 targets.Scientists at the University of Pennsylvania have developed a stapled Œ±-helical peptide for the treatment of HK. This stabilized peptide mimics the C-terminal Œ±-helix of HSV-1 DNA polymerase to block interaction between the polymerase and the HSV-1 processivity factor (PF). Without PF association, the polymerase rapidly dissociates from the DNA template, preventing productive genome replication.Successful blockade of HSV-1 DNA synthesis and HSV-1 infection by the peptide has been shown in vitro. These peptides can be prepared into a solution for topical administration and may be used alone or in addition to ACV. Systemically-delivered formulations may be further developed for additional cases of ACV-resistant HSV-1 infections.Advantages:Specific HSV-1 DNA polymerase blockadeSuitable for topical administrationStapled peptide structure increases protease resistance and functional lifetimeApplications:Treatment of HK infections alone or in combination with ACVTreatment of additional ACV-resistant HSV-1 infectionsPrevention of HSV-1 propagationThe stapled Œ±-helical peptide binds to the HSV-1 processivity factor (PF), preventing interaction with DNA polymerase (Pol) and inhibiting productive DNA synthesis.Stage of Development:Designed library of peptides with variable staple locationsVerified physical interaction between peptides and target PF proteinDemonstrated specific blockade of HSV-1 processive DNA synthesis and HSV-1 infection in vitroIntellectual Property:US PatentPendingReference Media:Ricciardi LabDesired Partnerships:LicenseCo-developmentCase ID:19-9046-tpNCSWeb Published:8/29/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/35877","**Summary:** A novel stapled peptide has been developed for the topical treatment of Herpes Ocular Keratitis (HK), a condition caused by Herpes Simplex Virus-1 (HSV-1). This peptide prevents HSV-1 DNA replication by mimicking the C-terminal Œ±-helix of the viral DNA polymerase, thereby disrupting its interaction with the processivity factor. In vitro studies have demonstrated the peptide's effectiveness in blocking HSV-1 DNA synthesis and HSV-1 infection. The formulation allows for topical administration, which may be effective on its own or in combination with existing therapies like acyclovir (ACV), especially in cases of ACV-resistant infections.

**Applications:** The primary application of this stapled peptide includes the treatment of Herpes Ocular Keratitis, a leading cause of corneal blindness. Additionally, it may also have potential applications against other manifestations of HSV-1 infections, particularly in cases where traditional treatments, such as acyclovir, are ineffective.

**Problem Solved:** The technology addresses the increasing problem of acyclovir-resistant Herpes Ocular Keratitis infections resulting from mutations in the HSV-1 thymidine kinase gene. By targeting a different mechanism of HSV-1 replication, the stapled peptide offers a new therapeutic option for patients suffering from recurrent infections and those who do not respond to current antiviral therapies.","A topically administered stapled peptide effectively prevents Herpes Simplex Virus-1 DNA replication, offering an improved treatment for Herpes Ocular Keratitis. This condition, caused by the recurrent activation of HSV-1, is the leading cause of corneal blindness globally."
"University of Pennsylvania","The g3mclass Software for Multiclass Disease Diagnosis and Reporting.","","","https://upenn.technologypublisher.com/technology/35400","Diagnostic software to stratify patients on biomarkers and therapeutic targets.Problem:Targeted therapy has revolutionized the treatment of cancer. The efficacy of such therapy is highly dependent on target levels that may increase, decrease, or remain unchanged in the tumor compared to healthy tissue. In clinical practice, the target‚Äôs status may be tested through methods such as immunohistochemistry (IHC), which relies on a trained professional to group samples using an arbitrary cutoff. Such a semi-quantitative approach may lead to over-/under- estimation of the target expression and ineffective health interventions. Molecular assays can measure multiple biomarkers but lag in multiclass diagnostic capabilities.Solution:The inventor developed an original software that uses tissue biomarkers and rigorous statistical analysis to classify patients by target expression with speed and precision.Advantages:Multiclass automated classification as opposed to conventional binary classificationHigh diagnostic performance in single-plex and multi-plex formatsInput from various platforms used for biomarker analysisThe methodology can be easily applied to other biomarkers (proteins and metabolites)The software has diverse applications including neurology, immunology, and metabolic diseasesThe applications could be extended to animal healthThe g3mclass-assisted autoclassification on ERBB2 mRNA. (A) A total mixture model and GMM's components for the test ERBB2 mRNA were obtained with the g3mclass. The data distribution is shown as a probability density function (PDF) overlaid on a histogram and estimated by the means values, standard deviation, and weights of each component. The total GMM (gray); separate components are as follows: green‚Äîclass 0 with the mean value of reference; class/es with the mean value lower than that of reference (green) and class/es with the mean value higher than that of reference (red). (B) Graphs: Examples of the multiclass (g3mclass) vs. subsequent binary classifications (conventional) of invasive breast cancer on ERBB2 mRNA.Stage of Development:Software proven to run on multiple platforms (macOS, Linux, and Windows) with clinical dataIntellectual Property:CopyrightReference Media:Guvakova, MAJCO Clin Cancer Inform 2023 July; 7: e2300013Guvakova, MA & Sokol, SSci Rep 2022 Nov 5; 12(1): 18742Desired Partnerships:Non-Esclusive LicenseCo-developmentCase ID:19-8759-tpNCSWeb Published:8/12/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/35400","**Summary:** The diagnostic software is designed to improve the stratification of patients based on biomarkers and therapeutic targets, particularly in the context of cancer treatment. It addresses the limitations of current testing methods, such as immunohistochemistry, which depend heavily on subjective assessments and can lead to inaccuracies in determining target expression levels. This innovative software leverages advanced statistical techniques to classify patients with high precision and speed, facilitating better-tailored therapeutic interventions.

**Applications:** The software can be applied across various medical fields, including oncology, neurology, immunology, and metabolic diseases. Its capabilities may also be extended to animal health. The software supports multiclass automated classification, making it suitable for use in both single-plex and multi-plex biomarker analysis.

**Problem Solved:** The technology addresses the challenge of accurately determining target levels in tumors versus healthy tissue, thus enhancing the efficacy of targeted therapies. It improves upon conventional diagnostic methods that may lead to erroneous classifications, ensuring more effective health interventions by providing robust and automated classifications of multiple biomarkers simultaneously.","The software assists in the diagnosis and reporting of multiclass diseases by stratifying patients based on biomarkers and therapeutic targets. It addresses the challenge of varying target levels in tumors compared to healthy tissue, which are typically assessed using methods like immunohistochemistry that depend on a trained professional's interpretation."
"University of Pennsylvania","Automated Micro-Particle Robotic Swarm for the Chemical and Mechanical Removal of Biofilms","","","https://upenn.technologypublisher.com/technology/35281","Wirelessly activated iron oxide nanoparticles (IONPs) forming micro-robots that chemically and mechanically remove biofilms with high precision and efficacy by magnetic control.Technology Overview:Biofilms are extremely difficult to eliminate. They are made up of bacterial cells encapsulated in a protective, sticky matrix that helps them to firmly attach to a variety of surfaces, which ultimately lead to infections, biofouling, and biocorrosion. Biofilms are often resistant to traditional antibacterial treatments so removing them is an important challenge.Most current strategies for treating biofilms rely on antimicrobials (e.g. antibiotics), which have been shown to be ineffective due to antibiotics‚Äô inability to penetrate or break down the structure of biofilm. Therefore, new methods for biofilm treatment and removal are required.Dr. Koo, along with his collaborators, have developed a novel approach to eliminate biofilm which utilizes Catalytic Antimicrobial Robots (CARs) built with IONPs. CARs were designed to tackle all facets of biofilm resistance by simultaneously degrading the protective matrix, killing the embedded bacteria, and physically removing the biodegraded products.Activated IONPs are targeted to and through biofilms with submicrometer precision using a magnetic field, wherein they aggregate to form CARs. Upon contact with the biofilm, CARs produce bio-actives which kill bacteria and degrade the protective matrix; while in parallel, CARs mechanically remove the biodegraded biofilm material. The use of the CARs alone, or in combination with known methods, offers increased potential for full biofilm removal and reduction of contamination.Advantages:Can remove biofilms from hard to access small areasWireless technologyPrecise and automated complete removal of biofilmRetrievable after usageTunable technology; can be fashioned into various shapes and forms depending on the needApplications:Medical device companies, cleaning device companies, health systems, and food manufacturers who need effective tools for controlling biofilm infections will use our automated micro-particle robotic swarm for the degradation and removal of biofilmsStage of Development:Reduction to practiceIntellectual Property:ZA2021/04331IN479834US, EP, MX, CN, KR, CA, JP, BR, IL, AU PatentsPendingReference Media:Hwang G, et al.,Science Robotics, 2019 Apr 24; 4(29): eaaw2388Baillie, KUPenn Today 2019 Apr 24Desired Partnerships:LicenseCo-developmentCase ID:19-8727-tpNCSWeb Published:8/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/35281","**Summary:** Iron oxide nanoparticles (IONPs) are utilized to create micro-robots capable of chemically and mechanically eliminating biofilms with high precision through magnetic control. These biofilms, composed of bacterial cells within a protective matrix, present significant challenges due to their resistance to conventional antibacterial treatments. The developed Catalytic Antimicrobial Robots (CARs) address biofilm resistance by degrading the matrix, killing the bacteria, and physically removing the degraded materials.

**Applications:** The technology is applicable in various fields where biofilms pose challenges, such as healthcare to prevent infections, marine environments to combat biofouling, and industry sectors to reduce biocorrosion. 

**Problem Solved:** This approach effectively addresses the limitations of existing antimicrobial strategies that struggle to penetrate biofilm structures, providing a novel and efficient solution for the removal and treatment of biofilms.","Wirelessly activated iron oxide nanoparticles (IONPs) function as micro-robots that utilize magnetic control for the chemical and mechanical removal of biofilms. This technology addresses the challenges posed by biofilms, which are resistant to traditional antibacterial methods due to their protective matrix."
"University of Pennsylvania","Therapy Overcoming Resistance of Refractory Prostate Cancer","","","https://upenn.technologypublisher.com/technology/34978","Inhibition of cyclin-dependent-kinase 7 (CDK7) for treatment of refractory castration-resistant prostate cancer (CRPC) through reduction of androgen receptor transcriptional activity.Technology Overview:Prostate cancer is the most common non-cutaneous malignancy, and the second leading cause of cancer-related death in men of the western world. While effective therapies exist for clinically localized prostate cancer, progression to metastatic CRPC is essentially incurable. The Androgen receptor (AR) is the most frequent driver of resistance mechanism in CRPC patients.Dr. Asangani and his team at the University of Pennsylvania have developed a new approach for the treatment of CRPC by blocking AR signaling at the transcriptional level. The researchers found that AR transcriptional activity relies on activation through a ‚Äúphosphoswitch‚Äù catalyzed by CDK7.CDK7 phosphorylates the co-activator MED1 which forms a complex with AR leading to AR-mediated gene transcription. Inhibition of CDK7 disrupts the formation of this MED1-AR complex and blocks AR function. This approach allows to overcome several resistance mechanisms including AR amplification, mutation, and de novo androgen synthesis.Advantages:Treatment overcoming resistance of CRPCApplications:Treatment of advanced prostate cancerTreatment of advanced prostate cancer refractory to second generation anti-androgensPotential therapy for other hormonally driven cancersStage of Development:In vivo data using genetic and pharmacologic inhibitionIntellectual Property:US PatentPendingReference Media:Rasool, R et al.;Cancer Discov 2019 Nov 9(11): 1538.Desired Partnerships:LicenseCo-developmentCase ID:19-8898-tpNCSWeb Published:7/15/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/34978","**Summary:** The technology focuses on inhibiting cyclin-dependent-kinase 7 (CDK7) as a novel treatment for refractory castration-resistant prostate cancer (CRPC) by reducing androgen receptor (AR) transcriptional activity. Prostate cancer is a prevalent malignancy and a leading cause of cancer-related deaths among men, especially in western countries. The primary driver of resistance in CRPC is the androgen receptor. Researchers at the University of Pennsylvania have discovered that blocking AR signaling at the transcriptional level through CDK7 inhibition disrupts the formation of the MED1-AR complex, thereby blocking AR function. This method effectively addresses various resistance mechanisms, including AR amplification, mutation, and de novo androgen synthesis.

**Applications:** The treatment is applicable for advanced prostate cancer, particularly in cases resistant to second-generation anti-androgens, and may also have potential therapeutic applications in other hormonally driven cancers.

**Problem Solved:** This technology addresses the significant challenge of treating advanced CRPC, which remains largely incurable and develops resistance to existing therapies, by targeting and overcoming the underlying mechanisms of resistance associated with androgen receptor signaling.","Inhibition of cyclin-dependent-kinase 7 (CDK7) targets the reduction of androgen receptor transcriptional activity as a treatment for refractory castration-resistant prostate cancer (CRPC). Prostate cancer is the most prevalent non-skin malignancy and the second leading cause of cancer-related deaths among men in the western world."
"University of Pennsylvania","Bifurcation-based embodied logic and autonomous actuation","","","https://upenn.technologypublisher.com/technology/38476","A stimuli-responsive self-actuating 3D-printed material capable of performing complex timed functions and simple logical operations in response to multiple stimuli.Technology Overview:Mechanical systems with nonlinear properties are known to be highly sensitive to structural changes, particularly at geometric branch points. Such stimuli-responsive materials are useful for creating active materials with applications in microfluidics, medical devices, and robotics. However, available systems exhibit variable functionality due to high sensitivity to stimuli and low controllability of structural changes. Current technologies require rigid electronics, wires, control systems, or human intervention for proper function, which limits their use in many environments.The technology is a stimuli-responsive anisotropic composite material that autonomously and reversibly changes structure upon contact with a defined trigger. The actuation is driven by the release of internal stresses accumulated due to the response of the anisotropic material to the external stimuli. The functionality of the material is coupled with Finite Element Analysis calculations to determine the optimal geometry for desired functions. The result is a self-powered device capable of performing simple logical operations and precisely timed resettable movements and is scalable from microscopic to building-size scales.Advantages:Combined structural and functional control over the materialThe structure-material combination is a sensor, actuator, and device all in oneNo need for external power or control systemsAutonomously and reversibly changes structureOptimizable geometry for particular tasks.Applications:Self-powered remote single-task devicesBiomedical devices, particularly for drug deliverySoft roboticsDeployable structuresStage of Development:Prototypes developed using 3D printed PDMS/fiberglass composites and hydrogels with cellulose fibersPrototype devices were developed that take advantage of simple Boolean logic and timed actuation. These include a hopper that jumps when an undesired chemical is introduced, a flytrap that only closes when mechanically perturbed during a pre-programed interval of time, and a box that only opens when in the presence of both an oil and water.Studies are on-going to extend the technique to light-responsive and temperature-responsive materials.Intellectual Property:US PatentPendingReference Media:Jiang, Y et al.;Nat Commun 2019 Jan, 10-128Desired Partnerships:LicenseCo-developmentCase ID:17-8231-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38476","**Summary:** A stimuli-responsive self-actuating 3D-printed material has been developed that is capable of performing complex timed functions and simple logical operations in response to multiple stimuli. This anisotropic composite material autonomously changes its structure upon contact with specific triggers, utilizing internal stress release to drive the actuation. The technology merges functionality with Finite Element Analysis calculations to optimize geometry for various applications, resulting in a self-powered device with scalable capabilities from microscopic to architectural sizes. 

**Applications:** The technology can be applied in various fields, including microfluidics, medical devices, and robotics, where active materials are crucial for functionality.

**Problem Solved:** This technology addresses the limitations of current mechanical systems that are highly sensitive to stimuli yet exhibit low controllability and variable functionality. By eliminating the need for rigid electronics, wires, and human intervention, it enhances operational reliability and adaptability across diverse environments.","A stimuli-responsive self-actuating 3D-printed material can perform complex timed functions and simple logical operations in response to multiple stimuli. This technology leverages mechanical systems with nonlinear properties, making it suitable for applications in microfluidics, medical devices, and robotics."
"University of Pennsylvania","Broad Non-Typeable Haemophilus Influenzae Vaccine","","","https://upenn.technologypublisher.com/technology/35201","Problem:Haemophilus influenzae (H. influenzae) colonizes in the upper respiratory tract causing a wide variety of diseases, including otitis media, conjunctivitis, sinusitis, pneumonia, and meningitis. H. influenzae strains are classified into 6 serotypes depending on antibody specificity to the bacterial capsule. There is also a genetically diverse group of strains that do not express a capsule, termed non-typeable H. influenzae (NTHi). NTHi is now one of the leading causes of otitis media in children and exacerbation of chronic obstructive pulmonary disease (COPD) in adults. Current efforts in NTHi vaccine development focus on generating antibodies against surface antigens, but have had limited success due to the antigenic diversity among NTHi strains.Solution:Dr. Hao Shen discovered that a cellular response from CD4 T-cells (Th17) is the required immune mechanism of protection against NTHi lung infections and is broadly protective against different NTHi strains, unlike antibody responses that are highly strain specific.Drs. Hao Shen and Brian Akerley discussed screening for conserved NTHi antigens recognized by T-cells, and Dr. Akerley developed a list of conserved NTHi proteins based on published genomic data as potential target antigens. Dr. Shen screened these proteins and identified conserved protein antigens that are recognized by Th17 during NTHi infection, including protein antigens 0259 and 0264 that are conserved among 97% of NTHi strains.Dr. Shen showed that immunization with protein antigens 0259 and 0264 induce antigen-specific Th17 cellular responses that recognize different NTHi strains and protect against the lung infection. Therefore, immunization with these protein antigens provide broad protection against infections by different NTHi strains.Advantages:Broadly protective against different strains of NTHi; not limited to strain-specific surface antigensCan be effectively administered subcutaneously, intramuscularly, intraperitoneally, or intravenouslyApplications:Non-typeable H. influenzae vaccineProtective against influenza co-infectionsStage of Development:Target identifiedPreclinical proof of conceptIntellectual Property:US11,357,845Reference Media:Li, Wenchao et al.;Proc Natl Academ Sci USA 2018 July; 115(30); E7149.Desired Partnerships:LicenseCo-developmentCase ID:19-8990-tpNCSWeb Published:7/30/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/35201","**Summary:** This technology addresses the challenge posed by non-typeable Haemophilus influenzae (NTHi), which is responsible for various diseases like otitis media and COPD exacerbations. Current vaccine efforts have struggled due to the antigenic diversity of NTHi strains. Researchers discovered that a CD4 T-cell response, specifically Th17, is essential for protection against NTHi lung infections and offers broader protection than traditional antibody responses. They identified conserved protein antigens recognized by Th17 cells, including proteins 0259 and 0264, which are present in 97% of NTHi strains, indicating a promising target for vaccine development.

**Applications:** The vaccine may be used to prevent NTHi-related diseases such as otitis media in children and exacerbations of chronic obstructive pulmonary disease in adults, potentially broadening the protective efficacy across multiple strains of NTHi.

**Problem Solved:** This technology provides a solution to the limitations of existing vaccines that focus solely on antibody generation. By targeting T-cell responses to conserved antigens, it aims to offer effective protection against the diverse strains of NTHi responsible for significant morbidity.","Haemophilus influenzae colonizes the upper respiratory tract and causes diseases such as otitis media, conjunctivitis, sinusitis, pneumonia, and meningitis. Non-typeable H. influenzae (NTHi), a genetically diverse group of strains that do not express a capsule, is now one of the leading causes of otitis media."
"University of Pennsylvania","A Point-of-Care Fentanyl Test Capable of Detecting ‚â•1 ng/ml Fentanyl","","","https://upenn.technologypublisher.com/technology/34834","Fentanyl is a synthetic opioid agonist that is almost 50-100 times more potent than morphine, and illicit fentanyl is the fastest growing overdose substance in the United States. Rapid identification of fentanyl in suspected overdose patients is critical for prompt treatment. This invention describes an easy to use point-of-care test to rapidly identify fentanyl in patient urine or on objects to detect the illicit transportation of fentanyl.Solution:This technology is a competitive lateral flow immunoassay test strip capable of acting as a point-of- care (POC) diagnostic to provide rapid ‚Äòon-site‚Äô detection of ‚â•1 ng/ml fentanyl in a nonlaboratory settings.Unlike other lateral flow assays to detect fentanyl, the described invention is the first lateral flow assay with cutoff at the clinical meaningful level of 1 ng/ml. The unique characteristics of the invention enabling this level of sensitivity compared to existing assays are covered by a US provisional patent application and may be shared under a CDA.Problem:In 112 adults that died of intravenous fentanyl overdose, the fentanyl concentrations in the urine averaged 3.9 ng/mL. Currently, commercially available point-of-care fentanyl tests fail to detect the presence of fentanyl if it is below 10 ng/ml. Sensitive fentanyl detection is essential for properly treating overdose victims, and transporting overdose patients to a hospital. The reliance on current clinical fentanyl tests significantly delays proper intervention.Advantages:10x greater sensitivity than current commercially available point-of-care fentanyl testsFast results and easy to useApplications:Identification of trace amounts of fentanyl on shipments/packages to screen for the illicit transportation of fentanylCan be used in the field, emergency vehicles, or emergency rooms to rapidly identify individuals with fentanyl overdoseIndividual results of clinical urine samples tested using the fentanyl strip and the LC-MS/MS method. Y-axis is fentanyl equivalent concentration as determined by the LC-MS/MS method, calculated as (LC-MS/MS fentanyl + LC-MS/MS norfentanyl x 0.08).To validate the performance of the fentanyl strip, two groups of clinical urine samples were tested using both the fentanyl strip and an LC-MS/MS method validated according to Clinical Laboratory Improvement Act (CLIA) standards. Using the LC-MS/MS as gold standard method with 1 ng/mL fentanyl or 10 ng/mL norfentanyl as cutoffs, the clinical sensitivity of the fentanyl strip is calculated to be 100% (95% confidence interval (CI) 75.8-100%), and the clinical specificity is 99.5% (95% CI 97.3-99.9%). The incidence of fentanyl/norfentanyl-positivity in this ED population is 5.5%. The positive and negative predictive values (95% CI) of the fentanyl strip test are 92.3% (66.7-98.6%) and 100% (98.2-100%) respectively.Stage of Development:Bench prototypeIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:19-9020-tpNCSWeb Published:7/10/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/34834","**Summary:** This invention provides a novel point-of-care test capable of rapidly detecting at least 1 ng/ml of fentanyl in urine or on surfaces. It utilizes a competitive lateral flow immunoassay, distinguishing itself from existing tests by offering a sensitivity level that is clinically relevant for identifying fentanyl in overdose situations. The technology is designed for use in non-laboratory settings, facilitating immediate identification and intervention.

**Applications:** The primary applications include emergency medical settings, substance abuse treatment facilities, and law enforcement for rapid identification of fentanyl in suspected overdose cases or during drug transportation investigations. 

**Problem Solved:** The technology addresses the critical need for sensitive detection of fentanyl in a timely manner, which is essential for effectively treating overdose victims. Existing tests on the market often miss fentanyl concentrations below 10 ng/ml, which can delay life-saving medical interventions. By offering detection at clinically meaningful levels, this invention enhances patient outcomes in overdose scenarios.","Fentanyl is a potent synthetic opioid that poses a significant overdose risk in the U.S., necessitating quick detection in suspected cases. The described invention is a convenient point-of-care test designed to rapidly identify fentanyl in urine or on objects, aiding in the detection of illicit fentanyl transport."
"University of Pennsylvania","Multipoint Injection Technology for Efficient Intracerebral Drug Delivery","","","https://upenn.technologypublisher.com/technology/37169","Multipoint injection technology improves therapeutic coverage and infusion rate, reduces the number of injections required and minimizes surgical time.Technology Overview:The use of adeno-associated virus (AAV) for therapeutic gene transfer to the brain has reached the clinical stage and is being used for treatment of diseases of the brain, such as Parkinson‚Äôs Disease, where the therapeutic target can be any superficial or deep brain structure. Thus far, AAV has been delivered to the brain via injection with a single cannula. Initial trials have shown inefficient and sub-therapeutic dosage in one injection, requiring serial injections to three separate areas of the putamen, lengthening and complicating the surgical procedure.In a collaboration between the University of Pennsylvania and Children's Hospital of Philadelphia, Dr. Vitale and Dr. Gonzalez-Alegre have developed an intracerebral drug delivery system that consists of three flexible, retractable silicone microcannulas housed within a single central catheter. This device delivers AAV to the full putamen through a single trajectory with double the infusion rate. This reduces the number of injections and minimizes surgical time.The flexible silicone microcannulas minimize acute trauma and bleeding compared with conventional metal cannulas. The technology is expected to be compatible with treatment of other brain regions using any fluid-based drug delivery system, such as chemotherapeutic agents for glioblastoma.Advantages:3x volume infused with a single injectionReduced length, cost and risk of surgical procedureCompatible with MRI and current surgical guidance workflowsCan be approved by the FDA via 510k pathway as class II medical deviceApplications:Delivery of gene therapiesDelivery of other fluid-based therapies to different areas of the brainBrain electrical activity recording for intraoperative diagnostic monitoringMultipoint Injection Technology (MINT) is a gene therapy delivery system that includes 3 retractable cannulas within a single catheter to reduce the number of injections required to achieve therapeutic dosage as well as minimize surgical time necessary to deliver therapy.Stage of Development:Bench prototype and some preclinical testingIntellectual Property:US PatentPendingEuropean PatentPendingReference Media :Prezelski, K et al.;Front Med Technol 2021 Oct 14, 3: 725844Desired Partnerships:LicenseCo-developmentCase ID:18-8489-tpNCSWeb Published:11/14/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/37169","**Summary:** The technology enhances intracerebral drug delivery by utilizing a system of three flexible, retractable silicone microcannulas within a single central catheter, allowing for efficient targeting of the putamen through a single trajectory. This approach increases the therapeutic coverage and infusion rate while reducing the number of injections and overall surgical time. The device is designed to minimize acute trauma and bleeding compared to traditional metal cannulas, improving patient outcomes.

**Applications:** The technology is primarily intended for the delivery of adeno-associated virus (AAV) for therapeutic gene transfer in brain diseases like Parkinson‚Äôs Disease, and it may also be applicable to other fluid-based drug delivery systems, including chemotherapeutic agents for glioblastoma and potentially other brain regions.

**Problem Solved:** Traditional methods of AAV delivery via single cannula injections often resulted in inefficient dosages and the need for multiple injections, complicating surgical procedures. This new technology addresses these issues by providing a more streamlined, effective approach to drug delivery, thus improving the efficiency and safety of intracerebral treatments.","Multipoint injection technology enhances therapeutic coverage and infusion rates while minimizing the number of injections and surgical time. It is utilized for adeno-associated virus (AAV) delivery in the treatment of brain diseases like Parkinson's Disease, targeting various brain structures."
"University of Pennsylvania","Guidance Device for Optimized Directional Placement of Chest Tubes","","","https://upenn.technologypublisher.com/technology/34676","A plastic device to guide directional placement of chest tubes. Unlike chest tube placement without guidance when using kelly clamps for stability, the chest tube guidance device places the tube in its intended intrathoracic direction correctly in the first instance, thereby avoiding repeat procedures and injury.Technology Overview:Drainage of air or fluid/blood accumulating in the pleural or chest cavity is required 5,000-10,000 times per year in the fields of trauma surgery, cardiaothoracic surgery, and emergency medicine. This is achieved through insertion of a chest tube into the thoracic cavity, with the tube ideally directed towards the apex of the lung to drain air, or towards the base to drain fluid or blood and to minimize tissue damage and reduce blood clots. However, this position is often not achieved because surgeons are blind to the motion of the chest tube once the tube is inside the thoracic cavity.Clinicians often use kelly clamps to stabilize the tube, but this directing force is limited to the incision site. When there is misplacement of a chest tube, an additional chest tube must be placed and in some cases major surgery is required to remove blood clots. This leads to increased procedures, morbidity/mortality and costs.To overcome these challenges, an L-shaped plastic chest tube introducer can be used to guide the chest tube into an optimal placement once inside the chest without interacting with the lungs and other tissues. The chest tube guidance device consists of an inner compartment and an external support. Once the guidance device is inserted, the inner component is removed and replaced with the chest tube, which is advanced and guided towards its intended direction inside the chest.The guidance device consists of a grip with handles (for the physician to direct chest tube placement while inside the intrathoracic cavity) and the attached plastic tube with inner and outer compartments.Advantages:Higher confidence when placing chest tubesReduced need for multiple tube placements and, in some cases, surgery to repair damageLess costly (when accounting for multiple placements and/or surgery)Application:Introducing chest tubes into the bodyStage of Development:Computer models of the device have been generatedSterile devices and clinical trials are in developmentIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:18-8703-tpNCSWeb Published:6/25/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/34676","**Summary:** A plastic device has been developed to enhance the directional placement of chest tubes during procedures to drain air, fluid, or blood from the thoracic cavity. This guidance device helps medical professionals position the chest tube accurately towards the apex of the lung or the base, minimizing the risks of misplacement and subsequent complications. By providing a stable introduction point without obstructing the lungs or surrounding tissues, the device reduces the need for repeat tube placements and potential invasive surgeries.

**Applications:** The technology is applicable in trauma surgery, cardiothoracic surgery, and emergency medicine, where it can significantly improve patient outcomes during chest tube placements required for drainage procedures.

**Problem Solved:** The device addresses the common issue of improper chest tube placement that can occur when surgeons are unable to visualize the tube's orientation within the thoracic cavity. By facilitating more accurate initial placement, it aims to decrease the incidence of repeat procedures, related morbidity and mortality, and healthcare costs associated with misplacement complications.","A plastic device is designed to guide the directional placement of chest tubes, ensuring correct intrathoracic placement to minimize the need for repeat procedures and reduce the risk of injury. This technology addresses the need for drainage of air, fluid, or blood in the pleural or chest cavity, which occurs 5,000-10,000 times annually in trauma surgery and cardiothoracic procedures."
"University of Pennsylvania","A method for highly selective nucleic acid enrichment for sensitive detection of mutations in cancer and genectic conditions.","","","https://upenn.technologypublisher.com/technology/38495","This technology increases the fraction of clinically relevant, rare mutant alleles (DNA and/or RNA) to enable high sensitivity detection with common downstream methods such as capped (XNA or PNA) PCR, ddPCR, and sequencing.Problem:Liquid biopsy is a simple, minimally invasive, rapidly developing diagnostic method to analyze cell-free nucleic acid fragments in body fluids to obtain critical information on patient health and disease status, enable personalized therapy, and replace invasive methods such as tissue biopsy.The sensitivity of available tests is, however, insufficient for patients at early disease stage and for cancer screening. Detection of alleles that contain critical clinical information is challenged by their very low concentrations and sequence homologies with abundant wildtype nucleic acids. This invention comprises of a high efficiency assay that reduces the concentrations of wildtype nucleic acids, DNA and/or RNA, and increases the fraction of clinically-relevant mutant alleles (DNA and/or RNA) to enable their downstream detection by a variety of methods.Solution:This invention utilizes DNA-guided Argonaute (Ago) endonuclease that cleaves guide-complementary DNA and RNA with single nucleotide precision, greatly increasing the fractions of clinically-relevant rare alleles in a patient sample to enhance the sensitivity of downstream detection methods such as drop digital PCR, sequencing, and clamped (e.g., XNA and PNA) enzymatic amplification, enabling detection of low-frequency (0.01%) mutant alleles.This invention has many advantages over competing technologies such as CRISPR Cas9-based, as Ago does not require targets to contain any specific (PAM-like) motifs; is a multi-turnover enzyme; cleaves ssDNA, dsDNA, and RNA targets in a single assay; is DNA-guided (less expensive and more stable than RNA guides), and operates at elevated temperatures, providing high selectivity and compatibility with polymerases.Advantages:Improves sensitivity of downstream detection and genotyping methodsCapable of enriching both DNA and RNA alleles in the same assayVersatile: does not require targets to contain specific (PAM-like) motifsTurnover enzymes: reduced enzyme consumptionHighly specific: resolves single nucleotide differences between sequences.Can be used as standalone kit for qualitative and quantitative assay to enrich rare sequences or integrated with existing downstream amplification such as capped (RT-) PCR/LAMP and/or sequencing.Amenable for incorporation into point of care devicesApplications:Increase the effectiveness and sensitivity of liquid biopsiesEnable detection of specific genetic materials (e.g., mutations associated with various types of cancers and fetal disorders; and strains of pathogensStage of Development:Reduction to practiceIn a proof of concept experiments, this invention enabled detection of cancer-related cell free alleles at fractions as low as 0.1% in blood samples from pancreatic cancer patients, in excellent agreement with tissue biopsy genotyping.Intellectual Property:PatentPendingReferences:Song et al.,Nucleic Acids Research 2020 Feb, 48(4): e19Swarts et al.Nucleic Acids Res, 2015, May 26, 43(10):5120.Sheng et al.Proc Natl Acad Sci, 2014 Jan 14, 111(2):652.Makarova et al.Biol Direct. 2009 Aug 25, 4:29.Desired Partnerships:LicensingCo-developmentCase ID:18-8416-tpNCSWeb Published:2/7/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38495","**Summary:** This technology enhances the sensitivity of detecting rare mutant alleles in nucleic acid samples by effectively reducing the abundance of wildtype nucleic acids. The method employs a DNA-guided Argonaute endonuclease that cleaves complementary DNA and RNA with high precision, thereby increasing the concentration of clinically relevant mutations in patient samples. This improved concentration allows for more sensitive downstream detection using techniques like drop digital PCR, sequencing, and clamped enzymatic amplification.

**Applications:** The technology is applicable in liquid biopsy diagnostics, which analyze cell-free nucleic acid fragments in body fluids. It is particularly valuable for early disease stage cancer detection and genetic condition screening, providing essential information for personalized therapy and potentially replacing more invasive tissue biopsy methods.

**Problem Solved:** The method addresses the challenge of insufficient sensitivity in existing tests for detecting low concentrations of clinically relevant mutant alleles, which are often difficult to distinguish from abundant wildtype nucleic acids. By significantly enhancing the detection of these rare alleles, it improves the overall effectiveness of cancer screening and diagnosis in patients at early stages of disease.","This technology enhances the detection of rare mutant alleles in DNA and RNA, improving sensitivity for methods like capped PCR, ddPCR, and sequencing. It addresses the need for effective analysis of cell-free nucleic acid fragments in liquid biopsies for better patient health assessments and personalized therapy."
"University of Pennsylvania","Camera Catheter for Gene Therapy Delivery and Therapeutic Interventions in the Subarachnoid Space","","","https://upenn.technologypublisher.com/technology/34615","Minimally invasive micro-catheter with an integrated camera (MIMIC) to reach suboccipital space of the cisterna magna via lumbar puncture for drug and gene-therapy delivery to the brainProblem:Open surgery is the standard of care for access to a diseased brain and spinal cord, but such surgeries are invasive, associated with significant morbidity, and can require long recovery times.Recent advances in gene therapy hold the potential to cure devastating neurological diseases. In order to be effective, circumvention of the blood brain barrier (BBB) is required for gene therapy treatment of neurological disorders such as Parkinson‚Äôs disease and glycogen storage diseases. One method to bypass the BBB is to place a needle via suboccipital puncture into the cisterna magna, a relatively large subarachnoid space located in the cranial vault. However, there is hesitation to utilize this technique due to potential for catastrophic injury to the brain and spinal cord.Solution:Bryan Pukenas, M.D., at the Hospital of the University of Pennsylvania, has developed a minimally invasive catheter that enables direct access for focal delivery of gene therapy vectors to the suboccipital space of the cranial vault in a minimally invasive manner.Traditionally, catheters are navigated using fluoroscopic guidance. However, navigating catheters with only fluoroscopic guidance in the spinal canal poses significant risk of spinal cord or nerve injury since one cannot see these structures using this method. In contrast, the MIMIC catheter utilizes an embedded micro-camera permitting real-time visualization of the spinal canal contents during catheter navigation and gives operators the ability to avoid vital structures like the spinal cord and nerves as the catheter is directed from the lumbar canal to the cranial vault.In addition to increased safety and simplicity, this approach is expected to reduce the amount of required gene vector material by 10-100 fold since gene transduction is much more efficient when delivered into the cisterna magna. The technology will change the procedure of gene therapy delivery to the brain from an inpatient surgery performed by an interventionalist /neurosurgeon to an outpatient procedure.Gene therapy may become accessible for patients who otherwise would not clinically qualify for gene therapy treatment due to risks associated with surgery and post-surgical care. Moreover, the cost of care will be dramatically reduced by moving towards an outpatient model and decreasing the amount of vector required for treatment.This invention has received over $90,000 in support from the Penn Medical Device Accelerator. The device has been tested in bench top spine models and a human cadaver. The technology is being further developed for additional application such as treatment of aneurysms, chemotherapy for brain tumors, epilepsy, laser ablation for brain tumors, etc.Advantages:Device is built using FDA-compliant Quality Management and Design ControlDevice is ISO13485 compliantSafer procedure compared to direct access to suboccipital spaceMinimally invasive delivery of gene and other therapies to the brainReduced complications and decreased resources for post-operative careShortened recovery timeReduced cost of treatment and patient careApplications:Localized delivery of gene therapy vectors to the brain from a lumbar puncture entry sitePotential for delivery of drugs, laser and thermal ablation therapies, cryotherapy, brain tumor treatments, aneurysm repair and focal epilepsy interventions in the brainStage of Development:Prototype successfully tested in a benchtop model, primate cadaver model and human cadaverConfirmed ability to navigate to suboccipital spaceConfirmed ability to visualize spinal cord and spinal nervesIntellectual Property:International PatentsPendingDesired Partnerships:LicenseCo-developmentCase ID:18-8675-tpNCSWeb Published:6/18/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/34615","**Summary:** The technology is a minimally invasive micro-catheter equipped with an integrated camera, designed to facilitate access to the suboccipital space of the cisterna magna via lumbar puncture. This enables the delivery of drugs and gene therapies directly to the brain, avoiding the complications associated with traditional open surgical methods.

**Applications:** The device is intended for gene therapy treatments of various neurological disorders, including Parkinson‚Äôs disease and glycogen storage diseases, where bypassing the blood-brain barrier is essential for therapeutic efficacy.

**Problem Solved:** The technology addresses the challenges associated with traditional surgical methods for accessing the brain and spinal cord, which are invasive and associated with significant morbidity and long recovery times. It also mitigates the risks involved with fluoroscopic navigation in the spinal canal, enhancing safety by providing real-time visualization of critical structures during the procedure.","A minimally invasive micro-catheter with an integrated camera is designed to access the suboccipital space of the cisterna magna via lumbar puncture for drug and gene therapy delivery to the brain. This approach aims to reduce the morbidity and recovery times associated with open surgery for treating neurological diseases."
"University of Pennsylvania","Targeting the Retinoic Acid Pathway to Bolster Immunotherapy","","","https://upenn.technologypublisher.com/technology/34482","A strategy to increase the effect of immune checkpoint blockade by targeting retinoic acid signaling in immunosuppressive solid tumors.Technology Overview:Sarcomas are solid tumors with more than 70 rare and often fatal subtypes. Typical survival rates are under 15% over 5 years. Sarcomas can prevent the formation of tumor-killing cells by eluding immune detection, a process termed immunosuppression. These tumors are largely resistant to immune checkpoint blockade (ICB), a cancer immunotherapy which promotes the formation of tumor-killing cells. More effective strategies to target sarcomas are needed.Recently, Dr. Haldar and his team have found that sarcomas can suppress the immune system through the secretion of retinoic acid (RA), a molecule which favors the formation of immune cells unable to detect tumors. Their latest findings demonstrate that inhibiting the RA pathway in sarcomas triggers a tumor rejection response by directly boosting the formation of tumor-detecting immune cells.Dr. Haldar‚Äôs team has developed a combination therapy to bolster existing immunotherapy against sarcomas that produce high levels of RA. Their protocol combines conventional ICB therapy with molecules that block RA signaling in tumors, an approach found to greatly reduce the size and weight of tumors in mice (see figure). This strategy could enhance survival rates and quality of life for patients with sarcoma.Advantages:Renders immunotherapy efficient against unresponsive sarcoma subtypesCould potentiate other existing treatments such as chemotherapy or radiotherapyCould extend lifespan and increase quality of life of affected patientsApplications:Therapy against sarcomas resistant to immunotherapyPromising treatment against other cancer types using the RA pathwayBlocking retinoic acid (RA) signaling with RA receptor blocker BMS493 potentiates immune checkpoint blockade (ICB) agent anti-PD1 antibody (aPD1) to reduce tumor size in mice. Each line represents an individual mouse.Stage of Development:2 targets identified: RA synthesizing enzymes and RA receptorsPreclinical discoveryIntellectual Property:US PatentPendingReference Media:Postow MA et al.J Clin Oncol. 2015 Jun 10;33(17):1974.Desired Partnerships:LicenseCo-developmentCase ID:19-8980-tpNCSWeb Published:6/5/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/34482","**Summary:** A novel strategy has been developed to enhance the effectiveness of immune checkpoint blockade in treating sarcomas, which are solid tumors known for their immunosuppressive characteristics and high resistance to conventional therapies. Researchers, led by Dr. Haldar, discovered that sarcomas can create an environment conducive to immune evasion by secreting retinoic acid (RA), which promotes the development of immune cells that fail to detect tumors. By inhibiting the RA signaling pathway, the team observed a significant increase in the generation of tumor-detecting immune cells, leading to a positive tumor rejection response.

**Applications:** This strategy primarily targets sarcoma tumors, a group of solid tumors with numerous rare and aggressive subtypes, and aims to improve the efficacy of current immunotherapies, particularly for those patients whose tumors produce high levels of retinoic acid.

**Problem Solved:** The approach addresses the challenge of immunosuppression in sarcomas that limits the effectiveness of existing immune checkpoint blockade therapies, potentially improving survival rates and quality of life for patients suffering from these difficult-to-treat cancers.","A strategy has been developed to enhance the effectiveness of immune checkpoint blockade by targeting retinoic acid signaling in immunosuppressive solid tumors, specifically sarcomas, which have over 70 rare and often fatal subtypes and a typical 5-year survival rate of under 15%. These tumors are primarily resistant to immune checkpoint blockade due to their ability to evade immune detection."
"University of Pennsylvania","Enhancing the Efficacy of Tumor Immunotherapy by Targeting Endothelin Receptor B","","","https://upenn.technologypublisher.com/technology/34427","Antagonism of Endothelin Receptor B (ETRB) increases intratumoral T cell homing to tumors and enables tumor response to otherwise ineffective immunotherapyProblem:In spite of generating a tangible antitumor cellular immune response in peripheral blood, tumor vaccines have proven largely ineffective for treatment of solid tumors. The success of immune therapy partly depends on the ability of effector cells to infiltrate tumors which in turn is dependent on tumor microenvironment.T cell trafficking through lymphoid organs and peripheral tissues is tightly controlled through endothelial addressing signals regulating homing, adhesion and transendothelial migration. Endothelium provides a barrier that prevents T cell infiltration, and thus, there is a need for new pharmacologic intervention to improve cancer immunotherapy without increasing systemic inflammation.Solution:Dr. Coukos and his team at Penn have developed methods of treating and enhancing efficacy of immunotherapy for a solid tumor by modulating the expression or activity of effector proteins such as ETRB, ET-1, ICAM-1 to guide T-cells to the tumor cells. They have shown that ETBR signaling blocks T cell adhesion to endothelium and ETBR blockade restored adhesion of T cells in vitro and markedly increased T cell homing to tumors. In addition, the endothelial molecular signature which includes ETBR, could assist in the selection of patients for whom ETBR blockade may enhance immunotherapy.Advantages:Increase in anti-tumor immune responseApplications:Adjuvant therapy to tumor vaccinesStage of Development:In vivo dataIntellectual Property:US9,289,426US10,174,120Reference Media:Kandalaft, LE et al.;Clin Cancer Res. 2009 Jul 15;15(14): 4521.Buckanovich,RJ et al.;Nat Med. 2008 Jan;14(1):28.Desired Partnerships:LicenseCase ID:S4136-tpNCSWeb Published:5/29/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/34427","**Summary:** Antagonism of Endothelin Receptor B (ETRB) has been shown to enhance the efficacy of immunotherapy for solid tumors by increasing the homing of T cells to tumor sites. Research indicates that while tumor vaccines can evoke a strong antitumor immune response in peripheral blood, they often fail to translate to effective treatment due to challenges in T cell infiltration through the tumor microenvironment. Dr. Coukos and his team have developed approaches that involve modifying the activity of proteins like ETRB, ET-1, and ICAM-1, aiming to improve T cell adhesion and migration into tumors. Their findings suggest that blocking ETBR signaling facilitates T cell adhesion to tumor-associated endothelium, significantly improving T cell homing to tumors.

**Applications:** This technology could be applied to enhance existing immunotherapies for solid tumors, potentially leading to improved patient outcomes. It may also assist in the development of patient selection criteria based on the endothelial molecular signature that includes ETRB.

**Problem Solved:** The technology addresses the issue of ineffective antitumor responses due to the inability of T cells to infiltrate solid tumors, which is largely influenced by the tumor microenvironment's endothelial barriers. By targeting ETRB, it provides a pharmacological intervention that could improve T cell infiltration and the overall effectiveness of cancer immunotherapy without increasing systemic inflammation.","Antagonism of Endothelin Receptor B (ETRB) enhances the homing of intratumoral T cells and improves the response of tumors to previously ineffective immunotherapy. The efficacy of tumor vaccines is limited by the ability of effector cells to infiltrate solid tumors, which is influenced by the tumor microenvironment."
"University of Pennsylvania","MicroRNA Mimics for the Treatment of Pneumonia","","","https://upenn.technologypublisher.com/technology/32592","miR302-mimic is a therapeutic compound that accelerates regeneration of alveolar epithelial cells for treatment of bacterial pneumonia. Unlike standard treatment with antibiotics, which eliminate only the bacterial infection, this product would accelerate healing of the lungs to improve patient recovery time and could be given in conjunction with antibiotics.Technology Overview:Bacterial pneumonia is a leading cause of serious infection and death in children and the elderly worldwide. Even with antibiotic treatment, patients may become severely ill and require hospitalization and intensive care, followed by a prolonged recovery period. Recovery requires both eradication of the bacterial infection as well as repair to alveolar epithelial cells (AECs) caused by the infection. Failure to repair this damage increases susceptibility to recurring infection and increases the risk of development of chronic and progressive lung diseases including chronic obstructive pulmonary disease (COPD) and emphysema.Researchers in the laboratory of Dr. Hao Shen at the University of Pennsylvania in collaboration with Dr. Ying Tian at Temple University identified that increased expression of microRNA (miRNA) from the miR302 family coincided with regeneration of AECs. miRNA-mimics are double-stranded RNA molecules intended to ‚Äúmimic‚Äù native miRNAs. The Shen Lab found that administration of miR302-mimics to mice infected with bacterial pneumonia improves AEC regeneration and lung function, and enhances mouse recovery and survival.Addition of exogenous miR302 by miRNA mimics increases proliferation of lung progenitor cells and accelerates the repair of lung injury, which is expected to shorten patient recovery times. miR302-mimics could potentially be administered in conjunction with antimicrobial therapy to improve patient outcomes. This approach may also provide long-term benefits by reducing severe chronic pathological conditions, such as COPD, which are associated with repeated lung infections, injuries and defects in tissue regeneration.Advantages:Speeds regeneration of AECsExpected to reduce patient recovery time from bacterial pneumoniaMay accelerate treatment of injuries to lungs resulting from other causesApplications:Treatment of injured lungsTreatment of bacterial pneumoniaMice treated with miR302 show improved rates of survival (left) and faster recovery of body weight (right) than control mice. The image was taken from Wang et al. Proc Natl Acad Sci USA, 2019 [ahead of print].Stage of Development:Proof of concept demonstrated in miceIntellectual Property:US PatentPendingReference Media:Wang et al.Proc Natl Acad Sci USA, 2019 Apr 23 116(17): 8493.Desired Partnerships:LicenseCo-developmentCase ID:17-8344-tpNCSWeb Published:4/30/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/32592","**Summary:** This therapeutic compound, miR302-mimic, promotes the regeneration of alveolar epithelial cells, offering a novel approach to the treatment of bacterial pneumonia. Unlike traditional antibiotics, which focus solely on eradicating the bacterial infection, this therapy aims to expedite healing in the lungs, thereby enhancing overall recovery times. Research indicates that it can be safely administered alongside antibiotics, addressing both the infection and the resultant cellular damage.

**Applications:** The miR302-mimic technology can be used in clinical settings to treat bacterial pneumonia, particularly in vulnerable populations such as children and the elderly. It plays a crucial role in enhancing recovery in patients who are at risk of severe illness, hospitalization, or chronic lung diseases due to pneumonia.

**Problem Solved:** This technology addresses the limitations of standard antibiotic treatments by not only targeting the bacterial infection but also facilitating the repair of alveolar epithelial cells. By promoting quicker recovery from lung damage, it reduces the likelihood of recurrent infections and the potential development of chronic pulmonary conditions like COPD and emphysema.","miR302-mimic is a therapeutic compound that promotes the regeneration of alveolar epithelial cells to enhance healing in patients with bacterial pneumonia. It can be administered alongside antibiotics to improve recovery times, addressing both the infection and the lung healing process."
"University of Pennsylvania","Application of human 3D brain organoids in regenerative medicine and drug testing","","","https://upenn.technologypublisher.com/technology/39103","Problem:Current drug discovery strategies often utilize cell lines and animal models for compound development, drug screening, efficacy testing, and establishing dose-responses. However, such model systems are often limited, particularly for brain disorders and cancers.Traditional cell culture systems can unintentionally alter physiological properties of cells given the artificial 2D environment, while animal models are very costly and do not fully recapitulate human disorders or diseases, resulting in less efficient and expensive drug discovery. An improved high throughput model system is necessary that maintains fidelity to in vivo human physiological properties yet can be easily manipulated and tested.Solution:Dr. Song and colleagues have established human 3D brain organoid systems that closely resemble human development and have already been applied for modeling several brain disorders. Using a highly optimized protocol consisting of human stem cells, tissues or cancer cells, and miniaturized spinning bioreactors, 3D brain organoids can be synthesized that recapitulate in vivo properties, contain more functional and mature cells, and have increased yield, stability and survivability. These brain organoids have been utilized for understanding the underlying mechanism of the Zika virus, screening neuroprotective compounds, modeling glioblastoma and identifying personalized therapeutics.Technology Overview:The maintenance of cellular, mechanical and topographical cues in the 3D microenvironment enables enhanced in vitro modeling of brain cancer, and neuropsychiatric and neurodegenerative diseases, to improve and accelerate the efficiency, safety, discovery and cost of drug screening for brain cancer and neuropsychiatric and neurodegenerative diseases.(See image below for reference.) Overview of human 3D brain organoid generation and use in drug screening.Using human-derived cells (e.g., human stem cells, tissue, cancer cells)3D brain organoids are developed that recapitulate in vivo physiological properties. Applications for brain organoids includeevaluating brain development and disease modeling;use in cell therapy; andhigh throughput drug screening, where ultimately drug hits and validation willlead to the development of novel pharmacotherapies.Advantages:Improves efficiency and reduces costs of modeling brain disorders and cancers.Improves testing of personalized therapeutics and drug response.Maintains 3D brain-like cytoarchitecture that recapitulates and retains physiological properties compared to 2D cell lines.Applications:Test beds for drug screening and genomic manipulationModeling and understanding brain disease pathogenesisStage of Development:Reliable generation using miniaturized spinning bioreactorsApplied use for Zika virus (mechanism & screening of therapeutic compounds), and glioblastoma (screening personalized therapeutics)Reference Media:Qian, X et al.;Cell 2016 May 19, 165(5): 1238Qian, X et al.;Nat Protoc 2018 March, 13(3): 565Vissers, C et al.;Adv Drug Deliv Rev 2019 Aug, 148: 239.Desired Partnerships:Sponsored Research AgreementsCase ID:Song-Brain-OrganoidsWeb Published:3/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39103","**Summary:** Human 3D brain organoids have been developed to provide a more accurate model for drug discovery and regenerative medicine compared to traditional methods. These organoids are created from human stem cells and can mimic the physiological properties of human brain tissue, offering an enriched environment for studying brain disorders and testing potential therapies. The system provides enhanced yield, stability, and survivability of the organoids, making them suitable for high-throughput applications.

**Applications:** The organoids have been utilized to model various brain disorders, screen for neuroprotective compounds, investigate the mechanisms of the Zika virus, and study glioblastoma. They also assist in identifying personalized therapeutics, thereby directly contributing to advancements in regenerative medicine and drug testing protocols.

**Problem Solved:** The technology addresses the limitations of traditional drug discovery methods, which often rely on 2D cell cultures and animal models that do not accurately reflect human physiology or disease states. By providing a high-fidelity model that more closely resembles in vivo human brain conditions, the organoids enhance the efficiency and effectiveness of drug discovery, particularly for brain-related diseases.","Current drug discovery strategies often rely on cell lines and animal models, which can be limited in their application to brain disorders and cancers due to altered physiological properties and high costs. Traditional cell culture systems may not accurately represent human diseases, highlighting the need for more effective model systems."
"University of Pennsylvania","Portable Assay Platform for Detection of Single Molecules","","","https://upenn.technologypublisher.com/technology/32372","A simple, inexpensive, and portable lateral flow assay platform that uses platinum nanoparticles to amplify signals and achieve single-molecule sensitivity.Technology Overview:Point-of-care (POC) diagnostics are able to provide rapid on-site results in non laboratory settings and play a key role in public health for rural and under-developed areas of the world. However, most traditional POC platforms are limited by low sensitivity and lack of quantification, and therefore cannot meet certain clinical needs. Traditional diagnostics often require expensive equipment, complex imaging, or laboratory expertise to operate, and therefore, cannot be used in low-resource settings.This technology is a simple, inexpensive, ultra-sensitive, and portable platinum nanoparticle-initiated bubbling digital assay (PNDA) platform for POC tests. A microfluidic array is decorated with antibodies for the target biomarker in close proximity to platinum nanoparticles, which catalyze the generation of oxygen microbubbles. The digital assay platform uses this ‚Äúexpress bubbling‚Äù to transform and amplify the signal, thus enabling the detection of single molecules.A widely available handheld microscope (or smart phone accessory) can be used to perform a readout from the PNDA Chip. The PNDA technology can be incorporated into a lateral flow assay (LFA) to provide a quantitative distance-based test readout. The entire immunoassay process can be integrated on to the LFA to process a single drop of sample in one step.Advantages:Low cost through the use of common reagentsOne-step, simple assay procedureCan be used in non-laboratory environmentsHigh sensitivity (single-molecule level)Complex imaging and fluorescence are not requiredQuantitative outputApplications:Point-of-care and portable health diagnosticsSingle-molecule detectionChemical tests in non-laboratory settingsThe platinum nanoparticle-initiated bubbling digital assay (PNDA). (A) PNDA can be fabricated as a microfluidic chip that (B) traps oxygen microbubbles that are generated in the presence of a particular biomarker. The hexagonal pillar array provides a digital signal that can be visualized by widely available handheld microscopes. (C) Microbubbles are generated when a single target molecule binds to the PNDA Chip.Stage of Development:Developed and tested in a laboratory environmentIntellectual Property:US, Canadian, & EuropeanPendingReference Media:Li et al,RSOC, Analyst, 2019 May 21, 144(10): 3314Desired Partnerships:LicenseCo-developmentCase ID:18-8594-tpNCSWeb Published:4/18/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/32372","**Summary:** The described technology is an innovative and cost-effective portable platform designed for point-of-care diagnostics that utilizes platinum nanoparticles to enhance signal detection to the level of single molecules. It features a microfluidic array coated with specific antibodies that interact with a target biomarker, facilitating the generation of oxygen microbubbles that amplify the assay signal. This technology allows for rapid and quantitative results using a simple readout device, such as a handheld microscope or smartphone accessory.

**Applications:** This platform can be utilized in various point-of-care diagnostic settings, particularly in rural and under-developed areas where access to laboratory facilities and expensive equipment is limited. Its capability to provide rapid diagnostic results could be beneficial for public health applications, especially in infectious disease testing, chronic disease monitoring, and potentially in environmental testing for pollutants or pathogens.

**Problem Solved:** The technology addresses key limitations of traditional point-of-care diagnostic systems, including low sensitivity and the need for complex laboratory equipment or expertise. By enabling the detection of single molecules, it allows for greater diagnostic accuracy and the potential for quantitative results, making diagnostics more accessible in low-resource settings.","A portable lateral flow assay platform utilizes platinum nanoparticles to amplify signals, achieving single-molecule sensitivity. This technology aims to provide rapid point-of-care diagnostics, addressing limitations in sensitivity and quantification often found in traditional platforms."
"University of Pennsylvania","MAJIQ and VOILA: the next generation for sequencing analyses","","","https://upenn.technologypublisher.com/technology/38430","MAJIQ and Voila are two software packages that together detect, quantify, and visualize local splicing variations (LSV) from RNA-Seq data.Problem:Over 90% of human genes undergo alternative splicing, resulting in different gene products, potentially conveying different function. This underlying complexity to gene expression is still not well understood and mapping splicing variations remains a substantial challenge.Solution:Dr. Yoseph Barash and his lab have developed new methods that improve the detection and accuracy of mapping gene splicing variations, thus shining a light on previously poorly studied transcripts. These innovative tools, MAJIQ and VOILA, have the potential to identify variations associated with a multitude of processes ranging from gene function to disease.MAJIQ Builder: Uses RNA-Seq (BAM files) and a transcriptome annotation file (GFF3) to define splice graphs and known/novel Local Splice Variations (LSV).MAJIQ Quantifier: Quantifies relative abundance (PSI) of LSVs and changes in relative LSV abundance (delta PSI) between conditions w/wo replicates.Voila: A visualization package that combines the output of MAJIQ Builder and MAJIQ Quantifier using interactive D3 components and HTML5. Voila creates interactive summary files with gene splice graphs, LSVs, and their quantification.Stage of Development:Ready to useIntellectual Property:CopyrightReference Media:Vaquero-Garcia, J et al.;eLife 2016 Feb;5:e11752Sotillo, E. et al.;Sotillo et al. Cancer Discov, 2015 Dec, 5(12): 1282Norton, S et al.;Bioinformatics, 2018 May, 34(9): 1488Desired Partnerships:One click licenseCase ID:16-7706-tpNCSWeb Published:2/3/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38430","**Summary:** MAJIQ and VOILA are advanced software tools designed to detect, quantify, and visualize local splicing variations (LSV) from RNA-Seq data. Developed by Dr. Yoseph Barash and his lab, these tools enhance the detection and mapping of gene splicing variations, addressing significant challenges in understanding the underlying complexity of gene expression. The MAJIQ Builder establishes splice graphs and identifies known and novel LSVs, while the MAJIQ Quantifier measures the relative abundances of these variations and their changes between different conditions. Voila complements these functionalities by creating interactive visual representations of the results, utilizing D3 components and HTML5 for user-friendly summaries.

**Applications:** The software packages have applications in genetics and molecular biology research, particularly in identifying splicing variations that could be associated with various biological processes, including gene function and disease mechanisms. They facilitate deeper insights into alternative splicing, a phenomenon affecting over 90% of human genes.

**Problem Solved:** The technology addresses the substantial challenge of accurately mapping and understanding the complexities of alternative splicing in human genes, which has significant implications for gene function and potential disease associations. By improving detection methods, MAJIQ and VOILA shed light on previously poorly studied transcripts and their roles in various biological processes.","MAJIQ and Voila are software packages designed to detect, quantify, and visualize local splicing variations from RNA-Seq data, addressing the challenges posed by the high prevalence of alternative splicing in human genes. Developed by Dr. Yoseph Barash and his lab, these tools enhance the understanding of splicing variations and their implications for gene expression."
"University of Pennsylvania","Reconfigurable colloid-crystal materials for fine control over particle motion","","","https://upenn.technologypublisher.com/technology/32351","A nematic liquid crystal system functionalized with colloidal microbots.Problem:Particle motion is of great interest for designing materials that depend on the particle behavior to exhibit a specific functionality. Elastic colloids are useful for the development of functional materials for particle manipulation. Nematic liquid crystals are fluid, like liquids, but also have well-defined structural organization, like crystals.Embedding colloids in these materials provides strong control over the particle motion and ensures a smooth elastic energy field for the particles. Current techniques have similarly tried to alter the energy landscape for particles in colloid-nematic crystal systems, but fail to robustly control the particles, and either do not solicit a response or drastically change the crystal configuration.Solution:The researchers envision controllable, reconfigurable liquid/crystal systems. To achieve this innovation the inventors leverage surface features in boundary walls that cause unique boundary conditions that can control the movement and action of microbots within the system. These colloidal systems and microbots can be fabricated for specific application requirements.Advantages:Improved control over particlesNo drastic change in configuration of crystalsDefects can be used to drive particle motion for colloidal assemblyApplications:Materials/surfaces that self-repair or self-healTargeted delivery tools, such as drug deliveryManufacturing on a micro-scaleCargo-delivery in micro-robotsFigures: (a)Elastic energy field and the resulting forces for colloids near the wall in a Saturn ring configuration (c) Schematic of the experimental setup (N denotes rubbing direction) (f + g) A magnetic particle with a Saturn ring defect, placed near a hill, with wall to wall separation (yellow) 60 Œºm and (blue) 42 ŒºmStage of Development:Ongoing experimental work with cargo-carrying prototypesPrototypes will be used for proof-of-concept experiments that test control of unstable points and path planning of particlesColloidal assembly at the defect sites will be demonstratedIntellectual Property:PatentPendingReference Media:Luo, Y et al;Nat Commun 2018 Sept 21, 9(1): 3841.Case ID:18-8616-tpNCSWeb Published:4/16/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/32351","**Summary:** A nematic liquid crystal system has been developed that is functionalized with colloidal microbots, allowing for enhanced control over particle motion. Elastic colloids embedded in these materials facilitate the manipulation of particles by creating a smooth elastic energy field. The innovation overcomes limitations of existing techniques that fail to provide robust control or lead to drastic changes in crystal configuration. The researchers utilize unique boundary conditions introduced by surface features in boundary walls to achieve this control, allowing for a reconfigurable and controllable liquid/crystal system tailored for specific applications.

**Applications:** The technology can be applied in the creation of materials and surfaces that have self-repair or self-healing capabilities, as well as in targeted delivery systems such as drug delivery and precision manufacturing on a micro-scale.

**Problem Solved:** The technology addresses the challenge of controlling particle motion in colloid-nematic crystal systems without significantly altering the crystal structure, thus enabling the design of functional materials that rely on specific particle behaviors.","The study involves a nematic liquid crystal system enhanced with colloidal microbots to achieve fine control over particle motion. This approach leverages the unique properties of elastic colloids to develop functional materials for particle manipulation."
"University of Pennsylvania","High Precision Bone Metastases and/or Fracture Identification From Dual Energy X-ray Absorptiometry Exams Using Artificial Intelligence Techniques.","","","https://upenn.technologypublisher.com/technology/35193","Problem:Osteoporosis causes a reduction in bone density, which can result in bone fractures, particularly in the spine, forearms, and the hip. Osteoporosis does not present any symptoms, and yet it is estimated that more than 20 million people have this debilitating disease. Therefore, regular examination, especially in patients over the age of 65, is recommended.Diagnosis is typically done by bone density measurement using Dual energy x-ray absorptiometry (DEXA) examination. DEXA is currently considered to be the gold standard for the diagnosis of osteoporosis. Even with 50 million scans per year, a large portion of metastases and fractures remain unnoticed by radiologists. This can lead to increased treatment cost and morbidity downstream.Solution:Advances in computing have created numerous opportunities for artificial intelligence (AI) to solve clinically important imaging problems, with promising applications that would benefit patients. Most notably, AI outperformed radiologists in diagnosis of pneumonia from chest X-rays.The inventors developed an AI algorithm using random forest classifiers to assist radiologists in measuring bone mineral density. The algorithm can be implemented on current scanners. Experimental data shows improvement in sensitivity (77.8%), specificity (100%), and accuracy (98%) of lumbar bony metastasis detection, and improvement in sensitivity (61%), specificity (91%), and accuracy (85%) of lumbar fracture detection, which can reduce treatment cost and offer significant benefits to patients.Advantages:Can be easily and inexpensively installed and implemented on existing machines.High accuracy (98%), sensitivity (77.8%) and specificity (100%) in detecting bony metastases.High accuracy (85%) sensitivity (61%) and specificity (91%) in detecting factures.Can reduce cost of care by better identifying bony metastatic disease and/or fractures.Applications:Bone mineral density measurementBony metastasis and fracture detection from dual x-ray absorptiometry (DEXA) examsStage of Development:Algorithm is fully developed to detect bony metastases and/or fractures in the spine.Proof of concept has been successfully established in-vivo in over two hundred patients.Inventors aim to expand the application to detect other bone diseases and conditions such as Paget‚Äôs disease in the spine.Investigators aim to optimize the method to detect metastases and/or fractures in other regions such as the hip.Intellectual Property:CopyrightReference Media:Mehta & Sebro;Int J Comput Assist Radiol Surg 2019 May, 14(5): 903.Desired Partnerships:LicenseCo-developmentCase ID:19-8729-tpNCSWeb Published:7/29/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/35193","**Summary:** The technology addresses the challenge of detecting bone metastases and fractures in patients suffering from osteoporosis, which is a condition affecting over 20 million individuals and is often asymptomatic. Current diagnostic methods using Dual Energy X-ray Absorptiometry (DEXA) scans, though effective in measuring bone density, often miss a significant number of fractures and metastases, leading to increased healthcare costs and patient morbidity. The developed AI algorithm, utilizing random forest classifiers, enhances the diagnostic capabilities of these examinations, leading to improved detection rates for both metastases and fractures.

**Applications:** The primary applications of this technology lie in improving the accuracy of DEXA scans for the diagnosis of osteoporosis-related bone metastases and fractures. This advancement is particularly beneficial for individuals over the age of 65, who are at greater risk of such conditions. The AI integration can be implemented in existing DEXA scanners to provide radiologists with improved diagnostic support.

**Problem Solved:** The technology effectively addresses the inadequacies in current DEXA scanning protocols where many fractures and metastases go undetected. By enhancing sensitivity, specificity, and accuracy, the AI algorithm aims to facilitate earlier and more reliable diagnoses, ultimately leading to reduced treatment costs and improved patient outcomes.","Osteoporosis leads to a reduction in bone density and is estimated to affect over 20 million individuals, particularly causing fractures in the spine, forearms, and hip. Regular DEXA examinations are recommended for diagnosing this condition, especially in patients over 65 years of age."
"University of Pennsylvania","Deep Learning, Self-Supervised Algorithm for Fast and Accurate Image Registration","","","https://upenn.technologypublisher.com/technology/31943","A deep learning algorithm for fast and accurate, non-rigid image registration that does not require a training data set.Problem:Medical image registration is necessary for aligning multiple clinical images from a single patient as well as for associating medical images from multiple subjects or patients in research studies. Conventional medical image registration can be time consuming and challenging for certain types of images. Therefore, new methods use deep learning techniques like convolutional neural networks, which often employ training image datasets to learn informative image features. These techniques can improve the speed and accuracy of registration. However, in some cases training datasets are unavailable or do not accurately represent the image at hand.Solution:To overcome these challenges, this image registration algorithm uses deep learning methods to identify the appropriate spatial transformations required to align medical images. While other deep learning methods have relied on previously acquired training data, this method directly trains fully convolutional networks to independently estimate spatial transformations.To account for potentially large deformations between images, a multi-resolution strategy is adopted to jointly learn spatial transformations at different spatial resolutions. Because the registration of pairs of images also serves as a training procedure, the algorithm simultaneously optimizes and learns spatial transformations for the image registration.Advantages:Fast image registration (~200 ms per image pair)Improved image alignment compared to current state-of-the-art techniquesMulti-resolution registration strategy that accounts for deformations at different scalesApplications:Medically necessary imaging that requires fast image registrationLarge clinical research studies that require accurate image registration(a) A reference brain space defined by an individual brain image. (b) Mean of brain images of 40 different subjects, registered to the reference brain space using affine spatial transformation. (c) Mean of brain images of 40 different subjects, registered to the reference brain space using the current state-of-the-art in image registration, and (d) the image registration is further enhanced by the deep learning algorithm.Stage of Development:Developed and tested in a laboratory environmentIntellectual Property:US11,854,202US11,348,227Desired Partnerships:LicenseCo-developmentCase ID:18-8500-tpNCSWeb Published:4/5/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31943","**Summary:** A deep learning algorithm has been developed for non-rigid image registration that operates without the need for a training dataset. It utilizes fully convolutional networks to identify the necessary spatial transformations for aligning medical images and employs a multi-resolution strategy to handle significant deformations between images. The registration process itself serves as a means of training, allowing the algorithm to optimize spatial transformations in real-time.

**Applications:** This technology is applicable in the medical field for aligning multiple clinical images from individual patients, as well as for associating medical images across different subjects in research studies. It can enhance the quality and analysis of medical imaging, ultimately improving diagnostic and treatment planning processes.

**Problem Solved:** The technology addresses the challenges associated with traditional medical image registration, which can be time-consuming and complex, especially when training datasets are not available or are inadequate. By eliminating the dependence on training data, this algorithm streamlines the registration process while maintaining high levels of accuracy and speed.","A deep learning algorithm has been developed for fast and accurate non-rigid image registration without the need for a training data set. This approach aims to improve the efficiency of aligning multiple clinical images from a single patient and associating medical images from different subjects in research studies."
"University of Pennsylvania","Automating the ABCDE Ventilator Bundle in the ICU: An app to facilitate implementation of the bundle and improve outcomes for mechanically ventilated patients.","","","https://upenn.technologypublisher.com/technology/31940","This app provides automated, around-the-clock, patient screening for the both sedation and ventilator weaning. Real-time data on ABCD(E) documentation and performance is displayed on an electronic dashboard while timely alerts to mobile devices inform bedside providers.Problem:Mechanical ventilation [MV], while often necessary, can lead to a multitude of hospital-acquired conditions such as ICU-associated delirium, which has been shown to be strongly associated with increased morbidity and mortality rates both while in the hospital and post-acute care. Further, MV is a prime target for improving both patient outcomes and cost savings, since MV is the single biggest determinant in ICU Length of Stay [LOS], the single greatest driver of cost for an inpatient admission.Current evidence shows that coordination between different care team disciplines to screen and conduct weaning trials can improve patient outcomes, but they are largely performed manually and on a set schedule, translating into many missed opportunities to improve those very outcomes.Solution:Dr. Fuchs and colleagues have created the ABCDE app to continuously screen patients based on data in the electronic health record and alert the care team upon the patient reaching clinical readiness for weaning from sedation and ventilation. This information plus delirium scoring and progress with exercise is displayed in real-time on an electronic dashboard for review by ICU teams and ICU leadership.Simultaneously, alerts are sent to the respiratory therapist [RT] and registered nurse [RN], who then coordinate weaning of both the ventilator and sedative medications collaboratively. The system also provides real-time insight into the status of patients for both clinicians and ICU administration assessing patient flow. Additionally, it can evaluate for missed opportunities in order to identify operational processes for optimization.A pilot study showed that the system reduced significantly time on mechanical ventilation and ICU length of stay. It is now implemented across the UPHS.Implementation of an automated screening system such as the ABCDE app addresses failures in timing and coordination between care team members and provides data-driven insights into ICU operations that current solutions do not address.Advantages:Automated screening conducted on a continuous basisNo manual initiation requiredAutomatic communication to all care team membersReports on historical trends for operational optimizationApplications:Integration into an EHR with ICU moduleStand-alone app for use in ICUsCoordination of RN and RT in performing ventilator and sedation weaning trialsReal-time patient status reportingHistorical reporting to identify missed opportunitiesStage of Development:Ready for licensingIntellectual Property:CopyrightReference Media:Girard, TD et al.;Lancet. 2008 Jan 12, 371(9607): 126Balas, MC et al.;Crit Care Nurse. 2012 Aug, 32(4): 15Desired Partnerships:LicenseCase ID:16-7668-tpNCSWeb Published:4/5/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31940","**Summary:** This app provides automated, continuous patient screening for sedation and ventilator weaning in the ICU, using real-time data from the electronic health records. It displays ABCD(E) documentation and performance metrics on an electronic dashboard and sends timely alerts to bedside providers to inform them of a patient's readiness for weaning. 

**Applications:** The application is intended for use in the ICU for managing mechanically ventilated patients, aiming to streamline the weaning process and enhance multidisciplinary communication among care teams to improve patient outcomes.

**Problem Solved:** The technology addresses several critical issues associated with mechanical ventilation, such as ICU-associated delirium and extended ICU length of stay, both of which can increase morbidity and mortality rates. By facilitating continuous screening and timely interventions, the app enhances coordination among care teams, ultimately aiming to reduce missed opportunities for improving patient outcomes and lowering healthcare costs.","The app automates patient screening for sedation and ventilator weaning in the ICU, providing real-time data on ABCD(E) documentation via an electronic dashboard and alerting bedside providers on mobile devices. This technology aims to improve outcomes for mechanically ventilated patients and address issues like ICU-associated delirium linked to mechanical ventilation."
"University of Pennsylvania","Modified Polymer System for Improved Cartilage Repair","","","https://upenn.technologypublisher.com/technology/34378","Improved cartilage repair via injectable modified polymers that target damaged tissues and enhance cellular responseProblem:Cartilage damage is one of the most common ailments in the aging population. Tissue damage, particularly cartilage damage, can occur due to traumatic injury, degeneration with time, and other soft tissue injuries. The inability of these to heal properly after an injury results in mechanical wear and altered mechanics in adjacent tissues. These degenerative changes leave the tissues vulnerable to damage, often leading to their failure.Solution:The invention is a system of modified polymers that target damaged tissues and improve their repair process. The polymer acts by sealing the damaged cartilage and creating an environment that facilitates tissue healing. Current treatments involve application of glues or polymers directly to the injury site but are not living, something that the technology presented here achieves by delivering polymers intraarticularly to specific tissues, recruiting cells and directing their response. This targeting mechanism leads to enhanced and efficient healing. Moreover, the material is also tunable and can promote cartilage formation or anti-inflammatory effects, allowing for a treatment plan that can be customized to the patient‚Äôs tissue damage.Advantages:Treatment can be customized to the patient and type of tissue damageEnhanced delivery of therapeuticsProvided via intraarticular injection or applied arthroscopically near the defectImproved cartilage repairAbility to seal damaged cartilage and restore proper fluid flowApplications:Injectable therapeuticIn conjunction with stem cells injections to improve delivery, repair and/or regenerationDamaged tissue removal treatments e.g. cartilage debridement, meniscectomyTissue repair treatmentsTop Figure: Cartilage defects can cause increased fluid flow and loss of matrix proteins, including proteoglycans. This leads to elevated strain levels in the adjacent tissues, leaving tissues susceptible to wear, and ultimately joint-wide OA.Bottom Figure: This technology has the potential to treat damaged tissues. The first option restores fluid flow with a barrier at the focal defect interface and reduces the rate of degeneration. The second option would promote cartilage repair. The third would direct cells to the defect, providing an anti-inflammatory benefit, and improving the healing process. Currently, the proposed technique is option one, or a living fibrous ‚Äúbiosealant‚Äô.Stage of Development:Theoretical design based on individually verified principles in polymer modification has been developedIntegrated binding of the microenvironment has been established.The effect of the material‚Äôs tunable nature on cell mechano-response have been confirmed.The biomaterial‚Äôs implementation and retention in a pilot animal study has been achieved.Next steps are to optimize and characterize the therapeutic, detail the in vitro response of cells to varying biomaterial mechanics, and further test the material preclinically.Intellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:18-8501-tpNCSWeb Published:5/22/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/34378","**Summary:** This technology introduces a system of modified polymers designed to improve the repair of damaged cartilage through targeted delivery and enhanced cellular responses. The polymers seal the injured cartilage and create an optimal environment for tissue healing, facilitating a more effective repair process. Unlike traditional treatments, these polymers are living materials that can be delivered directly to the damage site, allowing for better integration and healing. The system is tunable, enabling customization based on the patient's specific type of tissue damage and healing needs.

**Applications:** The modified polymer system can be used in clinical settings for the treatment of cartilage damage resulting from injury, degeneration, or soft tissue injuries. It is applicable in orthopedic surgeries through intraarticular injections or arthroscopic procedures, aiming to restore normal function and alleviate pain in affected joints.

**Problem Solved:** The technology addresses the challenges associated with healing cartilage damage, which is particularly problematic in the aging population. By providing a more effective treatment option that enhances natural healing processes, it mitigates the issues related to mechanical wear and the risk of further damage in adjacent tissues due to poor healing of injuries.","Injectable modified polymers have been developed to target damaged tissues and enhance cellular response for improved cartilage repair. This innovative approach addresses the common issue of cartilage damage in the aging population, which can result from trauma or degeneration, leading to mechanical wear and altered mechanics in adjacent tissues."
"University of Pennsylvania","Protein Sequences for Therapeutic Applications in Management of Obesity, Cachexia and Nausea","","","https://upenn.technologypublisher.com/technology/31867","Non-naturally occurring protein sequences that enhance or suppress the activity of hormone associated with obesity and nauseaProblem:Growth differentiation factor-15 (GDF15) is a broadly expressed hormone, whose level often correlates with progression of many diseases. It has been shown in multiple species that the elevated level of GDF15 drives weight loss primarily by reducing total food intake.The increased level of GDF15 is also seen after a cancer therapy that often associates with nausea and emesis. It was only in 2017 when a receptor responsible for mediating the anorectic actions of GDF15 was identified. Hence, the hormone and its receptor are promising therapeutic targets for the treatment of disorders such as obesity, anorexia, and nausea associated with chemotherapy. Nausea from chemotherapy and morning sickness is difficult to manage and can be extremely debilitating and compromise individual quality of life.Solution:The inventors created non-naturally occurring peptides that can enhance or suppress the effects of the hormone GDF15. By targeting the hormone receptor, these compounds can be useful to treat obesity by ennhancing the action of the hormone and cachexia as well as nausea associated with chemotherapy or morning sickness by suppressing its expression.Advantages:New targets that will help the discovery of drug for treating obesity, cachexia, or nauseaCan be designed to target the specific site only avoiding brain penetrationPotential to increase quality of life for people suffering from obesity, cachexia, and nauseaApplications:Use as drug to treat obesity or cachexiaUse as drugs to overcome nausea associated with chemotherapy and morning sicknessStage of Development:Preclinical DiscoveryIntellectual Property:US,European,Canadian&AustralianPatents PendingDesired Partnerships:LicenseCo-developmentCase ID:19-8758-tpNCSWeb Published:3/27/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31867","**Summary:** Non-naturally occurring protein sequences have been developed to modulate the activity of growth differentiation factor-15 (GDF15), a hormone involved in regulating weight and nausea. These peptides can enhance the hormone's effects to combat obesity or suppress its effects to alleviate nausea associated with cancer treatments and morning sickness.

**Applications:** The technology can be applied in treating disorders linked to obesity, anorexia, cachexia, and chemotherapy-induced nausea, potentially improving patient quality of life.

**Problem Solved:** The invention addresses the challenge of managing nausea during chemotherapy and the effects of GDF15 in promoting weight loss through decreased food intake, providing new therapeutic avenues for patients affected by these conditions.","Non-naturally occurring protein sequences can modulate the activity of hormones related to obesity and nausea, specifically targeting growth differentiation factor-15 (GDF15), which correlates with disease progression and is linked to reduced food intake and increased nausea following cancer therapy. Elevated GDF15 levels promote weight loss and are associated with cancer treatments."
"University of Pennsylvania","Improved PARP Inhibitors for Imaging and Treatment of Cancer and Neurodegenerative Diseases","","","https://upenn.technologypublisher.com/technology/45923","Novel high-affinity PARP inhibitors with various properties for imagining and treating cancer and inflammation-related diseasesTechnology Overview:The poly(ADP-ribose) polymersase-1 (PARP-1) enzyme is heavily involved in propagating neurodegeneration and cancer. In neurodegeneration PARP-1 causes cell death, while in cancer PARP-1 acts as DNA damage response enzyme that promotes survival of cancer cells with mutations within DNA repair genes. Therefore, PARP-1 inhibitors are used for treatment of cancers that harbor DNA repair genes mutations, such as BRCA-1 and BRCA-2. PARP-1 can also serves as a target for delivery of therapeutics radionuclides including alpha, beta, and auger emitting radionuclides. In neurodegeneration, PARP-1 can serve as a biomarker of neurodegeneration and as a therapeutic target for treating neuroinflammation.Dr. Mach and his team at Penn investigated the pharmacological impact of incorporating spirodiamine motifs into the phthalazine architecture of FDA approved PARPi olaparib. The team developed several first in class compounds that show high PARP-1 affinity and various catalytic inhibition, DNA damage properties, and cytotoxicity. These new drugs potentially can be used- as PET imaging agents for neurodegenerative diseases;- as PET diagnostic agents for determining PARP-1 expression in patient‚Äôs tumor prior to treatment with PARP-1 inhibitors;- to deliver cytotoxic radionuclides directly to cancer chromatin;- for treatment of PARP-1-mediated neurodegeneration;- for treatment of cancers harboring DNA repair genes mutations; and- for treating inflammatory related diseases.Advantages:High PARP-1 affinityVarious cytotoxicityReduced drug efflux through pump P glycoproteinPotentially increased access to brainApplications:Cancer imagining, therapy, and radiotherapyNeuroimaging and neuroinflammation treatmentStage of Development:In vitro dataOngoing in vivo experimentsIntellectual Property:US11,542,282Japanese, and Canadian PatentsPendingReference Media:Lengyel-Zhand, Z et al.;Pharmacol Ther 22 Feb 230: 107968. (pdf)Puentes, LN et al.;Mol Neurobiol 2021 Aug 58(8): 3641 (pdf)Puentes, LN et al.;Front Aging Neurosci 2021 Jun 18 13: 704041Reilly, SW et al.J Med Chem, 2018 Jun 28, 61(12): 5367Reilly, SW et al.ACS Omega, 2018 Aug 31, 3(8): 9997Reilly, SW et al.Bioorg Chem, 2019 March, 83: 242Desired Partnerships:LicenseCo-developmentCase ID:18-8465-tpNCSWeb Published:2/16/2022Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45923","**Summary:** Novel high-affinity PARP inhibitors have been developed with potential applications in imaging and treating various cancers and neurodegenerative diseases. These inhibitors target the PARP-1 enzyme, which plays a crucial role in promoting cancer cell survival and contributing to neurodegeneration. The research team at Penn created compounds that exhibit strong binding affinity to PARP-1 and display properties suitable for both diagnostic and therapeutic purposes.

**Applications:** The developed PARP inhibitors can be utilized as PET imaging agents for neurodegenerative diseases and as diagnostic agents to assess PARP-1 expression in tumors prior to treatment. Additionally, they hold promise for delivering cytotoxic radionuclides directly to cancer chromatin and for treating conditions associated with PARP-1-mediated neuroinflammation.

**Problem Solved:** These advancements address the need for more effective imaging and treatment options for cancers with DNA repair gene mutations and for neurodegenerative diseases, by targeting the role of PARP-1 in these conditions. The inhibitors aim to improve therapeutic outcomes by allowing for precise targeting of affected cells and pathways.","Novel high-affinity PARP inhibitors target the PARP-1 enzyme, which contributes to cell death in neurodegeneration and promotes survival in cancer cells with DNA repair gene mutations. These inhibitors are utilized for the imaging and treatment of cancer and inflammation-related diseases."
"University of Pennsylvania","Single viral vector for expression of both CAR/TCR and immune modulators for cancer immunotherapy","","","https://upenn.technologypublisher.com/technology/31155","A single lentiviral vector system as an expression platform for constitutive immune receptor expression and inducible antigen-dependent immunomodulatory molecule expression in primary immune cells for enhanced immunotherapy efficacyProblem:Adoptive cancer immunotherapy, like chimeric antigen receptor T cell (CAR T) therapy, has had extraordinary clinical outcomes in the treatment of certain blood cancers. However, challenges remain due to safety risks such as cytokine release syndrome (CRS) and off-tumor toxicities. Targeting solid tumors is challenging due to immunosuppressive mechanisms and a hostile tumor microenvironment. Therefore, more advanced engineered T cells are necessary to improve targeting, localization, and autonomous regulation in hopes of overcoming the immunosuppression of the microenvironment to improve the efficacy and safety of cancer immunotherapy.Solution:Dr. Powell and colleagues have developed a novel, broadly-applicable all-in-one lentiviral system with highly optimized transcriptional elements that allow multiple functionalities to be produced simultaneously and specifically in response to contact with tumor antigen. This platform combines a constitutively expressed immune receptor (CAR/TCR) with an immunomodulatory effector molecule whose expression can be autonomously triggered by immune receptor signaling or the tumor microenvironment.This technology facilitates efficient and localized expression of effector molecules, potentially augmenting the treatment efficacy and limiting toxicities of adoptive cancer immunotherapy. Further, compared to current two-vector systems for transducing multiple transgenes, delivery of a single vector encoding constitutively and inducible expressed modules improves transduction efficiency, homogeneity of cell product and eliminates screening steps providing improved engineered T-cell manufacturing work-flows, shorter manufacturing timelines, and reduced manufacturing costs.Advantages:Autonomous, inducible and localized expression of effector molecules along with constitutive immune receptor expression in a single vector system may improve efficacy and/or limit toxicities of adoptive cancer immunotherapySingle vector gene delivery achieves a homogenous population of engineered immune cells without screening steps, improving T-cell manufacturing work-flows and reducing manufacturing costs.‚ÄúPlug-and-play‚Äù single lentiviral system to generate a combination of different immune receptors and immune modulators, with varying levels of expressionThis platform enables high-throughput and quantitative screening and identification of antigen specific immune cells, such as CAR T cells, TCR modified cells or endogenous TILs.Applications:Provides a simplified platform for inducible expression of effector molecules in immune receptor-engineered T-cells for clinical applications.This single vector expression system provides an effective platform for researchers to construct and screen the combination of CAR/TCR and immune modulators of interest.Selected constructs can be used in adoptive cancer immunotherapy (e.g. CAR T) to improve the efficacy and/or minimize treatment-related complications (e.g., CRS, off-target toxicities) of engineered T-cells.This platform enables high-throughput and quantitative screening and identification of antigen specific immune cells, such as CAR T cells, TCR modified cells or endogenous TILs.Top Figure: Concept of engineered T cell with a single lentiviral vector with both constitutive immune receptor expression and autonomous antigen-induced immune modulator expression. Immune receptor (CAR or TCR) is expressed constitutively, whereupon its activation by a specific antigen the endogenous NFAT signaling is rewired to the inducible expression of immune modulator molecules from the same lentiviral construct.Bottom Figure: Proof-of-principle of single lentiviral system enabling constitutive expression of CAR and antigen-inducible expression eGFP in transduced primary T cells. (a) Primary T cells were engineered with a prototype all-in-one lentivirus and stimulated with CSC (ionomycin and phorbol myristate acetate) or anti-CD3/CD28 beads. Expression of reporter genes was monitored by fluorescence microscopy and flow cytometry (b) Signaling induced by Her2-targeting CAR activates the system only in co-culture with Her2 positive cancer cell line.Stage of Development:Completed in vitro testing with successful transduction and activation of lentiviral vector systems in primary human T cells of various combinations of immune receptors and immune modulatorsIntellectual Property:Patent PendingDesired Partnerships:LicenseCo-developmentCase ID:17-8348-tpNCSWeb Published:1/23/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31155","**Summary:** A novel lentiviral vector system has been developed for cancer immunotherapy, enabling the simultaneous expression of chimeric antigen receptors (CAR) or T cell receptors (TCR) and immunomodulatory molecules in primary immune cells. This system allows for constitutive expression of immune receptors while also enabling the inducible expression of effector molecules in response to tumor antigens, aiming to enhance the therapeutic efficacy and safety of engineered T cells.

**Applications:** This technology can be applied in the development of advanced T cell therapies for both hematological malignancies and solid tumors. Its ability to modulate immune responses in real-time has potential implications for improving the outcomes of adoptive cell therapies and addressing challenges associated with the tumor microenvironment.

**Problem Solved:** The technology addresses significant challenges in cancer immunotherapy, including the safety risks of cytokine release syndrome and off-tumor toxicities, as well as the difficulties in targeting solid tumors due to immunosuppressive mechanisms. By allowing for more precise and regulated expression of effector molecules within the tumor microenvironment, this approach aims to enhance the efficacy and safety profile of T cell therapies.","A single lentiviral vector system enables both consistent expression of immune receptors and regulated expression of immunomodulatory molecules in primary immune cells. This platform aims to enhance the efficacy of adoptive cancer immunotherapy while addressing safety challenges like cytokine release syndrome."
"University of Pennsylvania","Algorithm for semantic labeling of objects during localization and mapping in robotic vision","","","https://upenn.technologypublisher.com/technology/31574","Probabilistic data association technique for labeling, mapping, and sensing objects during robotic traversal.Technology Overview:Simultaneous Localization and Mapping (SLAM) is a well-studied problem in robotics wherein a robot or autonomous vehicle uses its sensors to localize itself in relation to the environment, then updates a map of what it has seen as it traveled. These maps are typically point clouds that provide obstacle positions without the providing any context.Penn professors Konstantinos Daniilidis and George Pappas have created a new algorithm that is more robust at recognizing new objects (such as a door or chair in an office setting) and classifying them correctly regardless of object orientation or sensor pose. This results in the first method to tightly couple inertial, geometric, and semantic observations into a single optimization framework. The method has been tested successfully in indoor and outdoor scenarios, demonstrating applicability for autonomous vehicle or home and warehouse robot applications.Advantages:Low computational costNo expensive hardware requiredReal-time SLAM and object recognitionStage of Development:Prototype and software developed for integration with robotic platformsIntellectual Property:US11,187,536Reference Media:Best Paper Winner--2017 IEEE International Conference on Robotics and AutomationBowman, SL et al.;2017 IEEE International Conference on Robotics and Automation (ICRA), 2017: 1722Desired Partnerships:LicenseCo-developmentCase ID:17-8324-tpNCSWeb Published:3/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31574","**Summary:** The technology presents a probabilistic data association technique for the labeling, mapping, and sensing of objects as robots traverse environments. It enhances simultaneous localization and mapping (SLAM) by enabling better recognition and classification of objects, such as doors and chairs, regardless of their orientation or the robot's sensor pose. The method integrates inertial, geometric, and semantic observations into a unified optimization framework, effectively producing more informative maps that include contextual understanding of obstacles. The algorithm has been successfully tested in both indoor and outdoor environments.

**Applications:** The algorithm is suitable for use in autonomous vehicles and robots designed for home and warehouse operations, facilitating improved object recognition and environmental interaction.

**Problem Solved:** The technology addresses the limitations of traditional SLAM methods that typically produce point clouds devoid of contextual information, enabling robots to better recognize and classify objects in real-time while maintaining low computational costs and not requiring expensive hardware.","The technology utilizes a probabilistic data association technique for labeling, mapping, and sensing objects as a robot traverses its environment. This approach enhances the typical point clouds generated during simultaneous localization and mapping by providing contextual information about obstacles."
"University of Pennsylvania","Fracture-resistant and ultrathin nanocardboard for structrual applications","","","https://upenn.technologypublisher.com/technology/29689","Hollow, sandwich-like nanostructure that is joined by periodic, rigid webbing to increase bending stiffness and prevent fracture.Technology Overview:Mechanical metamaterials are increasingly used for structural applications. In particular, sandwich structures consisting of two planar face sheets connected by a webbing or foam core, can provide an optimal design for applications that require low weight and high-stiffness. Despite their utility, currently available sandwich plates are prone to fracture or permanent deformation when mechanically loaded and have not been scaled to the nanometer scale.To overcome this issue, a new ‚Äúnanocardboard‚Äù sandwich-like structure, has been invented. The nanocardboard is composed of two nanometer thick plates that are separated by a microscale gap and joined by rigid, periodic webbing. The meta-material is fabricated in a single step of atomic layer deposition of alumina on a silicon mold that contains the webbing.The optimal webbing can be a honeycomb lattice, basket-weave pattern or cylinders packed in hexagonal packing. The final, optimized basketweave webbing structure is ultrathin, ultralight, has a high bending stiffness, and resists fracture and deformation when mechanically loaded. Furthermore, the material exhibits excellent thermal-insulating properties, making it well suited for high heat applications and electrical insulation.Advantages:Improved resilience to fracture and deformation during loading or shearing of the materialSingle-step fabricationUltrathin and ultralight (~1 g m-2)Excellent thermal and electrical insulatorApplications:Nano- and micro-electromechanical systemsNanoscale thermal insulationBiological membranesNanorobotics and microflyer wingsScanning probe cantileversInterstellar lightsailsThe nanocardboard structures are comprised of (A) two nanometer thick plates separated by a hollow microscale gap and joined by (B) periodic webbing that, in combination, allow the material to withstand fracture and deformation during mechanical loading and shearing. (C) A 13mm-diameter nanocardboard plate at macroscale.Stage of Development:Developed and tested in a laboratory environmentDemonstrated scale at 1 centimeter-square sizeIntellectual Property:US11,027,514Reference Media:Lin, C et al.;Nat Commun 2018 9, Article number: 4442.Desired Partnerships:LicenseCo-developmentCase ID:18-8375-tpNCSWeb Published:11/6/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29689","**Summary:** A novel ultrathin and fracture-resistant nanocardboard has been developed utilizing a hollow, sandwich-like nanostructure with periodic, rigid webbing. This material is fabricated through atomic layer deposition of alumina on a silicon mold and consists of two nanometer-thick plates separated by a microscale gap. The engineered webbing can take various forms, such as honeycomb lattice or basket-weave patterns, contributing to its increased bending stiffness and resistance to mechanical loading. This technology offers significant benefits in terms of resilience, lightweight design, and thermal insulation.

**Applications:** The nanocardboard is suitable for structural applications that demand low weight and high stiffness, including aerospace components, automotive parts, and building materials. Its excellent thermal-insulating properties also make it advantageous for high-heat applications and electrical insulation.

**Problem Solved:** The technology addresses the issues of fracture and permanent deformation commonly found in traditional sandwich structures used in structural applications when subjected to mechanical loads. By enhancing the material's resilience and stiffness while ensuring it remains ultrathin and lightweight, this innovation offers a solution to the limitations of existing materials in the nanometer scale.","This technology involves a hollow, sandwich-like nanostructure with periodic, rigid webbing that enhances bending stiffness and reduces the risk of fracture. Mechanical metamaterials, particularly sandwich structures, are utilized for structural applications where low weight and high stiffness are essential."
"University of Pennsylvania","MRI Measurement of Abdominal Wall Muscle Compliance for Surgical Planning and Outcome Prediction","","","https://upenn.technologypublisher.com/technology/38501","A device and imaging method for non-invasive measurement of abdominal muscle elasticity and pre-operative prediction of successful hernia repairProblem:Two million abdominal surgeries are performed annually in the United States. Ventral hernia is one of the most common and serious post-operative complications with an incidence of approximately 13% amongst patients undergoing abdominal operations.Despite advances in medical imaging, pre and post-operative assessment of the abdomen and hernia repair currently relies on basic clinical evaluation of patients. However, clinical assessment poorly predicts the outcome of hernia repair surgeries. Failed repairs generate un-closable midline defects; these defects require additional surgery to reconstruct the abdominal wall using a synthetic mesh. The procedure is expensive and carries a risk of chronic infection and additional complications.Solution:To better identify patients at risk for developing a hernia pre or post abdominal surgery, we have created a predictive method centered on abdominal muscle mechanical properties. This method uses magnetic resonance (MR) tissue-tagging in combination with an MR-compatible device that deforms the abdominal wall muscle synchronous with the imaging cycle.MR tissue-tagging is an imaging method that uses RF pulses to create a visible grid on organs undergoing cyclic motion to visualize the tissue deformation, which can then be used to compute the elastic properties of the abdominal muscle. This method has the potential to be used before the hernia repair surgery to determine the optimum hernia repair procedure and after surgery to predict repair outcome in patients.Advantages:Non-invasive assessment of muscle abdominal muscle complianceUsable with any conventional MRI scannerMore accurate prediction of failed hernia repair than conventional clinical methodsEarly prediction of failed hernia repair surgery can prevent later complex surgeryApplications:Measuring abdominal muscle deformation and elasticityPredicting ventral hernia development in patientsStage of Development:Prototype developedIn-vivo experiments on healthy subjects have been performedInventors propose to conduct additional in-vivo testing in hernia repair patients for validationIntellectual Property:US PatentPendingReference Media:Dougherty L. et al., Measuring Abdominal Wall Muscle Deformation Using MR Tissue Tagging Proceedings ofISMRM-ESMRMB, Paris, France, June 16-21, 2018Desired Partnerships:LicenseCo-developmentCase ID:18-8518-tpNCSWeb Published:2/7/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38501","**Summary:** A non-invasive device and imaging method has been developed to measure the elasticity of abdominal muscles and predict the outcomes of hernia repair surgeries. This technology aims to enhance the pre-operative assessment of patients by evaluating the mechanical properties of abdominal muscles, which can help identify individuals at risk for complications related to hernia repairs.

**Applications:** The technology can be used in surgical planning for abdominal procedures, particularly for predicting the success of ventral hernia repairs. It provides valuable insights into muscle compliance that can guide clinical decision-making in the context of surgical interventions.

**Problem Solved:** This approach addresses the limitations of clinical evaluations that poorly predict the outcomes of hernia repairs, which affect approximately 13% of patients undergoing abdominal surgery. By providing a more accurate assessment of muscle elasticity, the technology aims to minimize the incidence of failed repairs and reduce the need for costly and risky corrective surgeries.","A non-invasive imaging method has been developed to measure abdominal muscle elasticity and predict the success of hernia repairs before surgery. Ventral hernias are a significant complication, occurring in about 13% of patients undergoing abdominal surgeries."
"University of Pennsylvania","Method to Produce CT-Like 3D Images of Bones and Hard Tissue From MRI Sequences","","","https://upenn.technologypublisher.com/technology/38499","Problem:Computed tomography (CT) is an imaging technique that enables 3D visualization of skeletal tissue. However, CT imaging exposes patients to hazardous radiation, which can be problematic for patients who require repeated scans or those in the pediatric population wherein the risks associated with radiation are greater.Magnetic resonance imaging (MRI) is another imaging method that is widely used by clinicians. It exploits the magnetic properties of objects placed in a strong magnetic field to produce images by emitting radio frequency (RF) pulses to an object and detecting an RF ‚Äúecho‚Äù from the object. Unlike CT, MRI does not expose patients to hazardous radiation, however, standard MRI sequences only visualize soft tissue. Current imaging sequences do not capture signal from bones because it is significantly shorter than the delay between the RF pulse and the detected echo. Recent ultra-short echo time methods have addressed this problem; however, they suffer from minimal contrast between soft and hard tissues. MRI scans are also inherently slower than CT scans as MRI data acquisition involves repeated measurement of the echoes obtained with minor changes in the total magnetic field in every repetition, which generates redundant data.Solution:This method combines long echo and short echo 3D imaging methods to distinguish signals from hard and soft tissues. Furthermore, it achieves this with considerably shorter scan times by incorporating ‚Äúcompressed sensing‚Äù, a mathematical technique that uses prior knowledge from data acquisition to eliminate redundant data.Advantages:An alternative to CT imaging without the harmful effects of radiationSimultaneous imaging of soft-tissue (brain, cartilage, etc.) and bone structureNear 10-fold shorter scan times than similar MRI protocolsImplementable on any MRI scannerApplications:Bone and hard tissue imagingPediatric imagingStage of Development:Methodology has been developedInventors propose to conduct additional clinical studies in humansIntellectual Property:US PatentPendingReference Media:Proceedings ofISMRM-ESMRMB, Paris, France, June 16-21, 2018Desired Partnerships:LicenseCo-developmentCase ID:18-8473-tpNCSWeb Published:2/7/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38499","**Summary:** This technology addresses the limitations of standard MRI in visualizing bone and hard tissue by combining long and short echo imaging methods, which allows for better differentiation between hard and soft tissues. The approach incorporates compressed sensing techniques to significantly reduce the scan times compared to traditional MRI, making it more efficient while maintaining image quality.

**Applications:** The method can be used in clinical settings for patients requiring detailed imaging of skeletal tissues, particularly in scenarios where repeated imaging is necessary, such as monitoring bone health, assessing injuries, or planning surgeries. This is especially beneficial for pediatric patients and others who are vulnerable to radiation exposure.

**Problem Solved:** The technique mitigates the risk associated with CT scans by providing a safe alternative that does not involve radiation exposure. It enhances the visualization of hard tissues through MRI, addressing the challenges of previous methods that either posed risks due to radiation or lacked adequate differentiation between tissue types, thus improving patient care and diagnosis.","Computed tomography (CT) provides 3D visualization of skeletal tissue but involves hazardous radiation exposure, particularly concerning for repeat scans and pediatric patients. In contrast, magnetic resonance imaging (MRI) uses magnetic fields and is widely utilized by clinicians without the associated radiation risks."
"University of Pennsylvania","Reactive and continuous space-time control of multi-drone-fleets","","","https://upenn.technologypublisher.com/technology/29051","System for continuously controlling quadrotor drone behavior using Signal Temporal Logic (STL) as the mission specification languageProblem:Autonomous drones are increasingly being used for advanced applications such as package delivery, surveillance, and infrastructure monitoring. However, the requirement of complex instructions for spatial, temporal, and reactive navigation makes controlling drone systems challenging. Most existing encoding systems are simplified and limited, and do not consider timing constraints, scalability, or real-world behaviors.Solution:Dr. Mangharam and colleagues at the University of Pennsylvania have designed a new algorithm to control quadrotor drone behavior continuously using Signal Temporal Logic (STL). The method enables the consideration of explicit timing requirements and use of the full expressiveness of STL to optimize a smooth trajectory for drone movement. The system offers continuous-time STL satisfaction, feasible movement trajectories, and real-time drone control with scalability, providing a control framework for mission planning and execution for fleets of quadrotors.Advantages:Avoids oversimplifying abstractions while using off-the-shelf sensors and limited computationHandles complex spatial, temporal and reactive requirements for drone missionsScales well for problems involving up to 16 dronesMaximizes robustness in generating trajectories for quadrotors in continuous-timeMultiple autonomous drone missions in an urban environment. (Figure adapted)Stage of Development:Proof of concept on 16 drones in simulation and with 8 actual quadrotor drones.Intellectual Property:PatentPendingReference Media:Pant, YV et al;2018 ACM/IEEE 9th International Conference on Cyber-Physical Systems (ICCPS), 2018: 186Desired Partnerships:LicenseCo-developmentCase ID:18-8622-tpNCSWeb Published:10/22/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29051","**Summary:** A system has been developed for the continuous control of quadrotor drones, utilizing Signal Temporal Logic (STL) to specify mission requirements. This innovative approach addresses the challenges associated with controlling autonomous drones by integrating complex spatial, temporal, and reactive navigation rules, which are often oversimplified in existing methods. The introduced algorithm allows for real-time control and facilitates the creation of smooth and feasible trajectories while maintaining robustness and scalability, capable of managing fleets of up to 16 drones.

**Applications:** This technology is applicable to various advanced drone operations, including package delivery, surveillance, and infrastructure monitoring in urban environments, requiring precise temporal and spatial navigation.

**Problem Solved:** The solution overcomes the limitations of traditional drone control systems that fail to account for complex timing constraints and real-world behaviors, thus enabling more efficient and reliable multi-drone missions.","The system utilizes Signal Temporal Logic (STL) to continuously control the behavior of quadrotor drones for various autonomous applications. It addresses the challenges of spatial, temporal, and reactive navigation in multi-drone fleets, which are often inadequately managed by existing encoding systems."
"University of Pennsylvania","Use of MAPK Pathway Inhibitors for the Treatment of Friedreich Ataxia","","","https://upenn.technologypublisher.com/technology/38390","A novel treatment for rare disease Friedreich ataxia using p38 or MK2 kinase inhibitorsProblem:Currently there are no approved drugs to treat FA and the resultant disability, prolong the life of a FA patient, or cure the disorder.Solution:Work in the Wilson Lab led to a surprising discovery that p38 MAP kinase inhibitors (many of which are in clinical trials for various indications) rescue disease phenotypes of cells affected by FA. This suggests that the p38 kinase (or MK2) can be possible targets for therapeutic intervention in Friedreich ataxia.rules, are highly specific to FA, and are active in the low nanomolar range. Several optimized modifications of the lead compounds have been generated.Technology Overview:Friedreich ataxia (FA) is an autosomal recessive, inherited neuro- and cardio-degenerative disorder characterized by progressive ataxia of all four limbs, skeletal deformities, and hypertrophic cardiomyopathy. FA is the most prevalent inherited ataxia, affecting about 1 in 50,000 people in the United States. The estimated carrier prevalence is 1:110.Onset of symptoms can vary from childhood to adulthood with most patients being confined to a wheelchair by their late 20s. Myocardial failure and/or arrhythmias are the most common cause of premature death. It is commonly believed that FA is caused by mitochondrial dysfunction caused by the decreased expression of the protein Frataxin.Advantages:A number of p38 kinase inhibitors are being tested in clinical trials for various indicationsRegulatory fast-track: FA is a FDA designated orphan disease with no approved treatmentAccess to the expertise and resources of Wilson‚Äôs lab (see Inventor‚Äôs Bio)Intellectual Property:USPendingReference Media:Cotticelli, MG et al.;Sci Rep 2018 March 22, 8(1): 5007Desired Partnerships:LicenseSponsored researchCollaborationCase ID:15-7449-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38390","**Summary:** Friedreich ataxia (FA) is a rare inherited neuro- and cardio-degenerative disorder characterized by progressive motor impairment, skeletal deformities, and often hypertrophic cardiomyopathy, with onset typically occurring between childhood and adulthood. A groundbreaking discovery from the Wilson Lab revealed that p38 MAP kinase inhibitors can effectively rescue disease phenotypes in cells affected by FA, suggesting that these inhibitors could serve as valid therapeutic targets for treating the condition. Several optimized variants of the lead compounds have been developed, demonstrating high specificity to FA and effective activity at low nanomolar concentrations.

**Applications:** The developing p38 or MK2 kinase inhibitors aim to provide a targeted treatment for patients with Friedreich ataxia, potentially altering the course of the disease by alleviating its symptoms and improving quality of life.

**Problem Solved:** Currently, there are no approved medications to treat Friedreich ataxia, prolong patient life, or offer a cure for the disorder. The identified inhibitors present a novel approach to address the unmet medical need for therapeutic options in this debilitating condition.","A novel treatment using p38 MAP kinase inhibitors has shown promise in rescuing disease phenotypes in cells affected by Friedreich ataxia, as discovered in the Wilson Lab. Currently, there are no approved drugs for the treatment of this rare disease."
"University of Pennsylvania","Gene therapy for treatment of Duchenne Muscular Dystrophy (DMD)","","","https://upenn.technologypublisher.com/technology/38536","Duchenne Muscular Dystrophy (DMD) therapy deletes let-7c miRNA binding sites using CRISPR-Cas9 based genome editing and AAV based delivery.Problem:Duchenne Muscular Dystrophy (DMD) is a fatal disease characterized by progressive muscle degeneration and weakness that affects 1 in 3,500 live-born males worldwide, and which ultimately causes death in the twenties due to respiratory or cardiac failure. It is caused by mutations in the DMD gene leading to an absence or severe reduction of dystrophin, a protein that helps keep muscle cells intact. There is currently no cure for DMD and all dystrophin-based approaches are associated with immunoreactivity limiting their long-term efficacy.Solution:Dr. Khurana and colleagues at University of Pennsylvania developed a method to upregulate utrophin, a dystrophin homolog protein, using CRISPR-Cas9 based genome editing and AAV-based delivery. The inventors have previously demonstrated in a mouse model that inhibiting the interaction between the let-7c miRNA and utrophin gene, which normally acts to represses expression, is able to increase utrophin expression and functionally rescue dystrophic phenotype. This discovery led to the present method that genomically edits the microRNA binding sites in the utrophin gene to ultimately upregulate utrophin expression.Unlike dystrophin-targeting gene therapy, this method is particularly attractive for therapeutic strategies, as extremely high levels of utrophin are not associated with toxicity or immunoreactivity.Advantages:No immunoreactivity associated with high levels of utrophin in vivoRescues dystrophic phenotypeApplication:Therapeutic for Duchenne Muscular DystrophyGene editing method to delete interaction between miRNA and utrophin gene leading to increased expression of utrophin.Stage of Development:In vitro dataAnimal studies plannedIntellectual Property:US PatentPendingReference Media:Mishra et al.PLoS One 2017 12(10): e0182676Desired Partnerships:LicenseCo-developmentCase ID:18-8707-tpNCSWeb Published:2/13/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38536","**Summary:** Gene therapy for Duchenne Muscular Dystrophy (DMD) employs CRISPR-Cas9 based genome editing to delete let-7c miRNA binding sites, coupled with AAV-based delivery to enhance utrophin expression. This innovative approach aims to counteract the absence of dystrophin, a crucial protein for muscle stability, by boosting levels of utrophin, which can functionally compensate for the lack of dystrophin. Early research in mouse models demonstrated that disrupting the let-7c miRNA's repressive influence on the utrophin gene leads to improved expression and alleviates dystrophic symptoms. 

**Applications:** This technology is targeted specifically at treating Duchenne Muscular Dystrophy, a severe genetic disorder affecting primarily young males. By enhancing utrophin levels, it has the potential to slow the progression of muscle degeneration and improve quality of life for affected individuals.

**Problem Solved:** The therapy addresses the critical problem of DMD, which results from mutations that prevent the production of dystrophin, leading to muscle weakness and eventual death from respiratory or cardiac failure. By focusing on upregulating utrophin instead of dystrophin, this method seeks to provide a viable treatment option that may circumvent the immune responses associated with traditional dystrophin-based therapies.","Duchenne Muscular Dystrophy (DMD) is a fatal disease characterized by progressive muscle degeneration that affects 1 in 3,500 live-born males and typically leads to death in the twenties due to respiratory or cardiac failure. A proposed therapy utilizes CRISPR-Cas9 genome editing to delete let-7c miRNA binding sites, with AAV-based delivery to address the underlying genetic mutations in the DMD gene."
"University of Pennsylvania","Accurate, High-Throughput Quantification of HIV Reservoirs Using Optical Scanning","","","https://upenn.technologypublisher.com/technology/38314","HIV viral protein expression and functional virus reservoir size are rapidly and accurately quantified using optical scanningProblem:HIV can incorporate itself into the DNA of a host cell without producing circulating virus. When lying dormant in these reservoirs, HIV cannot be detected and eradicated by the immune system of the host.As most of the HIV DNA in these reservoirs is hypermutated and incapable of producing infectious virions, a major hurdle in efforts to cure HIV, and to manage care of patients on antiretroviral therapy, is accurately quantifying the size of infection-competent viral reservoirs without interference from defective HIV DNA.Current methods to quantify viral load are labor-intensive and prone to systematic errors.Solution:This invention identifies replication-competent HIV reservoirs by screening for the presence of one protein (Gag) and downregulation of another (CD4) on the surface of cells. These features of cells infected with replication-competent HIV are encoded at disparate ends of the viral DNA; consequently, one of these features without the other is unlikely to occur in a cell that contains a replication competent provirus (the form of HIV integrated into the human chromosome).Fiber-optic assay scanning technology couples high-throughput optical scanning methods with an assay that recognizes target proteins via binding of dye-bearing antibodies to selectively identify cells infected with functional HIV. This method has the potential to quantify HIV reservoirs with faster results, improved accuracy, less labor, less technical expertise, and smaller required sample sizes.Advantages:Improved accuracy of HIV reservoir quantificationDistinguishes between replication competent and defective provirusesRapid, high-throughput quantificationFaster turn-around timeSmaller samples toleratedApplications:Monitoring HIV patients who are receiving antiretroviral therapy to determine baseline and induced reservoir expressionClinical research to determine the effects of new drugs such as latency reversal agents on HIVFiber-optic assay scanning technology (FAST) images show HIV Gag (red) and internalized CD4 (green) on the surface of cells. These images can be merged (right) to identify and quantify cells infected with replication-competent HIV that is expressed. A nuclear stain (blue) is used to show cells.Stage of Development:Proof of conceptIntellectual Property:US10620112Reference Media:DeMaster, LK et al.;J Virol 2016 March 1 90(5): 2165Graf, EH et al.;PLoS One 2013 Aug 7 8(8): e71879Desired Partnerships:LicenseCo-developmentCase ID:15-7391-tpNCSWeb Published:1/28/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38314","**Summary:** This technology provides a rapid and accurate means of quantifying HIV reservoirs by identifying the presence of the Gag protein and the downregulation of CD4 on the surface of cells. The method leverages optical scanning technology coupled with a fiber-optic assay to detect specific protein markers, allowing for the identification of cells infected with replication-competent HIV, which is crucial in understanding the size and nature of these viral reservoirs.

**Applications:** The primary applications include advancing HIV research, improving patient care for those on antiretroviral therapy, and developing strategies for achieving a functional cure by accurately quantifying infection-competent viral reservoirs.

**Problem Solved:** The technology addresses the challenge of quantifying HIV reservoirs that are largely non-infectious due to hypermutation, which complicates existing methods that are labor-intensive and prone to systematic errors. By focusing on specific protein expressions indicative of replication-competent HIV, it offers a more reliable evaluation of viral reservoirs that are often undetectable by conventional techniques.","HIV viral protein expression and functional virus reservoir size can be rapidly and accurately quantified using optical scanning techniques. These reservoirs contain hypermutated HIV DNA that cannot produce infectious virions, posing a significant challenge in the efforts to cure and manage HIV."
"University of Pennsylvania","Method for Rapid 3D Printing From Medical Images","","","https://upenn.technologypublisher.com/technology/45124","Method and software product allowing for direct conversion of any three dimensional image (e.g., CT, MRI, ultrasound, PET, etc.) into 3D printable instructions (i.e., G-Code).Problem:Medical Digital Imaging and Communications in Medicine (DICOM) image files generated by CT or MRI scanners can be utilized to generate the instruction for 3D printers. However, the conventional method has several limitations such as significant user interaction, image manipulation, high processing time, and computer memory restrictions. The current method requires an intermediate step of converting DICOM files into StereoLithography (STL) format file before conversion into the G-code instructions readable by 3D printers. This leads to a loss of structural information.Solution:Dr. Rajapakse at the University of Pennsylvania has developed computer code that converts DICOM to G-Code without going through STL conversation. This approach substantially reduces the time to obtain a 3D print, provides greater customizability - from changing print speeds to allowing for different extrusion amounts for either increased porosity or better adhesion to varying print paths.The code accounts for parameters such as printer‚Äôs resolution and speed of the extruder and allows for choosing the method of printing, from linear, to any inputted angle rotation between each layer. This method can be used also for bioprinting for various applications, such as bone, cartilage, muscle tissue fabrication, etc. and can be utilized for convenient and rapid 3D printing of patient-specific structures.Advantages:Patient-personalized 3D printsHigh speed and resolutionImproved printing controlHigh customizabilityApplications:Novelty items - 3D printing of embryos, brain, etcMedical and bio- 3D printing: reconstructive surgery, bone, cartilage, teeth, various tissues fabrication and incorporation etc.Medical training purposesMedical phantomsStage of Development:Tested on various CT and MRI data ‚Äì Bone, cartilage, muscle, nose, lung, heart, liver, tongue, etc.Intellectual Property:US11,872,764Reference Media:Hong, AL et al.,Proceedings of the SPIE Medical Imaging. 2017, p.10138.Lee, DZ et al.Proceedings of the SPIE Medical Imaging, Houston, TX, 2018.Gadaleta, D et al.Proceedings of the SPIE Medical Imaging, Houston, TX, 2018.Desired Partnerships:LicenseCo-developmentCase ID:18-8407-tpNCSWeb Published:10/14/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45124","**Summary:** The technology involves a method and software product that enables the direct conversion of three-dimensional medical images, such as those generated by CT, MRI, ultrasound, and PET scans, into 3D printable instructions (G-Code) without the intermediate step of converting to STL format. This approach simplifies the process, minimizes user interaction, reduces processing time, and addresses memory restrictions associated with conventional methods while preserving structural information.

**Applications:** The new method can be applied in various fields including medical imaging, prosthetics, and bioprinting, with potential usage in fabricating bone, cartilage, and muscle tissues, thereby enhancing the versatility and effectiveness of 3D printing in medical applications.

**Problem Solved:** This technology resolves limitations of traditional methods that necessitate significant user interaction and lengthy processing times, while preventing the loss of structural information inherent in the conversion to STL format, ultimately streamlining the pathway from medical imaging to 3D printing.","A method and software product enable the direct conversion of three-dimensional medical images, such as those from CT, MRI, ultrasound, and PET scans, into 3D printable instructions (G-Code). This approach addresses limitations of conventional methods, which require substantial user interaction, image manipulation, and lengthy processing times."
"University of Pennsylvania","Antibodies for targeting CAR-T cells to acute Myeloid Leukemia cells","","","https://upenn.technologypublisher.com/technology/42243","Technology Overview:Acute myeloid leukemia (AML) is a major form of acute leukemia in elder adults. The treatment of AML has changed little in the past decades and the overall 5-year survival rate remains very poor in the AML patients. AML relapsed from chemotherapy is highly aggressive with poor prognosis. While adaptive cell therapy via chimeric antigen receptor (CAR)-expressing T cells is quite successful for treating acute and chronic lymphoblastic leukemia by targeting CD19, this approach has not yet been extensively explored for AML.UsingSequential Tumor-selated Antibody and antigen Retrieving (STAR) technologyDr. Hua, MD, PhD at the University of Pennsylvania Medical School and his team have identified unique nanobodies that were able to effectively target CAR-T cell to eliminate AML cells in animal models.Advantages:Nanobodies show high affinity and low immunogenicity in humansNanobodies have small size (12-15 kDa)Capable of recognizing uncommon or hidden epitopesAble to bind into cavities or active sites of protein targetsApplications:CAR-T cell therapies for AMLAntibody-drug conjugates targeting AML cellsPotential use for AML diagnosis, treatment monitoring, and imagingStage of Development:Validated in animal modelValidated for switchable CAR-T system in animal modelIntellectual Property:USPatent PendingDesired Partnerships:LicenseCo-developmentCase ID:18-8498-tpNCS-01Web Published:11/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42243","**Summary:** A novel approach has been developed to enhance CAR-T cell therapy for treating acute myeloid leukemia (AML) using uniquely identified nanobodies that facilitate the targeting of CAR-T cells to AML cells. Traditional treatments for AML have shown limited progress, leaving patients with a poor prognosis, particularly after chemotherapy relapse. This new method utilizes STAR technology to effectively target and eliminate AML cells in animal models, and the nanobodies involved exhibit high affinity and low immunogenicity, making them suitable for human applications.

**Applications:** The technology is applicable for CAR-T cell therapies specifically tailored for AML, potential development of antibody-drug conjugates aimed at targeting AML cells, and may also be utilized in AML diagnosis, treatment monitoring, and imaging.

**Problem Solved:** The approach addresses the significant challenge of effectively treating acute myeloid leukemia, particularly in patients who have relapsed after chemotherapy, by providing a targeted method that could enhance the efficacy of existing cellular therapies, potentially improving survival outcomes for these patients.","Acute myeloid leukemia (AML) is a significant type of acute leukemia in older adults, with a persistently low overall 5-year survival rate and a poor prognosis for patients who relapse after chemotherapy. The use of chimeric antigen receptor (CAR)-expressing T cells has been successful in treating other leukemias but has limitations for AML."
"University of Pennsylvania","Antibody discovery platform for CAR-T cell targeting and drug conjugation","","","https://upenn.technologypublisher.com/technology/42223","Technology Overview:Screening platform for identification of potent and specific nanobodies for (i) directing CAR-T cells to cancer cells, (ii) drug conjugation, or (iii) tumor imaging or diagnosis.Identification of antibodies capable of mediating CAR-T killing is challenging due to several reasons. First, the antibody has to have certain affinity to allow for sufficient binding time permitting the T cell to kill the target cells. Second, the scFv derived from the antibody must be conserve the affinity and specificity, followed by fusion with the rest of the CAR construct. Third, the antibody must bind to the appropriate location of the cell surface protein on the cancer cell to allow a certain distance between the T cell surface and the tumor cell surface to form effect immune synapse. There is a need for technologies allowing for efficient identification of potent, specific antibodies for CAR-T cell therapies.Dr. Xiaxin Hua and his team have developed Sequential Tumor-related Antibody and antigen Retrieving (STAR) technology that allows to efficiently identify nanobodies fully capable of binding to tumor cell surface antigens and guide the CAR-T cells in vivo to the specific tumors. Nanobodies are tested for cross-reactivity with other tissues in vivo. The technology was successfully validated for generating nanobodies for targeting AML andneuroendrocrine tumors, tested in switchable CAR system.Advantages:Can be used for various tumor types/linesNanobodies have small size, high affinity, low immunogenicity in humansNanobodies are capable of recognizing uncommon or hidden epitopesNanobodies able to bind into cavities or active sites of protein targetsApplications:Identification of tumor-specific nanobodies that can be used for:CAR-T cell targetingConjugation with anticancer drugsTumor diagnosis, treatment monitoring, and imagingStage of Development:Unique nanobodies successfully targeting AML and neuroendocrine tumorsIntellectual Property:USPatent PendingDesired Partnerships:LicenseCo-developmentCase ID:18-8498-tpNCS-03Web Published:11/2/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/42223","**Summary:** Dr. Xiaxin Hua and his team have developed a screening platform that facilitates the identification of potent and specific nanobodies suitable for directing CAR-T cells to cancer cells, drug conjugation, and tumor imaging or diagnosis. This platform, known as Sequential Tumor-related Antibody and antigen Retrieving (STAR) technology, addresses the challenges associated with finding antibodies that can effectively mediate CAR-T cell killing, including the need for adequate binding affinity, preservation of specificity in scFv constructs, and appropriate binding locations on tumor cell surface proteins. The platform has been validated for generating nanobodies targeting acute myeloid leukemia (AML) and neuroendocrine tumors using a switchable CAR system.

**Applications:** The technology can be utilized for various tumor types and lines, enhancing the specificity and efficacy of CAR-T cell therapies, facilitating drug conjugation for targeted therapy, and improving tumor imaging and diagnosis.

**Problem Solved:** The technology addresses the existing challenges in identifying effective antibodies for CAR-T cell therapies, specifically the need for potent binding to tumor antigens while avoiding cross-reactivity with normal tissues, thus improving the therapeutic outcome and safety of cancer treatments.","The technology is a screening platform designed to identify potent and specific nanobodies that can direct CAR-T cells to cancer cells, facilitate drug conjugation, or assist in tumor imaging and diagnosis. It addresses the challenges in finding antibodies that can effectively mediate CAR-T cell killing by ensuring appropriate affinity for binding and preservation of specific binding characteristics."
"University of Pennsylvania","Antibodies for targeting CAR-T cells to neuroendocrine tumors","","","https://upenn.technologypublisher.com/technology/39332","Technology Overview:Neuroendocrine tumors (NETs) pose serious threats to patients‚Äô well-being as malignant diseases, and most patients with metastatic NETs succumb to the disease. Using Sequential Tumor-related Antibody and antigen Retrieving (STAR) technology Dr. Xianxin Hua, MD, PhD at the University of Pennsylvania Medical School and his team have identified unique nanobodies which are being tested for their ability to eliminate neuroendocrine tumors in an animal model.Advantages:Nanobodies show high affinity and low immunogenicity in humansSmall size (12-15 kDa)Capable of recognizing uncommon or hidden epitopesAble to bind into cavities or active sites of protein targetsApplications:CAR-T cell targeting to NET cellsConjugation with anticancer drugs to target NET cellsTumor diagnosis, treatment monitoring, and imagingStage of Development:Being validated in animal model to successfully target CAR-T cells to the tumor cells, and for switchable CAR-TIntellectual Property:USPatent PendingDesired Partnerships:LicenseCo-developmentCase ID:18-8498-tpNCS-02Web Published:3/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39332","**Summary:** The technology utilizes Sequential Tumor-related Antibody and Antigen Retrieving (STAR) to identify unique nanobodies that target neuroendocrine tumors (NETs), which are serious cancers often leading to patient mortality in cases of metastasis. The developed nanobodies exhibit high affinity with low immunogenicity and the ability to recognize uncommon epitopes, making them suitable for binding to specific tumor targets. The current stage of development involves validation in animal models to enhance the targeting of CAR-T cells toward NET cells.

**Applications:** The primary applications include enhancing CAR-T cell targeting to NET cells, conjugation with anticancer drugs for focused treatment, and use in tumor diagnosis, treatment monitoring, and imaging.

**Problem Solved:** This technology addresses the challenge of effectively targeting and treating neuroendocrine tumors, which are typically resistant to conventional therapies and pose significant health threats to patients.","Dr. Xianxin Hua and his team at the University of Pennsylvania Medical School are utilizing STAR technology to identify unique nanobodies aimed at targeting neuroendocrine tumors, which are significantly harmful to patients. These nanobodies are currently being tested for their efficacy in eliminating neuroendocrine tumors in animal models."
"University of Pennsylvania","Early Detection of Pancreatic Cancer","","","https://upenn.technologypublisher.com/technology/54467","A 2-protein panel blood test for early detection of pancreatic ductal adenocarcinoma.Problem:Pancreatic cancer is the third leading cause of cancer related death in the US and is predicted to become the second leading cause of cancer mortality by 2020. Most pancreatic ductal adenocarcinoma (PDAC) patients are diagnosed at an advanced stage of disease, and their tumors are not surgically resectable, contributing to an overall 5-year survival rate of 7%. The lack of early diagnosis has made it challenging to develop therapeutics to slow or reverse PDAC.Currently CA19-9 is used to assess disease progression in PDAC patients. However its use is not recommended for general screening because (1) it is elevated in certain nonmalignant pancreatic conditions, such as chronic pancreatitis (2) it produce false negatives in individuals who do not express Lewis blood group antigens.Other secreted markers have been reported for PDAC including blood or urine proteins, exosomes, microRNAs, and epigenetic marks in circulating nucleosomes. However, most are discovered in advanced PDAC or cell lines that are not representative of earlier stages, when detection would be most relevant, although recent candidates have been tested or discovered in prediagnostic samples of PDAC. There is an urgent need for early detection of PDAC to be able to contemplate efficient therapeutic intervention.Solution:In an effort to develop early diagnostic prognostic, Dr. Kenneth Zaret at the Perelman School of Medicine has developed a 2-protein panel for early detection of pancreatic ductal adenocarcinoma.Advantages:Assay done via ELISANo biopsy neededEarly detection of pancreatic cancerApplication:Early diagnostic of pancreatic cancerROC curves for THBS2, CA19-9, and THBS2 + CA19-9 concentrations in plasma samples from patients with all stages of PDAC versus healthy controls. (D) PDAC, n = 197; controls, n = 140 studies.Stage of Development:Identified a two proteins-signature in plasma that detect early stage pancreatic ductal adenocarcinomaFuture plans include prospective validation of this signatureIntellectual Property:US PatentPendingReference Media:Kim et al.,Sci. Transl. Med. 2017 July 12; 9(398): eaah5583CBS NewsNIH/NCICase ID:18-8359-tpNCSWeb Published:6/21/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54467","**Summary:** A blood test consisting of a two-protein panel has been developed for the early detection of pancreatic ductal adenocarcinoma (PDAC). The current challenges in accurately diagnosing PDAC stem from the fact that most patients are diagnosed at an advanced stage when surgical options are not viable, resulting in a low five-year survival rate. Traditional markers like CA19-9 are inadequate for routine screening due to their association with noncancerous conditions and potential false negatives. Although some promising markers have been identified, they often pertain to advanced disease rather than early detection, highlighting the need for improved diagnostic tools.

**Applications:** This technology could be utilized in clinical settings for the early identification of pancreatic cancer, potentially leading to timely treatment interventions and better patient outcomes. It may serve as a valuable tool for healthcare providers to screen at-risk individuals more effectively.

**Problem Solved:** The technology addresses the significant issue of late-stage diagnosis in pancreatic cancer patients, thereby aiming to improve early detection rates, allowing for earlier therapeutic strategies that could significantly enhance survival outcomes and reduce mortality rates associated with PDAC.","A 2-protein panel blood test has been developed for the early detection of pancreatic ductal adenocarcinoma (PDAC), which is the third leading cause of cancer-related death in the US. Most PDAC patients are diagnosed at an advanced stage, resulting in a low overall 5-year survival rate of 7%."
"University of Pennsylvania","Gene Therapy for the Treatment of Retinal Degeneration and Vision Loss","","","https://upenn.technologypublisher.com/technology/27847","Recombinant adeno-associated virus (rAAV) expressing the gene for retinitis pigmentosa GTPAse regulation (RPGR) for the functional and structural rescue of photoreceptor cells of the eye as gene therapy for retinal degeneration and vision loss.Technology Overview:Retinitis pigmentosa (RP) is a genetic form of early-onset retinal degeneration that occurs in 1 in 4000 individuals worldwide. Mutations in the RPGR gene are the leading cause of the X-linked form of RP (XLRP), where symptoms rapidly progress from impaired nighttime vision, to reduced visual field and loss of visual acuity, to patients ultimately becoming legally blind. However, there are currently no successful treatments available for patients suffering from XLRP.Dr. Beltran and colleagues at the University of Pennsylvania and the University of Florida have been developing an AAV-mediated gene therapy for the treatment of XLRP. Recombinant AAV carrying a stabilized form of the human RPGR gene under the control of a retinal photoreceptor promoter were synthesized. Delivery of the vector in preclinical RPGR XLRP canine models revealed that, depending upon the timing of administration, treatment could either prevent disease development or arrest its progression. Additionally, for those studies wherein degeneration had already begun, treatment was able to restore the remaining photoreceptors‚Äô structure and function. This approach has demonstrated long-lasting therapeutic effects (>2 years) after one injection, making this a clinical candidate ready for additional development.Advantages:Prevents progression of retinitis pigmentosaImproves photoreceptor cell function for improved visual functionApplications:Use in gene therapy for treatment of heritable X-linked retinitis pigmentosa cause by a mutation in the RPGR geneStage of Development:In vivo preclinical testing ‚Äì determining effective therapeutic range, establishing long-term efficacy of correctionIntellectual Property:US9,770,491US10,383,922EP2,872,183AU2013287281CA2,878,171JP6,199,965NZ704275Reference Media:Beltran et al.Proc Natl Acad Sci USA, 2012 Feb 7; 109(6): 2132Beltran et al.Proc Natl Acad Sci USA, 2015 Oct 27; 112(43): E5844Desired Partnerships:LicenseCase ID:Y6159-tpNCSWeb Published:6/7/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/27847","**Summary:** Recombinant adeno-associated virus (rAAV) expressing the retinitis pigmentosa GTPase regulator (RPGR) gene has been developed as a gene therapy to address retinal degeneration and vision loss due to retinitis pigmentosa (RP), specifically the X-linked form (XLRP). The therapy aims to rescue the function and structure of photoreceptor cells, with preclinical studies indicating that timely vector administration can either prevent disease onset or halt progression. Furthermore, in cases where photoreceptor degeneration has commenced, the treatment has shown the ability to restore function and structure and maintains significant therapeutic effects for over two years following a single injection.

**Applications:** This gene therapy is specifically designed for patients suffering from X-linked retinitis pigmentosa, focusing on restoring vision by targeting the genetic basis of the disease through the delivery of the RPGR gene.

**Problem Solved:** The technology addresses the absence of effective treatments for X-linked retinitis pigmentosa, which leads to severe vision loss and legal blindness, by providing a potential therapy that can prevent, arrest, or even reverse retinal degeneration in affected individuals.","Recombinant adeno-associated virus (rAAV) expressing the RPGR gene is being investigated as a gene therapy for retinal degeneration and vision loss caused by retinitis pigmentosa (RP). RP is a genetic condition affecting approximately 1 in 4000 individuals worldwide, with mutations in the RPGR gene being the primary cause of the X-linked form of the disease."
"University of Pennsylvania","Therapeutic to Mitigate Epilepsy and Autism Development in Newborn Seizure Patients","","","https://upenn.technologypublisher.com/technology/38500","Neonatal brains are at high risk for seizures due to heightened electrical activity corresponding to neural development. Though anticonvulsant drugs exist to treat the seizures immediately, certain synaptic receptors (CP-AMPARs) become highly expressed, increasing the likelihood of developing epilepsy and autism-spectrum disorders. The inventors propose using CP-AMPAR blockers such as IEM-1460 to curb CP-AMPAR activity and prevent development of epilepsy and other neurological disorders.Problem:Neonatal brains are constantly in a state of electrical excitation due to the heightened neural activity required during development. They are therefore prone to hypoxic seizures, which can lead to long term synaptic development issues.AMPA receptors (AMPARs) are involved in the synaptic transmission of neurotransmitters in the central nervous system and one subset of these AMPARs are calcium-permeable (CP-AMPARs) because they lack the GluR2 subunit. In infants experiencing hypoxic seizures, these CP-AMPARs are upregulated and simultaneously, MeCP2, a transcription factor linked to autism spectrum disorder (ASD) becomes phosphorylated. MeCP2 is involved with synapse and dendrite development and neuronal maturation and thus, disruptions in its expression can lead to ASDs or epilepsy.AMPAR blockers have been considered as antiepileptogenetic drug candidates though they are not specific enough to target only CP-AMPARs.Solution:The inventors have therefore proposed using CP-AMPAR blockers such as IEM-1460 to inhibit CP-AMPAR activity and reduce MeCP2 phosphorylation. These CP-AMPAR blockers prevent the permeation of calcium into the neurons and as a result, the MeCP2 phosphorylation is inhibited.Advantages:Highly specific therapeutic that can be dose-adjusted for the patient‚Äôs ageEffectively reduces calcium influx into the neuron to inhibit MeCP2 phosphorylationApplications:An age-specific therapeutic to be used in patients who have suffered from neonatal seizuresCould be part of a drug cocktail along with other AMPAR blockers to effectively block epileptogenesisTop: Hippocampal GLUA2 expression decreases 48 h post hypoxia induced seizure. Surface GluA2 expression decreases 48 h post-HS. A, B) Immunohistochemistry of surface GluA2 (green) and synapsin (red) in (A) control and (B) post-HS inCA1 S. radiatum of the hippocampus of P12 Long-Evans rats 48 h post-HS. Circles highlight colocalization; Bar=2 Œºm. C) Quantification shows a significant decrease in surface GluA2/Synapsin colocalization in post-HS rats compared to controls overmultiple thresholds represented as a percentage of the control at each threshold; post-HS n=11 fields from 6 rats; control=8 fields from5 rats; p = 0.04 by t-test of control vs. HS at each threshold. D) Averaged traces of AMPAR eEPSCs at‚àí60 and +40 mV while blocking NMDARs and GABARs show that rectification increases post-HS. E) Summary of AMPAR eEPSC ratio at‚àí60 mV to +40 mV; n= 5 control and 6 post-HS, p = 0.014 by t-test. Data are represented as mean ¬± SE.Bottom: CP-AMPAR antagonists reduce MeCP2 phosphorylation. AMPARs and LT-VGCCs mediate hypoxic seizure (HS)-induced MeCP2 S421 phosphorylation in vivo in P10 rats. Increased MeCP2 S421 phosphorylation 3h. post-HS (HS+V: n=17 vs. C+V n=14, p=0.0003) can be attenuated by in vivo pre-treatment with the AMPAR antagonist NBQX (20mg/kg, i.p.) (HS+NBQX: n=9, vs. HS+V, p<0.0001), the CP-AMPAR blocker IEM-1460 (20mg/kg, i.p.) (HS+IEM-1460: n=9, vs. HS+V p=0.0099), or the LT-VGCC antagonist nimodipine (10mg/kg, i.p.) (HS+NIMO: n=9, vs. HS+V p=0.0051)Stage of Development:PreclinicalIntellectual Property:US PatentPendingReference Media:Lippman-Bell et al.Mol Cell Neurosci. 2016 Oct; 76: 11.Sun, H, et al.;Cell Rep 2018 May 29 23(9): 2533Rosenberg, EC, et al.;Neurobiol Dis 2018 August 116: 120Desired Partnerships:LicenseCo-developmentCase ID:18-8515-tpNCSWeb Published:2/7/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38500","**Summary:** This technology addresses the heightened risk of seizures in neonatal brains, which can lead to long-term synaptic development issues, including epilepsy and autism spectrum disorders. It involves the use of CP-AMPAR blockers like IEM-1460 to inhibit the activity of calcium-permeable AMPA receptors that become overly expressed following hypoxic seizures. By targeting these specific receptors, the proposed intervention aims to limit the upregulation of CP-AMPARs and prevent the associated pathological changes linked to neurological disorders.

**Applications:** The primary application of this technology is in the treatment of newborns experiencing hypoxic seizures, with the potential to reduce the incidence of epilepsy and autism spectrum disorders. It can also be extended to clinical settings focused on pediatric neurology, providing a novel approach for managing neonatal seizures and their long-term consequences.

**Problem Solved:** The technology addresses the challenge of managing seizures in neonates, which can disrupt synaptic development and lead to serious neurological conditions such as epilepsy and autism. By using CP-AMPAR blockers to specifically target and inhibit the receptors involved, it helps prevent the adverse effects associated with the upregulation of these receptors in the developing brain.","Neonatal brains are susceptible to seizures due to increased electrical activity during development, and high expression of CP-AMPARs can lead to epilepsy and autism-spectrum disorders. The inventors propose utilizing CP-AMPAR blockers like IEM-1460 to reduce CP-AMPAR activity and prevent the onset of these neurological disorders."
"University of Pennsylvania","Novel Activity-Based Probes for TET Enzymatic Activity","","","https://upenn.technologypublisher.com/technology/27794","Method and probes for detecting and quantifying epigenetic regulator TET enzymatic activity. This method can be used for high throughput screening of TET inhibitors or activators.Problem:Ten eleven translocation (TET) enzymes are important epigenetic regulators. TETs catalyze the step-wise oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in genomic DNA, promoting DNA demethylation and gene expression changes. Assessing TET activity remains experimentally challenging.Currently available commercial kits are indirect assays of TET activity, limited in scope, laborious, and cannot be used in vivo.Solution:Dr. Kohli and his team at Penn have developed an improved enzyme assay for TET. Dr. Kohli has engineered specific probes for TETs that yield unique reaction intermediates, can be easily detected, and their abundance is a direct measurement of TET activity. This method presents a novel, facile, and valuable tool for evaluating TET activity.Advantages:Direct measurement of TET enzymatic activityStraightforward methodologyCan be used to detect TET1, TET2, and TET3 activityCan be used to determine when and where specific TET enzymes are active in particular cellular nichesApplications:Measure TET enzymatic activity directly in vitro or in vivoHigh throughput screen for TET modulators, inhibitors or activatorsStage of Development:In vitro dataReference Media:Ghanty et al.,J Am Chem Soc. 2018 Dec 19; 140(50): 17329Desired Partnerships:LicenseCo-developmentCase ID:18-8629-tpNCSWeb Published:6/1/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/27794","**Summary:** This technology offers a method and probes for the direct detection and quantification of TET enzymatic activity, specifically addressing the limitations of current commercial kits which provide only indirect assays and lack in vivo applicability. The method utilizes engineered probes that result in unique reaction intermediates, allowing for straightforward detection and providing a direct measurement of TET activity. This advancement facilitates the evaluation of TET enzymes‚Äîspecifically TET1, TET2, and TET3‚Äîwithin various cellular contexts.

**Applications:** The technology can be applied to measure TET enzymatic activity both in vitro and in vivo, enabling high throughput screening for TET modulators, inhibitors, or activators, which is crucial for research in epigenetics and potential therapeutic development.

**Problem Solved:** The development addresses the experimental challenges associated with assessing TET activity, providing a more efficient and reliable tool compared to existing indirect assays, which are labor-intensive and limited in scope. This solution supports better understanding and manipulation of TET enzymatic functions in genomic regulation.","The method and probes described are designed for detecting and quantifying the enzymatic activity of Ten eleven translocation (TET) enzymes, which are key epigenetic regulators that facilitate the oxidation of 5-methylcytosine. This approach enables high-throughput screening for potential TET inhibitors or activators."
"University of Pennsylvania","Low Cost, Mobile, Wearable EEG Device with High Quality Nanowire Sensors","","","https://upenn.technologypublisher.com/technology/54510","Mobile, wearable, low cost electro-encephalogram (EEG) devices that offer research grade signals may provide a wealth of information regarding the brain states of individuals. This knowledge can be effectively utilized to develop personalized treatment protocols in medicine and individual customer‚Äìbased advertisements for marketing.The inventors aim to establish sensitive, objective biomarkers that can vastly improve the quality of life of patients and customer satisfaction in business. This breakthrough device is being developed and commercialized through a University of Pennsylvania start-up, Cogwear LLC.Problem:In the last few years, the demand for advanced imaging techniques for brain monitoring has surpassed the available options. The global EEG devices market was valued at US $879 million in 2014 and is expected to expand at a CAGR of 6.8% during the forecast period from 2015 to 2021 [Global Data].The EEG is one of the few methods of visualizing brain function and is the mainstay of diagnosis of seizure disorders as well as many other neurologic conditions. Conventional EEG devices used in research and in the clinic provide high-quality signals, that is, good signal-to-noise ratio. However, these devices are not conducive for mobile real world applications because they are wired devices that tether participants to a given location, limiting the activities that they can perform. Furthermore, these devices are not amenable for long-term use because the electrodes typically require electrolytic gel to make contact with the scalp, which dries out over time, thereby reducing signal quality and increasing discomfort due to dried salt deposits.There are currently no viable options for a research grade EEG device that can be worn for prolonged periods of time and are mobile enough to benefit from participants‚Äô real world interactions.Solution:The present invention is an EEG device that is not only affordable, mobile, and wearable, but also provides research-grade signal quality.This EEG device uses silver nanowire-based dry electrodes that produce signal quality comparable to traditional wet electrodes. These sensors are biocompatible and are relatively straightforward to fabricate. Such a device would allow for continuous monitoring of an individual‚Äôs brain activity, allowing for the identification of specific biomarkers of individual behaviors in various settings.The applications are innumerable within the clinic and in consumer research, including continuous healthcare monitoring applications, personalized treatment protocols in medicine, individual customer-based advertisements for marketing, and optimal training programs in sports and music.Furthermore, given the research-grade signal produced by this device, it is feasible that silver nanowire based electrodes could entirely replace the existing wet electrodes in every current clinical application.Advantages:Mobile, Comfortable, No wet electrodes, Better and longer recordings.Applications:Medical:Identify functional biomarkers underlying medical conditions, including depression, anxiety, ADHD, PTSD (Wearable Diagnostic and Monitoring Devices1, Global Market 2015: $1.4B)Marketing/ Commercial Usage:Individualized consumer marketing (Neuromarketing Technology2, Global Market 2015: $21.0M)Training of athletes/musicians (Health and Fitness Wearables3, Global Market 2015, $1.7B)Video gaming (Wearable Gaming Hardware4, Global Market 2015, $1.24B)Anti-fatigue wearables (Health Self-Monitoring Peripherals5, Global Market 2014, $3.2B)Stage of Development:Prototype built and tested.Intellectual Property:US PatentPendingReference Media:Volk, S.;Wharton Magazine Spring/Summer 2018: 44.Desired Partnerships:LicenseCo-developmentSponsored researchCase ID:18-8425-tpNCSWeb Published:6/26/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54510","**Summary:** Mobile, wearable, and low-cost electro-encephalogram (EEG) devices featuring high-quality nanowire sensors can provide research-grade brain activity signals. These devices are being developed by Cogwear LLC, a start-up from the University of Pennsylvania, with the aim of establishing sensitive biomarkers that improve patient quality of life and enhance customer satisfaction through personalized applications.

**Applications:** The technology is intended for diverse applications, including the development of personalized treatment protocols in medicine and customized advertisements in marketing based on individual brain states.

**Problem Solved:** The invention addresses the growing demand for advanced brain monitoring techniques, as conventional wired EEG devices are limited to specific locations and not suitable for long-term use, thus hindering real-world mobile applications and continuous monitoring of brain activity.","Mobile, low-cost EEG devices with high-quality nanowire sensors can offer research-grade brain signal data, enabling the development of personalized treatment protocols in medicine and targeted marketing strategies. The inventors seek to establish sensitive biomarkers to enhance patient quality of life and customer satisfaction."
"University of Pennsylvania","High Resolution Functional Imaging of Individual Cone Photoreceptors in the Living Human Eye","","","https://upenn.technologypublisher.com/technology/27751","A non-invasive in vivo imaging technique using enhanced ophthalmoscopy to assess the intrinsic function of individual photoreceptor cells while maintaining high spatial resolution. This technique could be applied for both diagnostic purposes as well as the precise measurement of treatment response to both existing and experimental therapies for retinal diseases.Technology Overview:Functional assessments of vision, such as visual acuity, visual fields, microperimtery, and electroretingorams are critical for the diagnosis, treatment, and prognosis of retinal diseases. These techniques are sensitive only for examining the function of a large area of retina and have insufficient resolution for detecting functional changes anywhere close to the scale of individual cones. This represents a significant gap in our ophthalmic assessment capabilities, especially given that current therapeutic approaches are attempting to restore function to individual photoreceptors.Noninvasive cellular-scale observation of the structure of human photoreceptor cells is made possible through the use of adaptive optics (AO) enhanced ophthalmoscopes, but establishing noninvasive objective measures of photoreceptor function on a similar scale has been more difficult.The inventors have developed a technique to assess the intrinsic function of individual photoreceptor cells using AO enhanced ophthalmoscope images acquired with near-infrared light. The images have high spatial resolution (single cell level) with low signal-to-noise ratio and could be easily incorporated into, and improve upon, existing AO enhanced ophthalmoscopes using infrared illumination.Advantages:Functional, rather than structural, retinal imagingHigh spatial resolution (at the single cell level)Applications:Use in Ophthalmology clinics as an objective assessment of cone function.Monitoring retinal function as a primary or secondary outcome in clinical trials of new retinal gene therapies.Early and accurate diagnosis and surveillance of degenerative retinal diseases in the clinic.Top: The figure shows the cone intrinsic reflectance response measured from the stimulated and control trials. (A) Repeat control trials (cool colored lines) and stimulated trials (warm colored lines) show a clear, measurable, and reliable intrinsic reflectance response. (B) All trials for a given condition were then combined using pooled standard deviation, and the stimulus-evoked intrinsic reflectance response was taken as the difference between the stimulated and control pooled standard deviations. These results strongly indicate that the absorption of light by cone photopigment initiates a reflectance response, thereby making the intrinsic reflectance response a direct, non-invasive measure of photoreceptor function.Bottom: Preliminary results demonstrate that the Reflectance response can be used to measure non-functioning photoreceptors in those suffering retinopathies.Stage of Development:Human proof-of-concept studies completedFuture experiments will further optimize image acquisition and processing and determine the mechanistic origin of the functional responseIntellectual Property:US11,607,125Reference Media:Cooper, RF et al.;Biomed Opt Express 2018 Apr 1; 9(4): 1842Desired Partnerships:LicenseCo-developmentCase ID:18-8578-tpNCSWeb Published:5/22/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/27751","**Summary:** This technology employs a non-invasive imaging technique utilizing enhanced ophthalmoscopy to evaluate the functional capabilities of individual cone photoreceptors in the living human eye. It ensures high spatial resolution and focuses on assessing intrinsic photoreceptor function, which is crucial for both diagnosing retinal diseases and measuring the responsiveness of these cells to various treatments.

**Applications:** The primary applications include diagnostic assessments for retinal diseases and precise monitoring of therapeutic responses to established as well as experimental treatments focused on restoring function to individual photoreceptors. The ability to observe individual cone functionality can lead to improved evaluation of therapies aimed at retinal restoration.

**Problem Solved:** The technology addresses the significant limitation of current ophthalmic assessment methods, which lack the resolution necessary to detect functional changes at the individual cone level. Traditional methods are only adept at evaluating larger areas of the retina, leaving a gap in understanding the health and function of individual photoreceptors, which is critical as modern therapies target these specific cells for restoration of vision.","A non-invasive in vivo imaging technique utilizing enhanced ophthalmoscopy enables the assessment of the intrinsic function of individual photoreceptor cells with high spatial resolution. This technology can be applied for diagnostic purposes and to measure treatment responses for various retinal diseases."
"University of Pennsylvania","Imaging-Based Early Diagnostic and Prognostic for Osteoporosis and Hip Fracture Risk","","","https://upenn.technologypublisher.com/technology/38479","High-resolution MRI and CT images analysis software evaluating 3D bone structure and allowing for accurate assessment of (i) bone strength and health, (ii) risk for osteoporosis development, and (iii) risk for hip fracture.Problem:Osteoporosis affects 50 million Americans and more than 200 million people worldwide. It leads to reduced bone strength and increased risk of fracture. Hip fracture in particular is a devastating event with 50% of sufferers losing ability to walk and 20% of suffers dying from it.More than 2 million fractures and 300,000 hip fractures occur annually in the U.S. resulting in $20 billion and $12B in annual healthcare expenses, respectively. Currently, greater than 50% of the individuals with osteoporosis are not detected by bone density testing, the standard-of-care diagnostic test. More accurate and earlier diagnosis is needed and could lead to earlier treatment and the prevention of fractures, saving healthcare costs.Solution:Dr. Rajapakse and Dr. Chang have developed a software applied to high resolution MRI or CT images of bone microstructure for detailed evaluation of the mechanical strength of the bone. It allows for simulation of various loading conditions, takes into account shape, geometry and distribution of the trabecular building blocks during stress to describe mechanical integrity and accurately determines osteoporosis development and hip fracture risk.Advantages:Can be used with images from standard clinical MRI or CT machinesMore accurate prediction of osteoporosis development and hip fracture than DEXAEarlier detection and treatment of bone loss, leading to lower healthcare costsMore accurate monitoring of bone loss and treatment effectivenessEarly screening for predisposed patients (with osteoporosis, family history, metastatic cancer, diabetes, renal diseases)Applications:Diagnosis and prognosis of osteoporosis and bone pathologiesDriver for early treatment for patients with high riskMonitoring of disease progression and therapy responseStage of Development:Data from ~1000 patientsValidation data from cadaver bone exposed to mechanical stressIntellectual Property:US11,202,602Reference Media:Chang, G et al.;Radiology, 2014 August 272(2): 464Rajapkse, CS et al.;Radiology, 2017 Jun, 283 (3): 854Agten, CA et al.;Radiology, 2017 Nov, 285(2): 506Desired Partnerships:LicenseCo-developmentCase ID:17-8291-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38479","**Summary:** High-resolution MRI and CT image analysis software has been developed to evaluate 3D bone structure for the assessment of bone strength and health, as well as the risks associated with osteoporosis and hip fractures. This software enables detailed evaluations of mechanical strength by simulating different loading conditions and considers the bone's shape and geometry. 

**Applications:** The technology can be utilized in clinical settings with standard MRI or CT machines to facilitate improved diagnosis and monitoring of osteoporosis and hip fracture risk, ultimately aiding in patient management and treatment decision-making.

**Problem Solved:** Osteoporosis affects a significant portion of the population, leading to diminished bone strength and a marked increase in fracture risk, particularly hip fractures, which have severe consequences on mobility and mortality. The high prevalence of undiagnosed osteoporosis due to limitations of current bone density tests creates a need for more accurate and earlier diagnostic methods, which this technology addresses, potentially reducing healthcare costs associated with fractures.","High-resolution MRI and CT image analysis software evaluates 3D bone structure to assess bone strength, health, and the risk of osteoporosis and hip fracture. Osteoporosis affects 50 million Americans and over 200 million people globally, significantly increasing fracture risk, particularly hip fractures, which severely impact mobility and can be fatal."
"University of Pennsylvania","clampFISH probes for high-grain, single molecule amplification of RNA","","","https://upenn.technologypublisher.com/technology/38475","A non-enyzmatic, high-gain signal amplification method for fluorescent detection of RNA to achieve greater than 400 times signal amplification. This makes signal detection possible under low-magnification and separation of cells by RNA levels via flow cytometry.Technology Overview:Many amplification approaches rely on enzymes to achieve amplification. However, these for single nucleic acid amplification, existing approaches are non-specific and do not readily allow for measurements of large populations of cells for heterogeneity in gene expression. Alternative systems for single nucleic acid amplification require unique microscopy techniques.Researchers at Penn have demonstrated, through the use of click chemistry, that their clampFISH can achieve exponential amplification of target probes that detect single nucleic acids. Over 6 rounds of amplification they have achieved a 120-fold increase for RNA with very low background noise. This process makes the amplification technique viable for high throughput methods (flow cytometer) for measurement of single transcripts within a cell. The technology is currently being translated to multiplexed applications.Advantages:High Amplification of Single Nucleic Acid in TissueLow Background NoiseLends itself to high throughput and multiplexed applicationsRelieves the use of non-specific, bulky enzymes (less steps to achieve desired amplification)No need for high-powered cameraApplications:Amplification for high-throughput and possibly multiplexing systemsStage of Development:Prototype and Demonstration Model DevelopedMultiplexed DemonstratedIntellectual Property:PatentPendingDesired Partnerships:LicenseCo-development (this replaces collaboration or sponsored research)Case ID:17-8198-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38475","**Summary:** A non-enzymatic amplification method for fluorescent detection of RNA has been developed, achieving greater than 400 times signal amplification while maintaining low background noise. This technique allows for the detection of single RNA molecules and facilitates the separation of cells based on RNA levels using flow cytometry. By employing click chemistry, researchers have demonstrated exponential amplification of target RNA probes through multiple rounds of amplification, enabling the measurement of gene expression heterogeneity in large cell populations. The technology supports high-throughput methods and is being adapted for multiplex applications.

**Applications:** The technology can be utilized for high-throughput RNA detection, flow cytometry applications, and multiplexed analysis of gene expression, making it suitable for research in various fields including molecular biology, genomics, and clinical diagnostics.

**Problem Solved:** The method addresses challenges associated with existing amplification techniques that rely on enzymes, which are often non-specific and inadequate for analyzing large populations of cells. By providing high signal amplification without the complications of enzyme reliance, the technology enables accurate and efficient measurement of single RNA transcripts, facilitating better insights into cellular heterogeneity in gene expression.","A non-enzymatic signal amplification method achieves over 400 times amplification for fluorescent detection of RNA, enabling low-magnification signal detection and RNA-based cell separation via flow cytometry. Unlike existing approaches, this method provides specificity without relying on enzymes, facilitating measurements across large populations."
"University of Pennsylvania","Passive multidirectional illumination in light-sheet flourecense microscopy","","","https://upenn.technologypublisher.com/technology/31575","Problem:Light-sheet fluorescence microscopy enables rapid scanning of biological samples to reconstruct a 3-dimensional image of the sample. However, images generally contain artifacts (shadows, stripes, etc.) that are caused by illumination inhomogeneity due to absorption or scattering within the sample. These artifacts can occlude observation of biological phenomena in a sample. Moreover, current products use expensive and technologically demanding instrumentation to address these issues.Solution:Researchers in Professor Douglas Durian‚Äôs laboratory in the University of Pennsylvania‚Äôs Department of Physics and Astronomy have developed methods to passively generate multidirectional illumination in a light-sheet imaging system using a light shaping diffuser. The outcomes include the elimination of optical artifacts, similar to those described above. An add-on device incorporating this method into an optical microscope would provide a cost-effective alternative to current prohibitively expensive stand-alone equipment.Advantages:Cost-effective multidirectional illuminationElimination of optical artifacts in light-sheet fluorescence microscopyAdd-on device compatible with commercial optical microscopesApplications:3-D light-sheet fluorescent imaging of biological samples (tissue or cells)3-D imaging of colloidal and granular materials for particle tracking (soil mechanics, flow behavior, and rheology)Stage of Development:PrototypeProof-of-Concept Data GeneratedIntellectual Property:US PatentPendingReference Media:Durian GroupPublicationsSalili, S. M. et al.;Rev Sci Instrum 2018 March 89(3): 036107Desired Partnerships:LicenseCo-developmentCase ID:18-8462-tpNCSWeb Published:3/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31575","**Summary:** Researchers at the University of Pennsylvania have developed a method to generate passive multidirectional illumination in light-sheet fluorescence microscopy, addressing issues of illumination inhomogeneity that lead to optical artifacts, such as shadows and stripes, which can obscure observations of biological phenomena. By utilizing a light shaping diffuser, this method aims to eliminate these artifacts and provide a cost-effective add-on device compatible with existing optical microscopes, reducing the need for expensive standalone equipment.

**Applications:** The technology can be applied to 3-D light-sheet fluorescent imaging of biological samples, including tissues and cells. Additionally, it can be used for 3-D imaging of colloidal and granular materials for applications in particle tracking, soil mechanics, flow behavior, and rheology.

**Problem Solved:** The development addresses the problem of optical artifacts generated by illumination inhomogeneity in light-sheet fluorescence microscopy, which can hinder the observation of important biological phenomena in samples. It also provides a more affordable and accessible solution compared to existing high-cost microscopy systems.","Light-sheet fluorescence microscopy allows for quick imaging of biological samples to create 3D reconstructions, but images often exhibit artifacts due to uneven illumination from absorption or scattering. Existing solutions require costly and complex equipment, which limits their accessibility."
"University of Pennsylvania","High performance cageless bearings with minimal frictional loss","","","https://upenn.technologypublisher.com/technology/38480","The invention is a cageless bearing with rolling separator elements. The design will reduce friction by ensuring the rolling elements are only ever in pure rolling, as opposed to sliding contact which involves higher frictional losses. Additionally, these elements are not in sliding contact with the inner race. Categories for applications include portable medical devices, toys and consumer robotic applications with medium force requirements.Technology Overview:The global bearings market size was valued at USD 81.6 billion in 2015 and is expected to grow, significantly, owing to the increasing commercial and industrial machinery and manufacturing activity. Bearings are used in virtually every machine that contains a rotating shaft to rotate freely with minimal friction.The design of conventional cageless bearing systems is inefficient due to both sliding and incidental friction losses as well as viscous losses due to requirement of lubrication. Hence the main problem is mechanical inefficiency. Additionally, some of the systems also incorporate complex components into their design, such as gear teeth or harmonic gear cups that increase cost. For heavy-duty vehicles, 26% of the fuel energy is spent overcoming parasitic frictional losses such as bearing loss. If bearing loss can be significantly reduced, the fuel efficiency of such systems could be significantly improved.Researchers at Penn have described a normal cageless bearing with added rolling separator elements to overcome these issues. The proposed bearing system eliminates sliding friction losses by ensuring that all contacting surfaces have the same velocity which leads to pure rolling, thereby reducing incidental contact. This design can be modified into a friction drive transmission device with a small form factor by splitting the outer race into two parts. The result is a low cost, low noise and high efficiency system with no sliding, incidental, and viscous losses.Advantages:High efficiency and high-performance systemNo sliding, viscous and incidental friction lossesLow noiseLow cost due to reduced manufacturing and assembly costs (no cage or gear teeth)Eliminates need for lubricationTransmission has a small form factorApplications:High performance with low frictional loss bearingThis no-slip bearing system can be modified to become combined friction drive transmission and bearing.The bearing can be used in combination with Prendo‚Äôs robot arm product (PI‚Äôs UPstart company)Example categories for applications include portable medical devices, toys and consumer robotic applications with medium force requirementsStage of Development:Prototype developedIntellectual PropertyPatentPendingDesired Partnerships:LicenseCo-developmentCase ID:17-8302-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38480","**Summary:** The invention features a cageless bearing design that utilizes rolling separator elements to facilitate pure rolling motion, minimizing frictional losses compared to traditional sliding contact bearings. This results in increased mechanical efficiency and reduced lubrication requirements. The technology aims to overcome the inefficiencies associated with conventional bearing systems, which often suffer from sliding and incidental friction losses. 

**Applications:** Potential applications for this technology include portable medical devices, toys, and consumer robotic devices that require medium force.

**Problem Solved:** The technology addresses mechanical inefficiencies caused by sliding friction in conventional bearings, which can lead to significant energy loss. By reducing frictional losses in bearings, the technology has the potential to improve fuel efficiency in heavy-duty vehicles and other machinery that rely heavily on rotating shafts.","The invention features a cageless bearing with rolling separator elements that minimizes friction by maintaining pure rolling contact without sliding. It is applicable in portable medical devices, toys, and consumer robotic applications that require medium force."
"University of Pennsylvania","Therapeutic Targets for T-Cell Lymphomas and Other Types of Cancer","","","https://upenn.technologypublisher.com/technology/39348","Interdependence of oncogenic and epigenetic mechanisms in T-cell lymphoma.Technology Overview:Anaplastic large cell lymphoma (ALCL) is a highly malignant type of Non-Hodgkin‚Äôs T cell lymphoma in which chromosomal translocation leads to the expression of a fusion oncoprotein Tyrosine Kinase - Nucleophosmin/Anaplastic Lymphoma Kinase or NPM/ALK.Dr. Wasik showed that NPM/ALK positive cancer cells have a selective loss of STAT5A, a tumor suppressor protein and a reciprocal inhibitor of NPM/ALK. (U4592)NPM/ALK, acting through STAT3 transcription factor, selectively inhibits expression of STAT5a gene. Induction of STAT5a expression, either by gene transduction or application of DNA methyltransferase inhibitor to reverse the gene silencing, results in the inhibition of NPM/ALK expression and, consequently, death of the malignant cells.The invention also provides a method to diagnose malignancy and monitor patient‚Äôs response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.Dr. Wasik also demonstrated that NPM/ALK induces the expression of immunosuppressive protein CD274, also known as PD-L1 or B7-H1 through STAT3. (V4957)This invention provides methods for inhibiting an oncogenic protein or its down-stream effector to suppress expression of a cell-surface protein (PDL-1) involved in inhibiting immune response against malignant cells thereby enhancing the immunogenicity of a cell. The invention includes inhibitors of function or expression of oncogenic ALK tyrosine kinase and/or other oncogenic proteins and their effectors such as STAT3 responsible for induction of expression of CD274 or its functional immunosuppressive equivalent. This approach may represent an attractive (and not mutually exclusive) alternative to inhibiting CD274 and similar immunosuppressive with antibodies.In addition, Dr. Wasik developed transformed CD4+ T cells by expressing NPM-ALK in normal human CD4+ T lymphocytes.The NPM-ALK CD4 transformed cells become immortalized and display morphology and immunophenotype of patient derived anaplastic large-cell lymphomas. This is the first method to succeed in immortalizing these cells and the first to transform normal human cells of any kind using a well-defined single oncogene relevant to human disease.Combined, these results demonstrate the relevance of targeting NPM-ALK or its downstream effectors as a potential immuno-onco-therapeutic approach. Given their uniqueness, these NPMALK transformed normal human CD4+ T cells may also be used to study therapeutic strategies aimed at prevention of cancer development.Applications:Immuno-onco-therapeutic targets in lymphoma and other types of cancerResearch tool to study cell transformation including its very early stages and to screen for compounds that could be effective in treating anaplastic large-cell lymphomas (ALCL)Research tool to generate immortalized, although abnormal, T lymphocytes from both, healthy individuals and patients with autoimmune and other diseases.Stage of Development:Proof of concept in vitroIntellectual Property:US9,486,469US10,166,251US9,255,279Reference Media:Zhang, Q et al.;Nat Med 2007 Nov 13(11): 1341.Marzec, M et al.;Proc Natl Acad Sci USA 2008 Dec, 105(52): 20852.Zhang, Q et al.;Am J Path 2013 Dec 183(6): 1971Desired Partnerships:LicenseCo-developmentCase ID:Z6498-tpNCSWeb Published:3/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39348","**Summary:** The technology revolves around the interdependence of oncogenic and epigenetic mechanisms in T-cell lymphoma, specifically focusing on anaplastic large cell lymphoma (ALCL). It highlights the role of the fusion oncoprotein NPM/ALK, which arises from chromosomal translocation and leads to the selective loss of the tumor suppressor protein STAT5A. The suppression of STAT5A by NPM/ALK, mediated through the STAT3 transcription factor, can be countered by inducing STAT5A expression to promote the death of malignant cells. Additionally, the technology offers methodologies for diagnosing malignancy and monitoring patient responses based on DNA methylation of the Stat5a gene. Furthermore, it addresses the induction of the immunosuppressive protein PD-L1 by NPM/ALK and proposes methods to inhibit this protein, thereby enhancing the immune response against cancer cells.

**Applications:** This technology can be utilized in the diagnosis and monitoring of T-cell lymphomas, particularly ALCL, through genetic and epigenetic analysis. It provides potential therapeutic strategies to induce tumor cell death and enhance immune responses in patients by targeting oncogenic proteins and immunosuppressive pathways.

**Problem Solved:** The invention addresses the challenges posed by T-cell lymphomas related to the oncogenic activity of the NPM/ALK fusion protein and its effects on tumor suppressor mechanisms, as well as the role of immune evasion through PD-L1 expression. By providing methods to counteract these mechanisms, it aims to improve outcomes for patients suffering from these malignancies.","Anaplastic large cell lymphoma (ALCL) is characterized by chromosomal translocation resulting in the expression of the NPM/ALK oncoprotein. Dr. Wasik demonstrated that NPM/ALK positive cancer cells exhibit a selective loss of the tumor suppressor protein STAT5A, which normally inhibits NPM/ALK."
"University of Pennsylvania","Human Monoclonal Autoantibodies to ADAMTS13 and Uses Thereof","","","https://upenn.technologypublisher.com/technology/38313","Human anti-ADAMTS13 antibodies cloned from patients with acquired thrombotic thromobocytopenia purpura (TTP) for use in targeted therapies, and generation of animal models that recapitulate pathologic features of TPP.Technology Overview:Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening blood disorder where blood clots form throughout the body to block the flow of oxygen-rich blood to major organs.Acquired TTP is caused by the generation of autoantibodies to the ADAMTS13 metalloprotease enzyme to block its activity and cause inappropriate platelet clotting. First-line treatment involves plasmapheresis to lower autoantibody levels and replenish ADAMTS13 through transfusion of donor plasma. However, treatment is nonspecific, expensive, and not always effective. Additionally, the development of therapies has been limited by the lack of animal models specific to the human autoantibodies.Dr. Donald Siegel and colleagues have cloned and sequenced human monoclonal ADAMTS13 autoantibodies from patients with acquired TTP. They have identified the specific sequences that block ADAMTS13 function to cause TTP pathogenesis. Using these recombinant human ADAMTS13 autoantibody sequences, a novel TTP murine model has been generated that recapitulates key pathologic features, and new therapeutics, such as anti-idiotypic antibodies, are currently being developed for the targeted TTP treatment, which improves specificity over current treatment methods.Advantages:Provides an alternative improved, targeted and cheaper treatment for acquired TTPImproves animal models of TTP for more accurate testing of human therapeutic agentsApplications:Development of more effective, targeted therapies for TTP, such as anti-idiotypic agentsGeneration of improved animal models of TTP that permits testing of therapeutics targeting human antibody/ADAMTS13 interactionStage of Development:Human anti-ADAMTS13 antibodies have been sequenced and binding sites identifiedPathogenicity of ADAMTS13 autoantibodies established in an animal modelCurrently developing humanized antibodies from anti-idiotypic antibodiesIn vivo testing, humanized TRMIntellectual Property:US11,597,778Reference Media:Ostertag et al.Transfusion, 2016, 56(7) - 1763.Ostertag et al.Transfusion, 2016, 56(7) - 1775.Desired Partnerships:LicenseCo-developmentCase ID:15-7389-tpNCSWeb Published:1/28/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38313","**Summary:** Human monoclonal autoantibodies to ADAMTS13 have been cloned from patients suffering from acquired thrombotic thrombocytopenic purpura (TTP). This technology enables the identification of specific sequences that inhibit the function of the ADAMTS13 metalloprotease enzyme, leading to the pathogenesis of TTP. Additionally, a novel murine model has been developed based on these recombinant antibodies, recapitulating key pathological features of TTP.

**Applications:** The autoantibodies can be used in the development of targeted therapies for TTP, potentially improving treatment efficacy and patient outcomes. Furthermore, the newly created murine model can aid in preclinical studies to evaluate therapeutic strategies and the pathophysiology of TTP.

**Problem Solved:** This technology addresses the limitations of current TTP treatments, which are often nonspecific, costly, and may not effectively lower autoantibody levels. By providing a means to create targeted therapies, it offers improved specificity in treatment, which may lead to more effective management of the disorder and better patient care.","Human anti-ADAMTS13 antibodies, cloned from patients with acquired thrombotic thrombocytopenic purpura (TTP), are utilized in targeted therapies and the development of animal models that mimic the pathologic features of TTP. Acquired TTP is characterized by the formation of autoantibodies against the ADAMTS13 metalloprotease, leading to life-threatening blood clotting throughout the body."
"University of Pennsylvania","A language assessment to determine healthy (salutogenic) empathy","","","https://upenn.technologypublisher.com/technology/38477","Researchers at Penn have developed a natural-language and social media- language based evaluation tool set for natural language (including social media posts) that provides a salutogenic empathy scoreProblem:Empathy refers to a variety of states and traits involving a reaction to another‚Äôs suffering. Empathy is a highly sought after trait in certain domains. Yet empathy is poorly understood which has led to inconsistent ways of measuring it. Research suggests that there are different types of empathy, which have varying impacts on our well-being and helping behavior. Salutogenic empathy; i.e. ‚Äúputting oneself into the person‚Äôs shoes‚Äù -while avoiding an emotional reaction - has been shown to be adaptive, health-promoting, and more conducive to effective helping behavior. Measuring this empathy in individuals would be valuable.Solution:Adults use social media regularly. Sites such as Facebook and Twitter consist of large informal networks of users who provide updates on: their thoughts, opinions, feelings, activities, and interactions with other people. We use these databases of autobiographical and longitudinal data to gain insights into the personality, thoughts and feelings, action tendencies, and physical and psychological health outcomes of users. Social media-based models have the advantage of basing predictions and insights on years of autobiographical data, while still remaining based in the ground truth of a self-reported assessment.The World Well Being Project has created a lexicon that analyzes social media posts to provide a near real-time analysis of the salutogenic empathy of a social media user. The use of an unobtrusive tool allows for passive monitoring of large population sizes that does not face the bias associated with traditional psychological questionnaires.Advantages:Near real-time analysisUses existing social media information streamsDoes not require direct interaction with analysis groupCan be narrowly defined to analyze a groupCould be utilized to monitor salutogenic empathy over time.Applications:Evaluating the salutogenic empathy of the general or a defined population (a team, workforce, event participants, etc‚Ä¶)Stage of Development:The salutogenic empathy lexicon has been developed and is ready for use.Intellectual Property:Copyright, Trade SecretReference Media:Body of publications available through theWorld Well Being ProjectDesired Partnerships:LicensingCo-developmentResearch useCase ID:17-8269-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38477","**Summary:** Researchers at Penn have created a tool for evaluating natural language, including social media content, to assess salutogenic empathy. Empathy encompasses a range of emotional responses to others' suffering, but different types of empathy can have varied effects on well-being and assisting others. Salutogenic empathy, which allows individuals to empathize without experiencing emotional distress, has been associated with better health and more effective helping behaviors. This empathy scoring tool aims to provide a more consistent and comprehensive measure of empathy.

**Applications:** The evaluation tool can be utilized in various settings, including healthcare, education, and social work, to assess and enhance the empathetic skills of individuals. It can inform targeted interventions and training programs aimed at improving empathetic responses that promote well-being. Additionally, the tool can aid in research on empathy's role in community interactions and support networks.

**Problem Solved:** The tool addresses the challenge of inconsistently measuring empathy, a trait that is crucial in many domains but poorly understood. By utilizing social media language and self-reported assessments, it offers a reliable way to gauge salutogenic empathy in a nuanced manner, thereby contributing to enhanced understanding and practical applications of empathy in social contexts.","Researchers at Penn have created a natural-language evaluation tool to measure empathy, including analysis of social media language, that provides a salutogenic empathy score. This tool addresses the inconsistencies in measuring empathy, which is a trait valuable in various fields."
"University of Pennsylvania","TNF-R1 Selective Allosteric Inhibitors","","","https://upenn.technologypublisher.com/technology/54475","Tumor Necrosis Factor (TNF) is a potent pro-inflammatory cytokine whose dysregulation has been found to cause rheumatoid arthritis, stroke and a broad range of inflammatory disease. Inhibition of TNF receptors has become an effective means to ameliorate inflammatory disease, however, pan TNF-R antagonists increase risk of infection and malignancy. Using a novel structure based design approach to identify small molecule compounds that bind to an allosteric site on TNF-R1, thus inhibiting binding of TNF-alpha to TNF-R1 and reducing activation of the TNF-alpha/TNF-R1 signaling pathway, the inventors have uncovered a new class of compounds that are effective at inhibiting the pathologic side-effects of TNF signaling while preserving the patient's ability to mount an immune response against pathogens. Lead candidates are potent, highly specific and have been demonstrated to ameliorate arthritis in vivo.Intellectual Property:US8,765,810US9,096,607US8,318,699EPO1845970EPO2305246EPO2298295Canada2596355Australia2006210778Reference Media:Murali, R. et al.PNAS. 2005 Aug 2; 102(31): 10970Case ID:R3651-tpNCDWeb Published:6/21/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54475","**Summary:** Tumor Necrosis Factor (TNF) is a significant pro-inflammatory cytokine linked to several inflammatory diseases such as rheumatoid arthritis and stroke. Current treatment approaches that involve inhibiting TNF receptors can lead to increased risks of infection and malignancy. The inventors have developed a new class of selective allosteric inhibitors that specifically target an allosteric site on TNF-R1, thereby blocking TNF-alpha from binding to the receptor and subsequently reducing the harmful effects associated with TNF signaling. These compounds enable the immune system to retain its ability to fight infections while effectively mitigating the detrimental consequences of TNF signaling. The lead candidates have shown high potency and specificity, and have demonstrated efficacy in alleviating arthritis in animal models.

**Applications:** The allosteric inhibitors can be utilized in the treatment of inflammatory diseases, particularly rheumatoid arthritis, and potentially other conditions associated with dysregulated TNF signaling. They may also have applications in reducing the risks of infections and malignancy commonly seen with traditional pan TNF-R antagonists.

**Problem Solved:** The technology addresses the challenge of balancing effective anti-inflammatory treatment with the risk of serious side effects such as increased susceptibility to infections and malignancy that arise from pan TNF-R antagonism. By selectively inhibiting TNF-R1, the approach preserves immune system function while providing a targeted therapeutic effect against inflammatory diseases.","Tumor Necrosis Factor (TNF) is a pro-inflammatory cytokine linked to several inflammatory diseases, and inhibiting TNF receptors can mitigate these conditions. However, pan TNF-R antagonists may raise the risk of infection and cancer, prompting the exploration of selective allosteric inhibitors that target an allosteric site on TNF-R1."
"University of Pennsylvania","Adhesive hydrogels for wet applications (Non-catechol based)","","","https://upenn.technologypublisher.com/technology/38481","Biocompatible hydrogels exhibit robust adhesion in wet conditions to substrates with wide range of chemistries and moduli.Technology Overview:Recent interest in developing wet adhesion for biomedical and environmental applications have leveraged catechol-functionalized materials to achieve these results. However, catechol moieties can produce cytotoxic concentrations of reactive oxygen species which limit their biocompatibility. Existing alternatives to catechol-based systems require harsh conditions, heat, light exposure, or non-physiological pH to function.Researchers at the University of Pennsylvania‚Äôs Department of Chemical Engineering have developed an adhesive hydrogels material that adheres to substrates underwater by applying slight pressure for less than one minute. Adhesion is insensitive to ionic strength of solutions or temperature. The result is a wet adhesive for use in biological or environmental applications that does not require exotic, harmful, toxic, or a specialty surface chemistry to achieve adhesion.Advantages:BiocompatibleCan bind between surfaces of differing chemical and mechanical properties (i.e., between organic and plastic materials, or between hard and soft surfaces)High strength adhesive propertiesNot ToxicNo Harsh or Non-Biologically conducing curing element/environmentApplications:Adhering tissue to medical devices/implantsAttaching materials together in wet environmentsAdhesion to porcine liver. Demonstration of adherence to: Polystyrene, PDMS, and Non-Adhesive HydrogelsStage of Development:Proof of ConceptIntellectual Property:PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:17-8315-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38481","**Summary:** Biocompatible hydrogels have been developed that exhibit strong adhesion under wet conditions to a variety of substrates with differing chemical compositions and mechanical properties. This technology addresses the limitations of existing catechol-based materials, which can produce toxic reactive oxygen species, and avoids the need for harsh curing conditions. The adhesive properties are activated by applying slight pressure for less than one minute, making it functional regardless of ionic strength or temperature.

**Applications:** The adhesive hydrogels can be used for adhering tissue to medical devices and implants, attaching materials in wet environments, and demonstrating adhesion to biological tissues such as porcine liver and synthetic materials like polystyrene and PDM.

**Problem Solved:** This technology provides a biocompatible adhesive solution that maintains strong adhesion in wet conditions without the toxic effects associated with traditional catechol-based adhesives or the need for demanding application conditions, enhancing safety and versatility in biomedical and environmental applications.","Biocompatible hydrogels demonstrate strong adhesion in wet conditions to various substrates, addressing recent needs in biomedical and environmental applications. While catechol-functionalized materials have been popular for wet adhesion, their use raises concerns about cytotoxicity, prompting a search for non-catechol alternatives that do not require harsh conditions."
"University of Pennsylvania","Therapeutic approach for treatment of Duchenne Muscular Dystrophy","","","https://upenn.technologypublisher.com/technology/38315","Technology Overview:Duchenne Muscular Dystrophy (DMD) is the most common X-linked fatal neuromuscular disorder, affecting approximately 1 in every 3500 male births. It is characterized by progressive degeneration of skeletal and cardiac muscle due to a defective form of the gene dystrophin. There is currently no cure for DMD and the available treatment options have limited ability to address the underlying cause of DMD: dystrophin absence or dysfunction.Dr. Khurana at the University of Pennsylvania has been interested in targeting utrophin, the homolog of dystrophin, as an approach for treating DMD. Previous work has demonstrated that increasing utrophin expression can compensate for the lack of functional dystrophin in DMD, resulting in improved muscular integrity and strength.In collaboration with Dr. Wilton at Murdoch University, the researchers have developed a strategy for increasing utrophin expression, which has been validated in a mouse model of DMD. The approach targets let7c, a microRNA that normally suppresses expression of utrophin. Through the use of site blocking oligonucleotides, the interaction of let7c with utrophin is disrupted, resulting in the elevation of utrophin expression and rescue of the DMD phenotype. These findings suggest a potential therapeutic approach for DMD.Advantages:Efficacy demonstrated in mouse modelNo observed toxicityApplications:Treatment of DMDStage of Development:Studies completed in mouse model of DMD (mdx mouse)Intellectual Property:US11,028,389Case ID:15-7411-tpNCSWeb Published:1/28/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38315","**Summary:** The technology addresses Duchenne Muscular Dystrophy (DMD), a severe neuromuscular disorder caused by the absence or dysfunction of dystrophin, affecting 1 in every 3500 male births. Current treatments do not target the underlying cause of the disease, leading researchers, including Dr. Khurana from the University of Pennsylvania, to explore the potential of increasing utrophin expression as an alternative. Utrophin is a homolog of dystrophin, and previous research indicated that elevated levels of utrophin could compensate for dystrophin deficiency, improving muscle integrity and strength. The collaboration with Dr. Wilton resulted in a validated strategy that disrupts the activity of the microRNA let7c, which normally suppresses utrophin expression. By using site blocking oligonucleotides, the interaction between let7c and utrophin is inhibited, leading to increased utrophin levels and amelioration of the DMD phenotype in mouse models.

**Applications:** The primary application of this technology is the treatment of Duchenne Muscular Dystrophy.

**Problem Solved:** This therapeutic approach seeks to address the fundamental issue of dystrophin absence or dysfunction by increasing utrophin expression, thereby improving muscle function and integrity in patients with DMD.","Duchenne Muscular Dystrophy (DMD) is an X-linked neuromuscular disorder affecting approximately 1 in every 3500 male births, characterized by progressive muscle degeneration due to a defective dystrophin gene. There is currently no cure for DMD, and existing treatments have limited effectiveness in addressing the absence or dysfunction of dystrophin."
"University of Pennsylvania","Design of Canine Antibodies for Targeted Therapeutics","","","https://upenn.technologypublisher.com/technology/39138","Methods for generating single chain variable region Fragments (scFvs) for use as targeting agents for the treatment of infectious, inflammatory, and neoplastic diseases in dogs.Problem:Cancer is the leading cause of death in our current canine pet population. Previous studies have found that 45% of dogs aged 10 years or older and 23% of dogs of any age die from cancer. The gold standard of veterinary cancer therapy is systemic administration of chemotherapeutic agents that inhibit cell division and induce cell death. These agents are not tumor-specific and frequently cause adverse side effects which limit the dose that can be given and potentially the therapeutic efficacy.Solution:Dr. Nicola Mason has devised a patented method to generate and isolate canine scFvs for in vivo use as immune targeted therapeutics. These therapeutics could include, but are not limited to, those in the immune-oncology space including bi-specific antibodies, BITEs, Chimeric Antigen Receptors for use in T cells, targeted delivery agents for toxins and chemotherapeutics. Furthermore, the technology could also be utilized to generate neutralizing antibodies for infectious diseases such as parvovirus, distemper, and parainfluenza.This approach has the potential to revolutionize the $9.7 billion canine healthcare market (Wall Street Journal) as well as promote the use of a comparative One Health approach in dogs to accelerate human drug development and inform human clinical trial design.Applications:Tumor associated antigen targeting (Bi-specific antibodies, BITEs etc)Chimeric Antigen Receptor T cells (CAR T cells)Targeted Drug DeliveryDiagnostic imaging studiesToxin neutralizationBacterial and viral targetingIdentification of allo-antigensStage of Development:Ready for useIntellectual Property:US8,722,587Reference Media:Braganza A., et al.Vet Immunol Immunopathol.2011 Jan; 139(1): 27Desired Partnerships:LicenseCase ID:U4763-tpNCSWeb Published:3/11/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39138","**Summary:** Methods have been developed to generate single chain variable region fragments (scFvs) specifically for use as targeting agents in treating infectious, inflammatory, and neoplastic diseases in dogs. Cancer is a significant issue among dogs, with a notable percentage of older dogs succumbing to the disease. Traditional cancer therapies are associated with systemic side effects and lack tumor specificity, leading to reduced efficacy. The patented method introduced by Dr. Nicola Mason allows for the creation of canine scFvs that serve as immune-targeted therapeutics, potentially including bi-specific antibodies and chimeric antigen receptors. These therapeutics also extend to generating neutralizing antibodies for infectious diseases.

**Applications:** The technology can be applied in the treatment of various canine cancers, using targeted therapies to improve treatment outcomes while minimizing adverse effects. It has potential applications in immuno-oncology, delivering targeted therapies for infectious diseases such as parvovirus, distemper, and parainfluenza.

**Problem Solved:** This technology addresses the urgent need for more effective cancer treatments in dogs that minimize side effects and improve therapeutic outcomes, responding to the critically high rates of cancer-related mortality in the canine population. By providing targeted therapeutics, it also aims to enhance the efficacy of treatments and contribute to the overall health of dogs.","The study outlines methods for generating single chain variable region fragments (scFvs) designed as targeting agents to treat infectious, inflammatory, and neoplastic diseases in dogs. It highlights that cancer is the leading cause of death among dogs, with a significant percentage of both older and younger dogs affected."
"University of Pennsylvania","2D metal carbides and nitrides (MXenes) electrodes","","","https://upenn.technologypublisher.com/technology/54487","Problem:Current implantable devices for recording and stimulating electrical activity in the body are fabricated with metal based components. The metal components pose issues for long term implantation and functionality, including scarring, inflammation, degradation and fatigue. Furthermore, the physical properties of metals are typically inadequate to achieve good quality recording and stimulation performance.Solution:MXene‚Äôs offer a unique combination of electrical conductivity, strength, flexibility and volumetric capacitance (300-400 F/cm3). Furthermore, by varying processing parameters, the MXenes are >90% transparent. The electrochemical impedance of MXene neural sensors measured at 1 kHz is 4 times smaller than that of gold electrodes of the same size. When used for recording of neural signal in vivo, this reduction in impedance significantly suppresses noise from electrical interference (> 400-fold reduction compared to gold electrodes) and from electronic noise in the electrode itself (50% less than gold).The MXene ECoG electrodes were tested in vivo in an anesthetized rat, where they were placed on the exposed cortex, showing significantly reduced baseline noise compared to gold electrodes of the same size. Excitingly, penetrating MXene depth electrodes recorded unit activity (individual neuron spiking activity), which was not detected on the gold contacts. (Fig.1A & 1B).Advantages:Significant suppression of electrical interference and electronic noise in the electrode.Better electrical conductivity, strength, flexibility and volumetric capacitance.Better optical properties than metals including tunable optical transparency (>90 %)Unique ability to record single unit neuron activity.Applications:$1,054 million (2015) Global Medical Electrodes Market, reaching $1,328 million by 2022Clinical applications in neurodegenerative disease; epilepsy and cardiovascular disorders including as Pacemaker electrodes (Cardiovascular), DBS electrodes (ie. Parkinson‚Äôs Disease), BMI electrodes, intracranial EEG electrodes, and penetrating intracortic electrode arrays.Transparent biological sensors for imaging and intracellular recordings.Stage of Development:Fabrication of two types of electrodes for measuring ECoG and individual neuronsCharacterization of electrochemical impedanceEnhanced performance during in vivo testingIntellectual Property:US11,925,466Reference Media:Anasori, Be. et al.;Nature Reviews Materials, 2: 16098Case ID:17-8285-tpNCSWeb Published:6/24/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54487","**Summary:** The technology addresses limitations associated with conventional metal components in implantable devices used for recording and stimulating electrical activity in the body. Metal components lead to complications such as scarring, inflammation, degradation, and inadequate performance. In contrast, MXenes present advantages such as high electrical conductivity, strength, flexibility, and excellent volumetric capacitance. Additionally, they exhibit greater than 90% transparency when processing parameters are altered. In vivo testing demonstrated that MXene neural sensors have a much lower electrochemical impedance compared to gold electrodes, leading to significant noise reduction during neural signal recording.

**Applications:** MXenes can be used in neural sensor technologies and advanced implantable devices, particularly for in vivo applications where precision in recording neural signals is critical. Their unique properties make them suitable for both cortical and penetrating electrode designs.

**Problem Solved:** The use of MXenes solves the issues related to long-term durability and functionality of metal-based electrodes by reducing scarring and inflammation, while also improving the quality of neural signal recording through minimized electrical interference and electronic noise.","Current implantable devices using metal components face challenges such as scarring, inflammation, degradation, and inadequate electrical performance. MXenes provide a promising alternative due to their electrical conductivity and strength, potentially improving long-term functionality in these devices."
"University of Pennsylvania","Heart disease diagnostic and prognostic","","","https://upenn.technologypublisher.com/technology/39352","Indicators for treatment of bicuspid aortic valve and aortopathies.Problem:Bicupsid aortic valve (BAV) is the most common congenital heart defect in the US, with an approximate incidence of 1 in 50 births. BAV frequently leads to valve dysfunction and is associated with serious adverse aortic events such as aortic aneurysm, dissection and rupture. The primary surgical intervention for BAV is aortic valve replacement.The clinical parameters (aortic diameter, expansion rate, ratio of aortic area to body weight) currently used to determine whether surgical intervention is needed for patients with BAV are imperfect as many BAV patients do not meet these criteria, but may go on to develop a serious aortic event before surgical intervention is indicated. There is a need for the development of alternative diagnostic methods and indicators for surgical intervention for BAV patients in order to reduce the risk of patients developing life-threatening cardiac events.Solution:Research conducted by Drs. Giovanni Ferrari and Emanuela Branchetti demonstrates that plasma levels of the soluble receptor for advanced glycation end products (sRAGE) may be a novel biomarker for BAV and related aortopathies. Elevated sRAGE was found to be highly associated with both BAV and aortopathies. Importantly, sRAGE elevation was independent of aortic diameter and the ratio of aortic area to body weight, which are two clinical parameters currently used to assess whether a patient should undergo surgery. This work suggests that circulating plasma sRAGE levels could be used in the diagnosis of BAV and aortopathies and to identify patients needing surgical intervention.Advantages:Novel diagnostic parameter for BAV and aortopathiesSimple blood test measurementApplications:Diagnosis of BAV and associated aortopathiesIndicator for surgical intervention for BAV and associated aortopathiesStage of Development:Validation complete in surgical cohort of 135 patientsIntellectual Property:US11,668,721PCTActiveReference Media:Branchetti, E et al.;Arterioscler Thromb Vasc Biol, 2014 Oct; 34(10): 2349.Desired Partnerships:LicenseCo-developmentCase ID:Z6510-tpNCSWeb Published:3/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39352","**Summary:** Research indicates that elevated levels of the soluble receptor for advanced glycation end products (sRAGE) can serve as a novel biomarker for patients with bicuspid aortic valve (BAV) and related aortopathies. This discovery is significant as traditional clinical parameters, such as aortic diameter and the ratio of aortic area to body weight, often fail to accurately predict serious adverse events in BAV patients. Elevated sRAGE levels were found to be highly associated with both BAV and aortopathies, providing a potentially more reliable indicator for assessing the need for surgical interventions.

**Applications:** The findings could lead to improved diagnostic techniques for identifying patients with BAV and related aortopathies, thereby facilitating timely surgical interventions and potentially preventing serious complications like aortic aneurysm, dissection, and rupture.

**Problem Solved:** The technology addresses the inadequacy of current clinical parameters used to determine surgical intervention in BAV patients, as many individuals may be at risk for life-threatening cardiac events despite not meeting established criteria for surgery. By introducing sRAGE as a biomarker, it enhances the ability to identify patients in need of timely medical intervention.","Bicuspid aortic valve (BAV) is the most prevalent congenital heart defect in the US, occurring in about 1 in 50 births, and often results in valve dysfunction and severe aortic complications. The main surgical treatment for BAV is aortic valve replacement, with critical clinical parameters including aortic diameter and expansion rate for assessment."
"University of Pennsylvania","Novel class of therapeutics for treatment of lupus and other autoimmune and inflammatory conditions","","","https://upenn.technologypublisher.com/technology/54465","First in class compounds inhibiting BRISC deubiquitinating enzymes for treatment of autoimmune diseases.Problem:Lupus is an autoimmune disease affecting approximately 5 million people worldwide. Lupus results in a hyperactive immune system and multisystem pathologic changes to joints, skin, kidneys, blood cells, and lungs. Immunosuppressive drugs are the current standard of care for lupus patients, but have unfavorable side effects and limitations leaving a need for alternative treatment methods.Solution:A majority of individuals with lupus display elevated expression of type-1 interferon (IFN) inducible genes in circulating immune cells and peripheral tissues, which correlates with disease severity. Dr. Roger Greenberg has discovered that BRISC deubiquitinating enzymes play a critical role in IFN and other inflammatory cytokine responses and showed that BRISC deficiency in mice reduces activation of immune cells and ameliorates lupus.Dr. Greenberg‚Äôs team includes a medicinal chemist, structural biologist, and molecular biologist. They have reported the structural basis of BRISC activation and developed the first high throughput screen for small molecule BRISC inhibitors. They have obtained several potent and specific lead BRISC inhibitors and are optimizing them using medicinal chemistry and rational drug design approaches. This novel class of therapeutics present potential utility in treatment of lupus as well as other autoimmune and inflammatory conditions driven by elevated cytokine responses.Advantages:First in class therapeuticsNumerous drug analogs undergoing further optimizationBRISC knockout and enzymatically inactive knock-in mouse modelsStructural biology of BRISC in active and inactive statesNovel high throughput screening technology for BRISC inhibitorsApplications:Treatment of lupus and other autoimmune and inflammatory diseasesStage of Development:Lead BRISC inhibitors with IC50~1.5ŒºMSeveral series of compound analogsIntellectual Property:PCT PendingReference Media:Zheng et al.Cell Rep, 5(1): 180-93, 2013Zeqiraj et al.Mol cell,59(6): 970-83, 2015.Desired Partnerships:LicenseCo-developmentCase ID:16-7774-tpNCSWeb Published:6/21/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54465","**Summary:** This technology focuses on a new class of compounds designed to inhibit BRISC deubiquitinating enzymes, which are pivotal in the inflammatory responses associated with lupus and potentially other autoimmune diseases. The discovery originated from the observation that individuals with lupus exhibit elevated levels of type-1 interferon-inducible genes, correlating with the severity of the disease. A significant finding is that the deficiency of BRISC in mice leads to reduced immune cell activation and alleviates lupus symptoms. The research team has successfully identified multiple lead inhibitors aimed at BRISC and is in the process of optimizing them through medicinal chemistry and rational drug design.

**Applications:** The primary application is in the treatment of lupus, an autoimmune disease, as well as in the management of other autoimmune and inflammatory conditions that are influenced by elevated inflammatory responses.

**Problem Solved:** Current treatments for lupus largely rely on immunosuppressive drugs, which often entail serious side effects and limitations. This novel therapeutic approach aims to provide a safer and more effective alternative by targeting specific mechanisms underlying the disease‚Äôs pathology, particularly through modulation of the immune response mediated by BRISC deubiquitinating enzymes.","First-in-class compounds targeting BRISC deubiquitinating enzymes offer a potential new therapeutic approach for treating autoimmune diseases, including lupus, which affects approximately 5 million people globally. Current standard treatments involve immunosuppressive drugs, which have significant side effects and limitations, highlighting the need for alternative therapies."
"University of Pennsylvania","Improved stress and nutrient response in plants via root hair regulation","","","https://upenn.technologypublisher.com/technology/38473","This technology is aimed at improving crop production in the era of global climate change and rising fertilizer costs.Problem:Feeding 7 Billion people is a global concern, and this problem continues to grow year-to-year. A large problem for the agricultural industry is finding a way to grow food on less arable land, while also decreasing expensive inputs (water, nutrients, chemicals, etc‚Ä¶), while still maintaining competitive yields. By identifying plants that can grow in stressed environments as effectively as normal conditions, we can begin to address this problem. A key driver for this will be plants that can more effectively take in water and nutrients, which will allow them to grow successfully in more challenging environments.Solution:Research within Professor Gregory‚Äôs laboratory in the Biology Department at the University of Pennsylvania has led to the discovery of gene regulation opportunities for improving crop plant traits in response to water, heat, and nutrient-stressed situations. The over expression of a particular gene causes an increase in surface area of the root by increasing the number of root hairs. Plants regulate the ratio of root hair to non-hair cells depending on environmental signals.Studies have shown that increasing the root hair population increases the uptake of nutrients (e.g. phosphate) and water which enhances the plants ability to survive in stress environments; such as heat, drought, or nutrient deficient situations.Plants grown under nutrient-poor conditions develop a higher density and longer hair cells. Roots can only absorb inorganic phosphates, present at very low concentrations in soil. This is why phosphate starvation is one of the most common nutrient stresses in plants, and is characterized by increased root hair length, increased root hair density, increased lateral root production branching away from primary roots, and upregulated secretion of acid phosphatases to produce inorganic phosphate from organic phosphate that can be subsequently absorbed by the plant. Testing has shown that overexpression of the targeted gene improves plant tolerance to phosphate starvation through a cascade of processes that results in increased phosphate uptake through changes in the root system.Advantages:Could be designed to promote optimal nutrient uptake in less arable situations or under stress of heat, nutrient deprivation, and/or droughtCould increase growth and development in plants based on increase in efficiency of absorption of nutrientsApplications:Develop crops that are readily able to survive in stressed situations or with the use of fewer nutrient inputsIntellectual Property:US10,526,614Reference MediaFoley, S et al.;Dev Cell 2017 Apr 24 41(2): 204.Penn TodayDesired Partnerships:LicensingCo-developmentCase ID:17-8052-tpNCS-2Web Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38473","**Summary:** This technology focuses on enhancing crop production amid global climate challenges and rising fertilizer costs by identifying plants capable of thriving in stressed environments. It leverages the understanding that plants can optimize their root structures in response to environmental cues, particularly by increasing the number of root hairs to improve water and nutrient absorption. Research has revealed opportunities for gene regulation to promote these beneficial traits, allowing plants to perform better under conditions of heat, drought, and nutrient deficiency.

**Applications:** The technology can be applied in agriculture to develop genetically modified or selected crop varieties that exhibit improved resilience to climate stresses, contributing to more efficient food production on limited arable land. It may also reduce dependency on chemical inputs, ultimately lowering costs associated with fertilizers, water, and other agricultural necessities while maintaining competitive yields.

**Problem Solved:** The technology addresses the urgent challenge of feeding a growing global population despite decreasing available arable land and increasing farming costs. By enabling crops to better endure environmental stress, it aims to sustain agricultural productivity in the face of climate change and resource scarcity.","The technology focuses on enhancing crop production by optimizing root hair regulation to improve plants' responses to stress and nutrient availability. This approach addresses the challenge of feeding a growing global population by enabling food production on less arable land while reducing reliance on costly agricultural inputs."
"University of Pennsylvania","Topical Treatment for Autoimmune Disorders","","","https://upenn.technologypublisher.com/technology/54112","Treatment method for autoimmune diseases such as diabetes, multiple sclerosis, atherosclerosis, and rheumatoid arthritis using skin application of a vitamin D analog where topical treatment leads to systemic immunoregulation.Problem:Immunomodulatory drugs are typically administered systemically and often lead to severe side effects. Moreover, intravenous injections of such drugs are burdensome for patients and drive additional cost and risks. Whenever treatment involves biological compounds it further increases the cost and requires special storage, shipping, and handling.Solution:Many inflammatory diseases are mediated by inappropriately activated T cells. Regulatory T cells (Tregs), on the other hand, limit such inappropriate T cell activation, and prevent inflammatory diseases. Dr. Kambayashi has discovered that topical administration of a vitamin D3 analog MC903 leads to the release of keratinocyte-derived thymic stromal lymphopoietin (TSLP) by skin cells into circulation, which then systemically increases the number of Tregs. He further has shown that this Treg expansion leads to attenuation of inflammatory diseases such as type I and type II diabetes, multiple sclerosis, atherosclerosis, and rheumatoid arthritis in mouse models. Thus use of transdermal patch delivering MC903 provides a promising approach for treatment autoimmune and inflammatory diseases.Advantages:Topical treatment producing systemic effectMC903 has limited systemic absorption and half-life preventing systemic toxicitiesMC903 is used for psoriasis treatment (expired patent, available generics)Application:Patch or other method of transdermal deliveryStage of Development:Mouse models of type I diabetes (NOD mouse)Multiple sclerosis (EAE mouse model)Atherosclerosis (ApoE KO mouse model)Rheumatoid arthritis (serum-induced arthritis)Intellectual Property:US10,391,107US10,980,820US11,752,159Reference Media:Leichner, TM et al;J Autoimmun, 2017 May, 79: 39.Desired Partnerships:LicenseCo-developmentCase ID:15-7433-tpNCSWeb Published:5/3/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54112","**Summary:** Topical administration of a vitamin D3 analog, MC903, has been shown to induce systemic immunoregulation through the release of thymic stromal lymphopoietin (TSLP) by skin cells. This mechanism promotes the expansion of regulatory T cells (Tregs), which are crucial in preventing inappropriate T cell activation and associated inflammatory diseases. Initial studies indicate that this approach can effectively attenuate autoimmune disorders such as type I and type II diabetes, multiple sclerosis, atherosclerosis, and rheumatoid arthritis in mouse models. The treatment is delivered through a transdermal patch, offering a non-invasive alternative to traditional systemic immunomodulatory therapies.

**Applications:** This treatment method could be applicable for managing several autoimmune and inflammatory diseases, specifically type I and type II diabetes, multiple sclerosis, atherosclerosis, and rheumatoid arthritis, thereby enhancing patient compliance and safety through topical administration.

**Problem Solved:** The technology addresses the challenges associated with traditional immunomodulatory drugs, which are often administered systemically and can cause severe side effects. It also mitigates the burdens of intravenous drug delivery, reducing costs and complexity related to storage and handling, particularly for biological compounds.","Topical application of a vitamin D analog is being explored as a treatment for autoimmune disorders like diabetes, multiple sclerosis, atherosclerosis, and rheumatoid arthritis, leading to systemic immunoregulation. This method could reduce the severe side effects associated with systemic immunomodulatory drugs and alleviate the burdens of intravenous administration for patients."
"University of Pennsylvania","Image processing algorithm that enables accurate feature tracking on rapidly moving objects","","","https://upenn.technologypublisher.com/technology/38471","Engineers at the University of Pennsylvania have developed an algorithm that works in conjunction with high speed cameras to enable feature tracking on extremely fast moving objects. This innovative algorithm could enable rapid object tracking, inform robotic positioning, and improve image stabilization.Problem:The speed with which standard cameras can capture motion is inherently limited by their collection frame rates. As a result, novel ‚Äúevent-based‚Äù cameras that can take images with a very high time resolution (1 micro-second) have recently been developed. These cameras have the ability to capture the movement of very fast-moving objects.However, current methods to process the videos taken by the ‚Äúevent-based‚Äù cameras are unable to accurately track features or objects captured in the videos. Thus, there is a need for an algorithm that can track the movement of fast-moving features and objects recorded in the videos of ‚Äúevent-based‚Äù cameras.Solution:To address this gap in technology, members of the Daniilidis Lab developed an image processing algorithm that is capable of tracking features on extremely fast moving objects imaged by the ‚Äúevent-based‚Äù cameras. Their algorithm relies upon probabilistic data associations to accurately track features over time. In addition to enabling rapid object tracking with relevant uses in automation and military defense, this technology could be used to inform robotic positioning and improve image stabilization.Advantages:Enables feature tracking on extremely fast-moving objectsCan be used in conjunction with high speed ‚Äúevent-based‚Äù camerasMore accurate than standard feature-tracking methods used with frame-based camerasApplications:Fast object tracking (with uses in automation and military defense)Image stabilizationRobotic positioning3D image reconstructionStage of Development:The algorithm has been developed and validated.Intellectual Property:US11,138,742Reference Media:2017 IEEE International Conference on Robotics and Automation (ICRA):Event-based Feature Tracking with Probabilistic Data AssociationThe code for this research can be foundhereDesired Partnerships:LicenseCo-developmentCase ID:17-8049-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38471","**Summary:** Engineers at the University of Pennsylvania have created an image processing algorithm that facilitates accurate tracking of features on extremely fast-moving objects when used with high-speed cameras. This algorithm addresses the limitations of standard cameras, which struggle with slower frame rates and are inadequate for videos captured by innovative event-based cameras that achieve a time resolution of 1 micro-second. The algorithm employs probabilistic data associations to effectively monitor these rapid movements.

**Applications:** The technology has diverse applications, including rapid object tracking in automated systems, robotic positioning, and enhancing image stabilization. It may also have potential usage in military defense contexts.

**Problem Solved:** This technology resolves the challenge of accurately tracking features in videos from event-based cameras, which conventional processing methods fail to do due to the high speed of the moving objects captured.","Engineers at the University of Pennsylvania have developed an algorithm that works with high-speed cameras to enable accurate feature tracking on rapidly moving objects. This algorithm could enhance rapid object tracking, inform robotic positioning, and improve image stabilization."
"University of Pennsylvania","Robotics and sensing for precision agriculture","","","https://upenn.technologypublisher.com/technology/38304","Problem:Farmers face a number of challenges that reduce their yields. Plant diseases, water stress, and other conditions result in fewer crops brought to market, ultimately leading to economic losses. Many of these conditions are detected today with the human eye, but regularly surveying thousands of acres with human scouts is impractical and uneconomical.Solution:Researchers at the University of Pennsylvania have developed robotic systems for precision agriculture, providing detailed crop monitoring on a large scale. Unmanned Aerial Vehicles (UAVs) can travel in swarms across a wide area, quickly surveying an entire field or orchard. These vehicles are equipped with a custom suite of sensors that can perform functions such as fruit counting, disease detection, thermal stress mapping, and other intelligence gathering functions. Providing this data allows for more efficient use of resources, early intervention to stop the spread of plant diseases, and improved crop yields.Advantages:Regular surveying over wide areasPlant-specific or tree-specific intelligenceApplications:Fruit countingDisease detectionHeat stress mappingYield estimationStage of Development:Prototypes demonstrated in the field for various cropsIntellectual Property:US10,395,110Reference Media:Das, J et al.2015 IEEE International Conference on Automation Science and Engineering (CASE), 2015: 462.Sarkar, SK et al.2016 IEEE International Conference on Robotics and Automation (ICRA), 2016: 5143.Desired Partnerships:License or Co-DevelopmentCase ID:15-7280-tpNCSWeb Published:1/28/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38304","**Summary:** Researchers at the University of Pennsylvania have developed robotic systems aimed at enhancing precision agriculture. These systems utilize unmanned aerial vehicles (UAVs) equipped with a variety of sensors to monitor crops over large areas, enabling efficient detection of issues such as plant diseases, water stress, and yield estimates. By providing actionable data, these robots facilitate early intervention and optimal resource use, which enhances overall crop yield.

**Applications:** The technology is applicable for fruit counting, disease detection, heat stress mapping, and yield estimation, thus offering comprehensive monitoring capabilities across various types of crops.

**Problem Solved:** This technology addresses the challenges faced by farmers, such as the impracticality of manually surveying thousands of acres, which can lead to unnoticed plant diseases and resource misallocation, ultimately resulting in reduced crop yields and economic losses.","Farmers face challenges such as plant diseases and water stress that reduce crop yields and lead to economic losses, making human scouting impractical for large areas. Researchers at the University of Pennsylvania have developed robotic systems for precision agriculture to enable detailed crop monitoring."
"University of Pennsylvania","High-performance ceramic anodes for solid oxide fuel cells","","","https://upenn.technologypublisher.com/technology/29861","Problem:Solid Oxide Fuel Cells (SOFCs) generate electricity by oxidizing hydrocarbon fuels at high temperatures. Most SOFCs have anodes made from cermets (ceramic-metal composites), usually mixtures of nickel and ceramics such as yttria-stabilized zirconia (YSZ). However, these anodes perform poorly with fuels that contain sulfur, such as gasoline, diesel, and jet fuel. Other metallic anodes have poor thermal stability or do not tolerate oxidation well. Anodes with improved performance would make it easier to use SOFCs with commonly-available commercial fuels.Solution:Researchers at the University of Pennsylvania have developed high-performance SOFC ceramic anodes with improved electrocatalytic activity and redox stability for use with hydrocarbon fuels. These anodes provide high fuel efficiency and high cell power density at operating temperatures less than 800C. This design features a thin functional layer and a thick conduction layer, allowing materials in each layer to be optimized independently. This produces a thermally stable and redox-stable anode due to the low metal content, compatible with sulfur-containing fuels.Advantages:Lower temperature operation (<800C)Thermal stability and redox stabilityCompatible with commercial fuels (gasoline, diesel, jet fuel).Stage of Development:Laboratory prototypeIntellectual Property:US8,021,799Reference Media:Gross, M et al.Electrochemical and Solid-State Letters 2007 Jan 19, 10(4): B65Desired Partnerships:LicenseCase ID:T4325-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29861","**Summary:** Researchers at the University of Pennsylvania have developed high-performance ceramic anodes for solid oxide fuel cells (SOFCs) that demonstrate improved electrocatalytic activity and redox stability, making them suitable for use with various hydrocarbon fuels, including those containing sulfur. These anodes operate efficiently at lower temperatures (below 800¬∞C) and consist of a thin functional layer combined with a thick conduction layer, allowing for independent optimization of the materials, leading to a thermally stable design with reduced metal content.

**Applications:** The developed anodes are intended for use in solid oxide fuel cells powered by commonly available commercial fuels like gasoline, diesel, and jet fuel, expanding the potential applications of SOFC technology in various energy systems.

**Problem Solved:** The innovation addresses the limitations of traditional cermet anodes, which perform poorly with sulfur-containing fuels and suffer from thermal instability and oxidation issues. By enhancing anode performance, this technology facilitates the use of solid oxide fuel cells with a wider range of hydrocarbon fuels.","Solid Oxide Fuel Cells (SOFCs) utilize cermet anodes, typically composed of nickel and yttria-stabilized zirconia (YSZ), but these anodes struggle with sulfur-containing fuels. Alternative metallic anodes face challenges with thermal stability and oxidation tolerance, highlighting the need for improved anode performance."
"University of Pennsylvania","Field effect transistors constructed with colloidal nanocrystals","","","https://upenn.technologypublisher.com/technology/25314","Problem:The next generation of electronics for mobile and wearable devices requires integrated circuits that are flexible and energy-efficient. Manufacturing processes to meet these needs must go beyond traditional fabrication capabilities and explore new materials, while providing a low-cost, scalable solution.Solution:Dr. Cherie Kagan‚Äôs research group at the University of Pennsylvania has fabricated the first transistors entirely made from colloidal nanocrystals (NCs). NCs are promising for electronics because their properties can be tuned by changing the particle size and surface chemistry.In this new work, NCs are deposited using an additive method to create a field effect transistor (FET). New processing steps have been developed to engineer metallic, semiconducting, and insulating NCs into stable and compatible integrated layers. This process eliminates high-temperature processing steps so the FET can be patterned on a flexible plastic substrate.Advantages:All-nanocrystal fabricationCompatible with flexible electronicsLow-voltage, high performance FETsScalable process for large-scale device fabricationStage of Development:Functional FET arrays fabricated using this processIntellectual Property:US10,593,755Desired Partnerships:LicenseCase ID:16-7875-tpNCSWeb Published:5/19/2017Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/25314","**Summary:** This technology describes a novel approach to fabricating field effect transistors (FETs) using colloidal nanocrystals (NCs), developed by Dr. Cherie Kagan‚Äôs research group at the University of Pennsylvania. The NCs allow for customizable electronic properties through adjustments in particle size and surface chemistry. The fabrication process involves an additive method to deposit NCs while circumventing high-temperature steps, enabling the transistors to be patterned on flexible plastic substrates. Functional FET arrays have been successfully created, demonstrating compatibility with flexible electronics and achieving low-voltage, high-performance characteristics.

**Applications:** This technology is particularly suited for the next generation of mobile and wearable electronic devices, which demand flexible, energy-efficient integrated circuits. The all-nanocrystal fabrication process presents opportunities for large-scale device manufacturing in various consumer electronics applications.

**Problem Solved:** The innovation addresses the challenges of traditional electronics manufacturing by providing a low-cost, scalable solution that meets the growing requirements for flexibility and energy efficiency in modern electronic devices.","Dr. Cherie Kagan‚Äôs research group at the University of Pennsylvania has developed the first transistors made entirely from colloidal nanocrystals, addressing the need for flexible and energy-efficient integrated circuits for mobile and wearable devices. This innovation represents a potential low-cost, scalable solution beyond traditional fabrication processes."
"University of Pennsylvania","Non-invasive detection of EGFRvIII mutations in Glioblastoma using MRI","","","https://upenn.technologypublisher.com/technology/24160","Technology Overview:GBM has a highly variable molecular, spatial and temporal fingerprint making analysis difficult. Current methods require tissue biopsies which fail to capture the heterogeneity of GBM, and damage healthy tissue.Epidermal growth factor receptor (EGFR), a cell growth regulator, is mutated and/or overexpressed in most intractable GBM cases. The EGFRvIII mutation is expressed only in cancer tissue. Detecting EGFRvIII is valuable for diagnosing and determining treatment options; however, invasive procedures are required and consistent follow-ups are nearly impossible. An accurate, reproducible, non-invasive method for diagnosis of GBM with EGFRvIII mutation is needed.The inventors have developed a non-invasive imaging marker of EGFRvIII by using dynamic susceptibility contrast MRI (DSC-MRI) and advanced statistical procedures, where the spatial and temporal location of EGFRvIII can be accurately determined by patients‚Äô MRI phenotype. This resolves the need of repeated biopsies and provides useful preoperative information on the mutation status as well as the means for potential continuous non-invasive monitoring of the mutation during and after therapy.Advantages:Useful in pre-operative evaluation, enabling decisions on aggressiveness of treatmentRobust, non-invasive and easy to preform testEnable post-operative monitoring of EGFRvIII expressing regions over timeApplication:A diagnostic tool for treatment and monitoring of GBMBlack hatch marks (right) indicate representative highest EGFRvIII expression.Stage of Development:Tested in a cohort of 142 patientsIntellectual Property:US11,107,217Reference Media:Bakas, S. et al.;Clin Cancer Res 2017 Aug,23(16): 4724.Bilello, M et al.;NeuroImage Clin 2016 Mar, 12: 34.Macyszyn, L et al.;Neuro-oncology 2016 March 18(3): 417Desired Partnerships:LicenseCo-developmentCase ID:14-7156-tpNCSWeb Published:2/22/2017Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/24160","**Summary:** The technology offers a non-invasive imaging marker for the detection of the EGFRvIII mutation in glioblastoma multiforme (GBM) using dynamic susceptibility contrast MRI (DSC-MRI) and advanced statistical analysis. Traditional methods that rely on tissue biopsies have limitations due to the heterogeneous nature of GBM and the potential for damage to healthy tissue. The EGFRvIII mutation, which is specific to cancer tissue and plays a crucial role in tumor growth, can be accurately identified through the patients' MRI phenotype. This innovative approach eliminates the need for repeated invasive procedures and enables the monitoring of mutation status preoperatively and throughout treatment.

**Applications:** The technology serves as a diagnostic tool for both the treatment and ongoing monitoring of glioblastoma, providing valuable information for pre-operative evaluations and aiding in decisions regarding treatment aggressiveness. Additionally, it facilitates post-operative tracking of regions expressing EGFRvIII over time.

**Problem Solved:** This technology addresses the challenges posed by the invasive nature of traditional biopsy methods, which do not capture the full heterogeneity of GBM and make consistent follow-up nearly impossible. By offering a non-invasive and reproducible alternative for the detection of EGFRvIII mutations, it enhances diagnostic accuracy and provides a continuous monitoring capability during and after therapy.","Current methods for analyzing glioblastoma (GBM) require tissue biopsies, which do not adequately capture the tumor's heterogeneity and can harm healthy tissue. The EGFRvIII mutation, specific to cancer tissue and prevalent in many difficult-to-treat GBM cases, is crucial for accurate diagnosis and treatment planning."
"University of Pennsylvania","An Iron Chelator for Protection Against Retinal Degeneration","","","https://upenn.technologypublisher.com/technology/39102","Problem:Degenerative diseases of the retina such as age-related macular degeneration (AMD) are the leading cause of vision loss and blindness. Approximately 120 million people worldwide suffer from AMD. There is a need to further understand the pathogenesis of retinal degeneration in order to develop new therapeutics to prevent and treat these diseases.Solution:Iron has been implicated in the pathogenesis of several degenerative diseases including those affecting the retina (e.g. AMD) and in neurodegenerative diseases such as Alzheimer‚Äôs Disease and Parkinson‚Äôs Disease. Previous studies have shown that iron-mediated oxidative stress can lead to cell death. Iron levels may also be elevated in disease states, such as the case for AMD where iron is elevated in the retina.Dr. Joshua Dunaief and researchers in his lab hypothesized that the iron chelator salicylaldehyde isonicotinoyl hydrazone (SIH) may be effective in preventing retinal degeneration. Studies in human retinal pigment epithelial (RPE) cells demonstrated that SIH was protective against cell death caused by stressors including hydrogen peroxide, staurosporine, and blue light. These findings suggest that SIH may have a therapeutic role in retinal degenerative diseases.Advantage:Small molecule for prevention of retinal degenerationApplications:Age-related macular degenerationRetinitis pigmentosaStargardt diseaseUsher syndromeStage of Development:Studies completed in human RPE cellsIntellectual Property:US8,501,789Reference Media:Lukinova et al.Invest Ophthalmol Vis Sci, 2009 Mar, 50(3): 1440Desired Partnerships:LicenseCo-developmentCase ID:S4273-tpNCSWeb Published:3/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39102","**Summary:** Research indicates that iron plays a significant role in the pathogenesis of retinal degeneration diseases such as age-related macular degeneration (AMD). Elevated iron levels have been associated with oxidative stress, leading to cell death in retinal tissues. Dr. Joshua Dunaief and his team explored the potential of an iron chelator, salicylaldehyde isonicotinoyl hydrazone (SIH), to mitigate these effects. Their studies on human retinal pigment epithelial (RPE) cells showed that SIH protected these cells from stress-induced death, suggesting its potential as a therapeutic agent in treating retinal degenerative conditions.

**Applications:** The technology is applicable in the treatment and prevention of age-related macular degeneration, retinitis pigmentosa, Stargardt disease, and Usher syndrome.

**Problem Solved:** This approach addresses the oxidative stress and cell death associated with elevated iron levels in retinal degenerative diseases, which are a significant cause of vision loss and blindness globally.","Degenerative diseases of the retina, particularly age-related macular degeneration (AMD), affect approximately 120 million people globally and are a leading cause of vision loss and blindness. Research indicates that iron plays a role in the pathogenesis of these retinal degenerative diseases, highlighting the need for new therapeutics."
"University of Pennsylvania","Small molecule inhibitors of Integrin Œ±2Œ≤1","","","https://upenn.technologypublisher.com/technology/29866","Problem:There is a need for new therapeutics that prevent cardiovascular diseases with minimal effects on normal blood clotting. Integrin Œ±2Œ≤1 is a good therapeutic target since it can lead to cardiovascular diseases including stroke or myocardial infarction when overexpressed, but does not severely impair normal bleeding when under-expressed.Integrin Œ±2Œ≤1 has been implicated in several other disease states including cancer metastasis, wound healing, viral infections (such as rotaviruses), and glomerular injury. Therefore, novel inhibitors of integrin Œ±2Œ≤1 could have potential benefits in preventing cardiovascular disease, as well as in several other therapeutic applications.Solution:Drs. DeGrado and Bennett led the development of novel small molecule inhibitors of integrin Œ±2Œ≤1, based on a prolyl-2,3-diaminopropionic acid (DAP) scaffold. These compounds have been shown to inhibit human platelet adhesion and arterial thrombosis in a mouse model with IC50 values in the nanomolar range.Advantages:Inhibition of integrin Œ±2Œ≤1IC50 values in nanomolar rangeApplications:Cardiovascular diseasesCancer metastasisWound healingViral infectionsGlomerular injuryStage of Development:Primary human cells and mouse modelIntellectual Property:US8,987,306US8,258,159US7,910,609Reference Media:Miller MW et al.Proc Natl Acad Sci USA, 2009 Jan 20 106(3): 719.Choi S et al.J Med Chem, 2007 Nov 1 50(22): 5457.Borza CM et al.J Am Soc Nephrol, 2012 June 23(6): 1027.Desired Partnerships:LicenseCo-developmentCase ID:U4878-tpNCSWeb Published:11/28/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29866","**Summary:** Small molecule inhibitors targeting integrin Œ±2Œ≤1 have been developed to address cardiovascular diseases while minimizing the impact on normal blood clotting. Integrin Œ±2Œ≤1 is a therapeutic target as its overexpression is associated with cardiovascular complications, such as stroke and myocardial infarction, while its under-expression does not significantly affect normal bleeding. These inhibitors were created by researchers Drs. DeGrado and Bennett, utilizing a prolyl-2,3-diaminopropionic acid (DAP) scaffold, and have demonstrated efficacy in inhibiting human platelet adhesion and arterial thrombosis in mouse models, with IC50 values in the nanomolar range.

**Applications:** The potential applications of these small molecule inhibitors include the prevention and treatment of cardiovascular diseases, cancer metastasis, wound healing, viral infections, and glomerular injury.

**Problem Solved:** The development of these inhibitors addresses the need for new therapeutics that can effectively prevent cardiovascular diseases without severely affecting normal blood clotting, providing a targeted approach to managing this significant health concern.","Integrin Œ±2Œ≤1 is a therapeutic target for preventing cardiovascular diseases like stroke and myocardial infarction, as its overexpression is linked to these conditions while its under-expression minimally affects normal blood clotting. Additionally, integrin Œ±2Œ≤1 is associated with other disease states, including cancer metastasis, wound healing, and viral infections."
"University of Pennsylvania","Expedited Assay and Analysis to Determine Acute Myeloid Leukemia Patient Prognosis","","","https://upenn.technologypublisher.com/technology/23884","An inexpensive high-throughput clinical diagnostic method for assessing genomic DNA methylation at multiple specific loci coupled with a scoring system allowing for AML prognosis classification.Problem:Acute myeloid leukemia (AML) is the most common acute leukemia in adults and affects 12.2 per 100,000 people older than 65 years old. Only 50-80% of patients reach complete remission (CR) as a result of standard chemotherapy while the rest suffer from side effects without significant benefit to their health.Variable response to chemotherapy in AML represents a major treatment challenge. While clinical and genetic features incompletely predict outcome, there is a clear correlations between patient outcome in AML and DNA methylation patterns. However, tests directly measuring multiple-locus DNA methylation are expensive and technically challenging.There is a need for a better, cheaper, and readily available diagnostic test to inform clinicians about appropriate treatment and better identify AML patients who are likely to achieve remission.Solution:Dr. Carroll and Dr. Wertheim have developed a strategy, multi-locus microsphere HpaII tiny fragment enrichment by ligation-mediated PCR (xMELP), to simultaneously analyze the DNA methylation pattern at up to 50 loci.This technique is inexpensive and easily performed in a clinical molecular pathology laboratory. Inventors used xMELP to analyze methylation pattern at 18 loci in AML patients and determined methylation statistic (M-score) for 166 patients with de novo AML and in independent cohort of 383 patients from the Eastern Cooperative Oncology Group (ECOG).M Score segregates AML patients into prognostic subgroups with significantly distinct mortality risk (P = 0.009). In the ECOG study, M-score was associated with death (P = 0.011) and failure to achieve CR (P = 0.034). Median survival was 26.6 months versus 10.6 months for low and high M-score groups. Thus, the xMELP assay and associated M-score can be used for prognosis and for clinical decision making in AML patients.Advantages:QuantifiableInexpensive and simple (2 reaction tubes needed)Fast (2 days)Utilizes standard clinical lab equipmentApplications:Simultaneous analysis of DNA methylation at up to 50 lociAML mortality prognosis to inform clinicians on appropriate treatmentsMethod can be applied for development of prognostic test for cancers with demonstrated correlation between DNA methylation and clinical prognosis (T-cell and B-cell lymphoblastic leukemia, NSCLC, ovarian carcinoma, melanoma etc)Stage of Development:Developed xMELP assay and random forest classifier with a training set of an AML patient cohortValidated in three cohorts of patients from UPENN, ECOG and MD Anderson.Intellectual PropertyUS Patent11,473,131Reference Media:Wertheim et al.Clin Chem. 2015 Jan; 61(1): 249DiNardo et al.Am J Hematol 2016; EpubLuskin et al.JCI Insight 2016, 1(9): e87323Wertheim et al.J Mol Diagn 2014 March 16(2): 207Desired Partnerships:LicenseCo-developmentCase ID:15-7238-tpNCSWeb Published:1/27/2017Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/23884","**Summary:** An inexpensive high-throughput clinical diagnostic method has been developed to assess genomic DNA methylation at multiple specific loci, providing a scoring system for classifying acute myeloid leukemia (AML) patient prognosis. The method addresses the variable response of AML patients to chemotherapy and seeks to provide more accurate predictions of treatment outcomes through the analysis of DNA methylation patterns, which are correlated with patient outcomes.

**Applications:** This diagnostic method can be used in clinical settings to identify AML patients who are more likely to achieve complete remission, helping clinicians optimize treatment strategies on an individual basis. The technique enables a cost-effective assessment of genomic methylation patterns and enhances patient stratification in AML management.

**Problem Solved:** The technology offers a solution to the challenges posed by the variable response to chemotherapy in AML, where only 50-80% of patients achieve complete remission, and existing tests for determining DNA methylation are both expensive and technically complex. It provides a more accessible and straightforward approach to prognostication, allowing for better-informed clinical decisions and potentially reducing unnecessary side effects from ineffective treatments.","An inexpensive high-throughput clinical diagnostic method has been developed to assess genomic DNA methylation at multiple specific loci, providing a scoring system for the prognosis classification of acute myeloid leukemia (AML) patients. AML is the most common acute leukemia in adults, impacting 12.2 per 100,000 individuals over 65, with only 50-80% achieving complete remission through standard chemotherapy."
"University of Pennsylvania","A pouch-based cassette for bio-detection with timer-based actuator","","","https://upenn.technologypublisher.com/technology/39104","Bio-detection cassette with automated actuator for self-contained immunoassay devices and lab-on-a-chip assaysTechnology Overview:The Bau Lab has developed a device that sequentially delivers multiple reagents into a microfluidics based lab-on-a-chip system. Protrusions on a rotating wheel sequentially press plastic balls onto flexible diaphragms, capping chambers storing reagents and/or wash solutions. In an alternative embodiment of the device, a pouching actuator is controlled by a spring-driven mechanical timer. The actuator consists of a timing dial, actuation disc, ball-holding plate, cassette socket and platform, and timer spring box. Delivery sequence is determined by the number and relative position of balls and protrusions on the holding plate and actuation disc, respectively.Advantages:Portable, handheld platformFully integrated, automatic sample preparation, target purification, and amplificationRapid analysis timeLow costReusable or disposable timer-based actuatorDiagnostic performance on par with existing lab-based testsApplications:Point-of-care diagnosticsLab-on-a-chipImmunoassaysTop: Immunoassay chip with integrated actuator. Bottom: Schematic diagram of mechanically activated actuatorStage of Development:Proof-of-concept prototype developed with demonstrated feasibility of molecular marker detection in oral fluidIntellectual Property:US 8,697,007US 8,691,592Reference Media:Qiu X. et al.Sens Actuators B Chem, 2011 Dec 15, 160(1): 1529.Liu C. et al.Lab Chip, 2009 March 21, 9(6): 768Desired Partnerships:LicenseCo-developmentCase ID:T4403-tpNCSWeb Published:3/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39104","**Summary:** The newly developed device by the Bau Lab is a bio-detection cassette that automates the sequential delivery of multiple reagents in a microfluidics-based lab-on-a-chip system. It incorporates a timer-based actuator that can be either reusable or disposable, which controls the delivery sequence through a mechanism involving a spring-driven timer. The system is designed for rapid analysis and provides diagnostic performance comparable to traditional lab-based tests while being portable and cost-effective.

**Applications:** The technology is applicable in point-of-care diagnostics, lab-on-a-chip systems, and immunoassays, facilitating rapid and efficient analysis in various medical and research settings.

**Problem Solved:** The device addresses the need for automated and efficient sample preparation and analysis for bio-detection, overcoming limitations of traditional laboratory methods by providing a portable, user-friendly, and integrated solution for rapid diagnostic testing.","The Bau Lab has developed a device that sequentially delivers multiple reagents into a microfluidics-based lab-on-a-chip system, using a rotating wheel to press plastic balls onto flexible diaphragms. An alternative design features a pouching actuator controlled by a spring-driven mechanism."
"University of Pennsylvania","Discovery of diazaxanthylidenes for live cell molecular imaging, cell activation, and binding disease-relevant nucleic acids","","","https://upenn.technologypublisher.com/technology/31572","Synthesis of organelle-specific photoactivatable fluorescent probes for live cell imagingTechnology Overview:The Chenoweth Lab has uncovered a synthetic route to generate fluorescent compound libraries from a diazaxanthilidene scaffold of the azaxanthone family that can be used for organelle-specific staining, live cell molecular imaging, and cell activation. Xanthones and azaxanthones are classes of natural products that bind nucleic acids and have been implicated in therapeutic applications, including cancer, cardiovascular disease, and infectious diseases. The compounds are also able to specifically bind disease-relevant DNA and RNA sequences.Novel derivatives of 2,2‚Äô-diazaxanthylidine, with desirable properties for live cell imaging, were generated after photolysis and N-alkylation. Both the excitation and emission wavelengths are tunable, so different parts of the light spectrum can be exploited. Single cells can be easily activated and tracked, in addition to sequentially activated. Both mitochondria and lysosome stains have shown excellent specificity, reduced cytotoxicity, and greater protection against photobleaching compared to commercially available compounds.Advantages:Subcellular specificity and binding of nucleic acidsReduced cytotoxicityGreater resistance to photobleachingWater soluble and cell permeableTunable excitation and emission maxima with large Stokes shiftsApplications:Organelle-specific fluorescent dyes for live cell imaging and tracking via fluorescence microscopySpatiotemporally controlled sequential photoactivation of single cellsPhotoconvertable dye can track pre-excitation state in addition to post-excitation stateFrom Tran MN et al. Angew.Chem. Int. Ed.2015, 54, p. 6442-6446.Stage of Development:Proof of concept and in vitro testingIntellectual Property:US10,487,089Reference Media:Tran MN et al.Chem Sci2015 Aug 1 6(8): 4508.Tran MN & Chenoweth, DM;Angew. Chem. Int. Ed.Engl 2015 May 26, 54(22): 6442.Rarig, R-A F et al.J. Am. Chem. Soc. 2013 June 19, 135(24): 9213.Desired Partnerships:LicenseCo-developmentCase ID:Z6753-tpNCSWeb Published:3/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31572","**Summary:** The Chenoweth Lab has developed a synthetic method to produce a range of fluorescent compounds derived from diazaxanthylidene, a scaffold in the azaxanthone family. These compounds are capable of organelle-specific staining, enabling live cell molecular imaging and cell activation. They have been shown to bind specifically to disease-relevant DNA and RNA, with applications in various therapeutic areas, including cancer, cardiovascular diseases, and infections. The newly created derivatives demonstrate enhanced properties for imaging, including tunable excitation and emission wavelengths, while also exhibiting lower cytotoxicity and increased resistance to photobleaching.

**Applications:** The technology can be used to create organelle-specific fluorescent dyes for live cell imaging and tracking, with particular focuses on specific organelles such as mitochondria and lysosomes. The ability to activate and track single cells, as well as sequentially activate them, further enhances its utility in biological research and potential therapeutic monitoring.

**Problem Solved:** This technology addresses the need for effective fluorescent probes that not only exhibit subcellular specificity and reduced toxicity but also improve resistance to photobleaching in live cell imaging. By providing tunable spectral properties and the ability to bind nucleic acids relevant to various diseases, it offers significant advantages over existing fluorescent compounds in biological and medical research.","The Chenoweth Lab has developed a synthetic method to create fluorescent compounds from a diazaxanthilidene scaffold, enabling organelle-specific staining and live cell imaging. These xanthone and azaxanthone derivatives can bind nucleic acids and have potential therapeutic applications."
"University of Pennsylvania","GRP8 as a target for improving plant stress response to water and nutrient starvation","","","https://upenn.technologypublisher.com/technology/38472","Genetically engineered plants for increased resistance to nutrient stressProblem:The plant root epidermis absorbs water and nutrients from the environment, using long hair-like projections from root hair cells to increase surface area. Plants regulate the ratio of root hair to nonhair cells based on environmental signals, with plants grown under nutrient-poor conditions developing higher density and longer hair cells. Roots can only absorb inorganic phosphates, present at very low concentrations in soil, making phosphate starvation one of the most common nutrient stresses in plants. Furthermore, the molecular mechanisms regulating root hair cell fate and phosphate starvation response are not well understood.Solution:The Gregory Lab has discovered that the overexpression of the GRP8 gene (glycine-rich RNA-binding protein) increases the number of root hairs on the surface of plant roots, increasing the surface area for water and nutrient absorption. This finding is the first identification of GRP8 as a promising target for crop plant trait improvement, with connections to stress response to water and nutrient deprivation.GRP8 overexpression was also determined to improve plant tolerance to phosphate starvation, with acid phosphatase levels in Arabidopsis roots correlating with GRP8 abundance. By measuring the expression of phosphate starvation response genes under normal growth conditions, GRP8 was found to positively regulate the transcripts of phosphate transporters and their upstream activators.Advantages:GRP8 gene is highly conserved among ground plantsEnhanced resistance to environmental stress conditions, including drought and nutrient deprivationApplications:Crop plant trait improvementImprove energy efficiency by reducing need for fertilizer applicationImages of root hairs with normal in (A), upregulated production in (B), and downregulated production in (C).Stage of Development:Proof-of-concept testingIntellectual Property:US10,526,614Reference MediaFoley, S et al.;Dev Cell 2017 Apr 24 41(2): 204.Bailie, KPenn Today2017 April 24Desired Partnerships:LicenseCo-developmentCase ID:17-8052-tpNCS-1Web Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38472","**Summary:** Genetically engineered plants have been developed to enhance resistance to nutrient stress, particularly phosphate starvation, which is prevalent in nutrient-poor conditions. The GRP8 gene, a glycine-rich RNA-binding protein, when overexpressed, has been shown to increase the density and length of root hairs, thus expanding the surface area available for water and nutrient absorption. This discovery establishes GRP8 as a significant target for improving crop plant traits related to stress responses, particularly in adverse environmental conditions.

**Applications:** The technology can be used to develop crop varieties that exhibit enhanced tolerance to phosphate starvation and improve water and nutrient uptake efficiency, potentially leading to increased agricultural productivity in challenging growing conditions.

**Problem Solved:** The technology addresses the challenge of nutrient stress in plants, specifically phosphate starvation, by allowing for better regulation and enhancement of root hair development, thereby facilitating greater nutrient and water absorption in environments where these resources are limited.","Plants adjust the density and length of root hair cells in response to nutrient-poor conditions to enhance water and nutrient absorption. Roots primarily absorb inorganic phosphates, which are found in low concentrations in the environment."
"University of Pennsylvania","A disposable self-heating cartridge for point-of-care molecular diagnostics","","","https://upenn.technologypublisher.com/technology/39316","A water-activated, self-heating, instrument-free microfluidic diagnostic cartridgeProblem:Many molecular diagnostic devices require elevated temperatures to carry out biochemical reactions, such as those needed for nucleic acid amplification, including loop-mediated isothermal amplification (LAMP). The temperature is typically regulated with external electrical power, controller, and heating elements, which increases cost and complexity. Lateral flow immunoassays, while offering straightforward and rapid detection, suffer from low sensitivity and specificity.Solution:Researchers in the Bau Lab have developed a point-of-care microfluidic diagnostic cartridge that can amplify nucleic acids isothermally with high specificity. The device is integrated with an exothermic heater and temperature regulator that provides a steady temperature without needing external electric power. A porous paper strip determines the rate of water supply for heater activation, triggered by an exothermic reaction with a magnesium alloy. A phase-change material of paraffin is embedded in the cartridge to maintain the temperature at the desired level, i.e., 60oC-65oC for LAMP. The cartridge utility has been demonstrated by amplifying and detecting E. coli DNA using LAMP, detecting as few as 10 molecules in a sample.Advantages:Self-contained device without specialized instrumentation or electricityMaintain consistent desired temperature independent of ambient temperatureUse in clinic, home, field, or resource-poor settingsLow-cost disposable deviceApplications:Cartridge for isothermal nucleic acid amplification and visual fluorescent or colorimetric detectionPoint-of-care diagnostic deviceDetect viruses, bacteria, and pathogens borne in bodily fluidsFrom Liu et al, 2011. Photograph of water-activated, self-heating, non-instrumented cartridge for isothermal amplification of nucleic acids.Stage of Development:Proof-of-concept and prototype developed with demonstrated utility of nucleic acid amplification and detectionIntellectual Property:US 9,233,368Reference Media:Lu C. et al.Lab Chip, 2011 May 7, 11(16): 2686.Desired Partnerships:LicenseCo-developmentCase ID:X5912-tpNCSWeb Published:3/19/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39316","**Summary:** Researchers have developed a microfluidic diagnostic cartridge that is water-activated and self-heating, designed for point-of-care molecular diagnostics. This device enables isothermal amplification of nucleic acids with high specificity, addressing the need for elevated temperatures in biochemical reactions without the requirement for external power sources. The cartridge utilizes an exothermic heater activated by a magnesium alloy, along with a porous paper strip to control water flow, and incorporates a phase-change material to maintain the temperature around 60¬∞C-65¬∞C, which is suitable for LAMP. Its effectiveness has been demonstrated through the amplification and detection of E. coli DNA, with the capability to detect as few as 10 DNA molecules in a sample.

**Applications:** This technology can be utilized in clinical settings, at home, in the field, or in remote locations for molecular diagnostics, specifically for tests that require nucleic acid amplification such as LAMP.

**Problem Solved:** The technology addresses the challenges associated with traditional molecular diagnostic devices, which typically require costly and complex external power sources for temperature regulation. By providing a self-contained, instrument-free solution that maintains a consistent temperature, it simplifies the process of nucleic acid amplification and improves the feasibility of point-of-care testing.","A novel self-heating, water-activated microfluidic diagnostic cartridge enables point-of-care molecular diagnostics without the need for external power or complex heating systems. This innovation allows for the necessary elevated temperatures for biochemical reactions, such as nucleic acid amplification, to be achieved efficiently."
"University of Pennsylvania","Cationic steroids as antimicrobial agents","","","https://upenn.technologypublisher.com/technology/39286","Antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugateOverview Technology:The emergence of antibiotic-resistant bacteria is a rising health crisis that requires the development of new antibacterial agents. Cationic steroids disrupt bacterial membranes via physical and chemical mechanisms that prevent bacteria from evolving resistance to membrane-permeabilizing cationic amphipathic molecules.Researchers in the Diamond Lab have identified a new method of use for the cationic corticosteroid disubstituted dexamethasone spermine (D2S) as an anti-bacterial agent for both Gram-positive (e.g. MRSA) and Gram-negative (e.g. E. coli) organisms that can cause life-threatening situations, particularly in hospital-based infections. D2S has been demonstrated to exhibit antibacterial activity against clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa from cystic fibrosis sputa and biofilms. Furthermore, D2S enhances S. aureus susceptibility to antibiotics, including amoxicillin, tetracycline, and amikacin.Advantages:Small cationic steroidResists proteolytic activity of pepsinD2S maintained in ascites, cerebrospinal fluid, saliva, and bronchoalveolar lavage fluidEnhanced S. aureus susceptibility to antibioticsAdaptable to large-scale manufacturingApplications:Antibacterial developmentAnti-inflammatory agentFrom Bucki et al, 2010. Bactericidal activity of dexamethasone (filled black triangle), spermine (open triangle), dexamethasone-spermine (filled diamond), and D2S (open diamond) against P. aeruginosa.Stage of Development:Proof-of-concept in vitro and in vivo mouse dataIntellectual Property:US 9,180,132Reference Media:Myint M. et al.Bioorg Med Chem Lett, 2015 July 15, 25(14): 2837.Bucki R. et al.Antimicrob Agents Chemother, 2010 June, 54(6): 2525.Fein D.E. et al.Mol Pharmacol, 2010, 78(3): 402.Desired Partnerships:LicenseCase ID:W5277-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39286","**Summary:** Cationic steroids have been identified as promising antimicrobial agents due to their ability to disrupt bacterial membranes and prevent the evolution of resistance. The cationic corticosteroid disubstituted dexamethasone spermine (D2S) has shown antibacterial activity against critical Gram-positive and Gram-negative bacteria, including MRSA and E. coli, particularly in clinical isolates and biofilms associated with cystic fibrosis. D2S not only exhibits potent antibacterial effects but also enhances the susceptibility of Staphylococcus aureus to several antibiotics. This compound is resistant to proteolytic degradation and remains effective in various bodily fluids, making it suitable for therapeutic applications.

**Applications:** The primary applications of D2S include its use as an antibacterial agent and an anti-inflammatory agent, potentially addressing infections in clinical settings and contributing to improved therapeutic strategies against resistant bacterial strains.

**Problem Solved:** The technology addresses the urgent need for new antibacterial agents in the face of antibiotic-resistant bacteria, offering a novel strategy to combat infections that are difficult to treat, especially in hospital environments, while also increasing the effectiveness of existing antibiotics.","Cationic steroids, including a novel cationic disubstituted dexamethasone-spermine conjugate, have been shown to disrupt bacterial membranes, presenting potential as new antibacterial agents amid rising antibiotic resistance. These compounds operate through mechanisms that hinder bacterial resistance to membrane-permeabilizing cationic amphipathic molecules."
"University of Pennsylvania","Islet Œ≤ cells exosome profile as biomarker platform for early diagnosis and monitoring of diabetes","","","https://upenn.technologypublisher.com/technology/54464","Quantitative RNA, proteomic, and metabolite profiling of islet Œ≤ cells-specific exosomes in patient plasma/serum as marker for monitoring metabolic diseases, such as type I or type II diabetes, metabolic syndrome, and obesity.Problem:Metabolic disorders including type I or type II diabetes, morbid obesity, and metabolic syndrome affect over 1/3 of the US population. There is a critical clinical need for biomarker platforms that would allow for early diagnosis, prognosis, and monitoring of these conditions.Solution:Exosomes are extracellular microvesicles released by many tissue types into bodily fluids. They carry tissue specific RNA and protein cargoes reflecting the conditional status of the originating tissue. Islet Œ≤ cells are also known to release exosomes that are specific to the tissue.Dr. Vallabhajosyula at Penn discovered that transmembrane protein ion channel regulator FXYD2 is expressed on the surface of the islet Œ≤ cell exosomes and can be used for isolation and purification of islet Œ≤ cell-specific exosomes.Islet exosomes demonstrated expression profile differences in type I diabetes patients compared to normal controls, including reduced insulin levels. The Inventor analyzed differences in microRNA, long RNA, as well as proteomic and metabolite profiles. Together, the ability to isolate islet Œ≤ cell specific exosomes from patients‚Äô blood can potentially be used as a novel biomarker platform to monitor patients with type I and type II diabetes and other metabolic diseases.Advantages:Diagnostic platform for early prognosis and diagnosis of metabolic diseasesApplications:Method of isolation and purification of islet Œ≤ cells specific exosomes from serum/plasmaStage of Development:Small size human sample dataIntellectual Property:US PatentPendingReference Media:Under ReviewDesired Partnerships:LicenseCo-developmentCase ID:15-7302-tpNCSWeb Published:6/21/2024Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/54464","**Summary:** Quantitative profiling of RNA, proteins, and metabolites in exosomes derived from islet Œ≤ cells presents a promising method for early diagnosis and monitoring of metabolic diseases such as type I and type II diabetes, metabolic syndrome, and obesity. Islet Œ≤ cells release exosomes that contain specific RNA and protein markers that reflect the physiological status of these cells. The expression of the transmembrane protein FXYD2 has been identified as a key marker for isolating and purifying these islet Œ≤ cell-specific exosomes. Research indicates distinct differences in the exosomal profile between type I diabetes patients and healthy controls, particularly noting reduced insulin levels in the former.

**Applications:** This technology can be applied to develop a biomarker platform aimed at improving early diagnosis, prognosis, and monitoring of metabolic disorders, especially diabetes. It can facilitate personalized treatment strategies and potentially improve patient outcomes by enabling more accurate tracking of disease progression and response to therapy.

**Problem Solved:** The technology addresses the critical clinical need for effective biomarker platforms that can provide early diagnosis and monitoring of prevalent metabolic disorders, which currently affect over one-third of the US population. By utilizing islet Œ≤ cell-specific exosomes, healthcare providers can gain insights into the metabolic status of patients, thereby enhancing disease management and therapeutic interventions.","The study analyzes the RNA, proteomic, and metabolite profiles of islet Œ≤ cell-specific exosomes found in patient plasma or serum to identify potential biomarkers for monitoring metabolic diseases, including type I and type II diabetes, metabolic syndrome, and obesity. Addressing the significant prevalence of these disorders in the US population, the research aims to fulfill the clinical need for effective early diagnosis and monitoring solutions."
"University of Pennsylvania","Ruthenium photolinkers for manipulating molecular structure and function in materials science and biology","","","https://upenn.technologypublisher.com/technology/38265","New paradigm for caging and photoreleasing polymeric systems with visible light responsive ruthenium photolinkers.Problem:Photochemical methods can manipulate and regulate molecular structure, function, and localization. Site-specifically incorporating a photolabile moiety within an oligonucleotide has remained a synthetic challenge. Moreover, methods for achieving multiplexing of caged molecules with multiple caging chromophores are not widely available, with antisense morpholinos, used to block mRNA translation in model organisms, as the primary focus of caged oligo development.Solution:The Dmochowski Lab has developed the first visible light responsive ruthenium-based photolinker that can circularize biomolecules. More specifically, a Ru(bpy)2(3-ethynylpyridine)2 (RuBEP) compound has been created, where the ethynyl moieties are reacted with a bis-azido oligonucleotide and click chemistry.This concept can be readily expanded to cage peptides, lipids, or other polymers. The ruthenium photolinker can be blue- or red-shifted, and the bioconjugation chemistry can also be altered.The researchers have implemented the technology using RuBEP-caged circular morpholinos that targeted early development zebrafish genes, where uncaged morpholinos successfully achieved gene knockdown.Advantages:Visible light excitation and activation of caged oligosRuthenium photolinker amenable to caging oligos and large biomoleculesMild synthetic conditionsApplications:Molecular caging to study amino acids, peptides, oligonucleotides, neurotransmitters, and other biologically relevant moleculesPhotochemical methodsGene regulation and expressionControl structure and function of biopolymers, materials, biological systemsFrom Griepenburg et al, 2015. RuBEP photolinker conjugated with 25mer bis-azido morpholino formed caged antisense morpholino; subsequent 450 nm irradiation restored biologically active morpholino.Stage of Development:In vitro proof-of-concept and in vivo regulation of zebrafish gene expressionIntellectual Property:US11,046,721Reference Media:Griepenburg J.C. et al.Chem. Sci., 2015 Apr 1, 6(4): 2342Desired Partnerships:LicenseCo-developmentCase ID:15-7215-tpNCSWeb Published:1/27/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38265","**Summary:** New photochemical methods using visible light responsive ruthenium photolinkers offer a novel approach for manipulating molecular structure and function. The Dmochowski Lab has developed a ruthenium-based photolinker, Ru(bpy)2(3-ethynylpyridine)2 (RuBEP), which can be site-specifically incorporated into biomolecules, allowing for the circularization of oligonucleotides through click chemistry. This technology expands the capability for caging not only oligonucleotides but also peptides, lipids, and other polymers, with the flexibility to modify the light responsiveness and bioconjugation chemistry of the photolinker. The application of this technology has been demonstrated with RuBEP-caged circular morpholinos targeting genes in zebrafish during early development, resulting in successful gene knockdown.

**Applications:** The technology has potential applications in molecular caging to study amino acid interactions, gene regulation, and functional manipulation of various biomolecules. It is particularly relevant in materials science and biology, where it can facilitate precise control over biomolecular interactions and pathways.

**Problem Solved:** The technology addresses the challenges associated with the site-specific incorporation of photolabile moieties into oligonucleotides and the lack of multiplexing methods for multiple caging chromophores. By allowing for visible light activation of caged molecules, it provides a more versatile and effective means for manipulating and regulating molecular functions within biological and material contexts.","Researchers have developed visible light-responsive ruthenium photolinkers that enable a new approach for caging and photoreleasing polymeric systems. This innovation addresses the challenges of site-specific incorporation of photolabile moieties within oligonucleotides and the limited methods for multiplexing caged molecules."
"University of Pennsylvania","Tumor Mitochondria Vaccine for the Treatment of Cancer","","","https://upenn.technologypublisher.com/technology/38082","Problem:Progression in cancer immunotherapy has been rapid with a number of products currently available and many others in late stage clinical development. However, clinical response to immunotherapies is variable and dependent on cancer types as well as specific characteristics or genetic mutations within a patient‚Äôs individual tumor. There is a need for tumor-specific therapies with applicability to a range of cancer types.Solution:The Facciabene lab at the University of Pennsylvania has developed a technology that uses Tumor Associated Mitochondria Antigens (TAMAs) extracted from the tumor as a cancer vaccine. The technology involves pulsing dendritic cells with TAMAs.In an in vivo model of renal cell carcinoma (RCC) the vaccine elicits a cytotoxic T-cell response and provides long-term protection from tumor progression when used either prophylactically or therapeutically.The Facciabene lab has established that TAMAs can produce an effective anti-tumor immune response in RCC. Future work will validate the data in human RCC and investigate additional cancer types and combinations with other immunotherapies.Advantages:Long-term protection from tumor progression demonstrated in RCCPotential use in other cancer types with mutations in mitochondrial proteins (e.g. kidney, colorectal, ovarian, breast, bladder, lung, pancreatic)Utilization of a dendritic cell platform validated in humansApplications:Cancer immunotherapyPotential in metabolic or mitochondrial diseasesStage of Development:In vitro and in vivo animal dataHuman RCC sample evaluation of mitochondrial mutations and correlation with survival and immune cell infiltrationIntellectual Property:US PatentPendingReference Media:Kreeger, K.Penn Medicine News - 2015 Oct 26Pierini S et al.;J Immunol 2015 Oct 15, 195(8): 4020Desired Partnerships:LicenseCo-developmentCase ID:14-7082-tpNCSWeb Published:1/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38082","**Summary:** The technology developed at the Facciabene lab utilizes Tumor Associated Mitochondria Antigens (TAMAs) extracted from tumors to create a cancer vaccine. By pulsing dendritic cells with TAMAs, the vaccine has shown effectiveness in eliciting a cytotoxic T-cell response in an in vivo model of renal cell carcinoma (RCC), demonstrating long-term protection against tumor progression both prophylactically and therapeutically. Ongoing research aims to validate these findings in human RCC and explore the technology's applicability in additional cancer types and in combination with other immunotherapies.

**Applications:** The primary application is in cancer immunotherapy, with potential uses extending to other cancer types such as kidney, colorectal, ovarian, breast, bladder, lung, and pancreatic cancers, particularly those with mutations in mitochondrial proteins.

**Problem Solved:** The technology addresses the variability in clinical responses to existing immunotherapies by providing a tumor-specific therapy that may be applicable across various cancer types, thus enhancing the effectiveness and applicability of cancer treatments.","The Facciabene lab at the University of Pennsylvania is developing a tumor mitochondria vaccine that aims to provide a tumor-specific therapy applicable to various cancer types. This approach addresses the variability in clinical responses observed with existing immunotherapies, which can depend on specific cancer types and individual tumor characteristics."
"University of Pennsylvania","New Therapy for Skin Infections in Companion Animals","","","https://upenn.technologypublisher.com/technology/38466","A selective method for treating bacterial skin and ear infections in dogs, cats, and horses.Problem:Pyoderma, or bacterial infection of the skin, is the most common dermatologic problem encountered in cats and dogs. The two main organisms causing pyoderma in companion animals are Staphylococcus pseudintermedius and Staphylococcus schleiferi. Currently, the same antibiotics are used for treating both human and animal staphylococcal infections.Recently these species have been developing resistance to antibiotics such as methicillin, sulfonamides and tetracycline, leaving limited treatment options, particularly for animals with repetitive skin infections. The global anti-infective market for companion animals was valued at $977 million of the total $7.5 billion animal pharmaceutical market in 2014 and is expected to reach over a billion dollars by 2019.Solution:Research led by Dr. Dan Beiting has demonstrated that unlike the Staphylococcus species that commonly affect humans, the veterinary forms utilize an alternative metabolic pathway. This finding renders these two species susceptible to different therapeutic regimens that do not affect the more common S. aureus. By using an existing antibiotic, fosmidomycin, known to target this distinct mechanism, a potent and effective method to restrict the two veterinary forms of Staphylococcus has been developed.Advantages:Selectively targets bacteria associated with veterinary skin and ear infectionsWill not contribute to interspecies transmission of drug resistanceStage of Development:In vitro proof of conceptIntellectual Property:US10,772,900Reference Media:Misic, A et al.,mSphere 2016 Sep 28, 1(5): e00258Desired Partnerships:LicenseCo-developmentCase ID:16-7922-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38466","**Summary:** This technology provides a targeted approach to treating bacterial skin and ear infections specifically in companion animals such as dogs, cats, and horses. Research indicates that the strains of Staphylococcus causing pyoderma in these animals have developed resistance to conventional antibiotics, which limits treatment options. By focusing on the unique metabolic pathways of the veterinary strains, the therapy utilizes fosmidomycin, an existing antibiotic, to effectively combat resistant Staphylococcus pseudintermedius and Staphylococcus schleiferi while minimizing impacts on human-related bacteria.

**Applications:** The therapy is intended for use in veterinary medicine, specifically for the treatment of pyoderma and other bacterial skin and ear infections in companion animals.

**Problem Solved:** The therapy addresses the significant challenge of antibiotic resistance in bacterial skin infections in companion animals, which has become more prevalent due to previous antibiotic treatments being ineffective against resistant strains. By using a method that targets the unique bacterial profiles found in these animals, the solution aims to enhance treatment efficacy and restore workable options for managing recurring infections.","A new selective method has been developed for treating bacterial skin and ear infections in dogs, cats, and horses, addressing the common issue of pyoderma caused by Staphylococcus pseudintermedius and Staphylococcus schleiferi. The use of the same antibiotics for both human and animal staphylococcal infections has become problematic due to the development of resistance in these bacterial species."
"University of Pennsylvania","Reusable silicon-based cross-coupling agents for the production of natural products, pharmaceuticals, and other organic materials","","","https://upenn.technologypublisher.com/technology/39334","Cross-coupling reactions without the generation of waste productsProblem:Catalytic carbon-carbon bond formation based on cross-coupling reactions (CCRs) plays a central role in the production of natural products, pharmaceuticals, agrochemicals, and organic materials. Coupling reactions with organometallic reagents and organic halides facilitate a plethora of bond-forming reactions in modern synthetic chemistry.The problem, however, with all current cross-coupling reactions is that they lead to the formation of the stoichiometric production of waste products, such as in:the Suzuki CCR boronic acid;the Negishi CCR organozinc waste;the Stille CCR organotin waste; andKumada organomagnesium.Solution:The Smith Lab has developed silicon-based transfer agents for palladium-mediated cross-coupling processes to yield aryl-aryl, alkenyl-aryl, and alkenyl-alkenyl coupled products. This reaction can occur in one pot with high yield and purity of the product, while eliminating the problems of lithium-halogen exchange, homocoupling from other palladium-mediated methods, including the Suzuki organoboron, Negishi organozinc, Stille organotin, and Kumada organomagnesium, and the stoichiometric production of waste products.Advantages:High product yieldNo unwanted byproducts or homocouplingExcellent specificitySupport catalyst on polymer that can be readily recovered without significant loss of cross-coupling activityFacile product purificationMild reaction conditionsApplications:Cross-coupling synthetic reactionsNatural products, pharmaceuticals, agrochemicals, small molecules, fine chemicalsSynthetic overview of silicon-based cross-coupling reaction. From Smith et al, 2012.Stage of Development:Lab-scale synthesis of wide range of cross-coupled aryl compoundsIntellectual Property:US9,499,660US9,850,261EP2859002Reference Media:Martinez-Solorio D. et al.J Am Chem Soc, 2016 Feb 17, 138(6): 1836.Nguyen M.H. et al.Org. Lett., 2014 April 4, 16(7): 2070.Nguyen M.H. et al.Org. Lett., 2013 Aug 16, 15(16): 4258.Martinez-Solorio D. et al.Org. Lett., 2013 May 17, 15(10): 2454.Smith A.B. et al.J Am Chem Soc, 2012 March 14, 134(10): 4533.Smith A.B. et al.Angew. Chem. Int. Ed., 2011 Sept 12, 50(38): 8904.Mott, APenn News2014 Aug 18.Desired Partnerships:LicenseCo-developmentCase ID:Y6226-tpNCSWeb Published:3/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39334","**Summary:** The technology involves the development of silicon-based transfer agents that facilitate palladium-mediated cross-coupling reactions, specifically designed to form carbon-carbon bonds without producing waste byproducts. These reactions yield products such as aryl-aryl, alkenyl-aryl, and alkenyl-alkenyl compounds with high purity and yield, while addressing the inefficiencies associated with traditional cross-coupling methods like the Suzuki, Negishi, Stille, and Kumada reactions. The silicon-based agents enable a one-pot reaction process, enhancing specificity and allowing for easy recovery of the catalyst with minimal loss of activity.

**Applications:** This technology can be applied in the production of natural products, pharmaceuticals, agrochemicals, and other organic materials through effective and environmentally friendly cross-coupling reactions.

**Problem Solved:** The innovation resolves the issue of waste generation in traditional cross-coupling reactions by eliminating the stoichiometric byproducts associated with organometallic reagents and organic halides, thereby improving the overall efficiency and sustainability of the synthesis process in organic chemistry.","Cross-coupling reactions are essential for synthesizing natural products, pharmaceuticals, and organic materials but currently generate waste products. This research focuses on developing reusable silicon-based cross-coupling agents to minimize waste in these catalytic carbon-carbon bond formations."
"University of Pennsylvania","CD4 mimetic small molecule inhibitors of HIV-1 entry","","","https://upenn.technologypublisher.com/technology/39323","Therapeutic development for HIV-1 infection and prevention of transmissionProblem:A global pandemic of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) persists, with about 34 million people worldwide currently infected and 2.5 million people newly infected with the virus annually.Inhibition of the initial HIV entry into the host cell has proven elusive to develop therapeutics for HIV-1 infection. Cellular infection by HIV-1 begins when the viral envelope glycoprotein gp120 binds to the T-cell receptor protein CD4 anchored to the cell membrane. This binding event induces a conformational change that exposes the binding site for the transmembrane chemokine co-receptor (CCR5 or CXCRC4), and the rearranged protein helix bundle inserts into the host cell membrane for viral entry.Solution:In a cross-university collaboration, researchers have utilized structure-based drug design and synthesized dual hotspot small molecule HIV-1 entry inhibitors in a novel structural paradigm for inhibiting the CD4-gp120 protein-protein interaction. More specifically, these inhibitors interact with the Phe43 cavity and aspartic acid D368 within the glycoprotein gp120. The D368 residue makes important contacts with CD4, and compounds that interact with this residue block the interaction with CD4 with higher potency and across a range of HIV-1 strains than previously characterized CD4-mimetic compounds. Furthermore, these new compounds do not activate HIV-1 infection of CD4-negative, CCR5-expressing cells.Advantages:Improved antiviral potencyAntagonists of entry into CD4-negative cellsGreater breadth of activity against multiple HIV-1 strains that previously described CD4-mimetic compoundsSmall molecule antagonists of viral attachment and entry processMinimize undesirable side effectsApplications:Therapeutic for HIV-1 infected individualsMicrobicide to prevent acquisition of HIV-1 infectionFrom LaLonde et al, 2012.Stage of Development:In vitro proof-of-conceptIntellectual Property:US 9,403,763Reference Media:LaLonde J.M. et al.J. Med. Chem., 2012 May 10, 55(9): 4382.C&EN Newshighlight.Desired Partnerships:LicenseCo-developmentCase ID:Y6120-tpNCSWeb Published:3/19/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39323","**Summary:** The development of small molecule inhibitors targeting HIV-1 entry aims to address the ongoing global pandemic of HIV and AIDS, which affects millions worldwide and results in millions of new infections annually. Therapeutics that inhibit the initial entry of HIV-1 into host cells have long been challenging to create. The HIV-1 infection mechanism begins when the viral envelope protein gp120 binds to the CD4 receptor on T-cells, leading to further interactions that facilitate viral entry. Researchers from multiple universities have utilized structure-based drug design to create dual hotspot small molecule inhibitors that disrupt the CD4-gp120 interaction more effectively than existing compounds. These new inhibitors target the Phe43 cavity and aspartic acid D368 within gp120, blocking the interaction with CD4 with greater potency and effectiveness against various HIV-1 strains.

**Applications:** The inhibitors developed may serve as therapeutic agents for the treatment of HIV-1 infection and could also contribute to strategies for preventing the transmission of the virus.

**Problem Solved:** This technology seeks to overcome the challenge of developing effective HIV-1 entry inhibitors, specifically targeting the crucial interaction between CD4 and gp120, thereby providing a novel approach to inhibit the infection process more efficiently than previous treatments.","Therapeutic development for HIV-1 infection faces challenges, with approximately 34 million people currently infected and 2.5 million new infections annually. Inhibiting the initial entry of HIV-1 into host cells has been difficult to achieve."
"University of Pennsylvania","A novel isostere to replace the carboxylic acid functional group in pharmaceuticals and other compounds","","","https://upenn.technologypublisher.com/technology/39317","Cycloalkyl-dione derivatives with improved pharmacokinetic and toxicological properties for drug designProblem:Isosteric replacement of a specific group of atoms with a moiety with similar physicochemical properties is a strategy employed by medicinal chemists to improve the properties of biologically active compounds. For example, carboxylic acid isosteres are used to substitute the carboxylic acid moiety in pharmaceutical compounds to improve potency, selectivity, stability, and pharmacokinetics, while retaining the functionality of the carboxylic acid. Carboxylic acids are a common functional group in small molecules that bind to protein targets. However, these moieties can be detrimental in pharmaceuticals because of limited permeability across biological membranes, toxicity, and metabolic instability, although the water solubility and acidity conferred are beneficial for facilitating electrostatic interactions with the biological target. A facile method to predict the outcome of an isosteric replacement does not exist.Solution:Because cyclopentane-1,3-dione has a pKa value comparable to carboxylic acids, the researchers explored this unit as a carboxylic acid isostere and its use in drug design. Derivatives of a known thromboxane A2 prostanoid receptor antagonist were synthesized, and the biological activity was comparable to the parent compound as determined by functional and radioligand-binding assays.Advantages:Improved pharmacokinetic, toxicological, and safety profilesModulate drug target/off-target interactionsTunable lipophilicity, acidity, and other chemical properties of biologically active compoundsCompounds able to cross blood/brain barrierApplications:Compounds with carboxylic acid moieties, including pharmaceuticals, polymers, solvents, food additivesStructure of known thromboxane receptor antagonist 12 (top) and overlap of the carboxylic acid moiety of (12) with cyclopentane-1,3-dione (CPD) derivatives attached at either C2 or C4/C5 (bottom, A or B, respectively). From Ballatore et al, 2011Stage of Development:In vitro proof-of-conceptIntellectual Property:US 8,530,520Reference Media:Lassalas P. et al.J. Med. Chem., 2016 April 14, 59(7): 3183.Ballatore C. et al.Bioorg. Med. Chem. Lett., 2014 Sept 1, 24(17): 4171.Ballatore C. et al.ChemMedChem., 2013 March, 8(3): 385.Ballatore C. et al.J. Med. Chem., 2011 Oct 13, 54(19): 6969.Desired Partnerships:LicenseCo-developmentCase ID:X5956-tpNCSWeb Published:3/19/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39317","**Summary:** Cycloalkyl-dione derivatives have been identified as isosteric replacements for carboxylic acid functional groups in pharmaceuticals, aiming to enhance the pharmacokinetic and toxicological profiles of drugs while maintaining their biological activity. The synthesis of these derivatives offers a potential alternative that retains the necessary acidity and water solubility, which are crucial for binding to protein targets without the usual drawbacks associated with carboxylic acids.

**Applications:** The technology can be applied in drug design to create more effective pharmaceuticals with reduced toxicity and enhanced stability. Specifically, the derivatives can be utilized in the development of compounds targeting various biological receptors, such as thromboxane A2 prostanoid receptor antagonists.

**Problem Solved:** The innovation addresses the limitations of traditional carboxylic acids in drug formulation, which include issues with permeability across biological membranes, toxicity, and metabolic instability, while still utilizing their beneficial properties for electrostatic interactions with biological targets.","Isosteric replacement of carboxylic acid functional groups with cycloalkyl-dione derivatives aims to enhance the pharmacokinetic and toxicological properties of pharmaceuticals. This strategy seeks to improve potency, selectivity, stability, and overall effectiveness of biologically active compounds."
"University of Pennsylvania","A flow cell for electron microscope imaging with multiple flow streams","","","https://upenn.technologypublisher.com/technology/39313","Nanoaquarium: nanofluidic platform for in situ TEM imaging of fluid-mediated samplesProblem:Many nanoscale phenomena occur in liquid media, including nanoparticle and colloidal formation, nanowire liquid phase growth, electrochemical deposition and etching for batteries, and biological interactions. Real-time, in situ transmission electron microscope (TEM) imaging at nanoscale resolution would enhance the scientific understanding of these processes. Traditional TEM suffers from sample evaporation under high vacuum and requires very thin samples.Solution:The Bau Lab has designed a device, termed the nanoaquarium, which allows for the concurrent flow of multiple sample streams for electron microscope imaging. This versatile flow cell will aid in studying dynamic nanoscale processes in fluids.The flow cell is sandwiched between two thin silicon nitride membranes using wafer-scale processing to enable mass production and hermetic sealing without polymers or glue for leak-free operation. Furthermore, there are on-chip integrated electrodes for sensing and actuation. The device (without flow control) was used to examine nanoparticle aggregation, bubble formation and growth, electrodeposition, crystallization, and patterning with electrons.Advantages:Image processes in liquid media in real-timeIntegrated electrodes for actuation, sensing, electrochemical studies, temperature controlOn-chip storage of reagentsPneumatic pumping to improve control of liquid-based experimentsFully enclosed reservoir isolated from sample holderApplications:Study liquid samples with transmission electron microscopyDynamic experiments including electrochemical deposition, electric field-induced self-assembly, reactions at liquid interfacesBiological interactions, protein conformational changes, nanoparticle migration, lipid membrane biophysicsFrom Grogan J.M. et al, 2012.Stage of Development:Prototype developed and proof-of-concept imaging without flow controlIntellectual Property:US9,196,457Reference Media:Schneider N.M. et al.Adv. Struct. Chem. Imag, 2016 Feb 26, 2(2).Schneider N.M. et al.J. of Phys. Chem C, 2014 Aug 28, 118(38): 22373.Grogan J.M. et al.Nano Letters, 2014 Jan, 14(1): 359.Grogan J.M. et al.Physical Review E, 2011, 83(6).Grogan J.M. and Bau H.H.J. of MEMS, 2010, 19(4): 885.Bau lab websiteDesired Partnerships:LicenseCo-developmentCase ID:X5829-tpNCSWeb Published:3/18/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39313","**Summary:** The technology involves a novel flow cell designed to facilitate electron microscope imaging of fluid-mediated samples, enabling real-time, in situ observation of nanoscale phenomena such as nanoparticle aggregation, bubble formation, and electrochemical processes. The device, known as the nanoaquarium, employs a configuration where multiple sample streams can flow concurrently, thus allowing for dynamic studies in fluid environments at nanoscale resolution. It is constructed between two thin silicon nitride membranes, ensuring hermetic sealing and leak-free operation through wafer-scale processing. The integrated on-chip electrodes provide capabilities for sensing, actuation, and electrochemical studies, supporting a variety of experimental applications.

**Applications:** The flow cell can be used to examine various processes including nanoparticle and colloidal formation, nanowire liquid phase growth, electrochemical deposition and etching relevant to battery technology, and a range of biological interactions. It also supports the analysis of crystallization and patterning with electrons in liquid environments, enhancing the understanding of these complex phenomena.

**Problem Solved:** The technology addresses the challenges of traditional transmission electron microscopy, which struggles with sample evaporation due to high vacuum conditions and requires thin samples. By using a versatile flow cell, it allows for the examination of samples in their natural liquid state without the limitations imposed by vacuum conditions, thereby facilitating a better understanding of nanoscale processes occurring in fluids.","The proposed nanoaquarium is a nanofluidic platform designed for in situ transmission electron microscope (TEM) imaging of fluid-mediated samples, enabling real-time observation of nanoscale phenomena in liquid media. This approach addresses the issue of sample evaporation that typically hinders traditional TEM imaging."
"University of Pennsylvania","Tri-functionalized cryptophane biosensors for biomolecular imaging and MRI diagnostics","","","https://upenn.technologypublisher.com/technology/39112","Cryptophanes with high xenon affinity enable ultrasensitive detection of analytes in solution using Xe-129 NMR/MRITechnology Overview:The Dmochowski Lab has developed biosensors comprised of tri-functionalized cryptophane with high affinity for hyperpolarized 129Xe. These biosensors can be designed to detect molecular markers associated with cancer and other disease. More specifically, a biosensor has been synthesized that detects matrix metalloproteases (MMPs), which are frequently upregulated in many cancers.The MMP enzyme cleaves the peptide covalently attached to the 129Xe biosensor, resulting in a change in the chemical environment of 129Xe readily detectable by a 0.5 ppm chemical shift in NMR. The features of these tri-functionalized cryptophanes enable the detection of picomolar concentrations of cryptophane biosensors by a technique known as Hyper-CEST NMR/MRI. Additional xenon biosensors have been designed to target integrin receptors, folate receptor, and carbonic anhydrase. In most cases, binding the cryptophane biosensor to its protein target produces a measureable change in the Xe-129 NMR chemical shift.Advantages:Tri-functionalized cryptophanes well-solubilized in waterHighest known affinity for xenonVery favorable Xe exchange kineticsUltrasensitive analyte detectionTri-functionalized cryptophane biosensors can be designed that each yield distinct 129Xe NMR chemical shifts and can be targeted to different biomarkersApplications:Biosensors129Xe MRI diagnostics next-generation platformBiomolecular imaging and enhancement of existing 1H MRI technologyFrom Khan et al, 2015. Folate-conjugated cryptophane to target cryptophane to membrane-bound folate receptors that are overexpressed in many human cancers.Stage of Development:In vitro proof-of-concept testingIntellectual Property:US 8,222,022Reference Media:Riggle B.A. et al.J Am Chem Soc, 2015 Apr 29, 137(16): 5542.Taratula O. et al.Supramol. Chem., 2015 Jan 1, 27(1-2): 65.Khan N.S. et al.Bioconjugate Chem., 2015, 26(1): 101.Taratula O. et al.Org Lett, 2012 July 20, 14(14): 3580.Taratula O. et al.Org Lett, 2011 Mar 18, 13(6): 1414.Bai Y. et al.Anal Chem, 2012 Nov 20, 84(22): 9935.Hill PA et al.J Am Chem Soc, 2007 Aug 1, 129(30): 9262.Desired Partnerships:LicenseCo-developmentCase ID:T4532-tpNCSWeb Published:3/9/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39112","**Summary:** Tri-functionalized cryptophane biosensors have been developed that exhibit a high affinity for hyperpolarized 129Xe, enabling ultrasensitive detection of specific biomolecules through Xe-129 NMR/MRI. These biosensors can detect molecular markers related to various diseases, including cancer, by utilizing a synthetic biosensor that targets matrix metalloproteases (MMPs) known to be upregulated in many forms of cancer. The MMP enzyme acts on the biosensor, leading to a detectable change in the chemical environment of the 129Xe, identified by a chemical shift in NMR. The technology also includes other biosensors designed to detect integrin receptors, folate receptor, and carbonic anhydrase, providing measurable Xe-129 NMR changes upon binding.

**Applications:** The primary applications of these biosensors include biomolecular imaging and MRI diagnostics, focusing on cancer detection and possibly other diseases through the identification of specific biomarkers related to physiological and pathological processes.

**Problem Solved:** This technology addresses the challenge of detecting low concentrations of biomolecular markers associated with diseases, particularly cancer, by providing a highly sensitive method of detection using xenon-based NMR technology.","The Dmochowski Lab has developed tri-functionalized cryptophane biosensors with high affinity for hyperpolarized 129Xe, enabling ultrasensitive detection of molecular markers linked to diseases such as cancer. One specific biosensor synthesized targets matrix metalloproteases (MMPs), which are often upregulated in various conditions."
"University of Pennsylvania","An efficient method to produce high yield analogs of Hemi-Phorboxazole A with anticancer and antifungal activities","","","https://upenn.technologypublisher.com/technology/39285","A two-step, high yield, method for synthesizing naturally derived, Hemi-Phorboxazole A analogsProblem:(+)-Phorboxazole A and B, extracted from the sponge Phorbas sp., display extraordinary anti-proliferative activity against National Cancer Institute‚Äôs (NCI) panel of 60 human tumor cell lines. Due to their complex structures, the reported syntheses of Phorboxazole A and B analogues consist of 100 total steps with an average yield of 4%. The limited availability of these compounds has precluded the evaluation of their biological activity. As such, there is a need for improved syntheses of these compounds, featuring fewer steps while providing higher yield and selectivity.Solution:Researchers in the Smith Lab have developed a two-step, high yield (85%) method for preparing Hemi-Phorboxazole A from a known precursor. Two analogues of Hemi-Phorboxazole were designed and synthesized in this manner. One analogue exhibits anti-proliferation activities of human cancer cell lines HCT-116 (colon) and SPKB-3 (breast). Another analogue shows antifungal activity against Candida albicans.Advantages:Efficient two-step method to synthesize complex and scarce molecules, compared to previously-reported syntheses having 100 stepsImproved synthetic yield (~85%) over other reported procedures (average 4%)Less expensive process than other known proceduresApplications:Antitumor activities for colon and breast cancer cell linesAntifungal activity against Candida albicansSynthesis of completely synthetic (+)-hemi-phorboxazole A. From Smith AB et al, 2009.Stage of Development:In vitro testing in human cell linesIntellectual Property:US8,957,097Reference Media:Smith AB et al.Org. Lett., 2009 Aug 20, 11(16): 3766.Dalisay DS et al.Org. Lett., 2009 Apr 2, 11(9): 1967.Desired Partnerships:LicenseCase ID:W5271-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39285","**Summary:** A two-step, high-yield method has been developed for synthesizing Hemi-Phorboxazole A analogs, addressing the complex and lengthy traditional synthesis that involved 100 steps and yielded only 4%. This new method achieves a yield of approximately 85% and results in two designed analogues. One of these analogues demonstrates notable anti-proliferative activity against HCT-116 (colon) and SPKB-3 (breast) human cancer cell lines, while the other exhibits antifungal activity against Candida albicans.

**Applications:** The analogs can be used for treating colon and breast cancers due to their antitumor activities, as well as for antifungal applications targeting Candida albicans.

**Problem Solved:** The technology addresses the limited availability of Hemi-Phorboxazole A and its analogs, which had hindered the assessment of their biological activities. By providing an efficient and higher-yielding synthesis, it overcomes the previous lengthy processes and enables further exploration of these compounds' therapeutic potential.","A two-step method has been developed to efficiently synthesize high-yield analogs of Hemi-Phorboxazole A, which exhibits significant anticancer and antifungal activities. Previous syntheses of Phorboxazole A and B analogs required 100 steps with an average yield of 4%, limiting their availability for further study."
"University of Pennsylvania","Phorboxazole compounds as potent anti-tumor agents","","","https://upenn.technologypublisher.com/technology/39080","Problem:Phorboxazoles are naturally occurring compounds that have been isolated from the marine sponge Phorbas, endemic to the western coast of Australia. Previous screens of phorboxazoles against the National Cancer Institute human cell line panel indicated the most potent cytotoxicity assayed.While the mechanism of action in vivo is unknown, phorboxazole arrests the cell cycle at S phase without interfering with microtubule stability. Because of the antimitotic bioactivity, structural complexity, and extreme natural scarcity of the compound, efforts have been underway for the total synthesis of this natural product.Solution:Researchers in the Smith Lab in the University of Pennsylvania Department of Chemistry have completed the total synthesis of phorboxazole compounds and derivatives.The Petasis-Ferrier rearrangement was utilized to construct two tetrahydropyran rings in the phorboxazole macrolide ring, along with an extension of the Julia olefination and application of a novel bifunctional oxazole linchpin. This sequence gave an overall yield of 3-6% in a stereocontrolled, highly convergent Stille coupling to unite the macrocycle with the sidechain. Structure-activity relationship studies on phorboxazole analogs and initial biological screening in leukemia, breast cancer, and brain tumor cell lines have demonstrated extremely potent anticancer activity.Advantages:Anti-proliferative activityAntifungal and antibiotic activitySynthetic scheme does not rely on use of restricted marine spongeHigh yield and stereoselectivity compared to previously demonstrated synthesis of phorboxazolesApplications:Potential pharmaceuticals and therapeutics for cancer, inhibiting cancer cell division or inducing apoptosis in malignant cellsStage of Development:Proof-of-principle and in vitro testingIntellectual Property:US7,485,631Reference Media:Smith AB et al.Tetrahedron, 2011 Jul 8, 67(27-28): 5069.Smith AB et al.J. Org. Chem., 2008 Feb 15, 73(4): 1201.Smith AB et al.J. Org. Chem., 2008 Feb 15, 73(4): 1192.Smith AB et al.Org. Lett., 2006 Feb 16, 8(4): 797.Smith AB et al.;J Am Chem Soc. 2001 Nov 7;123(44):10942.Desired Partnerships:LicenseCo-developmentCase ID:R3855-tpNCSWeb Published:3/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39080","**Summary:** Phorboxazoles are naturally occurring compounds from the marine sponge Phorbas, found on the western coast of Australia, and have shown potent cytotoxicity in previous screenings against cancer cell lines. Despite their antitumor potential, the mechanism by which phorboxazoles act in vivo remains unclear, although they are known to arrest the cell cycle at the S phase without affecting microtubule stability. Researchers at the University of Pennsylvania have successfully completed the total synthesis of phorboxazole compounds and derivatives using sophisticated synthetic methodologies, achieving a yield of 3-6%. Structure-activity relationship studies and biological screenings have indicated that these compounds exhibit significant anticancer activity across various cancer types, including leukemia, breast cancer, and brain tumors.

**Applications:** The developed phorboxazole compounds and derivatives can be utilized in cancer treatment due to their potent anti-proliferative activity. Additionally, their antifungal and antibiotic properties may open avenues for broader medicinal applications beyond oncology.

**Problem Solved:** The synthesis of phorboxazole compounds addresses the challenge of their extreme natural scarcity and the need for effective anti-tumor agents that can disrupt cancer cell proliferation without compromising microtubule stability.","Phorboxazoles, isolated from the marine sponge Phorbas, have demonstrated strong cytotoxicity against human cell lines in National Cancer Institute screenings. They arrest the cell cycle at the S phase without affecting microtubule stability."
"University of Pennsylvania","Microfabricated device for measuring and manipulating human cardiac tissue","","","https://upenn.technologypublisher.com/technology/31567","Engineered cardiac microtissues embedded within 3D micropatterned matricesProblem:Engineered myocardial tissue is needed to develop organ mimetic models and replace damaged tissue in vivo. Faithfully modeling cardiac tissue biology would enable studies of cardiac physiology and pathophysiology in vitro.Solution:The Chen Lab has developed human cardiac microtissues (hCMTs), which are microscale constructs of cardiac cells embedded within 3D matrices, in microfabricated tissue gauges (¬µTUGs). The hCMTs are formed on a platform that incorporates microelectromechanical systems (MEMS) cantilevers, which simultaneously constrain and report forces generated by the hCMTs.This technique allows for the production of functional CMTs from readily available cells, with monitoring of the contraction frequency, duration, and forces. Monitoring of the impact of physical (i.e. matrix and boundary mechanics, electrical stimulation) and chemical changes on the maturation, structure, and function of cardiac tissue can be conducted. This model provides reproducible morphogenetic phenotyping that is absent in current two-dimensional culture models.Advantages:Intermediate preclinical screening between cell culture and animal testingReal-time measurements to facilitate dose-response curvesMonitor response to serial applications of multiple pharmaceuticalsApplications:Pharmacological studies of effects on cardiac tissuePersonalized medicineFrom Boudou et al, 2012. Temporal evolution of CMTs in (A), recording of tension as function of time in (B), temporal evolution of spontaneous beating frequency in (C), and of contraction duration of beating in (D)Stage of Development:Prototype developed and proof-of-concept testingIntellectual Property:US9,512,396Reference Media:Boudou, T et al.Tissue Eng Part A, 2012 May, 18(9-10): 910.Zhao et al.Adv. Mater.,2013 March 25, 25(12): 1699.Desired Partnerships:LicenseCo-developmentCase ID:Y6091-tpNCSWeb Published:3/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31567","**Summary:** The developed technology consists of engineered human cardiac microtissues embedded within three-dimensional micropatterned matrices, allowing for accurate simulation and study of cardiac tissue biology. It utilizes microelectromechanical systems (MEMS) cantilevers to both constrain the microtissues and report on the forces they generate, enabling detailed monitoring of contraction frequency, duration, and force dynamics. This platform is designed to facilitate the investigation of how various physical and chemical factors affect the maturation and functioning of cardiac tissues, providing an improvement over traditional two-dimensional culture systems.

**Applications:** The technology is applicable in pharmacological studies to evaluate the effects of drugs on cardiac tissue, supports personalized medicine approaches, and serves as an intermediate preclinical screening tool between standard cell culture techniques and animal testing. It also allows for real-time measurements that aid in the creation of dose-response curves and the assessment of tissue responses to multiple pharmaceutical agents.

**Problem Solved:** This technology addresses the need for engineered myocardial tissues to develop organ mimetic models and to replace damaged cardiac tissue in vivo by providing a more realistic platform for studying cardiac physiology and pathophysiology than existing two-dimensional cultures. It helps researchers to accurately model cardiac tissue biology and conduct reproducible phenotyping for more effective drug development and personalized treatment strategies.","The Chen Lab has developed human cardiac microtissues (hCMTs), which are microscale constructs of cardiac cells embedded in three-dimensional micropatterned matrices for measuring and manipulating cardiac tissue. This innovation aims to create engineered myocardial tissue for organ mimetic models and to facilitate studies of cardiac physiology and pathophysiology in vitro."
"University of Pennsylvania","One-step generation of stimuli-responsive, multifunctional polyelectrolyte microcapsules","","","https://upenn.technologypublisher.com/technology/23524","Nanoscale interfacial complexation in emulsions and spontaneous droplet hatching for microcapsulesProblem:Polyelectrolyte microcapsules can be prepared by a layer-by-layer assembly method to form nanoengineered shells that are sensitive to external stimuli and enable the encapsulation, protection, and release of active agents. Conventional synthesis approaches suffer from low efficiency and do not accommodate incorporating hydrophilic and hydrophobic materials simultaneously.Solution:Researchers in the Lee Lab have developed a nanoscale interfacial complexation in emulsion (NICE) method that involves the complexation of two polymers that self-assemble to form an insoluble layer at an oil-water interface.The method uses a microfluidic device that contains a water-oil-water interface. The polymer complex is formed at the outermost water-oil interface, and the material to be encapsulated is introduced at the innermost water layer. Oppositely charged polymers are sequentially deposited onto a sacrificial solid core to form polyelectrolyte complex-based coatings on the solid particle. The core particle is removed via dissolution to form a hollow microcapsule, with target encapsulants introduced through the microcapsule shell by tuning the permeability to achieve microencapsulation.Advantages:Ability to encapsulate range of materials with different chemical propertiesHigher encapsulation efficiency than layer-by-layer assembly methodsResponsive to changes in chemical gradients, ionic strength, or pHFunctionalize with nanomaterials for response to magnetic field or lightHighly monodisperse polymer shellsOne-step processApplications:Encapsulate materials for controlled releaseSynthesize highly monodisperse shells with variety of chemistriesDrug deliveryCell mimicryFood industryStage of Development:Proof-of-principle production of polyelectrolyte nanocapsules; device fabricationIntellectual Property:US11,040,324Reference Media:Kim M. et al.ACS Macro Letters, 2016 Apr 19, 5(4): 487.Kim M. et al.ACS Nano, 2015 Aug 25, 9(8): 8269.Desired Partnerships:LicenseCo-developmentCase ID:15-7465-tpNCSWeb Published:11/17/2016Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/23524","**Summary:** Researchers have developed a novel method for creating polyelectrolyte microcapsules that allows for the effective encapsulation of both hydrophilic and hydrophobic materials through a nanoscale interfacial complexation technique. This method utilizes a microfluidic device to facilitate the self-assembly of polymers at a water-oil interface, forming an insoluble layer that enables the encapsulation of active agents within hollow microcapsules. The process involves the sequential deposition of oppositely charged polymers onto a sacrificial core, followed by its removal to yield a microcapsule with adjustable permeability.

**Applications:** The multifunctional polyelectrolyte microcapsules can be utilized in various sectors, including drug delivery systems, where they provide targeted release of therapeutic agents; agricultural applications for controlled release of fertilizers or pesticides; and advanced materials science for creating responsive coatings and encapsulation systems.

**Problem Solved:** This technology addresses the limitations of conventional polyelectrolyte microcapsule synthesis, which often results in low encapsulation efficiency and difficulties in incorporating diverse material types. By enabling higher encapsulation efficiency and responsiveness to external stimuli, this method broadens the potential applications of microcapsules in various fields.","Polyelectrolyte microcapsules can be efficiently prepared using a one-step method that allows for the simultaneous incorporation of both hydrophilic and hydrophobic materials, addressing limitations of traditional layer-by-layer assembly techniques. This innovative approach enables the creation of stimuli-responsive, multifunctional microcapsules suitable for encapsulating, protecting, and releasing active agents."
"University of Pennsylvania","Hyperpolarized Gas Delivery to Subject in MRI Scanner for Enhanced Pulmonary Diagnostics and Disease Progression Monitoring","","","https://upenn.technologypublisher.com/technology/39340","Device for the optimal mixing and delivery of MRI gaseous contrast agentsProblem:Gaseous contrast agents, and more specifically, hyperpolarized (HP) noble gases, such as helium-3 and xenon-129, are used for investigational imaging of respiratory gas in lungs by MRI for the purpose of assessing regional lung function. The ultimate goals of such imaging methods include diagnosis, evaluation, and monitoring progression of respiratory diseases, as well as evaluating the efficacy of therapeutic interventions.The pulmonary diseases that can benefit from such an imaging modality include obstructive lung diseases (e.g. emphysema, chronic bronchitis, and asthma) and interstitial lung diseases (e.g. cystic fibrosis and idiopathic pulmonary fibrosis).Recently, sophisticated imaging methodologies have been developed based on HP gas MRI technology to extract richer and more valuable information about lung function. At the same time, these new technologies impose certain requirements on the delivery pattern and mixture content of the HP gas during the imaging session ‚Äì requirements that have not yet been met. HP gases depolarize very rapidly in vivo due to interaction with other respiratory gas components and airway tissue. Depolarization of the HP gas limits the obtainable signal in MR images and has a negative effect on measurements accuracy.Solution:To address this concern, researchers at the University of Pennsylvania have developed systems and methods that permit real-time mixing of HP gas and oxygen in order to prevent premature depolarization of the contrast gas while maintaining proper gas levels (Fi02) for the subject‚Äôs safety. The developed system further permits control of the delivered tidal volume (VT) at a specific level in order to image the lung at the same inflation volume over the sequence of several breaths, both for physiological stability and for matching images from different breaths; i.e. image co-registration.Advantages:Ensures that the same proportional amount of HP gas and oxygen is flowing into the lungs throughout the respiratory cycleEnsures proper mixing of gasesDelivers highly accurate quantitative imaging of fractional ventilation in human subjectsAllows the subject to maintain a respiratory pattern very similar to normal breathingStage of Development:Working prototypeHuman trialIntellectual Property:US9,999,756Desired Partnerships:LicenseCo-developmentCase ID:Y6310-tpNCSWeb Published:3/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39340","**Summary:** This technology focuses on a device designed for the optimal mixing and delivery of hyperpolarized (HP) gases, such as helium-3 and xenon-129, used as gaseous contrast agents in MRI for assessing lung functionality. The method aims to enhance imaging quality and provides valuable insights into pulmonary diseases by delivering HP gases in a manner that mitigates rapid depolarization, which can degrade imaging quality and measurement accuracy.

**Applications:** The technology is applicable in the diagnosis, evaluation, and monitoring of a variety of pulmonary diseases, including obstructive lung diseases like emphysema, chronic bronchitis, and asthma, as well as interstitial lung diseases such as cystic fibrosis and idiopathic pulmonary fibrosis. It is also designed to assess the efficacy of therapeutic interventions in these diseases.

**Problem Solved:** The primary problem addressed is the rapid depolarization of HP gases during in vivo imaging, which affects the quality of MRI signals and the accuracy of measurements. By improving the delivery and mixing of the HP gas, the technology enhances the imaging capabilities and diagnostic utility for examining lung function and disease progression.","Hyperpolarized noble gases like helium-3 and xenon-129 serve as gaseous contrast agents for MRI, allowing for the assessment of regional lung function. These imaging techniques aim to diagnose, evaluate, and monitor respiratory diseases and the effectiveness of therapeutic interventions."
"University of Pennsylvania","Repair of Radiation-Induced Bone Damage in Cancer Patients Using Sclerostin Antibody to Fix Breaks in DNA","","","https://upenn.technologypublisher.com/technology/23427","Bone damage and/or fractures are common side effects of radiotherapy in cancer patients. Current treatments for radiation induced bone damage only reduce existing damage and can produce adverse side effects. On the other hand, sclerostin antibody repairs bone damage by facilitating repair of double strand breaks in DNA.Problem:Bone damage and/or fractures are common side effects of radiotherapy that pose a major health threat to cancer patients. Current treatments for radiation induced bone damage include teriparatide, raloxifine, bisphosphonates, and salmon synthetic calcitonin. These treatments inhibit bone resorption by suppressing osteoclast activity or triggering osteoclast death. Many of these approaches have adverse side effects, such as reflux disease, esophageal erosion, muscle aches, and cardiovascular events.Solution:In comparison to conventional treatments that simply reduce radiation damage, sclerostin antibody (Scl-Ab) actually repairs radiation induced bone damage. It reverses radiation damage in osteoblasts by activating the canonical Wnt/Œ≤-catenin pathway, which facilitates repair of double strand breaks in DNA.In a rat model, the administration of sclerostin antibody (Scl-Ab) injections for 4 weeks post radiation treatment significantly contributed to DNA repair, and reduced bone damage. These results suggest that Scl-Ab treatment post radiation therapy can reverse radiation-induced bone damage in a clinical setting.Advantages:Enhances DNA repair in bone following radiation treatmentAntibody well characterized and currently being tested in clinical trialsApplications:Reduction of bone damage caused by radiation therapyStage of Development:Testing in rat models has shown that injection of the sclerostin antibody (Scl-Ab) treatment for 4 weeks following radiation treatment significantly contributed to DNA repair, and reduced bone damageScl-Ab is currently being tested in clinical trialsReference Media:Chandra, A et al.J. Biol Chem, 2015 Jan 2, 290(1): 157Desired Partnerships:Co-developmentCase ID:15-7378-tpNCSWeb Published:10/28/2016Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/23427","**Summary:** Radiation therapy commonly leads to bone damage and fractures in cancer patients, creating significant health risks. Traditional treatments primarily focus on reducing damage and often result in adverse side effects. In contrast, the sclerostin antibody has the ability to actively repair radiation-induced bone damage by promoting the repair of double strand DNA breaks. Studies in rat models demonstrate that administering sclerostin antibody after radiation therapy enhances DNA repair and mitigates bone damage effectively.

**Applications:** The sclerostin antibody treatment can be utilized in clinical settings for cancer patients undergoing radiation therapy, aiming to repair radiation-induced bone damage and improve overall bone health post-treatment.

**Problem Solved:** The technology addresses the significant problem of radiation-induced bone damage in cancer patients, overcoming the limitations and side effects of existing treatments that only diminish damage without promoting healing.","Radiotherapy in cancer patients often leads to bone damage and fractures, which current treatments can only partially address while potentially causing adverse effects. Sclerostin antibody has been shown to repair such bone damage by facilitating the repair of double strand breaks in DNA."
"University of Pennsylvania","Composite materials for bone and tissue reconstruction","","","https://upenn.technologypublisher.com/technology/29850","Problem:Materials used for bone transplants, and as scaffolds for tissue restoration, need particular features to work well. Current materials have shortcomings that complicate treatment.- Dried silica gels are very attractive because of their nanometer-sized pores, but they lack larger pores that exist in natural bone.- Composite materials may have larger pores, but the fibers are usually dense ceramics which are less biocompatible.There is a need for materials that combine the high surface area of dried gels with the larger pores of fibrous composites.Solution:Researchers at the University of Pennsylvania have developed a fibrous composite of biocompatible silica gels and biodegradable polymers that preserves the nanometer-sized pores in the fibers, and the bone-like pores between the fibers. The fibers can be hollow to further increase the surface area, lower the density, and provide the open channels advantageous for transport and cellular activities.The polymers form bonding and linkage at the intersections of fibers to strengthen the composites. Such composites show good mechanical strength and readily induce bone-like growth. They can be easily applied to a surface for patches or coatings. They can also be easily formed into contoured objects that retain shapes during handling.Advantages:Increased porosity and surface areaControlled biodegradabilityLight weight, low-density materialsControlled mechanical propertiesStage of Development:PrototypeIntellectual Property:US8,580,291Desired Partnerships:LicenseCase ID:O2779-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29850","**Summary:** Researchers at the University of Pennsylvania have developed a new type of fibrous composite material that combines biocompatible silica gels with biodegradable polymers. This innovative material maintains the beneficial nanometer-sized pores found in dried silica gels while also incorporating larger, bone-like pores between the fibers. The hollow fibers increase surface area and lower density, facilitating transport and cellular activities, while the polymers strengthen the composite by forming bonds at fiber intersections.

**Applications:** The generated composites can be used for bone transplants and as scaffolds for tissue restoration. They are suitable for applications requiring patches or coatings and can be shaped into contoured objects.

**Problem Solved:** Current materials for bone transplants and tissue scaffolds lack the necessary pore structures and biocompatibility, limiting their effectiveness. This new composite addresses these shortcomings by integrating high surface area with larger pores, improving mechanical strength, promoting bone-like growth, and providing controlled biodegradability.","Current materials for bone transplants and tissue scaffolds have limitations, including the lack of larger pores in dried silica gels and the low biocompatibility of dense ceramic fibers in composite materials. There is a demand for materials that effectively combine high surface area with suitable pore sizes for better compatibility and functionality."
"University of Pennsylvania","Cable-based gait rehabilitation","","","https://upenn.technologypublisher.com/technology/38261","New approaches to restore mobilityProblem:According to the American Heart Association, 6.8M American adults have experienced a stroke, and another person has a stroke every 40 seconds. After a stroke, people often have weakness on one side that results in an irregular gait. Many patients have difficulty adjusting to a regular gait and suffer from impaired mobility. The need for physical therapy will grow in coming years as the world cares for an ageing population.Solution:Researchers at the University of Pennsylvania have created a cable-based gait rehabilitation device that could provide improved outcomes for physical therapy patients. This device consists of a harness that is worn by the user, a cable with an active braking system attached to the harness, and force sensors on the user‚Äôs foot. Sensors monitor the user‚Äôs gait, and the brake is applied to the cable to provide resistance on the swing of the weaker limb. This system trains the weaker leg, so that the user‚Äôs gait adjusts and, ultimately, the corrected gait persists after training with the device.Advantages:Active retraining of the affected limbLow-cost systemStage of Development:PrototypeIntellectual Property:US10,456,318Reference MediaHu, S. et al.;Sensors (Basel) 2021 Oct 5 21(19): 6617.Desired Partnerships:LicenseCo-developmentCase ID:14-7158-tpNCSWeb Published:1/27/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38261","**Summary:** New approaches to restore mobility have been developed to aid individuals who have suffered a stroke, as many experience strength loss and motor control difficulties leading to irregular gait patterns. Researchers at the University of Pennsylvania designed a cable-based gait rehabilitation device that includes a harness, an active braking system integrated with a cable, and foot sensors that track gait performance. This innovative system applies resistance to the swing phase of the weaker limb, facilitating active retraining and improving the user‚Äôs overall gait, which is intended to remain corrected after the training period. 

**Applications:** The technology can be utilized in physical therapy settings for stroke recovery and rehabilitation, catering particularly to patients with gait irregularities due to unilateral weakness. It may also serve the ageing population needing assistance with mobility and gait adjustments.

**Problem Solved:** This technology addresses the significant problem of impaired mobility among stroke patients, offering a targeted approach to retrain and strengthen the affected limb, thereby enhancing overall gait stability and independence in daily activities.","Approximately 6.8 million American adults have experienced a stroke, with one occurring every 40 seconds, leading to mobility issues due to weakness on one side and irregular gait. Researchers are developing new approaches to restore mobility in stroke patients, addressing the increasing demand for physical therapy as the population ages."
"University of Pennsylvania","Polarization-based shadow analysis","","","https://upenn.technologypublisher.com/technology/29859","Capturing hidden details with polarized lightProblem:Most cameras only capture information on the intensity and color of light. Polarization is another characteristic of light that can provide useful information, but conventional cameras do not provide polarization data. Shadows pose a difficult problem for machine vision and image analysis techniques, because they can hide objects and make edges unclear. Polarization information could provide enhanced object recognition, edge recognition, and detection of shadow-occluded objects.Solution:Researchers at the University of Pennsylvania have developed an imaging technique that captures data at 3 different polarization angles using a standard camera. This method of data capture shows more information that would not be detectable by the unaided eye or a normal camera.Polarization analysis can detect objects in shadows, segment and separate complex overlapping shadows from multiple sources, and help detect edges and hidden details that would not be visible in standard intensity-based images. This process could provide better object recognition for systems that require visual feedback to navigate and interact with the environment.Advantages:Improved analysis for images with shadowsDetection of objects in dark areas of an imageImplementation with standard camerasStage of Development:PrototypeIntellectual Property:US Patent8,396,319Desired Partnerships:LicenseCase ID:S4277-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29859","**Summary:** A new imaging technique has been developed that captures data at three different polarization angles using a standard camera, enhancing the ability to detect and analyze objects obscured by shadows. This method leverages polarization characteristics of light to reveal details that conventional cameras miss, leading to improved object recognition, edge detection, and the ability to identify shadow-occluded objects. 

**Applications:** The technology can be applied in various fields such as machine vision, image analysis, and systems requiring visual feedback for navigation and interaction, potentially benefiting industries like robotics, security, and autonomous vehicles.

**Problem Solved:** The imaging technique addresses the limitations of traditional cameras that only capture light intensity and color, which can obscure important visual information in shadowed areas. By utilizing polarization data, it enhances the detection of hidden details and improves the clarity of images where shadows are present.","Most cameras capture only light intensity and color, neglecting polarization, which can provide additional useful information. Utilizing polarization data can improve object recognition and edge detection, particularly in challenging scenarios like shadows that obscure objects."
"University of Pennsylvania","Nanocrystal circuits for flexible electronics","","","https://upenn.technologypublisher.com/technology/43172","New fabrication techniques for CdSe QD FETsProblem:Many researchers are attempting to create flexible electronics, which could have applications for new mobile and wearable devices. However, traditional semiconductor materials are not flexible, so new materials and fabrication techniques are needed to make flexible electronics possible.Solution:Researchers at the University of Pennsylvania have created flexible electronic materials based on CdSe quantum dot (QD) thin-film field effect transistors (FETs). A new processing technique enables low-cost, wide-area fabrication of QD thin films in a process compatible with plastic substrates. An additional doping step makes these devices stable when exposed to air. This makes air-exposed fabrication techniques such as photolithography and atomic layer deposition possible.The fabrication technique developed at Penn has been used to create QD FET based transistors, invertors, amplifiers, NOR & NAND gates, and ring oscillators. Electron mobility for these materials has been demonstrated from 13-22 cm^2/Vs, orders of magnitude higher than previous QD FET efforts, producing results comparable or superior to silicon FETs.Advantages:Air-stable fabricationWide-area fabrication (up to 4 inch demonstrated in laboratory)Compatible with flexible plastic substratesComparable performance to silicon electronicsStage of Development:PrototypeIntellectual Property:US9,336,919US10,096,734US10,096,733Reference Media:Stinner, FS et al.Nano Letters 2015 Oct 14 15(10): 7155.Desired Partnerships:LicenseCo-developmentCase ID:Y6232-tpNCSWeb Published:3/10/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/43172","**Summary:** Researchers at the University of Pennsylvania have developed new fabrication techniques for CdSe quantum dot (QD) thin-film field effect transistors (FETs) that allow for the production of flexible electronic materials. These techniques enable low-cost, wide-area fabrication of QD thin films compatible with plastic substrates and include an additional doping step to ensure stability when exposed to air. The fabrication process allows for the construction of various electronic components such as transistors, inverters, amplifiers, NOR and NAND gates, and ring oscillators, achieving electron mobility between 13-22 cm¬≤/Vs, which is significantly higher than previous QD FET efforts and comparable to silicon FETs.

**Applications:** The technology is intended for flexible electronics, particularly for new mobile and wearable devices, expanding the possibilities of integrating electronics into various applications that require flexibility.

**Problem Solved:** Traditional semiconductor materials lack the flexibility necessary for innovative electronics, necessitating the development of new materials and fabrication techniques to create devices that can be used in flexible electronic formats.","Researchers at the University of Pennsylvania have developed flexible electronic materials utilizing CdSe quantum dot thin-film field effect transistors. This advancement addresses the challenge of creating flexible electronics, which are necessary for mobile and wearable devices."
"University of Pennsylvania","Non-contact fingerprint scanner","","","https://upenn.technologypublisher.com/technology/29854","Latent fingerprint detection using non-destructive imagingProblem:Latent fingerprints, the marks left by contact with a surface, have been used by forensic science since the 19th century. Often the fingerprints left on objects of interest are hard to detect with the unaided eye, and they may be only partial prints or of low quality.The current technique for extracting fingerprints involves applying a powder and removing the fingerprint with tape. This method, however, is destructive of the original fingerprint and may not work well on all surfaces.Solution:Researchers at the University of Pennsylvania have developed a non-destructive imaging technique that can provide high-quality images of fingerprints suitable for forensic analysis without disturbing the original evidence.Light reflected from a surface is usually polarized at an angle, and this information can be used to perform analysis of surface discontinuities, such as the residue left by a fingerprint. Polarization imaging can help detect fingerprints that would not normally be visible, and do so with a high image quality. Because this technique is non-destructive and non-contact, important forensic evidence can be preserved for future analysis.Advantages:Non-contact, non-destructive techniqueNo harsh solvents or toxic powders requiredPreserves evidence for additional analysisStage of Development:PrototypeIntellectual Property:US Patent7,489,391Reference Media:Lin, SS et al.J Opt Soc Am A Opt Image Sci Vis 2006 Sept 23(9): 2137.Desired Partnership:LicenseCase ID:Q3544-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29854","**Summary:** Researchers at the University of Pennsylvania have developed a non-destructive imaging technique for latent fingerprint detection that allows for high-quality imaging of fingerprints without disturbing the original evidence. This technique leverages polarized light to analyze surface discontinuities caused by fingerprints, enhancing the visibility of prints that are typically hard to detect with the naked eye. 

**Applications:** This technology can be used in forensic science for crime scene investigations, facilitating the preservation and analysis of crucial evidence without altering or damaging it. It may also find applications in security and access control systems that require fingerprint recognition without physical contact.

**Problem Solved:** The method addresses the limitations of traditional fingerprint extraction techniques, which can be destructive and may not yield usable prints from all surfaces. By providing a non-contact and non-destructive solution, it allows forensic analysts to obtain high-quality fingerprint images while preserving the original marks for further examination.","Latent fingerprints are often difficult to detect and may be partial or low quality, complicating forensic investigations. The traditional method of extracting fingerprints using powder and tape is destructive to the original print."
"University of Pennsylvania","Nanocircuits at optical frequencies","","","https://upenn.technologypublisher.com/technology/29855","Problem:Conventional electric circuit elements operate in the radio frequency (RF) domain. However, shrinking circuits down to smaller sizes presents some difficulties as the metallic elements do not behave the same way at the nanoscale. If circuit elements could be created that operate at optical frequencies, they could be made much smaller than conventional electronics. This would require nano-scale circuit elements such as resistors, capacitors, and inductors at sizes orders of magnitude smaller than today‚Äôs electronics.Solution:Researchers at the University of Pennsylvania have created nanostructures that act as optical circuit elements. These nanostructures could be used for data storage and computing at scales much smaller than existing devices. The devices are fabricated using certain metals such as gold or silver that exhibit surface plasmon resonance at optical frequencies. Nanoparticles created from a combination of plasmonic (gold, silver) and non-plasmonic materials (Au2S, SiO2) can produce properties that will act as inductors, resistors, capacitors, diodes, and inverters in the optical domain. Fabrication and operation of these devices has been demonstrated at infrared wavelengths, using optical nano-circuit elements formed from an array of Silicon Nitride nanorods.Advantages:Circuit elements at the nanoscaleOperation at optical frequenciesStage of Development:PrototypeIntellectual Property:US9,008,471South Korea10-1165520Japan4861312Reference Media:Engheta, N et al.;Phys Rev Lett 2005 Aug 26, 95(9): 095504Sun, Y et al.;Nature Materials 2012 Jan, 11: 208Desired Partnerships:LicenseCase ID:Q3625-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29855","**Summary:** Researchers at the University of Pennsylvania have developed nanostructures that function as optical circuit elements, enabling circuits to operate at optical frequencies rather than traditional radio frequencies. This advancement allows for the creation of circuit components, such as resistors and capacitors, at a nanoscale that is significantly smaller than current electronic devices. These components are constructed from plasmonic metals like gold and silver, which exhibit surface plasmon resonance, as well as non-plasmonic materials, enabling a range of circuit functionalities in the optical domain. The initial demonstrations of these devices have been conducted at infrared wavelengths, showcasing their potential effectiveness.

**Applications:** The technology has potential applications in data storage and computing, specifically in the development of devices that are significantly smaller and more efficient than existing electronic technologies.

**Problem Solved:** This innovation addresses the limitations of conventional electric circuit elements, which face difficulties when scaled down to the nanoscale. By creating circuit elements that operate at optical frequencies, the technology allows for more compact designs and enhanced performance in electronic circuits.","Conventional electric circuit elements function in the radio frequency domain, but their metallic components do not perform effectively at the nanoscale. Developing nano-scale circuit elements that operate at optical frequencies could lead to significantly smaller circuits than traditional electronics."
"University of Pennsylvania","Gene Therapy for Leber Congenital Amaurosis Ciliopathy","","","https://upenn.technologypublisher.com/technology/38439","AAV-mediated gene therapy approach for the treatment of Leber congenital amaurosis retinopathies resulting from NPHP5 mutationsProblem:Leber congenital amaurosis (LCA) is an autosomal recessive disorder characterized by retinal dystrophy and severe visual impairment within the first year of life. LCA occurrence, while rare (1/50,000 ‚Äì 1/33,000 of live births), is the leading cause of childhood blindness. Due to its early onset, LCA has been more challenging to treat as opposed to later onset retinopathies such as retinitis pigmentosa.To date, at least 15 different mutated genes have been associated with LCA. Of these 15 different genes, one (RPE65) is currently the subject of multiple ongoing gene therapy clinical trial studies. This particular gene mutation only accounts for approximately 16% of all LCA cases, therefore additional therapeutic approaches are needed so that a larger population of LCA patients have treatment options.Solution:Work in the laboratories of Drs. Gustavo Aguirre, William Beltran, Samuel Jacobson, and Artur Cideciyan has resulted in the development of an AAV-mediated gene therapy approach for treating LCA disorders arising from a mutation in the Nephrocystin-5 (NPHP5) gene. Using a large animal model system, the team has observed a robust recovery of retinal function and sustained vision for periods greater than 2 years after injection with the construct.Advantages:First long-term successful gene therapy of a ciliopathy causing LCA.Different AAV vectors provide effective therapeutic rescue.Successful treatment in early, mid and more advanced stages of the disease.Efficacy demonstrated in a large animal model (human-size eye) affected by a naturally-occurring form of NPHP5-LCA.Stage of Development:In vivo proof of concept demonstratedIntellectual Property:US PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:16-7749-tpNCSWeb Published:2/3/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38439","**Summary:** AAV-mediated gene therapy has been developed as a treatment for Leber congenital amaurosis (LCA) caused by mutations in the NPHP5 gene. This therapy aims to address the severe visual impairment associated with LCA, which typically manifests within the first year of life and leads to childhood blindness. The therapeutic approach has shown promising results in a large animal model, demonstrating a robust recovery of retinal function and sustained vision for over two years post-treatment.

**Applications:** The gene therapy can potentially be applied to a broader population of LCA patients, particularly those with NPHP5 mutations, offering a new treatment option beyond the currently available therapies targeting the RPE65 gene.

**Problem Solved:** This gene therapy addresses the urgent need for effective treatments for LCA, which affects approximately 1 in 50,000 to 1 in 33,000 live births and is a leading cause of blindness in children. By targeting a specific genetic mutation associated with the disease, this approach aims to improve visual outcomes and quality of life for affected individuals.","Leber congenital amaurosis (LCA) is an autosomal recessive disorder that causes retinal dystrophy and severe visual impairment in infants, with a prevalence of 1 in 50,000 to 1 in 33,000 live births, making it the primary cause of childhood blindness. AAV-mediated gene therapy is being explored as a treatment specifically for LCA caused by NPHP5 mutations."
"University of Pennsylvania","Polarization imaging sensor for enhanced scene analysis","","","https://upenn.technologypublisher.com/technology/29858","Problem:Along with intensity and color, polarization is a property of light that can provide useful information for scene analysis. However, the human eye and most cameras cannot detect polarization.Gathering polarization data could aid machine vision in detecting information about surfaces, material properties, shadows, and illumination sources. A camera that could easily incorporate polarization imaging could provide better detail and scene analysis that conventional cameras.Solution:Researchers at the University of Pennsylvania have created an image sensor with real-time polarimetric extraction capability at the focal plane.A micropolarizer array mounted on the imaging sensor filters the incoming light through two polarization filters offset at 45 degrees to each other. For each given 2x2 pixel area, both light intensity and polarization information are captured.The data captured by the imaging sensor can be used to calculate the Stokes parameters which quantify the polarization of the light. A complete image sensor is made up of sets of these 2x2 pixel blocks, with the current lab prototype consisting of a 256x256 imager. A polarization imaging camera based on this design could provide additional data for scene analysis and computer vision using a property of light that is often ignored.Advantages:Detect polarization of light for a complete imageAdditional, often undetected information about shadows and illumination sourcesEnhanced imaging and analysis for computer visionStage of Development:PrototypeIntellectual Property:US Patent7,582,857Desired Partnerships:LicenseCase ID:S4194-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29858","**Summary:** Researchers at the University of Pennsylvania have developed an image sensor that can extract polarimetric data in real-time at the focal plane, which enhances scene analysis beyond the capabilities of conventional cameras. This sensor employs a micropolarizer array that filters incoming light through two polarization filters set at 45 degrees, allowing it to capture both light intensity and polarization information over 2x2 pixel areas. The prototype currently features a 256x256 imager that can calculate Stokes parameters, providing comprehensive data for analyzing surfaces, material properties, shadows, and illumination sources.

**Applications:** This technology can be utilized in various fields requiring advanced imaging capabilities, including machine vision, autonomous vehicles, environmental monitoring, and any applications that benefit from enhanced detail in scene analysis.

**Problem Solved:** Traditional cameras and the human eye are unable to detect light polarization, which limits the information available for analyzing scenes. The new imaging sensor addresses this by capturing and processing polarization data, leading to improved detection of surface characteristics, shadows, and lighting conditions that are often overlooked.","Polarization is a property of light that can enhance scene analysis but is not detectable by the human eye or most cameras. Developing a camera that integrates polarization imaging could improve the detail and information gathered in machine vision, aiding in the detection of surface properties, shadows, and illumination sources."
"University of Pennsylvania","Ruthenate materials with large magnetoresistance effects","","","https://upenn.technologypublisher.com/technology/29849","Problem:Magnetoresistive materials can change their electrical resistance when subject to an applied magnetic field. This property can be used for non-volatile resistance switching memory in which high and low resistance states are used to encode data. A similar effect called EPIR (electric-pulse induced resistance) can be used to change material resistance with electrical pulses. To utilize such materials in electronics, nontoxic substances are needed that can easily be integrated with modern semiconductor processing.Solution:Researchers at the University of Pennsylvania have developed ruthenate materials that exhibit large magnetoresistance and electric pulse induced resistance switching effects. These ruthenate formulations from the perovskite family are shown to have a magnetoresistive effect of 18% or more when a magnetic field is applied. These materials can exhibit both MR and room-temperature EPIR effects.The family of ruthenate materials are non-toxic and compatible with CMOS processing, which could make them very useful for MR or EPIR based resistive memory devices.Advantages:Large magnetoresistance and electrical pulse induced resistanceNon-toxic compositionsApplications:Resistance switching nonvolatile memoryStage of Development:Laboratory prototypeIntellectual Property:US7,211,199US8,652,347Reference Media:Mamchik & Chen. (2003).Appl Phys Lett 2003 Jan, 82(4): 613.Desired Partnerships:LicenseCase ID:O2773-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29849","**Summary:** Researchers at the University of Pennsylvania have developed ruthenate materials that demonstrate a significant magnetoresistive effect of 18% or more in applied magnetic fields, along with electric pulse induced resistance switching effects. These materials belong to the perovskite family and are characterized as non-toxic and compatible with CMOS processing, making them suitable for integration into modern semiconductor technologies. The materials are currently in the laboratory prototype stage.

**Applications:** The primary applications of these ruthenate materials are in the development of non-volatile memory utilizing resistance switching mechanisms. Their magnetoresistive and electric pulse induced resistance features position them well for use in advanced resistive memory devices.

**Problem Solved:** The technology addresses the need for non-toxic magnetoresistive materials that can be easily integrated into current semiconductor processing techniques, which enhances the potential for the development of efficient and reliable non-volatile memory systems.","Magnetoresistive materials alter their electrical resistance in the presence of a magnetic field, enabling applications in non-volatile resistance switching memory. The use of nontoxic substances that are compatible with modern electronics is essential for effective integration of these materials."
"University of Pennsylvania","One-step synthesis of cationic steroids for gene delivery, anti-inflammatory activity, and antimicrobial activity.","","","https://upenn.technologypublisher.com/technology/29847","Reagents for improved DNA lipofection, depot anti-inflammation, and/or topical antimicrobial therapyTechnology Overview:Researchers in the Diamond Lab have developed a versatile new class of pharmacologically-active molecules with multiple applications. These molecules deliver plasmids (pDNA), adenovirus (AdV), and adeno-associated virus (AAV) to cultured cells and to pulmonary epithelium in vivo. In addition to their gene delivery capabilities, the structure of the molecules allows them to function as slow-release prodrugs for local treatment of vector-associated inflammation. Importantly, this therapeutic effect may synergize with the gene that is delivered.The anti-inflammatory effect of the cationic steroids does not require DNA, and as the prodrugs degrade, they break down into non-toxic materials with pharmacological activity. The molecules can be readily synthesized in one-step from inexpensive precursors in a scalable reaction and purified in gram quantities. Additionally, the cationic steroids have potent antimicrobial activity against gram-positive and gram-negative bacteria, including clinical strains of MRSA and pseudomonas.Advantages:Efficient delivery of genes to cultured cellsSynergistic combination of gene delivery and anti-inflammatory effects to enhance gene therapyRapid production of compound in large quantitiesPotent and rapid bactericidal activity against drug-resistant bacteriaApplications:Gene therapy via non-viral gene deliverySlow-release therapeutics for treatment of inflammationEnhancer of DNA vaccinesPulmonary infectionsSynthesis of a cationic steroid for gene delivery and anti-inflammatory activity. From Gruneich et al, 2004.Stage of Development:Proof-of-concept and mouse in vivo dataIntellectual Property:US7,442,386US9,056,048HK1066485Reference Media:Gruneich JA et al.Gene Ther 2004 Apr, 11(8): 668.Gruneich JA and Diamond SL.J. Gene Med,2007 May, 9(5): 381(pdf).Desired Partnerships:LicenseCo-developmentCase ID:N2612-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29847","**Summary:** Researchers in the Diamond Lab have developed a new class of pharmacologically-active cationic steroids that serve multiple purposes, including efficient delivery of plasmids, adenoviruses, and adeno-associated viruses to cultured cells and pulmonary epithelium in vivo. These molecules are capable of functioning as slow-release prodrugs for localized treatment of vector-associated inflammation, which can enhance the efficacy of gene therapy. The anti-inflammatory effects of these compounds do not depend on the presence of DNA, and they decompose into non-toxic substances upon degradation. Moreover, they can be synthesized quickly from low-cost precursors, allowing for large-scale production.

**Applications:** The technology can be applied in gene therapy through non-viral delivery systems, slow-release therapeutics for managing inflammation, and topical antimicrobial treatments targeting both gram-positive and gram-negative bacteria, including drug-resistant strains like MRSA and pseudomonas.

**Problem Solved:** The new cationic steroids address several challenges in gene therapy, such as the need for efficient gene delivery methods, reduction of inflammation associated with vector use, and the management of infections from drug-resistant bacteria.","Researchers in the Diamond Lab have developed a new class of pharmacologically-active cationic steroids that can deliver various types of genetic material, including plasmids and viruses, to cultured cells and pulmonary epithelium in vivo. These molecules also exhibit anti-inflammatory and antimicrobial properties, making them versatile for applications in gene delivery, anti-inflammatory treatment, and topical antimicrobial therapy."
"University of Pennsylvania","Therapeutic Vaccine for Myasthenia Gravis","","","https://upenn.technologypublisher.com/technology/38270","Vaccine offering potential cure for rare autoimmune disorder Myasthenia Gravis.Problem:Myasthenia gravis (MG) is caused by an antibody-mediated autoimmune response to muscle nicotinic acetylcholine receptors (AChRs) of skeletal muscles that impairs neuromuscular transmission, resulting in weakness and fatigability. The prevalence in the U.S. is estimated at 20 cases per 100,000 people. The cause for the autoimmune response to AChRs in MG is not known.Current treatment options include acetylcholinesterase inhibitors (with modest efficacy at improving neurotransmission) and nonspecific immunosuppressants (whose beneficial effects may be delayed for up to 18 months and can cause severe side effects). No specific immunosuppressive therapy is available.Solution:Dr. Jon Lindstrom and his team at Penn have developed a specific immunosuppressive therapy with great potential for treating MG. The vaccine utilizes cytoplasmic domains of human AChR subunits and incomplete Freund‚Äôs adjuvant.When tested in rat models of the experimental autoimmune myasthenia gravis (EAMG), which is considered the gold standard animal model for MG, the vaccine was demonstrated to be a safe and rapidly suppressed established chronic EAMG providing long-term, possibly permanent, resistance to re-induction of EAMG. The next planned steps are to optimize dose and schedule with an adjuvant such as alum that can be used in humans and test the vaccine in cats with naturally occurring MG.Advantages:long-lasting benefits, potentially permanent protectionpotent, safe, and rapidly actingprevention as well as reversal of chronic MGpotential veterinary use (cats, dogs and other animals can be affected by MG)Stage of Development:In vivo data including data on dose and treatment paradigmsIntellectual Property:US11,235,040Reference Media:Luo, J & Lindstrom;J Immunol 2014 Nov 15; 193(10): 5044Desired Partnerships:LicenseCo-developmentCollaborationCase ID:15-7271-tpNCSWeb Published:1/27/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38270","**Summary:** A therapeutic vaccine has been developed as a potential cure for Myasthenia Gravis (MG), a rare autoimmune disorder characterized by an antibody-mediated attack on muscle nicotinic acetylcholine receptors, leading to impaired neuromuscular transmission and resultant weakness. The vaccine, created by Dr. Jon Lindstrom and his team at Penn, uses cytoplasmic domains of human AChR subunits and incomplete Freund's adjuvant to provide targeted immunosuppression. In studies with rat models of experimental autoimmune myasthenia gravis (EAMG), the vaccine demonstrated safety and efficacy in rapidly suppressing chronic EAMG, offering long-term resistance to disease recurrence. Future steps will focus on optimizing the formulation for human use and testing in feline models of MG.

**Applications:** The vaccine is aimed at treating Myasthenia Gravis and could potentially be used in human patients as well as in animals, specifically cats with naturally occurring MG.

**Problem Solved:** The technology addresses the challenges associated with current MG treatments, which mainly include acetylcholinesterase inhibitors and broad-spectrum immunosuppressants that have limited efficacy and significant side effects. The vaccine offers a specific and potentially more effective immunotherapy option, reducing the adverse effects and delays associated with existing treatment modalities.","Myasthenia gravis (MG) is an autoimmune disorder characterized by an antibody-mediated response that targets muscle nicotinic acetylcholine receptors, leading to muscle weakness and fatigue. It affects approximately 20 individuals per 100,000 people in the U.S., and the underlying cause of the autoimmune response remains unknown."
"University of Pennsylvania","Small Molecule Antivirals for Therapeutic Applications","","","https://upenn.technologypublisher.com/technology/38067","Antiviral compounds that competitively disrupt virus-host interactions to inhibit disease progression and transmissionProblem:Hemorrhagic fever viruses such as Ebola, Marburg, and Lassa are some of the deadliest viruses in the world and yet, there are currently no vaccines or therapeutics available to control their infection and transmission.The 2014 Ebola outbreak had devastating effects on the economies, healthcare systems and communities in the West African countries of Sierra Leone, Guinea and Liberia. This outbreak also had an impact on the U.S. economy, with $2.4 billion dollars (the most from any country worldwide) being donated in the form of personnel, technical expertise and resources to establish three new emergency operation centers to control the epidemic (CDC).While the number of hemorrhagic fever incidences has declined since 2014, a broad spectrum antiviral that is effective at controlling these viruses is urgently needed.Solution:Dr. Harty and his team have identified small molecules that inhibit infectivity and spread of hemorrhagic fever viruses. These antiviral compounds disrupt key interactions between viral late (L) budding domains and mammalian host proteins. L domains are highly conserved motifs present in a wide array of RNA virus matrix proteins including filoviruses, arenaviruses, rhabdoviruses, paramyxoviruses and retroviruses, thus making these antivirals applicable to a vast assortment of human pathogens.Advantages:Broadly applicable to viruses containing L-domainLittle to no risk of viruses developing resistancNew class of ""host-oriented"" therapeuticsBrief course of treatmentStage of Development:In vitro studies with live virus and virus like particles are completeIn vitro toxicity studies are completeSAR of >150 compounds completed with two lead series identifiedNext stage is in vivo animal model studiesIntellectual Property:US10,160,756Reference Media:Lu, J et al.;J Virol. 2014 May; 88(9): 4736Han, Z et al.;J Virol. 2014 Jul; 88(13): 7294Loughran, HM et al.;Bioorg Med Chem Lett. 2016 Aug 1; 26(15): 3429Desired Partnerships:LicenseCo-developmentCase ID:14-7018-tpNCSWeb Published:1/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38067","**Summary:** Antiviral compounds have been developed that competitively disrupt virus-host interactions, effectively inhibiting the progression and transmission of hemorrhagic fever viruses, such as Ebola, Marburg, and Lassa. These viruses pose significant risks to global health, and the lack of available vaccines or therapeutics underscores the urgency for new solutions. The 2014 Ebola outbreak highlighted the devastating impacts these viruses can have on economies and healthcare systems, especially in affected regions like West Africa. 

**Applications:** The small molecule antivirals discovered by Dr. Harty and his team are designed to inhibit the infectivity and spread of several hemorrhagic fever viruses. Their mechanism involves disrupting key interactions between viral late budding domains and mammalian host proteins. Due to the highly conserved nature of L domains found in a broad range of RNA viruses, these compounds may be effective against numerous pathogens, including filoviruses, arenaviruses, rhabdoviruses, paramyxoviruses, and retroviruses.

**Problem Solved:** The technology addresses the critical gap in therapeutic options for controlling and preventing infections caused by some of the deadliest viruses known, particularly in light of the significant societal and economic consequences observed during viral outbreaks like Ebola. By providing a mechanism to inhibit vital virus-host interactions, these small molecule antivirals offer a promising avenue for reducing the threat of hemorrhagic fever viruses.","Hemorrhagic fever viruses like Ebola, Marburg, and Lassa are among the deadliest in the world, with no vaccines or therapeutics currently available to control their infection and transmission. The 2014 Ebola outbreak severely impacted the economies, healthcare systems, and communities of West African countries such as Sierra Leone and Guinea."
"University of Pennsylvania","Antimicrobial coating for medical device, biosensor, nanofluidic, and drug delivery applications","","","https://upenn.technologypublisher.com/technology/39311","Multifunctional, chemically modified chitosan surfaces and charged polymer brushes with protection against microbes and changes in pHProblem:Chitosan, a cationic polysaccharide, is a biocompatible and biodegradable coating material. While chitosan has been used for drug delivery, wound dressings, and tissue materials, this material has not been fully realized as a biomaterial coating due to its limited solubility at physiological conditions. At low pH, chitosan is a water-soluble cationic polyelectrolyte, while at pH above 6.5, chitosan is uncharged and becomes insoluble in water.Solution:Researchers at Penn and Thomas Jefferson University have developed a new formulation of chitosan by modifying the molecule with quaternary ammonium salts, enhancing solubility in water.Grafting a thin layer of this modified chitosan and immobilizing on a surface generates resistance to biofilm formation due to the material‚Äôs enhanced microbicidal activities. Furthermore, there is a pH-dependent swelling behavior, which could be exploited to initiate drug release or control the width of channels in nanofluidic devices. The grafted chitosan has been shown to reduce bacterial colonization of S. aureus compared to silicon oxide and APTES modified silicon oxide surfaces.Advantages:Stable coating on grafted surface from pH 3-8pH-dependent swellingAntibacterial propertiesTunable formulationInexpensive manufacturingPrevent patient infections from medical devices by reducing biofilm formationApplications:Long-term multifunctional coating of medical devicesVentilators, endotracheal tubes, stents, implants, nanofluidic devicesBiosensorsControlled drug deliveryStage of Development:Proof-of-concept material characterization and testing with S. aureus biofilmIntellectual Property:US9,950,097Reference Media:Lee HS et al.J. Mater. Chem., 2012, 22, p. 19605.Lee HS et al.Langmuir, 2011 Oct 18 27(20): 12458.Desired Partnerships:LicenseCo-developmentCase ID:X5797-tpNCSWeb Published:3/18/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39311","**Summary:** Multifunctional, chemically modified chitosan surfaces have been developed, featuring charged polymer brushes that provide protection against microbial growth and adapt to changes in pH. This innovation addresses the limited solubility of natural chitosan at physiological pH levels by altering its molecular structure with quaternary ammonium salts, enhancing its performance as a biocompatible and biodegradable coating material for various applications.

**Applications:** The modified chitosan can be utilized in medical devices, biosensors, nanofluidic applications, and drug delivery systems. Its properties allow for the prevention of biofilm formation, making it particularly suitable for use in environments susceptible to bacterial colonization. 

**Problem Solved:** The technology overcomes challenges associated with the use of chitosan as a biomaterial coating, specifically its limited solubility in physiological conditions and difficulty in preventing microbial adhesion, offering a stable and effective solution to reduce biofilm formation on surfaces, thereby minimizing the risk of patient infections related to medical devices.","Chitosan, a biocompatible and biodegradable cationic polysaccharide, has potential applications as a coating material but is limited by its solubility at physiological conditions. Despite its uses in drug delivery and wound dressings, its full potential as a biomaterial coating has not been realized due to these solubility challenges."
"University of Pennsylvania","Antimicrobial polymer layers for medical devices and controlled drug delivery","","","https://upenn.technologypublisher.com/technology/32430","Stimuli-responsive bilayer coating to prevent bacterial infectionProblem:Hospital acquired infections are a leading cause of death in the US, with about 10% of hospitalized patients developing an infection, a medical cost of $5 billion. Implantable devices are prone to biofilm formations, causing infections in the patient. Existing medical devices have coatings to promote contact killing of microbes or resistance to adhesion, but the coatings may not be biocompatible or have maximum efficacy.Solution:Researchers in the Composto and Eckmann Labs have developed a novel bilayer system that combats biofilm formation. The outer layer is a pH-responsive chitosan-based formulation that is resistant to bacterial adhesion, while the inner layer is an anionic poly acrylic acid monolayer grafted directly on to the device.The composition of this bilayer brush allows for antibiotic to be loaded and retained. If a biofilm forms, the pH decreases, causing the outer chitosan layer to swell, yielding controlled release of antibiotic. Because antibiotic release occurs only in when bacterial growth is detected, the patient minimizes exposure to drug.Advantages:Prevent biofilm formation and eradicate bacterial growthTunable properties allow for control of drug deliveryMinimize exposure to antibiotic, a critical step in combating antibiotic resistance and growth of superbacteriaApplications:Coating of implantable medical devices, including catheters, shunts, and stentsStimuli-responsive drug delivery systemsGenerate multifunctional grafted bilayersStage of Development:Proof-of-concept demonstration of antibiotic loading and release to eradicate bacterial adhesion and growthIntellectual Property:US11,052,177Reference Media:Lee HS et al.Biomacromolecules, 2015 Feb 9, 16(2): 650.Lee HS et al.J. Mater. Chem. BMater Biol Med, 2013 Dec 14, 1(46): 6382.Desired Partnerships:LicenseCo-developmentCase ID:Z6626-tpNCSWeb Published:4/22/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/32430","**Summary:** Researchers have developed a bilayer coating system designed to prevent bacterial infections associated with implantable medical devices. The outer layer consists of a pH-responsive chitosan-based formulation that resists bacterial adhesion, while the inner layer is made of an anionic poly acrylic acid monolayer that can retain and release antibiotics. This unique design allows for controlled antibiotic release triggered by the presence of a biofilm, thus minimizing unnecessary drug exposure and helping to address concerns related to antibiotic resistance.

**Applications:** The technology is applicable for coating various implantable medical devices, including catheters, shunts, and stents, as well as for controlled drug delivery systems.

**Problem Solved:** The bilayer coating addresses the issue of hospital-acquired infections, which significantly impact patient health and incur substantial medical costs. By preventing biofilm formation on medical devices and allowing for controlled antibiotic delivery, it reduces the risk of infection and minimizes the potential for antibiotic resistance.","Hospital-acquired infections affect 10% of hospitalized patients in the US, leading to significant medical costs and complications related to implantable devices, which are susceptible to biofilm formation. Current coatings on medical devices often lack biocompatibility or optimal effectiveness, highlighting the need for improved antimicrobial strategies."
"University of Pennsylvania","Smart blocks for virtual-physical interaction","","","https://upenn.technologypublisher.com/technology/31571","Enhanced interaction between the virtual and physical worldsProblem:Currently, most games and toys consist of either virtual objects or physical objects, with no interaction between the two. A method of connecting the virtual and physical worlds could enhance design, collaboration, and entertainment in new ways. Some existing systems can represent a physical object in a virtual environment by using a RFID tag, but this is a limited solution that cannot represent the actual state or orientation of the object.Solution:Researchers at the University of Pennsylvania have created a new smart block technology that connects the physical and virtual world. As the blocks are connected together, they can detect their position and orientation, as well as identify which blocks are on top and below them. The data from the blocks is relayed to a virtual representation which changes in real time as the user manipulates the blocks. In addition to merely sensing the presence of another block, putting a certain block in the right position or building a certain shape could trigger events in both the physical and virtual world. The block could light up in the physical world, or unlock an animation in the virtual world, representing a new level of physical-virtual interaction.Applications:Games, models, and entertainmentRobot state estimation and monitoringManufacturingStage of Development:PrototypeIntellectual Property:US11,213,747Desired Partnerships:LicenseCo-developmentCase ID:16-7751-tpNCSWeb Published:3/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31571","**Summary:** Researchers at the University of Pennsylvania have developed a smart block technology that enhances interaction between the physical and virtual worlds by detecting the position and orientation of connected blocks. Unlike traditional systems that may utilize RFID tags for basic identification, these blocks convey real-time data on their arrangement, allowing for seamless integration of physical actions with virtual responses. The technology enables physical manipulations of the blocks to trigger corresponding events in both realms, such as lighting effects or animations, significantly improving user engagement.

**Applications:** The technology can be applied in games, model building, entertainment, robot state estimation and monitoring, and manufacturing.

**Problem Solved:** The solution addresses the current limitation where most games and toys operate separately in either the virtual or physical domain, allowing for new possibilities in design and collaboration through enriched interactive experiences.","Most games and toys currently lack interaction between virtual and physical objects, limiting their design and entertainment potential. While some systems use RFID tags to represent physical objects in a virtual environment, this approach is constrained and does not capture the actual state or orientation of the objects."
"University of Pennsylvania","Method and microfluidic chip for two-stage multiplexed isothermal enzymatic amplification","","","https://upenn.technologypublisher.com/technology/38434","On-chip two-step nucleic acid amplification for point-of-care and clinical molecular detection of multiple diseases and co-infectionsProblem:Polymerase chain reaction methods (PCR) for nucleic acid amplification have revolutionized molecular diagnostics and genetics research. Nested PCR relies on two successive runs of thermal cycling and two sets of primers, reducing non-specific amplification that occurs with traditional PCR. However, this method is not optimal for point-of-care applications because of its complexity and the risk of contamination that can occur upon manual transfer of the products from the first amplification round to the second round. Furthermore, thermal cycling requires specialized automated equipment that is not practical for resource-poor regions.Solution:The Bau Lab has devised a two-step nucleic acid amplification method, termed Rapid Amplification (RAMP). The first amplification step uses recombinase polymerase amplification (RPA), and the second step relies on loop-mediated isothermal amplification (LAMP), amplifying secondary targets within the products of the first round of amplification.Both amplification and detection are carried out under isothermal conditions, simplifying or eliminating instrumentation. Moreover, the researchers have designed and tested a microfluidic chip device by which RAMP and other nucleic acid amplification methods, including nested PCR and isoPCR, may be carried out. The device is comprised of multiple hydraulically connected reaction chambers; the products of the first amplification stage transfer to the second amplification reactor by diffusion.Advantages:High sensitivityRapid assayDetect multiple targets simultaneously without loss of specificitySimplify instrumentationLower risk of sample contamination with entire process in closed systemMethod compatible with on-chip processing of designed microfluidic deviceSixteen-plex assay demonstrated (higher level of multiplexing is possible)Applications:Diagnostic testing in clinical and point-of-care settingsTop: A microfluidic chip for two-stage amplification, featuring a central multiplex RPA reactor (green) and 16 branching LAMP reactors (blue) for specific targets and controls.Bottom: An example of a 16-plex, two-stage RAMP assay designed to detect (1) S. mansoni, (2) HIV-1 clade B, (3) S. haematobium, (4) P. falciparum, (5) S. japonicum, (6) B. malayi, (7) S. stercoralis, (8) Drug-resistant salmonella, (9) ZIKV-America strain (mex 2-81, Mexico), (10) ZIKV-Africa strain (MR 766, Uganda), (11) HPV-58, (12) HPV-52, (13) HPV-35, (14) HPV-45, (15) HPV-18, and (16) HPV-16. Amplification curves when the sample contains HPV-16 (100 copies), ZIKV (American strain, 50 PFU), and none of the other targets.Stage of Development:Prototype developed and in vitro multiplex testingIntellectual Property:US11,118,206Reference Media:Song, J et al.;Clin Chem 2017 March, 63(3): 714.Desired Partnerships:LicenseCo-developmentCase ID:16-7708-tpNCSWeb Published:2/3/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38434","**Summary:** The technology describes a two-step nucleic acid amplification method that integrates recombinase polymerase amplification (RPA) and loop-mediated isothermal amplification (LAMP) in a microfluidic chip designed for point-of-care diagnostic applications. This method addresses the limitations of traditional polymerase chain reaction (PCR) techniques, particularly nested PCR, by executing both amplification steps under isothermal conditions, thus avoiding the complexity and contamination risks associated with thermal cycling. The microfluidic chip facilitates streamlined processes for amplification and detection, making it more suitable for resource-limited settings.

**Applications:** The technology is applicable for clinical molecular detection of multiple diseases and co-infections, particularly in point-of-care scenarios where rapid and reliable diagnostics are essential. Its isothermal nature allows it to be used in settings lacking sophisticated laboratory equipment.

**Problem Solved:** This method solves the issues of complexity, contamination risk, and the need for specialized equipment associated with traditional thermal cycling PCR techniques, making nucleic acid amplification more accessible and practical for use in resource-poor environments.","This work addresses the limitations of traditional polymerase chain reaction methods (PCR) for nucleic acid amplification, particularly in point-of-care applications, by introducing an on-chip two-step nucleic acid amplification technique. The method utilizes nested PCR to reduce non-specific amplification while allowing for multiplexed detection of multiple diseases and co-infections."
"University of Pennsylvania","Fluorinated building blocks for organic synthesis and macromolecule synthesis","","","https://upenn.technologypublisher.com/technology/39343","Synthesis of trifluoromethylated alkylboron compounds and incorporation into small molecules and macromoleculesProblem:Fluorinated macromolecules are widely utilized in industry, with the most notable example being Teflon, or perfluorotetrafluoroethylene (PTFE). Additionally, methods for incorporating CF3 into small organic molecules are not well developed, but are needed to expand the chemical repertoire for fluorine incorporation into pharmaceuticals, agrochemicals, and materials.Solution:Researchers in the Molander Lab have developed a metal-free synthetic route to incorporate CF3 groups and other fluorinated alkyl chains into small molecules as well as macromolecules using organoboron intermediates to generate newfound, polyfluorinated entities. These organoboron building blocks are bench-stable, with indefinite shelf-life. The synthetic methods developed allow the introduction of CF3 at sp3-hybridized centers via a novel carbon-carbon bond connection.Advantages:Low surface tension and coefficient of frictionHigh chemical and thermal stabilityMore readily soluble than existing fluoropolymersExcellent dielectric propertiesPhysical properties potentially superior to Teflon / PTFEBiodegradabilityApplications:Non-stick coatingsLubricantsSurfactantsWiringsCompositesBench-stable, trifluoromethylated building blocks for pharmaceutical and agrochemical applicationsStage of Development:Proof-of-conceptIntellectual Property:US9,856,275Reference Media:Ryu D. et al.Chem. Eur. J.,2016 Nov 98, 22(1): 120.Molander G.A. and Ryu D.Angew. Chemie Intl Ed,2014 Oct 24, 53(51): 14181.Argintaru O.A. et al.Angew. Chemie Intl Ed,2013 Nov 7, 52(51): 13656.Desired Partnerships:LicenseCo-developmentCase ID:Z6435-tpNCSWeb Published:3/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39343","**Summary:** The technology involves the synthesis of trifluoromethylated alkylboron compounds that can be incorporated into small molecules and macromolecules. Researchers have developed a metal-free synthetic route that enables the introduction of CF3 groups and other fluorinated alkyl chains. This method utilizes organoboron intermediates to create stable polyfluorinated entities with indefinite shelf-life, allowing for versatility in various applications.

**Applications:** The applications of this technology include non-stick coatings, lubricants, surfactants, wirings, and composites. Additionally, the trifluoromethylated building blocks are suitable for pharmaceutical and agrochemical applications.

**Problem Solved:** The technology addresses the limited methods for incorporating CF3 into small organic molecules, which are necessary for expanding the chemical repertoire in the production of fluorinated macromolecules, particularly in industries reliant on materials like Teflon. The developed methods enhance the availability and functionality of fluorinated compounds for robust industrial and commercial applications.","Fluorinated macromolecules, such as Teflon, are important in industry, yet methods for incorporating trifluoromethyl (CF3) groups into small organic molecules remain underdeveloped. The research addresses this gap by synthesizing trifluoromethylated alkylboron compounds and integrating them into various small molecules and macromolecules."
"University of Pennsylvania","Non-perturbative, site-specific labeling of Œ±-synuclein for studying amyloid disease and screening therapeutics","","","https://upenn.technologypublisher.com/technology/38468","Fluorescently labeled Œ±-synuclein to examine destabilization of synuclein fibrils by small molecules and therapeutics for neurodegenerative diseasesProblem:Misfolding of the neuronal protein Œ±-synuclein triggers oligomerization and the formation of amyloid fibrils that are the pathological hallmarks of Parkinson‚Äôs disease. The molecular mechanism of synuclein misfolding has not been elucidated, and therefore, screening of compounds that block or reverse aggregation can establish novel mechanisms of action.Previous efforts to employ small molecule probes, such as Thioflavin T and Congo Red, in drug screening experiments have been unfavorable, as the probes compete with candidate compounds for binding sites on synuclein. There is no cure for these progressive neurodegenerative diseases, although therapeutics and biologics are in development. A high-throughput screening method to examine fibril disaggregation as a measure of therapeutic efficacy would be advantageous to the pharmaceutical industry developing the next generation of therapeutics.Solution:Researchers in the Petersson Lab have developed a minimally-perturbative fluorescence polarization assay to monitor the local conformational dynamics of Œ±-synuclein. Synuclein has been site-specifically labeled with the fluorophores, chromatographically purified, and characterized with mass spectrometry. The non-perturbing nature of the labels has been validated by in vitro kinetics experiments, quantification of the incorporated labeled protein, and TEM imaging of the synuclein fibrils. The labeled synuclein can be used to examine fibril formation and destabilization in in vitro and cellular models of neurodegenerative disease propagation and progression.Advantages:Site-specific, homogeneous fluorophore attachmentHigh-throughputNon-perturbative to proteinApplications:High-throughput screening for small moleculesOptimization of lead compounds for Parkinson‚Äôs disease and other amyloidogenic neurodegenerative diseasesStudy misfolding and fibrillization of synuclein in vitro and in cellsStage of Development:In vitro proof-of-conceptIntellectual Property:Tangible research materialReference Media:Haney CM et al.Org. Biomol. Chem., 2016 Feb 7, 14(5): 1584Desired Partnerships:LicenseCo-developmentCase ID:16-7930-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38468","**Summary:** The development involves using fluorescently labeled Œ±-synuclein to investigate how small molecules and therapeutics can destabilize synuclein fibrils associated with neurodegenerative diseases, particularly Parkinson's disease. This technique aims to clarify the molecular mechanisms underlying Œ±-synuclein misfolding and aggregation, which result in pathological amyloid fibrils. Traditional small molecule probes used for drug screening have proven ineffective due to competition for binding sites, highlighting the need for more effective methods to assess potential therapeutics.

**Applications:** This technology can be utilized in high-throughput screening of compounds aimed at blocking or reversing the aggregation of Œ±-synuclein, facilitating the discovery of new therapeutic agents for treating neurodegenerative diseases. The minimally-perturbative fluorescence polarization assay developed by the Petersson Lab allows researchers to better understand the conformational dynamics of Œ±-synuclein while evaluating drug efficacy.

**Problem Solved:** The technology addresses the challenges faced in investigating the aggregation of Œ±-synuclein by providing a more effective and non-perturbative approach to screen small molecules and therapeutics. It overcomes limitations of previous compound screening methods that were hindered by competition with traditional fluorescent probes, thereby enhancing the ability of pharmaceutical companies to develop new treatments for neurodegenerative diseases.","The study utilizes fluorescently labeled Œ±-synuclein to investigate the destabilization of synuclein fibrils caused by small molecules and potential therapeutics for neurodegenerative diseases such as Parkinson's. It highlights the need to screen compounds that may inhibit or reverse the aggregation process associated with the misfolding of Œ±-synuclein."
"University of Pennsylvania","A genetically encoded Œ≤-lactamase reporter for ultrasensitive 129Xe NMR and MRI in mammalian cells","","","https://upenn.technologypublisher.com/technology/38452","Hyperpolarized xenon chemical exchange saturation transfer (CEST) contrast agent for molecular imagingProblem:While genetically encoded optical reporters have enabled biomolecular imaging, the strong scattering of light by tissue is problematic. Optical reporters are limited to examining single cells and transparent model organisms. Alternate non-invasive imaging methods, such as magnetic resonance imaging (MRI), are needed for monitoring gene expression and cell migration in vivo. Furthermore, despite excellent spatiotemporal resolution, 1H MRI reporter genes are limited by low detection sensitivity.Solution:Researchers in the Dmochowski Lab have developed a genetically encoded, single protein reporter for hyperpolarized 129Xe NMR and MRI with high saturation contrast for use in molecular imaging applications. Hyperpolarized xenon provides enhanced detection sensitivity. Because 129Xe is nontoxic, it can be safely delivered via inhalation or injection in vivo. Furthermore, its small size and hydrophobicity allow for interactions with proteins, occupying hydrophobic cores, substrate-binding sites, and channel pores, enabling the study of biological phenomena.129Xe chemical exchange saturation transfer (CEST) occurs between the aqueous solvent and Œ≤-lactamase, either in solution or inside a cell. Xenon CEST interactions with Œ≤-lactamase yield a distinct saturation peak and chemical shift. The x-ray crystal structure of the binding of xenon to Œ≤-lactamase has been elucidated, which will inform the design of additional CEST agents.Advantages:Nontoxic, readily deliverable to cells and in vivoHigh molecular sensitivityNoninvasive imaging methodHigh contrastApplications:Molecular imagingContrast agentsElucidate biological processes, normal and diseased physiological statesStudy cryptic pockets in proteinsStage of Development:Proof-of-conceptIn vitro and in vivo testingIntellectual Property:US11,300,640Reference Media:Wang Y. et al.Angew Chem 2016 July 25 55(31): 8984.Roose B.W. et al.ACS National Meeting, March 13, 2016 12:10PM.Single-protein reporter for hyperpolarized xenon magnetic resonance imaging.Dmochowski, I.J. et al.ACS National Meeting, March 14, 2016 1:35PM.Xenon: new applications in materials chemistry and biosensing.Desired Partnerships:LicenseCo-developmentCase ID:16-7836-tpNCSWeb Published:2/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38452","**Summary:** Researchers have developed a genetically encoded Œ≤-lactamase reporter that enhances hyperpolarized 129Xe NMR and MRI for molecular imaging in mammalian cells. This system utilizes the nontoxic nature of hyperpolarized xenon, which can be administered safely via inhalation or injection, and benefits from the unique interactions between xenon and the Œ≤-lactamase protein. The technology leverages chemical exchange saturation transfer (CEST) to achieve high sensitivity and distinct signal peaks, making it suitable for in vivo imaging applications.

**Applications:** This technology can be applied in various fields of biomedical research, particularly in gene expression monitoring and cell migration studies. It has potential uses in drug development, cancer research, and other areas requiring non-invasive imaging techniques.

**Problem Solved:** The developed system addresses the limitations of traditional optical reporters, which struggle with tissue light scattering and are restricted to single-cell or transparent organism studies. It also improves upon conventional 1H MRI reporter genes by providing a higher detection sensitivity, facilitating more accurate in vivo observations of biological processes.","A novel genetically encoded Œ≤-lactamase reporter has been developed for use in ultrasensitive 129Xe NMR and MRI within mammalian cells. This approach addresses limitations of optical reporters by providing a non-invasive method for monitoring gene expression and cell migration in vivo."
"University of Pennsylvania","Musashi1/2 Mouse Strains and Embryonic Stem Cells","","","https://upenn.technologypublisher.com/technology/38071","Various mouse strains and embryonic stem cell lines useful in studying Musashi 1 and/or 2 signalingTechnology Overview:The mammalian Musashi (Msi) protein family consists of two members, Musashi 1 (Msi1) and Musashi 2 (Msi2), which are RNA binding proteins that have been shown to regulate stem cell self-renewal and tumorigenesis in numerous tissues. While the initial in vitro studies have laid the groundwork for understanding the molecular function of Msi proteins, it has been a challenge to study the role of this protein family in vivo, due to functional redundancy between Msi1 and Msi2 and embryonic lethality of Msi1-/-/Msi2-/- double knockout mice (unpublished).Research in the laboratory of Dr. Chris Lengner has resulted in the development of multiple tools for the in vivo investigation of Msi family protein function. These tools enable spatio-temporal control of Msi1 and/or Msi2 gain and loss of function:Doxycycline-inducible Msi1 transgenic mouse strainMsi1 Conditional knockout mouse strain (designated Msi1flox/flox)Msi1/2 Conditional knockout mouse strain (designated Msi1flox/flox; Msi2flox/flox)Msi1/2 knockout mouse embryonic stem cellsDoxycycline-inducible Msi1 mouse embryonic stem cellsDoxycycline-inducible Msi2 mouse embryonic stem cellsMsi2 Conditional knockout mouse strain (Msi2flox/flox - available via Jackson Laboratories))Doxycycline-inducible Msi2 transgenic mouse strain (available via Jackson Laboratories)Applications:Cancer researchDrug screeningStem cell researchDevelopmental studiesReference Media:Li, N et al.,Cell Rep,2015 Dec 22, 13(11): 2440Taggart, J et al.,Nat Commun,2016 Feb 22; 7: 10739Wang, S et al.,Nat Commun, 2015 Mar 16; 6: 6517Park, SM et al.,J Clin Invest. 2015 Mar 2; 125(3): 1286Park, SM et al.;J Exp Med 2014 Jan 13; 211(1): 71Desired Partnerships:LicenseCo-developmentCase ID:14-7040-tpNCSWeb Published:1/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38071","**Summary:** This technology encompasses various mouse strains and embryonic stem cell lines designed to investigate the signaling pathways of Musashi 1 (Msi1) and Musashi 2 (Msi2), which are RNA binding proteins playing critical roles in stem cell self-renewal and tumorigenesis. Research has developed tools that allow for precise control over the gain and loss of function of these proteins in vivo, addressing difficulties caused by their functional redundancy and the embryonic lethality observed in double knockout models.

**Applications:** The technology can be utilized in cancer research, drug screening, and stem cell research, offering valuable insights into the roles of Musashi proteins in these fields.

**Problem Solved:** The development of these mouse strains and embryonic stem cell lines addresses the challenges in studying the in vivo functions of Musashi proteins due to their redundancy and the complications arising from embryonic lethality in double knockout scenarios.","The Musashi protein family, including Musashi 1 and Musashi 2, consists of RNA binding proteins that regulate stem cell self-renewal and tumorigenesis. Various mouse strains and embryonic stem cell lines are available for studying the signaling pathways associated with these proteins."
"University of Pennsylvania","Click-active Janus particles","","","https://upenn.technologypublisher.com/technology/38453","Scalable synthesis and functionalization of clickable Janus particles via seeded emulsion polymerizationProblem:Amphiphilic Janus particles are biphasic colloids, where each face has distinct chemical properties. Janus particles are useful for stabilizing multiphasic fluid mixtures, such as emulsions. Current methods make Janus particles rely on surface functionalization or phase separation, which have low throughput or require stringent synthesis conditions. Incorporating a secondary monomer is technically challenging for Janus particles and has been previously demonstrated only for seed/core particles.Solution:Researchers in the Stebe and Lee Labs have developed a bulk synthesis method for generating click-active polystyrene-poly (propargyl acrylate) Janus particles using phase separation with seeded emulsion polymerization to obtain seed particles. Functionalization is achieved through cross-linking and thiol-alkyne click chemistry.This technique has been demonstrated with 3 different click reactions, and the morphology has been characterized with scanning electron microscopy. The method can be expanded to seed particles with hydrophobic monomers and a variety of click-active monomers. Particle morphology, composition, and surface charge can all be controlled, achieving chemical flexibility; furthermore, click reactions can occur throughout the bulk of particles or only at the particle surface.Advantages:Bulk synthesis from commercially available reagentsRapid functionalization of a single clickable Janus particle via click-reactions with pendant groups to transform the chemical composition, surface charge, and particle shape in a matter of minutes.Functionalization without harsh conditionsTailor particles for particular chemical properties, such as wetting, adhesion, catalysis, and biological recognitionFabricate stable particles with diverse compositionsSequential click chemistry can be performedApplications:Stabilize emulsionsTunable materialsStage of Development:Proof-of-principleIntellectual Property:US PatentPendingReference Media:Bradley L.C. et al.J Am Chem Soc 2016 Sept 14, 138(36): 11437.Richards, V;Nat Chem 2016 Oct 21,8(11):996.Desired Partnerships:LicenseCo-developmentCase ID:16-7872-tpNCSWeb Published:2/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38453","**Summary:** Researchers have developed a scalable method for synthesizing clickable Janus particles that incorporates a bulk synthesis technique through seeded emulsion polymerization. This process allows for the generation of polystyrene-poly(propargyl acrylate) Janus particles with distinct chemical properties on either side. The functionalization of these particles is achieved using cross-linking and thiol-alkyne click chemistry. The method enables control over the morphology, composition, and surface charge of the particles, providing significant chemical flexibility. Characterization of the particles has been executed using scanning electron microscopy.

**Applications:** The synthesized Janus particles can be utilized for stabilizing multiphasic fluid mixtures, such as emulsions. Their adjustable properties allow for potential applications in various fields including materials science, pharmaceuticals, and food technology, where stable emulsions are crucial. The ability to perform click reactions within the bulk or on the surface of the particles enhances their functional capabilities.

**Problem Solved:** This technology addresses the limitations of existing methods used to produce amphiphilic Janus particles, which often involve low throughput, stringent synthesis conditions, and difficulties in incorporating secondary monomers. By providing a more efficient and flexible synthesis and functionalization approach, the development overcomes these challenges, enhancing the scalability and utility of Janus particles in practical applications.","Amphiphilic Janus particles are biphasic colloids with distinct chemical properties on each face, useful for stabilizing multiphasic fluid mixtures like emulsions. Current synthesis methods have low throughput or require stringent conditions, prompting the need for improved techniques."
"University of Pennsylvania","Gene Therapy for Macular Degeneration","","","https://upenn.technologypublisher.com/technology/38311","Gene therapy targeting disposal of toxic intracellular lipid debris and lipofuscin in wet age related macular degeneration.Problem:Macular degeneration is a genetic eye disorder that affects the retina resulting in progressive vision loss. Macular degeneration has two main forms, Stargardt‚Äôs macular degeneration (STGD) which affects juveniles, and age related macular degeneration (AMD) which affects older individuals.While a fairly small proportion of the population has STGD, with an estimated prevalence of 1 in 8,000 to 10,000, AMD affects a significantly larger segment at 2 million people in 2010 in the U.S. alone. There are currently few treatment options for macular degeneration disorders and therefore a serious need for innovative solutions.Solution:Work in the lab of Dr. Kathleen Boesze-Battaglia has resulted in a novel therapeutic approach which targets the underlying cause of macular degeneration vision loss, the accumulation of toxic lipid debris including lipofuscin.Lipofuscin is a fatty yellow pigment which builds up in cells underlying the macula, eventually causing cell death and vision loss. Utilizing a unique gene therapy method, Dr. Boesze-Battaglia has achieved a significant reduction in the amount of lipofuscin accumulation in a well-established in vivo model system. Taken together, this technology could be used to potentially delay or prevent the onset of vision loss in patients suffering from macular degeneration disorders.Advantages:Potential treatment for wet AMD ‚Äì accounts for 80% of cases.Target is gene defect independentLimits lipid debris accumulationMay delay serious vision loss if used earlyStage of Development:In vitro and In vivo proof of conceptIntellectual Property:US11,273,227Reference Media:Frost, LS et al.;Mol Neurobiol 2015 Dec; 52(3): 1135.Desired Partnerships:LicenseCo-developmentCase ID:15-7361-tpNCSWeb Published:1/28/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38311","**Summary:** A novel gene therapy has been developed to address the accumulation of toxic intracellular lipid debris, specifically lipofuscin, in cases of wet age-related macular degeneration. This approach targets the underlying cause of vision loss associated with various forms of macular degeneration, particularly addressing the needs of a substantial population affected by age-related macular degeneration. Initial laboratory results indicate a significant reduction in lipofuscin accumulation in an established in vivo model.

**Applications:** This gene therapy could be utilized as a treatment strategy for patients suffering from wet age-related macular degeneration, potentially delaying or preventing vision loss. Its implications may extend to other forms of macular degeneration, offering a broader therapeutic avenue for retinal disorders.

**Problem Solved:** The technology addresses the critical need for effective treatment options for macular degeneration disorders, particularly the accumulation of lipofuscin that leads to cell death and progressive vision loss. By directly targeting this accumulation, the therapy presents a promising solution to a condition with limited existing treatments.","Macular degeneration is a genetic eye disorder leading to progressive vision loss, with two primary forms: Stargardt‚Äôs macular degeneration in juveniles and age-related macular degeneration in older individuals. The gene therapy discussed targets the removal of toxic intracellular lipid debris and lipofuscin in wet age-related macular degeneration."
"University of Pennsylvania","Physiology-independent control algorithm for an artificial pancreas","","","https://upenn.technologypublisher.com/technology/38405","An insulin pump control system that works automatically without user inputProblem:Diabetic patients can use insulin pumps to deliver insulin after a meal. Continuous glucose monitoring (CGM) systems are also used to record glucose levels throughout the day. These systems could be unified via a closed-loop control algorithm to create an artificial pancreas that requires no input, manual blood testing, or manual dosing by the user. However, this is a difficult problem to solve because of the physical variation among individuals, the difficulty of quantifying nutrition, and the risks of serious outcomes if the incorrect dosage of insulin is given.Solution:Researchers at the University of Pennsylvania have developed a closed-loop control algorithm to enable an artificial pancreas system for Type 1 Diabetes patients. This algorithm is independent of the user‚Äôs physiology and requires no user input about nutrition. The algorithm uses past information about insulin doses provided by the pump and glucose data provided by the CGM. From only this data, the system is trained to accurately guess when a meal has taken place and what the appropriate magnitude insulin dose should be, without any user input about the timing or content of the meal itself. The new algorithm was tested using an FDA-accepted diabetes physiological model with varying patient parameter settings resulting in a 99.6% correct detection rate, outperforming other models.Advantages:Accurate meal prediction without user inputImproved patient quality of lifeStage of Development:Prototype software toolIntellectual Property:US10,792,423Reference Media:Towards a Model-Based Meal Detector for Type I DiabeticsDesired Partnerships:LicenseCo-developmentCase ID:16-7626-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38405","**Summary:** This technology describes an automated insulin pump control system designed for Type 1 Diabetes patients that integrates with continuous glucose monitoring (CGM) to function effectively as an artificial pancreas. The system employs a closed-loop control algorithm developed by researchers at the University of Pennsylvania. This algorithm operates independently of the user's physiological data and eliminates the necessity for any user input about nutrition. By analyzing past insulin doses and glucose data, the system can accurately determine when meals occur and the required insulin dosage, achieving a 99.6% correct detection rate according to testing with an FDA-accepted diabetes physiological model.

**Applications:** The primary application of this technology is in diabetes management for patients with Type 1 Diabetes. It provides a fully automated solution for insulin delivery, reducing the need for manual input and blood testing.

**Problem Solved:** The technology addresses the challenges of existing insulin pump systems that require user input regarding meal timing and content, which can be unpredictable and vary greatly among individuals. It also mitigates the risks associated with incorrect insulin dosing, enhancing patient safety and improving quality of life for diabetics.","An automatic insulin pump control system can integrate with continuous glucose monitoring (CGM) to create a closed-loop system for diabetic patients, functioning as an artificial pancreas without user input or manual adjustments. The development of this system presents challenges due to physiological complexities."
"University of Pennsylvania","3D-Printing at the Nanoscale","","","https://upenn.technologypublisher.com/technology/38404","Problem:3D printing has enabled new methods of manufacturing, but most existing techniques are limited to the macro scale. A 3D printing technique for the nano-scale could be applied to problems such as creating new coatings, making nanoscale patterns, or fabricating MEMS devices.Solution:Researchers at the University of Pennsylvania have created a new technique for 3D printing at a nanoscale using tribofilm formation. A standard atomic force microscope (AFM) probe is used as a scriber in a liquid environment. A nanoparticle ""ink"" dispersed in this liquid will form a tribofilm at the contact surface when the scriber is brought in contact with the substrate. Highly controlled 3D patterns can be built up using this technique. The researchers have demonstrated lines with widths and out-of-plane height varying between 10nm-100nm. This new technique opens up many possibilities for additive manufacturing at the nanoscale.Advantages:Nanoscale patterning without masks or resistsUses standard AFM equipmentCan be used for fabricating new MEMS/NEMS devicesApplications:Micro/Nano electromechanical systemsCoatings, semiconductor devicesStage of Development:Proof of conceptIntellectual Property:US10,768,202Desired Partnerships:LicenseCo-developmentCase ID:16-7624-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38404","**Summary:** Researchers at the University of Pennsylvania have developed a novel technique for 3D printing at the nanoscale, overcoming limitations of existing macro-scale methods. This technique utilizes tribofilm formation with a standard atomic force microscope (AFM) probe as a scriber in a liquid medium, where a nanoparticle ""ink"" forms a tribofilm at the contact surface upon interaction with the substrate. Demonstrated patterns have widths and heights ranging from 10nm to 100nm, enabling precise 3D structures without the need for masks or resists.

**Applications:** The technology can be applied in the fabrication of micro/nano electromechanical systems (MEMS and NEMS), coatings, and semiconductor devices, potentially revolutionizing additive manufacturing at the nanoscale.

**Problem Solved:** This approach addresses the lack of effective nanoscale 3D printing techniques, enabling the creation of intricate nanoscale patterns and coatings, and facilitating the development of advanced MEMS devices, thus expanding the capability and applications of 3D printing technology.","Researchers at the University of Pennsylvania have developed a novel 3D printing technique at the nanoscale using tribofilm formation, employing a standard atomic force microscope (AFM) probe as a scriber in a liquid medium. This advancement could enable the creation of new coatings, nanoscale patterns, and the fabrication of MEMS devices."
"University of Pennsylvania","Smart Toy Gym for early detection of developmental disorders","","","https://upenn.technologypublisher.com/technology/23013","Detecting disorders for infants in a natural play environmentProblem:Currently, it is difficult to diagnose developmental disorders in very young children (< 11 months). Certain neurological and motor impairments would benefit from early intervention and rehabilitation if they could be detected in the first year. Disorders such as Cerebral Palsy have no biomarkers and must be diagnosed by observation. The earlier intervention can begin, the greater the likelihood of improved outcomes. Existing systems for detecting these problems involve the child sitting in a special chair, or wearing markers for video motion capture, and are generally cumbersome.Solution:Researchers at the University of Pennsylvania have created a Smart Toy Gym that could provide data capture for diagnosis in a child-friendly natural play environment. This system appears similar to existing toys, but it is equipped with sensors to capture data about the child's movements and reactions. The data from the child's movements can be compared to past datasets to provide an early warning for developmental disorders. This system is not specific to any one disorder and can be sent home with the patient, allowing easier and more comfortable detection of disorders in young children.Advantages:Natural, familiar play environmentNo special equipment required for the child to wearCan be used as an at-home or doctor‚Äôs office solutionEarly detection of difficult to diagnose problemsStage of Development:PrototypeIntellectual Property:PatentPendingDesired Partnerships:LicenseCo-developmentCase ID:16-7746-tpNCSWeb Published:10/11/2016Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/23013","**Summary:** This technology enables the early detection of developmental disorders in infants, particularly those under 11 months, by utilizing a Smart Toy Gym designed to function in a natural play environment. It captures data on children's movements and reactions through integrated sensors, allowing for comprehensive observations without the need for cumbersome equipment. The technology compares this data to existing datasets, providing an early warning system for various developmental disorders, and is designed for use both at home and in clinical settings.

**Applications:** The Smart Toy Gym can be used in both at-home environments and clinical settings to monitor infant development and detect potential neurological and motor impairments. It serves as a tool for pediatricians and parents to facilitate early diagnosis and intervention.

**Problem Solved:** The technology addresses the challenge of diagnosing developmental disorders in very young children, particularly conditions like Cerebral Palsy, which currently rely on observation without definitive biomarkers. By enabling early detection through natural play, it enhances the potential for timely interventions, thereby improving future outcomes for affected children.","Diagnosing developmental disorders in infants under 11 months is challenging, as conditions like Cerebral Palsy lack biomarkers and rely on observation for detection. Early intervention can significantly improve outcomes for affected children."
"University of Pennsylvania","Novel soft material synthesis with liquid phase architecture and interfacially active particles","","","https://upenn.technologypublisher.com/technology/38391","Solvent transfer-induced phase separation to tailor bijel fiber propertiesProblem:Bicontinuous interfacially jammed emulsions (bijels) are novel soft materials that consist of two interwoven pore networks, each containing a liquid that is immiscible with the other. The interface is stabilized by nanoparticles, providing high interfacial surface areas and robust mechanical properties. Bijels have been limited to a small number of compatible oils and hydrophilic liquids. Allowing reactants in the aqueous phase and products in the oil phase would create a continuous reactor, surpassing intrinsic limitations of emulsion microreactors.Solution:Researchers in the Stebe and Lee labs have designed a method based on solvent transfer-induced phase separation (STRIPS) to continuously generate asymmetric and hierarchical bijels. Using ternary liquid-liquid phase separation with a liquid architecture expands the possibilities of colloidal emulsions that can be generated. Phase separation is induced by extraction of a solvent from a homogeneous ternary mixture. The technique uses a rapid injection of a homogeneous mixture of three liquids into a continuous phase, with ethanol as a solvent to allow homogeneous mixing of the other two immiscible liquids. Exposing the liquid fiber to UV light polymerizes the material, with the internal structure tuned by the nanoparticle concentration. Multiple length scales can be accommodated for size-selective transport and separations.Advantages:High interfacial surface areasCompatible with wide range of materialsSize-selectiveControl overall bijel shapeContinuous reactorApplications:Filtration membranes to separate out pollutants, viruses, and bacteria from contaminated waterEmulsions for food and cosmeticsFog harvesting for drinking water, crop irrigation, and forest restorationFiber scaffolds for tissue engineeringCatalytically active particles on surfacesContinuous chemical reactionsRefining biofuelsStage of Development:Proof-of-principle production of microparticle, fiber, and membrane bijel structuresIntellectual Property:US11,20,597Reference Media:Haase MF et al.ACS Nano, 2016, 10(6): 6338.Haase MF et al.Adv Mater,2015, 27: 7065.Lerner, E.Penn News2016 Jan 26.University of PennsylvaniaScience Daily2016 Jan 28.Desired Partnerships:LicenseCo-developmentCase ID:15-7452-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38391","**Summary:** The technology involves a novel method for the synthesis of novel soft materials called bijels, which consist of two interwoven pore networks of immiscible liquids stabilized by nanoparticles. This method leverages solvent transfer-induced phase separation, allowing for the continuous generation of asymmetric and hierarchical bijels. By utilizing a homogeneous ternary mixture and inducing phase separation through solvent extraction, the approach expands the range of colloidal emulsions that can be created. The generated material can be polymerized using UV light, and its internal structure can be adjusted by varying the concentration of nanoparticles. This technique supports multiple length scales, enabling size-selective transport and separations.

**Applications:** The bijels synthesized using this method could find applications in areas such as microreactors, where reactants in the aqueous phase and products in the oil phase streamline chemical processes. Other potential applications include filtration, drug delivery systems, and materials with advanced mechanical properties in various engineering fields.

**Problem Solved:** The method addresses the limitations of existing bijel materials, which have been restricted to a limited range of compatible liquids. By overcoming these limitations, it allows for the design of more versatile emulsion systems that can operate continuously, thereby increasing efficiency in various chemical processes and enabling new functionalities in material design.","Bicontinuous interfacially jammed emulsions (bijels) are innovative soft materials formed by two interwoven pore networks containing immiscible liquids, stabilized by nanoparticles to enhance mechanical properties. Their application has been restricted to a limited selection of compatible oils and hydrophilic liquids."
"University of Pennsylvania","Synthesis of arylboronate esters and biaryl compounds","","","https://upenn.technologypublisher.com/technology/31563","Technology Overview:Aryl boronate esters and biaryls are of interest for certain pharmaceutical and electronic material applications. Penn scientists have developed a chemical methodology for the sequential Ni-catalyzed borylation with a novel in-situ prepared reagent and Ni-catalyzed cross-coupling to form biaryls. This process is useful for the production of aryl boronate esters and biaryl compounds, key chemical building blocks and intermediates for the Sukuzi cross-coupling process.Early results suggest that the process can be implemented as a three-step one-pot methodology comprising two-stages, one-pot in-situ preparation of neopentylglycolborane coupled with Ni-catalyzed borylation of aryl halides followed by complementary Ni/Pd-catalyzed cross-coupling with aryl bromides, iodides, chlorides mesylates, and tosylates. The latter two aryls are inexpensive coupling partners with arylboronic acids and provide a desirable method of carbon-carbon bond formation starting from phenols.This complementary approach gives rise to the rapid synthesis of biaryls, and demonstrates the synthetic competitiveness of in situ prepared neopentylglycolborane versus that of tetra(alkoxy)diboron derivatives.Advantages:The use of Ni-based catalyst, neopentylglycolborane, and simple dppe and dppp ligands, reduce the cost compared to diboron or Pd-based catalyst methods.Novel reagent, neopentylglycolborane, has potential or broad applicability, including metal-catalyzed borylation as well as uncatalyzed hydroboration.One pot method reduces time required and processing demands to reach the end product.Applications:Novel boronic acids and boronic esters for the synthesis of pharmaceuticals and other fine chemicals, in particular those with sensitive functionality.Processing of biaryls and potentially heterobiaryls for liquid crystalline systems, organic and polymer light emitting diodes (O/PLEDS) and other organic electronic materials.The stability of neopentylglycolborane in solution should allow for its production, storage, and likely purification and commercialization of the reagent.Stage of Development:Demonstrated in laboratory conditions with a wide array of substrates as well as various bases, catalysts, and ligands, showing range of applicability.Intellectual Property:US8,530,689Reference Media:Rosen, BM et al.;Org Lett; 2008 May 17; 10(12): 2597.Wilson, DA et al.;Org Lett, 2008 Nov 6 10(21): 4879.Desired Partnerships:LicenseCo-developmentCase ID:U4807-tpNCSWeb Published:3/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31563","**Summary:** Aryl boronate esters and biaryls are important for pharmaceutical and electronic material applications. Scientists have created a chemical method involving sequential Ni-catalyzed borylation using a newly developed in-situ reagent, along with Ni-catalyzed cross-coupling to synthesize biaryls. This can be executed as a three-step one-pot procedure that facilitates the efficient preparation of aryl boronate esters and biaryl compounds. The method leverages an inexpensive in-situ prepared neopentylglycolborane and allows for carbon-carbon bond formation using various aryl halides and arylboronic acids, showcasing efficiency and synthetic competitiveness.

**Applications:** The technology is applicable in the synthesis of pharmaceutical compounds and electronic materials, focusing on producing key chemical building blocks necessary for diverse chemical processes like the Suzuki cross-coupling reaction.

**Problem Solved:** This methodology addresses the need for cost-effective and efficient synthesis of biaryls and aryl boronate esters, providing a novel approach that reduces reliance on more expensive catalysts and reagents, thus potentially lowering production costs in chemical synthesis.","Penn scientists have developed a method for synthesizing arylboronate esters and biaryl compounds through sequential Ni-catalyzed borylation and cross-coupling using a novel in-situ prepared reagent. This process is valuable for producing key chemical building blocks for the Suzuki cross-coupling process."
"University of Pennsylvania","NETIFY","","","https://upenn.technologypublisher.com/technology/38470","For online retailers who want to increase sales, NETIFY is a tool for creating real-time recommendation networks that match customers to provide social incentives to try new products. Unlike Amazon.com, recommendations do not come from a statistical engine, but from real people with personalities and histories who provide social encouragement to try new options. ""It's Match.com for shopping.""Problem:Online networks today are centered on primarily one of two premises, either a social network of ‚Äúpeople you may know‚Äù or ‚Äúcustomers who bought this item also bought‚Ä¶‚Äù recommendations. A key component missing from these networks is the person who is most similar to you as a consumer. As the ecommerce market has continued to grow, valued at $1.25 trillion dollars worldwide and $262 billion in the U.S. in 2013, retailers are constantly looking for ways set themselves apart from the competition.Solution:NETIFY is a mobile social network that delivers live, real-time social networks in any online context to consumers. The social networking algorithm constructs networks of shoppers based on a range of characteristics (demographic, behavioral, geographical, etc.). The characteristics are determined by the setting ‚Äì i.e. the relevant characteristics for matching clothes shoppers on Gap.com are not the same as they are for matching grocery shoppers on WholeFoods.com. NETIFY provides the voyeuristic peek into another person‚Äôs shopping cart, allowing a customer to learn from other‚Äôs good ideas, and try them out herself. The reason this works is that it‚Äôs all in the match. By putting the right people together, we can create the right influences.Advantages:Relies on social context of users, not productsNo need to search for people relevant to the userReal-time connectionApplications:Online retailersGrocery storesFinancial servicesHealthcareStage of Development:Prototype in developmentReference Media:Centola, DScience, 2010 Sep 3; 329(5996): 1194Centola, DScience, 2011 Dec 2; 334(6060): 1269van der Leij, MJScience, 2011 Dec 2; 334(6060): 1220Zhang, J et. al.,Prev Med Rep. 2015; 2: 651Desired Partnerships:LicenseCo-developmentCase ID:16-7932-tpNCSWeb Published:2/6/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38470","**Summary:** NETIFY is a tool designed for online retailers aimed at increasing sales through the creation of real-time recommendation networks that connect customers. Unlike traditional recommendation engines that utilize statistical data, NETIFY relies on human connections, drawing parallels to matchmaking services by highlighting shoppers with similar tastes, thereby enhancing the shopping experience through social interaction.

**Applications:** This technology can be applied in various online retail contexts, allowing retailers to tailor their recommendations based on diverse characteristics relevant to specific markets, such as clothing or groceries. It serves as a mobile social network that facilitates real-time connections between consumers during their shopping experiences.

**Problem Solved:** NETIFY addresses the limitations of existing online recommendation systems that often rely on generic algorithms or superficial social networks. By connecting customers with similar profiles, it fills the gap of personalized engagement in ecommerce, helping retailers differentiate themselves in a highly competitive market.","NETIFY is a tool designed for online retailers to enhance sales by creating real-time recommendation networks that connect customers for social encouragement to try new products. Unlike traditional recommendation systems, NETIFY uses real individuals to provide suggestions, akin to a matchmaking service for shopping."
"University of Pennsylvania","New tandem epoxidation and oxidation reactions for intermediates in asymmetric organic synthesis","","","https://upenn.technologypublisher.com/technology/29853","Highly enantio- and diastereoselective synthesis of epoxy alcohols from an aldehydeProblem:About half of the top-selling pharmaceuticals are single enantiomers, the precursors of which are chiral substances of high optical purity. Controlling the stereochemistry of these materials and creating stereogenic centers allows for the preparation of medicinally relevant target molecules as single enantiomers.There has been a dearth of efficient methods for synthesizing epoxy alcohols, key intermediates in asymmetric organic synthesis.One prominent reaction is the Sharpless asymmetric epoxidation of prochiral allylic alcohols to yield enantio-enriched epoxy alcohols that readily undergo regioselective ring-opening reactions. Epoxy alcohols contain up to three functional groups (olefin, carbinol, and epoxide), for high synthetic potential in generating natural products and pharmaceutical compounds. However, there are chemoselectivity issues in differentiating allylic double bonds when synthesizing allylic epoxy alcohols.Solution:Researchers in the Walsh Lab have developed an enantio- and diastereoselective one-pot synthesis method for acyclic and allylic epoxy alcohols under mild conditions with high yields and in high enantiomeric excess. The method employs an initial asymmetric carbon-carbon bond forming reaction by adding an organozinc or divinylzinc reagent to an aldehyde. The resulting allylic alkoxide intermediate is epoxidized in situ in the presence of an oxidant, such as air, and a titanium tetraalkoxide catalyst. Epoxy alcohols with up to three contiguous stereocenters are formed in one pot.Advantages:Stereoselective and chemoselectiveOne-pot approach for streamlined synthesisCircumvents need to prepare and isolate decomposition-prone intermediatesCompatible with wide range of substrates and catalystsGenerate up to 3 contiguous stereocentersApplications:Versatile intermediates in asymmetric organic synthesisEnantiomeric drug synthesisNatural product synthesisStage of Development:Proof-of-principle testingIntellectual Property:USSN8,236,976Reference Media:Kelly A.R. et al.J Am Chem Soc, 2005, 127(42): 14668.Kim H.Y. et al.J Am Chem Soc, 2005, 127(38): 13138.Lurain A.E. et al.J Org Chem, 2005, 70(4): 1262.Lurain A.E. et al.J Am Chem Soc, 2004 Oct 27, 126 (42): 13608.Desired Partnerships:LicenseCo-developmentCase ID:Q3444-tpNCSWeb Published:11/27/2018Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/29853","**Summary:** Researchers have developed a highly enantio- and diastereoselective one-pot synthesis method for acyclic and allylic epoxy alcohols that operates under mild conditions, achieving high yields and significant enantiomeric excess. The process initiates with an asymmetric carbon-carbon bond formation by the addition of an organozinc or divinylzinc reagent to an aldehyde. This reaction produces an allylic alkoxide intermediate, which is subsequently epoxidized in situ using an oxidant.

**Applications:** The synthesized epoxy alcohols serve as crucial intermediates in asymmetric organic synthesis, particularly in the development of single enantiomer pharmaceuticals and other medicinally relevant compounds. Their versatile structure enables the generation of various natural products and pharmaceutical agents with high optical purity.

**Problem Solved:** This method addresses the significant challenges associated with the synthesis of epoxy alcohols, specifically the inefficiencies and chemoselectivity issues encountered with existing techniques. By providing a streamlined and effective approach to create these key intermediates, it enhances the capability to control stereochemistry and develop high-purity chiral substances necessary for pharmaceutical applications.","The synthesis of epoxy alcohols from aldehydes has been developed to enhance enantio- and diastereoselectivity, addressing the need for chiral substances in pharmaceutical manufacturing. This method aims to improve the efficiency of producing key intermediates essential for creating single enantiomer drugs."
"University of Pennsylvania","Directional speakers for warning systems","","","https://upenn.technologypublisher.com/technology/38451","Directing a beam of sound at any angleProblem:Most audio warning systems have no way of targeting the individuals that need to receive a message. These warnings might be ignored or missed by the people that need to hear them. Directed sound systems can create a narrow ‚Äúbeam‚Äù of sound rather than a wave that spreads in all directions. These systems work by emitting directed, high-frequency ultrasonic signal that demodulates in air, producing sound focused in a narrow beam.This technique has been known for some time, but it can only travel in a straight line perpendicular to the source. A controllable beam of sound could change the angle of the beam to track a target and direct a warning at a specific personSolution:Researchers at the University of Pennsylvania have created a phased array directed speaker that can change the beam angle. By using a series of ultrasound sources, each with a different time delay, the beam can be angled and moved. This system could be used to target a specific individual and direct a warning message to one person specifically. Additional applications could include variable audio directionality for audiovisual and entertainment systems.Advantages:Directed sound at a variable angleWarnings can be directed at a specific targetBeam of sound can move as targets moveApplications:Pedestrian warning systems and other audio warning systemsAudiovisual personalized entertainmentStage of Development:Prototype SystemIntellectual Property:US11,317,204Desired Partnerships:LicenseCase ID:16-7832-tpNCSWeb Published:2/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38451","**Summary:** The technology involves a directed sound system that creates a narrow beam of sound, allowing for targeted audio warnings. Traditional warning systems often fail to effectively reach specific individuals, leading to missed or ignored alerts. The developed phased array directed speaker can alter the angle of the sound beam in real-time, enabling precise warnings directed at specific targets. This system utilizes multiple ultrasound sources with varying time delays to manipulate the beam direction.

**Applications:** This technology can be applied in pedestrian warning systems and other audio warning systems, as well as in personalized audiovisual entertainment systems and on stages for enhanced directional audio experiences.

**Problem Solved:** The technology addresses the issue that many audio warning systems are inefficient in delivering messages to the intended recipients, which may result in critical information being overlooked. By enabling the directional control of sound, it ensures that warnings reach the specific individuals who need to hear them.","Most audio warning systems lack the ability to target specific individuals, leading to potential ignored or missed messages. Directional speakers utilize high-frequency ultrasonic signals to produce sound in a focused, narrow beam that can be directed at specific locations."
"University of Pennsylvania","Novel therapeutic use of protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitor for acute lung injury treatment","","","https://upenn.technologypublisher.com/technology/38449","Mitigating lung injury and lung inflammation through PERK pathway inhibitionProblem:Acute lung injury, induced by long-term treatment with a mechanical ventilator, and acute respiratory distress syndrome (ARDS) affects 190,000 patients per year in the United States, with associated mortality of 35-40%. The highest numbers of deaths are in patients with sepsis, pneumonia, or aspiration. ARDS is characterized by sudden breathlessness within hours to days of an inciting event, including trauma, sepsis, drug overdose, blood transfusion, and aspiration. ARDS is a life-threatening condition caused by widespread inflammation of the lungs that can lead to multisystem organ failure. Currently, there is no specific therapy for acute lung injury or lung inflammation, and adjunctive strategies that modulate the deleterious effects of mechanical ventilation are needed.Solution:During lung injury, the Margulies Lab has discovered, in vitro with a rat epithelial stretch model and in vivo with ventilated rats and pigs, that protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibition reduces the activation of the integrated stress response (ISR) signaling pathway that is induced upon mechanical stretch. Upon mechanical stretch, PERK is phosphorylated and initiates the signaling cascade. PERK inhibition in the ISR pathway improves mechanical stretch-induced epithelial monolayer permeability, mitigating mechanical stretch-induced cell death and tight junction dissociation. Inhibiting the ISR pathway in vivo may reduce acute lung injury during large tidal volume ventilation.This work represents the first implication of the PERK pathway in lung injury, as well as a new use of a commercially available PERK inhibitor previously connected with cancer and neurodegenerative diseases, and diseases with activated unfolded protein response pathways.Advantages:Use commercially available PERK inhibitor for alternate indication to treat lung injury and inflammationNew method of use for existing compoundSafety previously tested in humansPotential therapeutic where one does not exist for this conditionApplications:Acute lung injuryVentilator-induced lung injuryAcute respiratory distress syndromeLung inflammationStage of Development:Proof-of-concept and in vivo testingIntellectual Property:US11,026,945Reference MediaDolinay, T et al.;Respir Res 2018 Aug 22 19(1): 157.Desired Partnerships:LicenseCo-developmentCase ID:16-7828-tpNCSWeb Published:2/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38449","**Summary:** The technology addresses acute lung injury and lung inflammation by inhibiting the protein kinase RNA-like endoplasmic reticulum kinase (PERK) pathway. Research conducted by the Margulies Lab using both in vitro and in vivo models has demonstrated that PERK inhibition can significantly reduce the activation of the integrated stress response (ISR) signaling pathway triggered by mechanical stretch due to ventilation. This inhibition improves epithelial monolayer permeability and decreases cell death and tight junction dissociation caused by mechanical stretch.

**Applications:** The primary application of this technology is in the treatment of acute lung injury and acute respiratory distress syndrome (ARDS), particularly in patients subjected to prolonged mechanical ventilation. It may be beneficial for patients experiencing lung inflammation due to various conditions, including sepsis, pneumonia, and aspiration.

**Problem Solved:** The technology offers a potential therapeutic approach for a serious health issue, which currently has no specific treatment. By mitigating lung injury associated with mechanical ventilation, it addresses the urgent need for adjunctive strategies to manage acute lung injury and reduce the associated high mortality rates from ARDS.","Acute lung injury and ARDS affect approximately 190,000 patients annually in the U.S., with a mortality rate of 35-40%, particularly in those with sepsis, pneumonia, or aspiration. The condition is marked by sudden breathlessness occurring hours to days after an inciting event."
"University of Pennsylvania","High efficiency, superhydrophobic clamshell plasma separator for point-of-care diagnostics","","","https://upenn.technologypublisher.com/technology/38064","Membrane-based, sedimentation-assisted plasma separatorProblem:High sensitivity, point-of-care clinical tests, such as HIV viral load, require large volumes of plasma extracted from whole blood. Centrifugation is widely used for separating plasma, but it is not always accessible in resource-poor settings.Current microfluidic systems require extensive blood dilution that adversely affects the limit of detection, which is critical in high sensitivity tests such as viral load detection.Solution:The Bau lab has developed a point-of-care device for highly efficient, rapid plasma separation using a superhydrophobic material and gravitational sedimentation. This is the second generation plasma separator device from the lab.The plasma separator has a clamshell design, with a superhydrophobic top cover and bottom substrate. In order to increase the membrane separation capacity and plasma yield, the separation membrane is at the top of the whole blood film.By adding the superhydrophobic coating, surface bioadhesion of the blood is minimized, the blood clotting time is increased, and blood cell hemolysis is reduced. Furthermore, the loss of target biomolecules is prevented, with high recovery efficiency.This device can be used without external instrumentation and in resource-poor regions without electricity or specially trained medical personnel.Advantages:Low-cost and disposableRapid process (<10 min)Easy to administerNo requirement for electrical powerMinimal surface adhesion and blood cell hemolysisApplications:Separate plasma from whole bloodDetect viral load when combined with nucleic acid testing on microfluidic chipUse in resource-poor regions without trained staff, laboratory facilities, or electricityStage of Development:Prototype developed and in vitro proof-of-concept testingIntellectual Property:US10,690,653China107533046EPPendingReference Media:Liu, C et al.Lab On a Chip 2016, 16(3),: 553.Liu, C et al.Anal Chem 2013 Nov 5, 85 (21): 10463.Donges, JPenn News2015 Oct 27Desired Partnerships:LicenseCo-developmentCase ID:14-6973-tpNCSWeb Published:1/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38064","**Summary:** A novel plasma separator has been developed that utilizes a membrane-based, sedimentation-assisted method for efficient plasma separation from whole blood. This device features a clamshell design with a superhydrophobic top cover and bottom substrate that enhances plasma yield and reduces blood cell hemolysis. By minimizing surface bioadhesion, the separator improves blood clotting time and recovery efficiency of target biomolecules. The device operates without the need for centrifugation, making it suitable for use in resource-limited settings and does not require electricity or specialized training.

**Applications:** The technology is applicable for point-of-care diagnostics, particularly in high-sensitivity clinical tests such as HIV viral load detection, where large volumes of plasma are essential for accurate results. It can be utilized in environments lacking advanced medical infrastructure.

**Problem Solved:** The device addresses the challenges of plasma separation in resource-poor settings, where centrifugation is not feasible and existing microfluidic systems may compromise the accuracy of test results due to extensive blood dilution. By providing a rapid, efficient, and low-cost solution, it enables reliable diagnostic testing without the need for complex equipment.","A novel membrane-based plasma separator utilizes sedimentation to extract large volumes of plasma from whole blood for high-sensitivity point-of-care diagnostics, addressing the limitations of centrifugation and existing microfluidic systems. This technology aims to improve accessibility and detection limits in resource-poor settings, particularly for tests like HIV viral load."
"University of Pennsylvania","Chemical modifications to strengthen and stabilize collagen for biomaterials and biomedicine","","","https://upenn.technologypublisher.com/technology/31566","Unnatural amino acid substitution for hyperstable collagen-based materialsTechnology Overview:The Chenoweth Lab has discovered an unnatural amino acid substitution in collagen to dramatically improve the strength and stability of collagen for a wide range of biomaterial and biomedical applications. More specifically, the researchers have created a new class of collagen mimetic peptides with an unnatural amino acid substitution of aza-glycine that stabilizes the triple helical structure of collagen via increasing the number of interfacial hydrogen bonds, improving the material‚Äôs strength.Collagen is the most abundant protein in mammals, present in tendons, ligaments, cartilage, bones, blood vessels, skin, and tissue. Hydrogen bonding is critical in maintaining structural integrity in natural biopolymer systems, so it is advantageous to maximize the number of hydrogen bonds with minimal perturbation to the structure and function of the biomolecule.This report is the first atomic modification to the main chain backbone of collagen to affect glycine, the result of which yields triple helix hyperstability and significantly faster folding kinetics.Advantages:Improved strength and stability of collagenFaster folding kineticsMaximize number of hydrogen bonds within collagenApplications:Self-assembling biomimetic materialsCosmetics and cosmeceuticalsSkin grafts, wound healingCosmetic/plastic surgeryJoint repairTissue engineering and regenerative medicineDrug deliveryStage of Development:Reduction to PracticeIntellectual Property:US10,174,083Reference Media:Kaznel, AJ et al.;J Am Chem Soc 2017, 139(28): 9427Zhang, Y et al.;J Am Chem Soc 2016, 138(31): 9751Zhang, Y et al.;J Am Chem Soc 2015 Oct 7, 137(39): 12422Borman, S.;Am Chem Soc 2015 Sept 24, 93(38): 7Lerner, E. 2015 Oct 8Highlight in Penn Current, 2015Desired Partnerships:LicenseCase ID:16-7669-tpNCSWeb Published:3/1/2019Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/31566","**Summary:** This technology introduces a novel approach to enhance the strength and stability of collagen by utilizing an unnatural amino acid, aza-glycine, to create a new class of collagen mimetic peptides. This modification increases the number of interfacial hydrogen bonds, thereby stabilizing the triple helical structure of collagen and improving its material strength. The research highlights the first atomic modification to collagen's main chain, specifically targeting glycine, which results in hyperstability of the triple helix and faster folding kinetics. 

**Applications:** The enhanced collagen materials can be employed in a variety of fields including self-assembling biomimetic materials, cosmetics and cosmeceuticals, skin grafts and wound healing, cosmetic and plastic surgery, joint repair, tissue engineering and regenerative medicine, as well as drug delivery.

**Problem Solved:** The technology addresses the challenges of insufficient strength and stability in natural collagen, providing a solution that enhances its structural integrity and functionality for various biomedical and biomaterial applications while also facilitating faster folding kinetics.","The Chenoweth Lab has identified an unnatural amino acid substitution, aza-glycine, in collagen that enhances its strength and stability. This innovation has led to the development of a new class of collagen mimetic peptides suitable for various biomaterial and biomedical applications."
"University of Pennsylvania","Diamond-like carbon coating for Heat Assisted Magnetic Recording (HAMR)","","","https://upenn.technologypublisher.com/technology/39333","New materials to make advanced recording technology possibleProblem:Heat-Assisted Magnetic Recording (HAMR) could provide hard drive storage densities in the TB/in^2 range, as compared to today‚Äôs GB/in^2 capability. HAMR operates by heating the disk with a laser, which momentarily changes the storage medium‚Äôs magnetic coercivity, allowing data to be written to the disk at a higher density than conventional methods.Hard disks are currently coated with a protective outer layer of hydrogenated amorphous carbon, which degrades above 150C. Finding a suitable disk coating material that can survive high temperatures without interfering with magnetic recording and data retrieval will be a key enabling technology for HAMR.Solution:Researchers at the University of Pennsylvania have developed a new coating that could provide several advantages for HAMR-enabled hard drives. In this process, a thin (2nm) layer of Silicon Oxide-doped diamond-like carbon (SiO DLC) is deposited onto the disk as a replacement for the amorphous carbon layer. This material is highly temperature resistant and can withstand the temperatures required for HAMR without degrading. This coating is stable up to at least 300C, making it well-suited for HAMR.Advantages:Uniform deposition demonstrated on a large (300 mm) surface in the laboratoryHigh temperature resistance up to 300CImproved performance as compared to conventional amorphous carbon coatingsStage of Development:Fabrication method demonstrated in laboratoryIntellectual Property:US9,478,244Desired Partnerships:LicenseSponsored ResearchCase ID:Y6210-tpNCSWeb Published:3/20/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39333","**Summary:** Researchers at the University of Pennsylvania have developed a new coating material for hard drives that enhances the capabilities of Heat-Assisted Magnetic Recording (HAMR). The coating consists of a thin layer of Silicon Oxide-doped diamond-like carbon (SiO DLC) that boasts high temperature resistance, remaining stable up to at least 300¬∞C, which is significantly higher than the degradation point of current hydrogenated amorphous carbon coatings. This advancement is essential for increasing data storage densities in hard drives from GB/in¬≤ to the TB/in¬≤ range.

**Applications:** The new diamond-like carbon coating can be applied to HAMR-enabled hard drives, facilitating the storage of larger amounts of data without compromising performance. It is particularly useful in consumer electronics, enterprise data storage, and any applications where high-density data storage is critical.

**Problem Solved:** The developed coating addresses the limitations of existing protective layers that degrade at temperatures above 150¬∞C, which have hindered the implementation of HAMR technology. By providing a stable and temperature-resistant layer, the coating enables higher density data writing and reading without losing integrity, thereby making HAMR a viable option for future storage solutions.","Heat-Assisted Magnetic Recording (HAMR) aims to increase hard drive storage densities to the TB/in¬≤ range by using a laser to temporarily heat the disk, allowing for higher density data writing. Currently, hard disks are protected with a coating of hydrogenated amorphous carbon."
"University of Pennsylvania","Graphene metamaterials","","","https://upenn.technologypublisher.com/technology/39306","Advanced optical materials made possible using grapheneProblem:Plasmonic nanostructures are used to create metamaterials with unusual optical properties. Most metamaterials to date have been constructed using noble metals, however, these metals have inherent losses that degrade the metamaterial's optical properties.Graphene does not have these limitations, and by tuning graphene‚Äôs properties, researchers at the University of Pennsylvania have discovered a new way of creating improved metamaterials.Solution:Layers of graphene can be dynamically tuned to control their conductivity. Different electrical fields can be applied to change the conductivity of certain regions of a graphene layer. The change in conductivity results in controlled optical properties for graphene metamaterials. Surface plasmons are highly confined on single-layer graphene, resulting in improved optical performance as compared to noble metal metamaterials. Optical waveguides, Fresnel optics, Luneburg lenses, and other optical devices can be created using single layers of graphene.Advantages:Improved optical properties as compared to noble metal metamaterialsSingle-layer graphene construction can be used to create one-atom-thick optical elementsStage of Development:Laboratory proof of conceptIntellectual Property:US9,952,383Reference Media:Vakil, A., & Engheta, N.Science 2011 Jun, 332(6035): 1291(Graphic featured referenced from this article)Desired Partnerships:License or Sponsored ResearchCase ID:W5607-tpNCSWeb Published:3/18/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39306","**Summary:** Advanced optical materials made from graphene present a novel approach to creating metamaterials with unique optical properties. Unlike traditional metamaterials that rely on noble metals, which suffer from inherent losses, graphene's characteristics allow for enhanced optical performance. Researchers have demonstrated that by dynamically tuning the conductivity of graphene layers through applied electrical fields, it is possible to achieve controlled optical properties. Single-layer graphene exhibits highly confined surface plasmons, leading to significant improvements over noble metal-based metamaterials.

**Applications:** The technology enables the development of various optical devices, including optical waveguides, Fresnel optics, and Luneburg lenses, utilizing one-atom-thick optical elements made from single layers of graphene.

**Problem Solved:** This technology addresses the limitations of plasmonic nanostructures created from noble metals, specifically the inherent losses that degrade optical properties, by utilizing graphene's adjustable conductivity and excellent optical performance to create more efficient metamaterials.","Researchers at the University of Pennsylvania have developed advanced optical materials using graphene to create metamaterials with improved properties, overcoming the limitations of plasmonic nanostructures made from noble metals, which suffer from inherent losses. By tuning graphene's characteristics, they have discovered a new approach to enhancing these materials."
"University of Pennsylvania","Image segmentation and computer vision with RGB-D cameras","","","https://upenn.technologypublisher.com/technology/39292","Utilizing off-the-shelf hardware for advanced 3D visionProblem:Robots and autonomous vehicles need to identify objects to interact with their environment and avoid obstacles. Distinguishing a wall from a door or seeing an object placed against a similarly-colored background is simple for a human, but can be difficult for a machine. Various techniques have been developed to solve this problem, but they often involve expensive sensor hardware and require a large amount of computational power.Solution:A computational technique developed by researchers at the University of Pennsylvania can segment images to easily identify objects using simple RGB-D cameras. A color image and depth data are gathered using the camera, and that data is then processed to find objects. From the color data, edges and discontinuities can be identified to locate distinct items. The depth data is used to find which objects stand out in 3D space. The segmentation from the color and depth data is matched together to identify discrete objects in a fast and computationally efficient manner. This method provides simple and cost-effective 3D computer vision for robotics using sensors such as the Microsoft Kinect.Advantages:Uses low-cost RGB-D sensorsFast and efficient segmentation based on color and depth dataIdeal for mobile autonomous applicationsStage of Development:Proof of concept prototypeIntellectual Property:US9,449,233US8,867,793Reference Media:Taylor, C & Cowley, ASegmentation and analysis of RBG-D dataRSS 2011 Workshop on RGB-D Cameras. Vol. 90. 2011. (Graphic featured referenced from this paper)Desired Partnerships:LicenseCase ID:W5413-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39292","**Summary:** This technology utilizes RGB-D cameras to perform image segmentation and enhance computer vision capabilities for robots and autonomous vehicles. It addresses the challenge of object identification and obstacle avoidance in complex environments, which can be difficult for machines. The method combines color and depth data from the camera to identify distinct objects efficiently, employing a computational technique developed by researchers at the University of Pennsylvania.

**Applications:** This technology is applicable in robotics and autonomous vehicles, particularly in mobile autonomous applications that require environmental interaction and navigation.

**Problem Solved:** The technology resolves the difficulty machines face in distinguishing objects in a scene, such as differentiating a wall from a door or recognizing objects against similar-colored backgrounds, by providing a cost-effective and efficient solution for 3D vision using low-cost RGB-D sensors.","Robots and autonomous vehicles require effective object identification to interact with their environment and prevent collisions, which poses challenges due to similarities in color and structure. Traditional solutions often rely on costly sensors and significant computational resources."
"University of Pennsylvania","NetEgg: Automated code generation for software-defined networks","","","https://upenn.technologypublisher.com/technology/38406","Software synthesis for fast and easy network configurationProblem:Software-Defined Networking (SDN) usually requires network administrators to be skilled in programming languages such as C++, Python, or Ruby. However, many IT operators tasked with installing routers or other network components may lack the skills to program SDN equipment. Due to a shortage of trained staff, implementing SDN across an entire enterprise can become very time consuming and costly.Solution:NetEgg is a software solution developed by researchers at the University of Pennsylvania to generate SDN code based on simple user input. The IT operator can lay out the configuration of the network using a visual interface, and NetEgg will generate the code required for SDN. The software synthesis algorithm automatically infers the controller state and flow-table rules for the network to correctly process events and update the state. NetEgg generates code within seconds and has a low performance overhead, automatically generating policies that perform as well as manually-implemented network polices. The tool includes automated checking to determine if any scenarios conflict with each other, with reporting of any bad policies back to the user. By putting these tools in the hands of all IT operators, NetEgg makes implementing SDN easy and cost-effective.Advantages:Generates SDN policies without programmingAutomatic conflict checkingFast and low-cost implementationStage of Development:Prototype software toolIntellectual Property:US9,729,582Reference Media:Yuan, Y et al.;IEEE/ACM 26(5): 2104.Desired Partnerships:License or Sponsored ResearchCase ID:16-7634-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38406","**Summary:** NetEgg is a software solution developed by researchers at the University of Pennsylvania designed to automate the code generation for software-defined networks (SDN) based on user input. It enables IT operators to configure networks using a visual interface, eliminating the need for them to possess programming skills. The software synthesizes the required SDN code instantaneously, with minimal performance overhead, and produces policies that are comparable in performance to those created manually. Additionally, NetEgg includes automated conflict checking, alerting users to any conflicting scenarios.

**Applications:** NetEgg can be utilized in enterprises looking to implement SDN without requiring extensive programming knowledge from their IT staff. It is particularly beneficial for organizations facing a shortage of trained personnel capable of programming SDN equipment, allowing for efficient and cost-effective network configurations.

**Problem Solved:** The technology addresses the challenge posed by the need for skilled programming in the implementation of SDN, which often leads to delays and increased costs in network setup. By providing a user-friendly interface that generates necessary code automatically, NetEgg streamlines the process of SDN deployment, making it accessible to a broader range of IT operators.","NetEgg is a software solution designed to automate code generation for Software-Defined Networking (SDN), addressing the challenge of network administrators lacking programming skills. It aims to simplify and accelerate network configuration, reducing the time and costs associated with implementing SDN in enterprises."
"University of Pennsylvania","Flying Smartphones","","","https://upenn.technologypublisher.com/technology/38398","The onboard sensing and computing power of a smartphone can be used to control autonomous aerial vehiclesProblem:Micro aerial vehicles capable of autonomous navigation are often expensive and intimidating for the inexperienced user. Much of the cost associated with these vehicles is due to the dedicated sensing and control systems that are required for navigation. Modern smartphones contain similar sensors and a powerful, efficient processor, but until now no one has been able to perform all of the sensing and control for an aerial vehicle with just a phone.Solution:Researchers at the University of Pennsylvania have developed the first aerial vehicle with all sensing, computation, and control performed on a consumer smartphone. The phone‚Äôs existing cameras, inertial measurement unit, and processor are used to determine position and send commands to the aerial vehicle. No additional sensors are required, the phone simply plugs into the vehicle. This technology offers the opportunity to make unmanned aerial systems much more accessible to the consumer market. This system replaces much of the professional grade hardware with the user‚Äôs own smartphone, which could lead the way to much cheaper and more accessible autonomous aerial vehicles.Advantages:No special phone or equipment required ‚Äì plugs directly into a consumer smartphoneAll sensing, navigation, and computation performed on the phoneReduced complexity and barriers to entry for unmanned aerial vehiclesStage of Development:PrototypeIntellectual Property:US10,037,028Reference Media:A Smartphone Is the Brain for This Autonomous Quadcopter- IEEE SpectrumLoiana, G et al.IEEE Robotics & Automation Magazine 2015 June, 22(2): 24Desired Partnerships:License or Sponsored ResearchCase ID:15-7534-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38398","**Summary:** Researchers at the University of Pennsylvania have developed an innovative aerial vehicle that leverages the onboard sensing and computing capabilities of a consumer smartphone to control its navigation. This groundbreaking approach eliminates the need for dedicated sensing and control systems, which are typically costly and complex. The smartphone's existing hardware, including its cameras and inertial measurement unit, is utilized to determine the vehicle's position and send navigation commands, thus simplifying the technology and making it more user-friendly.

**Applications:** This technology can be used in a variety of sectors, including recreational drone flying, aerial photography, surveillance, and potentially inspection or delivery services where lightweight, autonomous navigation is beneficial. It has the potential to make unmanned aerial systems more accessible to the general public, opening up new opportunities for hobbyists and small businesses.

**Problem Solved:** The development addresses the high cost and intimidation factor associated with traditional autonomous aerial vehicles, which often require specialized equipment and expertise to operate. By utilizing consumer smartphones for navigation and control, this technology reduces complexity, barriers to entry, and overall expenses, making aerial vehicles more approachable for inexperienced users.","Micro aerial vehicles for autonomous navigation are often costly and challenging for inexperienced users due to their specialized sensing and control systems. Smartphones, equipped with comparable sensors and powerful processors, can potentially leverage their onboard technology to control these aerial vehicles."
"University of Pennsylvania","Keyboard Alternative Technology: Better typing for smartphones","","","https://upenn.technologypublisher.com/technology/38393","Enabling a faster and easier way to type on mobile devicesProblem:Most mobile devices now feature touchscreens instead of keypads. However, typing using a touchscreen is often imprecise, resulting in a slower typing speed and frequent errors. When the touchscreen keyboard opens it covers half the screen, obscuring content the user may wish to see. These frustrations are well known to any smartphone user, and typing on a touchscreen is still not as fast or easy as using a computer keyboard.Solution:Researchers at the University of Pennsylvania have developed a Keyboard Alternative Technology (KAT) for fast and easy typing on mobile devices. KAT consists of touch sensors on the back of the phone, with an onscreen character map and swipe gestures used for input.The user holds the phone with two fingers of each hand on the backside of the phone. By swiping up, down, left, and right, a character is selected for input, with the thumbs on the front side of the phone used for scrolling and selection. The number of available swipe gestures combined with selection for special characters allows the KAT system to produce a total of 228 characters, more than enough for the full set of 128 ASCII characters or the 101-key QWERTY keyboard. KAT makes typing on mobile devices much easier than it is today.Advantages:Easier and more natural typing on mobile devicesMore of the screen available to display contentStage of Development:PrototypeIntellectual Property:US10,387,032Desired Partnerships:License or Sponsored ResearchCase ID:15-7462-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38393","**Summary:** Researchers at the University of Pennsylvania have developed a technology that allows for faster and easier typing on smartphones by utilizing touch sensors on the back of the device. This system enables users to input characters via swipe gestures on the back panel while using their thumbs for scrolling and selection on the front screen. The technology features a character map that supports a total of 228 characters, accommodating the full range of ASCII characters and more. 

**Applications:** The technology is intended for use in mobile devices, enhancing the typing experience for users frustrated with traditional touchscreen keyboards by providing an alternative input method that keeps the main screen visible.

**Problem Solved:** The technology addresses the common difficulties associated with touchscreen typing, including imprecision, slower typing speeds, frequent errors, and the obstruction of screen content by the keyboard interface.","Touchscreens on mobile devices often lead to imprecise typing, resulting in slower speeds and frequent errors, while also obscuring content on the screen. This creates frustrations for users who find typing on touchscreens less efficient than using a traditional computer keyboard."
"University of Pennsylvania","Tunable Adhesion","","","https://upenn.technologypublisher.com/technology/38078","Turning adhesion on or off to open new possibilities for process controlProblem:Advanced manufacturing processes require methods to delicately handle fragile materials. Certain materials are too compliant and brittle to transfer them with vacuum or mechanical handling, and traditional adhesives may leave behind an unacceptable residue.Some researchers have experimented with bio-inspired adhesion, but these systems are difficult to apply on an industrial scale. A way to temporarily adhere to surfaces during assembly would open up new methods of manufacturing for semiconductors, electronics, and other products.Solution:Researchers at the University of Pennsylvania have developed a new tunable composite material with high adhesion under normal loading and weak adhesion when shear is applied, making the surface adhesion easily controllable.A micro-scale composite structure is patterned using a stiff post surrounded by a compliant core. A contact surface made up of an array of these posts has strong adhesion in the normal direction but can be easily removed by applying a shear force. This makes manipulation of thin layers of delicate material possible, because no damaging handling forces are applied, and no residue is left behind.Adhesive contact surfaces that use this method can easily be produced on a large scale, making this technology a practical solution as an applied process improvement.Advantages:Control over adhesion with no residue or handling damageEasy to manufacture and scale to component-size structuresStage of Development:Prototype developed on the scale of 1.5‚Äù x 1.5‚ÄùIntellectual Property:US10,549,483Reference Media:Minsky, H. K., & Turner, K. T.Appl. Phys. Lett. 106, 201604Penn Researchers Develop a New Type of Gecko-like Gripper- Lerner, E.; Penn Today 2015 June 15.Desired Partnerships:License or Sponsored ResearchCase ID:14-7050-tpNCSWeb Published:1/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38078","**Summary:** Researchers at the University of Pennsylvania have developed a tunable composite material that allows for controllable adhesion. This material exhibits high adhesion under normal loads but weakens when shear forces are applied, enabling easy removal without damaging delicate materials or leaving residue. A micro-scale structure consisting of stiff posts surrounded by a compliant core enables this functionality, facilitating the handling of fragile materials in advanced manufacturing processes. 

**Applications:** This technology can be applied in various fields, including semiconductor manufacturing, electronics assembly, and other processes that involve the delicate handling of brittle or compliant materials.

**Problem Solved:** The innovation addresses the challenges of manipulating fragile materials where traditional methods, such as vacuum or mechanical handling, may cause damage or leave residues. By enabling controlled adhesion, it allows for safer and cleaner handling processes in advanced manufacturing.","Researchers are exploring tunable adhesion systems to enable delicate handling of fragile materials in advanced manufacturing processes. Traditional methods, such as vacuum or mechanical handling, are inadequate for compliant and brittle materials, and existing bio-inspired adhesives pose challenges for industrial application."
"University of Pennsylvania","Network timing guarantees via the Middleware Assurance Substrate (MIDAS)","","","https://upenn.technologypublisher.com/technology/37805","A middleware guarantee of timing constraints and quality of service in distributed networksProblem:Real-time systems often require data delivery in a given amount of time. If the data arrives late the system may not function as intended. Heavy traffic or a denial of service attack can quickly overwhelm a network and cause downtime for critical assets.With current software tools, users can request quality of service through middleware platforms, but there is no way to guarantee delivery of the required quality of service.Solution:A real-time message bus called MIDAS developed at the University of Pennsylvania uses Software Defined Networking (SDN) protocols to automatically configure the network and deliver real-time guarantees of quality of service. This tool ensures that latency and quality requirements for critical network functions are maintained. The user can specify maximum end-to-end bounds for latency which are enforced by the middleware tool.The OpenFlow protocol, compatible with most consumer networking equipment, is used to communicate with networked assets. When a new asset comes online its requirements are checked against the network configuration and the other network priorities. If the new request can be added without violating other quality of service requirements, that new configuration is committed to the network, otherwise the request is denied. This prevents overload and allows quality of service to be guaranteed across a network.Advantages:Guaranteed latency and quality of serviceAvoids network overload caused by heavy traffic or DoS attacksAutomates functions that would normally require the attention of a network administratorKing, A. L., Chen, S., & Lee, I. (2014, June). The middleware assurance substrate: Enabling strong real-time guarantees in open systems with openflow. In Object/Component/Service-Oriented Real-Time Distributed Computing (ISORC),2014 IEEE 17th International Symposium on (pp. 133-140). IEEE.Stage of Development:Prototype software toolIntellectual Property:US9,270,527Desired Partnerships:License or Sponsored ResearchCase ID:14-6784-tpNCSWeb Published:1/10/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/37805","**Summary:** A middleware platform designed to provide guarantees for timing constraints and quality of service in distributed networks addresses the needs of real-time systems that require timely data delivery. The technology leverages a real-time message bus known as MIDAS, utilizing Software Defined Networking (SDN) protocols to configure networks dynamically and ensure compliance with latency and quality specifications. When new network assets connect, their requirements are assessed against existing configurations to maintain overall quality of service without causing overload. 

**Applications:** This technology is applicable in various real-time systems and distributed networks where timely data delivery is critical, such as in telecommunications, smart grid systems, automated industrial processes, and any setting where operational continuity depends on predictable network performance.

**Problem Solved:** The solution addresses the challenge faced by real-time systems of data arriving late, which can lead to system failures, particularly in the context of heavy network traffic or security threats like denial of service attacks. By guaranteeing quality of service through precise control of network latency and resource allocation, the middleware helps to prevent network overload and ensure that timely data delivery is consistently maintained.","The Middleware Assurance Substrate (MIDAS) addresses the issue of guaranteed timing constraints and quality of service in real-time distributed networks, where timely data delivery is crucial for system functionality. Current middleware solutions allow users to request quality of service, but they do not provide guarantees for timely delivery amid heavy traffic or denial of service attacks."
"University of Pennsylvania","GSH Adducts and Uses Thereof","","","https://upenn.technologypublisher.com/technology/39081","Technology Overview:Researchers at the University of Pennsylvania have discovered and characterized a novel endogenous cyclic glutathione (GSH) adduct (TOG) which represents the first member of a new class of biomarkers that can be used to quantify intracellular oxidative stress.Oxidative stress is involved in the pathogenesis of a variety of diseases including cardiovascular disease, cancer and neurodegenerative disease. It occurs as a result of increased production of reactive oxygen species (ROS) which in turn can cause increased lipid peroxidation mediated damage to DNA and proteins. TOG could be used as a biomarker in basic research and clinical studies, and also could be used as a biomarker to measure the efficiency of various drugs which are being developed to treat asthma and cardiovascular disease.Intellectual Property:US8,748,121Reference Media:Zhu, P., et al.Free Radic Biol Med. 2009 Oct 1;47(7):953Case ID:S3993-tpNCDWeb Published:3/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39081","**Summary:** Researchers at the University of Pennsylvania have discovered and characterized a novel cyclic glutathione (GSH) adduct known as TOG, which serves as a new class of biomarkers for quantifying intracellular oxidative stress. This oxidative stress is associated with various diseases, including cardiovascular disease, cancer, and neurodegenerative disorders, as a result of increased production of reactive oxygen species (ROS) that lead to damage in DNA and proteins.

**Applications:** TOG can be employed in basic research and clinical studies as a biomarker to measure oxidative stress. It may also serve to evaluate the efficacy of various developing drugs intended for the treatment of asthma and cardiovascular diseases.

**Problem Solved:** The technology addresses the challenge of measuring and understanding oxidative stress, which plays a critical role in the progression of several diseases, providing a potential tool for early diagnosis and treatment monitoring.","Researchers at the University of Pennsylvania have identified a new cyclic glutathione (GSH) adduct, termed TOG, which serves as a biomarker for quantifying intracellular oxidative stress. This oxidative stress is associated with various diseases, including cardiovascular diseases, cancer, and neurodegenerative disorders."
"University of Pennsylvania","Ex-Vivo Method to Maintain Hematopoietic Stem Cells","","","https://upenn.technologypublisher.com/technology/39288","An efficient way to improve outcomes of bone marrow and umbilical cord blood transplants to increase survival in blood cancer patients. The invention works by expanding hematopoietic stem cells in culture using a defined medium with specific inhibitor combinations.Problem:Expanding hematopoietic stem cells (HSCs) is paramount in stem cell research and for clinical use of HSCs. However, HSC homeostasis is not well understood and methods for HSC expansion have so far required the use of complex and expensive cocktails of cytokines and/or support cells.Solution:Dr. Klein and his team developed a method to expand and maintain HSCs ex-vivo using available GSK3 and mTOR inhibitors potentially enabling production of a greater number of long term HSCs without the use of exogenous hematopoietic cytokines and other factors. This combination, in mice, increases the number of HSCs, improves the frequency of engraftment, and shortens the time to hematopoietic recovery in transplant recipients. Additionally, these novel culture conditions offer an excellent research tool to explore HSC biology.Advantages:Maintenance and expansion of HSCs without inducing cell lineage commitmentMaintenance and expansion of HSCs without the need for cytokinesUse of clinically approved drugsApplications:Pre-treatment to increase efficacy of bone marrow transplantationPre-treatment to increase efficacy and survival rate of UCB transplantationPotential use to expand and maintain other stem cellsPotential research tool to expand HSCs that may be applied to other adult stem cellsStage of Development:Ex-vivo maintenance of HSCs, including cord blood HSCsIn-vivo data showing improved survival of recipients who received HSCs cultured in inhibitor combination.Intellectual Property:US9,050,315US9,452,187Reference Media:Huang, J. et al.;J Clin Invest, 2009, 119(12): 3519.Huang, J. et al.;Nat Med, 2012, 18(12): 1778.Desired Partnerships:LicenseCo-developmentCase ID:W5373-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39288","**Summary:** The technology presents an efficient method for expanding and maintaining hematopoietic stem cells (HSCs) ex-vivo, aimed at improving bone marrow and umbilical cord blood transplant outcomes for blood cancer patients. By utilizing specific combinations of GSK3 and mTOR inhibitors in a defined culture medium, the method facilitates the growth of HSCs without the complexity and cost associated with traditional cytokine cocktails. Preclinical studies in mice indicate that this approach increases the quantity of long-term HSCs, enhances engraftment success, and accelerates hematopoietic recovery post-transplant. This new culture system also serves as a valuable tool for investigating the biology of HSCs.

**Applications:** The method can be used as a pre-treatment to enhance the efficacy and survival rates of bone marrow and umbilical cord blood transplants. There is potential for expanding and maintaining other types of stem cells and for various research applications related to stem cell biology.

**Problem Solved:** The technology addresses the challenges associated with HSC expansion, which is crucial for both research and clinical applications. Traditional methods depend on complex and costly mixtures of cytokines and support cells, while this innovative approach simplifies the process, reduces costs, and avoids the induction of cell lineage commitment.","This invention enhances bone marrow and umbilical cord blood transplant outcomes by expanding hematopoietic stem cells (HSCs) in culture with a defined medium and specific inhibitor combinations. Current methods for HSC expansion are complex and require further understanding of HSC homeostasis."
"University of Pennsylvania","Naturally Derived Vaccine Adjuvant and Immunostimulant for Use in Humans and Animals","","","https://upenn.technologypublisher.com/technology/21824","Unique RNA molecule derived from defective viral genomes containing potent immunostimulatory and adjuvant propertiesProblem:The vaccine industry is steadily moving away from live-attenuated and whole-pathogen products, mostly due to safety concerns. As this trend continues, there is a need for new adjuvants in the marketplace to help boost the immunogenicity of the modern vaccine. For 70 years, the only approved adjuvant was aluminum, whose mechanism of action is still unknown. Over the years, many other adjuvants have been proposed but most have failed to be successful, at least in humans, due to toxicity, cost and stability.Solution:Dr. Lopez has optimized a short RNA motif (DDO) contained in naturally occurring replication defective viral genomes which contains exceptional immunostimulatory activity. This motif is stable, short in length, lacks the ability to replicate and is easily produced. DDOs can be modified, and transferred to other RNAs and vaccine viral vectors to enhance their activity. In addition, it can be combined with delivery/depot adjuvants for enhanced activity and targeting.While most classical adjuvants largely target the Toll-like receptor signaling pathway, the DDO operates through a distinct molecular pathway. This feature allows for the molecule to be used either singly or in combination with a traditional adjuvant for a synergistic effect. Taken together, this unique molecule is versatile in its applications and robust in its immunostimulatory capacity making it an ideal vaccine adjuvant.Advantages:StableCost-effectiveMultiple delivery mechanismsActivates a non-Toll receptor signaling pathwayCan be used alone or in combination with other adjuvantsStage of Development:Demonstrated in vivo and in vitroIntellectual Property:US10,624,964Reference Media:Xu, J et al.mBio, 2015 Oct 6; 6(5): e01265Mercado-Lopez, X et al.Vaccine, 2013 Nov 19; 31(48): 5713Desired Partnerships:Co-developmentCase ID:15-7499-tpNCSWeb Published:4/28/2016Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/21824","**Summary:** This technology describes a unique RNA molecule derived from defective viral genomes, which exhibits significant immunostimulatory and adjuvant properties for enhancing vaccine efficacy in both humans and animals. The RNA motif, known as DDO, is characterized by its stability, short length, and inability to replicate, making it a safe and easily produced option. It can be modified and incorporated into various vaccines, including delivery systems, and works via a distinct molecular pathway compared to traditional adjuvants.

**Applications:** The DDO RNA molecule can be utilized in the formulation of vaccines to improve their immunogenicity. It can be applied singly or in combination with other adjuvants to achieve enhanced immune responses. The versatility of the molecule suggests potential use in a broad range of vaccine types for both human and veterinary applications.

**Problem Solved:** The technology addresses the growing need for new, safer adjuvants as the vaccine industry pivots away from live-attenuated and whole-pathogen products due to safety concerns. By providing a stable and effective alternative to traditional adjuvants, it overcomes issues related to toxicity, cost, and stability that have plagued other proposed adjuvants.","The text discusses a unique RNA molecule derived from defective viral genomes that possesses potent immunostimulatory and adjuvant properties. It highlights the vaccine industry's shift away from live-attenuated and whole-pathogen products due to safety concerns, creating a need for new adjuvants to enhance vaccine immunogenicity."
"University of Pennsylvania","Polymer nanocomposite films with extremely high nanoparticle loading","","","https://upenn.technologypublisher.com/technology/38093","Material synthesis through capillary rise infiltrationProblem:Polymer nanocomposite films (PNCFs) combine the electronic, mechanical, and optical properties of nanoparticles with the flexibility of polymers to yield nanostructured films.PNCFs with extremely high nanoparticle concentrations are important components in energy storage and conversion devices, as well as in protective coatings. However, these PNCFs are difficult to prepare because of the poor processability of polymer-nanoparticle mixtures with high concentrations of nanoparticles; this problem is exacerbated with anisotropic nanoparticles.Solution:Using a technique based on capillary rise infiltration (CaRI) of polymer into a dense packing of nanoparticles, the Lee lab is able to obtain high packing densities.A two-layer film, comprised of a polymer layer and a nanoparticle layer, is generated and annealed at a temperature that imparts mobility to the polymer. The polymer infiltrates the interstices of the nanoparticle layer. This approach has been demonstrated with monodisperse polystyrene and titanium dioxide nanoparticles.Compared to films made from individual components, PNCFs generated from CaRI have superior mechanical properties, including hardness, modulus, scratch/wear resistance, and the ability to heal nanoparticle films with cracks that exist prior to annealing.Advantages:Straightforward, scalable process to generate PNCFsUniform nanoparticle distributionExtremely high filler concentrationsSynthesized material has superior mechanical propertiesApplications:Generation of high filler fraction PNCFs with different sets of polymers and nanoparticlesDye-sensitized solar cellsBatteriesSeparations/membranesCoatingsDisplay devicesInfiltration of polystyrene into TiO2 nanoparticle film due to capillary action.Stage of Development:Proof-of-principle testingIntellectual Property:US11,639,425Reference Media:Huang, Y et al:Nanoscale 2015, 2(7): 798.Desired Partnerships:LicenseCo-developmentCase ID:14-7115-tpNCSWeb Published:1/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38093","**Summary:** Polymer nanocomposite films (PNCFs) exhibit enhanced electronic, mechanical, and optical properties by integrating nanoparticles within a flexible polymer matrix. The conventional preparation of PNCFs is hindered by challenges related to the poor processability of high nanoparticle concentrations, particularly with anisotropic nanoparticles. A novel fabrication method utilizing capillary rise infiltration (CaRI) allows for the creation of these films by allowing polymer to penetrate a densely packed nanoparticle layer. The resulting two-layer structure is subjected to annealing, which facilitates the polymer's mobility and integration. This process has demonstrated significant improvements in mechanical properties, such as increased hardness, modulus, and resistance to scratches and wear, as well as the ability to spontaneously heal pre-existing cracks in the nanoparticle films.

**Applications:** PNCFs with high nanoparticle loading are poised for use in energy storage and conversion devices, as well as protective coatings, owing to their superior mechanical properties and flexibility.

**Problem Solved:** The technology addresses the difficulty of preparing PNCFs with extremely high nanoparticle concentrations, overcoming issues related to the processability of polymer-nanoparticle mixtures and enabling the development of films with enhanced performance characteristics.","Polymer nanocomposite films (PNCFs) combine the properties of nanoparticles and polymers, making them valuable for energy storage, conversion devices, and protective coatings. Preparing PNCFs with high nanoparticle concentrations is challenging due to the poor processability of polymer-nanoparticle mixtures."
"University of Pennsylvania","pH-responsive, shape changing amphiphilic Janus particles","","","https://upenn.technologypublisher.com/technology/38092","Stimuli-responsive colloid surfactants for thermodynamically stable emulsions and phase inversion emulsificationProblem:Janus particles are biphasic colloids that have distinct chemistries and contrasting properties on each side. Because of their amphiphilicity, Janus particles have the unique ability to stabilize multiphasic fluid mixtures, such as emulsions. Janus particles also have a strong tendency to segregate to and remain at fluid interfaces, leading to highly stable emulsions. However, current synthesis techniques generate only one type of emulsion, so a method where the chemical environment can be tuned on demand to generate different types of emulsions is desirable.Solution:Researchers in the Lee lab have designed a new approach to synthesize a new class of colloidal materials, highly uniform, pH-responsive Janus particles in emulsions, via seeded emulsion polymerization and acid hydrolysis. The hydrolysis of the composite particles leads to a drastic change in particle morphology.Janus particles with varying surface properties can be controlled by manipulating the chemical environment. The pH-dependent aggregation/dispersion behavior of the Janus particles generates both attractive and repulsive emulsions at low and high pH conditions, respectively. The ability to enable phase inversion allows for the generation of novel emulsions that cannot be achieved by traditional emulsion bulk synthesis methods.Advantages:Generate highly uniform, pH-responsive Janus particlesCompletely reverse amphiphilicity in response to changes in solution pHDynamically tunableEasier separation than amphiphilic surfactants to remove particles from productsApplications:Solid surfactantsStable, industrial emulsions; water-in-oil and oil-in-waterPaints, coatingsOil recoveryEmulsion-based reactionsCaption: Schematic illustration for synthesis of amphiphilic Janus particles and scanning electron microscopy images. From Tu et al, JACS, 2014.Stage of Development:Proof-of-principle testingIntellectual Property:US9,580,520US10,287,376Reference Media:Tu, F and Lee, D;J Am Chem Soc 2014 July 16, 136(28): 9999.Tu, F and Lee, D;Chem Commun (Camb) 2014 Dec 21, 50(98): 15549.Desired Partnerships:LicenseCo-developmentCase ID:14-7092-tpNCSWeb Published:1/23/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38092","**Summary:** This technology presents a novel method for synthesizing uniform, pH-responsive Janus particles that serve as effective surfactants for stabilizing multiphasic fluid mixtures, particularly emulsions. The synthesis utilizes seeded emulsion polymerization and acid hydrolysis to create particles with distinct surface properties that can be adjusted according to the pH of the environment. This pH responsiveness allows the particles to exhibit different aggregation and dispersion behaviors, facilitating the creation of both attractive and repulsive emulsions depending on the pH level.

**Applications:** The pH-responsive Janus particles can be utilized in various applications that require stable emulsions, including food industry formulations, pharmaceuticals, cosmetics, and materials science. Their ability to enable phase inversion is significant for developing novel emulsions that traditional methods cannot achieve, potentially opening new avenues for product innovation.

**Problem Solved:** The technology addresses the limitation of existing synthesis techniques that produce only one type of emulsion. By allowing for the tuning of the chemical environment, it enables the generation of diverse emulsification behaviors, leading to more versatile and stable emulsion systems.","Janus particles are biphasic colloids with different chemistries on each side, which enables them to stabilize multiphasic fluid mixtures like emulsions. Their amphiphilic nature allows them to segregate to fluid interfaces, resulting in highly stable emulsions."
"University of Pennsylvania","Nanowire phase change memory","","","https://upenn.technologypublisher.com/technology/39287","Problem:Phase Change Memory (PCM) is a leading contender to replace flash memory. In PCM devices, a material is heated to undergo glass transition, changing back and forth between the amorphous and crystalline state. However, existing PCM devices have experienced problems with reliability and threshold voltage drift. In order to make commercially viable PCM devices, better solutions are required.Solution:Researchers at the University of Pennsylvania have developed a nanowire-based PCM that shows better stress relaxation, and thus better long term reliability, than thin-film devices. The researchers discovered that stress relaxation behavior is the key cause of time-dependent drift in PCM device properties, which results in poor reliability. The design of the new PCM device uses exposed nanowires rather than conventional embedded thin films. These free-standing nanowires show much less long-term drift than thin film devices. The large surface area of the nanowires allows them to quickly and efficiently relax stress after phase change, resulting in better performance.Advantages:Faster relaxation of residual stressesBetter long term reliability and reduced temporal driftStage of Development:PrototypeIntellectual Property:US8,759,810Reference Media:Mitra, M., et al.;Appl Phys Lett, 96(22), 222111.Desired Partnerships:LicenseSponsored ResearchCase ID:W5329-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39287","**Summary:** Researchers at the University of Pennsylvania have developed a nanowire-based phase change memory device that offers improved stress relaxation and long-term reliability compared to traditional thin-film devices. This approach addresses the issues of reliability and threshold voltage drift experienced in conventional phase change memory, making it more viable for commercial applications. The design utilizes exposed nanowires which facilitate quicker and more efficient stress relaxation after phase changes, resulting in enhanced performance.

**Applications:** This technology could be utilized in various fields that require reliable and efficient memory storage solutions, potentially including consumer electronics, data centers, and computing devices where high durability and speed are essential.

**Problem Solved:** The new nanowire-based PCM technology mitigates the challenges of time-dependent drift and reliability issues in existing PCM devices, leading to improved long-term performance and reduced susceptibility to failure.","Researchers at the University of Pennsylvania have developed a nanowire-based phase change memory that addresses reliability and threshold voltage drift issues. This advancement aims to enhance the commercial viability of PCM devices, which are potential replacements for flash memory."
"University of Pennsylvania","Smart camera networks and target tracking","","","https://upenn.technologypublisher.com/technology/39079","Problem:The rise of small, networked devices means that cameras are now cheaper and easier to deploy than ever before. A network of cameras could track objects by establishing where targets are moving in each camera‚Äôs field of view. However, without a way to know where cameras and their targets are in relation to each other, it is difficult to accurately track an object.Solution:Researchers at the University of Pennsylvania have developed a way to localize smart cameras and track objects. Cameras that are in each other‚Äôs field of view can communicate with each other by sending pulsed infrared signals. Information about the camera position can be determined and the location of tracked objects can be established through triangulation.Using this technique, a network of cameras can communicate with each other and establish their spatial orientation to track moving objects. This technology could be used to create smart surveillance systems that can track targets spread across a building or a larger area.Advantages:Establishes spatial orientation of cameras relative to each otherTargets can be tracked as they move from one camera‚Äôs field of view to anotherAllows for smart, networked surveillance systemsStage of Development:Prototype systemIntellectual Property:US7,421,113US7,522,765Desired Partnerships:LicenseSponsored ResearchCase ID:R3779-tpNCSWeb Published:3/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39079","**Summary:** Researchers at the University of Pennsylvania have created a technology that enables the localization of smart cameras and tracking of objects through a networked system. By allowing cameras within each other's field of view to communicate using pulsed infrared signals, the cameras can determine their positions and calculate the locations of tracked objects via triangulation. This method allows for effective coordination among cameras, facilitating continuous tracking as subjects move across different cameras' fields.

**Applications:** This technology could be leveraged to develop advanced surveillance systems that monitor and track individuals or objects across extensive areas, such as buildings or outdoor environments, enhancing security and situational awareness.

**Problem Solved:** It addresses the challenge of accurately tracking moving objects across multiple camera views by providing a system for cameras to localize themselves and communicate their positions, thereby maintaining continuous tracking of targets as they transition from one camera's perspective to another.","Researchers at the University of Pennsylvania have developed a method to localize smart cameras and track objects effectively within a network of cameras. This advancement addresses the challenge of accurately tracking objects by determining the spatial relationships between the cameras and their targets."
"University of Pennsylvania","Diamond waveguides for photonic devices","","","https://upenn.technologypublisher.com/technology/38437","Problem:Photonic Integrated Circuits (PICs) can transmit information for computing using light rather than electricity. Using PICs on chips would allow for faster data transmission rates, lower power consumption, and less energy wasted through thermal dissipation. Diamond is a promising material for PICs due to its optical properties, however, fabrication difficulties have impeded progress in this area.Solution:Researchers at the University of Pennsylvania have developed a new fabrication method for diamond waveguides that could be integrated with standard CMOS processing. This would allow easier integration of photonic elements with standard integrated circuits. The fabrication technique surrounds a high refractive index material (diamond) with a low index material (SiO2), with an additional intermediate index cladding (Si3N4) over the top of the waveguide. This geometry and composition produces full confinement of a single optical mode in the waveguide.Difficulties associated with the current diamond-on-insulator approach are avoided with this new fabrication technique. Crucially, this waveguide structure is much better suited that the prior art to integration with CMOS processing, allowing photonic and electronic devices to be easily fabricated on the same chip. Producing a highly confined single mode waveguide with fewer fabrication issues than the prior art would be of great value in this emerging area.Advantages:Compatibility with CMOS componentsEasier scaling and manufacturing of photonic componentsStage of Development:PrototypeReference Media:Grote, R & Bassett, L;APL Photonics 2016 Aug 1; 1(7): 1302Intellectual Property:US10,585,243Case ID:16-7722-tpNCSWeb Published:2/3/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38437","**Summary:** Researchers at the University of Pennsylvania have developed a new fabrication method for diamond waveguides, which could facilitate the integration of photonic elements with standard CMOS processing. This innovative approach uses high refractive index diamond surrounded by low index SiO2 and an intermediate Si3N4 cladding, resulting in full confinement of a single optical mode in the waveguide. The technique addresses challenges associated with the diamond-on-insulator approach, offering better compatibility with CMOS technology, which is crucial for the fabrication of photonic integrated circuits.

**Applications:** The technology can be used in photonic integrated circuits (PICs) for faster data transmission, lower power consumption, and reduced thermal dissipation. This is particularly relevant for computing applications that rely on both optical and electronic components integrated on the same chip.

**Problem Solved:** The fabrication method overcomes difficulties in using diamond as a material for photonic devices, such as integration challenges and fabrication issues present in previous methods. This novel approach facilitates the development of highly confined single-mode waveguides that can coexist with traditional electronic components, ensuring efficient performance in photonic devices.","Photonic Integrated Circuits (PICs) can enhance data transmission rates and reduce power consumption by using light instead of electricity, but diamond's potential in this area has been hindered by fabrication challenges. Researchers at the University of Pennsylvania have created a new method to address these fabrication difficulties."
"University of Pennsylvania","Content-coupled interactive surfaces","","","https://upenn.technologypublisher.com/technology/38402","Problem:Many activities, such as self-guided exercise, can involve physical interactions with objects while following instructions from a video or website. However, most objects such as a yoga mat or dumbbells have no ‚Äúsmart‚Äù capabilities ‚Äì they cannot monitor the user‚Äôs actions or progress. Adding sensing and interactive components to this equipment can allow for a more personalized interactive experience.Solution:Researchers at the University of Pennsylvania have developed content-coupled objects that can track the user‚Äôs actions and provide feedback to a computer-controlled interactive program. As an example, the group has developed an interactive yoga mat that can sense the placement of a user‚Äôs feet and hands to determine the pose. This information is sent to the content display to pace the flow of an instructional video.Rather than proceeding at a fixed pace, the content can be displayed at the user‚Äôs own pace for people who are more or less experienced. Beginners who need more time can proceed at a slower pace as the flow of the content is based on the user‚Äôs actual movements. A display built into the mat can guide the user‚Äôs hands and feet to the correct pose. By closing the loop between the instructional content and the user‚Äôs physical state, the exercise experience is more personalized and interactive.Advantages:Interaction between a user‚Äôs physical state and virtual contentMore interactive and personalized experiencesApplicable to any variety of physical-virtual interactionsStage of Development:PrototypeReference Media:Jang, K. J., et al.2015 IEEE International Conference on Services Computing; 2015 27 June - 2 July: 301.Intellectual Property:US10,642,360Case ID:16-7617-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38402","**Summary:** Researchers at the University of Pennsylvania have developed technology that integrates sensing capabilities into traditional physical objects used in exercises, enabling them to track user actions and provide real-time feedback. An example is an interactive yoga mat that detects the placement of the user's feet and hands, allowing it to assess their pose and adjust the instructional video accordingly. This advancement facilitates a more personalized experience by allowing the content to be paced to match the user's ability level, making it suitable for beginners and advanced users alike.

**Applications:** This technology can be applied in various physical activity domains, including yoga, fitness training, rehabilitation exercises, and possibly in educational settings that involve physical engagement with instructional content. It has the potential to enhance self-guided exercises and improve the effectiveness of physical training programs.

**Problem Solved:** The technology addresses the lack of smart capabilities in typical exercise equipment that limits users' ability to receive feedback and personalized instruction during their workouts. By coupling physical interactions with responsive digital content, it creates a more engaging and adaptive exercise environment that caters to individual user needs and progresses at their own pace.","Researchers at the University of Pennsylvania have developed content-coupled objects that integrate sensing and interactive components into traditional exercise equipment. This advancement enables these objects to monitor user actions and progress, facilitating a more personalized interactive experience during self-guided exercise activities."
"University of Pennsylvania","Visible light absorbing ferroelectric materials for photovoltaics","","","https://upenn.technologypublisher.com/technology/39319","Problem:In the search for new routes to renewable sources of energy, fabrication of higher ‚Äìperforming, environment-friendly and chemically stable materials is constantly being pursued. Improving the efficiency of utilizing solar energy, the most abundant energy source, is expected to require the design of new photovoltaic materials that can absorb light in the whole UV-visible spectral range. Ferroelectic materials may provide a promising solution.Solution:Ferroelectrics have been attractive in the area of energy storage as they allow for coupling of light absorption with other functional properties. Dr. Andrew Rappe‚Äôs work has resulted into a family of single-phase solid oxide solutions that are low-cost, nontoxic, and most importantly, are able to access a wider range of bandgaps from 1.1 to 3.8 electronvolts. This allows these materials to capture a larger percentage of the solar spectrum, and suggest they may be a viable alternative to conventional semiconductor p-n junction solar cells for solar energy conversion.Technology Overview:The invention covers the bandgap engineering strategy wherein two different transition-metal cations located on the perovskite B-site create ferroelectric perovskites with low bandgaps, with one cation driving ferroelectricity and the other giving a bandgap in the visible range. The solid solutions were synthesized by standard solid-state synthesis and synchrotron X-ray diffraction was used to show the formation of a stable perovskite for all the solutions. The study was published in the highly reputed journal Nature and was featured on the cover.Advantages:Ability to capture solar energy 3 to 6 times more than the current state of the art ferroelectric technologyCan be fabricated using low-cost methods such as sol-gel thin-film deposition and sputteringUse of low cost, abundant materialsIntellectual Property:US9,484,475Reference Media:Grinberg, I et al.;Nature 2013 Nov, 503: 509Desired Partnerships:LicenseCo-developmentCase ID:Y6021-tpNCSWeb Published:3/19/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39319","**Summary:** This technology focuses on the development of ferroelectric materials that can absorb visible light, aiming to improve the efficiency of solar energy conversion. The materials are engineered through a bandgap strategy that utilizes two different transition-metal cations on the perovskite B-site, resulting in solid oxide solutions that demonstrate low-cost, nontoxic properties with bandgaps ranging from 1.1 to 3.8 electronvolts. This innovation allows for broader light absorption across the UV-visible spectrum, potentially offering a superior alternative to conventional semiconductor p-n junction solar cells.

**Applications:** The primary application of these ferroelectric materials is in the field of photovoltaics, specifically in solar energy conversion systems where efficient light absorption and energy storage are crucial. They could also have implications in other areas where energy efficiency is vital, such as in electronic devices and sensors that benefit from their unique coupling properties.

**Problem Solved:** The technology addresses the ongoing challenge of developing high-performance, environmentally friendly materials for renewable energy sources. By enhancing the light absorption capabilities across a wider spectrum and ensuring chemical stability, these materials aim to overcome the limitations of current photovoltaic systems, thus improving the overall efficiency and effectiveness of solar energy utilization.","The development of higher-performing, environmentally friendly, and chemically stable photovoltaic materials is essential for improving solar energy efficiency. Ferroelectric materials may offer a promising solution due to their ability to absorb light across the entire UV-visible spectrum."
"University of Pennsylvania","Robust Smart Windows: Reversible switching from transparent to color","","","https://upenn.technologypublisher.com/technology/38389","Problem:Commercial buildings in the United States alone account for nearly 40% of the total energy consumption. Among them, electricity is the largest energy source for buildings. Therefore, the design of new energy efficient materials and technologies is crucial to meet goals such as the Net-Zero Energy Commercial Building Initiative (CBI) put forward by the U.S. Department of Energy (DOE). Approaches to block or reflect intense sunlight when needed, and to capture the sun‚Äôs light and heat when desirable, remain complex and expensive to fabricate.Solution:A low cost, durable composite film used as a window ‚Äúshade‚Äù where the transparency can be tailored to adjust heat and light. The film could also be mounted between two panes of glass and motor controlled.Technology Overview:A composite film consisting of a thin layer of quasi-amorphous array of silica nanoparticles (NPs) is embedded in a bulk elastomeric polymer film.It is highly transparent (>90% transmittance in the visible wavelength) in the initial state.Upon mechanical stretching, the transmittance is dramatically reduced to 30% and displays angle-independent structural color at a strain >30%.The displayed reflective color is a so-called structural color, which could be tuned by the silica NP size; the color displayed is invariant with the applied strain.The switch between transparency and colored states has been reversibly cycled over 1000 times without losing the film‚Äôs structural and optical integrity.Advantages:The initial state is transparent vs. technologies such as polymer dispersed liquid crystals and electrochromic displays.The switch between transparency and colored states has been reversibly cycled at least 1000 times without losing the film‚Äôs structural and optical integrity.The ‚Äúwindow‚Äù can be massproduced using low-cost methods from abundant materials.In addition to light blocking smart windows, it can also be used for display or security applications.Intellectual Property:USPendingPCTPendingReference Media:Ge, D et al.;Adv Mater 2015 Apr, 27(15): 2489Case ID:15-7442-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38389","**Summary:** The technology involves a low-cost, durable composite film designed to act as a window shade, allowing for adjustable transparency to control heat and light entering buildings. The composite film consists of a thin layer of silica nanoparticles embedded in a bulk elastomeric polymer, which is highly transparent in its initial state. Through mechanical stretching, the film can reduce transmittance significantly while exhibiting structural color that can be tuned based on the size of the nanoparticles, maintaining optical integrity even after being cycled over 1000 times.

**Applications:** This technology can be applied in commercial buildings to enhance energy efficiency by reducing reliance on artificial lighting and climate control. It can potentially be used in residential applications as well, as well as in automotive or other transportation sectors where adjustable lighting and temperature control are beneficial.

**Problem Solved:** The technology addresses the high energy consumption in commercial buildings by providing a flexible and cost-effective solution for controlling light and heat entry. It simplifies the approach to managing sunlight exposure, offering a practical alternative to complex and expensive traditional shading and glazing methods.","Commercial buildings in the United States account for nearly 40% of total energy consumption, with electricity being the largest source. Developing new energy-efficient materials and technologies is essential to achieving initiatives like the Net-Zero Energy Commercial Building Initiative by the U.S. Department of Energy."
"University of Pennsylvania","Drug Discovery and Target Identification Platform Technology Using Random shRNA-Expressing Library","","","https://upenn.technologypublisher.com/technology/39324","shRNA library of 3 million sequences for identification of small-RNA therapeutic candidates, new targets and pathways, as well as conventional chemical-compound drugs in cell-culture disease models.Problem:ShRNA Drug Discovery: RNA interference (RNAi) using short hairpin RNA (shRNA) is commonly used to inhibit gene expression. shRNA-expressing libraries may have important applications in identifying RNA molecules/sequences with specific biological activity and thus therapeutic implications. Typically, shRNA libraries are limited to sequences that target single mRNAs. Because 7-nucleotide ‚Äúseed‚Äù sequences within shRNAs are sufficient for partial inhibition of target mRNAs, shRNAs are inherently promiscuous. Thus, the single-gene-targeting approach is complicated by off-target effects, which diminish therapeutic indices, and fails to take advantage of multi-gene targeting, which enhances potency.Discovery of Drugs, Targets, and Pathways: Traditional drug discovery process involving high-throughput screening is labor-intensive, expensive, often ineffective, and infeasible when cell-culture disease models are unsuitable for microtiter-plate formats.Solution:ShRNA Drug Discovery: To challenge the single-gene-targeting paradigm of small-RNA-based therapeutic initiatives, Dr. Wilson‚Äôs lab designed, synthesized, validated, and now further optimized shRNA-expressing libraries that are completely random at the nucleotide level.Three million shRNAs can be screened in a single tissue-culture flask, selecting for the desired phenotype with ‚Äúhit‚Äù sequences retrieved by PCR. Because the libraries are completely random, the screens are unbiased: favorable cell phenotypes reveal which shRNAs are most effective and least toxic. This approach allows identification of sequences that target multiple genes and/or act through non-canonical mechanisms.Discovery of Drugs, Targets, and Pathways: Random shRNA library screening can be combined with bioinformatic pattern analyses of hit sequences to identify targets, pathways, and conventional chemical-compound therapeutic candidates, bypassing in vivo delivery issues. Thus, each phenotypic screen has the potential to identify, (i) small-RNA therapeutic candidates, (ii) conventional, chemical-compound therapeutic candidates, (iii) target candidates for conventional drug development, and (iv) information on pathways relevant to disease mechanisms.Advantages:Screening, by phenotypic selection, of 3 million shRNAs in a single tissue-culture flaskScreening for efficacy, and lack of toxicity, simultaneouslyHit-optimization by random mutagenesis and re-screeningTranslation, using bioinformatics, of gene-expression profiles of ‚Äúhit‚Äù shRNAs to existing drugsInexpensive, simplified, fast method compared to high throughput screeningAbility to run positive and negative (cancer) screensUtilization of cell-culture disease models unsuitable for microtiter-plate formatsApplications:Identification of shRNA sequences that confer phenotypes of interest or modulate specific biological parametersIdentification of novel targets, pathways and existing drugs through bioinformatic pattern analysesDevelopment of novel therapeutics and biologic tools for a variety of diseases, including, e.g.Viral illnesses, by selecting for cell survival in viral cell-culture modelsCystic Fibrosis, by selecting for increased surface expression of F508del CFTRTRAIL-insensitive Malignancies, by selecting for increased surface expression of the TRAIL receptorHypercholesteremia, by selecting for increased surface expression of the LDL receptorParkinson Disease, by selecting for increased expression of PGC1-alphaType II Diabetes, by selecting for protection against inducers of ER stress and the unfolded protein response (UPR)Stage of Development:Synthesized, validated, and optimized library of 3 million sequencesIdentified shRNAs protecting an IL3-dependent cell line from IL3 withdrawalIdentified shRNAs that reverse phenotypic defects of Friedreich ataxia (FA) fibroblastsIdentified novel targets and existing drugs that reverse phenotypic defects of FA fibroblastsIntellectual Property:AU2007223980JP5463039EP2002037US9,163,231WO2015/020990US9,982,256US10,260,065US11,371,041Reference Media:Wang, Y et al.;PLoS One. 2014 Feb 3; 9(2):e87390Wang, Y et al.;PLoS One. 2008 Sept 9; 3(9):e3171Cotticelli, MG et al.;J Biomol Screen, 2015 Oct; 20(9): 1084Desired Partnerships:LicenseCo-developmentCase ID:Y6140-tpNCSWeb Published:3/19/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39324","**Summary:** This platform utilizes a library of three million random shRNA sequences for the identification of small-RNA therapeutic candidates as well as new drug targets and pathways in cell-culture disease models. By employing this extensive library, the technology facilitates the discovery of RNA molecules with specific biological activity, overcoming the limitations of traditional shRNA libraries that mainly target single mRNAs and suffer from off-target effects.

**Applications:** The technology can be applied in drug discovery, target identification, and pathway analysis, significantly enhancing the efficiency of identifying potential small-RNA therapeutics and chemical compound drugs in various disease models.

**Problem Solved:** The approach addresses the limitations of conventional RNAi methods that focus on single-gene targeting, which often leads to off-target effects and reduced therapeutic efficacy. It also provides a more effective solution to the traditional, labor-intensive, and costly high-throughput screening processes currently used in drug discovery, making it feasible to explore complex disease mechanisms in cell-culture models that are not suitable for microtiter-plate formats.","A shRNA library containing 3 million sequences is utilized to identify small-RNA therapeutic candidates, new targets, and pathways, as well as conventional chemical-compound drugs in cell-culture disease models. This approach leverages RNA interference (RNAi) to inhibit gene expression, facilitating the discovery of RNA molecules with specific biological activity and therapeutic potential."
"University of Pennsylvania","Complementary logic using piezoelectric MEMS switches","","","https://upenn.technologypublisher.com/technology/39289","Problem:New technologies and approaches are needed to miniaturize logic circuits and reduce power consumption.Solution:Researchers at the University of Pennsylvania have developed low-voltage complementary logic circuits using Aluminum Nitride piezoelectric MEMS switches. These switches have been used to create a low voltage (<1.5V) inverter with fast switching speeds (220 ns) which could represent an alternative to CMOS logic.An applied electric field is used to control the piezoelectric action of a thin-film Aluminum Nitride resonator and toggle the switch open or closed. These switches have a demonstrated reliability of 10^7 cycles and a resistance of 500 Ohm, which makes them suitable for logic circuits. The polarity of the switch can be inverted by applying the electric field to different electrodes of the same switch, making complementary action (p-type and n-type) possible with the same device. This low power alternative to CMOS could offer important advantages for miniaturization and reduced power consumption.Advantages:Reduced size and energy requirementsSame switch can be used as a P-type and N-type transistorDemonstrated reliabilityStage of Development:PrototypeIntellectual Property:US8,552,621Reference Media:Sinha, N., et al;J Microelectromechanical Systems, 2012 Apr, 21(2): 484.Desired Partnerships:LicenseCase ID:W5374-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39289","**Summary:** Researchers at the University of Pennsylvania have developed a novel approach to creating low-voltage complementary logic circuits using Aluminum Nitride piezoelectric MEMS switches. These switches operate with a voltage of less than 1.5V and have fast switching speeds of 220 ns, presenting an alternative to traditional CMOS logic. The technology utilizes an applied electric field to control the piezoelectric action of a thin-film resonator, allowing the switch to toggle between open and closed states. The switches have shown reliability of up to 10 million cycles and possess a resistance of 500 Ohm, making them suitable for logic circuit applications. Importantly, the same switch can function as both a P-type and N-type transistor, enabling complementary logic with a single device, which contributes to miniaturization and reduced power consumption. Currently, the technology is in the prototype stage and is protected under patent US8,552,621.

**Applications:** This technology could be utilized in various electronic devices where logic circuits are essential, particularly in applications needing miniaturization and improved energy efficiency, such as wearable electronics, IoT devices, and low-power computing systems.

**Problem Solved:** The development addresses the need for new technologies that miniaturize logic circuits while reducing power consumption, presenting a viable alternative to existing CMOS technology through lower voltage operation and enhanced energy efficiency.","Researchers at the University of Pennsylvania have developed low-voltage complementary logic circuits using Aluminum Nitride piezoelectric MEMS switches, achieving a low voltage inverter with switching speeds of 220 ns. This innovation presents a potential alternative to CMOS logic, utilizing an applied electric field to control the piezoelectric action."
"University of Pennsylvania","Piezoelectric label-free biosensor","","","https://upenn.technologypublisher.com/technology/39284","Problem:Existing sensors for biological materials or hazardous substances can be very limited in terms of sensitivity, and can typically only detect one substance per device.Solution:A new biosensor developed at the University of Pennsylvania combines label-free detection with high sensitivity. An Aluminum Nitride resonator is functionalized with single-stranded DNA coated nanotubes to detect biomolecules or hazardous substances. The sensitivity of this device has been shown to be better than similar FBAR resonator based sensors.Volatile organic compounds (VOCs) are adsorbed by the DNA coating, which changes the frequency response of the piezoelectric resonator and allows for detection. A prototype system was demonstrated to detect a variety of VOCs across a range of frequencies, which provides a proof of concept for a label-free system that can operate at a range of detection sensitivities.Advantages:Label-free detection of biological or hazardous substancesEnhanced detection as compared to FBAR based resonator devicesStage of Development:PrototypeIntellectual Property:US9,638,616Reference Media:Zuniga, C., et al.;Appl Phys Lett, 94(22): 223122.Desired Partnerships:LicenseCase ID:V5251-tpNCSWeb Published:3/17/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39284","**Summary:** A novel biosensor developed at the University of Pennsylvania utilizes a functionalized Aluminum Nitride resonator with single-stranded DNA coated nanotubes for the label-free detection of biomolecules and hazardous substances. This device demonstrates enhanced sensitivity compared to existing FBAR resonator based sensors, particularly through frequency response changes caused by the adsorption of volatile organic compounds (VOCs) onto the DNA coating. A prototype has successfully shown the capability to detect a variety of VOCs across multiple frequencies, highlighting its potential for versatile application.

**Applications:** The biosensor can be applied in contexts requiring the detection of biological materials and hazardous substances, including monitoring environmental pollutants, ensuring food safety, and medical diagnostics.

**Problem Solved:** The technology addresses the limitations of existing sensors that lack sensitivity and the ability to detect multiple substances simultaneously, offering a more efficient and sensitive solution for biosensing applications.","A new biosensor developed at the University of Pennsylvania utilizes an Aluminum Nitride resonator functionalized with single-stranded DNA coated nanotubes for label-free detection of biomolecules or hazardous substances. This device demonstrates high sensitivity, outperforming existing sensors that typically detect only one substance per device."
"University of Pennsylvania","Dual beam RF MEMS switches","","","https://upenn.technologypublisher.com/technology/39135","Problem:RF MEMS switches are an emerging solution for wireless technology, but these devices typically require large switching voltages and have problems with long term reliability.Solution:A new piezoelectric RF MEMS switch design from the University of Pennsylvania could overcome many of the challenges of electrostatic switches. This design provides a solution with high isolation, low insertion loss, and low power consumption.In this dual-beam switch, an electric field is used to control the actuation of a thin aluminum nitride piezoelectric membrane. The two beams of the switch are pushed toward each other in the closed state and pushed apart in the open state via the piezoelectric action. Both beams are actuated simultaneously, which avoids the problems other MEMS switches face from residual stress and inconsistent air gap. The resulting design has a low switching voltage (<20V) and fast switching times (<2 Œºs). The design of this switch is compatible with CMOS fabrication, allowing for easier on-chip integration.Advantages:Direct CMOS compatible fabricationLow switching voltage <20VFast switching time <2 ŒºsIncreased reliability, avoids issues with process-induced inconsistent airgapsImages fromhttp://iopscience.iop.org/article/10.1088/0960-1317/18/10/105011/metaStage of Development:PrototypeIntellectual Property:US8,604,670Reference Media:Mahameed, R. et al.;Journal of Micromechanics and Microengineering, 2008 Sept, 18(10): 105011.Desired Partnerships:LicenseCase ID:U4695-tpNCSWeb Published:3/11/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39135","**Summary:** A new piezoelectric RF MEMS switch design from the University of Pennsylvania offers a solution to common challenges faced by traditional RF MEMS switches, including high switching voltages and long-term reliability issues. This dual-beam switch utilizes an electric field to operate a thin aluminum nitride piezoelectric membrane, achieving high isolation, low insertion loss, and low power consumption. The switch is characterized by low switching voltage under 20V and fast switching times below 2 Œºs, with both beams actuated simultaneously to ensure consistent performance and reduced residual stress. The switch's design also allows for compatibility with CMOS fabrication, facilitating easier integration into existing technologies.

**Applications:** The dual-beam RF MEMS switch can be employed in various wireless communication systems and applications requiring efficient signal routing, such as in mobile devices, radar systems, and satellite communications, where reliable and efficient switching is crucial.

**Problem Solved:** This technology addresses the limitations of conventional RF MEMS switches by significantly reducing the required switching voltage and enhancing reliability, while also mitigating issues associated with process-induced inconsistencies in air gaps. The innovative design process leads to improved performance and lifespan of MEMS devices in wireless technology.","A new piezoelectric RF MEMS switch design from the University of Pennsylvania addresses challenges associated with conventional electrostatic switches, such as high switching voltages and long-term reliability issues. This dual-beam switch offers high isolation, low insertion loss, and low power consumption."
"University of Pennsylvania","Mouse Model of Gastric Cancer","","","https://upenn.technologypublisher.com/technology/38412","Rapid, novel mouse model of gastric cancer with metastasisTechnology Overview:University of Pennsylvania investigators developed a model of mixed type gastric cancer results from combinatorial conditional loss of the Cdh1 (E-cadherin), and p53 genes, and acquisition of expression of oncogenic Kras in gastric parietal cells. Mice exhibit significant disease related morbidity at a median of 77 days of age. Upon gross examination at necropsy 100% of mice present with enlarged, thickened, and whitened stomachs (linea plastic), epigastric lymph node metastases (100%) and mediastinal lymph node metastases (50%).Upon microscopic evaluation the primary tumors were characterized as mixed type gastric cancer containing >25% diffuse type cells. Microscopic observation confirmed the metastatic lesions through the use of the conditional YFP reporter allele (also present in the model) and further identified lung metastases in 100% of mice and liver metastases in 20% of mice.Advantages:Rapid model of gastric cancer100% penetranceEasy to follow disease progression using mouse weightMetastasis development that recapitulates progression of human cancerMetastasis development in 100% of miceConditional expression of YFP reporter in tumor tissue for tracking of metastatic phenotypeRobust signal to noise and great potential for improving gene/cell immunotherapy.Applications:Drug screeningDrug validationMetastasis StudiesMicrobiome StudiesCase ID:16-7648-tpNCSWeb Published:1/31/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38412","**Summary:** A novel mouse model of mixed type gastric cancer was developed by University of Pennsylvania researchers through the combinatorial conditional loss of the Cdh1 and p53 genes along with the expression of oncogenic Kras in gastric parietal cells. Mice develop significant morbidity by a median age of 77 days, consistently presenting with enlarged, thickened, and whitened stomachs, along with metastases to epigastric lymph nodes (100%) and mediastinal lymph nodes (50%). Microscopic analysis reveals the primary tumors as mixed type gastric cancer with over 25% diffuse type cells, and metastases were confirmed in the lungs (100%) and liver (20%) using a conditional YFP reporter allele.

**Applications:** The model can be utilized for drug screening, drug validation, metastasis studies, and microbiome studies.

**Problem Solved:** This technology provides a rapid and effective means to study gastric cancer progression and metastasis, closely mimicking human disease, which aids in the development of new therapies and understanding the underlying mechanisms of cancer.","University of Pennsylvania investigators developed a novel mouse model of mixed type gastric cancer through the combinatorial conditional loss of the Cdh1 and p53 genes, along with the expression of oncogenic Kras in gastric parietal cells. Mice exhibit significant disease-related morbidity by a median age of 77 days, with 100% presenting with enlarged, thickened, and white lesions upon necropsy."
"University of Pennsylvania","Single-chip multiple-frequency MEMS resonators","","","https://upenn.technologypublisher.com/technology/39109","Problem:The increasing use of networked devices is driving a need for smaller, more efficient wireless components. Making RF MEMS filters smaller and easier to integrate with CMOS on-chip fabrication would allow for cost and size savings.Solution:A new resonator design from the University of Pennsylvania allows the co-fabrication of multiple frequency filters on the same chip.A ladder structure composed of contour-mode Aluminum Nitride piezoelectric resonators is used to form low insertion loss bandpass filters. These devices can be designed to control their bandwidth and center frequency, allowing for multiple filters operating on different bands to be fabricated size by side. This integration allows for filters to be constructed 20x smaller than existing surface acoustic wave resonator based devices.The CMOS-compatible fabrication process could allow smaller filters and duplexers to be fabricated directly onto chips, reducing the size of mobile networked devices, and adding key value for Internet of Things devices.Advantages:Compatible with existing CMOS fabricationMultiple resonators can be fabricated on a single chip for use as filters or duplexers20x smaller than surface acoustic resonators for compact on-chip fabricationStage of Development:PrototypeIntellectual Property:US8,729,779Reference Media:Piazza, G., et al.;J Microelectromechanical Systems 2007 Apr, 16(2): 319.Desired Partnerships:LicenseCase ID:T4453-tpNCSWeb Published:3/9/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39109","**Summary:** A new resonator design developed by the University of Pennsylvania enables the co-fabrication of multiple frequency filters on a single chip using a ladder structure composed of contour-mode Aluminum Nitride piezoelectric resonators. This design results in low insertion loss bandpass filters that can be tailored to control bandwidth and center frequency, thus allowing for the integration of multiple filters operating on different frequency bands. The technology allows for the creation of filters that are 20 times smaller than traditional surface acoustic wave resonators, utilizing a CMOS-compatible fabrication process.

**Applications:** This technology can be applied to the development of compact wireless components for mobile networked devices, as well as for Internet of Things devices, where size and efficiency are critical. The ability to integrate multiple resonators on a single chip can enhance the performance of filters and duplexers in various electronic applications.

**Problem Solved:** The innovation addresses the growing demand for smaller and more efficient wireless components driven by an increase in networked devices. By enabling smaller RF MEMS filters that are easier to integrate with CMOS fabrication, this technology offers significant size and cost savings, ultimately facilitating more compact and capable mobile devices.","A new resonator design from the University of Pennsylvania enables the co-fabrication of multiple frequency filters on a single chip, addressing the demand for smaller and more efficient wireless components. This design utilizes a ladder structure of contour-mode Aluminum Nitride piezoelectric resonators to achieve low insertion loss."
"University of Pennsylvania","Repurposing of FDA-approved HER-inhibiting therapies for acute lung injury treatment","","","https://upenn.technologypublisher.com/technology/45151","Mitigating ventilator-induced lung injury and acute respiratory distress syndrome through HER2/HER3 signaling pathwayProblem:Acute lung injury, such as that induced by long-term treatment with a mechanical ventilator, and acute respiratory distress syndrome (ARDS) affects 190,000 patients per year in the United States, with associated mortality of 35-40%. The highest numbers of deaths are in patients with sepsis, pneumonia, or aspiration. ARDS is characterized by sudden breathlessness within hours to days of an inciting event, including trauma, sepsis, drug overdose, blood transfusion, and aspiration. ARDS is a life-threatening condition caused by widespread inflammation of the lungs that can lead to multisystem organ failure. Currently, there is no specific therapy for acute lung injury, and adjunctive strategies that modulate the deleterious effects of mechanical ventilation are needed.Solution:During mechanically-induced traumatic lung injury, the Margulies Lab has discovered, using cyclically stretched tissue and ventilated rats, that the HER (human epidermal growth factor receptor) family of genes, which regulates primary cellular signaling pathways, is upregulated during large stretch. The release of NRG1 (neuregulin) upon stretch induction binds to HER3, initiating HER2/HER3 heterodimerization and activation, which then initiates downstream signaling cascades, producing a ‚Äúleaky‚Äù epithelium.The Margulies Lab has in vitro and in vivo preclinical evidence that reducing NRG1 release, inhibiting NRG1/HER3 binding or HER2/HER3 heterodimerization and activation prevents ventilator-induced lung injury by protecting the epithelial barrier properties during stretch. Thus, FDA-approved HER-inhibiting cancer therapies currently in use or in clinical trials may be repurposed to reduce the incidence or severity of ventilator-induced lung injury and acute respiratory distress syndrome.Advantages:Use FDA-approved cancer drugs for alternate indicationSafety in humans previously studiedPotential therapeutic where one does not exist for this conditionApplications:Acute lung injuryVentilator-induced lung injuryAcute respiratory distress syndromeReproduced from Ware LB et al. NEJM, 2000, 342, p. 1334-1349. On left, the normal alveolus, and on right, the injured alveolus in the acute phase of acute lung injury and acute respiratory distress syndrome.Stage of Development:Proof-of-concept and in vivo testingIntellectual Property:US PatentPendingReference Media:Yehya et al.Am J of Physio Lung Cell and Mol Physiol,2015 Dec, 308(5): L443.DiPaolo et al.Am J of Physiol Lung Cell Mol Physiol,2013 July 15, 305(2): L141.Davidovich et al.Am J Respir Cell Mol Biol,2013 July, 49(1): 156.Davidovich et al.Cell Mol Bioeng, 2013June 1, 6(2): 175.Desired Partnerships:LicenseCo-developmentCase ID:15-7457-tpNCSWeb Published:10/20/2021Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/45151","**Summary:** Acute lung injury and acute respiratory distress syndrome (ARDS) significantly impact public health, with approximately 190,000 cases reported annually in the United States and a mortality rate of 35-40%. This condition is commonly associated with severe underlying issues such as sepsis, pneumonia, or aspiration and is characterized by rapid onset of breathlessness, leading to widespread lung inflammation and potential organ failure. Research indicates that during instances of mechanical trauma to the lungs, signaling pathways involving the HER family of genes are upregulated, leading to harmful effects such as epithelial leakiness. The Margulies Lab is investigating the potential of repurposing FDA-approved HER-inhibiting therapies to modulate these pathways and mitigate the adverse effects of mechanical ventilation.

**Applications:** The proposed therapy aims to treat patients suffering from mechanical ventilator-induced lung injuries and ARDS, thereby improving outcomes for those with severe respiratory conditions linked to various inciting factors like trauma and sepsis.

**Problem Solved:** The technology addresses the critical lack of specific therapies for acute lung injury and aims to reduce mortality and morbidity associated with ARDS by targeting the HER2/HER3 signaling pathway, which is known to exacerbate lung injury during mechanical ventilation.","Acute lung injury and acute respiratory distress syndrome (ARDS) affect 190,000 patients annually in the United States, resulting in a mortality rate of 35-40%, particularly among those with sepsis, pneumonia, or aspiration. ARDS is marked by sudden breathlessness that can develop within hours."
"University of Pennsylvania","Phytochelatin-based heavy metal detoxification in phytoremediation and agricultural applications","","","https://upenn.technologypublisher.com/technology/38454","AtPCS gene encoding multispecific heavy metal resistance factor from plantsProblem:Environmental contamination with heavy metals such as arsenic, cadmium, lead and/or mercury is implicated in human disease and agricultural losses. Industrial and mining activities, as well as natural mineral outcrops, have resulted in the contamination of soils and groundwater with heavy metals that are taken up by crops to decrease agricultural productivity and enter the human food chain. There is an urgent need for environmental cleanup to improve crop yield and decrease the heavy metal content of harvestable crops.The use of plants to extract heavy metals from the environment, in a process termed phytoremediation, is particularly appealing due to its low cost and the ease with which plants can be harvested, in contrast with conventional physical and chemical methods for environmental cleanup, which carry a price tag upward of $200 billion in the US alone.Solution:Professor Rea and colleagues have identified genes encoding multispecific heavy metal resistance factors from plants. These factors are involved in the synthesis of a class of peptides that play an important role in heavy metal tolerance by binding to heavy metals and decreasing their free concentrations. Transgenic plants expressing these genes can be used to remove heavy metals from the soil. In addition or alternatively, expression of these genes in a non-harvestable part of a plant can decrease the level of heavy metals in the harvestable parts. This discovery has significant market potential in agriculture and environmental safety applications.Advantages:More efficient, less expensive method to remove heavy metals from contaminated soils and groundwaterPotential for remediation of a broad range of heavy metalsBroaden and enhance the range of tools available for environmental remediationApplications:Transgenic plants for phytoremediationTransgenic arable crops with diminished heavy metal levels in their harvestable partsNew strategies for directed metabolic pathway engineeringGeneral structure of a representative phytochelatin (PC) synthesized by the AtPCS1 gene product phytochelatin synthase. The example shown is PC2, which contains two Œ≥-glutamylcysteine repeats. PC synthase, which localizes to the cytoplasm, catalyzes the heavy metal-activated synthesis of PCs to yield heavy metal-PC complexes that are transported into the vacuole.Stage of Development:Proof-of-conceptIntellectual Property:US10,370,675Reference Media:Cahoon, R et al.J. Biol. Chem., 2015, 290(28): 17321.Song, W et al.Proc Natl Acad Sci USA,2010 Dec 7, 107(49): 21187.Rea, Philip.Physiol. Plant,2012 May, 145(1): 154.Vatamaniuk, O et al.J Biol Chem, 2001 Jun 15, 276(24): 20817.Vatamaniuk, O et al.J. Biol. Chem.,2000 Oct, 275(40): 31451.Vatamaniuk, O et al.Proc Natl Acad Sci USA,1999 Jun 8, 96(12): 7110.Penn News2013 Nov 26PNASNews 2011 Feb 22Cozzarelli PrizeDesired Partnerships:LicenseCase ID:16-7874-tpNCSWeb Published:2/5/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/38454","**Summary:** The identified AtPCS gene encodes a multispecific heavy metal resistance factor from plants, which plays a vital role in the detoxification of heavy metals by synthesizing peptides that bind to these metals, thereby reducing their bioavailability. This genetic approach offers a means to develop transgenic plants capable of extracting heavy metals from contaminated environments, enhancing both environmental cleanup efforts and agricultural productivity. 

**Applications:** Transgenic plants expressing the AtPCS gene can be utilized for phytoremediation, effectively removing heavy metals from contaminated soils. Additionally, the expression of these resistance factors in non-harvestable parts of crops may help reduce heavy metal uptake by edible portions, subsequently decreasing heavy metal content in agricultural produce.

**Problem Solved:** This technology addresses the issue of heavy metal contamination in soils and groundwater resulting from industrial, mining activities, and natural sources, which adversely affects crop yields and poses health risks through the food chain. By employing plants to extract and sequester heavy metals, it offers a cost-effective and practical solution for environmental restoration and food safety, reducing reliance on expensive conventional cleanup methods.","Environmental contamination with heavy metals like arsenic, cadmium, lead, and mercury affects human health and reduces agricultural productivity. The AtPCS gene, which encodes a multispecific heavy metal resistance factor from plants, is important in addressing this contamination issue."
"University of Pennsylvania","High Spatial and Temporal Resolution Mapping of Brain Activity Using Flexible Multiplexed Electrode Arrays with Long Term Stability and Safety","","","https://upenn.technologypublisher.com/technology/39320","Flexible foldable actively multiplexed high density electrode array for mapping brain activity in-vivoProblem:Electrode arrays for recording and stimulating the brain are used throughout clinical medicine and basic neuroscience research, but are unable to sample large areas of the brain while maintaining high spatial resolution because of the need to individually wire each passive sensor at the electrode-tissue interface.Solution:New devices that integrate ultrathin and flexible silicon nanomembrane transistors into the electrode array, thereby enabling new dense arrays of thousands of amplified and multiplexed sensors that are connected using fewer wires. An ultrathin 25 micrometer small double sided, silica based electrode array capable of collecting electrical signals from neural grooves. The data is collected rapidly and is of high spatial and temporal resolution. Use of biologically compatible components for the device ensures long term stability and safety.Advantages:The flexible BMI device is highly conductive, is 25 micro-meters in size, and consists of flexible silicon electrodes that pick up neural electrical signals during seizures.The multiplex transistor is made of quality single-crystal silicon and it connects all the electrodes through a single wireThe device is encased in a polyimide cover to prevent electrical leakageThe data recorded by the device has a high accuracy rate (64%) for experimental predictionApplications:Stimulating the brainStudy of epileptic seizuresStage of Development:The BMI device has been pre-tested in cats under the influence of the seizure inducing drug PicrotoxinIntellectual Property:US Patent10,349,860U.S. Patent8,934,965EPO2713863Reference Media:Viventi, J et al.;Nat Neurosci, 2011 Dec, 14(12): 1599.Desired Partnerships:LicenseCollaborationCase ID:Y6045-tpNCSWeb Published:3/19/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39320","**Summary:** The technology involves a flexible, foldable, actively multiplexed high density electrode array designed for in-vivo mapping of brain activity. Traditional electrode arrays struggle with sampling large brain areas while maintaining high spatial resolution due to the extensive wiring required for passive sensors; this new device addresses that limitation. It incorporates ultrathin and flexible silicon nanomembrane transistors, allowing for dense arrays of thousands of amplified, multiplexed sensors connected through significantly fewer wires. The electrode array is 25 micrometers in size, collects electrical signals from deep neural grooves, and provides data with high spatial and temporal resolution. The use of biologically compatible materials ensures the device's long-term stability and safety.

**Applications:** This technology can be applied in various fields, including brain stimulation and the study of epileptic seizures. Its ability to provide detailed mapping of brain activity can enhance understanding of neurological conditions and potentially improve treatment strategies.

**Problem Solved:** The technology successfully addresses the challenge of recording and stimulating large areas of the brain with high spatial resolution, overcoming the limitations of traditional passive electrode arrays that require extensive wiring for each individual sensor. By integrating advanced transistors and a highly conductive, flexible design, it facilitates improved electrical signal collection while ensuring long-term stability and safety for in-vivo use.","New flexible, foldable, actively multiplexed electrode arrays have been developed to map brain activity in-vivo, overcoming limitations of traditional electrode arrays that require individual wiring for each sensor. These advanced devices utilize ultrathin and flexible silicon nanomembranes to achieve high spatial resolution while potentially covering larger brain areas."
"University of Pennsylvania","Classifying high-frequency oscillations in physiological recordings","","","https://upenn.technologypublisher.com/technology/39309","Method for automatic and unsupervised classification of high-frequency oscillations in physiological recordings.Problem:Automatic detection and classification of high frequency oscillations (HFO) data for use in clinical diagnosis and therapy has been limited. Currently, researchers visually inspect for high frequency oscillations.Solution:An algorithm to automatically extract quantitative local seizure information from multielectrode data. The automated HFO detection and classification algorithm is comprised of three major stages:- In the first stage, candidate HFO events are detected in the band-pass filtered iEEG.- In the second stage, a statistical model of the local background iEEG surrounding each candidate event is built. Events bearing too large a spectral similarity to the background activity according to the model are discarded from candidacy.- In the final stage, computational features are extracted from the retained candidates and these features are used, after a dimensionality reduction step, as inputs to a classifier.Advantages:Algorithm may process brain oscillations within the 100-500 Hz frequency range, action potentials and epileptic spikes, and other brain/body generated signalsAlgorithm may be implemented in intracranial electroencephalographic monitoring systems or brain-implantable devicesAlgorithm may enable quantitative seizure localization in devicesApplications:Intracranial electroencephalographic (iEEG) monitoring systems used in surgical evaluation for epilepsy patients who are unresponsive to antiepileptic drugsBrain-implantable devices that monitor, predict, abort, and/or control epileptic seizures by using the feedback to deliver a therapyStage of Development:Algorithm is developedContinuous long-term data from 9 patients has been usedIntellectual Property:U.S.9,236,698Reference Media:Blanco, J et al.;J Neurophysiol, 2010 Nov 104(5): 2900.Case ID:X5675-tpNCSWeb Published:3/18/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39309","**Summary:** A method has been developed for the automatic and unsupervised classification of high-frequency oscillations in physiological recordings, addressing the limitations of current manual inspection processes. The solution leverages an algorithm that operates in three stages: detecting candidate high-frequency oscillation events in filtered intracranial electroencephalographic (iEEG) data, building a statistical model of the local iEEG background, and extracting computational features from retained candidate events for classification. The algorithm is designed to accurately process brain oscillations within the 100-500 Hz frequency range, as well as action potentials and epileptic spikes. 

**Applications:** This technology is applicable in intracranial electroencephalographic monitoring systems, which are crucial for surgical evaluation and may also be implemented in brain-implantable devices to enhance clinical diagnosis and therapy.

**Problem Solved:** The method addresses the challenge of automatic detection and classification of high-frequency oscillation data in clinical settings, which has previously relied on time-consuming and subjective visual inspection methods, thereby improving the efficiency and accuracy of seizure localization and assessment in patients.","The text describes an algorithm designed for the automatic and unsupervised classification of high-frequency oscillations (HFOs) in physiological recordings, addressing the limitations of current methods that rely on visual inspection. This algorithm facilitates the extraction of quantitative local seizure information from multielectrode data to improve clinical diagnosis and therapy."
"University of Pennsylvania","Measuring and manipulating neuronal signals using implantable electronic microsensor arrays","","","https://upenn.technologypublisher.com/technology/39147","Problem:Most current implantable brain devices stimulate large regions of the brain without sensing. These devices are not able to access the fine multi-scale architecture comprising brain function and do not interact with the brain‚Äôs capacity for self-reorganization and repair.Solution:An implantable electronic micro-sensor array on flexible substrate for the measurement and manipulation of neuronal activity with circuitry to adapt performance based on input patterns.Advantages:Very high sensor density (20 nm spacing) improves signal quality and preserves space for effector circuits (electrical stimulators, optical emitters)Low temperature fabrication enables use of flexible polymer substrates to better adhere to curved tissue surfaces (brain, spinal cord, heart)Self-adaptive circuitry allows optimization of sensor and effector performance post-implantationApplications:Diagnosis and treatment of Parkinson‚Äôs, Alzheimer‚Äôs, paralysis, cachexia, and cardiac arrhythmia/ischemiaImplantable microarrays have been used to facilitate mental control of electronic devices by spinal injury patientsImplantable cardiac defibrillatorsStage of Development:Prototype arrays have been produced with channel sizes of 60 nm and 20 nmPrototypes have been used to monitor electrical activity in porcine heart and rat cortexIntellectual Property:U.S. Patent9,072,887Reference Media:Bink, H et al.;2011. Conf Proc IEEE Eng Med Biol Soc, 5400-3. doi: 10.1109/IEMBS.2011.6091335.Desired Partnerships:LicenseCollaborationCase ID:V4966-tpNCSWeb Published:3/11/2020Patent Information:App TypeCountrySerial No.Patent No.File DateIssued DateExpire DateDirect Link:https://upenn.technologypublisher.com/technology/39147","**Summary:** The technology addresses the limitations of existing implantable brain devices that stimulate broad areas without sensing by introducing an implantable electronic micro-sensor array on a flexible substrate designed to measure and manipulate neuronal activity. It features very high sensor density, low temperature fabrication for better tissue adherence, and self-adaptive circuitry that enhances performance after implantation. 

**Applications:** This technology can be applied in the diagnosis and treatment of conditions such as Parkinson‚Äôs, Alzheimer‚Äôs, paralysis, cachexia, and cardiac arrhythmia/ischemia. It can also facilitate mental control of electronic devices for spinal injury patients and has applications in implantable cardiac defibrillators.

**Problem Solved:** The solution overcomes the challenge of not accessing the intricate architecture of brain function and the inability to interact with the brain's self-repair mechanisms, thus enabling more precise monitoring and stimulation of neuronal activity for improved medical outcomes.","Current implantable brain devices stimulate large brain regions but lack sensing capabilities, limiting their interaction with the brain's intricate architecture and its ability to self-repair. A proposed solution is an implantable electronic micro-sensor array on a flexible substrate that measures and manipulates neuronal activity, featuring circuitry that adapts performance based on input patterns."
